{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "484be25f",
   "metadata": {},
   "source": [
    "## Loading data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "83b4fa11",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import pandas as pd\n",
    "import lightgbm as lgb\n",
    "\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "6a50e74f",
   "metadata": {},
   "outputs": [],
   "source": [
    "# filename = \"Lymphoma-P1\"\n",
    "filename = \"Lung_Cancer-P1\"\n",
    "df = pd.read_csv(f'../data/{filename}.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "340f73b1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Title</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Sponsor/Collaborators</th>\n",
       "      <th>...</th>\n",
       "      <th>Other IDs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Study Documents</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT01829373</td>\n",
       "      <td>Lung Cancer Vaccine Plus Oral Dietary Supplement</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Biological: vaccine 1650-G</td>\n",
       "      <td>Immunologic response to vaccine</td>\n",
       "      <td>Edward Hirschowitz|University of Louisville|Un...</td>\n",
       "      <td>...</td>\n",
       "      <td>BG1006</td>\n",
       "      <td>October 2011</td>\n",
       "      <td>June 2012</td>\n",
       "      <td>February 2013</td>\n",
       "      <td>April 11, 2013</td>\n",
       "      <td>NaN</td>\n",
       "      <td>April 11, 2013</td>\n",
       "      <td>University of Kentucky, Lexington, Kentucky, U...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01829373</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT00401778</td>\n",
       "      <td>Trial of RAD001 in Patients With Operable Non-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: RAD001</td>\n",
       "      <td>Clinical Response as Assessed Metabolically by...</td>\n",
       "      <td>Emory University</td>\n",
       "      <td>...</td>\n",
       "      <td>IRB00024810</td>\n",
       "      <td>November 2006</td>\n",
       "      <td>December 2013</td>\n",
       "      <td>December 2013</td>\n",
       "      <td>November 22, 2006</td>\n",
       "      <td>July 14, 2015</td>\n",
       "      <td>December 21, 2016</td>\n",
       "      <td>Emory University Winship Cancer Institute, Atl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00401778</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT00132054</td>\n",
       "      <td>Amrubicin and Irinotecan in Treating Patients ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: amrubicin hydrochloride|Drug: irinotecan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan Multinational Trial Organization|Nationa...</td>\n",
       "      <td>...</td>\n",
       "      <td>JMTO-LC03-03|CDR0000439464</td>\n",
       "      <td>May 2004</td>\n",
       "      <td>December 2006</td>\n",
       "      <td>November 2008</td>\n",
       "      <td>August 19, 2005</td>\n",
       "      <td>NaN</td>\n",
       "      <td>May 30, 2013</td>\n",
       "      <td>Gunma Cancer Center, Gunma, Japan|National Hos...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00132054</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT02429843</td>\n",
       "      <td>A Study of TRC105 in Combination With Paclitax...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: TRC105</td>\n",
       "      <td>Number of patients with a change in medical ma...</td>\n",
       "      <td>University of Alabama at Birmingham|Tracon Pha...</td>\n",
       "      <td>...</td>\n",
       "      <td>F150128005 (UAB 1504)</td>\n",
       "      <td>November 2, 2015</td>\n",
       "      <td>December 2018</td>\n",
       "      <td>December 2019</td>\n",
       "      <td>April 29, 2015</td>\n",
       "      <td>NaN</td>\n",
       "      <td>June 28, 2021</td>\n",
       "      <td>UAB Comprehensive Cancer Center, Birmingham, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02429843</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT00084799</td>\n",
       "      <td>Monoclonal Antibody Therapy in Treating Patien...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Biological: monoclonal antibody hu3S193</td>\n",
       "      <td>Confirmation of Tumor Targeting as Measured by...</td>\n",
       "      <td>Ludwig Institute for Cancer Research|National ...</td>\n",
       "      <td>...</td>\n",
       "      <td>LUD2002-015|MSKCC 04-012|CDR0000365621</td>\n",
       "      <td>July 26, 2004</td>\n",
       "      <td>January 25, 2006</td>\n",
       "      <td>December 20, 2006</td>\n",
       "      <td>June 11, 2004</td>\n",
       "      <td>February 8, 2022</td>\n",
       "      <td>October 10, 2022</td>\n",
       "      <td>Memorial Sloan-Kettering Cancer Center, New Yo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00084799</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>NCT01486602</td>\n",
       "      <td>Specialized Radiation Therapy and Chemotherapy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: carboplatin|Drug: paclitaxel|Radiation: ...</td>\n",
       "      <td>Maximum-tolerated RT dose fraction|Radiographi...</td>\n",
       "      <td>Alliance for Clinical Trials in Oncology|Natio...</td>\n",
       "      <td>...</td>\n",
       "      <td>CALGB 31102|CDR0000719011|NCI-2012-00087|U10CA...</td>\n",
       "      <td>March 2012</td>\n",
       "      <td>January 2017</td>\n",
       "      <td>January 16, 2018</td>\n",
       "      <td>December 6, 2011</td>\n",
       "      <td>NaN</td>\n",
       "      <td>January 19, 2018</td>\n",
       "      <td>Mayo Clinic Hospital, Phoenix, Arizona, United...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01486602</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>NCT00005022</td>\n",
       "      <td>Radiation Therapy Plus Combination Chemotherap...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: cisplatin|Drug: etoposide|Radiation: rad...</td>\n",
       "      <td>Frequency of patients developing unacceptable ...</td>\n",
       "      <td>Radiation Therapy Oncology Group|National Canc...</td>\n",
       "      <td>...</td>\n",
       "      <td>RTOG-9712|CDR0000065797</td>\n",
       "      <td>February 1998</td>\n",
       "      <td>October 2002</td>\n",
       "      <td>June 2010</td>\n",
       "      <td>January 29, 2004</td>\n",
       "      <td>NaN</td>\n",
       "      <td>November 3, 2013</td>\n",
       "      <td>University of Alabama at Birmingham Comprehens...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00005022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>NCT00004225</td>\n",
       "      <td>Gene Therapy Plus Radiation Therapy in Treatin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Biological: Ad5CMV-p53 gene|Radiation: radiati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eastern Cooperative Oncology Group|National Ca...</td>\n",
       "      <td>...</td>\n",
       "      <td>CDR0000067466|ECOG-8597</td>\n",
       "      <td>January 2000</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>January 27, 2003</td>\n",
       "      <td>NaN</td>\n",
       "      <td>July 7, 2010</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center at Vanderbilt ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00004225</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>NCT00052494</td>\n",
       "      <td>Combination Chemotherapy and Imatinib Mesylate...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: cisplatin|Drug: imatinib mesylate|Drug: ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>University Health Network, Toronto|National Ca...</td>\n",
       "      <td>...</td>\n",
       "      <td>PMH-PHL-008|CDR0000258487|NCI-5684</td>\n",
       "      <td>April 2003</td>\n",
       "      <td>February 2009</td>\n",
       "      <td>NaN</td>\n",
       "      <td>January 27, 2003</td>\n",
       "      <td>NaN</td>\n",
       "      <td>July 23, 2015</td>\n",
       "      <td>Princess Margaret Hospital, Toronto, Ontario, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00052494</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>NCT00045604</td>\n",
       "      <td>Imatinib Mesylate and Chemotherapy in Treating...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: cisplatin|Drug: imatinib mesylate|Drug: ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Memorial Sloan Kettering Cancer Center|Nationa...</td>\n",
       "      <td>...</td>\n",
       "      <td>CDR0000256923|MSKCC-02015|NCI-5653</td>\n",
       "      <td>July 2002</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>January 27, 2003</td>\n",
       "      <td>NaN</td>\n",
       "      <td>July 24, 2008</td>\n",
       "      <td>Memorial Sloan-Kettering Cancer Center, New Yo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00045604</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rank   NCT Number                                              Title  \\\n",
       "0     1  NCT01829373   Lung Cancer Vaccine Plus Oral Dietary Supplement   \n",
       "1     2  NCT00401778  Trial of RAD001 in Patients With Operable Non-...   \n",
       "2     3  NCT00132054  Amrubicin and Irinotecan in Treating Patients ...   \n",
       "3     4  NCT02429843  A Study of TRC105 in Combination With Paclitax...   \n",
       "4     5  NCT00084799  Monoclonal Antibody Therapy in Treating Patien...   \n",
       "5     6  NCT01486602  Specialized Radiation Therapy and Chemotherapy...   \n",
       "6     7  NCT00005022  Radiation Therapy Plus Combination Chemotherap...   \n",
       "7     8  NCT00004225  Gene Therapy Plus Radiation Therapy in Treatin...   \n",
       "8     9  NCT00052494  Combination Chemotherapy and Imatinib Mesylate...   \n",
       "9    10  NCT00045604  Imatinib Mesylate and Chemotherapy in Treating...   \n",
       "\n",
       "  Acronym     Status         Study Results   Conditions  \\\n",
       "0     NaN  Completed  No Results Available  Lung Cancer   \n",
       "1     NaN  Completed           Has Results  Lung Cancer   \n",
       "2     NaN  Completed  No Results Available  Lung Cancer   \n",
       "3     NaN  Completed  No Results Available  Lung Cancer   \n",
       "4     NaN  Completed           Has Results  Lung Cancer   \n",
       "5     NaN  Completed  No Results Available  Lung Cancer   \n",
       "6     NaN  Completed  No Results Available  Lung Cancer   \n",
       "7     NaN  Completed  No Results Available  Lung Cancer   \n",
       "8     NaN  Completed  No Results Available  Lung Cancer   \n",
       "9     NaN  Completed  No Results Available  Lung Cancer   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0                         Biological: vaccine 1650-G   \n",
       "1                                       Drug: RAD001   \n",
       "2  Drug: amrubicin hydrochloride|Drug: irinotecan...   \n",
       "3                                       Drug: TRC105   \n",
       "4            Biological: monoclonal antibody hu3S193   \n",
       "5  Drug: carboplatin|Drug: paclitaxel|Radiation: ...   \n",
       "6  Drug: cisplatin|Drug: etoposide|Radiation: rad...   \n",
       "7  Biological: Ad5CMV-p53 gene|Radiation: radiati...   \n",
       "8  Drug: cisplatin|Drug: imatinib mesylate|Drug: ...   \n",
       "9  Drug: cisplatin|Drug: imatinib mesylate|Drug: ...   \n",
       "\n",
       "                                    Outcome Measures  \\\n",
       "0                    Immunologic response to vaccine   \n",
       "1  Clinical Response as Assessed Metabolically by...   \n",
       "2                                                NaN   \n",
       "3  Number of patients with a change in medical ma...   \n",
       "4  Confirmation of Tumor Targeting as Measured by...   \n",
       "5  Maximum-tolerated RT dose fraction|Radiographi...   \n",
       "6  Frequency of patients developing unacceptable ...   \n",
       "7                                                NaN   \n",
       "8                                                NaN   \n",
       "9                                                NaN   \n",
       "\n",
       "                               Sponsor/Collaborators  ...  \\\n",
       "0  Edward Hirschowitz|University of Louisville|Un...  ...   \n",
       "1                                   Emory University  ...   \n",
       "2  Japan Multinational Trial Organization|Nationa...  ...   \n",
       "3  University of Alabama at Birmingham|Tracon Pha...  ...   \n",
       "4  Ludwig Institute for Cancer Research|National ...  ...   \n",
       "5  Alliance for Clinical Trials in Oncology|Natio...  ...   \n",
       "6  Radiation Therapy Oncology Group|National Canc...  ...   \n",
       "7  Eastern Cooperative Oncology Group|National Ca...  ...   \n",
       "8  University Health Network, Toronto|National Ca...  ...   \n",
       "9  Memorial Sloan Kettering Cancer Center|Nationa...  ...   \n",
       "\n",
       "                                           Other IDs        Start Date  \\\n",
       "0                                             BG1006      October 2011   \n",
       "1                                        IRB00024810     November 2006   \n",
       "2                         JMTO-LC03-03|CDR0000439464          May 2004   \n",
       "3                              F150128005 (UAB 1504)  November 2, 2015   \n",
       "4             LUD2002-015|MSKCC 04-012|CDR0000365621     July 26, 2004   \n",
       "5  CALGB 31102|CDR0000719011|NCI-2012-00087|U10CA...        March 2012   \n",
       "6                            RTOG-9712|CDR0000065797     February 1998   \n",
       "7                            CDR0000067466|ECOG-8597      January 2000   \n",
       "8                 PMH-PHL-008|CDR0000258487|NCI-5684        April 2003   \n",
       "9                 CDR0000256923|MSKCC-02015|NCI-5653         July 2002   \n",
       "\n",
       "  Primary Completion Date    Completion Date       First Posted  \\\n",
       "0               June 2012      February 2013     April 11, 2013   \n",
       "1           December 2013      December 2013  November 22, 2006   \n",
       "2           December 2006      November 2008    August 19, 2005   \n",
       "3           December 2018      December 2019     April 29, 2015   \n",
       "4        January 25, 2006  December 20, 2006      June 11, 2004   \n",
       "5            January 2017   January 16, 2018   December 6, 2011   \n",
       "6            October 2002          June 2010   January 29, 2004   \n",
       "7                     NaN                NaN   January 27, 2003   \n",
       "8           February 2009                NaN   January 27, 2003   \n",
       "9                     NaN                NaN   January 27, 2003   \n",
       "\n",
       "  Results First Posted Last Update Posted  \\\n",
       "0                  NaN     April 11, 2013   \n",
       "1        July 14, 2015  December 21, 2016   \n",
       "2                  NaN       May 30, 2013   \n",
       "3                  NaN      June 28, 2021   \n",
       "4     February 8, 2022   October 10, 2022   \n",
       "5                  NaN   January 19, 2018   \n",
       "6                  NaN   November 3, 2013   \n",
       "7                  NaN       July 7, 2010   \n",
       "8                  NaN      July 23, 2015   \n",
       "9                  NaN      July 24, 2008   \n",
       "\n",
       "                                           Locations Study Documents  \\\n",
       "0  University of Kentucky, Lexington, Kentucky, U...             NaN   \n",
       "1  Emory University Winship Cancer Institute, Atl...             NaN   \n",
       "2  Gunma Cancer Center, Gunma, Japan|National Hos...             NaN   \n",
       "3  UAB Comprehensive Cancer Center, Birmingham, A...             NaN   \n",
       "4  Memorial Sloan-Kettering Cancer Center, New Yo...             NaN   \n",
       "5  Mayo Clinic Hospital, Phoenix, Arizona, United...             NaN   \n",
       "6  University of Alabama at Birmingham Comprehens...             NaN   \n",
       "7  Vanderbilt-Ingram Cancer Center at Vanderbilt ...             NaN   \n",
       "8  Princess Margaret Hospital, Toronto, Ontario, ...             NaN   \n",
       "9  Memorial Sloan-Kettering Cancer Center, New Yo...             NaN   \n",
       "\n",
       "                                           URL  \n",
       "0  https://ClinicalTrials.gov/show/NCT01829373  \n",
       "1  https://ClinicalTrials.gov/show/NCT00401778  \n",
       "2  https://ClinicalTrials.gov/show/NCT00132054  \n",
       "3  https://ClinicalTrials.gov/show/NCT02429843  \n",
       "4  https://ClinicalTrials.gov/show/NCT00084799  \n",
       "5  https://ClinicalTrials.gov/show/NCT01486602  \n",
       "6  https://ClinicalTrials.gov/show/NCT00005022  \n",
       "7  https://ClinicalTrials.gov/show/NCT00004225  \n",
       "8  https://ClinicalTrials.gov/show/NCT00052494  \n",
       "9  https://ClinicalTrials.gov/show/NCT00045604  \n",
       "\n",
       "[10 rows x 27 columns]"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(10)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "dfae5ab6",
   "metadata": {},
   "source": [
    "## Convert datatime columns to duation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "aaf2d72a",
   "metadata": {},
   "outputs": [],
   "source": [
    "for col_name in ['Start Date', 'Primary Completion Date', 'Completion Date', 'First Posted', 'Last Update Posted']:\n",
    "    df[col_name] = df[col_name].apply(pd.to_datetime)\n",
    "df['duration'] = (df['Completion Date'] - df['Start Date']).dt.days"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "4c285e22",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Title</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Sponsor/Collaborators</th>\n",
       "      <th>...</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Study Documents</th>\n",
       "      <th>URL</th>\n",
       "      <th>duration</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT01829373</td>\n",
       "      <td>Lung Cancer Vaccine Plus Oral Dietary Supplement</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Biological: vaccine 1650-G</td>\n",
       "      <td>Immunologic response to vaccine</td>\n",
       "      <td>Edward Hirschowitz|University of Louisville|Un...</td>\n",
       "      <td>...</td>\n",
       "      <td>2011-10-01</td>\n",
       "      <td>2012-06-01</td>\n",
       "      <td>2013-02-01</td>\n",
       "      <td>2013-04-11</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-04-11</td>\n",
       "      <td>University of Kentucky, Lexington, Kentucky, U...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01829373</td>\n",
       "      <td>489.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT00401778</td>\n",
       "      <td>Trial of RAD001 in Patients With Operable Non-...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: RAD001</td>\n",
       "      <td>Clinical Response as Assessed Metabolically by...</td>\n",
       "      <td>Emory University</td>\n",
       "      <td>...</td>\n",
       "      <td>2006-11-01</td>\n",
       "      <td>2013-12-01</td>\n",
       "      <td>2013-12-01</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>July 14, 2015</td>\n",
       "      <td>2016-12-21</td>\n",
       "      <td>Emory University Winship Cancer Institute, Atl...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00401778</td>\n",
       "      <td>2587.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT00132054</td>\n",
       "      <td>Amrubicin and Irinotecan in Treating Patients ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: amrubicin hydrochloride|Drug: irinotecan...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Japan Multinational Trial Organization|Nationa...</td>\n",
       "      <td>...</td>\n",
       "      <td>2004-05-01</td>\n",
       "      <td>2006-12-01</td>\n",
       "      <td>2008-11-01</td>\n",
       "      <td>2005-08-19</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-05-30</td>\n",
       "      <td>Gunma Cancer Center, Gunma, Japan|National Hos...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00132054</td>\n",
       "      <td>1645.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT02429843</td>\n",
       "      <td>A Study of TRC105 in Combination With Paclitax...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: TRC105</td>\n",
       "      <td>Number of patients with a change in medical ma...</td>\n",
       "      <td>University of Alabama at Birmingham|Tracon Pha...</td>\n",
       "      <td>...</td>\n",
       "      <td>2015-11-02</td>\n",
       "      <td>2018-12-01</td>\n",
       "      <td>2019-12-01</td>\n",
       "      <td>2015-04-29</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>UAB Comprehensive Cancer Center, Birmingham, A...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02429843</td>\n",
       "      <td>1490.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT00084799</td>\n",
       "      <td>Monoclonal Antibody Therapy in Treating Patien...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Biological: monoclonal antibody hu3S193</td>\n",
       "      <td>Confirmation of Tumor Targeting as Measured by...</td>\n",
       "      <td>Ludwig Institute for Cancer Research|National ...</td>\n",
       "      <td>...</td>\n",
       "      <td>2004-07-26</td>\n",
       "      <td>2006-01-25</td>\n",
       "      <td>2006-12-20</td>\n",
       "      <td>2004-06-11</td>\n",
       "      <td>February 8, 2022</td>\n",
       "      <td>2022-10-10</td>\n",
       "      <td>Memorial Sloan-Kettering Cancer Center, New Yo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00084799</td>\n",
       "      <td>877.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>NCT01486602</td>\n",
       "      <td>Specialized Radiation Therapy and Chemotherapy...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: carboplatin|Drug: paclitaxel|Radiation: ...</td>\n",
       "      <td>Maximum-tolerated RT dose fraction|Radiographi...</td>\n",
       "      <td>Alliance for Clinical Trials in Oncology|Natio...</td>\n",
       "      <td>...</td>\n",
       "      <td>2012-03-01</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>2018-01-16</td>\n",
       "      <td>2011-12-06</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018-01-19</td>\n",
       "      <td>Mayo Clinic Hospital, Phoenix, Arizona, United...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01486602</td>\n",
       "      <td>2147.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>NCT00005022</td>\n",
       "      <td>Radiation Therapy Plus Combination Chemotherap...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: cisplatin|Drug: etoposide|Radiation: rad...</td>\n",
       "      <td>Frequency of patients developing unacceptable ...</td>\n",
       "      <td>Radiation Therapy Oncology Group|National Canc...</td>\n",
       "      <td>...</td>\n",
       "      <td>1998-02-01</td>\n",
       "      <td>2002-10-01</td>\n",
       "      <td>2010-06-01</td>\n",
       "      <td>2004-01-29</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2013-11-03</td>\n",
       "      <td>University of Alabama at Birmingham Comprehens...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00005022</td>\n",
       "      <td>4503.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>NCT00004225</td>\n",
       "      <td>Gene Therapy Plus Radiation Therapy in Treatin...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Biological: Ad5CMV-p53 gene|Radiation: radiati...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Eastern Cooperative Oncology Group|National Ca...</td>\n",
       "      <td>...</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2010-07-07</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center at Vanderbilt ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00004225</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>NCT00052494</td>\n",
       "      <td>Combination Chemotherapy and Imatinib Mesylate...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: cisplatin|Drug: imatinib mesylate|Drug: ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>University Health Network, Toronto|National Ca...</td>\n",
       "      <td>...</td>\n",
       "      <td>2003-04-01</td>\n",
       "      <td>2009-02-01</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2015-07-23</td>\n",
       "      <td>Princess Margaret Hospital, Toronto, Ontario, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00052494</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>NCT00045604</td>\n",
       "      <td>Imatinib Mesylate and Chemotherapy in Treating...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Completed</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Drug: cisplatin|Drug: imatinib mesylate|Drug: ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Memorial Sloan Kettering Cancer Center|Nationa...</td>\n",
       "      <td>...</td>\n",
       "      <td>2002-07-01</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2008-07-24</td>\n",
       "      <td>Memorial Sloan-Kettering Cancer Center, New Yo...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00045604</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 28 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rank   NCT Number                                              Title  \\\n",
       "0     1  NCT01829373   Lung Cancer Vaccine Plus Oral Dietary Supplement   \n",
       "1     2  NCT00401778  Trial of RAD001 in Patients With Operable Non-...   \n",
       "2     3  NCT00132054  Amrubicin and Irinotecan in Treating Patients ...   \n",
       "3     4  NCT02429843  A Study of TRC105 in Combination With Paclitax...   \n",
       "4     5  NCT00084799  Monoclonal Antibody Therapy in Treating Patien...   \n",
       "5     6  NCT01486602  Specialized Radiation Therapy and Chemotherapy...   \n",
       "6     7  NCT00005022  Radiation Therapy Plus Combination Chemotherap...   \n",
       "7     8  NCT00004225  Gene Therapy Plus Radiation Therapy in Treatin...   \n",
       "8     9  NCT00052494  Combination Chemotherapy and Imatinib Mesylate...   \n",
       "9    10  NCT00045604  Imatinib Mesylate and Chemotherapy in Treating...   \n",
       "\n",
       "  Acronym     Status         Study Results   Conditions  \\\n",
       "0     NaN  Completed  No Results Available  Lung Cancer   \n",
       "1     NaN  Completed           Has Results  Lung Cancer   \n",
       "2     NaN  Completed  No Results Available  Lung Cancer   \n",
       "3     NaN  Completed  No Results Available  Lung Cancer   \n",
       "4     NaN  Completed           Has Results  Lung Cancer   \n",
       "5     NaN  Completed  No Results Available  Lung Cancer   \n",
       "6     NaN  Completed  No Results Available  Lung Cancer   \n",
       "7     NaN  Completed  No Results Available  Lung Cancer   \n",
       "8     NaN  Completed  No Results Available  Lung Cancer   \n",
       "9     NaN  Completed  No Results Available  Lung Cancer   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0                         Biological: vaccine 1650-G   \n",
       "1                                       Drug: RAD001   \n",
       "2  Drug: amrubicin hydrochloride|Drug: irinotecan...   \n",
       "3                                       Drug: TRC105   \n",
       "4            Biological: monoclonal antibody hu3S193   \n",
       "5  Drug: carboplatin|Drug: paclitaxel|Radiation: ...   \n",
       "6  Drug: cisplatin|Drug: etoposide|Radiation: rad...   \n",
       "7  Biological: Ad5CMV-p53 gene|Radiation: radiati...   \n",
       "8  Drug: cisplatin|Drug: imatinib mesylate|Drug: ...   \n",
       "9  Drug: cisplatin|Drug: imatinib mesylate|Drug: ...   \n",
       "\n",
       "                                    Outcome Measures  \\\n",
       "0                    Immunologic response to vaccine   \n",
       "1  Clinical Response as Assessed Metabolically by...   \n",
       "2                                                NaN   \n",
       "3  Number of patients with a change in medical ma...   \n",
       "4  Confirmation of Tumor Targeting as Measured by...   \n",
       "5  Maximum-tolerated RT dose fraction|Radiographi...   \n",
       "6  Frequency of patients developing unacceptable ...   \n",
       "7                                                NaN   \n",
       "8                                                NaN   \n",
       "9                                                NaN   \n",
       "\n",
       "                               Sponsor/Collaborators  ... Start Date  \\\n",
       "0  Edward Hirschowitz|University of Louisville|Un...  ... 2011-10-01   \n",
       "1                                   Emory University  ... 2006-11-01   \n",
       "2  Japan Multinational Trial Organization|Nationa...  ... 2004-05-01   \n",
       "3  University of Alabama at Birmingham|Tracon Pha...  ... 2015-11-02   \n",
       "4  Ludwig Institute for Cancer Research|National ...  ... 2004-07-26   \n",
       "5  Alliance for Clinical Trials in Oncology|Natio...  ... 2012-03-01   \n",
       "6  Radiation Therapy Oncology Group|National Canc...  ... 1998-02-01   \n",
       "7  Eastern Cooperative Oncology Group|National Ca...  ... 2000-01-01   \n",
       "8  University Health Network, Toronto|National Ca...  ... 2003-04-01   \n",
       "9  Memorial Sloan Kettering Cancer Center|Nationa...  ... 2002-07-01   \n",
       "\n",
       "  Primary Completion Date Completion Date  First Posted Results First Posted  \\\n",
       "0              2012-06-01      2013-02-01    2013-04-11                  NaN   \n",
       "1              2013-12-01      2013-12-01    2006-11-22        July 14, 2015   \n",
       "2              2006-12-01      2008-11-01    2005-08-19                  NaN   \n",
       "3              2018-12-01      2019-12-01    2015-04-29                  NaN   \n",
       "4              2006-01-25      2006-12-20    2004-06-11     February 8, 2022   \n",
       "5              2017-01-01      2018-01-16    2011-12-06                  NaN   \n",
       "6              2002-10-01      2010-06-01    2004-01-29                  NaN   \n",
       "7                     NaT             NaT    2003-01-27                  NaN   \n",
       "8              2009-02-01             NaT    2003-01-27                  NaN   \n",
       "9                     NaT             NaT    2003-01-27                  NaN   \n",
       "\n",
       "  Last Update Posted                                          Locations  \\\n",
       "0         2013-04-11  University of Kentucky, Lexington, Kentucky, U...   \n",
       "1         2016-12-21  Emory University Winship Cancer Institute, Atl...   \n",
       "2         2013-05-30  Gunma Cancer Center, Gunma, Japan|National Hos...   \n",
       "3         2021-06-28  UAB Comprehensive Cancer Center, Birmingham, A...   \n",
       "4         2022-10-10  Memorial Sloan-Kettering Cancer Center, New Yo...   \n",
       "5         2018-01-19  Mayo Clinic Hospital, Phoenix, Arizona, United...   \n",
       "6         2013-11-03  University of Alabama at Birmingham Comprehens...   \n",
       "7         2010-07-07  Vanderbilt-Ingram Cancer Center at Vanderbilt ...   \n",
       "8         2015-07-23  Princess Margaret Hospital, Toronto, Ontario, ...   \n",
       "9         2008-07-24  Memorial Sloan-Kettering Cancer Center, New Yo...   \n",
       "\n",
       "  Study Documents                                          URL duration  \n",
       "0             NaN  https://ClinicalTrials.gov/show/NCT01829373    489.0  \n",
       "1             NaN  https://ClinicalTrials.gov/show/NCT00401778   2587.0  \n",
       "2             NaN  https://ClinicalTrials.gov/show/NCT00132054   1645.0  \n",
       "3             NaN  https://ClinicalTrials.gov/show/NCT02429843   1490.0  \n",
       "4             NaN  https://ClinicalTrials.gov/show/NCT00084799    877.0  \n",
       "5             NaN  https://ClinicalTrials.gov/show/NCT01486602   2147.0  \n",
       "6             NaN  https://ClinicalTrials.gov/show/NCT00005022   4503.0  \n",
       "7             NaN  https://ClinicalTrials.gov/show/NCT00004225      NaN  \n",
       "8             NaN  https://ClinicalTrials.gov/show/NCT00052494      NaN  \n",
       "9             NaN  https://ClinicalTrials.gov/show/NCT00045604      NaN  \n",
       "\n",
       "[10 rows x 28 columns]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "c167b59a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Remove invalid rows\n",
    "df = df[~df.duration.isna()]\n",
    "\n",
    "\n",
    "df = df.drop(['Start Date', 'Primary Completion Date', 'Completion Date', 'First Posted', 'Last Update Posted'], axis=1)\n",
    "\n",
    "#df.duration = df.duration.astype(int)\n",
    "df.columns = df.columns.str.lower()\n",
    "df.columns = df.columns.str.replace(\" \",\"_\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "a88443f2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>rank</th>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nct_number</th>\n",
       "      <td>NCT01829373</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>title</th>\n",
       "      <td>Lung Cancer Vaccine Plus Oral Dietary Supplement</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>acronym</th>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>status</th>\n",
       "      <td>Completed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_results</th>\n",
       "      <td>No Results Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>conditions</th>\n",
       "      <td>Lung Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>interventions</th>\n",
       "      <td>Biological: vaccine 1650-G</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>outcome_measures</th>\n",
       "      <td>Immunologic response to vaccine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>sponsor/collaborators</th>\n",
       "      <td>Edward Hirschowitz|University of Louisville|Un...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gender</th>\n",
       "      <td>All</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>age</th>\n",
       "      <td>21 Years and older   (Adult, Older Adult)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>phases</th>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enrollment</th>\n",
       "      <td>5.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>funded_bys</th>\n",
       "      <td>Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_type</th>\n",
       "      <td>Interventional</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_designs</th>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>other_ids</th>\n",
       "      <td>BG1006</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>results_first_posted</th>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>locations</th>\n",
       "      <td>University of Kentucky, Lexington, Kentucky, U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_documents</th>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>url</th>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01829373</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>duration</th>\n",
       "      <td>489.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                       0\n",
       "rank                                                                   1\n",
       "nct_number                                                   NCT01829373\n",
       "title                   Lung Cancer Vaccine Plus Oral Dietary Supplement\n",
       "acronym                                                              NaN\n",
       "status                                                         Completed\n",
       "study_results                                       No Results Available\n",
       "conditions                                                   Lung Cancer\n",
       "interventions                                 Biological: vaccine 1650-G\n",
       "outcome_measures                         Immunologic response to vaccine\n",
       "sponsor/collaborators  Edward Hirschowitz|University of Louisville|Un...\n",
       "gender                                                               All\n",
       "age                            21 Years and older   (Adult, Older Adult)\n",
       "phases                                                           Phase 1\n",
       "enrollment                                                           5.0\n",
       "funded_bys                                                         Other\n",
       "study_type                                                Interventional\n",
       "study_designs          Allocation: N/A|Intervention Model: Single Gro...\n",
       "other_ids                                                         BG1006\n",
       "results_first_posted                                                 NaN\n",
       "locations              University of Kentucky, Lexington, Kentucky, U...\n",
       "study_documents                                                      NaN\n",
       "url                          https://ClinicalTrials.gov/show/NCT01829373\n",
       "duration                                                           489.0"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(1).transpose()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a7107780",
   "metadata": {},
   "source": [
    "## Analze Outcome measures"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "2b7090c9",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(840, 23)\n",
      "[('overall survival', 111), ('progression-free survival', 75), ('progression free survival', 67), ('duration of response', 55), ('objective response rate', 50), ('', 45), ('maximum tolerated dose', 28), ('disease control rate', 26), ('response rate', 20), ('overall response rate', 20)]\n",
      "[('AEs', 363), ('Cmax', 144), ('PFS', 85), ('MTD', 80), ('Tmax', 72), ('ORR', 58), ('AUC', 51), ('OS', 50), ('DLTs', 50), ('DOR', 40), ('DLT', 39), ('Ctrough', 37), ('RECIST', 36), ('t1/2', 33), ('DCR', 31), ('PK', 31), ('Cmin', 26), ('RP2D', 26), ('AUClast', 23), ('ADA', 22), ('AUCtau', 18), ('anti-fucosyl-GM1', 17), ('CL', 16), ('ECG', 13), ('TTP', 13), ('SHBG', 13), ('AMG 888', 12), ('dn', 12), ('NSCLC', 11), ('PR', 11), ('SD', 11), ('OR', 11), ('AUC0-t', 11), ('HuMax-TF-ADC', 11), ('Conjugated and Non-conjugated', 11), ('RPTD', 10), ('TTR', 10), ('MMAE', 10), ('DoR', 10), ('AZ5104 and AZ7550', 10), ('Parts C Plus F', 10), ('PD', 9), ('AUCinf', 9), ('CL/F', 9), ('Vss', 9), ('T1/2', 8), ('AE', 8), ('ADAs', 8), ('RECIST v1.1', 8), ('BOR', 8), ('alone and in combination with osimertinib', 8), ('Parts B Plus D', 8), ('Bioequivalence', 8), ('Food Effect Bioavailability', 8), ('MSC1936369B', 8), ('All Cycles', 8), ('irRC', 7), ('irRECIST', 7), ('ECOG', 7), ('RD', 7), ('0-tau', 7), ('Vz/F', 6), ('Metabolites', 6), ('0-t', 6), ('EQ-5D', 6), ('R-150033', 6), ('AV-951', 6), ('Cmax and Cmin', 6), ('TEAE', 5), ('OMP-21M18', 5), ('QLQ-C30', 5), ('at Steady-state', 5), ('AUC0-inf', 5), ('0-12', 5), ('Rac', 5), ('CR or PR', 5), ('0-24', 5), ('Parts A and A1', 5), ('AUCt', 5), ('Eg. TMax', 5), ('Treatments A, B and C', 5), ('CBR', 4), ('Vz', 4), ('Grade 4', 4), ('0-inf', 4), ('AUC[0-t]', 4), ('LY2603618', 4), ('Metabolite', 4), ('0-last', 4), ('reference product', 4), ('NAb', 4), ('Closed to enrollment as of 12/6/06', 4), ('Cycle 1', 4), ('ss', 4), ('IERC', 4), ('HAHA', 3), ('sorafenib', 3), ('SAE', 3), ('NCI', 3), ('T-HALF', 3), ('Tlast', 3), ('CT', 3), ('CR', 3), ('QLQ-LC13', 3), ('s', 3), ('TAU', 3), ('CLss/F', 3), ('MRAUCtau', 3), ('AUC0-last', 3), ('Disease Control Rate [DCR]', 3), ('C24', 3), ('Response Rate', 3), ('tmax', 3), ('Cmax,ss', 3), ('Group B', 3), ('PD-L1', 3), ('0-504', 3), ('End of the 21-day Cycle', 3), ('MDASI', 3), ('Parts B and D', 3), ('Cycle 2 Day 1', 3), ('AUC0-24', 3), ('INF', 3), ('QTcF', 3), ('Cohort II', 3), ('TILs', 3), ('HR', 3), ('Vz/f', 3), ('PSA', 3), ('Treatment B', 3), ('ss, Max', 3), ('0-42 days', 3), ('DBP', 3), ('Cmax,ss, tmax,ss, Cmin,ss, AUCss, CLss/F', 2), ('extent of accumulation, renal clearance, time dependency of pharmacokinetics and amount of drug excreted', 2), ('RR', 2), ('peak time, Tmax', 2), ('PBMC', 2), ('DTH', 2), ('plasma', 2), ('Crizotinib + Erlotinib / Erlotinib Alone', 2), ('0-120', 2), ('Safety and Tolerability', 2), ('ELISA', 2), ('MRCss,Max', 2), ('BICR', 2), ('AUC[0-12]', 2), ('AUC[0-∞]', 2), ('Objective Response Rates [ORR]', 2), ('PDT', 2), ('SF-36', 2), ('t1/2,z', 2), ('0-24 Hours', 2), ('0-12 Hours', 2), ('OIRR', 2), ('Pemetrexed and Cisplatin', 2), ('LCSS', 2), ('IRC', 2), ('RANO', 2), ('IGF-1', 2), ('Objective Tumor Response Rate [ORR]', 2), ('TTF', 2), ('AUC[0-infinity]', 2), ('efficacy', 2), ('FDG-PET', 2), ('Css,Max', 2), ('EORTC QLQ-C30', 2), ('ng*hr/mL', 2), ('AUC0-infinity', 2), ('AUCτ,ss', 2), ('Cendinf', 2), ('AUC From Time 0 to 24 Hour After Dose', 2), ('PNET', 2), ('SBRT', 2), ('Part A2', 2), ('Vss/F', 2), ('complete or partial', 2), ('MEDI4736', 2), ('AUC0-∞', 2), ('λz', 2), ('days', 2), ('IV', 2), ('PFSRs', 2), ('AI', 2), ('CLT', 2), ('PBMCs', 2), ('sCD40L', 2), ('VEGF', 2), ('T½', 2), ('CL/f', 2), ('Racc', 2), ('BP', 2), ('ECHO', 2), ('Cancer Antigen 125 [Ovarian and Endometrial Cancer]', 2), ('Cav', 2), ('Parts A and B', 2), ('Parts A, B, and C', 2), ('BID', 2), ('β', 2), ('if possible', 2), ('mRECIST', 2), ('Pre-dose', 2), ('MPM', 2), ('Maximum Drug Concentration in Plasma', 2), ('Area Under the Plasma Concentration vs Time Curve From Zero to Infinity', 2), ('Maximum Drug Concentration in Plasma Divided by Dose', 2), ('AUC Divided by Dose', 2), ('AUC(0-tlast', 2), ('= Freedom From Recurrence', 2), ('RDI', 2), ('PET', 1), ('TUNEL Assay', 1), ('V1', 1), ('grade 3 or higher', 1), ('Common Toxicity Criteria version 3.0', 1), ('PBL', 1), ('COX-2', 1), ('toxicity-related symptoms', 1), ('EP', 1), ('only those with measurable disease', 1), ('BIBW 2992', 1), ('maximum tolerated dose, MTD and dose limiting toxicity, DLT', 1), ('RECIST1.1', 1), ('dose relating toxicity DLT', 1), ('Cmax, tmax, terminal rate constant, half life, AUC, clearance, volume of distribution, mean residence time', 1), ('analyzed from QLQ-BN20', 1), ('LM', 1), ('RA', 1), ('Complete Response and Partial Response', 1), ('ctDNA', 1), ('neo', 1), ('e.g. cytokines/chemokines, IL-2 receptor and neopterin', 1), ('urine', 1), ('whole body planar imaging', 1), ('als', 1), ('BMI', 1), ('Percentage of Participants With Objective Response', 1), ('Symbicort Turbuhaler', 1), ('e.g., methylation or gene expression changes', 1), ('AUC[0-28 Days]', 1), ('0-21 Days', 1), ('step 1', 1), ('step 2', 1), ('RECIST 1.1', 1), ('Complete Response [CR] or Partial Response [PR]', 1), ('CR, PR or stable disease', 1), ('LC-MS/MS', 1), ('complete response [CR] + partial response [PR]', 1), ('CR + PR + stable disease [SD]', 1), ('60 mg/m^2', 1), ('RECIST criteria', 1), ('AUC[0-21d]', 1), ('IHC', 1), ('FISH', 1), ('GLY12CYS', 1), ('AUC10', 1), ('AUC0 t', 1), ('PFSR', 1), ('0 - inf', 1), ('Gy', 1), ('PET-FDG', 1), ('characterised as local-regional, distant or both', 1), ('Eastern Cooperative Oncology Group', 1), ('Day 13-18', 1), ('Day 103 - 108', 1), ('complete response, partial response and stable disease', 1), ('IkappaB', 1), ('ECGs', 1), ('HGF', 1), ('GLI-1', 1), ('grade 2 or more', 1), ('AUC 0-28', 1), ('AUC 0-inf', 1), ('carboplatin/paclitaxel', 1), ('VTE', 1), ('CTC', 1), ('RT', 1), ('AUC(0-T', 1), ('Ctau', 1), ('AUC(TAU', 1), ('t1/2[lambda_z]', 1), ('mDOR', 1), ('G-CSF', 1), ('RBC', 1), ('ESA', 1), ('MAHE', 1), ('PBF-509+PDR001', 1), ('0-τ', 1), ('CTCAE', 1), ('Other Than DLT', 1), ('i.e., Occurs > 1 Year After the Start of SBRT', 1), ('ADC', 1), ('CR+PR', 1), ('CR + PR', 1), ('AUC[0-8]', 1), ('Cmax and Cmin for AMG 102 and AMG 479', 1), ('IL', 1), ('ORR:CR+PR', 1), ('RECIST CRITERIA', 1), ('3DRT', 1), ('Mean Organ Dose by Toxicity Level', 1), ('i-PDT', 1), ('Days -14 to -1', 1), ('Date of Photofrin Injection', 1), ('Day of Photodynamic Therapy', 1), ('30 Days Post Photofrin Injection', 1), ('6 Month Visit', 1), ('6 Months', 1), ('PERCIST', 1), ('BIRC', 1), ('DRR', 1), ('Including EGFR Mutations', 1), ('COR', 1), ('CDOR', 1), ('EORTC QLQ-LC13', 1), ('AUC0-day22', 1), ('IGF-BP-3', 1), ('> 30 days post-treatment', 1), ('EuroQol-5D-3L', 1), ('VAS', 1), ('Immunogenicity', 1), ('QoL', 1), ('partial or complete response', 1), ('complete response, partial response, and stable disease for ≥ 8 weeks', 1), ('HVLT-IR', 1), ('HVLT-DR', 1), (' DLT', 1), (' DCR', 1), (' DoR', 1), ('0-72', 1), ('Cmax, Tmax, AUC, half-life', 1), ('dose-limiting toxicities', 1), ('Assess the Tolerated Dose of the Combination Erlotinib and Enzastaurin', 1), ('Tau,ss', 1), ('MAP', 1), ('per RECIST 1.1', 1), ('EGFR', 1), ('clinical laboratory assessments, vital signs, weight, oxygen requirement and 12-lead ECG', 1), ('neutropenia', 1), ('RESIST', 1), ('Maximum Tolerated Dose', 1), ('DLTs During Cycle One', 1), ('MRCmax', 1), ('Group A', 1), ('ng/mL', 1), (' MTD', 1), ('RE', 1), ('CNS', 1), ('CDoR', 1), ('AUC[0-10]', 1), ('AUC[0-last]', 1), ('RPDII', 1), ('reference', 1), ('GSH', 1), ('Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean resistance time', 1), ('Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean residence time', 1), ('and prednisone', 1), ('RCR', 1), ('osimertinib only', 1), ('blood pressure, pulse, temperature, height, weight', 1), ('clinical chemistry, heamatology, urinalysis', 1), ('ECGS', 1), ('1', 1), ('good and bad', 1), ('Percentage of Participants With PFS at 3 Months', 1), ('Objective Response Rate [ORR]', 1), ('AUC[0-tlast]', 1), ('including UNG, TS, ERCC1, Ki-67 and TopoII-alpha', 1), ('PBT', 1), ('and its active metabolite, SU012662', 1), ('%', 1), ('PTF', 1), ('CR, PR and Stable Disease (SD', 1), ('Complete Response [CR] and Partial Response [PR]', 1), ('According to RECIST v1.1', 1), ('such as IL 2, IL-10, VEGF, sVEGFR2', 1), ('such as IL-2, IL-10, VEGF, sVEGFR-2', 1), ('AUC0-tz', 1), ('Human Anti-chimeric Antibody [HACA]', 1), ('based on blood pressure, body temperature, and laboratory tests', 1), ('dose escalation', 1), ('Cinf', 1), ('Exons 19, 20 and 21 and Others', 1), ('peak', 1), ('dsFv', 1), ('1.1', 1), ('PFT', 1), ('4D-CT', 1), ('FACT-TOI', 1), ('UCSD-SOB', 1), ('Cmax, %ID Brain', 1), ('Cmax, SUV Brain', 1), ('Tmax, Brain', 1), ('Kp', 1), ('Tss,Max', 1), ('AUCss', 1), ('CECs', 1), ('IGF-IR', 1), ('EORTC-QLQ-C30/-LC13', 1), ('Vd', 1), ('DR', 1), ('RO', 1), ('DOSD', 1), ('total exposure, and maximum and minimum serum concentrations', 1), ('SCLC', 1), ('tumor detection rate of BAY 86-9596 compared to FDG', 1), ('Standardized Uptake Values = SUVs', 1), ('ECG, blood pressure, Heart rate, Body temperature', 1), ('mRNA', 1), ('Parts A, A1, and A2', 1), ('Parts C and F', 1), ('28-day cycle', 1), ('IFN-y', 1), ('HAFA', 1), ('AUC [0-24h]', 1), ('MD', 1), ('M6 and M7', 1), ('MTDs', 1), ('AUC, Cmax', 1), ('AUC 0-tau', 1), ('Cavg', 1), ('AUC 0-infinity', 1), ('z', 1), ('EOT', 1), ('TTSP', 1), ('TCR', 1), ('Vigil™', 1), ('TFS', 1), ('Forced Expiratory Volume in the First Second [FEV1]', 1), ('Part II', 1), ('AUC0-24h', 1), ('RP2', 1), ('Overall Response Rate [ORR]', 1), ('MDASI-LC', 1), ('AUCextrap', 1), ('λ z', 1), ('Clast', 1), ('MRTinf', 1), ('CT and/or MR and/or FDG performed within 4 weeks of PET imaging', 1), ('Dosimetry', 1), ('t1/2z', 1), ('AR', 1), ('TRC105', 1), ('Disease Control Rate', 1), ('lesion volume', 1), ('BAY 94-9343', 1), ('225 mg/m2', 1), ('22 patients', 1), ('Response evaluation criteria in solid tumors, v 1.1', 1), ('by local investigator assessment', 1), ('DSD', 1), ('response rate according to the RECIST criteria', 1), ('0-T', 1), ('CLT/F', 1), ('CLR/F', 1), ('%UR', 1), ('%UR24', 1), ('MR_Cmax', 1), ('i.e., locally advanced head and neck cancer', 1), ('AUC [0-last]', 1), ('% injected dose/liter', 1), ('DC', 1), ('Outcome will be measured by a Chest Computed Tomography (CT', 1), ('Heparin Induced Thrombocytopenia', 1), ('those occurring without an antecedent DVT', 1), ('Via Recording of Maximum Tolerated Dose (MTD', 1), ('at doses up to 175 mg/m2', 1), ('at doses up to 225 mg/m2', 1), ('NE', 1), ('AUC[TAU]', 1), ('T-HALFeff', 1), ('NHL', 1), ('safety run-in', 1), ('number of Complete Responses + Partial Responses', 1), ('T 1/2', 1), ('LRCR', 1), ('Part 1 only', 1), ('as part of co-enrollment in Population Pharmacokinetics and Pharmacogenetics of Gemcitabine in Adult Patients with Solid Tumors\"', 1), ('DLBCL', 1), ('CTL', 1), ('Confirmed Response or Stable Disease (SD', 1), ('sCD27', 1), ('IFNg', 1), ('t½', 1), ('MRT', 1), ('AUC 0-24', 1), ('fresh or archived', 1), ('eg: lymphoid cell populations and serum cytokine levels', 1), ('1/2', 1), ('including: clinical chemistry, hematology, and urinalysis', 1), ('for cohort 6 only', 1), ('ICR', 1), ('previously treated patients with advanced/metastatic UCC with FGFR3 gene alterations', 1), ('PDGF', 1), ('VEGF-R', 1), ('PIGF', 1), ('FGF', 1), ('SUVmax', 1), ('Hb', 1), ('EORTC QLQ-OV28', 1), ('AUC[0-inf]', 1), ('Cmin,ss', 1), ('CRP', 1), ('IL-6R', 1), ('6D', 1), ('AUC[0-24]', 1), ('WBC', 1), ('Segmented and Blended', 1), ('area under the curve to last observed concentration time', 1), ('area under the curve extrapolated to infinity', 1), ('maximum plasma concentration', 1), ('time to maximum plasma concentration', 1), ('elimination half life', 1), ('clearance and volume of distribution', 1), ('Maximum Plasma Concentration', 1), ('Time of Maximum Plasma Concentration', 1), ('Area under the Plasma Concentration-time Curve from Time Zero to 24 hours', 1), ('Area under the Plasma Concentration-time Curve from Time Zero to the Last Measurable Concentration', 1), ('Area under the Plasma Concentration-time Curve from 0-time Extrapolated to Infinity', 1), ('Terminal Elimination Rate Constant', 1), ('Each Cycle = 28 Days', 1), ('AUC0-336h (Cycle 1 Only', 1), ('AUC336h, AUCinf, AUClast, AUCtau', 1), ('Immunologic Response Rate', 1), ('Pimasertib', 1), ('Tau', 1), ('MUGA', 1), ('slit lamp fundoscopy', 1), ('including but not limited to Response Evaluation Criteria in Solid Tumours (RECIST', 1), ('BoR', 1), ('OBD', 1), ('PCWG2', 1), ('Vdss', 1), ('Prostate Specific Antigen [Prostate Cancer]', 1), ('the signal to noise ratio', 1), ('NCAM', 1), ('including brain metastases', 1), ('solid tumors and acute myeloid leukemia (AML', 1), ('DCE', 1), ('DWI', 1), ('HRPC', 1), ('cubic centimeters', 1), ('Cmax in ng/mL', 1), ('hours', 1), ('pS6RP', 1), ('p4E-BP1', 1), ('pAKT', 1), ('CA-125', 1), ('Total Tumor H-score', 1), ('AUCextra%', 1), ('Escalation only', 1), ('such as CD8, FoxP3 and myeloid markers as appropriate', 1), ('i.e tumor', 1), ('C3D1', 1), ('Part C', 1), ('AUC(0-24', 1), ('CBR, defined as CR, PR or SD', 1), ('mAb', 1), ('V', 1), ('DF', 1), ('dose-limiting toxicity', 1), ('ELISPOT', 1), ('dosed continuously or on a 2/1 Schedule', 1), ('SLI', 1), ('qualitative improvement from baseline', 1), ('co-primary endpoint', 1), ('DDCR', 1), ('Adenoviral-mediated Interferon-alpha', 1), ('Non-SAE', 1), ('AELD', 1), ('AUC[0-tau]', 1), ('Cmax, C8hr, tmax, AUC, tlast, t½λz', 1), ('assessment of frequency of T-cells over time', 1), ('AUC[0 to Inf]', 1), ('Lambda z', 1), ('0 to Inf', 1), ('0 to t', 1), ('AUC, Cmax, tmax etc.', 1), ('AUC, Cmax, tmax, etc.', 1), ('Cmax After Multiple-dose Administration', 1), ('Cmax Divided by Dose After Multiple-dose Administration', 1), ('AUC(0-12', 1), ('Amount of Drug Excreted Via Urine During the Collection Interval 12 - 24 Hours Post Administration', 1), ('DOT', 1), ('Fibroblast Growth Factor 23', 1), ('Time to Reach Maximum Drug Concentration in Plasma', 1), ('Time of Last Plasma Concentration Above LLOQ', 1), ('Half-life Associated With the Terminal Slope', 1), ('Time to Reach Maximum Drug Concentration in Plasma After Multiple-dose Administration', 1), ('Time of Last Plasma Concentration Above LLOQ After Multiple-dose Administration', 1), ('= Short Form-36', 1), ('QLQ = Quality of Life Questionnaire, C = Cancer, LC = Lung Cancer', 1), ('PAI-1 = Plasminogen Activator Inhibitor Typ 1, p21 = CDK-Inhibitor 1 = Cyclin Dependent Kinase Inhibitor 1', 1), ('MFD', 1), ('CEOI', 1), ('Secondary Urothelial Carcinoma Cohort', 1), ('LDH', 1), ('pH', 1), ('TSH', 1), ('T3', 1), ('T4', 1), ('CR/PR/SD', 1), ('Pharmacokinetics', 1)]\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "from collections import defaultdict\n",
    "# Transfor string to class\n",
    "class_mapping = {}\n",
    "#col_names = ['Study Results']\n",
    "#for col_name in col_names:\n",
    "#    all[col_name].value_counts().head(10).index.tolist()\n",
    "measure_count = defaultdict(int)\n",
    "synonymous = {}\n",
    "processed_measure = {}\n",
    "invalid_row_ids = []\n",
    "print(df.shape)\n",
    "#df = df[df['outcome_measures'].apply(lambda x: type(x)==str)]\n",
    "#print(df.shape)\n",
    "df['outcome_measures'] = df['outcome_measures'].apply(lambda x: \"\" if type(x)!=str else x.replace(\";\", \"\"))\n",
    "skip_words = ['Phase', 'phase']\n",
    "for measures in df.outcome_measures:\n",
    "    new_measures = []\n",
    "    for measure in measures.split('|'):\n",
    "        if any(word in measure for word in [\"AEs\", \"Adverse Events\", \"Adverse events\", \"adverse events\"]):\n",
    "            measure = measure.lower()\n",
    "            synonymous[measure] = \"AEs\"\n",
    "        elif any(word in measure for word in [\"overall survival\", \"Overvall survival\"]):\n",
    "            measure = measure.lower()\n",
    "            synonymous[measure] = \"OS\"\n",
    "        else:\n",
    "            pattern = r\"\\((.*?)\\)\"\n",
    "            matches = re.findall(pattern, measure)\n",
    "\n",
    "            for w in skip_words:\n",
    "                matches = [match for match in matches if not w in match]\n",
    "\n",
    "            measure = re.sub(r\"\\([^()]*\\)\", \"\", measure)\n",
    "            measure = measure.strip()\n",
    "            measure = measure.lower()\n",
    "            if matches:\n",
    "                synonymous[measure] = matches[-1]\n",
    "\n",
    "        measure_count[measure] += 1\n",
    "        new_measures.append(measure)\n",
    "    processed_measure[measures] = new_measures\n",
    "\n",
    "sorted_measure_count = sorted(measure_count.items(), key=lambda x: x[1], reverse=True)\n",
    "print(sorted_measure_count[:10])\n",
    "#print(processed_measure[\"Define the Maximum Tolerated Dose (MTD) and Recommended Phase Two Dose (RPTD) of the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous NSCLC.|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Antitumor efficacy associated with administration of everolimus/pemetrexed/carboplatin/bevacizumab administration in patients with Stage IV non-squamous NSCLC.|Progression-free survival (PFS)|Overall Survival (OS)\"])\n",
    "#synonymous.update({\"Adverse Events\": \"AEs\",\n",
    "#                   \"Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs Leading to Discontinuation\": \"AEs\",\n",
    "#                   \"Number of Participants with Adverse events (AE) and Serious Adverse Events (SAEs)\": \"AEs\",\n",
    "#                   \"AEs, laboratory parameters\": \"AEs\",\n",
    "#                   \"Percentage of Participants with Adverse Events\": \"AEs\"\n",
    "#                  })\n",
    "from collections import Counter\n",
    "synonymous_count = Counter(synonymous.values())\n",
    "synonymous = {key:val for key, val in synonymous.items() if synonymous_count[val]>1}\n",
    "sorted_synonymous_count = sorted(synonymous_count.items(), key=lambda x:x[1])\n",
    "\n",
    "# merge synonymous with smaller count to larger count, ex: pfs->PFS\n",
    "#for i in range(len(sorted_synonymous_count)):\n",
    "#    if sorted_synonymous_count[i][1] > 1:\n",
    "#        for j in range(i+1, len(sorted_synonymous_count)):\n",
    "#            if sorted_synonymous_count[j][0].lower() == sorted_synonymous_count[i][0].lower():\n",
    "#                synonymous[sorted_synonymous_count[j][0]] = sorted_synonymous_count[i][0]\n",
    "#print(synonymous_count['mtd'])\n",
    "    \n",
    "print(sorted(synonymous_count.items(), key=lambda x:x[1], reverse=True))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "a02a62fa",
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4735\n"
     ]
    }
   ],
   "source": [
    "# merge similar measures\n",
    "import spacy\n",
    "import json\n",
    "\n",
    "spacy.prefer_gpu()\n",
    "nlp = spacy.load(\"en_core_web_md\")\n",
    "\n",
    "n_measure = len(measure_count)\n",
    "print(n_measure)\n",
    "merged_measure_count = {}\n",
    "\n",
    "\n",
    "# Union Find to group measures\n",
    "\n",
    "class DSU:\n",
    "    def __init__(self):\n",
    "        self.par = {x: x for x in synonymous.values()}\n",
    "        self.par.update({x: synonymous.get(x, x) for x in measure_count})\n",
    "        #for w1 in synonymous.values():\n",
    "        #    for w2 in measure_count:\n",
    "        #        if w1.lower() == w2.lower():\n",
    "        #            self.par[w2] = w1\n",
    "        # self.par[\"DLTs\"] = \"DLT\"\n",
    "\n",
    "    def find(self, x):\n",
    "        if self.par[x] != x:\n",
    "            self.par[x] = self.find(self.par[x])\n",
    "        return self.par[x]\n",
    "\n",
    "    def union(self, x, y):\n",
    "        if self.find(x) == self.find(y):\n",
    "            return False\n",
    "        else:\n",
    "            self.par[self.find(x)] = self.find(y)\n",
    "            return True\n",
    "\n",
    "dsu = DSU()\n",
    "\n",
    "def merge_synonymous_words_by_spacy():\n",
    "    synonymous_list = defaultdict(list)\n",
    "    for x, y in synonymous.items():\n",
    "        synonymous_list[y].append(x)\n",
    "    c = 0\n",
    "    for m1, _ in sorted_measure_count[:100]:\n",
    "        c += 1\n",
    "        print(m1, c)\n",
    "        if m1 in synonymous:\n",
    "            print(synonymous[m1])\n",
    "            continue\n",
    "        highest_score_class, highest_score = None, 0\n",
    "        doc1 = nlp(m1)\n",
    "        for class_name, members in sorted(synonymous_list.items(), key=lambda x: sum(measure_count[y] for y in x[1]), reverse=True)[:100]:\n",
    "            for m2 in members:\n",
    "                doc2 = nlp(m2)\n",
    "                similarity_score = doc1.similarity(doc2)\n",
    "                if similarity_score < 0.3:\n",
    "                    break\n",
    "                if similarity_score > 0.9 and similarity_score > highest_score:\n",
    "                    highest_score_class = class_name\n",
    "                    highest_score = similarity_score\n",
    "        if not highest_score_class:\n",
    "            highest_score_class = m1\n",
    "        synonymous[m1] = highest_score_class\n",
    "        synonymous_list[highest_score_class].append(m1)\n",
    "        print(f\"new synonymous {highest_score_class}\")\n",
    "\n",
    "    for x, _ in sorted_measure_count:\n",
    "        par = synonymous[x]\n",
    "        if par not in merged_measure_count:\n",
    "            merged_measure_count[par] = measure_count[x]\n",
    "        else:\n",
    "            merged_measure_count[par] += measure_count[x]\n",
    "    \n",
    "    for i in range(100):\n",
    "        # print(i)\n",
    "        m1, count1 = sorted_measure_count[i]\n",
    "        doc1 = nlp(m1)\n",
    "        for j in range(i+1, 100):\n",
    "            m2, count2 = sorted_measure_count[j]\n",
    "            doc2 = nlp(m2)\n",
    "\n",
    "            # Compute the similarity between the two sentences\n",
    "            if doc1.similarity(doc2) > 0.95:\n",
    "                # print(f\"{m1}, {m2}\")\n",
    "                dsu.union(m2, m1)\n",
    "\n",
    "    for x in dsu.par:\n",
    "        dsu.par[x] = dsu.find(x)\n",
    "        \n",
    "    merged_measure_members = {par: [] for par in dsu.par.values()}\n",
    "    for x in dsu.par:\n",
    "        merged_measure_members[dsu.par[x]].append(x)\n",
    "\n",
    "    with open(\"../data/synonymous_measure.json\", \"w\") as f:\n",
    "        json.dump(merged_measure_members, f)\n",
    "        parent = dsu.par\n",
    "\n",
    "    \n",
    "\n",
    "    \n",
    "    \n",
    "def merge_synonymous_words_by_sentence_transformer():\n",
    "    \n",
    "    from sentence_transformers import SentenceTransformer, util\n",
    "    if True: # filename == \"Lymphoma-P1\":\n",
    "\n",
    "        model = SentenceTransformer('all-MiniLM-L6-v2')\n",
    "\n",
    "\n",
    "        for i in range(100):\n",
    "            print(i)\n",
    "            m1, count1 = sorted_measure_count[i]\n",
    "            for j in range(i+1, 100):\n",
    "                m2, count2 = sorted_measure_count[j]\n",
    "                embeddings = model.encode([m1, m2], convert_to_tensor=True)\n",
    "                cosine_scores = util.cos_sim(embeddings, embeddings)\n",
    "                # Compute the similarity between the two sentences\n",
    "                #if 'number of participants who experienced an adverse event' in [m1, m2]:\n",
    "                #    print(f\"{m1}, {m2}: {cosine_scores[0][1]}\")\n",
    "                if cosine_scores[0][1] > 0.825:\n",
    "                    print(f\"{m1}, {m2}: {cosine_scores[0][1]}\")\n",
    "                    dsu.union(m2, m1)\n",
    "                    print(f\"synonymous with {dsu.par[m1]}\")\n",
    "\n",
    "        for x in dsu.par:\n",
    "            dsu.par[x] = dsu.find(x)\n",
    "        for x, _ in sorted_measure_count:\n",
    "            par = dsu.par[x]\n",
    "            if par not in merged_measure_count:\n",
    "                merged_measure_count[par] = measure_count[x]\n",
    "            else:\n",
    "                merged_measure_count[par] += measure_count[x]\n",
    "\n",
    "if filename == \"Lymphoma-P1\":\n",
    "    merge_synonymous_words_by_sentence_transformer()\n",
    "                          \n",
    "    merged_measure_members = {par: [] for par in dsu.par.values()}\n",
    "    for x in dsu.par:\n",
    "        merged_measure_members[dsu.par[x]].append(x)\n",
    "    with open(\"../data/synonymous_measure.json\", \"w\") as f:\n",
    "        json.dump(merged_measure_members, f)\n",
    "        parent = dsu.par\n",
    "else:\n",
    "    merged_measure_members = {par: [] for par in dsu.par.values()}\n",
    "    with open(\"../data/synonymous_measure.json\") as f:\n",
    "        merged_measure_members.update(json.load(f))\n",
    "        parent = dsu.par\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "2ddea092",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('PFS', 165), ('OS', 126), ('ORR', 111), ('AEs', 86), ('DOR', 74), ('DLT', 59), ('Cmax', 45), ('', 45), ('MTD', 41), ('disease control rate', 26)]\n",
      "{'AEs': ['AEs', 'adverse events profile', 'safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory fl, assessed by number of subjects with adverse events (aes)', 'frequency of adverse events', 'number of participants reporting treatment-emergent adverse events', 'number of dose limiting toxicity incidents as per national cancer institute (nci) common terminology criteria for adverse events (ctcae) version (v) 3.0 (phase i)', 'frequency and severity of adverse events assessed by ctcae v3.0', 'number of treatment-emergent adverse events (teaes)', 'adverse events (aes)', 'percentage of participants with adverse events.', 'adverse events evaluated by ctcae 4.03', 'number of participants experiencing clinical and laboratory adverse events (aes)', 'safety: incidence and severity of (serious) adverse events n each patient according to the nci-ctcae4.03 grading', 'proportion of patients with toxicities as assessed by the national cancer institute common terminology criteria for adverse events (nci/ctcae) version 3.0 grade >/= 3 to the magnicon generated idiotype (id) vaccine', 'number of participants with treatment-related adverse events as assessed by ctcae v4.0', 'incidence rate of dose-limiting toxicities and adverse events', 'all adverse events or adverse reactions, during the treatment cycle (twenty one days)', 'safety as assessed by and adverse events, laboratory assessments and physical examinations', 'mtd based on the incidence of dose-limiting toxicity (dlt) assessed by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0', 'part i: number of participants experiencing treatment-emergent adverse events and treatment-emergent serious adverse events', 'part ii: number of participants experiencing treatment-emergent adverse events and treatment-emergent serious adverse events', 'safety attributable to 99mtc-1-thio-d-glucose injections (incidence and severity of adverse events)', 'safety and tolerability of cpi-0610 as assessed by: frequency of adverse events and serious adverse events changes in hematology and clinical chemistry values changes in physical examination, vital signs, electrocardiogram, echo and ecog score', 'aes', 'saes', 'participants reporting dose limiting toxicity (dlt) adverse events (aes) for participants in the de cohort and the mtd confirmation cohort for arm 1', 'participants reporting dlt aes for participants in the de cohort and the mtd confirmation cohort for arm 2', 'occurrence of adverse events grade ≥ 3 as assessed by ctcaev5', 'comparison of aes between the two study arms', 'frequency of ka2237 related adverse events and laboratory abnormalities', 'percentage of participants with adverse events (aes) graded according to the national cancer institute (nci) common terminology criteria for adverse events version 4.0 (ctcae v4.0)', 'safety of treatment using the national cancer institute (nci) hematologic common terminology criteria for adverse events (ctcae) version 3.0', 'to evaluate number of participants with adverse events with r-ice plus bortezomib (vr-ice)', 'number of participants who experience adverse events as a measure of safety and tolerability', 'occurrence of adverse events (aes), serious adverse events (saes) assessments of clinical laboratory values and vital sign measurements.', 'percentage of patients with treatment emergent adverse events (teaes) selected for comparability assessment of bi 695500 and rituximab (mabthera®)', 'number of participants reporting one or more treatment-emergent adverse events (teaes) and serious adverse events (saes)', 'safety as measured by grade and frequency of adverse events', 'number of participants with treatment-emergent adverse events by severity', 'number of participants with treatment-related adverse events (aes) and serious adverse events (saes)', 'percentage of subjects with adverse events', 'number of subjects with adverse events', 'adverse events', 'number of participants with adverse events (aes) and serious adverse events (saes)', 'percentage of participants with adverse events (aes) or serious adverse events (saes)', 'incidence and severity of adverse events, dose-limiting toxicities, and changes in laboratory test results.', 'percentage of participants with adverse events (aes)', 'tolerability of study treatment as measured by dose interruptions, dose reductions, dose intensity, and treatment discontinuation due to aes', 'safety of hbi-8000 in japanese patients with nhl for whom no other standard therapy is suitable with incidence and severity of adverse events graded according to the nci-ctcae version 4.03', 'safety and tolerability of lee011, as assessed by grade and frequency of adverse events, serious adverse events, and changes in lab values, vital signs and ecgs.', 'incidence and severity of adverse events through 1 month after completing treatment', 'percentage of participants with adverse events (aes) and serious adverse events (saes)', 'number of participants with adverse events as a measure of safety and tolerability', 'to evaluate the the number of subjects with adverse events who receive sb-485232 when given in combination with ofatumumab', 'number of participants with treatment emergent adverse events (teaes) using ctcae version 4.03', 'number of participants with non-serious treatment-emergent adverse events (teaes) and serious adverse events (saes) as a measure of safety and tolerability of denileukin diftitox', 'adverse events and lab abnormalities.', 'safety as measured by adverse events, severity of hematologic toxicity, the use of supportive care and the percentage of human anti-murine antibody positivity', 'maximum tolerated dose (mtd) of idelalisib and lenalidomide, determined according to incidence of dose-limiting toxicity (dlt) graded using the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0 (phase i)', 'number of participants with treatment-emergent adverse events (aes) and serious adverse events (saes)', 'number of participants with grade 3 or higher grades treatment-emergent adverse events (teaes) based on severity', 'define incidence and severity of adverse events, defined according to ctcae v 4.0.', 'number and frequency of adverse events', 'dose escalation and expansion part: number of participants with adverse events (aes) and serious adverse events (saes)', 'incidence and severity of aes and saes, incl. changes in laboratory parameters, vital signs and ecgs.', 'percentage of participants with adverse events (aes) - part 1', 'percentage of participants with adverse events (aes) - part 2', 'number of participants with treatment emergent adverse events (teaes) and serious adverse events (saes)', 'incidence of dose-limiting toxicity and adverse events', 'number of participants with adverse events', 'incidence of adverse events', 'incidence of laboratory abnormalities', 'incidence of adverse events by nci ctcae v4.0 grade and associated dose of gdc-0349', 'incidence of adverse events and laboratory abnormalities', 'number of patients with adverse events', 'occurrence of adverse events', 'number of participants with adverse events and serious adverse events', 'number of participants with abnormal clinical laboratory values reported as adverse events', 'number of participants with clinically significant changes in vital signs reported as adverse events', 'number of participants experiencing adverse events considered to be at least possibly related to the study drug', 'number of participants with serious and non-serious adverse events assessed by the common terminology criteria in adverse events (ctcae v4.0).', 'occurrence of adverse events by nci ctcae grade and associated dose of gdc-0941', 'part 1: percentage of participants who experience a dose-limiting toxicity (dlt) per common terminology criteria for adverse events, version 4.0 (ctcae 4.0)', 'number of participants with treatment-emergent adverse events by frequency and grade in each cohort of dose and dosing schedule and the total number of participants with the treatment-emergent adverse events', 'percentage of participants with adverse events (aes) - relapsed/refractory population', 'percentage of participants with aes - first-line population', 'number of participants with clinically significant change in laboratory parameters reported as aes', 'number of participants with clinically significant change in vital sign reported as aes', 'number of adverse events', 'number of participants with infusion-related reaction and with drug-related adverse events.', 'severity of the adverse events', 'incidence, nature, and severity of adverse events', 'number of participants with adverse events (aes), grade 3 and 4 aes, serious adverse events (saes), discontinuations for aes', 'the safety of lenalidomide evaluated based on the severity of adverse events and their causality', 'percentage of participants reporting one or more treatment-emergent adverse events (teaes), grade 3 or higher adverse events (aes), serious adverse events (saes) and aes leading to discontinuation', 'safety as assessed by adverse events', 'adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ecgassessment of pharmacokinetic endpoints of 506u78, ara-g and intracellular ara-gtp concentration.', 'evaluation of the safety profile of wp1220 applied topically (adverse events)', 'number of participants with abnormal laboratory values reported as aes', 'number of participants with clinically significant change in weight reported as aes', 'the number of serious drug-related teaes (treatment-emergent adverse events)', 'the number of non-serious drug-related teaes', 'assessment of treatment related adverse events (aes).', 'assessment of treatment emergent adverse events (aes) meeting dose-limiting toxicity (dlt) criteria.', 'number of participants with clinically significant teaes related to laboratory abnormalities', 'phase i stage i: percentage of participants with adverse events and serious adverse events', 'safety: incidence and severity of adverse events', 'maximum tolerated dose of the combination of ibrutinib with standard dosing r-ice, graded using the common terminology criteria for adverse events 4.0', 'adverse events as a measure of safety of intrathecal administration of rituximab', 'part 1: assessment of treatment emergent adverse events (aes) meeting dlt criteria.', 'part 2: assessment of treatment emergent adverse events (aes) meeting dlt criteria.', 'part 3: assessment of treatment emergent adverse events (aes) meeting dlt criteria.', 'safety: incidence of adverse events', 'occurrence of study related adverse events defined as nci ctcae 4.0 > grade 3 possibly, probably, or definitely related to study treatment.', 'incidence of treatment-emergent adverse events', 'incidence of treatment-related adverse events', 'incidence of toxicities according to the common terminology criteria for adverse events version 4', 'number of participants with adverse events based on the ctcae v.4', 'incidence and severity of adverse events', 'number of participants with serious and non-serious adverse events', 'safety of the study treatments when given in combination [incidence of adverse events]', 'assess the safety and tolerability of arq 092 in subjects with advanced solid tumors and recurrent malignant lymphoma by monitoring frequency and severity of adverse events', 'incidence of aes, change in safety and efficacy parameters', 'number of participants with adverse events (aes)', 'aes as characterized by type, frequency, severity (as graded by ctcae) and relationship to study drug', 'percentage of participants with grade 3 or higher adverse events considered at least possibly related to treatment', 'number of participants with treatment emergent adverse events (teaes) and treatment emergent serious adverse events (tesaes)', 'number of participants with vital signs abnormalities recorded as treatment-emergent adverse events (teaes)', 'number of participants with clinically significant laboratory abnormalities recorded as treatment-emergent adverse events (teaes)', 'treatment-emergent adverse events (teaes) related to chemistry abnormalities occurring in greater than (>) 5 percent of participants', 'safety and tolerability: frequency and severity of adverse events (ctcae v4.03)', 'incidence of treatment-emergent adverse events (safety and tolerability)', 'incidence and severity of treatment-emergent adverse events (teaes)', 'incidence and severity of adverse events (aes) in the follow-up period', 'number of participants who experienced a dose-limiting toxicity (dlt) during cycle 0 and cycle 1 based on national cancer institute common terminology criteria for adverse events version 3.0 (ctcae v 3.0)', 'number of participants affected by adverse events by meddra system organ class (soc) and preferred term (pt)', 'number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events', 'to assess the safety and tolerability of fimepinostat in combination with anti-cancer regimens by evaluating the number of participants with adverse events assessed using the nci common terminology criteria for adverse events (ctcae, v4.0).', 'number of subjects with treatment emergent adverse events', 'phase 1: occurrence and severity of grade 3 or higher treatment emergent adverse events (teaes) according to national cancer institute common terminology criteria for adverse events (nci-ctcae v4.03)', 'phase 1 and phase 2: occurrence and severity of treatment emergent adverse events (teaes), aes of special interest, and treatment-related aes, according to the nci-ctcae version 4.03', 'phase 1 and phase 2: incidence of laboratory abnormalities as graded by national cancer institute common terminology criteria for adverse events (nci-ctcae) version 4.03', 'adverse events according to nci ctcae v. 3.0', 'number of subjects with adverse events as a measure of safety and tolerability', 'to assess the safety and tolerability of cn1 in patients with advanced solid tumor or b-cell lymphoma through adverse events/serious adverse events', 'incidence of treatment-emergent adverse events as a measure of safety', 'phase ib: percentage of participants with adverse events (aes)', 'arm g+h (phase ii nf cohort): percentage of participants with aes', 'phase ii: percentage of participants with aes', 'phase 1: safety and tolerability as assessed by adverse events and changes in clinical and laboratory assessments', 'phase 2: number of treatment-emergent adverse events', 'number, frequency and type of adverse events', 'part 1: safety: subject incidence of treatment emergent adverse events, dose limiting toxicities, the severity of adverse events and clinically significant changes in safety laboratory tests, physical examinations, or vital signs.', 'number of participants reporting one or more treatment emergent adverse events (teaes) and serious adverse events (saes)', 'number of participants with teaes related to investigations system organ class for laboratory values', 'number of participants with teaes related to vital signs', 'number of participants with treatment-emergent adverse events and serious adverse events', 'number of participants with clinically significant changes or abnormalities in clinical laboratory values reported as aes', 'number of participants with grade 3-5 adverse events', 'frequency of grade 3 or higher treatment-related adverse events by ctcae 4.03', 'percentage of participants with adverse events and serious adverse events', 'incidence of non-serious adverse events as a measure of safety and tolerability, phase ii', 'number of participants with treatment-emergent adverse events (teaes) or treatment-emergent serious adverse events (tesaes)', 'number of participants with treatment-emergent adverse events (teaes) related to clinical laboratory abnormalities', 'number of participants with treatment-emergent adverse events (teaes) related to vital signs, physical findings abnormalities', 'safety: adverse events, vital signs, clinical and laboratory parameters, physical exams, and ecgs', 'number of patients with treatment-related adverse events (aes) and serious aes (saes)', 'number of patients with adverse events as a measure of safety and tolerability', 'safety and tolerability of ⁸⁹zr-df-iab22m2c assessed by local and systemic signs and symptoms of infusion reactions,incidence of adverse events,changes in laboratory test results,dose limiting toxicities,vital signs and 12-lead electrocardiogram findings', 'safety, tolerability,and dose limiting toxicities will be determined using aes,pe,ophthalmologic examinations,clinical laboratory tests,vital signs, ecgs and echocardiograms/muga scans.', 'number of participants with adverse events (e.g. toxicity)', 'mtd of carfilzomib, determined by incidence of dose-limiting toxicity (dlt) as assessed by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0', 'incidence of grade 3 or greater adverse events summarized using the nci ctcae version 4.0', 'incidence of adverse events (aes)', 'phase 1 and 2: percentage of participants experiencing adverse events (aes)', 'phase i of the study: to analyze the adverse events of lr-eshap (frequency and severity of the adverse events)', 'phase ii of the study: to analyze the adverse events of lr-eshap and asct. (frequency and severity of the adverse events)', 'number of participants with dose-limiting toxicity (dlt) in accordance with national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 3.0 as determined by the efficacy and safety evaluation committee (esec)', 'participants with treatment-emergent adverse events (teaes) associated with romidepsin', 'mtd of pomalidomide when given in combination with dexamethasone determined by dose-limiting toxicities graded according to national cancer institute common terminology criteria for adverse events (nci ctcae) version 4.0', 'incidence of adverse events, graded according to ctcae 4.0', 'phase 1b: number of participants with treatment-emergent adverse events (teaes), serious teaes, and discontinuations due to teaes', 'phase 2: number of participants with teaes, serious teaes, and discontinuations due to teaes', 'number of participants with treatment-emergent adverse events (teaes) and serious adverse events (saes)', 'number of participants with adverse events in diffuse large b-cell lymphoma (dlbcl) population', 'number of participants with adverse events in non-dlbcl population', 'safety: percentage of participants with adverse events', 'incidence of treatment emergent adverse events (safety and tolerability)', 'number of participants with a grade 3 or higher toxicity graded according to national cancer institute common terminology criteria for adverse events version 4.0', 'adverse events by frequency, severity, and duration pharmacokinetics immunogenicity response duration time to progression', 'number of participants with adverse events (aes) and serious adverse events (saes) (phase 1)', 'number of participants with abnormal clinical laboratory values reported as aes (phase 1)', 'number of participants with clinically significant vital signs values reported as aes (phase 1)', 'number of participants with adverse events (aes) and serious adverse events (saes) (phase 1 and 2)', 'number of participants with abnormal clinical laboratory values reported as aes (phase 1 and 2)', 'number of participants with clinically significant vital signs reported as aes (phase 1 and 2)', 'incidence of related adverse events [safety and tolerability]', 'collection of adverse events', 'percentage of participants with adverse events', 'maximum tolerated dose of carfilzomib with hyper-cvad, defined as the dose that produces dose limiting toxicity in 17% or fewer (1/6) of patients, graded according to national cancer institute common terminology criteria for adverse events (nci ctcae) v4', 'changes in vital signs and the number adverse events', 'evaluate incidence and severity of aes, serious aes, trph-222-related aes, aes leading to death or discontinuation from treatment', 'tolerability of treatment as measured by number of participants with grade 3 or higher adverse events', 'incidence and nature of dose-limiting toxicities and adverse events of special interest', 'incidence, nature, and severity of all adverse events and serious adverse events', 'number of participants with treatment-emergent adverse events', 'incidence of adverse events requiring dose delay or discontinuation of ibrutinib', 'overall incidence of grade ≥3 adverse events (aes) per nci ctcae v4.0', 'overall incidence of serious adverse events (saes)', 'summary of adverse events (aes) and serious adverse events (saes)', 'treatment-related adverse events (all grades) with an overall incidence greater than or equal to 10%', 'percentage of participants experiencing treatment-emergent adverse events (teaes) and serious adverse events (saes) within 28 days of idelalisib exposure', 'percentage of participants experiencing teaes related to idelalisib within 28 days of idelalisib exposure', 'percentage of participants experiencing teaes and saes beyond 28 days of idelalisib exposure', 'percentage of participants experiencing teaes related to idelalisib beyond 28 days of idelalisib exposure', 'incidence of adverse events assessed using nci ctcae version 4', 'mtd defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity assessed using national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4', 'maximum tolerated dose (mtd) defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities dlt graded according to common terminology criteria for adverse events (ctcae) version 3.0', 'number of participants with serious and non-serious adverse events assessed by the common terminology criteria in adverse events (ctcae v3.0).', 'incidence of adverse events as graded by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (utilized for adverse event reporting beginning april 1, 2018)', 'safety and tolerability of asp3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ecgs) and clinical observations', 'adverse events graded according to national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0', 'adverse events described using the nci ctcae criteria', 'mtd of silicon phthalocyanine 4 defined as the dose immediately below the dose in which 2 or more of 6 patients experience a grade 4 toxicity assessed using national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0', 'incidence of all adverse events graded according to nci ctcae, v4.0', 'severity of all adverse events graded according to nci ctcae, v4.0', 'number of patients who experienced adverse events', 'number of subjects with study related adverse events.', 'number of participants with adverse events, injection site reactions, and concomitant medications', 'incidence of serious adverse events', 'number of participants with treatment-emergent adverse events (teaes) and treatment-emergent serious adverse events (tesaes)', 'number of participants with electrocardiogram (ecg) abnormalities recorded as treatment-emergent adverse events (teaes)', 'number of capillary leak syndrome (cls) participants with weight changes, albumin, hypotension, edema, hypoxia, and pulmonary adverse events (aes)', 'number of participants with clinically significant laboratory tests reported as adverse events [phase 1]', 'number of participants with treatment-emergent adverse events [phase 1]', 'number of participants with treatment-emergent adverse events [phase 2]', 'number of participants with clinically significant laboratory tests reported as adverse events [phase 2]', 'adverse events in terms of dose-limiting toxicity (dlt) and mtd of bendamustine hydrochloride (phase i)', 'number of participants with serious adverse events', 'number of subjects with serious and non-serious adverse events', 'the number of adverse events, serious adverse events, and dose limiting toxicities as a measure of safety and tolerability', 'frequency and severity of clinical adverse events', 'number of participants with serious and non-serious adverse events assessed by the common terminology criteria in adverse events (ctcae v4.0)', 'number of participants with treatment emergent adverse events categorized by severity', 'number of participants with treatment-related treatment emergent adverse events', 'phase 1: percentage of participants who experienced adverse events (aes) from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy', 'phase 1: percentage of participants who experienced serious adverse events (saes) from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy', 'phase 2: percentage of participants who experienced aes from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy', 'phase 2: percentage of participants who experienced saes from the first dose of protocol therapy through 30 days after administration of the last dose of protocol therapy', 'phase 1: number of ata positive and ata negative participants with aes and saes', 'phase 2: number of ata positive and ata negative participants with aes and saes', 'assessment of the number of events and number and percentage of patients with treatment-emergent aes', 'safety analysis - number of participants with serious adverse events', 'safety analysis - number of participants with adverse events leading to discontinuation', 'safety analysis - number of participants with adverse events leading to dose delay or reduction', 'safety analysis - number of participants with drug related adverse events', 'number of patients who experienced serious aes', 'number of patients who experienced non-serious aes', 'safety and tolerability of cobomarsen based on vital signs, physical examination, clinical laboratory tests, ecg, and incidence and severity of adverse events', 'number of participants with treatment-emergent adverse events (teaes)', 'establish the recommended phase 2 dose (rp2d) for the nhl and all indications according to the observed adverse events, including potential dose-limiting toxicities (dlt).', 'the incidence of dose-limiting toxicities and the severity of adverse events', 'incidence of proarrhythmic adverse events', 'number of participants with treatment-emergent adverse events (aes) and serious adverse events (saes) in portion a', 'number of participants with treatment-emergent aes by maximum national cancer institute common terminology criteria for adverse event (nci ctcae) grade in portion a', 'number of participants with treatment-emergent aes and saes in portion b', 'number of participants with treatment-emergent aes by maximum nci ctcae grade in portion b', 'number of participants with adverse events graded according to common toxicity criteria (ctc) (phase i)', 'number of participants with adverse events graded according to ctc (phase ii)', 'number of patients with treatment-emergent adverse events', 'intensity of adverse events (aes)', 'percentage of participant experiencing adverse events (aes) for each treatment arm as assessed by common terminology criteria for adverse events version 4.0 (ctcae v4.0) (phase ii)', 'recommended phase ii dose of vorinostat determined according to dose-limiting toxicities graded using common terminology criteria for adverse events version 4.0 (ctcae v4.0) (phase i)', 'number of patients with aes and saes', 'documenting adverse events (aes), serious adverse events (saes), dose limiting toxicities (dlts) (graded according to nci-ctcae version 4.02) and laboratory parameters and determining their causality in relation to bi-1206.', 'documenting aes, saes (graded according to nci-ctcae version 4.02) and laboratory parameters and determining their causality in relation to bi-1206 and, where appropriate, anti-cd20 antibody.', 'number of subjects with adverse events as assessed by ctcae 4.03', 'mtd of alisertib defined as the highest dose tested in which less than 33% of patients experienced dose-limiting toxicity (dlt) graded according to the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version (v.)4.0', 'summary of participants with treatment emergent adverse events (teaes)', 'toxicity as assessed by number of participants experiencing adverse events grade 3 or higher as defined by ctcae v2.0', 'frequency and severity of adverse events', 'mtd, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (dlt) graded according to the revised national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0', 'number of participants and severity of aes', 'number of adverse events (aes)', 'incidence of adverse events/ serious adverse events', 'incidence of aes/saes', 'number of patients with serious adverse events', 'frequency and severity of adverse events graded according to ctcae v4.0', 'phase i : number of participants with treatment-related adverse events as assessed by ctcae v4.03', 'phase ii : number of participants with treatment-related adverse events as assessed by ctcae v4.03', 'number of adverse events after car 20/19-t cell infusion', 'number of participants with teaes and saes', 'frequency of adverse events for entinostat', 'number of participants with treatment emergent adverse events (aes)', 'occurrence of adverse events (aes)', 'occurrence of serious adverse events (saes)', 'occurrence of study related adverse events', 'number of grade 1-4 treatment related adverse events', 'number of participants who discontinued study therapy due to aes', 'safety and tolerability of cb-839: incidence of adverse events', 'adverse events (aes) and changes in laboratory values and vital signs. pharmacokinetic parameter values for gsk2126458, change from baseline in protein markers in tumor and/or blood. blood glucose and insulin levels. tumor response, recist defined', 'number of participants with serious adverse events possibly, probably, and/or definitely related to subcutaneous (s.c. rhil-15) by grade who have refractory or relapsed chronic and acute adult t-cell leukemia (atl)cancer', 'dose-escalation and recommended phase 2 dose (rp2d) cohort: number of participants with treatment emergent adverse events (teaes) and serious adverse events (saes)', 'adverse events according to nci ctcae v.4.0', 'safety and tolerability of urelumab in combination with rituximab as measured by incidence of adverse events (aes), serious aes, death, vital sign changes, electrocardiograms (ecgs), physical examination results, and laboratory test abnormalities', 'an evaluation of general safety will be undertaken: · number of systemic clinical and biological adverse events occurring during the study. · number of patients who prematurely discontinued study treatment for reasons linked to the general safety.', 'tolerability of tacrolimus as assessed by percentage of participants with treatment-emergent adverse events', 'number of participants with one or more drug (or procedure)-related adverse events (aes) or any serious aes', 'number of participants reporting adverse events (ae)', 'number of participants discontinuing due to aes', 'number of participants who experienced one or more adverse events (aes):', 'occurrence of drug-related grade 3 or 4 systemic or local adverse events (defined using the nci ctcae version 3.0)', 'treatment-emergent adverse events', 'characterize the adverse events associated with cdx-1127 administration', 'subjects with treatment emergent adverse events', 'number of adverse events possibly caused by α-tea', 'analysis of adverse events', 'mtd of everolimus, defined as the dose that produces dose-limiting toxicity (dlt) in =< 1/6 patients, determined by incidence of dlt graded according to the national cancer institute common terminology criteria for adverse events (ctcae) version 4.0', 'incidence and severity of adverse events as defined by the nci ctcae version 4.03', 'number of participants with treatment-emergent adverse events (teaes) (all causality)', 'number of participants with teaes (treatment-related)', 'number of participants with treatment-emergent adverse events (teaes) (all causality) by severity (by maximum common terminology criteria for adverse events [ctcae] grade)', 'number of participants with teaes (treatment-related) by severity (by maximum ctcae grade)', 'number of patients with adverse events as a measure of tolerability', 'incidence and nature of adverse events (aes)', 'adverse events and other safety assessments', 'comparison of daily versus twice daily dosing: incidence of adverse events', 'mtd of lenalidomide after allogeneic hematopoietic stem cell transplantation graded according to the national cancer institute common terminology criteria for adverse events (nci ctcae) v4.0', 'phase 1 study: percentage of participants experiencing adverse events defined as dose limiting toxicities (dlts) of chidamide.', 'number of participants with treatment-related adverse events as assessed by ctcae v5.0.', 'number of participants having treatment-emergent adverse events', 'number of participants with adverse events as a measure of dose limiting toxicities of the combination of methoxyamine and fludarabine', 'incidence, severity and relationship of treatment-emergent adverse events', 'safety, as measured by vital signs, clinical laboratory tests,ecog performance status, physical exams, 12 lead ecgs incidence and severity of adverse events', 'number of participant with adverse events (ae)', 'maximum tolerated dose (mtd) of ipilimumab according to the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (phase i)', 'maximum tolerated dose (mtd) of nivolumab according to the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (phase i)', 'incidence of adverse events as assessed by national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 5.0 (phase ib)', 'number of participants with treatment-related adverse events and/or toxicity as assessed by ctcae 4.03.', 'number of subjects with treatment-emergent adverse events (teaes)', 'incidence of adverse events after pcar-19b infusion [safety and tolerability]', 'number of participants who experience treatment-emergent adverse events (teaes)', 'number of participants who experience serious treatment-emergent adverse events', 'number of participants who experience treatment-related treatment-emergent adverse events', 'number of participants who experience adverse events of interest (eoi)', 'incidence and severity of adverse events as a measure of safety and tolerability', 'the number of participants with adverse events as a measure of safety and feasibility', 'safety as evaluated by adverse events (incidence, severity, duration, causality, seriousness, type)', 'to determine the safety and tolerability of carfilzomib by evaluating the number of participants with adverse events as a measure of safety and tolerability.', 'overall toxicity profile documented by incidence of aes, saes, and/or dlts', 'number of participants with serious adverse events (saes) and common (>=5%) non-serious adverse events- part 1', 'number of participants with saes and common (>=5%) non-serious adverse events- part 2 (mm)', 'number of participants with saes and common (>=5%) non-serious adverse events- part 2 (nhl)', 'expansion cohort: number of participants with treatment-emergent adverse events (teaes) and treatment-related teaes', 'phase 1b and phase 2: number of participants with teaes', 'occurrence of adverse events grade 4 or grade 5 as assessed by ctcaev4', 'the maximum tolerated dose (mtd) and/or recommended phase 2 dose (rp2d) of epz-5676 as determined by incidence of protocol-specified dose-limiting adverse events.', 'the incidence of adverse events in patients treated with epz-5676', 'summary of participants reporting adverse events', 'incidence of dlt, defined as recurring grade 2 or greater non-hematological or grade 3 or greater hematological toxicities or skin rash graded using common terminology criteria for adverse events version 3.0 (ctcae-v3)', 'rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the nci common terminology criteria for adverse events (ctcae v.4.03) (scale 1 to 5)', 'phase 1, part 1 and 2: safety assessed by the frequency of adverse events, serious adverse events, and deaths', 'phase 2: safety and tolerability measured by the frequency of adverse events (aes), serious adverse events (saes), and deaths', 'summary of participants with adverse events (aes) in phase 1', 'summary of participants with adverse events (aes) in phase 2', 'phase 1: percentage of participants with treatment-emergent adverse events (teae) and serious treatment-emergent adverse events', 'phase 2: percentage of participants with treatment-emergent adverse events (teae) and serious treatment-emergent adverse events', 'number of participants with treatment-related adverse events as assessed by ctcae v4.03', 'adverse events as graded by nci common terminology criteria for adverse events (ctcae) v4.', 'incidence of treatment emergent adverse events (teaes)', 'incidence of any grade 3 or higher dose limiting toxicity graded (dlt) according to common terminology criteria for adverse events version 4.0', 'grade 3 adverse events after decitabine', 'safety and tolerability expressed by any grade adverse events (aes)', 'safety as determined by the number of participants with treatment-related adverse events', 'to determine the number of participants with adverse events as a measure of safety and tolerability', 'determine the safety profile (adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of abt-348 as monotherapy or in combination', 'adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements', 'maximum tolerated dose of vorinostat when given in combination with fludarabine phosphate, clofarabine, and busulfan before stem cell transplant assessed using common terminology criteria for adverse events version 4', 'safety data, including laboratory parameters and adverse events, will be collected for all patients in order to determine the qualitative and quantitative toxicity, and reversibility of toxicity, of on 01910.na.', 'number of participants with adverse events (aes), serious adverse events (saes), deaths, and discontinuation', 'number of participants with adverse events (aes), serious adverse events (saes), and aes leading to discontinuation', 'incidence and severity of adverse events graded according to the national cancer institute common terminology criteria for adverse events version 4.0 (phase ii)', 'number of patients with treatment-related adverse events', 'number of participants with adverse events and serious adverse events to evaluate long term safety', 'part 1 : number of participants experiencing adverse events', 'part 2: number of participants experiencing adverse events', 'incidence and nature of adverse events', 'phase ii: adverse events as a measure of safety'], 'OS': ['OS', 'overall response rate, cr rate, overall survival, pfs, and duration of response', 'overall survival', 'overall survival  in the study', 'overall-survival', 'kaplan-meier estimate of the overall survival  in the de cohorts', 'median overall survival at 1 year', 'evaluate response rates of infusions and compare relapse rates and overall survival to historical controls', 'evaluate preliminary data regarding overall survival and duration of overall response when abt-199 is administered in combination with bendamustine and rituximab.', 'dose escalation and dose expansion: overall survival', 'overall survival - part 1 and part 2', 'overall survival  rate in the cll, dlbcl, inhl, mcl, ptld cohorts', 'efficacy-overall survival', 'estimate progression free survival, clinical response rates to treatment, and overall survival to determine efficacy.', 'phase 1 and phase 2: overall survival  time', 'phase ii nf cohorts: overall survival', 'phase 2: efficacy as assessed by overall survival (os)', 'part 2: overall survival .', 'kaplan-meier estimates of overall survival', 'overall survival  rate at 2 years', 'progression free survival  and overall survival  as a measure of efficacy', 'progression-free survival , and overall survival', 'phase 1 and 2: overall survival', 'phase ii of the study: analyze effectiveness (complete remission (cr) rate (determined by positron emission tomography [pet]/ct), event-free survival (efs) and overall survival (os)', 'phase 2: overall survival', 'assess additional measures of anti-tumor activity, including duration of response, progression free survival, overall survival and time to response', 'evaluate overall survival (os)', 'overall survival (os)', 'disease outcome, time to progression, and overall survival at 2 years from start of therapy measured by clinical examination and serial mri scanning', 'the effect of tazemetostat monotherapy on overall survival (cohorts 4 and 5 only)', 'all phase i-ii participants: overall survival', 'all phase i participants: overall survival', 'overall survival  of patients with t-cell lymphoma on study', 'phase ii = overall survival', 'mean overall survival', 'rate of overall survival', 'recommended phase 2 dose  cohort: overall survival', 'part b, c, d, e and f: overall survival', 'number of overall survivals', 'overall survival  within one year', 'overall survival  and disease-free survival', 'antitumor activity of azd4573 in patients by assessing overall survival (os).', 'overall survival  time: phase ii', 'to evaluate overall survival.', 'overall survival  time', 'median overall survival  as estimated using the kaplan-meier method', 'to determine the time to response, remission duration, progression-free survival, event-free survival and overall survival of patients treated with carfilzomib.', 'efficacy as documented by complete remission (cr), time and duration of remission, event-free survival (efs), 4-month efs, disease-free survival (dfs), and overall survival', 'phase 2: overall survival  for subjects with glioblatoma', 'kaplan meier estimates of overall survival  for participants in phase 1', 'kaplan meier estimates of overall survival  for participants in phase 2', 'to determine the event-free, disease-free and overall survival of the conditioning regimen of clofarabine, ara-c and tbi followed by allosct in children with all and aml.', 'cp-cml and advanced phase participants: overall survival', 'part 1 and part 2: overall survival'], 'Cmax': ['Cmax', 'Tmax', 'maximum observed plasma concentration  under steady state of mil62', 'maximum observed plasma concentration  of duvelisib', 'time to maximum observed concentration  of duvelisib', 'maximum concentration', 'time at which maximum concentration', 'part i and part ii: maximum plasma concentration  for single-dose zanubrutinib', 'part i and part ii: time to maximum plasma concentration  for single-dose zanubrutinib', 'atezolizumab maximum serum concentration', 'obinutuzumab maximum serum concentration', 'peak plasma concentration', 'maximum measured concentration of bi 695500 and rituximab  in plasma  following dose 1', 'maximum measured concentration of rituximab  and bi 695500 in plasma  following dose 4', 'maximum blood concentration  of i 131 tst for the indicated antibody predose levels', 'time of cmax', 'maximum plasma concentration  of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib', 'time of maximum plasma concentration  of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib', 'maximum observed plasma concentration', 'time to reach maximum observed plasma concentration', 'part i: maximum drug concentration', 'part i: time at which cmax occurs', 'maximum serum concentration  of the cd20-cd3 bispecific antibody', 'pharmacokinetic parameter: maximum observed plasma concentration  measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.', 'pharmacokinetic parameter: time of maximum observed plasma concentration  at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.', 'pharmacokinetics: maximum concentration', 'pharmacokinetics: time to maximum concentration', 'maximum serum concentration  of denileukin diftitox', 'time to cmax  of denileukin diftitox in serum', 'maximum observed plasma concentration  of jnj-42756493', 'time to reach maximum observed plasma concentration  of jnj-42756493', 'maximum observed plasma concentration  gdc-0575', 'time to reach maximum observed plasma concentration  of gdc-0575', 'tmax: time to reach the maximum plasma concentration  for e7766', 'maximum plasma concentration  of apg-115 on day 1-3 and day 21-23 post apg-115 treatment on cycle 1', 'maximum plasma concentration', 'maximum observed serum concentration  for camidanlumab tesirine', 'time to reach the maximum serum concentration  for camidanlumab tesirine', 'maximum concentration  of ro6870810 and its potential metabolites- part 1 and part 2', 'pharmacokinetic indexes, cmax maximum concentration', 'tmax: time to reach maximum plasma concentration  of tazemetostat and its metabolite er-897387', 'tss,max: time to reach the maximum plasma concentration  at steady state of tazemetostat and its metabolite er-897387', 'rac : accumulation ratio of cmax for tazemetostat and its metabolite er-897387', 'maximum observed serum concentration  for dcds0780a total antibody', 'maximum observed plasma concentration  for acmmae', 'maximum observed plasma concentration  for unconjugated mmae', 'pharmacokinetics  of a single-dose belinostat ) according to degree of liver dysfunction: maximum plasma concentrations', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: metabolic ratios of maximum plasma concentrations  for the belinostat metabolic pathway', 'maximum concentration  values', 'parts 1 and 2: ulevostinag maximum plasma concentration', 'summary of milademetan pk parameter maximum plasma concentration', 'summary of milademetan pk parameter time to reach maximum plasma concentration', 'pharmacokinetics of obinutuzumab: maximum observed plasma concentration  - relapsed/refractory population', 'mk-2118 maximum plasma concentration', 'tmax: time to reach the maximum plasma concentration  for tak-659', 'pk-time to maximum plasma concentration', 'pk-maximum concentration in plasma', 'tmax: time to reach the maximum plasma concentration  for tak-659 and venetoclax', 'time of maximum observed serum concentration  of urelumab', 'maximum concentration  of asp4132', 'time of the maximum concentration  of asp4132', 'tmax: time to reach the maximum plasma concentration  for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a', 'time to reach maximum concentration', 'tmax: time to reach the maximum plasma concentration  for ixazomib', 'phase i: maximum observed concentration  of gdc-0032', 'pharmacokinetics: maximum concentration  of gdc-0853', 'maximum observed concentration  of amg 562', 'time of maximum concentration', 'determination of peak concentration  of abt-199 and/or rituximab.', 'determination of plasma peak concentration  of abt-199', 'time to maximal plasma concentration  when plerixafor is combined with rituximab', 'maximum observed serum concentration  for moxetumomab pasudotox', 'time to maximum plasma concentration', 'peak concentration', 'mk-8776 maximum plasma concentration', 'time of mk-8776 cmax', 'maximum plasma concentration -polatuzumab vedotin monotherapy', 'medi4736 maximum plasma concentration', 'tremelimumab maximum plasma concentration', 'azd9150 maximum plasma concentration', 'to assess pharmacokinetics  of fimepinostat when administered in combination with anti-cancer regimens as measured by maximum plasma concentration .', 'to assess pk of venetoclax when administered in combination with fimepinostat as measured by maximum plasma concentration .', 'phase 1 and phase 2: maximum observed plasma concentration  of single and multiple dose of avelumab', 'pharmacokinetics of bms-906024 and its metabolite bms-911557: maximum observed concentration', 'pharmacokinetics of bms-906024 and its metabolite bms-911557: time to reach maximum observed concentration', 'part a: tmax: time to reach the maximum observed plasma concentration  for ixazomib', 'part a: tmax: time to reach the maximum observed whole blood concentration  for tra', 'phamacokinetics: mean maximum observed plasma concentration  for ibrutinib', 'pharmacokinetics: mean time to maximum observed plasma concentration  for ibrutinib', 'pharmacokinetics: mean peak plasma concentration  for medi4736', 'tmax: time to reach the maximum plasma concentration  for alisertib in presence and absence of esomeprazole', 'tmax: time to reach the maximum plasma concentration  for alisertib in presence and absence of rifampin', 'peak serum concentration  of inotuzumab ozogamicin in participants receving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time to reach maximum concentration  of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'peak serum concentration  of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time of observed maximum concentration  of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin + rituximab on dosing day 1, day 30 and day 58', 'peak concentration  of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time to reach maximum concentration  of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'determine peak plasma concentration  after oral administration of [14c] tazemetostat', 'maximum plasma concentration  of ocrelizumab', 'maximum plasma concentration  of romidepsin in phase 1', 'time to maximum plasma concentration of romidepsin  in phase 1', 'tmax: time to reach the maximum plasma concentration  for eribulin mesylate', 'maximum concentration  of polatuzumab vedotin', 'venetoclax plasma pk: time to maximum observed plasma concentration', 'venetoclax plasma pk: maximum observed plasma concentration', 'maximum observed serum concentration  for adct-402', 'time to reach the maximum serum concentration  for adct-402', 'maximum observed plasma concentration  of durvalumab', 'time to maximum plasma concentration  of durvalumab', 'maximum observed plasma concentration  of lenalidomide', 'time to maximum observed plasma concentration  of lenalidomide', 'maximum observed plasma concentration  of ibrutinib', 'time to maximum observed plasma concentration  of ibrutinib', 'maximum plasma concentration  of lenvatinib', 'time to maximum plasma concentration  of lenvatinib', 'effect of food on the maximum plasma concentration  of lenvatinib', 'effect of food on time to maximum concentration  of lenvatinib', 'time to cmax', 'characterization of pk  of sb-743921 administered as a 1-hour intravenous infusion on day1', 'the maximum concentration  of the hlx01 and rituximab', 'maximum plasma concentration  of moxetumomab pasudotox', 'part 1 and part 2: maximum observed plasma concentration', 'maximum observed serum concentration  of obinutuzumab on day 1, cycle 1', 'time to maximum observed serum concentration  of obinutuzumab at cycle 8', 'tmax: time to reach the maximum observed plasma concentration  for brigatinib at cycle 1 day 1', 'tmax: time to reach the maximum observed plasma concentration  for brigatinib at cycle 2 day 1', 'maximum observed plasma concentration  on day 1: single dose', 'maximum observed plasma concentration  on day 8: multiple dose', 'maximum observed plasma concentration  on day 14/21 dose-corrected to 125 mg: multiple dose', 'maximum observed plasma concentration  on day 1: food effect', 'time to reach maximum observed plasma concentration  on day 1: single dose', 'time to reach maximum observed plasma concentration  on day 8: multiple dose', 'time to reach maximum observed plasma concentration  on day 14/21 dose-corrected to 125 mg: multiple dose', 'time to reach maximum observed plasma concentration  on day 1: food effect', 'pharmacokinetics: maximum plasma concentration  of s-warfarin and r-warfarin', 'pharmacokinetics: time of maximal plasma concentration  of s-warfarin and r-warfarin', 'pharmacokinetics: maximum observed drug concentration  at steady state of enzastaurin, its principle metabolites and total analyte', 'pharmacokinetics: time of maximal plasma concentration  of enzastaurin, its principle metabolites and total analyte', 'phase 1: median time to reach cmax  of brentuximab vedotin and tab in serum', 'phase 1: median time to reach cmax  of mmae in plasma', 'peak plasma concentration  of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously', 'maximum observed plasma concentration  of cc-223', 'time to maximum concentration  of cc-223', 'maximum observed concentration  of metabolite m1', 'time to maximum concentration  of metabolite m1', 'maximum observed plasma concentration  after a single dose of enasidenib on day -3', 'time of maximum plasma concentration  of enasidenib after a single dose on day -3', 'maximum observed plasma concentration  of metabolite agi-16903 after a single dose of enasidenib on day -3', 'time of maximum plasma concentration  of metabolite agi-16903 after a single dose of enasidenib on day -3', 'maximum observed plasma concentration  of enasidenib after multiple doses', 'time of maximum plasma concentration  of enasidenib after multiple doses', 'maximum observed plasma concentration  of metabolite agi-16903 after multiple doses of enasidenib', 'time of maximum plasma concentration  of metabolite agi-16903 after multiple doses of enasidenib', 'pf-05082566 maximum observed serum concentration  in portion a', 'pf-05082566 time for maximum observed serum concentration  in portion a', 'measurement of pk parameter maximum observed serum concentration  for bi-1206', 'maximum observed plasma concentration of romidepsin', 'time to maximum observed plasma concentration', 'pharmacokinetics of azacitidine combined with phenylbutyrate as measured by maximal plasma concentration', 'maximum observed plasma concentration of carfilzomib', 'time to maximum observed plasma concentration  of carfilzomib', 'pharmacokinetics : maximum plasma concentration  of abemaciclib', 'maximum plasma concentration  of obinutuzumab in nhl participants', 'pharmacokinetics : maximum  plasma concentration  of pevonedistat', 'pharmacokinetics : single-dose time to reach maximum  concentration  of pevonedistat', 'maximum concentration  of mk-8628/otx015', 'time to maximum concentration  of mk-8628/otx015', 'dose-escalation and recommended phase 2 dose  cohort: maximum observed plasma concentration  of crizotinib on day -7', 'dose-escalation and recommended phase 2 dose  cohort: maximum observed plasma concentration  of crizotinib on cycle 1 day 1', 'dose-escalation and recommended phase 2 dose  cohort: maximum observed plasma concentration  of crizotinib on cycle 1 day 15', 'dose-escalation and recommended phase 2 dose  cohort: maximum observed plasma concentration  of crizotinib on cycle 2 day 1', 'dose-escalation and recommended phase 2 dose  cohort: time to reach maximum observed plasma concentration  of crizotinib on day -7', 'dose-escalation and recommended phase 2 dose  cohort: time to reach maximum observed plasma concentration  of crizotinib on cycle 1 day 1', 'dose-escalation and recommended phase 2 dose  cohort: time to reach maximum observed plasma concentration  of crizotinib on cycle 1 day 15', 'dose-escalation and recommended phase 2 dose  cohort: time to reach maximum observed plasma concentration  of crizotinib cycle 2 day 1', 'midazolam interaction cohort: maximum observed plasma concentration  of midazolam when taken alone or taken with crizotinib', 'rp2d cohort: maximum observed plasma concentration  of crizotinib when taken with food', 'rifampin cohort: maximum observed plasma concentration  of crizotinib alone and when taken with rifampin', 'itraconazole cohort: maximum observed plasma concentration  of crizotinib when taken alone and when taken with itraconazole', 'maximum observed serum concentration  of urelumab and rituximab', 'pharmacokinetics : maximum concentration  of ly2875358, erlotinib and gefitinib', 'pharmacokinetics: maximum concentration  of ly3039478', 'pharmacokinetics: time to maximum concentration  of ly3039478', 'time to maximum observed plasma concentration of carfilzomib', 'maximum concentration  of ridaforolimus', 'maximum plasma concentration of azacitidine', 'time to maximum plasma concentration of azacitidine', 'maximum plasma concentration of azacitidine  after single and multiple doses of azacitidine', 'time to maximum plasma concentration of azacitidine  after single and multiple doses of azacitidine', 'maximum observed serum concentration  after a single dose on cycle 1 day 1', 'time to reach cmax  after a single dose on cycle 1 day 1', 'time to reach cmax  after multiple dose on cycle 1 day 21', 'maximum observed concentration  of plx2853.', 'time to peak concentration  of plx2853.', 'to determine the maximum observed plasma concentration  of prt543', 'to determine the time to reach maximum observed plasma concentration  of prt543', 'maximum observed plasma concentration  after single dose of alectinib: phase i', 'maximum observed plasma concentration  of alectinib', 'time to cmax  of alectinib', 'time to maximum plasma concentration  of venetoclax', 'maximum plasma concentration  of venetoclax', 'maximum observed concentration  of amg 404', 'time to maximum observed concentration  of amg 404', 'pharmacokinetics as measured by maximum drug serum concentration', 'pharmacokinetics as measured by time to maximum serum concentration', 'maximum observed concentration  of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1', 'time to reach maximum observed concentration  of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1', 'pharmacokinetics : maximum concentration  of merestinib and its metabolites', 'maximum observed plasma concentration  of abbv-075', 'pharmacokinetics of asp3026 by assessment of area under the curve over the time  and maximum concentration  in plasma and urine', 'pharmacokintetics : maximum plasma concentration', 'maximum plasma concentration  of selinexor', 'time to reach maximum observed plasma concentration  of ibrutinib', 'maximum observed plasma concentration  of selinexor', 'time to maximum observed concentration  of selinexor', 'maximum observed serum concentration  of abbv-621', 'maximum observed serum concentration  of venetoclax', 'time to cmax  of abbv-621', 'time to cmax  of venetoclax', 'bms-986016 maximum observed serum concentration', 'bms-986016 time of maximum observed serum concentration', 'maximum serum concentration  of sorafenib', 'pk - maximum observed plasma concentraion', 'part 1: maximum plasma concentration  of zanubrutinib', 'part 1: time to maximum plasma concentration  of zanubrutinib', 'pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : maximum observed concentration', 'pharmacokinetic parameter for monomethyl auristatin e : time to maximum concentration'], 'AUC': ['AUC', 'area under the plasma concentration versus time curve  of mil62 under steady state', 'area under the plasma concentration-time curve  of duvelisib', 'the area under the curve  of plasma concentration of drug', 'area under the curve  for gb241 and rituximab concentrations', 'area under the plasma concentration versus time curve', 'area under the concentration time curve  of i 131 tst for the indicated antibody predose levels', 'area under the concentration versus time curve', 'area under the curve  of vorinostat after single oral dosing', 'area under the concentration-time curve  of the cd20-cd3 bispecific antibody', 'pharmacokinetic parameter: area under the plasma concentration-time curve  measurement at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.', 'determination of peak concentration , trough concentration  and/or area under the concentration versus time curve  of abt-199, bendamustine and rituximab in the dose escalation cohort', 'pharmacokinetics: area under the curve', 'area under the plasma concentration versus time curve  of apg-115 on day 1 -3 and day 21 - 23 post apg-115 treatment on cycle 1', 'area under curve', 'area under the curve  of ro6870810 and its potential metabolites- part 1 and part 2', 'rac : accumulation ratio of auc for tazemetostat and its metabolite er-897387', 'area under the serum concentration-time curve  for dcds0780a total antibody', 'area under the curve  at 0 to 120, 0 to 168, and 0 to infinity hours', 'area under the curve  at 0 to 120 hours', 'area under the curve  at 0 to 168 hours', 'summary of milademetan pk parameter area under the curve', 'area under the plasma concentration versus time curve  of sct400', 'pk-area under the plasma concentration time curve', 'area under the concentration-time curve in a dosing interval .', 'phase i: area under the concentration-time curve  from zero to infinity of gdc-0032', 'area under the concentration-time curve in a dosing interval', 'pharmacokinetics: area under the concentration-time curve  of gdc-0853', 'area under the concentration-time curve', 'determination of area under the concentration versus time curve  of abt-199 and/or rituximab', 'determination of area under the concentration versus time curve  of abt-199', 'to assess pharmacokinetics  of fimepinostat when administered in combination with anti-cancer regimens as measured by area under the concentration-time curve .', 'to assess pk of venetoclax when administered in combination with fimepinostat as measured by area under the concentration-time curve .', 'pharmacokinetics of bms-906024 and its metabolite bms-911557: area under the concentration-time curve', 'area under the concentration-time curve  of polatuzumab vedotin', 'venetoclax plasma pk: area under the plasma concentration-time curve', 'determination of maximum observed plasma concentration , time to cmax , terminal phase elimination rate constant , terminal phase elimination half-life , & area under the plasma concentration-time curve  of abt-199', 'area under the plasma concentration versus time curve .', 'area under the curve', 'to estimate the dose for a given oral formulation that would yield similar exposure [area under the curve ] to 75 mg/m2 of the subcutaneous formulation.', 'area under the curve  for hlx01 and rituximab concentrations', 'area under the concentration-time curve  from 0 to 24 hours post azd3965 dosing', 'area under the plasma concentration vs. time curve  of cobomarsen following single and repeat doses administered intratumorally, subcutaneously or intravenously', 'area under the plasma concentration-time curve  over the dosing interval', 'pharmacokinetics : area under the plasma concentration versus time curve  of abemaciclib', 'pharmacokinetics : area under the curve  of plasma concentration of pevonedistat', 'area under the plasma concentration-time curve  0-72 hours', 'pharmacokinetics: area under the curve  of cb-839 concentration in blood', 'pharmacokinetics : area under the concentration time curve  of ly2875358, erlotinib and gefitinib', 'area under the curve  of ak117 as monotherapy or in combination with ak104 for assessment of pharmacokinetics', 'area under the concentration-time curve  of plx2853.', 'area under the plasma concentration-time curve  of amg 404', 'pharmacokinetics as measured by area under the drug-concentration curve', 'pk: area under the concentration time curve  of merestinib and its metabolites', 'phrmacokinetics : area under the curve  versus time curve', 'area under the curve  of selinexor', 'area under the serum/plasma concentration time curve  of abbv-621', 'area under the serum/plasma concentration time curve  of venetoclax', 'area under the plasma concentration versus time curve  of sorafenib', 'part 1: area under the plasma concentration-time curve from time 0 to infinity time  of zanubrutinib'], 'Vss': ['Vss', 'volume of distribution under steady state  of mil62', 'volume of distribution at steady state  of i 131 tst for the indicated antibody predose levels', 'volume of distribution at steady state', 'apparent volume of distribution at steady-state  of jnj-42756493', 'volume of distribution under steady-state conditions  of dcds0780a total antibody', 'volume of distribution under steady-state conditions  of acmmae', 'volume of distribution under steady-state conditions  of unconjugated mmae', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: volume of distribution at steady state', 'pharmacokinetics of obinutuzumab: volume of distribution at steady state  - relapsed/refractory population', 'pharmacokinetics  of bendamustine', 'steady-state volume of distribution  of inotuzumab ozogamicin in serum in participants receiving inotuzumab mtd+rituximab 375 mg/m^2 on dosing day 30 and day 58', 'steady-state volume  of inotuzumab ozogamicin antibody distribution in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'steady state volume of distribution  of ocrelizumab', 'steady-state volume of distribution  of polatuzumab vedotin', 'volume of distribution at steady state  for adct-402', 'volume of distribution at steady state  of obinutuzumab at cycle 8', 'pf-05082566 volume of distribution at steady state  in portion a', 'measurement of pk parameter volume of distribution  for bi-1206', 'volume of distribution at steady state  of carfilzomib', 'volume of distribution at steady state  of ridaforolimus', 'volume of distribution at steady state  of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1', 'volume of distribution at steady state  of sorafenib', 'pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : volume of distribution at steady state'], 't1/2': ['t1/2', 'terminal plasma half-life  of mil62 under steady state', 'part i and part ii: apparent terminal half life  for single-dose zanubrutinib', 'terminal exponential half-life  of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib in plasma', 'plasma decay half-life', 'terminal elimination phase half-life', 'apparent terminal half-life  of gdc-0575', 'terminal elimination half-life', 'half-life  of ro6870810 and its potential metabolites- part 1 and part 2', 'half-life  of dcds0780a total antibody', 'half-life  of acmmae', 'half-life  of unconjugated mmae', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: half-life', 'terminal phase half-life', 'pharmacokinetics of obinutuzumab: plasma half-life  - relapsed/refractory population', 'phase i: half-life  of gdc-0032', 'half life', 'terminal phase elimination half life  for moxetumomab pasudotox', 'mk-8776 terminal phase half-life', 'phase 1 and phase 2: half life  of single and multiple dose of avelumab', 'serum decay half-life  of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'serum decay half-life  of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab on dosing day 30 and day 58', 'terminal half-life  of medi551', 'terminal half-life  of medi0680', 'pharmacokinetics-pharmacokinetic parameters of kw-0761', 'determine the plasma terminal half-life  after oral administration of [14c] tazemetostat', 'terminal elimination half-life  of ocrelizumab', 'terminal half-life  of polatuzumab vedotin', 'apparent plasma half-life  of lenvatinib', 'elimination half-lfe .', 'elimination half life  of moxetumomab pasudotox', 'part 1 and 2: half-life associated with terminal slope  of a semi-logarithmic concentrationtime curve', 'apparent terminal half-life', 'estimate of the terminal elimination half-life in plasma', 'observed terminal elimination half-life', 'pharmacokinetics : terminal disposition phase half-life  of plasma concentration of pevonedistat', 'apparent terminal half-life  of mk-8628/otx015', 'dose-escalation and recommended phase 2 dose  cohort: plasma decay half-life  of crizotinib on day -7', 'apparent terminal half-life  of ridaforolimus', 'serum decay half-life  after multiple dose on cycle 1 day 21', 'half life  of plx2853.', 'steady-state elimination half-life', 'pharmacokinetics as measured by half life', 'terminal half-life  of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1', 'terminal phase elimination half-life  of abbv-621 in plasma', 'terminal phase elimination half-life  of venetoclax in plasma', 'pk - apparent terminal phase half-life', 'part 1: terminal elimination half-life  of zanubrutinib', 'pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : terminal or apparent terminal half-life'], 'PFS': ['PFS', 'progression-free survival', 'progression-free survival  in the study', 'progression free survival', 'part ii: progression free survival  of zanubrutinib in participants with fl and mzl', 'kaplan-meier estimate of the progression-free survival  in the de cohorts', 'progression free survival  according to lugano classification', 'median progression free survival', 'correlation between positron emission tomography  response and progression-free survival', 'progression free survival  of the combination of lenalidomide, with or without idelalisib', 'progression-free survival  as determined using recist v1.1', 'dose escalation and dose expansion: progression free survival', 'progression-free survival - part 1 and part 2', 'progression-free survival  assessed according to lugano classification', 'best overall response, duration of objective response, and progression-free survival  for patients with measurable disease according to recist', 'duration of response , time to progression  and progression-free survival  in the cll, dlbcl, inhl, mcl, ptld cohorts', 'efficacy: progression-free survival', 'efficacy-progression free survival', 'overall progression free survival', 'progression free survival  using recil 2017 response criteria for the anti-tumour activity of each therapy.', 'progression-free survival  at 12 and 24 months', 'dlbcl cohorts: progression free survival  based on pet-ct or ct only as determined by the investigator', 'phase 2: efficacy as assessed by progression-free survival', 'part 2: progression-free survival .', 'phase 1b/ 2: progression-free survival', 'kaplan-meier estimates of progression free survival', 'progression free survival  of phase i and phase ii participants', 'progression free survival  of previously treated and previously untreated participants', 'progression free survival  after treatment with afm 13', 'progression free survival  rate at 2 years', 'phase 1 and 2: progression-free survival', 'phase 2: progression free survival', 'evaluate progression-free survival', 'progress free survival', 'kaplan-meier estimate of progression-free survival', 'progression free survival  based on investigator assessment', 'antitumor activity of azd5153 in patients by assessing progression free survival .', 'progression free survival  [phase 2]', 'intracranial progression free survival', 'phase 2: progression-free survival', 'the effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on progression-free survival', 'part b: progression free survival  rate at 6 months for gbm participants', 'all phase i-ii participants: progression-free survival', 'phase i participants: progression-free survival', 'progression free-survival', 'progression free survival  of the combination in patients with t-cell lymphoma', 'progression free survival  of the study population', 'phase ii = progression free survival', 'mean progression free survival', 'progression-free survival  in phase ii of the study', 'progression free survival  at 12 months', 'phase 2a: median time to progression-free survival', 'recommended phase 2 dose  cohort: progression free survival', 'part b, c, d, e and f: progression free survival', 'progression-free survival  time', 'progression-free survival  for solid tumor participants', 'progression-free survival  according to recist v1.1 by irc: phase ii', 'progression free survival  as assessed by irc in safety population', 'progression-free survival  in participants with advanced or metastatic solid tumors', 'progression free survival  of patients with advanced malignancies treated with lipovnb', 'cp-cml and advanced phase participants: median progression-free survival', 'part 1 and part 2: progression-free survival', 'phase ii: progression free survival'], 'DOR': ['DOR', 'duration of response', 'part ii: duration of response  of zanubrutinib in participants with fl and mzl', 'duration of objective response  according to lugano classification', 'duration of objective response', 'dose expansion part: duration of response', 'duration of response  with rp6530', 'duration of overall response', 'efficacy-duration of response', 'duration of response  using recil 2017 response criteria for the anti-tumour activity of each therapy.', 'duration of remission', 'response duration', 'dlbcl cohorts: duration of response  based on pet-ct or ct only as determined by the investigator', 'phase 2: efficacy as assessed by duration of response', 'duration of complete response', 'duration of response  after treatment with afm 13', 'phase 1 and 2: duration of response', 'kaplan meier estimate of duration of response  for ptcl responders based on the modified 1999 iwc as assessed by the ier.', 'kaplan meier estimate of duration of response  for ptcl responders based on the modified 2007 iwc as assessed by the ier.', 'phase 2: duration of response', 'duration of response  [phase 2]', 'the effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on duration of response', 'duration of response  based on investigator assessment', 'duration of response  based on birc', 'duration of response  of the combination in patients with t-cell lymphoma', 'duration of response  of the study population.', 'mean duration of response', 'recommended phase 2 dose  cohort: duration of response', 'duration of response  according to recist v1.1 by investigator: phase i', 'duration of response  in participants with advanced or metastatic solid tumors', 'phase 1, part 2: duration of response  for subjects with advanced or metastatic scchn and advanced or metastatic nsclc', 'cp-cml and advanced phase participants: median duration of response', 'part 1 and part 2: duration of response'], 'EFS': ['EFS', 'participants with event-free survival', 'event-free survival', 'event-free survival - part 1 and part 2', 'event free survival', 'event-free survival  at 12 and 24 months', 'phase ii nf cohort: event-free survival  based on pet-ct or ct only, as determined by the investigator', 'phase 2: event-free survival', 'phase 2: event free survival', 'mean event-free survival', 'participants with event-free survival  in phase ii of the study', 'event-free survival  by morphological analysis', 'kaplan meier estimates of event-free survival  for participants in phase 1', 'kaplan meier estimates of event-free survival  for participants in phase 2'], 'DLT': ['DLTs', 'DLT', 'frequency of dose-limiting toxicities', 'dose limiting toxicities  during the first cycle', 'number of participants experiencing dose-limiting toxicities', 'safety as assessed by dose limiting toxicities', 'dose limiting toxicity', 'the occurrence of dose limiting toxicity', 'dose-limiting toxicity', 'percentage of participants with dose limiting toxicities', 'number of participants with dose limiting toxicities', 'phase ib- incidence of dose limiting toxicities  during the first cycle', 'dose timing part: incidence of dose limiting toxicities', 'part i: number of participants experiencing dose limiting toxicity', \"maximum tolerated dose  of hbi-8000 in adult japanese patients with non hodgkin's lymphoma  for whom no other standard therapy is suitable based on the frequency of dose-limiting toxicities  which occur within 28 days.\", 'percentage of participants with dose-limiting toxicities', 'subject grade of dose limiting toxicities', 'incidence of dose limiting toxicities', 'severity of dose limiting toxicities', 'maximum tolerated dose assessed by the number of subjects with dose-limiting toxicities', 'number of participants with dose-limiting toxicity', 'determination of the maximum tolerated dose  based on the occurrence of dose-limiting toxicity  in first cycle in caucasian patients', 'number of subjects with dose limiting toxicities  in first cycle in caucasian patients', 'determination of dose limiting toxicity', 'number of participants experiencing dose limiting toxicity  during combination treatment', 'dose escalation part: number of participants with dose-limiting toxicities', 'the number of patients with a dose-limiting toxicity  in the first treatment cycle', 'maximum tolerated dose  and dose limiting toxicity', 'number of participants who experienced dose-limiting toxicities', 'percentage of participants with dose-limiting toxiciities - part 1', 'number of participants with dose-limiting toxicities', 'number of participants experiencing dose limiting toxicities', 'dose limiting toxicities', 'incidence of dose limiting toxicities  - single agent', 'incidence of dose limiting toxicities  - combination agents', 'incidence of dose limiting toxicities  by nci ctcae v4.0 grade and associated dose of gdc-0349', 'occurrence of dose limiting toxicities', 'occurrence of dose-limiting toxicities', 'occurrence of dose-limiting toxicities  by nci ctcae grade and associated dose of gdc-0941', 'dose-limiting toxicities', 'percentage of participants with dose limiting toxicities  in cycle 1', 'number of participants with a dose limiting toxicity', 'safety: incidence of dose-limiting toxicities  of gdc-0853', 'incidence and nature of dose-limiting toxicities', 'incidence rate of dose limiting toxicities', 'number of participants experiencing a dose limiting toxicity', 'maximum tolerated dose  and dose-limiting toxicity', 'number of participants with and without dose limiting toxicities', 'number of participants with dose-limiting toxicities  during cycle 2 of study treatment', 'incidence of dose-limiting toxicities', 'dose limiting toxicity  rate', 'dose limiting toxicity  for phase i patients', 'dose limiting toxicities  of brentuximab vedotin and bendamustine', 'phase 1: number of participants experiencing dose-limiting toxicities', 'dose limiting toxicity rate', 'number of participants with dose limiting toxicities  in dlbcl population', 'safety: number of participants with dose-limiting toxicities', 'recommended dose of vorinostat for combination with gemcitabine/busulfan/melphalan  based on dose limiting toxicity', 'part 1: number of participants with dose limiting toxicities', 'incidence rate of dose limiting toxicities  occurring during first cycle of treatment', 'incidence of dose-limiting toxicity .', 'number of participants reporting a dose limiting toxicity', 'safety and tolerability of repeated ascending oral doses of 4sc-205. determination of the maximum tolerated dose  and dose-limiting toxicities .', 'to determine the dose-limiting toxicities  of mgd when administered once weekly to patients with relapsed or refractory cll/sll', 'number of participants with dose limiting toxicities  assessed in dose escalation phase of the study', 'number of dose-limiting toxicities  categorized as per the nature', 'safety analysis - number of participants with dose limiting toxicities  in the dlt evaluation phase', 'maximum tolerated dose of lenalidomide when given with obinutuzumab defined as the highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity', 'number of participants with dose-limiting toxicities  in first 2 cycles of portion a', 'number of patients with dose limiting toxicities', 'incidence of dose-limiting toxicity , phase i patients only', 'phase 1b: number of participants with dose-limiting toxicities', 'phase i: number of patients who experience a dose-limiting toxicity', 'dose-limiting toxicity  rates', 'mtd of lenalidomide when combined with alvocidib, defined as the maximum dose level with fewer than 2 of 6 patients experiencing dose limiting toxicity', 'number of participants with grades 3, 4 or 5 dose-limiting toxicity  related to study drug', 'number of participants with abemaciclib dose-limiting toxicity', 'safety during dose-limiting toxicity  observation period', 'phase 1: number of participants with a dose limiting toxicity', 'number of patients reporting dose-limiting toxicity', 'dose-limiting toxicities  for nk cells infusions after non-myeloablative transplantation for lymphoid malignancies', 'dose-escalation cohort: number of participants with dose-limiting toxicities', 'part a and f: number of participants with dose limiting toxicities', 'number of solid tumor participants with first-cycle dose-limiting toxicity', 'to describe dose limiting toxicities  of prt543', 'maximum tolerated dose  and dose-limiting toxicities  of combination treatment with bevacizumab and bortezomib', 'number of participants with dose limiting toxicities : phase i', 'to describe dose limiting toxicities  of prt1419', 'number of participants who experience dose-limiting toxicities', 'incidence of dose limiting toxicities  of the combination of palbociclib and dexamethasone', 'dose escalation part: dose limiting toxicities  occurence. dose expansion part: ae throughout the study.', 'to determine the maximum tolerated dose  and dose limiting toxicity', 'number of participants with dose limiting toxicity  events', 'number of participants with dose-limiting toxicities  during the determinative period- part 1', 'number of patients with grade 3-5 toxicities occurring within the dose limiting toxicity  period of auto3 infusion', 'number of patients with dose limiting toxicity  of auto3', 'phase i: number of participants with dose-limiting toxicities', 'maximum tolerated dose [mtd] determination by number of participants with dose limiting toxicity', 'dose limited toxicity', 'number of participants with merestinib dose-limiting toxicities', 'phase 1, part 1: safety and tolerability of epacadostat and nivolumab assessed by number of subjects with dose limiting toxicities', 'number of participants who experienced a dose limiting toxicity', 'incidence of dose-limiting toxicity', 'to determine the maximum tolerated dose  and dose limiting toxicity  of inno-406 when administered as a single agent to adult patients with imatinib-resistant or intolerant ph+ leukemias.', 'incidence of dose limiting toxicities  during the first cycle of study treatment', 'the maximum tolerated dose /recommended phase ii dose  is the dose at which less than or equal to 1 of 6 patients experience a dose limiting toxicity  with the next higher dose having at least 2 of 3 or 2 of 6 patients experiencing a dlt.', 'dose limiting toxicity  is defined as grade 4 acute gvhd within the first 90 days following infusion.', 'phase 1: number of participants with dose-limiting toxicities  as a measure of safety profile to determine recommended dose of ponatinib', 'determination of the safety and tolerability of bbi608 administered as monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib by assessing dose-limiting toxicities', 'part 1: number of participants experiencing dose-limiting toxicity'], '0-inf': ['0-inf', 'pharmacokinetic parameters of cpi-1205: auc, auc, auctau,ss, tmax, cmax, ctrough, t1/2, vd/f, cl/f', 'pharmacokinetic parameters of cpi-0610: auc, auc, auctau,ss, tmax, cmax, ctrough, t1/2, vd/f, cl/f', 'area under the plasma concentration-time curve from time 0 to infinity auc of ocrelizumab', 'pharmacokinetics  parameters of auc  calculated by plasma concentration of vinorelbine[', 'pharmacokinetics  parameters of auc  calculated by plasma concentration of majormetabolite, 4-o-deacetylvinorelbine', 'pharmacokinetics  parameters of mrt calculated by plasma concentration of vinorelbine', 'pharmacokinetics  parameters of mrt calculated by plasma concentration of 4-o-deacetylvinorelbine'], 'ASCT': ['ASCT', 'maximum tolerated dose  of carfilzomib  after autologous stem cell transplantation', 'efficacy of carfilzomib  after autologous stem cell transplantation', 'phase ii = feasibility of autologous stem cell transplant  after bv-ice = fraction of patients for whom harvest is possible', 'progression-free survival following autologous stem cell transplant'], 'ORR': ['CR', 'OR', 'ORR', 'CRR', 'complete response, partial response, stable disease', 'response rates', 'overall response rate', 'proportion of complete tumor responses defined as complete remission  as the objective status', 'complete response', 'overall response  based on best response observed during combination therapy.', 'objective remission rate', 'objective response rate  by irrc and recist 1.1', 'response rate', 'part ii: overall response rate  of zanubrutinib in participants with fl and mzl', 'part ii: complete response rate  of zanubrutinib in participants with fl and mzl', 'correlation between positron emission tomography  response and objective response', 'percentage of participants with objective response', 'complete response rate', 'objective response rate', 'expansion part: overall response rate', 'objective tumor response', 'complete response  based on pet/ct as determined by the investigator according to the 2014 lugano response criteria', 'partial response  as determined by best overall response  using cheson criteria', 'complete response  rate', 'complete response  rate as determined by the investigator based on the modified lugano response criteria- part 1 and part 2', 'complete response  rate, as determined by the icr and by the investigator on the basis of ct scans alone- part 1 and part 2', 'overall response rate  with rp6530', 'overall response rate  in the cll, dlbcl, inhl, mcl, and ptld cohorts', 'tumor response and progression as determined by proportion of patients with best overall response , progression-free survival , objective response rate , time to response, and duration of response', 'tumor response  according to cheson criteria and duration of response', 'complete response rate  percentage of participants experiencing positron emission tomography -negative complete response', 'overall response rate  percentage of participants who achieve a pr or cr according to the lugano criteria.', 'efficacy-objective response rate', 'objective response, defined as a partial response  or complete response', 'completion remission  rate', 'objective response rate  at the end of treatment', 'metabolic, pet-negative complete response  rate at the end of treatment', 'best objective response rate  until the end of study', 'metabolic, pet-negative complete response  rate until the end of study', 'efficacy as determined by objective response rate', 'phase ii: percentage of participants with objective response  at pra based on pet-ct as determined by investigator', 'phase 2: efficacy as assessed by objective response rate', 'phase 1: efficacy as assessed by objective response rate', 'overall response rate  with tenalisib and romidepsin combination', \"overall response rate  of nivolumab in combination with bendamustine hydrochloride in patients with hodgkin's lymphoma\", 'overall response rate  of phase i and phase ii participants', 'overall response rate  of previously treated and previously untreated participants', 'number of patients achieving complete response', 'preliminary estimate of overall response rate', 'complete response rate after 4 cycles and at the end of treatment', 'complete remission rate', 'objective response rate  per independent central review committee', 'phase 1 and 2: complete response rate', 'phase 1 and 2: objective response rate', 'complete response rate at the end of treatment', 'phase 2: overall response rate', 'phase 1b: complete response  rate', 'number of participants with complete remission', 'the percentage of subjects experiencing anti-cancer activity  at various dose levels when given multiple doses of cx-072 as a monotherapy or in combination with ipilimumab or vemurafenib', 'overall response rate  during durvalumab treatment', 'summary of best overall response by overall response rate  per investigator assessment', 'antitumor activity of azd5153 in patients by assessing overall response rate .', 'number of patients with a complete response', 'the number of patients with relapsed or refractory hl who achieved complete response', 'number of subjects with complete remission .', 'percentage of participants with complete response', 'overall response rate  of bendamustine hydrochloride and gemcitabine hydrochloride in patients with relapsed or refractory hodgkin lymphoma', 'phase 2: percentage of participants who achieved an overall response rate  per irf assessment per iwg criteria at eot visit', 'to evaluate the efficacy of autologous genetically modified tc-110 t cells in adult patients with r/r nhl as determined by overall response rate', 'all phase i-ii participants: overall response rate', 'phase i participants only: overall response rate', 'phase i-ii participants treated at the rp2d : overall response rate', 'phase i participants treated at the rp2d : overall response rate', 'objective response rate  based on evaluation by image assessment committee', 'complete response  defined as the proportion of subjects who achieve cr', 'complete response  to study treatment', 'percentage of participants with complete response  as assessed by response evaluation criteria in solid tumors', 'overall response rate  based on investigator assessment', 'proportion of participants who exhibit complete response  or partial response  [overall response rate ]', 'overall response rate  of the study population', 'phase i = preliminary overall response rate', 'number of participants who achieve complete remission  or cr with incomplete blood count recovery : overall remission rate', 'phase 2: number of participants who achieve cr, cri or partial remission : overall remission rate  plus pr', 'percentage of participants with a tumor response: objective response rate', 'phase ii: overall response rate', 'percentage of patient with complete remission  rate at the end of induction therapy', 'number of participants whose best response was partial response  or complete response', 'recommended phase 2 dose  cohort: percentage of participants with objective response', 'percentage of solid tumor participants with objective response', 'overall response rate  defined according to standard criteria for the relevant malignancy [phase1b]', 'antitumor activity of azd4573 in patients by assessing overall response rate .', 'complete response or remission  rate', 'objective response rate  in participants with advanced or metastatic solid tumors', 'the overall response rate', 'complete remission  rate', 'duration of complete remission', 'the complete remission  rate', 'to determine the rate of morphologic complete remission', 'objective-response rate', 'overall response rate - part 1', 'achievement of complete remission', 'overall response rate  where or = cr + crp + cri', 'objective response rate : percentage of participants with a complete or partial response', 'kaplan meier estimate of duration of remission  for participants who achieved overall remission  in phase 1', 'kaplan meier estimate of duration of remission  for participants who achieved overall remission  in phase 2', 'phase 2: objective response rate', 'overall objective response rates defined as morphologic, cytogenetic and molecular complete response  rates at the end of induction period', 'objective response rate  - part d'], 'MTD': ['MTD', 'maximum tolerated dose', 'dose-limiting toxicity  and maximum tolerated dose', 'safety as assessed by determination of the maximum tolerated dose', 'maximally tolerated dose', 'maximum tolerated dose  of tst/i 131 tst evaluated in the study', 'to perform a dose escalation trial of atc armed with cd20bi immunotherapy after pbsct to determine the maximum tolerated dose  of atc armed with cd20bi.', 'the maximum tolerated dose  of ruxolitinib in combination with standard dose bortezomib', 'tolerated dose  of clofarabine', 'determine the maximum tolerated dose  of ezn-2968.', 'determination of the maximum tolerated dose  of cep-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.', 'part 1: maximum tolerated dose  of jnj-42756493', 'maximum tolerated dose  of gdc-0575', 'determination of the maximal tolerated dose', 'maximum tolerated dose  of ca-170', 'maximum tolerated dose acceptable for participants', 'phase 1 maximum tolerated dose  for jnj-40346527', 'maximum tolerated dose  of dcds0780a', 'maximum tolerated dose  of nc-4016', 'determine the maximum tolerated dose  of snx-5422 when administered twice a week for 28 days.', 'maximum tolerated dose  of belinostat according to degree of liver dysfunction', 'maximum tolerated dosage  of selinexor/kpt-330 when combined with rice chemo in a relapsed/refractory aggressive b-cell lymphoma setting.', 'maximum tolerated dose  identified at different dosing schedules', 'maximum tolerated dose  of efavirenz', 'to establish the maximal tolerated dose  of lenalidomide in patients with recurrent cns nhl and intraocular nhl', 'dose limiting toxicities  and maximum tolerated dose  of cep 18770', 'determine the maximal tolerated dose  of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma', 'safety: maximum tolerated dose  of gdc-0853', 'maximum tolerated dose  of siplizumab', 'determine the maximum tolerated dose  of clofarabine in association with high-dose etoposide and cyclophosphamide followed by asct in patients with refractory lymphoma malignancies.', 'maximum tolerated dosed', 'maximum-tolerated dose  of pomalidomide', 'safety profile of mdx-1203 and determine the maximum tolerated dose', 'to determine the maximum tolerated dose', 'maximum tolerated dose  of crizotinib', 'maximum tolerated dose  of aurixim', 'identification of dose-limiting toxicity  and maximum tolerated dose', 'maximum tolerated dose  of lenalidomide, obinutuzumab, and chop', 'maximum tolerated dose  of lenalidomide in combination with rituximab', 'maximum tolerated dose  of everolimus with panobinostat', 'maximum tolerable dose  of bortezomib in combination with azacitidine', 'overall frequency of response with combination of bendamustine, ofatumumab, carboplatin, and etoposide at maximum tolerated dose', 'maximum tolerated dose  of medi-551', 'phase i maximum tolerated dose  of vorinostat', 'maximum tolerated dose for phase i patients', 'maximum tolerated dose  of bortezomib', 'maximum tolerated dose  of brentuximab vedotin and bendamustine', 'phase i: maximum tolerated dose  of lenalidomide', 'determine the maximum tolerated dose  - phase 1', 'maximum tolerated dose  of eribulin mesylate', 'maximum tolerated dose  of panobinostat + ice', 'maximum tolerated dose  of vorinostat given orally for 10 days in combination with cyclophosphamide, etoposide, prednisone and rituximab for elderly patients with relapsed diffuse large b-cell lymphoma', 'maximum tolerated dose  of iv amd3100 + g-csf in mobilization of peripheral blood stem cell in patients with lymphoma', 'maximum tolerated dose  of t-cells ± il-2', 'phase 1: determination of maximum tolerated dose  first without and then with administration of prophylactic g-csf.', 'maximum tolerated dose  for brentuximab vedotin', 'the maximum tolerated dose  of niacinamide in the combination of vorinostat and niacinamide', 'to determine the maximum tolerated dose  of mgd when administered once weekly to patients with relapsed or refractory cll/sll', 'maximum tolerated dose  of t-cell infusions', 'maximum tolerated dose  assessed in dose escalation phase of the study', 'determine maximum tolerated dose', 'maximum tolerated dose  of 90y-hat', 'maximum tolerated dose  and/or a recommended phase ii dose', 'phase i: the maximum tolerated dose  of temsirolimus in combination with bortezomib, rituximab and dexamethasone', 'maximum tolerated dose  of lenalidomide and choep', 'determination of non tolerated dose  and maximum tolerated dose', 'maximum tolerated dose )/recommended phase 2 dose of trigriluzole', 'dose limiting toxicity , maximum tolerated dose  for phase i', 'maximum tolerated dose  of gemcitabine with busulfan + melphalan', 'maximum tolerated dose  of the combination of pralatrexate and romidepsin', 'phase i : maximal tolerated dose  determination', 'maximum tolerated dose  of interleukin 15', 'maximum tolerated dose for cyclophosphamide', 'dose escalation: maximum tolerated dose  of tislelizumab', 'maximum tolerated dose  of mitoxantrone', 'phase i: maximum tolerated dose', 'determination of the maximum tolerated dose  in study participants receiving protocol therapy', \"to determine the toxicity profile and maximum tolerated dose  of hll1 when administered to patients with recurrent non-hodgkin's lymphoma and chronic lymphocytic leukemia\", 'dose-escalation cohort: maximum tolerated dose  of crizotinib', 'safety, tolerability, maximum tolerated dose , and dose-limiting toxicity of oral administration of xl184', 'maximum tolerated dose  of t-cells photochemically treated with psoralen and ultraviolet a', 'maximum-tolerated dose  of ionis-stat3rx in patients with advanced cancers.', 'maximum tolerated dose  of alisertib', 'to determine the maximally tolerated dose', 'maximum tolerated dose  of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies', 'maximum-tolerated dose  of yttrium-90-bc8-dota', 'maximum tolerated dose  of ps-341 in combination with doxil', '1. to establish the maximum tolerated dose of chilob 7/4', 'to evaluate the safety, tolerability, maximum tolerated dose , and efficacy pharmacokinetics of cpi-613 given twice weekly for three consecutive weeks in cancer patients', 'maximum tolerated dose  of the combination of palbociclib and dexamethasone defined as the highest dose level where a dlt occurs in at most one out of six patients treated', 'to determine the maximum tolerated doseof tak-901 in subjects with advanced hematologic malignancies.', 'maximum tolerated dose  in phase 1', 'maximum tolerated dose  of alemtuzumab', 'maximum tolerated dose  determination', 'to determine the maximum tolerated dose  and/or the safe, tolerated dose of clofarabine in combination with ara-c and tbi followed by allosct in children with all and anll.', 'maximal tolerated dose', 'maximum tolerated dose  of combination selinexor, fludarabine and cytarabine', 'determine maximum tolerated dose  of bp31510', 'maximum tolerated dose  of a 5-day continuous infusion schedule of nelarabine', 'maximum tolerated dose  of vemurafenib with carboplatin and paclitaxel', 'the maximum-tolerated dose  of alt-801', 'maximum tolerated dose  oxaliplatin', 'maximum tolerable dose  of photofrin® in pediatric subjects', 'phase i: maximum tolerated dose  of carfilzomib'], 'RP2D': ['RP2D', 'safety as assessed by determination of the recommended phase 2 dose', 'recommended phase 2 dose  of atezolizumab', 'recommended phase 2 dose', 'recommended phase 2 dose  of polatuzumab vedotin', 'recommended phase 2 dose  of venetoclax', 'recommended phase 2 dose  of ca-170', 'recommended phase 2 dose  of dcds0780a', 'maximum tolerated dose  and recommended phase 2 dose', 'determination of the maximum tolerated dose , dose-limiting toxicities , and recommended phase 2 dose  of the combination of lenalidomide and brentuximab vedotin', 'to determine dose-limiting toxicity , maximum tolerated dose , and/or recommended phase ii dose  of cn1 administered to patients with advanced solid tumor or b-cell lymphoma.', 'to determine the maximum tolerated dose  and/or recommended phase 2 dose  of the combination npi-0052 and vorinostat', 'the recommended phase 2 dose', 'recommended phase 2 dose  of brigatinib', 'maximum tolerated dose /recommended phase 2 dose level', 'determine the recommended phase 2 dose  of oral daily bmn 673', 'dose-escalation cohort: recommended phase 2 dose  of crizotinib', 'recommended phase 2 dose  cohort: percentage of participants with disease control at week 8', 'recommended phase 2 dose  cohort: percentage of participants with disease control at week 16', 'recommended phase 2 dose  cohort: probability of being event free at month 6', 'phase 1 study: maximum tolerable dose and recommended phase 2 dose  of chidamide among participants', 'to determine the recommended phase 2 dose  and schedule of prt543', 'recommended phase ii dose : phase i', 'recommended phase 2 dose  of alectinib', 'to determine the recommended phase 2 dose  and schedule of prt1419', 'determine the maximum tolerated dose  and/or recommended phase 2 dose  of epz-5676.', 'determine maximum tolerated dose  and/or recommended phase 2 dose  of npi-0052', 'recommended phase 2 dose  of selinexor', 'maximum tolerated dose  and/or recommended phase 2 dose  for abbv-621', 'to determine the safety, tolerability and recommended phase 2 dose  of arq 621 administered intravenously.'], 'AUClast': ['AUClast', 'part i and part ii: area under the plasma concentration-time curve from zero to the last measurable concentration  for single-dose zanubrutinib', 'pharmacokinetics of obinutuzumab: area under the concentration-time curve from time zero to last quantifiable concentration  - relapsed/refractory population', 'area under the concentration-time curve from time of dosing to the last measurable concentration  of asp4132', 'area under the curve  from time 0 to the last quantifiable time point -polatuzumab vedotin monotherapy', 'area under the steady-state serum concentration-time curve  of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'area under the steady-state concentration-time curve  of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'area under the concentration-time curve from time zero to last measurable concentration  of unconjugated mmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab', 'area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration  for adct-402', 'area under the plasma concentration-time curve from time zero to the last measurable concentration  of durvalumab', 'area under the plasma concentration-time curve from time zero to the last measurable concentration  of lenalidomide', 'area under the plasma concentration-time curve from time zero to the last measurable concentration  of ibrutinib', 'characterization of pk  of sb-743921 administered as a 1-hour intravenous infusion on day 1', 'characterization of pk  of sb-743921 administered as a 1-hour intravenous infusion on day 15', 'part 1 and 2: area under the plasma concentration time curve from time zero to time of last quantifiable concentration', 'area under the curve from time zero to the last measured concentration  on day 1: single dose', 'area under the curve from time zero to the last measured concentration  on day 8: multiple dose', 'area under the curve from time zero to the last measured concentration  on day 14/21 dose-corrected to 125 mg: multiple dose', 'area under the curve from time zero to the last measured concentration  on day 1: food effect', 'pf-05082566 area under the serum concentration-time profile  from time 0 to the time of the last measurable concentration  in portion a', 'measurement of pk parameter area under the serum concentration-time curve from time 0 to the last time point  for bi-1206', 'area under the plasma concentratio-time curve from time 0 to the time of the last measurable concentration', 'area under the concentration-time curve to last measureable timepoint  for carfilzomib', 'auc from time zero to last measurable concentration  after multiple dose of alectinib: phase i', 'area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration', 'part 1: area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration  of zanubrutinib'], 'AUC0-inf': ['AUC0-inf', 'part i and part ii: area under the plasma concentration-time curve zero to infinity  for single-dose zanubrutinib', 'area under the curve from time zero to extrapolated infinite time  of gdc-0575', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: area under the plasma concentration time curve extrapolated to infinity', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: area under the plasma concentration time curve extrapolated to infinity of belinostat', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: metabolic ratios of area under the plasma concentration time curve extrapolated to infinity  for the belinostat metabolic pathway', 'area under the plasma concentration-time curve from time zero to infinity  for carfilzomib', 'area under the concentration-time curve from time 0 extrapolated to infinity  of selinexor'], 'CL/F': ['CL/F', 'part i and part ii: apparent plasma clearance  for single-dose zanubrutinib', 'apparent clearance  of lenvatinib from plasma', 'apparent oral clearance  of gdc-0575', 'summary of milademetan pk parameter apparent clearance', 'pk-apparent total body clearance', 'oral clearance  for tak-659 and venetoclax', 'apparent total systemic clearance after single or multiple extravascular dosing  of asp4132', 'phase i: apparent clearance  of gdc-0032', 'plasma clearance', 'apparent total clearance of romidepsin  of romidepsin in phase 1', 'clearance corrected for the fraction of lenvatinib absorbed', 'apparent oral clearance  on day 1: single dose', 'apparent oral clearance  on day 8: multiple dose', 'apparent oral clearance  on day 14/21 dose-corrected to 125 mg: multiple dose', 'apparent oral clearance  on day 1: food effect', 'apparent total body clearance  of cc-223', 'apparent total body clearance  of mk-8628/otx015', 'rate at which drug is removed from blood stream', 'apparent total clearance of azacitidine', 'apparent total clearance of azacitidine  after single and multiple doses of azacitidine', 'apparent oral clearance  on cycle 1 day 21', 'pk - oral clearance', 'part 1: apparent clearance  of zanubrutinib'], 'Vz/F': ['Vz/F', 'part i and part ii: terminal apparent volume of distribution  for single-dose zanubrutinib', 'apparent terminal volume of distribution in the terminal phase of lenvatinib', 'apparent volume of distribution', 'pk-apparent volume of distribution', 'apparent volume of distribution during the terminal elimination phase after single or multiple extravascular dosing  of asp4132', 'apparent volume of distribution  of romidepsin in phase 1', 'part 1 and 2: apparent volume of distribution during the terminal phase after extravascular administration', 'apparent volume of distribution  on day 1: single dose', 'apparent volume of distribution  on day 8: multiple dose', 'apparent volume of distribution  on day 14/21 dose-corrected to 125 mg: multiple dose', 'apparent volume of distribution  on day 1: food effect', 'apparent volume of distribution  of cc-223', 'volume of distribution at steady state  of mk-8628/otx015', 'apparent volume of distribution of azacitidine', 'apparent volume of distribution of azacitidine  after single and multiple doses of azacitidine', 'apparent volume of distribution  on cycle 1 day 21', 'part 1: apparent volume of distribution  of zanubrutinib'], 'AUCss': ['AUCss', 'part i and part ii: area under the plasma concentration-time curve for steady state  zanubrutinib', 'pharmacokinetics: area under concentration-time curve over a dosing interval at steady state  of enzastaurin, its principle metabolites and total analyte'], 'Cmax,ss': ['Cmax,ss', 'part i and part ii: maximum plasma concentration at steady state  for zanubrutinib', \"pk: maximum observed drug concentration at steady state  of enzastaurin, it's metabolites and total analytes in plasma\"], 'counts': ['counts', 'spect-based 99mtc-1-thio-d-glucose value in tumor lesions', 'spect-based 99mtc-1-thio-d-glucose uptake value'], 'PD': ['PD', 'evaluate the pharmacodynamic  effects of cc-95775 on gene expression in peripheral blood and in tumor tissue.', 'investigate the effects of snx-5422 on hsp90 client proteins using pharmacodynamic  assays.', 'percentage of participants evaluable for confirmed response with complete response , cr unconfirmed , partial response , stable disease , and progressive disease', 'pharmacodynamic  indicators:', 'responsiveness of patient lymphoblasts to mtor inhibition using in-vitro and in-vivo pharmacodynamic  assessments.', 'determine pharmacodynamic  parameters in patients treated with intranodal injections of isf35.', 'determine the pharmacokinetic  and pharmacodynamic  profile of epz-5676', 'pharmacodynamics  blood flow part c'], 'PBMCs': ['PBMCs', 'changes in the expression of a set of genes in peripheral blood mononuclear cells  that are sensitive to bet inhibition', 'determination of rna transgene expression in samples of peripheral blood mononuclear cells  or marrow before and after infusion, analyzed by northern blotting/hybridization'], 'PR': ['PR', 'percentage of participants with best overall response  of complete response  or partial response  according to international response criteria for nhls in the mtd and ee cohorts', \"phase ii- overall response rate  = complete response  + partial response  according to the non-hodgkin's lymphoma international working group criteria\", 'objective response rate , defined as the proportion of participants with a best overall response of partial response  or cr, as determined by the investigator according to the 2014 lugano response criteria', 'percentage of participants with best overall response of complete response  or partial response  assessed according to lugano classification', 'percentage of participants with best response of clinical response  or partial response , determined by the investigator on the basis of ct scans alone', 'overall response rate: proportion of patients with confirmed complete response  and partial response', 'partial response  rate', 'partial response', 'percentage of participants with objective response [complete response  or partial response ], as assessed by using modified response criteria for nhl or cll', 'percentage of participants with complete response , unconfirmed cr , or partial response', 'overall complete response  and partial response  rate', 'response rate (complete response  and partial response )', 'number of participants with complete responses  and partial responses  as a measure of efficacy-orr', 'number of participants with complete responses  and partial responses  as a measure of efficacy', 'overall response rate defined as number of patients with an objective status of complete response , complete response/unconfirmed , or partial response  divided by total number of evaluable patients', 'percentage of patients who achieved overall response  as measured by complete response  and partial response', 'percentage of participants with partial response', 'phase 2: percentage of participants who achieved a partial remission  per irf assessment per iwg criteria at eot visit', 'percentage of participants with partial response  in phase ii of the study', 'partial response or remission  rate', 'to determine the rates of cytogenetic complete remission  morphologic complete remission with incomplete count recovery , overall response rate , partial remission , stable disease and hematologic improvement.', 'number of patients who achieved complete response  and partial response'], 'hours': ['hours', 'concentration  of ka2237 in serum/plasma over time', 'concentration  of ka2237 in urine over time', 'key pharmacokinetic parameters, half live  of each of the 3 main components of int230-6.'], 'Cmin': ['Cmin', 'obinutuzumab minimum serum concentration', 'atezolizumab minimum serum concentration', 'minimum serum concentration  of the cd20-cd3 bispecific antibody', 'minimum observed plasma concentration  of jnj-42756493', 'minimum observed plasma trough concentration  of gdc-0575', 'trough serum concentration  of ro6870810 and its potential metabolites- part 1 and part 2', 'parts 1 and 2: ulevostinag minimum plasma concentration', 'parts 1 and 2: pembrolizumab minimum plasma concentration', 'mk-2118 minimum plasma concentration', 'phase i: minimum observed concentration  of gdc-0032', 'minimum concentration', 'medi4736 minimum plasma concentration', 'tremelimumab minimum plasma concentration', 'azd9150 minimum plasma concentration', 'pharmacokinetics of bms-906024 and its metabolite bms-911557: minimum observed concentration', 'minimum observed serum trough concentration  of inotuzumab ozogamicin in participants receiving inotuzumab+rituximab on dosing day 30 and day 58', 'minimum observed serum trough concentration  of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin+rituximab on dosing day 30 and day 58', 'minimum observed serum trough concentration  of inotuzumab ozogamicin antibody in participants receiving inotuzumab mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'venetoclax plasma pk: minimum plasma concentration  within the dosing interval', 'pharmacokinetics : minimum concentration  of ramucirumab, merestinib and abemaciclib', 'trough observed serum concentration  of urelumab and rituximab', 'minimum observed serum concentration  after multiple dose on cycle 1 day 21', 'maximum observed concentration  of ak117 as monotherapy or in combination with ak104 and minimum observed concentration  of ak117 at steady stateconcentration  of ak117 at steady state', 'minimum observed plasma concentration  of ibrutinib'], 'RCL': ['RCL', 'determination of replication competent lentivirus  and hiv-1/vector recombination', 'absence of detection of vector-derived replication competent lentivirus'], 'R': ['R', 'impact of bortezomib alone and in combination with ice on ebv and hhv-8 lytic activation using serum viral loads', 'comparison of above outcomes to a parallel protocol employing ice +/- rituximab in patients with ebv/hhv-8-negative aids-nhl to assess whether bortezomib has additional effects beyond ice alone', 'assess the safety profile, to determine the maximum tolerated dose and recommended phase two dose of abt-199 when administered in combination with rituximab  in subjects with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.'], 'BOR': ['BOR', 'best overall response', 'best overall response ,', 'percentage of participants with best overall response , as assessed by using modified response criteria for nhl or cll', 'phase ii: percentage of participants with best objective response  based on pet-ct or ct only as determined by the investigator', 'investigator-reported best overall response  as determined from the response categories during treatment period.'], 'PK': ['PK', 'concentration-time profiles of pharmacokinetics  parameters - phase ib', 'determine the pharmacokinetic  profile determine the pd profile.', 'pharmacokinetic  profile of ca-170', 'pharmacokinetics  in humans of intravenously administered cx-3543.', 'pharmacokinetic  parameter: cmax of alobresib', 'pharmacokinetics  indicators:', 'auc pharmacokinetics  parameter for bcl201, idelalisib and gs-563117', 'cmax pharmacokinetics  parameter for bcl201, idelalisib and gs-563117', 'pharmacokinetic  profile of av-299, and erlotinib .', 'to assess the pharmacokinetic  profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through area under the plasma concentration-time curve', 'to assess the pharmacokinetic  profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through tmax', 'to assess the pharmacokinetic  profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through apparent volume of distribution at steady state', 'to assess the pharmacokinetic  profile of cn1 in patients with advanced solid tumor or b-cell lymphoma through accumulation factor based on auc 0-τ', 'the pharmacokinetic  profile of s 55746: area under the curve [auc]', 'maximum tolerated dose  and pharmacokinetics  of rp6530', 'trph-222 pharmacokinetics', 'prilinostat mesylate pharmacokinetics ：cmax', 'prilinostat mesylate pharmacokinetics ：tmax', 'prilinostat mesylate pharmacokinetics ：auc0-72h', 'prilinostat mesylate pharmacokinetics ：auc0-∞', 'prilinostat mesylate pharmacokinetics ：mrt', 'prilinostat mesylate pharmacokinetics ：vd', 'prilinostat mesylate pharmacokinetics ：t1/2', 'prilinostat mesylate pharmacokinetics ：clz/f', 'prilinostat mesylate pharmacokinetics ：vz/f', 'prilinostat mesylate pharmacokinetics ：ke', 'pharmacokinetic  parameter: cmax of tirabrutinib', 'the pharmacokinetic  profile of tazemetostat monotherapy and tazemetostat in combination with prednisolone', 'primary pharmacokinetics  parameter: auc0-last', 'primary pharmacokinetics  parameter: auc0-24h', 'primary pharmacokinetics  parameter: tmax', 'primary pharmacokinetics  parameter: cmax', 'secondary pharmacokinetics  parameter: t1/2', 'secondary pharmacokinetics  parameter: cl/f', 'secondary pharmacokinetics  parameter: vz/f', 'secondary pharmacokinetics  parameter: clss/f', 'secondary pharmacokinetics  parameter: racc', 'part b only: preliminary assessment of the effect of food on the pharmacokinetic  parameters of azd6738 via plasma analysis', 'pharmacokinetic - cmax', 'pharmacokinetic - tmax', 'pharmacokinetic - auc', 'determine the pharmacokinetic  profile of bmn 673', 'pharmacokinetics  of leucovorin', 'to determine the pharmacokinetic  profile of cxd101 following single and multiple dosing', 'pharmacokinetics  parameters of cmax calculated by plasma concentration of vinorelbine', 'pharmacokinetics  parameters of tmax calculated by plasma concentration of vinorelbine', 'pharmacokinetics  parameters of tmax calculated by plasma concentration of major metabolite,4-o-deacetylvinorelbine', 'pharmacokinetics  parameters of t1/2 calculated by plasma concentration of vinorelbine', 'pharmacokinetics  parameters of t1/2 calculated by plasma concentration of 4-o-deacetylvinorelbine', 'pharmacokinetics  of cpx-351', 'to determine the pharmacokinetic  profile of inno-406.', 'to evaluate plasma pharmacokinetics  of bpm31510'], '0-168': ['0-168', 'auc: area under the plasma concentration-time curve from time 0 to 168 hours postdose for ixazomib', 'auc of copanlisib after each copanlisib iv infusion during 2 cycles of copanlisib monotherapy'], 'T1/2': ['T1/2', 'terminal phase elimination half-life  for ixazomib', 'part i: the amount of time it takes for the drug concentration to decrease by half', 'pharmacokinetic parameter: apparent terminal half-life  at 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 6, 12, 24, 48, and 72 hours.', 'apparent terminal half-life  of camidanlumab tesirine', 'summary of milademetan pk parameter elimination terminal half life half-life', 'pk-terminal half-life', 'apparent terminal elimination half-life  of asp4132', 'elimination half-life', 'pk parameter: the apparent elimination half-life', 'to assess pharmacokinetics  of fimepinostat when administered in combination with anti-cancer regimens as measured by half-life .', 'to assess pk of venetoclax when administered in combination with fimepinostat as measured by half-life .', 'terminal phase elimination half-life  for alisertib in presence and absence of esomeprazole', 'phase elimination half-life  for alisertib in presence and absence of rifampin', 'plasma half life', 'part a: terminal elimination phase half-life  of cc-223', 'measurement of pk parameter half-life  for bi-1206'], '0-4': ['0-4', 'ae : amount of drug excreted in urine from 0 to 4 hours postdose', 'fe : fraction of dose excreted unchanged in urine from 0 to 4 hours postdose', 'assess the maximum overall grades 0- iv of acute gvhd and maximum severity  by involved organ system in patients who develop acute graft-versus-host disease.'], 'Phospho-Rb': ['Phospho-Rb', 'correlation coefficient between change from baseline in fluoro-l-thymidine positron emission tomography  maximum standard uptake value  and in phosphorylated retinoblastoma  percent positive cells at cycle 1 day 21', 'correlation coefficient between change from baseline in fluorodeoxyglucose positron emission tomography  maximum standard uptake value  and in phosphorylated retinoblastoma  percent positive cells at cycle 1 day 21', 'phosphorylated retinoblastoma  percent positive cells at baseline', 'phosphorylated retinoblastoma  percent positive cells at cycle 1 day 21'], 'TTP': ['TTP', 'time to tumor progression', 'time to progression', 'time to progression  of disease.', 'kaplan-meier estimates of time to tumor progression', 'kaplan meier estimate of time to progression  in ptcl participants based on the 1999 iwc as assessed by ier', 'kaplan meier  estimate of time to progression  in ptcl participants based on the modified 2007 iwc as assessed by ier', 'median time to progression', 'time to tumor progression  for solid tumor participants'], 'TD + Re-dose': ['TD + Re-dose', 'number of participants  during initial treatment exposed to the indicated dose levels of the therapeutic dose , re-dose, and total dose', 'number of participants during retreatment exposed to the indicated dose levels of the td, re-dose, and total dose'], 'Initial Treatment': ['Initial Treatment', 'tumor/organ dosimetry of tst/i 131 tst for all predoses', 'tumor/organ dosimetry at the indicated predoses of 475 mg, 95 mg, and 0 mg'], 'Par.': ['Par.', 'number of participants  with the indicated response as assessed by the investigator', 'number of participants  with confirmed response as assessed by the investigator'], 'CL': ['CL', 'clearance  of i 131 tst for the indicated antibody predose levels', 'pharmacokinetics: clearance', 'total clearance', 'clearance', 'clearance  of ro6870810 and its potential metabolites- part 1 and part 2', 'total clearance  of dcds0780a total antibody', 'total clearance  of acmmae', 'total clearance  of unconjugated mmae', 'pharmacokinetics  of single-dose belinostat  according to degree of liver dysfunction: clearance', 'clearance  values', 'systemic clearance  for moxetumomab pasudotox', 'clearance  of serum inotuzumab ozogamicin in participants receiving inotuzumab+rituximab on dosing day 30 and day 58', 'clearance  of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'systemic clearance  of ocrelizumab', 'clearance  of polatuzumab vedotin', 'apparent clearance  at steady state for adct-402', 'clearance  of durvalumab', 'clearance .', 'clearance  of moxetumomab pasudotox', 'pf-05082566 clearance  in portion a', 'measurement of pk parameter total body clearance  for bi-1206', 'clearance : apparent total plasma clearance.', 'apparent total plasma clearance', 'clearance  of carfilzomib', 'clearance  of ridaforolimus', 'clearance  of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1', 'pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : systemic clearance'], 'λz': ['λz', 'terminal phase rate constant  of radiolabeled 14^c-lenvatinib and non-radiolabeled lenvatinib in plasma', 'terminal phase rate constant', 'part 1 and 2: terminal elimination rate constant'], 'AUC(0-t': ['AUC(0-t', 'area under the plasma concentration-time curve from time zero to time t (auc)', 'area under the serum concentration-time curve from time 0 to time of last quantifiable concentration (auc)', 'pk - area under the plasma concentration-time curve (auc)'], 'AUC(0-inf': ['AUC(0-inf', 'area under the plasma concentration-time curve from time zero to infinity (auc)', 'area under the serum concentration-time curve from time 0 to infinity (auc)', 'area under the plasma concentration curve from time 0 to infinity (auc)'], 'CLr': ['CLr', 'renal clearance of lenvatinib', 'phase i: renal clearance  of gdc-0032', 'renal clearance  of lenvatinib', 'pharmacokinetics as measured by renal clearance'], 'C trough': ['C trough', 'minimum observed plasma trough concentration', 'trough concentration  for tak-659 and venetoclax'], 'AUCtau': ['AUCtau', 'area under the curve from time zero to end of dosing interval', 'phase i: auc from zero to tau  of gdc-0032', 'area under the steady-state serum concentration-time curve  of inotuzumab ozogamicin in participants receving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'area under the steady-state serum concentration-time curve  of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd+ rituximab 375 mg/m^2 on dosing day 1, day 30, and day 58', 'area under the serum concentration-time curve from time 0 to the end of the dosing interval  for adct-402', 'pf-05082566 auc from time 0 to time of dosing interval  in portion a', 'dose-escalation and recommended phase 2 dose  cohort: area under the curve from time zero to end of dosing interval  of crizotinib on day -7', 'dose-escalation and recommended phase 2 dose  cohort: area under the curve from time zero to end of dosing interval  of crizotinib on cycle 1 day 1', 'dose-escalation and recommended phase 2 dose  cohort: area under the curve from time zero to end of dosing interval  of crizotinib on cycle 1 day 15', 'dose-escalation and recommended phase 2 dose  cohort: area under the curve from time zero to end of dosing interval  of crizotinib on cycle 2 day 1', 'area under the curve from time zero to end of dosing interval  of crizotinib alone and when taken with rifampin', 'itraconazole cohort: area under the curve from time zero to end of dosing interval  of crizotinib when taken alone and when taken with itraconazole', 'area under the time-concentration curve from time 0 to the dosing interval  after a single dose on cycle 1 day 1'], 'AE': ['AE', 'parts i & ii: number of participants experiencing clinical or laboratory adverse experiences', 'number of subjects who experience an adverse event', 'adverse event', 'parts 1 and 2: percentage of participants who discontinue study drug due to an adverse event', 'number of participants who discontinue study treatment due to an adverse event', 'number of participants who experienced an adverse event', 'adverse event  type, severity and frequency', 'number of participants who experienced at least one adverse event', 'number of participants who discontinued study treatment due to an adverse event'], 'ADAs': ['ADAs', 'proportion of participants with anti-drug antibodies  to glofitamab', 'number of subjects who develop anti-drug antibodies', 'cohort 1a : percentage of participants with treatment emergent anti-drug antibodies  to polatuzumab vedotin', 'number of participants with anti-drug antibodies  to tislelizumab', 'number of subjects who develop detectable anti-drug antibodies  of ak117 as monotherapy or in combination with ak104'], 'RECIST': ['RECIST', 'antitumor activity that may be associated with lee011 treatment, as assessed by ct/mri response evaluation criteria for solid tumors  criteria v1.0 or cheson criteria 2007 for lymphomas.', 'percentage of participants with objective response as determined using response evaluation criteria in solid tumors  v1.1', 'phase ii: percentage of participants with clinical benefit, as assessed using response evaluation criteria in solid tumors  version 1.1', 'response evaluation criteria in solid tumors', 'tumor burden according to response evaluation criteria in solid tumors /revised response criteria malignant lymphoma', 'percentage of participants achieving objective response per response evaluation criteria in solid tumor  version 1.1 in portion a', 'phase 2: objective response rate  per response evaluation criteria in solid tumors  v1.1 for subjects with solid tumors and per cheson criteria for subjects with dlbcl'], 'PCR': ['PCR', 'polymerase chair reaction  analysis of biomarkers', 'number of patients achieving morphological remission (complete response or complete response with incomplete count recovery  and minimal residual disease -negative response in the bone marrow ).'], 'CT': ['CT', 'percentage of participants with cr, determined by an independent review committee  on the basis of positron emission tomography  and computed tomography  scans', 'percentage of participants with cr defined by computed tomography  scan using the modified lugano classification'], 'acMMAE': ['acMMAE', 'observed plasma concentration of polatuzumab vedotin antibody-conjugated mono-methyl auristatin e', 'aucinf of antibody conjugated monomethyl auristatin e  for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'ATAs': ['ATAs', 'percentage of participants with anti-therapeutic antibodies  to polatuzumab vedotin', 'percentage of paticipants with anti therapeutic antibodies  against polatuzumab vedotin', 'number of participants positive for anti-therapeutic antibodies  to atezolizumab', 'percentage of participants with anti-therapeutic antibodies  to atezo', 'percentage of participants with anti-therapeutic antibodies  to atezolizumab'], 'volume of distribution of blinatumomab': ['volume of distribution of blinatumomab', 'blinatumomab pk parameters  under civ', 'blinatumomab pk parameters  under sc administrations'], 'HL': ['HL', 'maximum tolerable dose  of bortezomib when given in combination with ice chemotherapy in participants with relapsed and refractory classical hodgkin lymphoma', 'complete remission rate  in cohort 3: relapsed/refractory  hodgkin lymphoma', 'objective response rate  in cohort 3: relapsed/refractory  hodgkin lymphoma', 'duration of response  in cohort 3: relapsed/refractory  hodgkin lymphoma', 'objective response rate  in programmed cell death ligand 1  positive participants in cohort 3: relapsed/refractory  hodgkin lymphoma', 'objective response rate  in programmed cell death ligand 1  negative participants in cohort 3: relapsed/refractory  hodgkin lymphoma', 'objective response rate  in programmed cell death ligand 1  indeterminate participants in cohort 3: relapsed/refractory  hodgkin lymphoma', 'progression-free survival  in cohort 3: relapsed/refractory  hodgkin lymphoma'], 'RD': ['RD', 'maximum tolerated dose  and recommended dose', 'complete response  rate as determined by independent radiological central review  using modified lugano response criteria- recommended dose  expansion - part 2', 'to determine the maximum tolerated dose  and the recommended dose  of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.', 'maximum tolerated dose  and/or recommended dose  of ldk378', 'response duration :', 'identify maximum tolerated  and/or recommended dose  and schedule for xmab14045 dosing'], 'Vz': ['Vz', 'volume of distribution at terminal phase', 'volume of distribution  of durvalumab', 'apparent total volume of distribution .', 'apparent total volume of distribution'], 'MMAE': ['MMAE', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, predose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 2, predose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, predose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 0.5 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 2, 0.5 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 0.5 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 4 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 4 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 24 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 24 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 48 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 48 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 72 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 72 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 96 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 96 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 144 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 144 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 1, 336 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 336 hour postdose', 'plasma concentration of monomethylauristatin e  and its metabolites at cycle 3, 480 hour postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, predose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 0-24 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 24-48 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 48-72 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 72-96 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 96-120 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 120-144 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 144-168 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 336-360 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 1, 480-504 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, predose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 0-24 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 24-48 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 48-72 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 72-96 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 96-120 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 120-144 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 144-168 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 336-360 hours postdose', 'amount of monomethylauristatin e  and its metabolites excreted in urine at cycle 3, 480-504 hours postdose', 'area under the plasma concentration-time curve  for unconjugated monomethyl auristatin e', 'monomethyl auristatin e  plasma concentrations', 'phase 1: mean maximum observed plasma concentration  of monomethyl auristatin e'], 'ADC': ['ADC', 'serum concentrations of antibody-drug conjugate', 'antibody-drug conjugate  serum concentrations'], 'TAb': ['TAb', 'serum concentration of total antibody', 'phase 1: mean maximum observed serum concentration  of brentuximab vedotin total conjugated and therapeutic antibody'], '0-t': ['0-t', 'area under the curve from time zero to the last quantifiable concentration [auc]', 'pk-auc'], '0-∞': ['0-∞', 'area under the curve from time zero to extrapolated infinity [auc]', 'pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity [auc] of s-warfarin and r-warfarin'], 'Lead-in + Expanded Cohorts': ['Lead-in + Expanded Cohorts', 'progression-free survival : evaluable population- part 2', 'progression-free survival : intent-to-treat population-part 2', 'overall survival : evaluable population- part 2', 'overall survival : intent-to-treat population: part 2', 'duration of overall response : part 2'], 'Expanded Cohorts': ['Expanded Cohorts', 'number of participants with best overall response : part 2', 'time-to-tumor progression: part 2'], 'MAD': ['MAD', 'maximal administered dose', 'maximum administered dose'], 'FFS': ['FFS', 'failure free survival', 'percentage of participants with failure free survival'], 'AI': ['AI', 'accumulation index  of jnj-42756493', 'accumulation index  for camidanlumab tesirine', 'accumulation index  for adct-402'], 'Rac': ['Rac', 'accumulation ratio  of gdc-0575', 'accumulation ratio  for tak-659 and venetoclax', 'accumulation ratio  on day 8: multiple dose', 'accumulation ratio  on day 14/21 dose-corrected to 125 mg: multiple dose', 'accumulation ratio  on cycle 1 day 21'], 'pCdk2': ['pCdk2', 'phospho-cyclin-dependent kinase 2  levels in fresh tumor', 'phospho-cyclin-dependent kinase 2  levels in skin tissue'], 'γ-H2Ax': ['γ-H2Ax', 'gamma-h2ax  levels in fresh tumor', 'gamma-h2ax  levels in skin tissue'], 'fe': ['fe', 'dose escalation part: fraction excreted  in urine for e7766', 'dose escalation part: fraction excreted  in feces for e7766', 'phase i: fraction dose excreted  of gdc-0032', 'fraction of unchanged lenvatinib excreted in the urine'], 'IWG': ['IWG', 'best overall response  per international myeloma working group  criteria for myeloma and per revised criteria for staging of the international working group  guidelines for lymphoma', 'duration of response per international myeloma working group  criteria for myeloma and per revised criteria for staging of the international working group  guidelines for lymphoma', 'progression free survival  per international myeloma working group  criteria for myeloma and per revised criteria for staging of the international working group  guidelines for lymphoma', 'phase i cohort t: percentage of participants with best overall response, as assessed using 2007 revised international working group  response criteria in malignant lymphoma', 'overall response in patients treated with lenalidomide according to the international working group  criteria', 'clinical efficacy  evaluated using the revised international working group criteria  for aml'], 'TEAE': ['TEAE', 'number of participants reporting at least one treatment emergent adverse event', 'number of participants who had at least one treatment-emergent adverse event'], 'SAE': ['SAE', 'number of participants reporting at least one treatment emergent serious adverse event', 'phase 1 and phase 2: number of participants with an adverse event  or a serious adverse event'], 'AUC0-last': ['AUC0-last', 'area under the serum concentration-time curve from time 0 to the time of the last quantifiable concentration  for camidanlumab tesirine', 'mk-8776 area under the curve of the plasma concentration versus time from time zero to the time of the last analytically quantifiable concentration', 'area under the plasma concentration-time curve from time zero to the last concentration measured  for carfilzomib'], 'AUC0-t': ['AUC0-t', 'area under the serum concentration-time curve from time 0 to the end of the dosing interval  for camidanlumab tesirine', 'area under the plasma concentration-time curve from time zero to the last measurable concentration  of romidepsin in phase 1', 'area under the plasma concentration time-curve from time 0 to the time of the last quantifiable concentration of romidepsin', 'area under the concentration-time curve from time 0 to t  of selinexor'], 'AUC∞': ['AUC∞', 'area under the serum concentration-time curve from time 0 to infinity  for camidanlumab tesirine', 'area under the plasma concentration-time curve from time zero to infinity  of romidepsin in phase 1', 'area under the plasma concentration-time curve from time 0 to infinity time'], 'ADA': ['ADA', 'number of participants with anti-drug antibody response  against camidanlumab tesirine', 'percentage of ant-drug antibodies  against rituximab - part 1 and part 2', 'presence of anti-drug antibody  titres in subjects treated with study drug a', 'anti drug antibodies', 'number of participants with positive anti-drug antibody  and neutralizing antibody', 'number of participants with positive anti-drug antibodies  for medi-551 and medi0680', 'number of participants with anti-drug antibodies  to pinatuzumab vedotin', 'number of participants with anti-drug antibody response  against adct-402', 'trph-222 anti-drug antibodies', 'number of participants with positive anti-drug antibody  for pf-05082566 in portion a', 'measurement of anti-drug antibody  response to bi-1206 during the bi-1206 treatment period using elisa', 'immunogenicity of urelumab in combination with rituximab as determined by blood sample measurements of anti-drug antibodies', 'concentration of anti-drug antibody', 'number of participants with anti-bms-986016 antibodies', 'number of participants with anti-nivolumab antibodies'], 'ECG': ['ECG', 'percentage of participants with clinically significant changes in vital signs, physical examination, clinical laboratory results and electrocardiogram  findings- part 1', 'percentage of participants with clinically significant changes in vital signs, physical examination, clinical laboratory results and electrocardiogram  findings- part 2', 'safety as assessed by electrocardiograms', 'incidence of clinically-significant changes in electrocardiograms s', 'change from baseline to end of treatment in clinical findings in electrocardiogram  qt, qtc interval and ventricular rate', 'number of patients with changes in electrocardiogram  results from baseline', 'number of participants with potentially clinical significant categorical changes from baseline in electrocardiogram  findings in qtc interval', 'electrocardiogram'], 'tmax': ['tmax', 'time of maximum concentration  of ro6870810 and its potential metabolites- part 1 and part 2', 'phase i: time to reach cmax  of gdc-0032', 'pharmacokinetics  of rituximab', 'time to reach peak plasma concentration .', 'part 1 and 2: time to reach maximum observed plasma concentration', 'time to reach maximum plasma concentration'], 'Vd': ['Vd', 'volume of distribution  of ro6870810 and its potential metabolites- part 1 and part 2', 'to assess pharmacokinetics  of fimepinostat when administered in combination with anti-cancer regimens as measured by volume of distribution .', 'to assess pk of venetoclax when administered in combination with fimepinostat as measured by volume of distribution .', 'volume of distribution .'], 'DoR': ['DoR', 'duration of response - part 1 and part 2', 'duration of response  with tenalisib and romidepsin combination', 'duration of response  of phase i and phase ii participants', 'duration of response  of previously treated and previously untreated participants', 'duration of response  per investigator assessment', 'antitumor activity of azd5153 in patients by assessing duration of response .', 'phase 2: duration of remission', 'part b, c, d, e and f: duration of response', 'duration of response  as assessed by irc in re population', 'duration of response  - part d'], 'DFS': ['DFS', 'disease-free survival - part 1 and part 2', 'disease-free survival', 'disease free survival', 'disease free survival  within one year', 'disease free survival  time'], 'Cheson 2007': ['Cheson 2007', 'objective response according to modified response criteria for acute myeloid leukemia  or revised response criteria for malignant lymphoma', 'objective response according to revised response criteria for malignant lymphoma', 'overall response rate as assessed according to the\"revised response criteria for malignant lymphoma\" .', 'clinical benefit rate as assessed according to the \"revised response criteria for malignant lymphoma\" .'], 's': ['s', 'incidence of dlt at each dose level', 'cumulative dlt', 'assess safety and tolerability of the rp2d of av-299 in expansion cohort.'], 'PET': ['PET', 'positron emission tomography  response for patients with detectable fdg tumor uptake at baseline', 'overall response , complete response , their duration, absorbed dose to normal organ and tumours, relapse pattern, the effect of radioimmunotherapy  in its own right as assessed by positron emission tomography', 'overall response rate  evaluated by computed tomography  or positron emission tomography /ct', 'phase 2: percentage of participants whose disease was positron emission tomography  negative after 2 cycles of protocol therapy per irf assessment', 'phase ii = number of patients positron emission tomography  4- after pet 2+'], 'AUC0-24': ['AUC0-24', 'parts 1 and 2: ulevostinag area under the plasma drug concentration-time curve from time zero to 24 hours', 'phase i stage 2 cohort c: auc from time zero to 24 hours  of midazolam prior to and after 14 days continuous gdc-0032 dosing', 'part 1 and part 2: area under the plasma concentration-time curve from time zero to 24 hours post dose', 'area under the concentration time-curve from 0-24 hours after a dose  for cc-223', 'area under the concentration time-curve from 0-24 hours after a dose  for metabolite m1', 'area under the plasma concentration time-curve from time 0 to 24-hour  for romidepsin'], 'RECIST 1.1': ['RECIST 1.1', 'part 2: objective response rate  as assessed by response evaluation criteria in solid tumors version 1.1', 'number of subjects with best overall tumor response by response evaluation criteria in solid tumors', 'median pfs by response evaluation criteria in solid tumors  as estimated using the kaplan-meier method', 'overall disease control rate as measured by response evaluation criteria in solid tumors'], 'Disease Progression/Relapse or Death': ['Disease Progression/Relapse or Death', \"number of participants with progression-free survival  events , according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\", \"number of participants with pfs events , according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\"], 'Disease Progression, Death, or Initiation of a New Anti-Lymphoma Therapy': ['Disease Progression, Death, or Initiation of a New Anti-Lymphoma Therapy', \"number of participants with event-free survival  event , according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\", \"number of participants with efs event , according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\"], 'CLss': ['CLss', 'pharmacokinetics of obinutuzumab: systemic clearance at steady state  - relapsed/refractory population', 'total systemic clearance at steady state  of obinutuzumab at cycle 8'], 'Ctrough': ['Ctrough', 'pharmacokinetics of obinutuzumab: plasma trough concentration  - relapsed/refractory population', 'trough concentration', 'determination of trough concentration  of abt-199 and/or rituximab', 'determination of trough concentration  of abt-199', 'pharmacokinetics  of sar245409', 'pharmacokinetics: mean trough plasma concentration  for medi4736', 'trough plasma concentration  of cobomarsen following each 4-week cycle of dosing', 'pf-05082566 pre-dose trough concentration during multiple dosing  in portion a', 'dose-escalation and recommended phase 2 dose  cohort: trough concentration  of crizotinib cycle 1 day 15', 'dose-escalation and recommended phase 2 dose  cohort: trough concentration  of crizotinib on cycle 2 day 1', 'itraconazole cohort: trough plasma concentration  of crizotinib when taken alone and when taken with itraconazole', 'trough plasma concentration  of alectinib', 'trough plasma concentration  of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1', 'bms-986016 trough observed serum concentration'], 'Last': ['Last', 'auc: area under the plasma concentration curve from time 0 to the time of the last quantifiable concentration of alisertib', 'auc: area under the plasma concentration curve from time 0 to the time of the last quantifiable concentration of alisertib in presence and absence of itraconazole in part a', 'auc: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib in presence and absence of rifampin'], 'HAHA': ['HAHA', 'incidence of human anti-human antibody  formation', 'number of participants positive for human anti-human antibodies  to obinutuzumab', 'monitor human anti-veltuzumab antibodies and human anti-milatuzumab', 'number of participants with positive human anti-human antibodies', 'immunogenicity measurement for human anti human antibodies  -characterizing the immunogenicity of bms-936564'], '0-24': ['0-24', 'auc: area under the plasma concentration-time curve from time 0 to time 24 hour for tak-659', 'urine [ae,ur]', 'auc: area under the plasma concentration-time curve from time 0 to 24 hours post-dose for brigatinib at cycle 1 day 1', 'auc: area under the plasma concentration-time curve from time 0 to 24 hours post-dose for brigatinib at cycle 2 day 1', 'rp2d cohort: area under the curve from time zero to last quantifiable concentration [auc ] of crizotinib when taken with food', 'auc: area under the plasma concentration-time curve from time 0 to 24 hours post-dose for ponatinib'], 'TTR': ['TTR', 'time to response', 'time to response  for ptcl participants with at least a pr based on the modified 1999 iwc as assessed by ier', 'time to response  for ptcl participants with at least a pr based on the modified 2007 iwc as assessed by ier', 'recommended phase 2 dose  cohort: time to response', 'cp-cml, ap-cml, bp-cml, and ph+all participants: median time to response', 'part 1 and part 2: time to response'], 'Cav,ss': ['Cav,ss', \"pk: average concentration during a dosing interval at steady state  of enzastaurin, it's metabolites and total analytes in plasma\", 'pharmacokinetics: average concentration during a dosing interval steady state  of enzastaurin, its principle metabolites and total analyte'], 'CSF': ['CSF', 'to define the extent of cerebrospinal fluid  penetration of lenalidomide.', 'cerebrospinal fluid  concentration of rituximab', 'mean percentage cluster of differentiation 19  - chimeric antigen-receptor  t-cells in blood, bone marrow  and cerebrospinal fluid'], 'BMS-663513': ['BMS-663513', 'dose-limiting toxicity and maximum tolerated dose of urelumab  as determined by the incidence of dose-limiting toxicities', 'maximum observed serum concentrations  of urelumab', 'minimum observed serum concentrations  of urelumab', 'area under the concentration-time curve in 1 dosing interval [auc] of urelumab', 'plasma half-life  of urelumab', 'total body clearance  of urelumab', 'volume of distribution at steady-state  of urelumab'], 'AUC24': ['AUC24', 'auc from the time of dosing to 24 hours  of asp4132', 'area under the plasma concentration-time curve from 0 to 24 hours  post-dose of venetoclax'], 'AUCinf': ['AUCinf', 'auc from the time of dosing extrapolated to time infinity  of asp4132', 'auc extrapolating to time of infinity -polatuzumab vedotin monotherapy', 'phase ib: auc from time zero to infinity  of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a', 'area under the serum concentration-time profile from time zero extrapolated to infinite time  of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'area under the serum concentration-time profile from time zero extrapolated to infinite time  of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m2 on dosing day 30 and day 58', 'area under the serum concentration-time curve from time 0 to infinity  for adct-402', 'area under the plasma concentration-time curve from time zero to infinity  of durvalumab', 'area under concentration-time curve from dosing extrapolated to infinity  of moxetumomab pasudotox', 'part 1 and 2: area under plasma concentration-time curve from time zero to infinity', 'area under the plasma concentration-time curve from time 0 extrapolated to infinity  for cc-223', 'pf-05082566 auc from time 0 to infinity  in portion a', 'area under the concentration-time curve from time 0 to infinity', 'dose-escalation and recommended phase 2 dose  cohort: area under the curve from time zero to extrapolated infinite time  of crizotinib on day -7', 'area under the curve from time zero to extrapolated infinite time  of midazolam when taken alone or taken with crizotinib', 'area under the concentration-time curve extrapolated to infinity  for carfilzomib', 'area under the plasma concentration  versus time curve extrapolated to infinity  after single dose of alectinib: phase i'], 'IRC': ['IRC', 'percentage of participants with cr, determined by the independent review committee  and investigator on the basis of ct scans alone', 'phase ii randomized and nf cohorts: percentage of participants with complete response  at primary response assessment  based on positron emission tomography -computed tomography  scan as determined by independent review committee', 'percentage of participants achieving complete response  at end of induction , as determined by the independent review committee  using modified lugano 2014 criteria', 'percentage of previously untreated dlbcl participants with complete response  defined by positron emission tomography-computed tomography  scan using the modified lugano classification assessed by independent review committee', 'percentage of participants with cr at end of treatment  based on positron emission tomographic/computed tomography  assessment determined by independent review committee  per lugano 2014 response criteria: cohorts e, g, and h', 'percentage of participants with complete response  at end of induction , as determined by the independent review committee  using modified lugano 2014 criteria', 'percentage of participants with objective response according to response evaluation criteria in solid tumors version 1.1  by independent review committee : phase ii'], 'Cycle 1 Day 15': ['Cycle 1 Day 15', 'cmax  of copanlisib', 'auc  of copanlisib', 'cmax  of m-1 metabolite', 'auc  of m-1 metabolite'], 'SD': ['SD', 'overall disease control rate: proportion of patients who have a best response rating of cr, pr or stable disease', 'evaluation of objective response  or stable disease .', 'evaluation of objective response  or stable disease  by recist v1.1', 'evaluation of objective response  or stable disease  by irecist', 'evaluation of objective response  or stable disease  by recil 2017.', 'stable disease', 'number of participants with complete response , partial response , stable disease , or progression as their best response', 'determination of duration of stable disease  as measured from time of 1st evidence of response to time of 1st evidence of progressive disease as measured by ct or mri.', 'duration of stable disease', 'percentage of participants with stable disease', 'percentage of participants achieving cr, pr or stable disease  according to recist v1.1 in re population', 'phase 2: duration of disease control, defined as cr, pr, and stable disease'], 'Except Cohorts T and T2': ['Except Cohorts T and T2', 'phase i all cohorts : percentage of participants with best overall response, as assessed using recist version 1.1', 'phase i all cohorts : duration of objective response, as assessed using recist version 1.1', 'phase i all cohorts : progression free survival, as assessed using recist version 1.1'], 'MUGA': ['MUGA', 'changes from baseline in clinical laboratory test  results, vital sign measurements, physical examination findings, and ecg and 2d echocardiogram/multiple-gated acquisition  scan results', 'transthoracic echocardiogram /multiple gated acquisition  scans'], 'Objective Response Rate': ['Objective Response Rate', 'orr and tumor response', 'preliminary anti-tumor activity of ibi188'], 'Arm 1': ['Arm 1', 'peak plasma concentration  of study drug a', 'area under the plasma concentration versus time curve  of study drug a'], 'Arm 2': ['Arm 2', 'peak plasma concentration  of study drug b', 'area under the plasma concentration versus time curve  of study drug b', 'peak plasma concentration  of acalabrutinib', 'area under the plasma concentration versus time curve  for acalabrutinib', 'the primary outcome of this study is to determine the mtd of daily oral bmn 673 in patients with aml and mds  and patients with cll and mcl .'], 'MRD': ['MRD', 'minimal residual disease  levels present at end of cycle 1 therapy in patients with bone marrow involvement.', 'minimal residual disease collection', 'rate of minimal residual disease  in bone marrow aspirate samples', 'minimal residual disease  - cll only', 'to evaluate the efficacy of autologous genetically modified tc-110 t cells in adult patients with r/r all as determined by overall response rate and minimum residual disease  negativity rates', 'number of participants with minimum residual disease', 'minimal residual disease', 'rate of minimal residual disease  < 0.01%', 'minimal residual disease  during treatment with alemtuzumab'], 'RPTD': ['RPTD', 'determination of dose limiting toxicity , maximum tolerated dose , recommended phase two dose , and lead-in period regimen', 'phase 1a: determine dose limiting toxicity , maximum tolerated dose  and recommended phase 2 dose  and schedule - intermittent dosing.', 'phase 1b: determine dose limiting toxicity , maximum tolerated dose  and recommended phase 2 dose  and schedule - continuous dosing.', 'phase 2a: continued assessment of safety profile at the recommended phase 2 dose  and schedule - continuous dosing.', 'determine the maximum tolerated dose  and recommended phase 2 dose  of abt-348 when administered as a monotherapy and in combination in subjects with advanced hematologic malignancies'], 'IV': ['IV', 'volume of distribution (vz/f for subcutaneous  administration vz for intravenous  administration)', 'number of dose-limiting toxicities  of subcutaneous recombinant human il-15  administered with 3 times per week intravenous  alemtuzumab'], 'ALL': ['ALL', 'to provide erwinase to patients with acute lymphoblastic leukemia  or non-hodgkins lymphoma who are intolerant or have developed hypersensitivity to e. coli asparaginase and/or peg-asparaginase', \"to determine the safety and tolerability of 5-aza-2'-deoxycytidine  administered daily for 5 days every other week in patients with relapsed or refractory acute lymphocytic leukemia .\"], 'NHL': ['NHL', 'to determine the feasibility of generating ebv specific cytotoxic t cell lines from patients with active ebv positive lymphoma including hodgkin disease  or non-hodgkin lymphoma .', 'change in disease burden using recist 1.1  or lugano criteria .', 'number of participants with grade change from baseline in vital signs-dbp & sbp-part 2', 'number of participants with change from baseline in heart rate and temperature-part 2', 'number of participants with grade change from baseline in clinical chemistry data-part 2', 'number of participants with change from baseline in clinical chemistry data with respect to normal range-part 2', 'number of participants with grade change from baseline in hematology data-part 2', 'number of participants with change from baseline in hematology data with respect to normal range-part 2', 'number of participants with worst-case urinalysis results post-baseline relative to baseline by dipstick method -part 2', 'change from baseline in urine protein excretion -part 2', 'number of participants with at least one confirmed positive post-baseline anti-drug antibody result- part 2', 'number of participants with antibodies to gsk2857916 in serum over time - part 2', 'orr-part 2'], 'complete and partial response': ['complete and partial response', 'overall response  rate', 'objective response'], 'AUCextrap': ['AUCextrap', 'percentage of aucinf -polatuzumab vedotin monotherapy', 'percentage of aucinf based on extrapolation'], 'Cl': ['Cl', 'to assess pharmacokinetics  of fimepinostat when administered in combination with anti-cancer regimens as measured by clearance .', 'to assess pk of venetoclax when administered in combination with fimepinostat as measured by clearance .', 'clearance  of sorafenib'], 'RECIST Version 1.1': ['RECIST Version 1.1', 'phase 2: confirmed best overall response  as per response evaluation criteria in solid tumors  and as adjudicated by the investigator', 'phase 1: confirmed best overall response  as per response evaluation criteria in solid tumors  and as adjudicated by the investigator', 'phase 1 and phase 2: duration of response  as per response evaluation criteria in solid tumors  and as adjudicated by the investigator', 'phase 1 and phase 2: time to response according to response evaluation criteria in solid tumors  and as adjudicated by the investigator', 'phase 1 and phase 2: progression-free survival according to response evaluation criteria in solid tumors  and as adjudicated by the investigator'], 'PD-L1': ['PD-L1', 'phase 1 and phase 2: tumor programmed death ligand 1  expression levels', 'overall response in participants with greater than or equal to 50% programmed death-ligand 1  expressing tumor cells'], 'CAR': ['CAR', 'maximum tolerated dose of anti-tumor necrosis factor  receptor superfamily member 8  chimeric antigen receptor  in participants with advanced cd30-expressing lymphomas', 'peak percentage and persistence at 1 month of peripheral blood mononuclear cells  that expressed the chimeric antigen receptor  t-cells', 'number of participants who received preparative chemotherapy followed by cluster of differentiation 19-chimeric antigen receptor : cd19 car t-cells with < grade 4 cytokine release syndrome', 'number of participants in which the prescribed dose of cluster of differentiation 19-chimeric antigen receptor : cd19 car t-cells were successfully manufactured', 'number of participants who were administered intensive chemotherapy prior to cluster of differentiation 19-chimeric antigen receptor : cd19 car infusion', 'death within 8 weeks of the study cell infusion thought to be definitely or probably related to chimeric antigen receptor  t cell therapy', 'duration of persistence of adoptively transferred cd19 chimeric antigen receptor -t cells', 'migration of adoptively transferred cd19 chimeric antigen receptor -t cells'], 'AUC0-t, AUC0-8': ['AUC0-t, AUC0-8', 'part a: effect of cyp3a inhibition by fluconazole on the pk of tazemetostat', 'part b: effect of increased gastric ph by omeprazole on the pk of tazemetostat', 'part a: pk of tazemetostat and its metabolites after administration alone and with fluconazole'], 'AUC0-t, AUC0-∞': ['AUC0-t, AUC0-∞', 'part b: the potential of tazemetostat to inhibit or induce cyp2c8 using repaglinide as a probe substrate', 'part b: the potential of tazemetostat to inhibit or induce cyp2c19 using omeprazole as probe a substrate'], 'Lyophilized': ['Lyophilized', 'arms g+h: : percentage of participants with treatment emergent adas to polatuzumab vedotin', 'arm g : area under concentration-time curve  of polatuzumab vedotin', 'arm g : maximum concentration  of polatuzumab vedotin', 'arm g : systemic clearance  of polatuzumab vedotin', 'arm g : steady-state volume of distribution  of polatuzumab vedotin', 'arm h : cmax of polatuzumab vedotin', 'arm h : auc of polatuzumab vedotin', 'arm h : cl of polatuzumab vedotin', 'arm h : vss of polatuzumab vedotin'], 'TINAS': ['TINAS', 'symptom severity and interference according to therapy-induced neuropathy assessment score  in arms a-f', 'peripheral neuropathy symptom severity: therapy-induced neuropathy assessment scale  overall neuropathy severity score'], '0-816': ['0-816', 'part a: auc: area under the plasma concentration-time curve from time 0 to 816 hrs post-dose for tra', 'part a: auc: area under the whole blood concentration-time curve from time 0 to 816 hrs post-dose for tra'], 'TRA': ['TRA', 'ratio of whole blood total radioactivity  cmax to plasma tra cmax', 'percent of total radioactivity  in urine and feces'], 'Tlast': ['Tlast', 'time of the last quantifiable serum concentration in a dosing interval  of inotuzumab ozogamicin in participants receving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time of the last quantifiable concentration in a dosing interval  of unconjugated calicheamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time of the last quantifiable concentration in a dosing interval  of serum inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time of last measurable concentration', 'time to last measurable plasma concentration  of alectinib'], 'Cav': ['Cav', 'average serum concentration at steady state  of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'average serum concentration  of inotuzumab ozogamicin antibody in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58'], 'Conjugated Plus Unconjugated': ['Conjugated Plus Unconjugated', 'auclast of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'time of the last quantifiable concentration in a dosing interval  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'area under the steady-state serum concentration-time curve  for total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30, and day 58', 'peak serum concentration  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58', 'average serum concentration  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'minimum observed serum trough concentration  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'clearance  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'steady-state volume  of total calicheamicin  distribution in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'mean residence time  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58', 'serum decay half-life  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58'], 'CR or PR': ['CR or PR', 'percentage of participants with objective response  at eoi as determined by the irc and investigator on the basis of pet-ct scans', 'percentage of participants with objective response  at eoi as determined by the irc and investigator on the basis of ct scans alone', 'percentage of participants with best response  during the study as determined by the investigator on the basis of ct scans alone', 'percentage of participants with objective response  at eoi, as determined by the irc using modified cheson 2007 criteria', 'percentage of participants with objective response  at eoi, as determined by the investigator using modified cheson 2007 criteria', 'percentage of participants with objective response  at eoi, as determined by the irc using lugano 2014 criteria', 'percentage of participants with objective response  at eoi, as determined by the investigator using lugano 2014 criteria', 'percentage of participants achieving objective response  as assessed by irc in chemotherapy-pretreated participants', 'percentage of participants achieving objective response  as assessed by irc in chemotherapy-naive participants', 'percentage of participants achieving objective response  as assessed by investigator in re population', 'percentage of participants achieving objective response  as assessed by investigator in chemotherapy-pretreated participants', 'percentage of participants achieving objective response  as assessed by investigator in chemotherapy-naive participants'], 'mcg/mL': ['mcg/mL', 'serum concentration of obinutuzumab', 'serum concentration of atezolizumab'], 'CR + PR': ['CR + PR', 'percentage of participants with objective response  at eoi, as determined by the investigator on the basis of pet-ct scans', 'percentage of participants with objective response  at eoi, as determined by the investigator on the basis of ct scans alone', 'overall response rate  of flavopiridol in patients evaluated utilizing the revised national cancer institute-sponsored working group guidelines', 'response rate: complete remission + partial remission'], 'PLT': ['PLT', 'platelet  nadir', 'the number of days from the date of the stem cell infusion to engraftment of absolute neutrophils  and platelets  will be determined based on daily cbc and differential counts.'], 'GVHD': ['GVHD', 'graft versus host disease', 'total number of subjects with grade ii-iv acute graft-versus-host-disease', 'time to severe graft versus host disease  or death', 'percentage of participants with grade ii-iv acute graft versus host disease', 'percentage of participants with grade iii-iv acute graft versus host disease', 'safety of reduced-dose tacrolimus as assessed by percentage of participants with severe graft versus host disease', 'number of patients with grade ii-iv and grade iii-iv acute graft versus host disease', 'number of patients with chronic graft versus host disease', 'graft-versus-host disease', 'incidence of grade ii-iv acute graft vs. host disease', 'number of participants without graft versus host disease', 'cumulative incidence of grade ii-iv acute graft-versus-host disease', 'incidence of chronic graft-versus-host disease', 'number of participants with graft versus host disease  greater than or equal to grade 3', 'cumulative incidence of grade ii - iv acute graft versus host disease', 'incidence of grade ii-iv and grade iii-iv acute graft-versus-host disease  after transplantation', 'complete and partial resolution of graft-vs-host disease', 'number of participants with graft versus host disease'], '14.8 MBq': ['14.8 MBq', 'total recovery and relative excretion of radioactivity in urine and feces after an oral 800 mg dose of [14c] tazemetostat containing approximately 400 µci  of radioactivity', 'determine the peak plasma concentration  of tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 µci  of radioactivity', 'determine the time to peak plasma concentration  tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 µci  of radioactivity'], 'TRM': ['TRM', 'transplant-related mortality', 'total number of subjects that experienced transplant-related mortality', 'occurrence of treatment related mortality', 'number of transplant-related mortality', 'incidence of transplant related mortality  within 100 days and one year', 'cumulative incidence of transplant related mortality'], 'once daily and twice daily': ['once daily and twice daily', 'maximum tolerated dose  of two dosing regimens', 'dose limiting toxicity  of two dosing regimens'], 'Protocol Appendix I': ['Protocol Appendix I', 'dose limiting toxicity  rate by the nci common toxicity criteria  v2.0 and the method of przepiorka et al', 'grade iii-iv toxicity rate in participants receiving an extended dosage regimen according to the nci common toxicity criteria  version 2.0 and the method of przepiorka et. al. .'], 'CBR': ['CBR', 'clinical benefit rate', 'clinical benefit rate - part 1'], 'IWC': ['IWC', 'percentage of ptcl participants with an overall best response in accordance with a modified international workshop response criteria  1999 in phase 2', 'objective responses assessed by international workshop criteria'], 't½': ['t½', 'terminal phase half-life of romidepsin  in phase 1', 'terminal phase half-life of romidepsin  in phase 1 at cycle 1, day 15', 'terminal elimination phase half-life  of durvalumab', 'terminal half-life  on day 14/21 dose-corrected to 125 mg: multiple dose', 'elimination half-life  of carfilzomib', 'terminal phase half-life of azacitidine', 'terminal phase half-life of azacitidine  after single and multiple doses of azacitidine', 'terminal half-life  of selinexor'], 'DLBCL': ['DLBCL', 'phase 1b: recommended phase 2 dose of lenalidomide in combination with fixed doses of ibrutinib and rituximab in participants with relapsed or refractory diffuse large b cell lymphoma', 'objective response rate  in participants pooled from cohort 5  relapsed/refractory  diffuse large b-cell lymphoma', 'overall survival  in participants pooled from cohort 5  relapsed/refractory  diffuse large b-cell lymphoma', 'duration of response  in participants pooled from cohort 5  relapsed/refractory  diffuse large b-cell lymphoma', 'objective response rate  in programmed cell death ligand 1  positive participants pooled from cohort 5 : relapsed/refractory  diffuse large b-cell lymphoma', 'objective response rate  in programmed cell death ligand 1  negative participants pooled from cohort 5 : relapsed/refractory  diffuse large b-cell lymphoma', 'objective response rate  in programmed cell death ligand 1  indeterminate participants pooled from cohort 5 : relapsed/refractory  diffuse large b-cell lymphoma', 'progression-free survival  in participants pooled from the cohort 5  relapsed/refractory  diffuse large b-cell lymphoma', 'orr in participants with diffuse large b-cell lymphoma'], 'WT': ['WT', 'evaluate the safety and tolerability of alrn-6924 in adult patients with advanced solid tumors or lymphomas with wild-type  tp53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - phase 1', 'evaluate the safety and tolerability of alrn-6924 in adult patients with advanced solid tumors or lymphomas with wild-type  tp53 who are refractory to or intolerant of standard therapy, or for whom no standard therapy exists - phase 2'], 'Pre-dose': ['Pre-dose', 'auc 0-t: area under the concentration-time curve from zero  to time of last quantifiable concentration for eribulin mesylate', 'auc 0-inf: area under the concentration-time curve from zero  extrapolated to infinite time for eribulin mesylate'], 'CR or Partial Response [PR]': ['CR or Partial Response [PR]', 'percentage of participants with objective response , as assessed by investigator using cheson criteria for dlbcl population', 'percentage of participants with objective response , as assessed by investigator using cheson criteria for non-dlbcl population'], 'Ratio of the Amount of Drug Actually Administered to the Amount Planned': ['Ratio of the Amount of Drug Actually Administered to the Amount Planned', 'relative dose intensity of polatuzumab vedotin  for dlbcl population', 'relative dose intensity of polatuzumab vedotin  for non-dlbcl population'], 'nATA': ['nATA', 'number of participants with antitherapeutic antibodies  and neutralizing ata', 'phase 1: percentage of participants who were antitherapeutic antibody  positive, persistently positive or transiently positive, and neutralizing antitherapeutic antibody  positive'], '0-tlast': ['0-tlast', 'auc', 'auc of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg'], 'LVEF': ['LVEF', 'left ventricular ejection fraction', 'change from baseline in left ventricular ejection fraction', 'change from baseline in left ventricular ejection fraction -trajectory'], 'Arms A and B, Cohort C': ['Arms A and B, Cohort C', 'percentage of participants with a best overall response  of complete response  or partial response  as determined by modified response and progression criteria for nhl: rituximab containing regimens', 'duration of objective response  as determined by modified response and progression criteria for nhl: rituximab containing regimens', 'percentage of participants with pd as determined by modified response and progression criteria for nhl or death due to any cause: rituximab containing regimens', 'progression-free survival  as determined by modified response and progression criteria for nhl: rituximab containing regimens', 'percentage of participants who died due to any cause: rituximab containing regimens', 'overall survival : rituximab containing regimens', 'area under the concentration-time curve from time zero to infinity  of rituximab: rituximab containing regimens', 'maximum observed concentration  of rituximab: rituximab containing regimens', 'systemic clearance  of rituximab: rituximab containing regimens', 'half-life  of rituximab: rituximab containing regimens', 'volume of distribution at steady state  of rituximab: rituximab containing regimens'], 'Cohorts E, G, and H': ['Cohorts E, G, and H', 'percentage of participants with cr at eot based on pet/ct assessment as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'percentage of participants with or at eot based on pet/ct assessment as determined by irc per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'percentage of participants with or at eot based on pet/ct assessment as determined by the investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'percentage of participants with best or based on pet/ct or ct assessment as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts'], 'Cohorts E + H and E + G': ['Cohorts E + H and E + G', 'percentage of participants with cr at eot based on ct assessment alone as determined by irc per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'percentage of participants with cr at eot based on ct assessment alone as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'percentage of participants with or at eot based on ct assessment alone as determined by irc per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'percentage of participants with or at eot based on ct assessment alone as determined by investigator per lugano 2014 response criteria: obinutuzumab-containing cohorts', 'cmax of obinutuzumab: obinutuzumab-containing cohorts', 'overall survival : obinutuzumab-containing cohorts', 'percentage of participants who died due to any cause: obinutuzumab containing cohorts', 'progression-free survival  as determined by modified response and progression criteria for nhl: obinutuzumab containing cohorts', 'percentage of participants with pd as determined by modified response and progression criteria for nhl or death due to any cause: obinutuzumab containing cohorts'], 'Single Dose': ['Single Dose', 'pharmacokinetics  parameters: auc0 - 24h & auclast in cycle 1 day 1 - dose escalation phase', 'pharmacokinetics  parameters: auc0 - 24h & auclast in cycle 2 day 1 - dose escalation phase', 'pk parameter: cmax in cycle 1 day 1 - dose escalation phase', 'pk parameter: cmax in cycle 2 day 1 - dose escalation phase', 'pk parameter: tmax in cycle 1 day 1 - dose escalation phase', 'pk parameter: tmax in cycle 2 day 1 - dose escalation phase'], 'Multiple Dose': ['Multiple Dose', 'pharmacokinetics  parameters: auc0 - 24h & auclast in cycle 2 day 1 - dose expansion phase', 'pk parameter: cmax in cycle 2 day 1 - dose expansion phase', 'pk parameter: tmax in cycle 2 day 1 - dose expansion phase'], 'AUC(0-24': ['AUC(0-24', 'area under the plasma concentration curve from time 0 to 24 hours (auc)', 'effect of food on the area under the curve from zero to 24 hours (auc)'], 'DCR': ['DCR', 'antitumor activity of azd5153 in patients by assessing the disease control rate .', 'disease control rate  of sra737', 'disease control rate  in participants with advanced or metastatic solid tumors', 'disease control rate : percentage of participants with a best overall response of complete response, partial response, and stable disease'], 'ECGs': ['ECGs', 'number of participants with clinically significant changes in electrocardiograms  [phase 1]', 'number of participants with clinically significant changes in electrocardiograms  [phase 2]'], 'ECHO': ['ECHO', 'number of participants with clinically significant changes in multigated acquisition / echocardiogram  [phase 1]', 'number of participants with clinically significant changes in multigated acquisition / echocardiogram  [phase 2]'], 'MRT': ['MRT', 'part 1 and 2: mean residence time of the drug in the systemic circulation from zero to infinity', 'mean residence time  extrapolated to infinity for carfilzomib'], 'AUC0-21': ['AUC0-21', 'area under the serum concentration versus time curve from 0 to day 21  of obinutuzumab at cycle 8', 'pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : partial area under the serum concentration-time curve after first dose and as appropriate'], 'DLBCL and FL Participants': ['DLBCL and FL Participants', 'percentage of participants with complete response , cr unconfirmed  at end of treatment  in nhl participants  per cheson 1999 criteria', 'percentage of participants with partial response , stable disease , and progressive disease  at end of treatment  in nhl participants  per cheson 1999 criteria', 'percentage of participants with best overall response  of cr, cru at anytime during study in nhl participants  per cheson 1999 criteria', 'percentage of participants with bor of pr, sd, and pd at anytime during study in nhl participants  per cheson 1999 criteria'], 'NK': ['NK', 'number of patients who received 2 doses of natural killer  cell infusions', 'immune reconstitution of normal killer  cells', 'in vivo natural killer  levels', 'to study the persistence, phenotype and function of donor natural killer  cells after infusion in research participants with chemotherapy refractory hematologic malignancies.', 'the tertiary objective will be to measure the time to immunologic reconstitution as defined by normal numbers of t and b cells, normal t-cell proliferative responses, normal natural killer  cell function, and normal immunoglobulin synthesis.', 'maximum tolerated dose of donor natural killer  cells'], 'cGVHD': ['cGVHD', 'number of participants with mild, moderate and/or severe chronic graft versus host disease', 'percentage of participants with chronic graft versus host disease', 'incidence of acute graft versus host disease  within 100 days and chronic graft versus host disease  within 1 year', 'chronic graft-versus-host disease  outcome'], 't½ ': ['t½ ', 'terminal half-life  on day 1: single dose', 'terminal half-life  on day 8: multiple dose', 'terminal half-life  on day 1: food effect'], '0 - ∞': ['0 - ∞', 'area under the curve from time zero to extrapolated infinite time [auc ] on day 1: single dose', 'area under the curve from time zero to extrapolated infinite time [auc ] on day 8: multiple dose', 'area under the curve from time zero to extrapolated infinite time [auc ] on day 1: food effect'], 'z': ['z', 'terminal phase rate constant [lambda ] on day 1: single dose', 'terminal phase rate constant [lambda ] on day 8: multiple dose', 'terminal phase rate constant [lambda ] on day 14/21 dose-corrected to 125 mg: multiple dose', 'terminal phase rate constant [lambda ] on day 1: food effect'], 'Ae': ['Ae', 'cumulative amount of drug recovered unchanged in the urine : single dose', 'cumulative amount of drug recovered unchanged in the urine : food effect'], 'Percent Ae': ['Percent Ae', 'percent dose recovered unchanged in urine : single dose', 'percent dose recovered unchanged  in urine: food effect'], 'Cdk4/6': ['Cdk4/6', 'correlation of cyclin-dependent kinases 4 and 6  with pd 0322991 dose', 'correlation of cyclin-dependent kinases 4 and 6  with exposure', 'correlation of cyclin-dependent kinases 4 and 6  with tumor response'], 'INRmax': ['INRmax', 'pharmacodynamics: maximum international normalised ratio  following warfarin alone', 'pharmacodynamics: maximum international normalised ratio  following concomitant administration of warfarin and enzastaurin'], 'INR': ['INR', 'pharmacodynamics: area under international normalised ratio-time curve auc following warfarin alone', 'pharmacodynamics: area under international normalised ratio-time curve auc following concomitant administration of warfarin and enzastaurin', 'pharmacodynamics: international normalised ratio  following enzastaurin alone'], 'EOT': ['EOT', 'phase 2: percentage of participants who achieved a complete remission  per independent review facility  assessment per international working group  criteria at end of treatment  visit', 'phase 2: immune reconstitution-change from baseline immunoglobulin g levels at end of treatment', 'phase 2: immune reconstitution-change from baseline in immunoglobulin m at the end of treatment'], 'AUC0-15': ['AUC0-15', 'phase 1: mean area under the serum concentration-time curve from day 0 to day 15  of brentuximab vedotin and tab', 'phase 1: mean area under the plasma concentration-time curve from day 0 to day 15  of mmae'], 'AUCt': ['AUCt', 'area under the plasma concentration-time curve from time 0 to the last measurable concentration  for cc-223', 'area under the plasma concentration-time curve from time 0 to the last measurable concentration  for metabolite m1'], 'AUC0-10': ['AUC0-10', 'area under the plasma concentration time curve from time zero to 10 hours postdose  of enasidenib after a single oral dose on day -3', 'area under the plasma concentration-time curve from time 0 to 10 hours postdose  for metabolite agi-16903 after a single dose of enasidenib on day -3', 'area under the plasma concentration-time curve from time 0 to 10 hours postdose  for enasidenib after multiple doses', 'area under the plasma concentration-time curve from time 0 to 10 hours postdose  for metabolite agi-16903 after multiple doses of enasidenib'], 'AUC0-72': ['AUC0-72', 'area under the plasma concentration time curve from time zero to 72 hours postdose  of enasidenib after a single dose on day -3', 'area under the plasma concentration-time curve from time 0 to 72 hours postdose  for agi-16903 after a single dose of enasidenib on day -3'], 'FCR': ['FCR', 'maximum tolerated dose  of vorinostat that can be combined with fludarabine phosphate, cyclophosphamide and rituximab', 'to eliminate residual disease  in patients who have achieved complete response  after fludarabine, cyclophosphamide, and rituximab  plus vorinostat', 'to estimate the rate of conversion of partial response  to complete response  after fludarabine, cyclophosphamide and rituximab  plus vorinostat'], 'AUC0-∞': ['AUC0-∞', 'area under the plasma concentration time-curve from time zero extrapolated to infinity .', 'area under the plasma concentration time-curve from time 0 extrapolated to infinity'], 'MED': ['MED', 'minimal effective dose  of azacitidine with phenylbutyrate', 'systemic photosensitivity as measured by minimum erythema dose  testing'], 'MFD': ['MFD', 'part a only: define either the maximum tolerated dose , if possible, or maximum feasible dose', 'determine the maximally-tolerated dose  and/or maximum-feasible dose  of jx-594'], 'aGVHD': ['aGVHD', 'occurrence of grade iii or iv acute graft-versus-host disease', 'incidence of treatment failure defined as primary graft failure, grade 3-4 acute graft versus host disease , or non-relapse mortality', 'percentage of participants with grades ii to iv acute graft-versus-host disease', 'acute graft-versus-host disease  outcome'], 'RFS': ['RFS', 'phase 2:relapse free survival', 'relapse free survival  for t-all/lbl participants', 'relapse-free survival  by morphological analysis'], 'rhIL-15': ['rhIL-15', 'maximum tolerated dose  of recombinant human interleukin-15  for 10 day dosing', 'maximum tolerated dose  of recombinant human interleukin-15  for 5 day dosing', 'maximum observed plasma concentration  of recombinant human interleukin-15', 'maximum tolerated dose  of recombinant human interleukin 15'], 'Css': ['Css', 'concentration of drug in plasma at steady state', 'steady state concentrations  of blinatumomab'], 'Partial Response [PR] Plus Complete Response [CR]': ['Partial Response [PR] Plus Complete Response [CR]', 'phase 2a: number of participants achieving overall response rate  as assessed by the investigator', 'phase 1: number of participants achieving overall response rate  as assessed by the investigator'], 'CD4': ['CD4', 'recovery of naïve cluster of differentiation 4  t cells', 'changes in cluster of differentiation 4  t cell receptor vbeta repertoire', 'immune reconstitution of cluster of differentiation 4  t cell populations'], 'CD8': ['CD8', 'recovery of naïve cluster of differentiation 8  t cells', 'immune reconstitution of cluster of differentiation 8  t cell populations'], 'SHBG': ['SHBG', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 1 day 15', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 2 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 4 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 6 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 9 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 12 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 15 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 18 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 21 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 24 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 27 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at cycle 30 day 1', 'geometric mean of ratio of total testosterone, free testosterone, sex hormone binding globulin , luteinizing hormone, follicle stimulating hormone, dihydroepiandrosterone sulfate, estradiol and prolactin levels in males at end of treatment'], 'Vd/F': ['Vd/F', 'rate of drug distribution within the blood stream', 'apparent volume of distribution uncorrected for fraction absorbed  of selinexor'], 'AUC(TAU': ['AUC(TAU', 'area under the concentration-time curve  in one dosing interval (auc) of urelumab', 'bms-986016 area under the concentration-time curve in one dosing interval (auc)'], 'MDS': ['MDS', 'objective response rate  in cohort 1: myelodysplastic syndrome', 'duration of response  in cohort 1: myelodysplastic syndrome', 'objective response rate  in programmed cell death ligand 1  positive participants in cohort 1: myelodysplastic syndrome', 'objective response rate  in programmed cell death ligand 1  negative participants in cohort 1: myelodysplastic syndrome', 'objective response rate  in programmed cell death ligand 1  indeterminate participants in cohort 1: myelodysplastic syndrome', 'marrow complete response  in cohort 1: myelodysplastic syndrome', 'cytogenic complete response in cohort 1: myelodysplastic syndrome', 'cytogenic partial response in cohort 1: myelodysplastic syndrome', 'erythroid response in cohort 1: myelodysplastic syndrome', 'neutrophil response in cohort 1: myelodysplastic syndrome', 'platelet response in cohort 1: myelodysplastic syndrome', 'response as per investigator assessment for patients with myelodysplastic syndromes'], 'MM': ['MM', 'objective response rate  in cohort 2: relapsed refractory/refractory  multiple myeloma', 'duration of response  in cohort 2: relapsed refractory/refractory  multiple myeloma', 'objective response rate  in programmed cell death ligand 1  positive participants in cohort 2: relapsed refractory/refractory  multiple myeloma', 'objective response rate  in programmed cell death ligand 1  negative participants in cohort 2: relapsed refractory/refractory  multiple myeloma', 'objective response rate  in programmed cell death ligand 1  indeterminate participants in cohort 2: relapsed refractory/refractory  multiple myeloma', 'progression-free survival  in cohort 2: relapsed refractory/refractory  multiple myeloma', 'time to progression  in cohort 2: relapsed refractory/refractory  multiple myeloma', 'stringent complete remission  in cohort 2: relapsed refractory/refractory  multiple myeloma', 'complete response  in cohort 2: relapsed refractory/refractory  multiple myeloma', 'number of participants with antibodies to gsk2857916 in serum over time- part 2'], 'Cohorts 4A+4B+4C+4D': ['Cohorts 4A+4B+4C+4D', 'objective response rate  in participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts', 'overall survival  in participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts', 'duration of response  in participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts', 'objective response rate  in programmed cell death ligand 1  positive participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts', 'objective response rate  in programmed cell death ligand 1  negative participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts', 'objective response rate  in programmed cell death ligand 1  indeterminate participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts', 'progression-free survival  in participants pooled from the cohort 4 non-hodgkin lymphoma  sub-cohorts'], 'Cohorts 4A, 4B, 4C, and 4D': ['Cohorts 4A, 4B, 4C, and 4D', 'objective response rate  in the cohort 4 non-hodgkin lymphoma  individual sub-cohorts', 'duration of response  in the cohort 4 non-hodgkin lymphoma  individual sub-cohorts', 'objective response rate  in programmed cell death ligand 1  positive participants in the cohort 4 non-hodgkin lymphoma  individual sub-cohorts', 'objective response rate  in programmed cell death ligand 1  negative participants in the cohort 4 non-hodgkin lymphoma  individual sub-cohorts', 'objective response rate  in programmed cell death ligand 1  indeterminate participants in the cohort 4 non-hodgkin lymphoma  individual sub-cohorts', 'progression-free survival  in the cohort 4 non-hodgkin lymphoma  individual sub-cohorts'], 'QD21D': ['QD21D', 'cmax: maximum observed concentration for alisertib as pill in capsule  with once daily for 21 days  dosing at day 1', 'cmax: maximum observed concentration for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21', 'tmax: time of first occurrence of cmax for alisertib as pill in capsule  with once daily for 21 days  dosing at day 1', 'tmax: time of first occurrence of cmax for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21', 'auct: area under the concentration time curve from time 0 to time t for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21', 'terminal half-life  for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21', 'accumulation ratio  for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21', 'peak/trough ratio for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21', 'clss/f: apparent oral clearance at steady state for alisertib as pill in capsule  with once daily for 21 days  dosing at day 21'], 'QD14D': ['QD14D', 'cmax: maximum observed concentration for alisertib as pill in capsule  with once daily for 14 days  dosing at day 1', 'cmax: maximum observed concentration for alisertib as pill in capsule  with once daily for 14 days  dosing at day 14', 'tmax: time of first occurrence of cmax for alisertib as pill in capsule  with once daily for 14 days  dosing at day 1', 'tmax: time of first occurrence of cmax for alisertib as pill in capsule  with once daily for 14 days  dosing at day 14', 'auct: area under the concentration time curve from time 0 to time t for alisertib as pill in capsule  with once daily for 14 days  dosing at day 14', 'accumulation ratio  for alisertib as pill in capsule  with once daily for 14 days  dosing at day 14', 'peak/trough ratio for alisertib as pill in capsule  with once daily for 14 days  dosing at day 14', 'clss/f: apparent oral clearance at steady state for alisertib as pill in capsule  with once daily for 14 days  dosing at day 14', 'cmax: maximum observed concentration for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 1', 'cmax: maximum observed concentration for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 14', 'tmax: time of first occurrence of cmax for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 1', 'tmax: time of first occurrence of cmax for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 14', 'auct: area under the concentration time curve from time 0 to time t for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 14', 'terminal half life for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 14', 'peak/trough ratio for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 14', 'clss/f: apparent oral clearance at steady state for alisertib as enteric coated tablet  with once daily for 14 days  dosing at day 14'], 'BID7D': ['BID7D', 'cmax: maximum observed concentration for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 1', 'cmax: maximum observed concentration for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7', 'tmax: time of first occurrence of cmax for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 1', 'tmax: time of first occurrence of cmax for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7', 'auct: area under the concentration time curve from time 0 to time t for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 1', 'auct: area under the concentration time curve from time 0 to time t for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7', 'terminal half-life  for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7', 'accumulation ratio  for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7', 'peak/trough ratio for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7', 'clss/f: apparent oral clearance at steady state for alisertib as enteric coated tablet  with twice daily for 7 days  dosing at day 7'], 'dn': ['dn', 'dose-normalized cmax [cmax ] after a single dose on cycle 1 day 1', 'dose-normalized auctau [auctau  ] after a single dose on cycle 1 day 1', 'dose-normalized auctau [auctau ] after multiple dose on cycle 1 day 21', 'dose-normalized cmax [cmax ] after multiple dose on cycle 1 day 21', 'dose-normalized auctau [auctau] in the fasted state for solid tumor participants', 'dose-normalized auctau [auctau] in the fed state for solid tumor participants', 'dose-normalized cmax [cmax] in the fasted state for solid tumor participants', 'dose-normalized cmax [cmax] in the fed state for solid tumor participants', 'dose-normalized auctau [auctau ] on cycle 2 day 1', 'dose-normalized cmax [cmax ] on cycle 2 day 1'], 'NICD': ['NICD', 'changes from baseline in notch intracellular domain  levels in peripheral blood for t-all/lbl participants', 'changes from baseline in notch intracellular domain  levels in bone marrow for t-all/lbl participants'], 'CB-NK': ['CB-NK', 'optimal nk cell dose level of chimeric antigen receptors .cd19-cd28-zeta-2a-icasp9-il15-transduced cord blood natural killer  cells in patients with relapsed/refractory cd19+ b lymphoid malignancies', 'toxicity of chimeric antigen receptors .cd19-cd28-zeta-2a-icasp9-il15-transduced cord blood natural liller  cells in patients with relapsed/refractory cd19+ b lymphoid malignancies', 'efficacy of chimeric antigen receptors .cd19-cd28-zeta-2a-icasp9-il15-transduced cord blood natural killer  cells in patients with relapsed/refractory cd19+ b lymphoid malignancies', 'response of chimeric antigen receptors .cd19-cd28-zeta-2a-icasp9-il15-transduced cord blood natural killer  cells in patients with relapsed/refractory cd19+ b lymphoid malignancies'], 'AML': ['AML', 'response as per investigator assessment for patients with acute myelogenous leukemia', 'response as per investigator assessment for patients with acute myelogenous leukemia  in expansion phase'], 'MWF Every Week': ['MWF Every Week', 'percentages of participants with histone acetylation induction in peripheral blood in arm 1 , group x', 'percentages of participants with histone acetylation induction in peripheral blood in arm 1 , group y', 'highest percent change in fetal hemoglobin from baseline in arm 1'], 'MWF Every Other Week': ['MWF Every Other Week', 'percentages of participants with histone acetylation induction in peripheral blood in arm 2 , group x', 'percentage of participants with histone acetylation induction in peripheral blood in arm 2 , group y', 'highest percent change of fetal hemoglobin from baseline in arm 2'], 'Part A': ['Part A', 'assessment of urine excretion of sar2690301', 'assessment of potential for cyp induction'], 'UCB': ['UCB', 'incidence of neutrophil recovery after umbilical cord blood  transplantation', 'incidence of platelet recovery after umbilical cord blood'], 'RANO': ['RANO', 'percentage of participants with cor according to response assessment in neuro-oncology  criteria by irc: phase ii', 'percentage of participants achieving cns objective response as assessed by irc according to radiology assessment in neuro-oncology  criteria'], '0-last': ['0-last', 'auc of alectinib metabolite', 'metabolite to parent ratio based on auc'], 'non-relapse': ['non-relapse', 'to evaluate the 100-day transplant-related  mortality, including relapse-related mortality associated with grade 4 toxicity.', 'to evaluate the 6 month transplant related  mortality.'], 'Bioequivalence': ['Bioequivalence', 'pharmacokinetics cmax - stage i', 'pharmacokinetics tmax - stage i', 'pharmacokinetics auc-t - stage i', 'pharmacokinetics auc-infinity - stage i', 'pharmacokinetics λz  - stage i', 'pharmacokinetics terminal half-life  - stage i', 'pharmacokinetics apparent total clearance  - stage i', 'pharmacokinetics apparent volume of distribution  - stage i'], 'Food Effect Bioavailability': ['Food Effect Bioavailability', 'pharmacokinetics cmax - stage ii', 'pharmacokinetics tmax - stage ii', 'pharmacokinetics auc-t - stage ii', 'pharmacokinetics auc-infinity - stage ii', 'pharmacokinetics λz  - stage ii', 'pharmacokinetics terminal half-life  - stage ii', 'pharmacokinetics apparent total clearance  - stage ii', 'pharmacokinetics apparent volume of distribution  - stage ii'], 'NRM': ['NRM', 'nonrelapse mortality', 'incidence  with nonrelapse mortality  by day 200'], 'bound and unbound': ['bound and unbound', 'at-101 level', 'paclitaxel level'], 'MDX-1338': ['MDX-1338', 'maximum observed serum concentration  of bms-936564  will be derived from serum concentration versus actual time', 'trough observed serum concentration  of bms-936564  will be derived from serum concentration versus actual time', 'time of maximum observed concentration  of bms-936564  will be derived from serum concentration versus actual time', 'area under the concentration-time curve from time zero extrapolated to infinite time [auc] of bms-936564  will be derived from serum concentration versus actual time', 'area under the concentration-time curve from time zero to the time of the last quantifiable concentration [auc] of bms-936564  will be derived from serum concentration versus actual time', 'area under the concentration-time curve in one dosing interval [auc] of bms-936564  will be derived from serum concentration versus actual time', 'half life  of bms-936564  will be derived from serum concentration versus actual time', 'total body clearance of bms-936564  will be derived from serum concentration versus actual time', 'volume of distribution at steady-state  of bms-936564  will be derived from serum concentration versus actual time', 'biomarker- characterizing the pharmacodynamic  profiles of bms-936564 . the main pd biomarkers are cell trafficking'], 'CBC': ['CBC', 'umbilical cord blood donor engraftment by chimerism and complete blood count', 'safety of ebola and marburg vaccines assessed by change from baseline in levels of complete blood count .'], 'DTH': ['DTH', \"wilm's tumor  delayed-type hypersensitivity\", 'keyhole limpet hemocyanin  delayed-type hypersensitivity'], 'irRECIST': ['irRECIST', 'number of subjects with best overall tumor response by immune-related response evaluation criteria in solid tumors', 'median progression-free survival  by immune-related response evaluation criteria in solid tumors  as estimated using the kaplan-meier method', 'overall disease control rate as measured by immune-related response evaluation criteria in solid tumors'], 'Donor Only': ['Donor Only', 'proportion of donors from whom a sufficient number of cells for transplantation are collected in no more than 2 lp procedures following mobilization with amd3100', 'proportion of donors who experience infusional toxicity'], 'Recipient Only': ['Recipient Only', 'proportion of recipients who experience grade 2-4 acute gvhd', 'proportion of recipients who successfully engraft by day +21 after transplant', 'proportion of recipients who experience chronic gvhd', 'proportion of recipients who experience mortality before day 100 after transplant'], 'IV Donor Arm Only': ['IV Donor Arm Only', 'to determine the pharmacokinetics of iv amd3100  as measured by cmax', 'to determine the pharmacokinetics of iv amd3100  as measured by mean auc from time 0 to infinity'], 'every 28 days constitute 1 cycle': ['every 28 days constitute 1 cycle', 'determine of marqibo® administered as a 60 minute intravenous infusion weekly , in children and adolescents with refractory solid tumors and hematologic malignancies.', 'determine dose limiting toxicities  of marqibo® administered as a 60 minute intravenous infusion weekly , in children and adolescents with refractory solid tumors and hematologic malignancies.'], 'CRh*': ['CRh*', 'rate of complete remission  including complete remission with partial hematological recovery', 'duration of complete remission  or complete remission with partial hematological recovery'], '24 Hour': ['24 Hour', 'change from baseline in urine protein excretion -part 1: gsk2857916 0.06 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 0.03 mg/kg and 0.12 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 0.24 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 0.48 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 0.96 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 1.92 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 2.50 mg/kg', 'change from baseline in urine protein excretion -part 1: gsk2857916 3.40 mg/kg and 4.60 mg/kg'], 'Cohorts A and B': ['Cohorts A and B', 'cutaneous toxicity of combining tseb and brentuximab vedotin in patients with mf or ss .', 'duration of complete skin response', 'overall toxicity', 'skin-related quality of life'], 'Cohort B': ['Cohort B', 'tumor response in lymph nodes', 'tumor response in blood'], '0 - last': ['0 - last', 'pharmacokinetics  parameters of auc calculated by plasma concentration ofvinorelbine', 'pharmacokinetics  parameters of auc calculated by plasma concentration of majormetabolite, 4-o-deacetylvinorelbine'], 'CHR': ['CHR', 'number of ph+ cml participants with confirmed complete hematologic response', 'participants with cml-cp: percentage of participants with complete hematologic response', 'time to complete hematologic response  in chronic phase cml, accelerated or blast phase cml, and ph+all', 'duration of complete hematologic response  in chronic phase cml, accelerated or blast phase cml, and ph+all'], 'MMR': ['MMR', 'number of ph+ cml participants with major molecular response', 'cp-cml, ap-cml, bp-cml, and ph+all participants: percentage of participants with major molecular response', 'participants with  major molecular response'], 'CCyR': ['CCyR', 'participants with cml-cp: time to complete cytogenetic response', 'participants with cml-ap/bp and ph+ all: time to complete cytogenetic response', 'participants with cml-cp: duration of complete cytogenetic response', 'participants with cml-ap/bp and ph+all: duration of complete cytogenetic response'], 'MCyR': ['MCyR', 'participants with cml-cp: time to major cytogenetic response', 'participants with cml-ap/bp and ph+all: time to major cytogenetic response', 'participants with cml-cp: duration of major cytogenetic response', 'participants with cml-ap/bp and ph+ all: duration of major cytogenetic response', 'phase 2, cp-cml participants: percentage of participants with major cytogenetic response', 'number of participants with major cytogenetic response'], 'MaHR': ['MaHR', 'time to major hematologic response  in accelerated or blast phase cml, and ph+all', 'duration of major hematologic response  in accelerated or blast phase cml, and ph+all', 'phase 2, bp-cml and ph+all: percentage of participants with major hematologic response', 'major hematologic response for relapsed philadelphia positive acute lymphoblastic leukemia'], 'OHR': ['OHR', 'time to overall hematologic response  in accelerated or blast phase cml, and ph+all', 'duration of overall hematologic response  in accelerated or blast phase cml, and ph+all'], 'β': ['β', 'terminal phase elimination rate constant  for abbv-621', 'terminal phase elimination rate constant  for venetoclax'], 'HARP MRI': ['HARP MRI', 'change from baseline in global strain', 'change from baseline in global strain -trajectory', 'change from baseline in regional strain', 'change from baseline in regional strain -trajectory'], 'LVEDVI': ['LVEDVI', 'change from baseline in left ventricular end diastolic volume index', 'change from baseline in left ventricular end diastolic volume index -trajectory'], 'LVESVI': ['LVESVI', 'change from baseline in left ventricular end systolic volume index', 'change from baseline in left ventricular end systolic volume index -trajectory'], 'Six Minute Walk Test': ['Six Minute Walk Test', 'change from baseline in exercise tolerance', 'change from baseline in exercise tolerance -trajectory'], 'NT-proBNP': ['NT-proBNP', 'change from baseline in n-terminal pro-brain natriuretic peptide', 'change from baseline in n-terminal pro-brain natriuretic peptide -trajectory'], 'toxicity profile of et190l1 artemis™ t-cell treatment': ['toxicity profile of et190l1 artemis™ t-cell treatment'], 'tmax of serum cytokine levels': ['tmax of serum cytokine levels'], 'time to baseline for serum cytokine levels': ['time to baseline for serum cytokine levels'], 'auc of serum cytokine levels': ['auc of serum cytokine levels'], 'duration of in vivo engraftment of et190l1 artemis™ t cells': ['duration of in vivo engraftment of et190l1 artemis™ t cells'], 'rate of disease response': ['rate of disease response'], 'anti-tumor responses': ['anti-tumor responses'], 'b cell depletion': ['b cell depletion'], 'mtd of everolimus in combination with r-chop': ['mtd of everolimus in combination with r-chop'], 'toxicity profile': ['toxicity profile'], 'proportion of patients who have a significant toxicity': ['proportion of patients who have a significant toxicity'], 'rate of efs': ['rate of efs'], 'objective response rate based on lugano classification criteria': ['objective response rate based on lugano classification criteria'], 'complete response rate based on lugano classification criteria': ['complete response rate based on lugano classification criteria'], 'percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study': ['percentage of participants who experienced a dose-limiting toxicity in dose escalation period of the study'], 'percentage of participants with best overall response': ['percentage of participants with best overall response'], 'systemic clearance of mil62 under steady state': ['systemic clearance of mil62 under steady state'], 'change in cluster of differentiation 19  b cells': ['change in cluster of differentiation 19  b cells'], 'change in cluster of differentiation 20  b cells': ['change in cluster of differentiation 20  b cells'], 'percentage of participants with positive anti-drug antibodies to mil62': ['percentage of participants with positive anti-drug antibodies to mil62'], 'disease control rate': ['disease control rate'], 'incidence rate of dose-limiting toxicities  observed during the dlt assessment period  at each dose level examined': ['incidence rate of dose-limiting toxicities  observed during the dlt assessment period  at each dose level examined'], 'time to next anti-lymphoma treatment': ['time to next anti-lymphoma treatment'], 'incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities': ['incidence of grade ≥ 2 renal toxicities, grade ≥ 2 neuropathy, and grade ≥ 3 toxicities'], 'pharmacodynamic effects of cpi-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3 changes in the expression of genes whose transcription may be altered by ezh2 inhibition': ['pharmacodynamic effects of cpi-1205 in lymphoma tissue: changes in levels of the trimethylated form of lysine residue 27 on histone 3 changes in the expression of genes whose transcription may be altered by ezh2 inhibition'], 'pharmacodynamic effects of cpi-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3': ['pharmacodynamic effects of cpi-1205 in bone marrow and in skin: changes in global levels of the trimethylated form of lysine residue 27 on histone 3'], 'disease response assessment will be performed using the 2014 lugano response criteria for hodgkin and non-hodgkin lymphoma': ['disease response assessment will be performed using the 2014 lugano response criteria for hodgkin and non-hodgkin lymphoma'], 'time to disease progression': ['time to disease progression'], \"duration of response, defined as date at which the patient's objective status is first noted to be either a cr or partial remission to the date progression is documented\": [\"duration of response, defined as date at which the patient's objective status is first noted to be either a cr or partial remission to the date progression is documented\"], 'survival': ['survival time', 'survival'], 'apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib': ['apparent clearance of parsaclisibin combination with rituximab, bendamustine and rituximab, or ibrutinib'], 'apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib': ['apparent volume of distribution of parsaclisib in combination with rituximab, bendamustine and rituximab, or ibrutinib'], 'laboratory safety variables': ['laboratory safety variables'], 'observe the activity of the combination against mantle cell lymphoma  in patients treated in this phase i study.': ['observe the activity of the combination against mantle cell lymphoma  in patients treated in this phase i study.'], 'relapse-free survival': ['relapse-free survival'], 'persistence of car-t cells in vivo': ['persistence of car-t cells in vivo'], '': [''], 'evaluation of the response to locally injected drugs': ['evaluation of the response to locally injected drugs'], 'evaluate the safety profile of multiple simultaneous microinjections using custom syringe': ['evaluate the safety profile of multiple simultaneous microinjections using custom syringe'], 'safety and immunogenicity': ['safety and immunogenicity'], 'antibody and t-cell responses against cd20': ['antibody and t-cell responses against cd20'], 'antitumor response': ['antitumor response'], 'immune responses': ['immune responses'], 'lowest plasma concentration': ['lowest plasma concentration'], 'concentration of drug in plasma': ['concentration of drug in plasma'], 'tolerance score of cd5789 0.01% cream': ['tolerance score of cd5789 0.01% cream'], 'the primary objectives of this study are to determine: a) the appropriate doses of bortezomib and 131i-tositumomab when used in combination. b) toxicities of the combination treatment.': ['the primary objectives of this study are to determine: a) the appropriate doses of bortezomib and 131i-tositumomab when used in combination. b) toxicities of the combination treatment.'], 'assessment of humoral idiotype-specific immune responses': ['assessment of humoral idiotype-specific immune responses'], 'assessment of cellular idiotype-specific immune responses': ['assessment of cellular idiotype-specific immune responses'], 'long-term safety/tolerability as determined by the proportion of patients with toxicities as assessed by the fda cber guidance for industry toxicity grading scale in preventive vaccine clinical trials and the nci/ctcae version 4.02 grade >/= 3': ['long-term safety/tolerability as determined by the proportion of patients with toxicities as assessed by the fda cber guidance for industry toxicity grading scale in preventive vaccine clinical trials and the nci/ctcae version 4.02 grade >/= 3'], 'correlation analysis of pd-l1 expression of tumor': ['correlation analysis of pd-l1 expression of tumor'], 'non-hematological toxicity > grade three, during the treatment cycle': ['non-hematological toxicity > grade three, during the treatment cycle'], 'pharmacokinetics profile': ['pharmacokinetics profile'], 'safety as assessed by mini-mental state examination': ['safety as assessed by mini-mental state examination'], 'toxicity profile assessed by nci ctcae version 4.0': ['toxicity profile assessed by nci ctcae version 4.0'], 'or rate assessed up to 10 years': ['or rate assessed up to 10 years'], 'cr rate assessed up to 10 years': ['cr rate assessed up to 10 years'], 'pfs assessed up to 10 years': ['pfs assessed up to 10 years'], 'part ii: partial response rate  of zanubrutinib in participants with fl and mzl': ['part ii: partial response rate  of zanubrutinib in participants with fl and mzl'], 'part i and part ii: time to steady plasma concentration  for zanubrutinib': ['part i and part ii: time to steady plasma concentration  for zanubrutinib'], 'part i: percentage of btk occupied in peripheral blood mononuclear cells in participants who received zanubrutinib': ['part i: percentage of btk occupied in peripheral blood mononuclear cells in participants who received zanubrutinib'], 'gamma camera-based whole-body 99mtc-1-thio-d-glucose uptake value': ['gamma camera-based whole-body 99mtc-1-thio-d-glucose uptake value'], 'tumor-to-background ratio': ['tumor-to-background ratio'], 'safety attributable to 99mtc-1-thio-d-glucose injections': ['safety attributable to 99mtc-1-thio-d-glucose injections'], 'non-tolerated dose': ['non-tolerated dose'], 'pharmacokinetics - cmax of cc-95775': ['pharmacokinetics - cmax of cc-95775'], 'pharmacokinetics - auc of cc-95775': ['pharmacokinetics - auc of cc-95775'], 'pharmacokinetics - tmax of cc-95775': ['pharmacokinetics - tmax of cc-95775'], 'pharmacokinetics - t1/2 of cc-95775': ['pharmacokinetics - t1/2 of cc-95775'], 'pharmacokinetics - cl/f of cc-95775': ['pharmacokinetics - cl/f of cc-95775'], 'pharmacokinetics - vz/f of cc-95775': ['pharmacokinetics - vz/f of cc-95775'], 'after these drugs are given for 2 courses, a second goal is to see how long a remission lasts.': ['after these drugs are given for 2 courses, a second goal is to see how long a remission lasts.'], 'a third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted.': ['a third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted.'], 'frequency of dose-limiting toxicities  associated with cpi-0610 administration during the first cycle  of treatment': ['frequency of dose-limiting toxicities  associated with cpi-0610 administration during the first cycle  of treatment'], 'pharmacodynamic effects of cpi-0610: changes in the expression of myc and other genes in tumor tissue changes in cellular proliferation and in the extent of apoptosis changes in tumor metabolism': ['pharmacodynamic effects of cpi-0610: changes in the expression of myc and other genes in tumor tissue changes in cellular proliferation and in the extent of apoptosis changes in tumor metabolism'], 'anti-lymphoma activity associated with cpi-0610 treatment': ['anti-lymphoma activity associated with cpi-0610 treatment'], 'auc0-inf': ['auc0-inf'], 'cmax': ['cmax'], 'cd19 positive b cells': ['cd19 positive b cells'], 'cd20 positive b cells': ['cd20 positive b cells'], 'antidrug antibodies of hlx01': ['antidrug antibodies of hlx01'], 'percentage of participants with a treatment emergent ae': ['percentage of participants with a treatment emergent ae'], 'percentage of participants with any grade 3/4 chemistry abnormality during therapy': ['percentage of participants with any grade 3/4 chemistry abnormality during therapy'], 'percentage of participants with any grade 3/4 hematology abnormality during therapy': ['percentage of participants with any grade 3/4 hematology abnormality during therapy'], 'percentage of participants with a best or of cr or pr according to international response criteria for nhls in the de cohorts': ['percentage of participants with a best or of cr or pr according to international response criteria for nhls in the de cohorts'], 'kaplan-meier estimates of the probability of being alive and free from pd or new anticancer therapy at 6, 12, and 24 months in the de cohorts': ['kaplan-meier estimates of the probability of being alive and free from pd or new anticancer therapy at 6, 12, and 24 months in the de cohorts'], 'kaplan-meier estimate of the pfs in the mtd confirmation/ee cohorts': ['kaplan-meier estimate of the pfs in the mtd confirmation/ee cohorts'], 'kaplan-meier estimates of the probability of being alive and free from pd or new anticancer therapy at 6, 12, and 24 months in the mtd confirmation/ee cohorts.': ['kaplan-meier estimates of the probability of being alive and free from pd or new anticancer therapy at 6, 12, and 24 months in the mtd confirmation/ee cohorts.'], 'kaplan-meier estimates of the probability of being alive at 6, 12, and 24 months in the de cohorts': ['kaplan-meier estimates of the probability of being alive at 6, 12, and 24 months in the de cohorts'], 'kaplan-meier estimate of the os in the mtd confirmation/ee cohorts': ['kaplan-meier estimate of the os in the mtd confirmation/ee cohorts'], 'kaplan-meier estimates of the probability of being alive at 6, 12, and 24 months in the mtd confirmation/ee cohorts': ['kaplan-meier estimates of the probability of being alive at 6, 12, and 24 months in the mtd confirmation/ee cohorts'], 'mean inotuzumab ozogamicin serum concentrations': ['mean inotuzumab ozogamicin serum concentrations'], 'severity and duration of grade ≥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea.': ['severity and duration of grade ≥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea.'], 'time to neutrophil engraftment': ['time to neutrophil engraftment'], 'time to platelet engraftment': ['time to platelet engraftment'], 'time to lymphoid recovery': ['time to lymphoid recovery'], 'non-relapse mortality': ['non-relapse mortality'], 'auc for gb241 and rituximab concentrations': ['auc for gb241 and rituximab concentrations'], 'maximum observed concentration of the gb241 and rituximab': ['maximum observed concentration of the gb241 and rituximab'], 'degree of clearance from baseline of cd19+ , cd20+ b-cells between the two study arms': ['degree of clearance from baseline of cd19+ , cd20+ b-cells between the two study arms'], 'comparison of the incidence rate of haca（host anti-chimeric antibody） between the two study arms': ['comparison of the incidence rate of haca（host anti-chimeric antibody） between the two study arms'], 'concentration  of key cytokine and intracellular signalling markers in immune cell subsets': ['concentration  of key cytokine and intracellular signalling markers in immune cell subsets'], 'maximum tolerated dose of bortezomib': ['maximum tolerated dose of bortezomib'], 'safety of 131i-anti-b1 radioimmunotherapy when combined with high-dose beam or beac chemotherapy & hsct': ['safety of 131i-anti-b1 radioimmunotherapy when combined with high-dose beam or beac chemotherapy & hsct'], 'difference in response rates & time to tx failure between historical control patients receiving high-dose beam or beac chemo. with autologous hsct and pateints receiving radioimmunotherapy and high-dose beam or beac chemo. with autologous hsct': ['difference in response rates & time to tx failure between historical control patients receiving high-dose beam or beac chemo. with autologous hsct and pateints receiving radioimmunotherapy and high-dose beam or beac chemo. with autologous hsct'], 'feasibility': ['feasibility'], 'safety as assessed by adverse event monitoring. patients will be questioned and toxicities recorded according to the international common toxicity criteria.': ['safety as assessed by adverse event monitoring. patients will be questioned and toxicities recorded according to the international common toxicity criteria.'], 'reconstitution of ebv-specific ctl immunity with anti-viral efficacy measured by immunological & virological assessment of blood samples including immunophenotyping, intracellular cytokine assays, cd107 cytotoxicity assays and ebv dna load analysis.': ['reconstitution of ebv-specific ctl immunity with anti-viral efficacy measured by immunological & virological assessment of blood samples including immunophenotyping, intracellular cytokine assays, cd107 cytotoxicity assays and ebv dna load analysis.'], 'optimal dose intensity of the intervention. clinical efficacy , biological efficacy , safety & efficacy of the 1st treatment schedule vs the 2nd schedule': ['optimal dose intensity of the intervention. clinical efficacy , biological efficacy , safety & efficacy of the 1st treatment schedule vs the 2nd schedule'], 'clinical efficacy': ['clinical efficacy'], 'percentage of participants with anti-therapeutic antibody response to atezolizumab and obinutuzumab': ['percentage of participants with anti-therapeutic antibody response to atezolizumab and obinutuzumab'], 'percentage of participants with best overall response according to lugano classification': ['percentage of participants with best overall response according to lugano classification'], 'percentage of participants with objective response  according to lugano classification': ['percentage of participants with objective response  according to lugano classification'], 'tazemetostat plasma concentrations': ['tazemetostat plasma concentrations'], 'survival of shi-tar-ccr5rz-marked cells in the peripheral blood, demonstrated by presence of transgene by q-pcr using primers specific for rhiv7-shi-tar-ccr5rz in serial samples of peripheral blood': ['survival of shi-tar-ccr5rz-marked cells in the peripheral blood, demonstrated by presence of transgene by q-pcr using primers specific for rhiv7-shi-tar-ccr5rz in serial samples of peripheral blood'], 'analysis of vector rescue by hiv': ['analysis of vector rescue by hiv'], 'ability to obtain suitable numbers of lentiviral vector treated hpc-a': ['ability to obtain suitable numbers of lentiviral vector treated hpc-a'], 'median duration of response': ['median duration of response'], 'median time to next therapy': ['median time to next therapy'], 'auc0-inf of ibi301 and rituximab': ['auc0-inf of ibi301 and rituximab'], 'percentage and absolute value of cd19+': ['percentage and absolute value of cd19+'], 'percentage and absolute value of cd20+ b-cell': ['percentage and absolute value of cd20+ b-cell'], 'positive rate of ada': ['positive rate of ada'], 'positive rate of nab': ['positive rate of nab'], 'safety profiles': ['safety profiles'], 'auc（0-t） of ibi301 and rituximab': ['auc（0-t） of ibi301 and rituximab'], 'number of participants who respond to treatment': ['number of participants who respond to treatment'], 'overall lymphoma response rate': ['overall lymphoma response rate'], 'safety as assessed using the ctcae': ['safety as assessed using the ctcae'], 'impact of bortezomib alone and in combination with rituximab, ifosfamide, carboplatin, and etoposide  on serum hiv viral loads and apobec3g levels': ['impact of bortezomib alone and in combination with rituximab, ifosfamide, carboplatin, and etoposide  on serum hiv viral loads and apobec3g levels'], 'safety of bortezomib alone in patients with relapsed or refractory aids-associated lymphomas': ['safety of bortezomib alone in patients with relapsed or refractory aids-associated lymphomas'], 'correlation of ebv/hhv-8 viral load changes with lymphoma response': ['correlation of ebv/hhv-8 viral load changes with lymphoma response'], 'area under the concentration  time curve of bi 695500 and rituximab  over the first dosing interval': ['area under the concentration  time curve of bi 695500 and rituximab  over the first dosing interval'], 'auc of bi 695500 and rituximab  over the fourth dosing interval': ['auc of bi 695500 and rituximab  over the fourth dosing interval'], 'area under the depletion-time curve of the cluster of differentiation 19+ b-cell count (% change from baseline ) in peripheral blood from pre-infusion on day 1 until last measurement on day 8': ['area under the depletion-time curve of the cluster of differentiation 19+ b-cell count (% change from baseline ) in peripheral blood from pre-infusion on day 1 until last measurement on day 8'], 'change from baseline  of cd19+ b-cells in peripheral blood measured after seven days on day 8': ['change from baseline  of cd19+ b-cells in peripheral blood measured after seven days on day 8'], 'overall response rate  (complete response  plus partial response ) evaluated approximately one month after last dose of bi 695500 or rituximab': ['overall response rate  (complete response  plus partial response ) evaluated approximately one month after last dose of bi 695500 or rituximab'], 'number of participants reporting at least 1 teae related to laboratory assessments': ['number of participants reporting at least 1 teae related to laboratory assessments'], 'number of participants with clinically significant change from baseline in vital signs': ['number of participants with clinically significant change from baseline in vital signs'], 'c0: initial plasma concentration after bolus intravenous administration': ['c0: initial plasma concentration after bolus intravenous administration'], 'rac: accumulation ratio for ixazomib': ['rac: accumulation ratio for ixazomib'], 'clr: renal clearance': ['clr: renal clearance'], 'emax: maximum observed effect for ixazomib': ['emax: maximum observed effect for ixazomib'], 'temax: time to maximum observed effect  for ixazomib': ['temax: time to maximum observed effect  for ixazomib'], 'overall best response': ['overall best response'], \"determine the toxicity and maximum tolerated dose of doxorubicin hcl liposome when administered with combination chemotherapy in patients with aids-associated non-hodgkin's lymphoma.\": [\"determine the toxicity and maximum tolerated dose of doxorubicin hcl liposome when administered with combination chemotherapy in patients with aids-associated non-hodgkin's lymphoma.\"], 'determine the optimal phase ii dose of doxorubicin hcl liposome to be administered with the combination chemotherapy regimen.': ['determine the optimal phase ii dose of doxorubicin hcl liposome to be administered with the combination chemotherapy regimen.'], 'determine the effect of this regimen on hiv viral load in these patients': ['determine the effect of this regimen on hiv viral load in these patients'], 'determine the clinical response to this regimen by these patients': ['determine the clinical response to this regimen by these patients'], 'maximum tolerated dose  as measured by the number of dose-limiting toxicities in each dose level': ['maximum tolerated dose  as measured by the number of dose-limiting toxicities in each dose level'], 'objective response rate as measured by cd30 expression': ['objective response rate as measured by cd30 expression'], 'change from baseline in maximum standard uptake value  at cycle 1 day 21': ['change from baseline in maximum standard uptake value  at cycle 1 day 21'], 'ki-67 composite score at baseline': ['ki-67 composite score at baseline'], 'ki-67 composite score at cycle 1 day 21': ['ki-67 composite score at cycle 1 day 21'], 'cyclin d1 composite score at baseline': ['cyclin d1 composite score at baseline'], 'cyclin d1 composite score at cycle 1 day 21': ['cyclin d1 composite score at cycle 1 day 21'], 'number of participants with laboratory test abnormalities': ['number of participants with laboratory test abnormalities'], 'correlation coefficient between plasma pd 0332991 concentration and change from baseline in biomarkers and suvmax at cycle 1 day 21': ['correlation coefficient between plasma pd 0332991 concentration and change from baseline in biomarkers and suvmax at cycle 1 day 21'], \"to assess the safety and tolerability of rad001 in japanese patients with relapsed or refractory non-hodgkin's lymphoma\": [\"to assess the safety and tolerability of rad001 in japanese patients with relapsed or refractory non-hodgkin's lymphoma\"], 'to assess the pharmacokinetics in japanese patients': ['to assess the pharmacokinetics in japanese patients'], 'to seek preliminary evidence of efficacy in this population': ['to seek preliminary evidence of efficacy in this population'], 'duration of response for all unconfirmed responders  as assessed by the investigator': ['duration of response for all unconfirmed responders  as assessed by the investigator'], 'time to progression of disease or death': ['time to progression of disease or death'], 'half-life: initial half-life  and terminal half-life  of i 131 tst for the antibody predose levels of 0 mg, 95 mg, and 475 mg': ['half-life: initial half-life  and terminal half-life  of i 131 tst for the antibody predose levels of 0 mg, 95 mg, and 475 mg'], 'number of participants who developed human anti-mouse antibodies  after receiving tositumomab': ['number of participants who developed human anti-mouse antibodies  after receiving tositumomab'], 'time to hama positivity from the first dosimetric dose': ['time to hama positivity from the first dosimetric dose'], 'number of participants with the indicated type of infection': ['number of participants with the indicated type of infection'], 'time to nadir for the indicated hematologic laboratory parameters': ['time to nadir for the indicated hematologic laboratory parameters'], 'time to recovery to baseline for the indicated hematologic laboratory parameters': ['time to recovery to baseline for the indicated hematologic laboratory parameters'], 'nadir values for the hematologic parameters anc, platelets, and wbc count': ['nadir values for the hematologic parameters anc, platelets, and wbc count'], 'nadir values for hemoglobin, a hematologic parameter': ['nadir values for hemoglobin, a hematologic parameter'], 'toxicity after every 3 courses of treatment and every month for up to a year after completion of study treatment': ['toxicity after every 3 courses of treatment and every month for up to a year after completion of study treatment'], 't-cell response after every 3 courses of treatment and every month for up to a year after completion of study treatment': ['t-cell response after every 3 courses of treatment and every month for up to a year after completion of study treatment'], 'toxicity and safety of concurrent chop and alemtuzumab': ['toxicity and safety of concurrent chop and alemtuzumab'], 'determine pharmacokinetics of alemtuzumab': ['determine pharmacokinetics of alemtuzumab'], 'determine immunosuppressive properties of alemtuzumab + chop': ['determine immunosuppressive properties of alemtuzumab + chop'], 'determine if fc receptor-gamma  polymorphism is predictive of response or toxicity with alemtuzumab treatment.': ['determine if fc receptor-gamma  polymorphism is predictive of response or toxicity with alemtuzumab treatment.'], 'evaluate the toxicities of atc infusions armed with cd20bi': ['evaluate the toxicities of atc infusions armed with cd20bi'], 'evaluate immune b-cell recovery after atc infusion': ['evaluate immune b-cell recovery after atc infusion'], 'change in cardiac assessment findings': ['change in cardiac assessment findings'], 'change in clinical laboratory test results': ['change in clinical laboratory test results'], 'change in physical exam finding, including vital signs': ['change in physical exam finding, including vital signs'], 'dose-limiting toxicity of high-dose melphalan in combination with yttrium y 90 ibritumomab tiuxetan': ['dose-limiting toxicity of high-dose melphalan in combination with yttrium y 90 ibritumomab tiuxetan'], 'toxicity': ['toxicity'], 'event occurrence up to 100 days after transplantation': ['event occurrence up to 100 days after transplantation'], 'complete remission 100 days after transplantation': ['complete remission 100 days after transplantation'], 'percent of participants recieving pembrolizumab per protocol schedule': ['percent of participants recieving pembrolizumab per protocol schedule'], 'in vivo cellular kinetics of tisagenlecleucel in blood, bone marrow, lymph nodes and other tissues by qpcr and flow cytometry': ['in vivo cellular kinetics of tisagenlecleucel in blood, bone marrow, lymph nodes and other tissues by qpcr and flow cytometry'], 'impact of pembrolizumab dosing strategy on the cellular kinetics of tisagenlecleucel by qpcr and flow cytometry': ['impact of pembrolizumab dosing strategy on the cellular kinetics of tisagenlecleucel by qpcr and flow cytometry'], 'immunogenicity measured by antibody titres specific to tisagenlecleucel molecule and by the presence of t lymphocytes activated by the tisagenlecleucel protein': ['immunogenicity measured by antibody titres specific to tisagenlecleucel molecule and by the presence of t lymphocytes activated by the tisagenlecleucel protein'], 'percentage of area under the plasma concentration curve extrapolated to infinity (%auc)': ['percentage of area under the plasma concentration curve extrapolated to infinity (%auc)'], 'percentage recovery of 14^c- lenvatinib related material in the urine': ['percentage recovery of 14^c- lenvatinib related material in the urine'], 'percentage recovery of 14^c- lenvatinib related material in the feces': ['percentage recovery of 14^c- lenvatinib related material in the feces'], 'cmax of incb053914 in combination with incb050465': ['cmax of incb053914 in combination with incb050465'], 'tmax of incb053914 in combination with incb050465': ['tmax of incb053914 in combination with incb050465'], 'cmin of incb053914 in combination with incb050465': ['cmin of incb053914 in combination with incb050465'], 'auc0-t of incb053914 in combination with incb050465': ['auc0-t of incb053914 in combination with incb050465'], 'cl/f of incb053914 in combination with incb050465': ['cl/f of incb053914 in combination with incb050465'], 'part i: total drug exposure': ['part i: total drug exposure'], 'tumor response .': ['tumor response .'], 'safety profile of osi-027': ['safety profile of osi-027'], 'pharmacokinetic profile of osi-027': ['pharmacokinetic profile of osi-027'], 'preliminary pharmacodynamic relationship with osi-027 systemic exposure': ['preliminary pharmacodynamic relationship with osi-027 systemic exposure'], 'preliminary antitumor activity of osi-027': ['preliminary antitumor activity of osi-027'], 'whether intra-csf administration of rituximab in combination with mtx in patients with recurrent cns and intraocular lymphoma is associated with neurotoxicity': ['whether intra-csf administration of rituximab in combination with mtx in patients with recurrent cns and intraocular lymphoma is associated with neurotoxicity'], 'to define the rate of tumor response  in the brain, spine, eye, or csf.': ['to define the rate of tumor response  in the brain, spine, eye, or csf.'], 'clinical response': ['clinical response'], 'proportion of participants with adas to mosunetuzumab': ['proportion of participants with adas to mosunetuzumab'], \"anti-tumor activity of hbi-8000 by overall response status based on cheson's response criteria for nhl and japan clinical oncology group  response criteria for adult t-cell lymphoma\": [\"anti-tumor activity of hbi-8000 by overall response status based on cheson's response criteria for nhl and japan clinical oncology group  response criteria for adult t-cell lymphoma\"], 'determine the maximum tolerated dose of absorbed radiation to critical organs delivered with this combination of study treatments': ['determine the maximum tolerated dose of absorbed radiation to critical organs delivered with this combination of study treatments'], 'primary outcome measures: maximum tolerated dose of lee011 when administered orally once daily, as assessed by frequency of dlts as a function of lee011 dose': ['primary outcome measures: maximum tolerated dose of lee011 when administered orally once daily, as assessed by frequency of dlts as a function of lee011 dose'], 'the pharmacokinetics  of lee011': ['the pharmacokinetics  of lee011'], 'any pharmacodynamic activity of lee011 treatment, as assessed by changes from baseline in biomarkers associated with the pharmacologic activity of lee011': ['any pharmacodynamic activity of lee011 treatment, as assessed by changes from baseline in biomarkers associated with the pharmacologic activity of lee011'], 'relationship between qtc prolongation and exposure to lee011 and/or any of its relevant metabolites.': ['relationship between qtc prolongation and exposure to lee011 and/or any of its relevant metabolites.'], 'safety': ['safety'], 'pharmacokinetics': ['pharmacokinetics', 'pharmacokinetic parameters'], 'pharmacodynamics': ['pharmacodynamics'], 'response': ['response'], 'to identify the mtd of tak-901 administered as either a 3-hour or 1-hour infusion.': ['to identify the mtd of tak-901 administered as either a 3-hour or 1-hour infusion.'], 'to adaptively adjust the estimate of the mtd of tak-901 from the escalation phase in an expansion cohort of subjects.': ['to adaptively adjust the estimate of the mtd of tak-901 from the escalation phase in an expansion cohort of subjects.'], 'to evaluate the pharmacokinetic profile of tak-901 and its primary metabolite .': ['to evaluate the pharmacokinetic profile of tak-901 and its primary metabolite .'], 'to evaluate disease response.': ['to evaluate disease response.'], 'to investigate the effect of tak-901 on tumor proliferation.': ['to investigate the effect of tak-901 on tumor proliferation.'], 'incidence and grade of clinical laboratory abnormalities through 1 month after treatment': ['incidence and grade of clinical laboratory abnormalities through 1 month after treatment'], \"disease response by the international workshop to standardize response criteria for non-hodgkin's lymphomas 2 weeks after completion of the first treatment cycle\": [\"disease response by the international workshop to standardize response criteria for non-hodgkin's lymphomas 2 weeks after completion of the first treatment cycle\"], 'immunogenicity by incidence of anti-ril-21 antibodies up to 1 month after treatment': ['immunogenicity by incidence of anti-ril-21 antibodies up to 1 month after treatment'], 'determine efficacy: best overall response': ['determine efficacy: best overall response'], 'define the duration of response': ['define the duration of response'], 'identify immunohistochemistry biomarkers': ['identify immunohistochemistry biomarkers'], 'identify phosphorylation biomarkers': ['identify phosphorylation biomarkers'], 'identify scd30 and tarc biomarkers': ['identify scd30 and tarc biomarkers'], 'determine the maximum tolerated dose': ['determine the maximum tolerated dose'], 'the best overall tumour response rate': ['the best overall tumour response rate'], 'dosimetry': ['dosimetry'], 'percentage of participants with cr, determined by the investigator on the basis of pet and ct scans': ['percentage of participants with cr, determined by the investigator on the basis of pet and ct scans'], 'percentage of participants with cr, determined by the investigator on the basis of ct scans alone': ['percentage of participants with cr, determined by the investigator on the basis of ct scans alone'], 'percentage of participants with cr, determined by the irc on the basis of ct scans alone': ['percentage of participants with cr, determined by the irc on the basis of ct scans alone'], 'percentage of participants with objective response, determined by an irc on the basis of pet and ct scans': ['percentage of participants with objective response, determined by an irc on the basis of pet and ct scans'], 'percentage of participants with objective response, determined by the investigator on the basis of pet and ct scans': ['percentage of participants with objective response, determined by the investigator on the basis of pet and ct scans'], 'percentage of participants with objective response, determined by an irc on the basis of ct scans alone': ['percentage of participants with objective response, determined by an irc on the basis of ct scans alone'], 'percentage of participants with objective response, determined by the investigator on the basis of ct scans alone': ['percentage of participants with objective response, determined by the investigator on the basis of ct scans alone'], 'percentage of participants with best response of cr or pr, determined by the investigator on the basis of ct scans alone': ['percentage of participants with best response of cr or pr, determined by the investigator on the basis of ct scans alone'], 'observed serum obinutuzumab concentration': ['observed serum obinutuzumab concentration'], 'observed serum rituximab concentration': ['observed serum rituximab concentration'], 'observed serum polatuzumab vedotin concentration': ['observed serum polatuzumab vedotin concentration'], 'observed plasma polatuzumab vedotin concentration': ['observed plasma polatuzumab vedotin concentration'], 'observed serum concentration of total antibody to polatuzumab vedotin': ['observed serum concentration of total antibody to polatuzumab vedotin'], 'observed plasma concentration of polatuzumab vedotin unconjugated mmae': ['observed plasma concentration of polatuzumab vedotin unconjugated mmae'], 'observed plasma venetoclax concentration': ['observed plasma venetoclax concentration'], 'percentage of participants with human anti-human antibodies  to obinutuzumab': ['percentage of participants with human anti-human antibodies  to obinutuzumab'], 'incidence of anti-blinatumomab antibodies': ['incidence of anti-blinatumomab antibodies'], \"determination of the maximum tolerated dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin's lymphoma\": [\"determination of the maximum tolerated dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin's lymphoma\"], \"determination of the recommended phase 2 dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin's lymphoma\": [\"determination of the recommended phase 2 dose of abt-199 when administered with bendamustine and rituximab in subjects with relapsed or refractory non-hodgkin's lymphoma\"], 'evaluate preliminary data regarding progression-free survival when abt-199 is administered in combination with bendamustine and rituximab': ['evaluate preliminary data regarding progression-free survival when abt-199 is administered in combination with bendamustine and rituximab'], 'evaluate preliminary data regarding objective response rate when abt-199 is administered in combination with bendamustine and rituximab': ['evaluate preliminary data regarding objective response rate when abt-199 is administered in combination with bendamustine and rituximab'], 'evaluate preliminary data regarding time to tumor progression when abt-199 is administered in combination with bendamustine and rituximab.': ['evaluate preliminary data regarding time to tumor progression when abt-199 is administered in combination with bendamustine and rituximab.'], 'percentage of patients with complete or partial response as measured by change in lesion severity using cails': ['percentage of patients with complete or partial response as measured by change in lesion severity using cails'], 'characterize and quantify the toxicity profile associated with clofarabine': ['characterize and quantify the toxicity profile associated with clofarabine'], 'determine the overall response rate, plus partial response of clofarabine': ['determine the overall response rate, plus partial response of clofarabine'], 'to evaluate the biologic effects of sb-485232 given in combination with ofatumumab': ['to evaluate the biologic effects of sb-485232 given in combination with ofatumumab'], 'plasma concentration of pralatrexate in combination with chop': ['plasma concentration of pralatrexate in combination with chop'], 'to assess the safety and to determine the maximum tolerated dose of pemetrexed given intravenously for the treatment of recurrent lymphoma invading the cns.': ['to assess the safety and to determine the maximum tolerated dose of pemetrexed given intravenously for the treatment of recurrent lymphoma invading the cns.'], 'to determine the plasma pharmacokinetics of pemetrexed and assess drug penetration into the csf.': ['to determine the plasma pharmacokinetics of pemetrexed and assess drug penetration into the csf.'], 'to provide preliminary evidence of pemetrexed activity against brain lymphoma my mri criteria of clearance of csf lymphoma cells.': ['to provide preliminary evidence of pemetrexed activity against brain lymphoma my mri criteria of clearance of csf lymphoma cells.'], 'to identify the time to complete response.': ['to identify the time to complete response.'], 'to provide a measure of reduction of enhancing tumor volume as compared to our nomogram of reduction of tumor volume for methotrexate recipients with brain lymphoma.': ['to provide a measure of reduction of enhancing tumor volume as compared to our nomogram of reduction of tumor volume for methotrexate recipients with brain lymphoma.'], 'recommended dose': ['recommended dose'], 'evaluate the safety and tolerability of cep-9722 in combination with gemcitabine and cisplatin': ['evaluate the safety and tolerability of cep-9722 in combination with gemcitabine and cisplatin'], 'cmax pharmacokinetics parameter': ['cmax pharmacokinetics parameter'], 'auc pharmacokinetics parameter': ['auc pharmacokinetics parameter'], 'pharmacodynamics assessment': ['pharmacodynamics assessment'], 'efficacy - will be assessed by tumor response evaluation of each patient': ['efficacy - will be assessed by tumor response evaluation of each patient'], 'the maximum tolerated dose of iodine-131 anti b-1 antibody in patients with previously treated nhl having more than 25% bone marrow involvement with lymphoma.': ['the maximum tolerated dose of iodine-131 anti b-1 antibody in patients with previously treated nhl having more than 25% bone marrow involvement with lymphoma.'], 'time to treatment failure': ['time to treatment failure'], 'phase i part: determination of the recommended dose of rad001 in combination with rituximab.': ['phase i part: determination of the recommended dose of rad001 in combination with rituximab.'], 'phase ii part: complete response rate': ['phase ii part: complete response rate'], 'number of participants with anti-therapeutic antibodies  to brentuximab vedotin': ['number of participants with anti-therapeutic antibodies  to brentuximab vedotin'], 'number of participants with markedly abnormal laboratory values': ['number of participants with markedly abnormal laboratory values'], 'determination of the recommended dose of cc-292 and lenalidomide in patients with relapsed/refractory b-cell lymphoma': ['determination of the recommended dose of cc-292 and lenalidomide in patients with relapsed/refractory b-cell lymphoma'], 'preliminary efficacy signals of the cc-292 + lenalidomide combination': ['preliminary efficacy signals of the cc-292 + lenalidomide combination'], 'observed maximum plasma concentration': ['observed maximum plasma concentration'], 'btk receptor occupancy': ['btk receptor occupancy'], 'selected dose of aflibercept based on dose limiting toxicities observed': ['selected dose of aflibercept based on dose limiting toxicities observed'], 'biomarkers': ['biomarkers'], 'maximum tolerated dose : part 1': ['maximum tolerated dose : part 1'], 'safety and tolerability profile': ['safety and tolerability profile'], 'tumor response assessment': ['tumor response assessment'], 'pharmacokinetics- cmax': ['pharmacokinetics- cmax'], 'pharmacokinetics - auc': ['pharmacokinetics - auc'], 'pharmacokinetics - tmax': ['pharmacokinetics - tmax'], 'pharmacokinetics - t1/2': ['pharmacokinetics - t1/2'], 'pharmacokinetics cl/f': ['pharmacokinetics cl/f'], 'pharmacokinetics - vz/f': ['pharmacokinetics - vz/f'], 'tumour size reduction': ['tumour size reduction'], 'best overall response based on all assessment': ['best overall response based on all assessment'], 'best overall response based on imaging data': ['best overall response based on imaging data'], 'plasma levels for gsk461364 will be taken at:schedule 1:day 1, 8, 15, & 22 for cycle 1 and day 1, 8 & 15 for subsequent cycles.schedule 2:day 1, 2, 8, 9, 15, & 16 for all cycles.schedule 3:day 1 to 5 for all cycles.': ['plasma levels for gsk461364 will be taken at:schedule 1:day 1, 8, 15, & 22 for cycle 1 and day 1, 8 & 15 for subsequent cycles.schedule 2:day 1, 2, 8, 9, 15, & 16 for all cycles.schedule 3:day 1 to 5 for all cycles.'], 'safety will be evaluated by: - physical exam at screen & then d1 for each cycle - 12 lead ecg & telemetry at screen & wk 1 to 3 for schedule 1 & 2, & wk 1 & 2  for schedule 3. - lab tests & ae monitoring throughout the study.': ['safety will be evaluated by: - physical exam at screen & then d1 for each cycle - 12 lead ecg & telemetry at screen & wk 1 to 3 for schedule 1 & 2, & wk 1 & 2  for schedule 3. - lab tests & ae monitoring throughout the study.'], 'elimination half life of jnj-42756493': ['elimination half life of jnj-42756493'], 'total clearance of jnj-42756493': ['total clearance of jnj-42756493'], 'number of participants with objective tumor response': ['number of participants with objective tumor response'], 'number of participants with an adverse event': ['number of participants with an adverse event'], 'number of participants with treatment related dose limiting toxicity as assessed by nci ctcae v4.0': ['number of participants with treatment related dose limiting toxicity as assessed by nci ctcae v4.0'], 'recommended phase ii dose of gdc-0575': ['recommended phase ii dose of gdc-0575'], 'pk-dose proportionality as assessed with cmax of gdc-0575': ['pk-dose proportionality as assessed with cmax of gdc-0575'], 'pk-dose proportionality as assessed with auc of gdc-0575': ['pk-dose proportionality as assessed with auc of gdc-0575'], 'duration of objective response as determined using recist v1.1': ['duration of objective response as determined using recist v1.1'], 'dose expansion part: percentage of participants with objective response': ['dose expansion part: percentage of participants with objective response'], 'dose expansion part: percentage of participants with disease control': ['dose expansion part: percentage of participants with disease control'], 'dose escalation part: percentage of participants with objective response': ['dose escalation part: percentage of participants with objective response'], 'dose escalation part: dor': ['dose escalation part: dor'], 'dose escalation part: percentage of participants with disease control': ['dose escalation part: percentage of participants with disease control'], 'cmax: maximum observed plasma concentration for e7766': ['cmax: maximum observed plasma concentration for e7766'], 'auc: area under the plasma concentration versus time curve for e7766': ['auc: area under the plasma concentration versus time curve for e7766'], 't1/2: terminal elimination half-life for e7766': ['t1/2: terminal elimination half-life for e7766'], 'cl/f: apparent total body clearance for e7766': ['cl/f: apparent total body clearance for e7766'], 'vd/f: apparent volume of distribution for e7766': ['vd/f: apparent volume of distribution for e7766'], 'clr: renal clearance for e7766': ['clr: renal clearance for e7766'], 'r: accumulation ratio for e7766': ['r: accumulation ratio for e7766'], 'dose escalation and dose expansion: change in tumor size in injected lesions and in distant non-injected lesions': ['dose escalation and dose expansion: change in tumor size in injected lesions and in distant non-injected lesions'], 'preliminary anti-tumor activity of ca-170 based on recist and immune related response criterion  for solid tumors or cheson for lymphoma': ['preliminary anti-tumor activity of ca-170 based on recist and immune related response criterion  for solid tumors or cheson for lymphoma'], 'to describe the dose limiting toxicities, adverse event profile, and phase ii recommended dose of camptothecin-20-o-propionate hydrate .': ['to describe the dose limiting toxicities, adverse event profile, and phase ii recommended dose of camptothecin-20-o-propionate hydrate .'], 'to perform a pharmacokinetic study of orally administered cz48 in the plasma. to assess responses by recist criteria and to follow patients for survival.': ['to perform a pharmacokinetic study of orally administered cz48 in the plasma. to assess responses by recist criteria and to follow patients for survival.'], 'response will be evaluated every 2 cycles , according to the revised recist guideline, version 1.1': ['response will be evaluated every 2 cycles , according to the revised recist guideline, version 1.1'], 'evaluate evidence of antitumor activity of cx-3543 by objective radiographic assessment.': ['evaluate evidence of antitumor activity of cx-3543 by objective radiographic assessment.'], 'pharmacodynamic evaluation of antitumor activity': ['pharmacodynamic evaluation of antitumor activity'], 'incidence of dlts during the first cycle of treatment with single agent mik665 during the dose escalation phase only': ['incidence of dlts during the first cycle of treatment with single agent mik665 during the dose escalation phase only'], 'tolerability: dose interruptions': ['tolerability: dose interruptions'], 'tolerability: dose reductions': ['tolerability: dose reductions'], 'tolerability: dose intensity': ['tolerability: dose intensity'], 'recommended dose of camidanlumab tesirine for part 2': ['recommended dose of camidanlumab tesirine for part 2'], 'volume of distribution for camidanlumab tesirine': ['volume of distribution for camidanlumab tesirine'], 'clearance of camidanlumab tesirine': ['clearance of camidanlumab tesirine'], 'overall response  rate as determined by independent radiological central review  using modified lugano response criteria- rd expansion - part 2': ['overall response  rate as determined by independent radiological central review  using modified lugano response criteria- rd expansion - part 2'], 'objective response rate, as determined by the icr and by the investigator on the basis of modified lugano response criteria- part 1 and part 2': ['objective response rate, as determined by the icr and by the investigator on the basis of modified lugano response criteria- part 1 and part 2'], 'objective response rate, as determined by the icr and by the investigator on the basis of ct scans alone- part 1 and part 2': ['objective response rate, as determined by the icr and by the investigator on the basis of ct scans alone- part 1 and part 2'], 'to determine the mtd of allogenetic nk cells': ['to determine the mtd of allogenetic nk cells'], 'to determine the overall response rate': ['to determine the overall response rate'], 'to evaluate the safety': ['to evaluate the safety'], 'to evaluate the pharmacokinetics of allogeneic nk cells': ['to evaluate the pharmacokinetics of allogeneic nk cells'], 'pharmacokinetic indexes, tmax': ['pharmacokinetic indexes, tmax'], 'pharmacokinetic indexes, maximum concentration': ['pharmacokinetic indexes, maximum concentration'], 'cmax: maximum plasma concentration of tazemetostat and its metabolite er-897387': ['cmax: maximum plasma concentration of tazemetostat and its metabolite er-897387'], 'auc: area under the plasma concentration-time curve from time zero to 12 hours post-dose of tazemetostat and its metabolite er-897387': ['auc: area under the plasma concentration-time curve from time zero to 12 hours post-dose of tazemetostat and its metabolite er-897387'], 'auc: area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of tazemetostat and its metabolite er-897387': ['auc: area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of tazemetostat and its metabolite er-897387'], 'auc: area under the plasma concentration-time curve from time 0 to infinity of tazemetostat and its metabolite er-897387': ['auc: area under the plasma concentration-time curve from time 0 to infinity of tazemetostat and its metabolite er-897387'], 'lambda z: terminal phase elimination rate constant of tazemetostat and its metabolite er-897387': ['lambda z: terminal phase elimination rate constant of tazemetostat and its metabolite er-897387'], 't1/2: terminal half-life of tazemetostat and its metabolite er-897387': ['t1/2: terminal half-life of tazemetostat and its metabolite er-897387'], 'cl/f: apparent total body clearance of tazemetostat': ['cl/f: apparent total body clearance of tazemetostat'], 'vz/f: apparent volume of distribution at terminal phase of tazemetostat': ['vz/f: apparent volume of distribution at terminal phase of tazemetostat'], 'mrt: mean residence time of tazemetostat and its metabolite er-897387': ['mrt: mean residence time of tazemetostat and its metabolite er-897387'], 'auc: area under the plasma concentration-time curve over the dosing interval of tazemetostat and its metabolite er-897387': ['auc: area under the plasma concentration-time curve over the dosing interval of tazemetostat and its metabolite er-897387'], 'css,av: average steady state plasma concentration of tazemetostat and its metabolite er-897387': ['css,av: average steady state plasma concentration of tazemetostat and its metabolite er-897387'], 'css,max: maximum steady state plasma concentration of tazemetostat and its metabolite er-897387': ['css,max: maximum steady state plasma concentration of tazemetostat and its metabolite er-897387'], 'css,min: minimum steady state plasma concentration of tazemetostat and its metabolite er-897387': ['css,min: minimum steady state plasma concentration of tazemetostat and its metabolite er-897387'], 'ptf: peak-trough fluctuation ratio of tazemetostat and its metabolite er-897387': ['ptf: peak-trough fluctuation ratio of tazemetostat and its metabolite er-897387'], 'clss/f: apparent total body clearance of tazemetostat at steady state': ['clss/f: apparent total body clearance of tazemetostat at steady state'], 'rss: steady state accumulation ratio of tazemetostat and its metabolite er-897387': ['rss: steady state accumulation ratio of tazemetostat and its metabolite er-897387'], 'ae: amount of unchanged drug tazemetostat excreted in urine': ['ae: amount of unchanged drug tazemetostat excreted in urine'], 'fe: fraction of tazemetostat dose excreted in urine': ['fe: fraction of tazemetostat dose excreted in urine'], 'clr: renal clearance of tazemetostat': ['clr: renal clearance of tazemetostat'], 'pk parameter: ctau of alobresib': ['pk parameter: ctau of alobresib'], 'pk parameter: auc0-24 of alobresib': ['pk parameter: auc0-24 of alobresib'], 'pk parameter: auctau of alobresib': ['pk parameter: auctau of alobresib'], 'pk parameter: tmax of alobresib': ['pk parameter: tmax of alobresib'], 'pk parameter: t1/2 of alobresib': ['pk parameter: t1/2 of alobresib'], 'tumor response': ['tumor response'], 'plasma concentration-time profile': ['plasma concentration-time profile'], 'safety and tolerance': ['safety and tolerance'], 'effectiveness of study drug': ['effectiveness of study drug'], 'pet and ct': ['pet and ct'], 'safety, tolerability, and maximum tolerated dose of oral administration of two formulations of xl147 in two treatment schedules': ['safety, tolerability, and maximum tolerated dose of oral administration of two formulations of xl147 in two treatment schedules'], 'safety and tolerability of oral dosing with xl147 capsules in subjects with lymphoma, and of xl147 capsules and tablets in subjects with solid tumors': ['safety and tolerability of oral dosing with xl147 capsules in subjects with lymphoma, and of xl147 capsules and tablets in subjects with solid tumors'], 'plasma pharmacokinetics of daily oral administration of xl147 in two treatment schedules': ['plasma pharmacokinetics of daily oral administration of xl147 in two treatment schedules'], 'pharmacodynamic effects of xl147 on tumor tissue when administered at the maximum tolerated dose in two treatment schedules': ['pharmacodynamic effects of xl147 on tumor tissue when administered at the maximum tolerated dose in two treatment schedules'], 'plasma pharmacokinetics of xl147 capsule and tablet formulations': ['plasma pharmacokinetics of xl147 capsule and tablet formulations'], 'to determine the safety and tolerability of afm13 monotherapy.': ['to determine the safety and tolerability of afm13 monotherapy.'], 'to determine the obd  or mtd  of afm13': ['to determine the obd  or mtd  of afm13'], 'to define the pharmacokinetic profile of afm13.': ['to define the pharmacokinetic profile of afm13.'], 'to analyse immunological markers of activity': ['to analyse immunological markers of activity'], 'to assess the immunogenicity of afm13.': ['to assess the immunogenicity of afm13.'], 'to assess the activity of afm13': ['to assess the activity of afm13'], 'phase 2 overall response rate': ['phase 2 overall response rate'], 'the number of participants affected by an adverse event': ['the number of participants affected by an adverse event'], 'maximum observed plasma concentration of jnj-40346527': ['maximum observed plasma concentration of jnj-40346527'], 'trough plasma concentration of jnj-40346527': ['trough plasma concentration of jnj-40346527'], 'minimum observed plasma concentration of jnj-40346527': ['minimum observed plasma concentration of jnj-40346527'], 'time of maximum observed plasma concentration of jnj-40346527': ['time of maximum observed plasma concentration of jnj-40346527'], 'area under the plasma concentration-time curve of jnj-40346527': ['area under the plasma concentration-time curve of jnj-40346527'], 'total drug clearance of jnj-40346527': ['total drug clearance of jnj-40346527'], 'accumulation index of jnj-40346527': ['accumulation index of jnj-40346527'], 'safety of rp6530': ['safety of rp6530'], 'serum concentration profiles of gwn323 as a single agent: cmax': ['serum concentration profiles of gwn323 as a single agent: cmax'], 'serum concentration profiles of gwn323 in combination with pdr001 and derived pk parameters: cmax': ['serum concentration profiles of gwn323 in combination with pdr001 and derived pk parameters: cmax'], 'presence and titer of anti-gwn323 antibodies': ['presence and titer of anti-gwn323 antibodies'], 'measurement of the effector/regulatory t cell ratio': ['measurement of the effector/regulatory t cell ratio'], 'serum concentration profiles of gwn323 as a single agent: auc': ['serum concentration profiles of gwn323 as a single agent: auc'], 'serum concentration profiles of gwn323 in combination with pdr001 and derived pk parameters: auc': ['serum concentration profiles of gwn323 in combination with pdr001 and derived pk parameters: auc'], 'presence and titer of anti-pdr001 antibodies': ['presence and titer of anti-pdr001 antibodies'], 'area under the plasma concentration-time curve  for dcds0780a conjugate': ['area under the plasma concentration-time curve  for dcds0780a conjugate'], 'obinutuzumab serum concentration': ['obinutuzumab serum concentration'], 'rituximab serum concentration': ['rituximab serum concentration'], 'percentage of participants with anti-dcds0780a antibodies': ['percentage of participants with anti-dcds0780a antibodies'], 'absolute lymphocyte count': ['absolute lymphocyte count'], 'change from baseline in intra-patient absolute lymphocyte counts': ['change from baseline in intra-patient absolute lymphocyte counts'], 'time to cd19+ b-cell count recovery to baseline value': ['time to cd19+ b-cell count recovery to baseline value'], 'duration of response assessed according to lugano classification': ['duration of response assessed according to lugano classification'], 'relative dose intensity  calculated as ratio of amount of drug actually administered to the amount planned': ['relative dose intensity  calculated as ratio of amount of drug actually administered to the amount planned'], 'determine the safety and the maximum tolerated dose of jnj-26481585. determine how jnj-26481585 and its metabolite, jnj-26395018, are absorbed, broken down and eliminated after oral administration': ['determine the safety and the maximum tolerated dose of jnj-26481585. determine how jnj-26481585 and its metabolite, jnj-26395018, are absorbed, broken down and eliminated after oral administration'], 'investigate the effect of food on the absorption, break down and elimination of jnj-26481585 and its metabolite, jnj-26395018. monitor the antitumor activity of jnj-26481585.': ['investigate the effect of food on the absorption, break down and elimination of jnj-26481585 and its metabolite, jnj-26395018. monitor the antitumor activity of jnj-26481585.'], 'cl': ['cl'], 'vss': ['vss'], 'vz': ['vz'], 'excretion profile of total and free  platinum': ['excretion profile of total and free  platinum'], 'blood concentrations of sgn-cd19a and metabolites': ['blood concentrations of sgn-cd19a and metabolites'], 'incidence of antitherapeutic antibodies': ['incidence of antitherapeutic antibodies'], 'incidence of grade 3 and 4 abnormalities in safety related laboratory parameters and associated dose of gdc-0349': ['incidence of grade 3 and 4 abnormalities in safety related laboratory parameters and associated dose of gdc-0349'], 'tumor response  and duration of the response': ['tumor response  and duration of the response'], 'pharmacokinetics parameters': ['pharmacokinetics parameters'], 'maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.': ['maximum tolerated dose of combined romidepsin, gemcitabine, dexamethasone and cisplatin.'], 'to characterize safety profile and feasibility, pharmacokinetics, drug-drug interactions. to obtain information on antitumor activity.': ['to characterize safety profile and feasibility, pharmacokinetics, drug-drug interactions. to obtain information on antitumor activity.'], 'overall response': ['overall response'], 'occurrence of grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0980': ['occurrence of grade 3 and 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0980'], 'pk parameters after doses of gdc-0980': ['pk parameters after doses of gdc-0980'], 'best overall response, duration of objective response, and progression-free survival for patients with measurable disease according to recist': ['best overall response, duration of objective response, and progression-free survival for patients with measurable disease according to recist'], 'pet response for patients with detectable fdg tumor uptake at baseline': ['pet response for patients with detectable fdg tumor uptake at baseline'], 'determine an effective and well-tolerated dose and schedule of pralatrexate with vitamin b12 and folic acid supplementation for patients with relapsed or refractory cutaneous t-cell lymphoma': ['determine an effective and well-tolerated dose and schedule of pralatrexate with vitamin b12 and folic acid supplementation for patients with relapsed or refractory cutaneous t-cell lymphoma'], 'characterize the safety profile of pralatrexate in patients with relapsed or refractory ctcl.': ['characterize the safety profile of pralatrexate in patients with relapsed or refractory ctcl.'], '-measure plasma concentrations of ipdr, idurd, and idurd metabolites after a single oral dose of ipdr.-determine the safety of administering a single oral dose of ipdr.': ['-measure plasma concentrations of ipdr, idurd, and idurd metabolites after a single oral dose of ipdr.-determine the safety of administering a single oral dose of ipdr.'], 'best overall response, duration of objective response, and progression-free survival for patients with measurable disease': ['best overall response, duration of objective response, and progression-free survival for patients with measurable disease'], 'identification of the maximum tolerated dose and identification of the recommended dose of xmab®2513 for evaluation in future studies.': ['identification of the maximum tolerated dose and identification of the recommended dose of xmab®2513 for evaluation in future studies.'], 'safety and tolerability': ['safety and tolerability'], 'assessment of immunogenicity': ['assessment of immunogenicity'], 'objective response rate, disease control rate, and progression free survival.': ['objective response rate, disease control rate, and progression free survival.'], 'change in solcd30': ['change in solcd30'], 'cmax: maximum observed concentration for alisertib': ['cmax: maximum observed concentration for alisertib'], 'tmax: time to first occurrence of cmax for alisertib': ['tmax: time to first occurrence of cmax for alisertib'], 'aucτ: area under the concentration-time curve from time 0 to end of dosing interval  for alisertib': ['aucτ: area under the concentration-time curve from time 0 to end of dosing interval  for alisertib'], 'dose normalized aucτ: area under the concentration-time curve from time 0 to time t for alisertib': ['dose normalized aucτ: area under the concentration-time curve from time 0 to time t for alisertib'], 't1/2: terminal half-life for alisertib': ['t1/2: terminal half-life for alisertib'], 'rac: accumulation ratio for alisertib': ['rac: accumulation ratio for alisertib'], 'ptr: peak trough ratio during a dosing interval, at steady state for alisertib': ['ptr: peak trough ratio during a dosing interval, at steady state for alisertib'], 'clss/f: apparent clearance after extravascular administration, at steady state, calculated using aucτ for alisertib': ['clss/f: apparent clearance after extravascular administration, at steady state, calculated using aucτ for alisertib'], 'best overall response rate based on investigator assessment': ['best overall response rate based on investigator assessment'], 'concentrations of relevant tumor markers': ['concentrations of relevant tumor markers'], 'best response': ['best response'], 'maximum tolerated dose of 4-hpr/lxs oral powder': ['maximum tolerated dose of 4-hpr/lxs oral powder'], 'level of fenretinide in normal peripheral blood mononuclear cells': ['level of fenretinide in normal peripheral blood mononuclear cells'], 'area under the curve  at 0 to infinity': ['area under the curve  at 0 to infinity'], 'mean residence times from day 0 to day 7': ['mean residence times from day 0 to day 7'], 'mean absorbed dose in the source organs and the target organs': ['mean absorbed dose in the source organs and the target organs'], 'number of participants with expected distribution of radioactivity in the circulatory system compared with uptake by other organs.': ['number of participants with expected distribution of radioactivity in the circulatory system compared with uptake by other organs.'], 'to evaluate safety of gp2013': ['to evaluate safety of gp2013'], 'area under the curve calculated from start of dose to the end of the dosing interval  of gp2013': ['area under the curve calculated from start of dose to the end of the dosing interval  of gp2013'], 'maximum observed concentration of gp2013': ['maximum observed concentration of gp2013'], 'time to reach maximum concentration of gp2013': ['time to reach maximum concentration of gp2013'], 'minimum  observed concentration during each dosing interval of gp2013': ['minimum  observed concentration during each dosing interval of gp2013'], 'terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of gp2013': ['terminal elimination rate constant calculated as the slope of the linear regression of the terminal phase of the logarithmic concentration-time profile of gp2013'], 'elimination half-life associated with the terminal slope of gp2013': ['elimination half-life associated with the terminal slope of gp2013'], 'to evaluate efficacy of gp2013': ['to evaluate efficacy of gp2013'], 'to evaluate the incidence of immunogenicity  against gp2013': ['to evaluate the incidence of immunogenicity  against gp2013'], 'to evaluate peripheral cd19+ b-cell count': ['to evaluate peripheral cd19+ b-cell count'], 'determine the cmax profile of ds 3078a': ['determine the cmax profile of ds 3078a'], 'effect on glucose metabolism': ['effect on glucose metabolism'], 'assess pharmacodynamic effects tumor glucose uptake': ['assess pharmacodynamic effects tumor glucose uptake'], 'assess tumor response': ['assess tumor response'], 'assess pharmacodynamic effects v-akt murine thymoma viral oncogene': ['assess pharmacodynamic effects v-akt murine thymoma viral oncogene'], 'determine the auc of ds 3078a': ['determine the auc of ds 3078a'], 'determine the tmax of ds 3078a': ['determine the tmax of ds 3078a'], 'determine the terminal half-life of ds 3078a': ['determine the terminal half-life of ds 3078a'], 'to determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose of cddo when administered in adult patients with solid tumors and lymphomas.': ['to determine the dose limiting toxicities, toxicity profile, and maximum tolerated dose of cddo when administered in adult patients with solid tumors and lymphomas.'], 'to obtain preliminary evidence of anti-tumor activity of cddo in this population.': ['to obtain preliminary evidence of anti-tumor activity of cddo in this population.'], 'best objective response based on recist criteria': ['best objective response based on recist criteria'], 'pk parameter': ['pk parameter'], 'pd parameter': ['pd parameter'], 'to establish the safety and tolerability of weekly  lmp400 in patients with refractory solid tumors and lymphomas': ['to establish the safety and tolerability of weekly  lmp400 in patients with refractory solid tumors and lymphomas'], 'evaluate the level of top1 in tumor biopsies pre and post- administration of lmp400': ['evaluate the level of top1 in tumor biopsies pre and post- administration of lmp400'], 'occurrence of grade 3 or 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0941': ['occurrence of grade 3 or 4 abnormalities in safety-related laboratory parameters and associated dose of gdc-0941'], 'pk parameters after single and multiple doses of gdc-0941': ['pk parameters after single and multiple doses of gdc-0941'], 'part 1 maximum tolerated dose of ibrutinib': ['part 1 maximum tolerated dose of ibrutinib'], 'the number of participants affected by a dose-limiting toxicity': ['the number of participants affected by a dose-limiting toxicity'], 'number of participants with potential drug-drug interactions between ibrutinib and vincristine': ['number of participants with potential drug-drug interactions between ibrutinib and vincristine'], 'mean plasma concentrations of ibrutinib': ['mean plasma concentrations of ibrutinib'], 'maximum observed plasma concentration of ibrutinib': ['maximum observed plasma concentration of ibrutinib'], 'time to reach the maximum plasma concentration of ibrutinib': ['time to reach the maximum plasma concentration of ibrutinib'], 'area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib': ['area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib'], 'elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of ibrutinib': ['elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of ibrutinib'], 'elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of vincristine': ['elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of vincristine'], 'partial area under the plasma concentration versus time curve of vincristine': ['partial area under the plasma concentration versus time curve of vincristine'], 'the number of participants with pharmacodynamic markers of ibrutinib in peripheral blood mononuclear cells': ['the number of participants with pharmacodynamic markers of ibrutinib in peripheral blood mononuclear cells'], 'the number of participants with biomarkers predictive of clinical response': ['the number of participants with biomarkers predictive of clinical response'], 'survival of subjects treated with kpt-330 + rice': ['survival of subjects treated with kpt-330 + rice'], 'progression-free survival of subjects treated with kpt-330 + rice': ['progression-free survival of subjects treated with kpt-330 + rice'], 'number of patients who demonstrate a response to kpt-330+rice': ['number of patients who demonstrate a response to kpt-330+rice'], 'number of patients who undergo stem cell collection after induction therapy with kpt-330 + rice': ['number of patients who undergo stem cell collection after induction therapy with kpt-330 + rice'], 'number of participants with dose-limiting toxicities at each dose level [level/cohort] and the total number of participants with dose-limiting toxicities': ['number of participants with dose-limiting toxicities at each dose level [level/cohort] and the total number of participants with dose-limiting toxicities'], 'number of participants with melanoma and diffuse large b cell lymphoma in dose expansion cohorts who achieved objective response per recist v1.1 and international working group, respectively': ['number of participants with melanoma and diffuse large b cell lymphoma in dose expansion cohorts who achieved objective response per recist v1.1 and international working group, respectively'], 'pharmacodynamic effect of milademetan assessed by increase in serum mic-1 levels over baseline': ['pharmacodynamic effect of milademetan assessed by increase in serum mic-1 levels over baseline'], \"percentage of participants with end of induction response, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\": [\"percentage of participants with end of induction response, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\"], \"percentage of participants with end of induction response, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\": [\"percentage of participants with end of induction response, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\"], \"percentage of participants with best overall response, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\": [\"percentage of participants with best overall response, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\"], \"percentage of participants with best overall response, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\": [\"percentage of participants with best overall response, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\"], \"percentage of participants with best overall response of complete response, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\": [\"percentage of participants with best overall response of complete response, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\"], \"percentage of participants with best overall response of complete response, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\": [\"percentage of participants with best overall response of complete response, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\"], \"pfs, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\": [\"pfs, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\"], \"pfs, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\": [\"pfs, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\"], \"efs, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\": [\"efs, according to 2007 revised response criteria for non hodgkin's lymphoma - relapsed/refractory population\"], \"efs, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\": [\"efs, according to 2007 revised response criteria for non hodgkin's lymphoma - first-line population\"], 'pharmacokinetics of obinutuzumab: auclast - first-line population': ['pharmacokinetics of obinutuzumab: auclast - first-line population'], 'pharmacokinetics of obinutuzumab: cmax - first-line population': ['pharmacokinetics of obinutuzumab: cmax - first-line population'], 'pharmacokinetics of obinutuzumab: clss - first-line population': ['pharmacokinetics of obinutuzumab: clss - first-line population'], 'pharmacokinetics of obinutuzumab: auc from time zero to 7 days  - relapsed/refractory population': ['pharmacokinetics of obinutuzumab: auc from time zero to 7 days  - relapsed/refractory population'], 'pharmacokinetics of obinutuzumab: auc7d - first-line population': ['pharmacokinetics of obinutuzumab: auc7d - first-line population'], 'pharmacokinetics of obinutuzumab: vss - first-line population': ['pharmacokinetics of obinutuzumab: vss - first-line population'], 'pharmacokinetics of obinutuzumab: t1/2 - first-line population': ['pharmacokinetics of obinutuzumab: t1/2 - first-line population'], 'pharmacokinetics of obinutuzumab: ctrough - first-line population': ['pharmacokinetics of obinutuzumab: ctrough - first-line population'], 'pharmacodynamics of obinutuzumab: number of participants with peripheral blood b-cell depletion - relapsed/refractory population': ['pharmacodynamics of obinutuzumab: number of participants with peripheral blood b-cell depletion - relapsed/refractory population'], 'pharmacodynamics of obinutuzumab: number of participants with peripheral blood b-cell depletion - first-line population': ['pharmacodynamics of obinutuzumab: number of participants with peripheral blood b-cell depletion - first-line population'], 'pharmacodynamics of obinutuzumab: time from end of treatment to b-cell recovery - relapsed/refractory population': ['pharmacodynamics of obinutuzumab: time from end of treatment to b-cell recovery - relapsed/refractory population'], 'pharmacodynamics of obinutuzumab: time from end of treatment to b-cell recovery - first-line population': ['pharmacodynamics of obinutuzumab: time from end of treatment to b-cell recovery - first-line population'], 'mk-2118 area under the concentration-time curve from 0 to 24 hours': ['mk-2118 area under the concentration-time curve from 0 to 24 hours'], 'pembrolizumab cmin': ['pembrolizumab cmin'], 'cmax: maximum observed plasma concentration of alisertib': ['cmax: maximum observed plasma concentration of alisertib'], 'auc∞: area under the plasma concentration curve from time 0 to infinity of alisertib': ['auc∞: area under the plasma concentration curve from time 0 to infinity of alisertib'], 'determine the pharmacokinetics of ds-8273a': ['determine the pharmacokinetics of ds-8273a'], 'safety and tolerability of the combination of abt-888 with topotecan hydrochloride in patients with refractory solid tumors and lymphomas establish the maximum tolerated dose of abt-888 with topotecan hydrochloride.': ['safety and tolerability of the combination of abt-888 with topotecan hydrochloride in patients with refractory solid tumors and lymphomas establish the maximum tolerated dose of abt-888 with topotecan hydrochloride.'], 'evaluate the pharmacokinetic of each agent alone and in combination determine the effects of the study treatment on the level of parp inhibition and dna damage in pbmcs and tumor samples.': ['evaluate the pharmacokinetic of each agent alone and in combination determine the effects of the study treatment on the level of parp inhibition and dna damage in pbmcs and tumor samples.'], 'persistence of car t cells in vivo': ['persistence of car t cells in vivo'], 'incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose': ['incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose'], 'changes in vital signs, physical examination findings, and clinical laboratory results': ['changes in vital signs, physical examination findings, and clinical laboratory results'], \"patient's best response as assessed by the investigator\": [\"patient's best response as assessed by the investigator\"], 'to determine the safety of giving 3rd party ebv-ctls': ['to determine the safety of giving 3rd party ebv-ctls'], 'to develop a third party bank of lmp-specific ctl': ['to develop a third party bank of lmp-specific ctl'], 'to measure the response rate': ['to measure the response rate'], 'cmax: maximum observed plasma concentration for tak-659': ['cmax: maximum observed plasma concentration for tak-659'], 'auclast: area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration for tak-659': ['auclast: area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration for tak-659'], 't1/2: terminal disposition half-life': ['t1/2: terminal disposition half-life'], 'pharmacodynamic effects': ['pharmacodynamic effects'], 'accumulation ratio': ['accumulation ratio'], 'changes in degree of pruritus': ['changes in degree of pruritus'], 'quality of life during therapy': ['quality of life during therapy'], 'changes in skin related symptoms': ['changes in skin related symptoms'], 'safety and toxicity by nci ctc toxicity scale in patients w/ recurr. or refract. cd20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr': ['safety and toxicity by nci ctc toxicity scale in patients w/ recurr. or refract. cd20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr'], 'duration of in vivo persistence of adoptively transferred cd20-specific cd8+ t cell clones by flow cytometry and quantitative polymerase chain reaction  during each infusion, weekly for 4 weeks, and then monthly for a year': ['duration of in vivo persistence of adoptively transferred cd20-specific cd8+ t cell clones by flow cytometry and quantitative polymerase chain reaction  during each infusion, weekly for 4 weeks, and then monthly for a year'], 'trafficking of cd8+ cd20-specific t cell clones to lymph nodes by gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year': ['trafficking of cd8+ cd20-specific t cell clones to lymph nodes by gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year'], 'development of host anti-scfvfc:zeta  immune responses by elisa and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year': ['development of host anti-scfvfc:zeta  immune responses by elisa and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year'], 'tumor responses to cyclophosphamide, vincristine, and prednisone  and to cytotoxic t-lymphocyte  infusions by cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year': ['tumor responses to cyclophosphamide, vincristine, and prednisone  and to cytotoxic t-lymphocyte  infusions by cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year'], 'the primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of ar-12.': ['the primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of ar-12.'], 'evaluate pk samples during c1, identify and use biomarkers to characterize the pd effects in surrogate and tumor tissue, establish a biologically active dose range, assess preliminary anti-tumor activity in cancer patients.': ['evaluate pk samples during c1, identify and use biomarkers to characterize the pd effects in surrogate and tumor tissue, establish a biologically active dose range, assess preliminary anti-tumor activity in cancer patients.'], \"pharmacokinetics : area under the concentration -time curve over a dosing interval at steady state  of enzastaurin, it's metabolites and total analytes in plasma\": [\"pharmacokinetics : area under the concentration -time curve over a dosing interval at steady state  of enzastaurin, it's metabolites and total analytes in plasma\"], \"pk: time of maximal plasma concentration at steady state  of enzastaurin, it's metabolites and total analytes in plasma\": [\"pk: time of maximal plasma concentration at steady state  of enzastaurin, it's metabolites and total analytes in plasma\"], \"pk: terminal elimination half-life of enzastaurin, it's metabolites and total analytes in plasma\": [\"pk: terminal elimination half-life of enzastaurin, it's metabolites and total analytes in plasma\"], 'therapeutic activity of dt2219arl': ['therapeutic activity of dt2219arl'], 'safety and tolerability of vorinostat  after autologous stem cell transplantation': ['safety and tolerability of vorinostat  after autologous stem cell transplantation'], 'clinical benefit': ['clinical benefit'], 'plasma concentrations of dtrmwxhs-12': ['plasma concentrations of dtrmwxhs-12'], '12-week objective response rate': ['12-week objective response rate'], '12-week non-progression rate': ['12-week non-progression rate'], 'cmax: maximum observed plasma concentration for tak-659 and venetoclax': ['cmax: maximum observed plasma concentration for tak-659 and venetoclax'], 'aucτ: area under the plasma concentration-time curve from time 0 to time over the dosing interval for tak-659 and venetoclax': ['aucτ: area under the plasma concentration-time curve from time 0 to time over the dosing interval for tak-659 and venetoclax'], 'peak-trough ratio  for tak-659 and venetoclax': ['peak-trough ratio  for tak-659 and venetoclax'], 'cr rate': ['cr rate'], 'duration of cr': ['duration of cr'], 'to assess the clinical efficacy lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular  response criteria.': ['to assess the clinical efficacy lenalidomide monotherapy as measured by cytologic, neurologic, radiographic, and ocular  response criteria.'], 'to define the immunological effects of lenalidomide using flow-cytometry csf as well as genomic markers of recurrent/refractory cns lymphoma.': ['to define the immunological effects of lenalidomide using flow-cytometry csf as well as genomic markers of recurrent/refractory cns lymphoma.'], 'to assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria.': ['to assess the clinical efficacy of combined intraventricular plus systemic rituximab administration in combination with lenalidomide as measured by cytologic, neurologic, and radiographic response criteria.'], 'to determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the csf after intraventricular rituximab administration.': ['to determine a potential impact of intravenous rituximab administration on the rate of rituximab clearance from the csf after intraventricular rituximab administration.'], 'safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests': ['safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests'], 'human anti-human antibodies': ['human anti-human antibodies'], 'safety as assessed by clinical laboratory tests': ['safety as assessed by clinical laboratory tests'], 'safety as assessed by vital signs': ['safety as assessed by vital signs'], 'objective response rate to asp4132': ['objective response rate to asp4132'], 'duration of response to asp4132': ['duration of response to asp4132'], 'disease control rate to asp4132': ['disease control rate to asp4132'], 'accumulation ratio of asp4132': ['accumulation ratio of asp4132'], 'percentage of participants with objective response, determined by the irc and investigator on the basis of pet and ct scans': ['percentage of participants with objective response, determined by the irc and investigator on the basis of pet and ct scans'], 'percentage of participants with objective response, determined by the irc and investigator on the basis of ct scans alone': ['percentage of participants with objective response, determined by the irc and investigator on the basis of ct scans alone'], 'observed serum and plasma polatuzumab vedotin concentration': ['observed serum and plasma polatuzumab vedotin concentration'], 'observed plasma lenalidomide concentration': ['observed plasma lenalidomide concentration'], 'percentage of participants with human anti-chimeric antibodies  to rituximab': ['percentage of participants with human anti-chimeric antibodies  to rituximab'], 'evaluation of response  in patients with bone marrow involvement.': ['evaluation of response  in patients with bone marrow involvement.'], 'unbound cmax: maximum observed plasma concentration for alisertib': ['unbound cmax: maximum observed plasma concentration for alisertib'], 'unbound auclast: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib': ['unbound auclast: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib'], 'unbound auc0-∞: area under the concentration-time curve from time 0 to infinity for alisertib': ['unbound auc0-∞: area under the concentration-time curve from time 0 to infinity for alisertib'], 'percentage of participants who experienced at least 1 treatment-emergent adverse event': ['percentage of participants who experienced at least 1 treatment-emergent adverse event'], 'percentage of participants who experienced at least 1 serious adverse event': ['percentage of participants who experienced at least 1 serious adverse event'], 'percentage of participants with clinically significant laboratory values': ['percentage of participants with clinically significant laboratory values'], 'percentage of participants with clinically significant vital signs': ['percentage of participants with clinically significant vital signs'], 'cmax: maximum observed plasma concentration for alisertib metabolites m1 and m2': ['cmax: maximum observed plasma concentration for alisertib metabolites m1 and m2'], 'tmax: time of first occurrence of cmax for alisertib metabolites m1 and m2': ['tmax: time of first occurrence of cmax for alisertib metabolites m1 and m2'], 'auclast: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib metabolites m1 and m2': ['auclast: area under the concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib metabolites m1 and m2'], 'dose-normalized trough concentration of alisertib on cycle 1 day 14': ['dose-normalized trough concentration of alisertib on cycle 1 day 14'], 'evaluation of wp1220 applied topically to index lesions via standard measurement scale': ['evaluation of wp1220 applied topically to index lesions via standard measurement scale'], 'cmax: maximum observed concentration of alisertib in presence and absence of itraconazole in part a': ['cmax: maximum observed concentration of alisertib in presence and absence of itraconazole in part a'], 'auc∞: area under the plasma concentration curve from time 0 to infinity of alisertib in presence and absence of itraconazole in part a': ['auc∞: area under the plasma concentration curve from time 0 to infinity of alisertib in presence and absence of itraconazole in part a'], 'cl/f: oral clearance of alisertib in presence and absence of itraconazole in part a': ['cl/f: oral clearance of alisertib in presence and absence of itraconazole in part a'], 'tmax: time to reach maximum plasma concentration of alisertib in presence and absence of itraconazole in part a': ['tmax: time to reach maximum plasma concentration of alisertib in presence and absence of itraconazole in part a'], 'terminal phase elimination half-life of alisertib in presence and absence of itraconazole in part a': ['terminal phase elimination half-life of alisertib in presence and absence of itraconazole in part a'], 'cmax: maximum observed plasma concentration for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a': ['cmax: maximum observed plasma concentration for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a'], 'auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a': ['auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib metabolites m1 and m2 in presence and absence of itraconazole in part a'], 'evaluation of the immunogenicity of sym022.': ['evaluation of the immunogenicity of sym022.'], 'evaluation of the immunogenicity of sym023.': ['evaluation of the immunogenicity of sym023.'], 'cmax: maximum observed plasma concentration for ixazomib': ['cmax: maximum observed plasma concentration for ixazomib'], 'auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for ixazomib': ['auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for ixazomib'], 'number of participants with clinically significant vital sign abnormalities': ['number of participants with clinically significant vital sign abnormalities'], 'pharmacokinetics of cep-18770 following single and multiple dose administration.': ['pharmacokinetics of cep-18770 following single and multiple dose administration.'], 'profile and time course of inhibition and recovery of proteasome activity': ['profile and time course of inhibition and recovery of proteasome activity'], 'antineoplastic activity evaluated with internationally accepted response criteria': ['antineoplastic activity evaluated with internationally accepted response criteria'], 'tolerability': ['tolerability'], 'adverse event,clinical laboratory tests,immunoglobulin,haha,objective response rate,duration of response,progression free survival,cd5,19,20,cd23 positive cells,complement ,pk parameters,': ['adverse event,clinical laboratory tests,immunoglobulin,haha,objective response rate,duration of response,progression free survival,cd5,19,20,cd23 positive cells,complement ,pk parameters,'], 'phase 1 stage 1: percentage of participants with dose-limiting toxicities': ['phase 1 stage 1: percentage of participants with dose-limiting toxicities'], 'phase i stage 1: maximum tolerated dose of gdc-0032': ['phase i stage 1: maximum tolerated dose of gdc-0032'], 'phase i: accumulation ratio   of gdc-0032': ['phase i: accumulation ratio   of gdc-0032'], 'phase i: recommended dose of single-agent gdc-0032': ['phase i: recommended dose of single-agent gdc-0032'], 'phase ii: percentage of participants with objective response, as assessed using recist version 1.1': ['phase ii: percentage of participants with objective response, as assessed using recist version 1.1'], 'phase i: time to achieve steady state of gdc-0032': ['phase i: time to achieve steady state of gdc-0032'], 'phase i cohort t: duration of objective response, as assessed using 2007 revised iwg response criteria in malignant lymphoma': ['phase i cohort t: duration of objective response, as assessed using 2007 revised iwg response criteria in malignant lymphoma'], 'phase i cohort t: progression free survival, as assessed using 2007 revised iwg response criteria in malignant lymphoma': ['phase i cohort t: progression free survival, as assessed using 2007 revised iwg response criteria in malignant lymphoma'], 'phase i cohort t2: percentage of participants with best overall response, as assessed using modified version of 2014 lugano response criteria in malignant lymphoma': ['phase i cohort t2: percentage of participants with best overall response, as assessed using modified version of 2014 lugano response criteria in malignant lymphoma'], 'phase i cohort t2: duration of objective response, as assessed using modified version of 2014 lugano response criteria in malignant lymphoma': ['phase i cohort t2: duration of objective response, as assessed using modified version of 2014 lugano response criteria in malignant lymphoma'], 'phase i cohort t2: progression free survival, as assessed using modified version of 2014 lugano response criteria in malignant lymphoma': ['phase i cohort t2: progression free survival, as assessed using modified version of 2014 lugano response criteria in malignant lymphoma'], 'phase i stage 2 food effect: cmax of gdc-0032 under fed condition': ['phase i stage 2 food effect: cmax of gdc-0032 under fed condition'], 'phase i stage 2 food effect: cmax of gdc-0032 under fasted condition': ['phase i stage 2 food effect: cmax of gdc-0032 under fasted condition'], 'phase i stage 2 food effect: auc of gdc-0032 under fed condition': ['phase i stage 2 food effect: auc of gdc-0032 under fed condition'], 'phase i stage 2 food effect: auc of gdc-0032 under fasted condition': ['phase i stage 2 food effect: auc of gdc-0032 under fasted condition'], 'phase i stage 2 cohort c: cmax of midazolam prior to and after 14 days continuous gdc-0032 dosing': ['phase i stage 2 cohort c: cmax of midazolam prior to and after 14 days continuous gdc-0032 dosing'], 'phase i stage 2 cohort c: tmax of midazolam prior to and after 14 days continuous gdc-0032 dosing': ['phase i stage 2 cohort c: tmax of midazolam prior to and after 14 days continuous gdc-0032 dosing'], 'phase i stage 2 cohorts e, n, p, q, r, s: auc0-24 of letrozole': ['phase i stage 2 cohorts e, n, p, q, r, s: auc0-24 of letrozole'], 'phase i stage 2 cohorts e, n, p, q, r, s: cmax of letrozole': ['phase i stage 2 cohorts e, n, p, q, r, s: cmax of letrozole'], 'phase i stage 2 cohorts e, n, p, q, r, s: tmax of letrozole': ['phase i stage 2 cohorts e, n, p, q, r, s: tmax of letrozole'], 'phase i stage 2 cohorts f, j, k, l, m and phase ii: auc0-24 of fulvestrant': ['phase i stage 2 cohorts f, j, k, l, m and phase ii: auc0-24 of fulvestrant'], 'phase i stage 2 cohorts f, j, k, l, m and phase ii: cmin of fulvestrant': ['phase i stage 2 cohorts f, j, k, l, m and phase ii: cmin of fulvestrant'], 'phase i stage 2 cohorts f, j, k, l, m and phase ii: tmax of fulvestrant': ['phase i stage 2 cohorts f, j, k, l, m and phase ii: tmax of fulvestrant'], 'phase i stage 2 cohort c: auc0-24 of gdc-0032 in combination with midazolam': ['phase i stage 2 cohort c: auc0-24 of gdc-0032 in combination with midazolam'], 'phase i stage 2 cohort c: cmax of gdc-0032 in combination with midazolam': ['phase i stage 2 cohort c: cmax of gdc-0032 in combination with midazolam'], 'phase i stage 2 cohort c: tmax of gdc-0032 in combination with midazolam': ['phase i stage 2 cohort c: tmax of gdc-0032 in combination with midazolam'], 'phase i stage 2 cohorts e, n, p, q, r, s: auc0-24 of gdc-0032 in combination with letrozole': ['phase i stage 2 cohorts e, n, p, q, r, s: auc0-24 of gdc-0032 in combination with letrozole'], 'phase i stage 2 cohorts e, n, p, q, r, s: cmax of gdc-0032 in combination with letrozole': ['phase i stage 2 cohorts e, n, p, q, r, s: cmax of gdc-0032 in combination with letrozole'], 'phase i stage 2 cohorts e, n, p, q, r, s: tmax of gdc-0032 in combination with letrozole': ['phase i stage 2 cohorts e, n, p, q, r, s: tmax of gdc-0032 in combination with letrozole'], 'phase i stage 2 cohorts f, j, k, l, m and phase ii: auc0-24 of gdc-0032 in combination with fulvestrant': ['phase i stage 2 cohorts f, j, k, l, m and phase ii: auc0-24 of gdc-0032 in combination with fulvestrant'], 'phase i stage 2 cohorts f, j, k, l, m and phase ii: cmin of gdc-0032 fulvestrant': ['phase i stage 2 cohorts f, j, k, l, m and phase ii: cmin of gdc-0032 fulvestrant'], 'phase i stage 2 cohorts f, j, k, l, m and phase ii: tmax of gdc-0032 fulvestrant': ['phase i stage 2 cohorts f, j, k, l, m and phase ii: tmax of gdc-0032 fulvestrant'], 'phase ii: duration of objective response, as assessed using recist version 1.1': ['phase ii: duration of objective response, as assessed using recist version 1.1'], 'phase ii: progression free survival, as assessed using recist version 1.1': ['phase ii: progression free survival, as assessed using recist version 1.1'], 'overall survival, as assessed using recist version 1.1': ['overall survival, as assessed using recist version 1.1'], 'phase ii: plasma concentration of gdc-0032': ['phase ii: plasma concentration of gdc-0032'], 'incidence of dose limiting toxicity at each tested dose level': ['incidence of dose limiting toxicity at each tested dose level'], 'number of participants with objective response: evaluable population': ['number of participants with objective response: evaluable population'], 'number of participants with objective response: intent-to-treat  population': ['number of participants with objective response: intent-to-treat  population'], 'efficacy: remission rate': ['efficacy: remission rate'], 'car-t proliferation': ['car-t proliferation'], 'cytokine release': ['cytokine release'], 'toxicity of the combination of ibrutinib with standard dosing r-ice, graded using the ctcae 4.0': ['toxicity of the combination of ibrutinib with standard dosing r-ice, graded using the ctcae 4.0'], 'overall response rate, defined as the sum of partial and complete responses as determined by revised international working group criteria for malignant lymphoma': ['overall response rate, defined as the sum of partial and complete responses as determined by revised international working group criteria for malignant lymphoma'], 'pk parameters of ibrutinib in the presence of r-ice as a measure of potential drug-drug interaction': ['pk parameters of ibrutinib in the presence of r-ice as a measure of potential drug-drug interaction'], 'serum concentration of rituximab': ['serum concentration of rituximab'], 'safety profile of the combination of lenalidomide and brentuximab vedotin': ['safety profile of the combination of lenalidomide and brentuximab vedotin'], 'treatment intensity.': ['treatment intensity.'], 'cytostatic response.': ['cytostatic response.'], 'event free survival.': ['event free survival.'], 'to determine mtd and dlt of gemcitabine oral formulation': ['to determine mtd and dlt of gemcitabine oral formulation'], 'ae/sae incidences': ['ae/sae incidences'], 'characterize the pk of d07001-f4': ['characterize the pk of d07001-f4'], 'maximum tolerated dose/maximum administered dose': ['maximum tolerated dose/maximum administered dose'], 'orr by predictive gene signature': ['orr by predictive gene signature'], 'evaluation of the immunogenicity of sym021 as a single agent and in combination with sym022 and sym023.': ['evaluation of the immunogenicity of sym021 as a single agent and in combination with sym022 and sym023.'], 'pharmacodynamic responses': ['pharmacodynamic responses'], 'objective response to gdc-0853': ['objective response to gdc-0853'], 'dose limiting toxicity assessment for each patient.': ['dose limiting toxicity assessment for each patient.'], 'pharmacokinetic/ pharmacodynamic assessments': ['pharmacokinetic/ pharmacodynamic assessments'], 'incidence of disease-related events': ['incidence of disease-related events'], 'incidence of clinically-significant changes in vital signs': ['incidence of clinically-significant changes in vital signs'], 'incidence of clinically-significant changes in physical examinations': ['incidence of clinically-significant changes in physical examinations'], 'incidence of clinically-significant changes in clinical laboratory tests': ['incidence of clinically-significant changes in clinical laboratory tests'], 'efficacy-overall response': ['efficacy-overall response'], 'pharmacokinetic and correlative studies': ['pharmacokinetic and correlative studies'], 'immune response as measured by the frequency of activated t-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of b-cell depletion': ['immune response as measured by the frequency of activated t-cells, absolute lymphocyte count, antibody dependent cell-mediated cytotoxicity, and kinetics and magnitude of b-cell depletion'], 'clinical anti-tumor response': ['clinical anti-tumor response'], 'antitumor activity based on cheson criteria': ['antitumor activity based on cheson criteria'], 'plasma concentration over time': ['plasma concentration over time'], 'number of participants with a response to therapy': ['number of participants with a response to therapy'], 'best clinical response': ['best clinical response'], 'duration of response, progression-free survival': ['duration of response, progression-free survival'], 'blood concentrations of sgn-75 and metabolites': ['blood concentrations of sgn-75 and metabolites'], 'assessment of the efficacy of each treatment by evaluation of overall response rate using recil 2017 response criteria': ['assessment of the efficacy of each treatment by evaluation of overall response rate using recil 2017 response criteria'], 'assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- describe engraftment kinetics-- describe the response rate-- describe relapse rate and event-free survival-- assess clofarabine p': ['assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- describe engraftment kinetics-- describe the response rate-- describe relapse rate and event-free survival-- assess clofarabine p'], 'cmax of venetoclax + navitoclax': ['cmax of venetoclax + navitoclax'], 'auc of venetoclax + navitoclax': ['auc of venetoclax + navitoclax'], 'tmax of venetoclax + navitoclax': ['tmax of venetoclax + navitoclax'], 'cl/f of venetoclax + navitoclax': ['cl/f of venetoclax + navitoclax'], 'number of participant who proceed to stem cell transplantation or chimeric antigen receptor t-cell  therapy': ['number of participant who proceed to stem cell transplantation or chimeric antigen receptor t-cell  therapy'], 'assess the pharmacokinetic profile  of arq 092': ['assess the pharmacokinetic profile  of arq 092'], 'assess pharmacodynamic activity': ['assess pharmacodynamic activity'], 'determine preliminary evidence of activity as defined by recist v 1.1': ['determine preliminary evidence of activity as defined by recist v 1.1'], 'determine recommended phase 2 dose': ['determine recommended phase 2 dose'], 'occurence of dlts for both schedules': ['occurence of dlts for both schedules'], 'assess the exploratory efficacy of the combination abt-199 and rituximab.': ['assess the exploratory efficacy of the combination abt-199 and rituximab.'], 'assess the exploratory efficacy of the combination abt-199 and rituximab': ['assess the exploratory efficacy of the combination abt-199 and rituximab'], 'igvh level': ['igvh level'], 'delayed cr': ['delayed cr'], 'percent of participants with positive anc engraftment': ['percent of participants with positive anc engraftment'], 'incidence of relapse': ['incidence of relapse'], 'lymphocyte and hematopoietic reconstitution': ['lymphocyte and hematopoietic reconstitution'], 'characteristics of the stem cell grafts': ['characteristics of the stem cell grafts'], 'characteristics of the natural killer cell grafts.': ['characteristics of the natural killer cell grafts.'], 'overall survival of patients treated without stem cell manipulation or nk cell infusion due to off therapy criteria': ['overall survival of patients treated without stem cell manipulation or nk cell infusion due to off therapy criteria'], 'the dose of temsirolimus that can be safely given with etoposide and cyclophosphamide.': ['the dose of temsirolimus that can be safely given with etoposide and cyclophosphamide.'], 'the response rate after treatment.': ['the response rate after treatment.'], 'dose-limiting toxicity（dlt）': ['dose-limiting toxicity（dlt）'], 'cd19+ b lymphocyte ratio': ['cd19+ b lymphocyte ratio'], 'orr': ['orr'], 'food effect - cmax': ['food effect - cmax'], 'preliminary efficacy assessment': ['preliminary efficacy assessment'], 'food effect - tmax': ['food effect - tmax'], 'food effect - auc': ['food effect - auc'], 'assess the safety and tolerability of emd 521873': ['assess the safety and tolerability of emd 521873'], 'to determine whether the mtd is reached with emd 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose cpa in patients with metastatic or locally advanced solid tumors or b-cell non-hodgkin lymphoma': ['to determine whether the mtd is reached with emd 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose cpa in patients with metastatic or locally advanced solid tumors or b-cell non-hodgkin lymphoma'], 'characterize the pk profile of emd 521873 alone or in combination with fixed lowdose cpa': ['characterize the pk profile of emd 521873 alone or in combination with fixed lowdose cpa'], 'evaluate the immunogenicity of emd 521873 alone or in combination with cpa measured by the induction of o specific antibodies against the genetically modified il-2 o fc-il2-specific antibodies o anti-idiotype antibodies': ['evaluate the immunogenicity of emd 521873 alone or in combination with cpa measured by the induction of o specific antibodies against the genetically modified il-2 o fc-il2-specific antibodies o anti-idiotype antibodies'], 'collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with emd 521873 alone or in combination with cpa': ['collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with emd 521873 alone or in combination with cpa'], 'evaluate survival': ['evaluate survival'], 'evaluate biological responses to emd 521873 alone or in combination with cpa as measured by o absolute cell numbers and ratios of lymphocyte subsets in defined combinations o change in serum level of sil2r and neopterin': ['evaluate biological responses to emd 521873 alone or in combination with cpa as measured by o absolute cell numbers and ratios of lymphocyte subsets in defined combinations o change in serum level of sil2r and neopterin'], 'exposure to bcl201 and idelalisib as measured by auc0-24h at c1d15': ['exposure to bcl201 and idelalisib as measured by auc0-24h at c1d15'], 'plasma concentration of bcl201, idelalisib and gs-563117': ['plasma concentration of bcl201, idelalisib and gs-563117'], 'determine the safety and adverse-event profile for combination therapy of sgn-40 with gemcitabine and rituximab.': ['determine the safety and adverse-event profile for combination therapy of sgn-40 with gemcitabine and rituximab.'], 'safety and tolerability of tru-016 administered iv in patients with cll or nhl': ['safety and tolerability of tru-016 administered iv in patients with cll or nhl'], 'preliminary indication of response as defined by nci 1996 criteria': ['preliminary indication of response as defined by nci 1996 criteria'], 'pharmacokinetic': ['pharmacokinetic'], 'pharmacodynamic': ['pharmacodynamic'], 'efficacy': ['efficacy'], 'correlation of efficacy to pharmacokinetic and/or pharmacodynamic effects of debio 1143': ['correlation of efficacy to pharmacokinetic and/or pharmacodynamic effects of debio 1143'], 'maximum-tolerated dose of lenalidomide in combination with bendamustine hydrochloride and rituximab': ['maximum-tolerated dose of lenalidomide in combination with bendamustine hydrochloride and rituximab'], 'ae': ['ae'], 'overall survival rate（osr）': ['overall survival rate（osr）'], 'maximum change from baseline in expression of pathway inhibition  in surrogate tissue  during copanlisib monotherapy': ['maximum change from baseline in expression of pathway inhibition  in surrogate tissue  during copanlisib monotherapy'], 'maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy': ['maximum change from baseline in plasma glucose during 2 cycles of copanlisib monotherapy'], 'maximum change from baseline in insulin during 2 cycles of copanlisib': ['maximum change from baseline in insulin during 2 cycles of copanlisib'], 'maximum change from baseline in c-peptide during 2 cycles of copanlisib': ['maximum change from baseline in c-peptide during 2 cycles of copanlisib'], 'fdg pet early response  after dosing with copanlisib for non-diabetic patients with detectable fdg tumor uptake at baseline': ['fdg pet early response  after dosing with copanlisib for non-diabetic patients with detectable fdg tumor uptake at baseline'], 'change from baseline in expression and / or phosphorylation of pi3k pathway proteins in paired tumor biopsies': ['change from baseline in expression and / or phosphorylation of pi3k pathway proteins in paired tumor biopsies'], 'the maximum tolerated dose of plerixafor when combined with rituximab as treatment for previously treated patients with chronic lymphocytic leukemia  or small lymphocytic lymphoma': ['the maximum tolerated dose of plerixafor when combined with rituximab as treatment for previously treated patients with chronic lymphocytic leukemia  or small lymphocytic lymphoma'], 'the principal toxicities and dose limiting toxicities of plerixafor when combined with rituximab': ['the principal toxicities and dose limiting toxicities of plerixafor when combined with rituximab'], 'area under the concentration-time curve from time zero to the last observed concentration  when plerixafor is combined with rituximab': ['area under the concentration-time curve from time zero to the last observed concentration  when plerixafor is combined with rituximab'], 'area under the concentration-time curve over the dosing interval   when plerixafor is combined with rituximab': ['area under the concentration-time curve over the dosing interval   when plerixafor is combined with rituximab'], 'area under the concentration-time curve from time zero to infinity  when plerixafor is combined with rituximab': ['area under the concentration-time curve from time zero to infinity  when plerixafor is combined with rituximab'], 'half-life  when plerixafor is combined with rituximab': ['half-life  when plerixafor is combined with rituximab'], 'duration of exposure to idela': ['duration of exposure to idela'], 'toxicity of administration of idela': ['toxicity of administration of idela'], 'plasma concentration of idela': ['plasma concentration of idela'], 'sub-study: plasma concentration of idela': ['sub-study: plasma concentration of idela'], 'plasma concentration of bendamustine': ['plasma concentration of bendamustine'], 'plasma concentration of everolimus': ['plasma concentration of everolimus'], 'plasma concentration of lenalidomide': ['plasma concentration of lenalidomide'], 'mtd, safety and toxicity': ['mtd, safety and toxicity'], 'pharmacokinetic profile of snx-5422': ['pharmacokinetic profile of snx-5422'], 'tumor response measured by x-rays or scans': ['tumor response measured by x-rays or scans'], 'the safety of two iv injections of auto ebv specific ctls will be determined through adverse event measurement. these ctls may be marked with the neomycin resistance gene introduced by a retroviral vector.': ['the safety of two iv injections of auto ebv specific ctls will be determined through adverse event measurement. these ctls may be marked with the neomycin resistance gene introduced by a retroviral vector.'], 'to determine the survival, immunological efficacy and anti-tumor effects of ebv specific cytotoxic t-lymphocyte lines.': ['to determine the survival, immunological efficacy and anti-tumor effects of ebv specific cytotoxic t-lymphocyte lines.'], 'biomarker: incidence of cd70+ tumors in target population': ['biomarker: incidence of cd70+ tumors in target population'], 'number of participants with abnormalities in ophthalmologic examination at end of treatment that were not present at baseline': ['number of participants with abnormalities in ophthalmologic examination at end of treatment that were not present at baseline'], 'number of participants with change from baseline in normal sinus rhythm findings in ecg': ['number of participants with change from baseline in normal sinus rhythm findings in ecg'], 'best overall tumor response': ['best overall tumor response'], 'percentage of participants with relapse of disease': ['percentage of participants with relapse of disease'], 'time to disease response': ['time to disease response'], 'area under the serum concentration time curve from time zero to infinity  for moxetumomab pasudotox': ['area under the serum concentration time curve from time zero to infinity  for moxetumomab pasudotox'], 'cd22 expression cells in peripheral blood by best response': ['cd22 expression cells in peripheral blood by best response'], 'number of participants with potential biomarkers of predicting capillary leak syndrome': ['number of participants with potential biomarkers of predicting capillary leak syndrome'], 'evaluate the safety and tolerability of vli.': ['evaluate the safety and tolerability of vli.'], 'determine the safety and maximum tolerated dose  of adenovirus-cd154  when injected directly into lymph nodes of patients with cll/sll.': ['determine the safety and maximum tolerated dose  of adenovirus-cd154  when injected directly into lymph nodes of patients with cll/sll.'], 'determine and monitor clinical and biological responses in patients treated with intranodal injections of ad-isf35.': ['determine and monitor clinical and biological responses in patients treated with intranodal injections of ad-isf35.'], 'dose limiting toxicity and recommended phase 2 dose': ['dose limiting toxicity and recommended phase 2 dose'], 'evaluate the effects of av-299 and combination of av-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.': ['evaluate the effects of av-299 and combination of av-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.'], 'study the preliminary antineoplastic activity of av-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of av 299 in combination with erlotinib in subjects with advanced solid tumor.': ['study the preliminary antineoplastic activity of av-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of av 299 in combination with erlotinib in subjects with advanced solid tumor.'], 'investigate the effect of av-299 and of the combination of av-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.': ['investigate the effect of av-299 and of the combination of av-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.'], 'assess dosing schedules of av-299 .': ['assess dosing schedules of av-299 .'], 'to determine the mtd of px-478 administered orally on days one to five of a 21 day cycle': ['to determine the mtd of px-478 administered orally on days one to five of a 21 day cycle'], 'to evaluate the safety profile of px-478 when administered orally on days one to five of a 21 day cycle': ['to evaluate the safety profile of px-478 when administered orally on days one to five of a 21 day cycle'], 'to evaluate pharmacodynamic measures of the effects of px 478 on the hif 1-alpha pathway, and related tumor markers': ['to evaluate pharmacodynamic measures of the effects of px 478 on the hif 1-alpha pathway, and related tumor markers'], 'to determine the pk profile of px 478 when administered orally on days one to five of a 21 day cycle': ['to determine the pk profile of px 478 when administered orally on days one to five of a 21 day cycle'], 'to evaluate the effects of px 478 on tumor blood flow and vascular permeability as measured by dce mri': ['to evaluate the effects of px 478 on tumor blood flow and vascular permeability as measured by dce mri'], 'to evaluate the anti-tumor activity of px 478 in patients with advanced malignancies': ['to evaluate the anti-tumor activity of px 478 in patients with advanced malignancies'], 'preliminary anti-tumour activity': ['preliminary anti-tumour activity'], 'area under the concentration': ['area under the concentration'], 'cd19+': ['cd19+'], 'overall survival at 12 and 24 months': ['overall survival at 12 and 24 months'], 'anti-tafasitamab antibodies formation': ['anti-tafasitamab antibodies formation'], 'recommended phase ii dose': ['recommended phase ii dose'], 'number of participants who discontinued study treatment due to an ae': ['number of participants who discontinued study treatment due to an ae'], 'determine mtd': ['determine mtd'], 'establish safety profile': ['establish safety profile'], 'maximum observed plasma concentration of jnj-42756493': ['maximum observed plasma concentration of jnj-42756493'], 'minimum observed plasma concentration of jnj-42756493': ['minimum observed plasma concentration of jnj-42756493'], 'time correspondent to the maximum observed plasma concentration of jnj-42756493': ['time correspondent to the maximum observed plasma concentration of jnj-42756493'], 'area under the plasma concentration-time curve from time 0 to 24 hours of jnj-42756493': ['area under the plasma concentration-time curve from time 0 to 24 hours of jnj-42756493'], 'half-life of jnj-42756493': ['half-life of jnj-42756493'], 'apparent volume of distribution of jnj-42756493': ['apparent volume of distribution of jnj-42756493'], 'total clearance of drug of jnj-42756493': ['total clearance of drug of jnj-42756493'], 'accumulation index of jnj-42756493': ['accumulation index of jnj-42756493'], 'number of participants with complete response': ['number of participants with complete response'], 'number of participants with partial response': ['number of participants with partial response'], 'number of participants with stable disease': ['number of participants with stable disease'], 'number of participants with progressive disease': ['number of participants with progressive disease'], 'safety, tolerability and maximum tolerated dose of orally administered pxd101 for each cohort': ['safety, tolerability and maximum tolerated dose of orally administered pxd101 for each cohort'], 'determine the pharmacokinetics of oral pxd101 when dosed once or twice daily at various dose levels': ['determine the pharmacokinetics of oral pxd101 when dosed once or twice daily at various dose levels'], 'explore anti-tumor activity': ['explore anti-tumor activity'], 'determine the safety, tolerability, and anti-tumor activity of orally administered pxd101 to patients with lymphoma': ['determine the safety, tolerability, and anti-tumor activity of orally administered pxd101 to patients with lymphoma'], 'maximum tolerated dose as assessed by nci ctcae v.30': ['maximum tolerated dose as assessed by nci ctcae v.30'], 'safety, tolerability, toxicity profile, and dose-limiting toxicities as assessed by nci ctcae v.30': ['safety, tolerability, toxicity profile, and dose-limiting toxicities as assessed by nci ctcae v.30'], 'pharmacokinetic profile as measured on days 1, 2, and 4 in course 1': ['pharmacokinetic profile as measured on days 1, 2, and 4 in course 1'], 'correlation of toxicity profile with pharmacokinetics': ['correlation of toxicity profile with pharmacokinetics'], 'preliminary antitumor activity of treatment in patients with measurable disease': ['preliminary antitumor activity of treatment in patients with measurable disease'], 'maximum tolerated dose of lapatinib and everolimus': ['maximum tolerated dose of lapatinib and everolimus'], 'proposed phase ii dose of polatuzumab vedotin': ['proposed phase ii dose of polatuzumab vedotin'], 'progression free survival , as assessed by using modified response criteria for non-hodgkin lymphoma  or chronic lymphocytic leukemia': ['progression free survival , as assessed by using modified response criteria for non-hodgkin lymphoma  or chronic lymphocytic leukemia'], 'duration of response, as assessed by using modified response criteria for nhl or cll': ['duration of response, as assessed by using modified response criteria for nhl or cll'], 'clearance-polatuzumab vedotin monotherapy': ['clearance-polatuzumab vedotin monotherapy'], 'volume of distribution at steady state-polatuzumab vedotin monotherapy': ['volume of distribution at steady state-polatuzumab vedotin monotherapy'], 'auclast - polatuzumab vedotin combined with rituximab': ['auclast - polatuzumab vedotin combined with rituximab'], 'aucinf-polatuzumab vedotin combined with rituximab': ['aucinf-polatuzumab vedotin combined with rituximab'], 'aucextrap-polatuzumab vedotin combined with rituximab': ['aucextrap-polatuzumab vedotin combined with rituximab'], 'cmax-polatuzumab vedotin combined with rituximab': ['cmax-polatuzumab vedotin combined with rituximab'], 'clearance-polatuzumab vedotin combined with rituximab': ['clearance-polatuzumab vedotin combined with rituximab'], 'volume of distribution at steady state-polatuzumab vedotin combined with rituximab': ['volume of distribution at steady state-polatuzumab vedotin combined with rituximab'], 'auclast of rituximab when given in combination with polatuzumab vedotin': ['auclast of rituximab when given in combination with polatuzumab vedotin'], 'aucinf of rituximab when given in combination with polatuzumab vedotin': ['aucinf of rituximab when given in combination with polatuzumab vedotin'], 'aucextrap of rituximab when given in combination with polatuzumab vedotin': ['aucextrap of rituximab when given in combination with polatuzumab vedotin'], 'cmax of rituximab when given in combination with polatuzumab vedotin': ['cmax of rituximab when given in combination with polatuzumab vedotin'], 'clearance of rituximab when given in combination with polatuzumab vedotin': ['clearance of rituximab when given in combination with polatuzumab vedotin'], 'volume of distribution at steady state-of rituximab when given in combination with polatuzumab vedotin': ['volume of distribution at steady state-of rituximab when given in combination with polatuzumab vedotin'], 'cr rate and the overall response rate, determination by independent review committee': ['cr rate and the overall response rate, determination by independent review committee'], 'the safety and tolerability of ldk378, including both acute and chronic toxicities': ['the safety and tolerability of ldk378, including both acute and chronic toxicities'], 'plasma concentration of ldk378': ['plasma concentration of ldk378'], 'preliminary anti-tumor activity of ldk378': ['preliminary anti-tumor activity of ldk378'], 'pk parameter: auclast': ['pk parameter: auclast'], 'pk parameter: auctau': ['pk parameter: auctau'], 'pk parameter: cmax': ['pk parameter: cmax'], 'pk parameter: tmax': ['pk parameter: tmax'], 'pk parameter: accumulation ratio': ['pk parameter: accumulation ratio'], 'blood concentration of sgn-cd19a and metabolites': ['blood concentration of sgn-cd19a and metabolites'], 'serum concentration of blinatumomab': ['serum concentration of blinatumomab'], 'objective tumor response according to the cheson criteria': ['objective tumor response according to the cheson criteria'], 'number of subjects experiencing dose-limiting toxicities': ['number of subjects experiencing dose-limiting toxicities'], 'individual medi4736 concentrations': ['individual medi4736 concentrations'], 'individual tremelimumab concentrations': ['individual tremelimumab concentrations'], 'individual azd9150 concentrations': ['individual azd9150 concentrations'], 'change from baseline of stat3 rna': ['change from baseline of stat3 rna'], 'baseline pd-l1 protein expression within the tumor': ['baseline pd-l1 protein expression within the tumor'], 'to determine the maximum tolerated dose  and recommended phase 2 dose  of oral fimepinostat  in combination with venetoclax and rituximab': ['to determine the maximum tolerated dose  and recommended phase 2 dose  of oral fimepinostat  in combination with venetoclax and rituximab'], 'to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating orr': ['to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating orr'], 'to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating dor': ['to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens by evaluating dor'], 'to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by os.': ['to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by os.'], 'to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by pfs.': ['to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by pfs.'], 'to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by orr.': ['to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by orr.'], 'to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by dor.': ['to evaluate the efficacy of fimepinostat in combination with anti-cancer regimens as measured by dor.'], 'to evaluate biomarkers of fimepinostat activity': ['to evaluate biomarkers of fimepinostat activity'], 'phase 1: occurrence of dose limiting toxicity': ['phase 1: occurrence of dose limiting toxicity'], 'phase 1 and phase 2: area under the plasma concentration-time curve from time zero to the last sampling time  of avelumab': ['phase 1 and phase 2: area under the plasma concentration-time curve from time zero to the last sampling time  of avelumab'], 'phase 1 and phase 2: minimum post-dose trough concentration of single and multiple dose of avelumab': ['phase 1 and phase 2: minimum post-dose trough concentration of single and multiple dose of avelumab'], 'phase 1 and phase 2: immunogenicity as measured by incidence of antidrug antibody  and neutralizing antibody': ['phase 1 and phase 2: immunogenicity as measured by incidence of antidrug antibody  and neutralizing antibody'], 'phase 1 and phase 2: tumor-infiltrating t-cell levels': ['phase 1 and phase 2: tumor-infiltrating t-cell levels'], 'phase 1 and phase 2: t-cell population in blood': ['phase 1 and phase 2: t-cell population in blood'], 'phase 1 and phase 2: number of t-cell, b-cell and nk-cell in blood': ['phase 1 and phase 2: number of t-cell, b-cell and nk-cell in blood'], 'phase 1 and phase 2: vaccination-related antibody concentrations': ['phase 1 and phase 2: vaccination-related antibody concentrations'], 'phase 1 and phase 2: body temperature': ['phase 1 and phase 2: body temperature'], 'phase 1 and phase 2: heart rate': ['phase 1 and phase 2: heart rate'], 'phase 1 and phase 2: respiratory rate': ['phase 1 and phase 2: respiratory rate'], 'phase 1 and phase 2: systolic and diastolic blood pressure': ['phase 1 and phase 2: systolic and diastolic blood pressure'], 'partial response rate': ['partial response rate'], 'safety of b001 as assessed by adverse reactions and events': ['safety of b001 as assessed by adverse reactions and events'], 'concentration-time curve of b001': ['concentration-time curve of b001'], 'pd results of b001': ['pd results of b001'], 'immunogenicity of b001': ['immunogenicity of b001'], 'orr of b001': ['orr of b001'], 'maximum-tolerated dose': ['maximum-tolerated dose'], 'quality of life': ['quality of life'], 'usefulness and feasibility of the sakk c-sga': ['usefulness and feasibility of the sakk c-sga'], 'association between who performance status, qol indicators, and sakk c-sga scores': ['association between who performance status, qol indicators, and sakk c-sga scores'], 'disease assessments in bone marrow & by computed tomography / magnetic resonance imaging': ['disease assessments in bone marrow & by computed tomography / magnetic resonance imaging'], 'pharmacokinetics of bms-906024 and its metabolite bms-911557: terminal phase elimination half-life': ['pharmacokinetics of bms-906024 and its metabolite bms-911557: terminal phase elimination half-life'], 'pharmacokinetics of bms-906024 and its metabolite bms-911557: accumulation index': ['pharmacokinetics of bms-906024 and its metabolite bms-911557: accumulation index'], 'maximal tolerated doses of bortezomib and vincristine when used in combination of bortezomib, rituximab and the chop chemotherapy regimen': ['maximal tolerated doses of bortezomib and vincristine when used in combination of bortezomib, rituximab and the chop chemotherapy regimen'], 'an estimate of the overall response rate  to bortezomib and rituximab -chop according to international workshop to standardize response criteria  criteria': ['an estimate of the overall response rate  to bortezomib and rituximab -chop according to international workshop to standardize response criteria  criteria'], 'to assess the safety and tolerability of cn1 in patients with advanced solid tumor or b-cell lymphoma through physical exam': ['to assess the safety and tolerability of cn1 in patients with advanced solid tumor or b-cell lymphoma through physical exam'], 'to assess the immunogenicity to cn1 in patients with advanced solid tumor or b-cell lymphoma through ada testing': ['to assess the immunogenicity to cn1 in patients with advanced solid tumor or b-cell lymphoma through ada testing'], 'to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through orr analysis': ['to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through orr analysis'], 'to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through dcr analysis.': ['to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through dcr analysis.'], 'to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through dor analysis.': ['to explore the anti-tumor efficacy of cn1 in patients with advanced solid tumor or b-cell lymphoma through dor analysis.'], 'progression free survival at 1 year': ['progression free survival at 1 year'], 'percentage change in tumour size': ['percentage change in tumour size'], 'safety of azd1152': ['safety of azd1152'], 'part a: cmax of tazemetostat during co-administration with fluconazole': ['part a: cmax of tazemetostat during co-administration with fluconazole'], 'part b: cmax of repaglinide during co-administration with tazemetostat': ['part b: cmax of repaglinide during co-administration with tazemetostat'], 'part b: cmax of omeprazole during co-administration with tazemetostat': ['part b: cmax of omeprazole during co-administration with tazemetostat'], 'part b: cmax of tazemetostat during co-administration with omeprazole': ['part b: cmax of tazemetostat during co-administration with omeprazole'], 'part a: tmax of tazemetostat after administration alone and with fluconazole': ['part a: tmax of tazemetostat after administration alone and with fluconazole'], 'part a: t1/2 of tazemetostat after administration alone and with fluconazole': ['part a: t1/2 of tazemetostat after administration alone and with fluconazole'], 'part a: cmax of tazemetostat metabolites after administration alone and with fluconazole': ['part a: cmax of tazemetostat metabolites after administration alone and with fluconazole'], 'part a: tmax of tazemetostat metabolites after administration alone and with fluconazole': ['part a: tmax of tazemetostat metabolites after administration alone and with fluconazole'], 'part a: t1/2 of tazemetostat metabolites after administration alone and with fluconazole': ['part a: t1/2 of tazemetostat metabolites after administration alone and with fluconazole'], 'part a: exposure of fluconazole after administration of 400 mg once daily for 4 days': ['part a: exposure of fluconazole after administration of 400 mg once daily for 4 days'], 'part a: cmax of fluconazole after administration of 400mg once daily for 4 days': ['part a: cmax of fluconazole after administration of 400mg once daily for 4 days'], 'part a: tmax of fluconazole after administration of 400mg once daily for 4 days': ['part a: tmax of fluconazole after administration of 400mg once daily for 4 days'], 'the antitumor activity of tazemetostat will be assessed in patients with diffuse large b-cell lymphoma , marginal zone lymphoma , follicular lymphoma  or advanced solid tumors .': ['the antitumor activity of tazemetostat will be assessed in patients with diffuse large b-cell lymphoma , marginal zone lymphoma , follicular lymphoma  or advanced solid tumors .'], 'cohort 1b : percentage of participants with treatment emergent adas to polatuzumab vedotin and obinutuzumab': ['cohort 1b : percentage of participants with treatment emergent adas to polatuzumab vedotin and obinutuzumab'], 'arm h : percentage of participants with cr at pra based on pet-ct as determined by the irc': ['arm h : percentage of participants with cr at pra based on pet-ct as determined by the irc'], 'arms a and c : percentage of participants with treatment emergent adas to polatuzumab vedotin': ['arms a and c : percentage of participants with treatment emergent adas to polatuzumab vedotin'], 'arms e and f : percentage of participants with treatment emergent adas to polatuzumab vedotin and obinutuzumab': ['arms e and f : percentage of participants with treatment emergent adas to polatuzumab vedotin and obinutuzumab'], 'phase ii: percentage of participants with cr at pra based on pet-ct as determined by the investigator': ['phase ii: percentage of participants with cr at pra based on pet-ct as determined by the investigator'], 'phase ii expansion cohorts and arm g : percentage of participants with cr at pra based on pet-ct as determined by the irc': ['phase ii expansion cohorts and arm g : percentage of participants with cr at pra based on pet-ct as determined by the irc'], 'phase ii: percentage of participants with or at pra based on pet-ct as determined by irc': ['phase ii: percentage of participants with or at pra based on pet-ct as determined by irc'], 'phase ii: percentage of participants with cr at pra based on ct only as determined by investigator': ['phase ii: percentage of participants with cr at pra based on ct only as determined by investigator'], 'phase ii: percentage of participants with cr at pra based on ct only as determined by irc': ['phase ii: percentage of participants with cr at pra based on ct only as determined by irc'], 'phase ii: percentage of participants with or at pra based on ct only as determined by investigator': ['phase ii: percentage of participants with or at pra based on ct only as determined by investigator'], 'phase ii: percentage of participants with or at pra based on ct only as determined by irc': ['phase ii: percentage of participants with or at pra based on ct only as determined by irc'], 'dlbcl cohorts: percentage of participants with bor based pet-ct or ct only as determined by irc': ['dlbcl cohorts: percentage of participants with bor based pet-ct or ct only as determined by irc'], 'dlbcl cohorts: dor based on pet-ct or ct only as determined by the irc': ['dlbcl cohorts: dor based on pet-ct or ct only as determined by the irc'], 'dlbcl cohorts: pfs based on pet-ct or ct only as determined by the irc': ['dlbcl cohorts: pfs based on pet-ct or ct only as determined by the irc'], 'phase ii nf cohort: percentage of participants with cr at pra based on pet-ct as determined by the investigator': ['phase ii nf cohort: percentage of participants with cr at pra based on pet-ct as determined by the investigator'], 'phase ii nf cohort: percentage of participants with or at pra based on pet-ct as determined by investigator': ['phase ii nf cohort: percentage of participants with or at pra based on pet-ct as determined by investigator'], 'phase ii nf cohort: percentage of participants with or at pra based on pet-ct as determined by irc': ['phase ii nf cohort: percentage of participants with or at pra based on pet-ct as determined by irc'], 'phase ii nf cohorts: percentage of participants with bor based on pet-ct or ct only as determined by the investigator': ['phase ii nf cohorts: percentage of participants with bor based on pet-ct or ct only as determined by the investigator'], 'phase ii nf cohorts: percentage of participants with bor based on pet-ct or ct only as determined by the irc': ['phase ii nf cohorts: percentage of participants with bor based on pet-ct or ct only as determined by the irc'], 'phase ii nf cohort: dor based on pet-ct or ct only as determined by the investigator': ['phase ii nf cohort: dor based on pet-ct or ct only as determined by the investigator'], 'phase ii nf cohort: dor based on pet-ct or ct only as determined by the irc': ['phase ii nf cohort: dor based on pet-ct or ct only as determined by the irc'], 'phase ii nf cohort: pfs based on pet-ct or ct only as determined by the investigator': ['phase ii nf cohort: pfs based on pet-ct or ct only as determined by the investigator'], 'phase ii nf cohort: pfs based on pet-ct or ct only as determined by the irc': ['phase ii nf cohort: pfs based on pet-ct or ct only as determined by the irc'], 'arm g : percentage of participants with cr at pra based on pet-ct as determined by the irc': ['arm g : percentage of participants with cr at pra based on pet-ct as determined by the irc'], 'arm g : percentage of participants with cr at pra based on ct only as determined by investigator': ['arm g : percentage of participants with cr at pra based on ct only as determined by investigator'], 'arm g : percentage of participants with cr at pra based on ct only as determined by irc': ['arm g : percentage of participants with cr at pra based on ct only as determined by irc'], 'arm g : percentage of participants with or at pra based on ct only as determined by investigator': ['arm g : percentage of participants with or at pra based on ct only as determined by investigator'], 'arm g : percentage of participants with or at pra based on ct only as determined by irc': ['arm g : percentage of participants with or at pra based on ct only as determined by irc'], 'plasma concentration of of polatuzumab vedotin analyte: acmmae': ['plasma concentration of of polatuzumab vedotin analyte: acmmae'], 'arm g+h : plasma concentration of of polatuzumab vedotin analyte: acmmae': ['arm g+h : plasma concentration of of polatuzumab vedotin analyte: acmmae'], 'serum concentration of of polatuzumab vedotin analyte: total ab': ['serum concentration of of polatuzumab vedotin analyte: total ab'], 'arm g+h : plasma concentration of polatuzumab vedotin analyte: total ab': ['arm g+h : plasma concentration of polatuzumab vedotin analyte: total ab'], 'plasma concentration of polatuzumab vedotin analyte: unconjugated mmae': ['plasma concentration of polatuzumab vedotin analyte: unconjugated mmae'], 'arm g+h : plasma concentration of polatuzumab vedotin analyte: unconjugated mmae': ['arm g+h : plasma concentration of polatuzumab vedotin analyte: unconjugated mmae'], 'phase ib: cmax of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a': ['phase ib: cmax of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a'], 'phase ib: cmax of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b': ['phase ib: cmax of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b'], 'phase ii: cmax of polatuzumab vedotin, bendamustine, and rituximab in arms a and c': ['phase ii: cmax of polatuzumab vedotin, bendamustine, and rituximab in arms a and c'], 'phase ii: cmax of bendamustine and rituximab in arms b and d': ['phase ii: cmax of bendamustine and rituximab in arms b and d'], 'phase ii: cmax of polatuzumab vedotin, obinutuzumab and bendamustine in arms e and f': ['phase ii: cmax of polatuzumab vedotin, obinutuzumab and bendamustine in arms e and f'], 'phase ib: aucinf of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b': ['phase ib: aucinf of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b'], 'phase ii: aucinf of polatuzumab vedotin, bendamustine, and rituximab in arms a and c': ['phase ii: aucinf of polatuzumab vedotin, bendamustine, and rituximab in arms a and c'], 'phase ii: aucinf of bendamustine and rituximab in arms b and d': ['phase ii: aucinf of bendamustine and rituximab in arms b and d'], 'phase ii: aucinf of polatuzumab vedotin, bendamustine, and obinutuzumab in arms e and f': ['phase ii: aucinf of polatuzumab vedotin, bendamustine, and obinutuzumab in arms e and f'], 'phase ib: cl of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a': ['phase ib: cl of polatuzumab vedotin, bendamustine, and rituximab in cohort 1a'], 'phase ib: cl of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b': ['phase ib: cl of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b'], 'phase ii: cl of polatuzumab vedotin, bendamustine and rituximab in arms a and c': ['phase ii: cl of polatuzumab vedotin, bendamustine and rituximab in arms a and c'], 'phase ii: cl of bendamustine and rituximab in arms b and d': ['phase ii: cl of bendamustine and rituximab in arms b and d'], 'phase ii: cl of polatuzumab vedotin, bendamustine and obinutuzumab in arms e and f': ['phase ii: cl of polatuzumab vedotin, bendamustine and obinutuzumab in arms e and f'], 'phase ib: vss of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1a': ['phase ib: vss of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1a'], 'phase ib: vss of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b': ['phase ib: vss of polatuzumab vedotin, bendamustine, and obinutuzumab in cohort 1b'], 'phase ii: vss of polatuzumab vedotin, bendamustine and rituximab in arms a and c': ['phase ii: vss of polatuzumab vedotin, bendamustine and rituximab in arms a and c'], 'phase ii: vss of bendamustine and rituximab in arms b and d': ['phase ii: vss of bendamustine and rituximab in arms b and d'], 'phase ii: vss of polatuzumab vedotin, bendamustine and obinutuzumab in arms e and f': ['phase ii: vss of polatuzumab vedotin, bendamustine and obinutuzumab in arms e and f'], 'phase 2: durable response rate': ['phase 2: durable response rate'], '1: assessment of anti-tumor activity: mri k-trans in [ 10^-3/min] and/or ceus in [arbitrary units] 2: pharmacokinetic profile: auc in [ng*h/ml]': ['1: assessment of anti-tumor activity: mri k-trans in [ 10^-3/min] and/or ceus in [arbitrary units] 2: pharmacokinetic profile: auc in [ng*h/ml]'], 'maximum tolerated dose of aurora kinase inhibitor at9283': ['maximum tolerated dose of aurora kinase inhibitor at9283'], 'recommended phase ii dose of at9283': ['recommended phase ii dose of at9283'], 'safety, tolerability, toxicity profile, and dose-limiting toxicity of at9283': ['safety, tolerability, toxicity profile, and dose-limiting toxicity of at9283'], 'pharmacokinetic profile of at9283': ['pharmacokinetic profile of at9283'], 'efficacy of at9283': ['efficacy of at9283'], 'part 2: objective response rate of amg 655 therapy as determined by using iwg criteria at the dose selected in part 1, in combination with bortezomib in subjects with mantle cell lymphoma': ['part 2: objective response rate of amg 655 therapy as determined by using iwg criteria at the dose selected in part 1, in combination with bortezomib in subjects with mantle cell lymphoma'], 'part 2: pk parameters for amg 655 on a 3 week dosing schedule.': ['part 2: pk parameters for amg 655 on a 3 week dosing schedule.'], 'part 2: subject incidence of anti-amg 655 antibody formation.': ['part 2: subject incidence of anti-amg 655 antibody formation.'], 'part 2: duration of response.': ['part 2: duration of response.'], 'part 1: subject incidence of anti-amg 655 antibody formation.': ['part 1: subject incidence of anti-amg 655 antibody formation.'], 'part 1: best tumor response, objective response rate and duration of response.': ['part 1: best tumor response, objective response rate and duration of response.'], 'part 1: maximum tolerated dose of amg 655 administered with bortezomib or vorinostat, if reached.': ['part 1: maximum tolerated dose of amg 655 administered with bortezomib or vorinostat, if reached.'], 'part 1: pk parameters for amg 655 on a 3 week dosing schedule.': ['part 1: pk parameters for amg 655 on a 3 week dosing schedule.'], 'overall survival median': ['overall survival median'], '3-year overall survival': ['3-year overall survival'], 'optimal bendamustine dosage for further studies': ['optimal bendamustine dosage for further studies'], 'part a: cmax: maximum observed plasma concentration for ixazomib': ['part a: cmax: maximum observed plasma concentration for ixazomib'], 'part a: auc: area under the plasma concentration-time curve from time 0 to 312 hrs post-dose for ixazomib': ['part a: auc: area under the plasma concentration-time curve from time 0 to 312 hrs post-dose for ixazomib'], 'part a: cmax: maximum observed plasma concentration of tra': ['part a: cmax: maximum observed plasma concentration of tra'], 'part a: tmax: time to reach the cmax for tra': ['part a: tmax: time to reach the cmax for tra'], 'part a: cmax: maximum observed whole blood concentration of tra': ['part a: cmax: maximum observed whole blood concentration of tra'], 'part a: cumulative percentage of ixazomib dose recovered in the urine': ['part a: cumulative percentage of ixazomib dose recovered in the urine'], 'part a: cumulative percentage of the total radioactivity dose excreted in feces': ['part a: cumulative percentage of the total radioactivity dose excreted in feces'], 'part a: cumulative percentage of the total radioactivity dose excreted in urine': ['part a: cumulative percentage of the total radioactivity dose excreted in urine'], 'part a: renal clearance of ixazomib': ['part a: renal clearance of ixazomib'], 'ixazomib and metabolites as percent of total radioactivity in plasma': ['ixazomib and metabolites as percent of total radioactivity in plasma'], 'ixazomib and metabolites as percent of total dose administered in urine': ['ixazomib and metabolites as percent of total dose administered in urine'], 'ixazomib and metabolites as percent of total dose administered in feces': ['ixazomib and metabolites as percent of total dose administered in feces'], 'response of participants treated at lenalidomide 20 mg': ['response of participants treated at lenalidomide 20 mg'], 'objective response rate of participants treated with lenalidomide 20 mg: overall response as % of participants with complete or partial response': ['objective response rate of participants treated with lenalidomide 20 mg: overall response as % of participants with complete or partial response'], 'cmax: maximum observed plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution': ['cmax: maximum observed plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution'], 'tmax: time of first occurrence of cmax for alisertib and drug-related material in plasma following a single dose of [^14c]-alisertib oral solution': ['tmax: time of first occurrence of cmax for alisertib and drug-related material in plasma following a single dose of [^14c]-alisertib oral solution'], 'auclast: area under the concentration-time curve from time 0 to time of the last quantifiable plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution': ['auclast: area under the concentration-time curve from time 0 to time of the last quantifiable plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution'], 'auc∞: area under the concentration-time curve from time 0 to infinity, calculated using the observed value of the last quantifiable plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution': ['auc∞: area under the concentration-time curve from time 0 to infinity, calculated using the observed value of the last quantifiable plasma concentration for alisertib and drug-related material following a single dose of [^14c]-alisertib oral solution'], 't1/2: terminal half life for alisertib and drug-related material in plasma following a single dose of [^14c]-alisertib oral solution': ['t1/2: terminal half life for alisertib and drug-related material in plasma following a single dose of [^14c]-alisertib oral solution'], 'cl/f: apparent clearance after extravascular administration, calculated using the observed value of the last quantifiable plasma concentration for alisertib following a single dose of [^14c]-alisertib oral solution': ['cl/f: apparent clearance after extravascular administration, calculated using the observed value of the last quantifiable plasma concentration for alisertib following a single dose of [^14c]-alisertib oral solution'], 'ratio of alisertib plasma cmax to drug-related material tra plasma cmax': ['ratio of alisertib plasma cmax to drug-related material tra plasma cmax'], 'ratio of whole blood tra auclast to plasma tra auclast': ['ratio of whole blood tra auclast to plasma tra auclast'], 'ratio of alisertib plasma auclast to drug-related material tra plasma auclast': ['ratio of alisertib plasma auclast to drug-related material tra plasma auclast'], 'ratio of whole blood tra auc∞ to plasma tra auc∞': ['ratio of whole blood tra auc∞ to plasma tra auc∞'], 'ratio of alisertib plasma auc∞ to drug-related material tra plasma auc∞': ['ratio of alisertib plasma auc∞ to drug-related material tra plasma auc∞'], 'fe: fraction of administered dose of [^14c]-alisertib excreted in urine': ['fe: fraction of administered dose of [^14c]-alisertib excreted in urine'], 'fe: fraction of administered dose of [^14c]-alisertib excreted in feces': ['fe: fraction of administered dose of [^14c]-alisertib excreted in feces'], 'ae: amount of [^14c]-alisertib excreted in urine': ['ae: amount of [^14c]-alisertib excreted in urine'], 'ae: amount of [^14c]-alisertib excreted in feces': ['ae: amount of [^14c]-alisertib excreted in feces'], 'fe: fraction of administered dose of alisertib excreted in urine': ['fe: fraction of administered dose of alisertib excreted in urine'], 'ae: amount of alisertib excretion in urine': ['ae: amount of alisertib excretion in urine'], 'renal clearance  of alisertib': ['renal clearance  of alisertib'], 'percentage of alisertib metabolites in plasma following a single dose of [^14c]-alisertib oral solution': ['percentage of alisertib metabolites in plasma following a single dose of [^14c]-alisertib oral solution'], 'percentage of alisertib metabolites in urine following a single dose of [^14c]-alisertib oral solution': ['percentage of alisertib metabolites in urine following a single dose of [^14c]-alisertib oral solution'], 'percentage of alisertib metabolites in feces following a single dose of [^14c]-alisertib oral solution': ['percentage of alisertib metabolites in feces following a single dose of [^14c]-alisertib oral solution'], 'number of participants with clinically significant changes or abnormalities in vital sign measurements': ['number of participants with clinically significant changes or abnormalities in vital sign measurements'], 'phase 1b/2 : overall response rate of number of participants': ['phase 1b/2 : overall response rate of number of participants'], 'phase 1b/ 2: duration of response': ['phase 1b/ 2: duration of response'], 'phase 1b/2: overall survival': ['phase 1b/2: overall survival'], 'pharmacokinetics: mean area under the plasma concentration-time curve from time 0-24 hours  for ibrutinib': ['pharmacokinetics: mean area under the plasma concentration-time curve from time 0-24 hours  for ibrutinib'], 'pharmacokinetics: mean terminal elimination half-life  for ibrutinib': ['pharmacokinetics: mean terminal elimination half-life  for ibrutinib'], 'pharmacokinetics: medi4736 accumulation ratio for cmax': ['pharmacokinetics: medi4736 accumulation ratio for cmax'], 'pharmacokinetics: medi4736 accumulation ratio for ctrough': ['pharmacokinetics: medi4736 accumulation ratio for ctrough'], 'bruton tyrosine kinase  occupancy': ['bruton tyrosine kinase  occupancy'], 'pharmacodynamics of ibrutinib in subjects with relapsed or refractory lymphomas': ['pharmacodynamics of ibrutinib in subjects with relapsed or refractory lymphomas'], 'pharmacodynamics of medi4736 in subjects with relapsed or refractory lymphomas': ['pharmacodynamics of medi4736 in subjects with relapsed or refractory lymphomas'], 'percentage of participants with an increase in frequency of lmp2-specific cd8+ t cells': ['percentage of participants with an increase in frequency of lmp2-specific cd8+ t cells'], 'days to neutrophil and platelet engraftment': ['days to neutrophil and platelet engraftment'], 'establish the safety and tolerability of the combination of abt-888 with metronomic cyclophosphamide in patients with refractory solid tumors and lymphomas. establish the mtd of the combination of abt-888 with metronomic cyclophosphamide.': ['establish the safety and tolerability of the combination of abt-888 with metronomic cyclophosphamide in patients with refractory solid tumors and lymphomas. establish the mtd of the combination of abt-888 with metronomic cyclophosphamide.'], 'evaluate the pharmacokinetics of abt-888 when administered combination with cyclophosphamide. evaluate for anti-tumor response.': ['evaluate the pharmacokinetics of abt-888 when administered combination with cyclophosphamide. evaluate for anti-tumor response.'], 'cmax: maximum observed concentration for alisertib in presence and absence of esomeprazole': ['cmax: maximum observed concentration for alisertib in presence and absence of esomeprazole'], 'auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib in presence and absence of esomeprazole': ['auclast: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for alisertib in presence and absence of esomeprazole'], 'auc∞: area under the plasma concentration-time curve from time 0 to infinity for alisertib in presence and absence of esomeprazole': ['auc∞: area under the plasma concentration-time curve from time 0 to infinity for alisertib in presence and absence of esomeprazole'], 'cmax: maximum observed concentration for alisertib in presence and absence of rifampin': ['cmax: maximum observed concentration for alisertib in presence and absence of rifampin'], 'auc∞: area under the plasma concentration-time curve from time 0 to infinity for alisertib in presence or absence of rifampin': ['auc∞: area under the plasma concentration-time curve from time 0 to infinity for alisertib in presence or absence of rifampin'], 'change from the time-matched baseline in the individually corrected qtc interval': ['change from the time-matched baseline in the individually corrected qtc interval'], 'change from the time-matched baseline in the fridericia correction of qtc': ['change from the time-matched baseline in the fridericia correction of qtc'], 'specific toxicities and the dose limiting toxicity  of bortezomib in combination with azacitidine as assessed by nci ctcae  v4.0': ['specific toxicities and the dose limiting toxicity  of bortezomib in combination with azacitidine as assessed by nci ctcae  v4.0'], 'correlation of the biological activity of azacitidine as a demethylating agent with clinical endpoints and plasma pharmacokinetics': ['correlation of the biological activity of azacitidine as a demethylating agent with clinical endpoints and plasma pharmacokinetics'], 'biological activity of bortezomib as a potential demethylating agent': ['biological activity of bortezomib as a potential demethylating agent'], 'correlation of intracellular concentration of azacitidine-triphosphate with global dna methylation and other biological endpoints as well as clinical response': ['correlation of intracellular concentration of azacitidine-triphosphate with global dna methylation and other biological endpoints as well as clinical response'], 'biologic role of micrornas in determining clinical response to the bortezomib plus azacitidine combination and achievement of the other pharmacodynamic endpoints': ['biologic role of micrornas in determining clinical response to the bortezomib plus azacitidine combination and achievement of the other pharmacodynamic endpoints'], 'to determine the maximum tolerated dose and phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors.': ['to determine the maximum tolerated dose and phase 2 dose of combination vorinostat and bortezomib to children with refractory or recurrent solid tumors.'], 'define toxicities and pharmacokinetics.': ['define toxicities and pharmacokinetics.'], 'to define antitumor activity, assess biological activity of bortezomib by measuring nf-kb activity in pbmc and to assess the biologic activity of bortezomib by measuring endoplasmic reticulum stress response using grp78 molecular chaperone marke...': ['to define antitumor activity, assess biological activity of bortezomib by measuring nf-kb activity in pbmc and to assess the biologic activity of bortezomib by measuring endoplasmic reticulum stress response using grp78 molecular chaperone marke...'], 'maximum tolerated dose  of inotuzumab ozogamicin in combination with rituximab': ['maximum tolerated dose  of inotuzumab ozogamicin in combination with rituximab'], 'percentage of participants with a treatment emergent adverse event': ['percentage of participants with a treatment emergent adverse event'], 'kaplan-meier estimates of the probability of being progression free at 6 months': ['kaplan-meier estimates of the probability of being progression free at 6 months'], 'kaplan-meier estimates of the probability of survival at 6 months': ['kaplan-meier estimates of the probability of survival at 6 months'], 'kaplan-meier estimates of the probability of being event free at 6 months': ['kaplan-meier estimates of the probability of being event free at 6 months'], 'auclast of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58': ['auclast of inotuzumab ozogamicin in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58'], 'mrt of inotuzumab ozogamicin in serum in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58': ['mrt of inotuzumab ozogamicin in serum in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58'], 'aucinf of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58': ['aucinf of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 30 and day 58'], 'time of observed maximum concentration  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58': ['time of observed maximum concentration  of total calicheamicin  in participants receiving inotuzumab ozogamicin mtd + rituximab 375 mg/m^2 on dosing day 1, day 30 and day 58'], 'percentage of participants achieving cr at eoi, as determined by the investigator using modified lugano 2014 criteria': ['percentage of participants achieving cr at eoi, as determined by the investigator using modified lugano 2014 criteria'], 'percentage of participants achieving cr at eoi, as determined by the irc and investigator using lugano 2014 criteria': ['percentage of participants achieving cr at eoi, as determined by the irc and investigator using lugano 2014 criteria'], 'serum concentration of lenalidomide': ['serum concentration of lenalidomide'], 'percentage of participants with cr at eoi, as determined by the investigator on the basis of positron emission tomography and computed tomography  scan': ['percentage of participants with cr at eoi, as determined by the investigator on the basis of positron emission tomography and computed tomography  scan'], 'percentage of participants with cr at eoi, as determined by investigator on the basis of ct scans alone': ['percentage of participants with cr at eoi, as determined by investigator on the basis of ct scans alone'], 'percentage of participants with best response of cr or pr during the study, as determined by the investigator on the basis of ct scans alone': ['percentage of participants with best response of cr or pr during the study, as determined by the investigator on the basis of ct scans alone'], 'serum obinutuzumab concentration': ['serum obinutuzumab concentration'], 'serum rituximab concentration': ['serum rituximab concentration'], 'serum atezo concentration': ['serum atezo concentration'], 'serum pola concentration': ['serum pola concentration'], 'percentage of participants with atas to pola': ['percentage of participants with atas to pola'], 'maximum tolerated dose of lenalidomide combined with bortezomib and rituximab in phase i participants': ['maximum tolerated dose of lenalidomide combined with bortezomib and rituximab in phase i participants'], 'time to best response of phase i and phase ii participants': ['time to best response of phase i and phase ii participants'], 'time to best response of previously treated and previously untreated participants': ['time to best response of previously treated and previously untreated participants'], 'overall survival of phase i and phase ii participants': ['overall survival of phase i and phase ii participants'], 'overall survival of previously treated and previously untreated participants': ['overall survival of previously treated and previously untreated participants'], 'number of participants with clinical response rates': ['number of participants with clinical response rates'], 'mtd of lenalidomide  progression free survival': ['mtd of lenalidomide  progression free survival'], 'number of patients with grade 3 or greater toxicity': ['number of patients with grade 3 or greater toxicity'], '5-year overall survival': ['5-year overall survival'], '5-year disease-free survival': ['5-year disease-free survival'], 'phase i: maximum-tolerated dose of bendamustine in combination with ofatumumab, carboplatin and etoposide': ['phase i: maximum-tolerated dose of bendamustine in combination with ofatumumab, carboplatin and etoposide'], 'phase i: overall frequency of response': ['phase i: overall frequency of response'], 'overall progression-free survival': ['overall progression-free survival'], 'total overall survival for transplant vs non-transplant': ['total overall survival for transplant vs non-transplant'], 'overall proportion of patients who are able to undergo stem cell transplant': ['overall proportion of patients who are able to undergo stem cell transplant'], 'overall safety and tolerability of the combination of bendamustine, ofatumumab, carboplatin, and etoposide': ['overall safety and tolerability of the combination of bendamustine, ofatumumab, carboplatin, and etoposide'], 'evaluation of safety and tolerability': ['evaluation of safety and tolerability'], 'disease response': ['disease response'], 'number of participants with best overall response': ['number of participants with best overall response'], 'mean peak and trough concentrations of medi551': ['mean peak and trough concentrations of medi551'], 'mean peak and trough concentrations of medi0680': ['mean peak and trough concentrations of medi0680'], 'number of participants with disease control': ['number of participants with disease control'], 'duration of disease control': ['duration of disease control'], 'percentage of intratumoral nk-cells and t-cells infiltration into tumors': ['percentage of intratumoral nk-cells and t-cells infiltration into tumors'], 'number of immune cells  in tumor and peripheral blood': ['number of immune cells  in tumor and peripheral blood'], 'level of plasma cytokine production plus release in tumor and peripheral blood as a function of treatment': ['level of plasma cytokine production plus release in tumor and peripheral blood as a function of treatment'], 'number of patients able to proceed to transplant': ['number of patients able to proceed to transplant'], 'number of patients achieving neutrophil engraftment': ['number of patients achieving neutrophil engraftment'], 'number of patients achieving platelet engraftment': ['number of patients achieving platelet engraftment'], 'overall survival at day 100 post-transplant': ['overall survival at day 100 post-transplant'], 'overall survival at day 365 post-transplant': ['overall survival at day 365 post-transplant'], 'disease response following salvage chemotherapy': ['disease response following salvage chemotherapy'], 'disease response 30 days post-transplant': ['disease response 30 days post-transplant'], 'disease response at 1 year post-transplant': ['disease response at 1 year post-transplant'], 'progression-free survival after stem cell transplant': ['progression-free survival after stem cell transplant'], 'days platelets count of < 100k/μl': ['days platelets count of < 100k/μl'], 'phase i: mtd / phase ii: orr': ['phase i: mtd / phase ii: orr'], 'efficacy: evaluate tumor response as measured by the composite assessment of index lesion disease severity . the primary endpoint will be the overall tumor response rate as assessed by the ca.': ['efficacy: evaluate tumor response as measured by the composite assessment of index lesion disease severity . the primary endpoint will be the overall tumor response rate as assessed by the ca.'], 'secondary efficacy endpoints include disease response assessed by the pga, duration of overall response, duration of ccr, duration of pr, time to response and time to progression of disease.': ['secondary efficacy endpoints include disease response assessed by the pga, duration of overall response, duration of ccr, duration of pr, time to response and time to progression of disease.'], 'safety and identification of dose-limiting toxicities': ['safety and identification of dose-limiting toxicities'], 'identification of the mtd': ['identification of the mtd'], 'complete response rate at 20 weeks': ['complete response rate at 20 weeks'], 'partial response rate at 20 weeks': ['partial response rate at 20 weeks'], 'overall response rate  at 20 weeks': ['overall response rate  at 20 weeks'], 'maximal tolerable dose  absorbed dose to the liver, safety and time to treatment failure': ['maximal tolerable dose  absorbed dose to the liver, safety and time to treatment failure'], 'number of participants with dose limiting toxicity for determination phase i  mtd of vorinostat': ['number of participants with dose limiting toxicity for determination phase i  mtd of vorinostat'], 'phase ii mtd of vorinostat': ['phase ii mtd of vorinostat'], 'any single mutation of oncogene and copy number variation in ctdna': ['any single mutation of oncogene and copy number variation in ctdna'], 'mutation of polygene and copy number variation in signal pathway': ['mutation of polygene and copy number variation in signal pathway'], 'pharmacokinetics-plasma kw-0761 concentrations': ['pharmacokinetics-plasma kw-0761 concentrations'], 'antitumor effect': ['antitumor effect'], 'safety profile': ['safety profile'], 'tumor-specific immune response': ['tumor-specific immune response'], 'treatment related toxicity': ['treatment related toxicity'], 'engraftment': ['engraftment'], 'relapse rate': ['relapse rate'], 'immunoreconstitution': ['immunoreconstitution'], 'serum concentration of cnto 328': ['serum concentration of cnto 328'], 'pharmacodynamics of cnto 328': ['pharmacodynamics of cnto 328'], 'plasma antibodies to cnto 328': ['plasma antibodies to cnto 328'], \"number of participants with castleman's disease who achieved tumor response\": [\"number of participants with castleman's disease who achieved tumor response\"], 'number of participants with multiple myeloma who achieved disease response': ['number of participants with multiple myeloma who achieved disease response'], \"number of participants with b-cell non-hodgkin's lymphoma and multiple myeloma who achieved clinical benefit\": [\"number of participants with b-cell non-hodgkin's lymphoma and multiple myeloma who achieved clinical benefit\"], \"number of participants with castleman's disease who achieved clinical benefit\": [\"number of participants with castleman's disease who achieved clinical benefit\"], \"number of participants with b-cell non-hodgkin's lymphoma who achieved disease response\": [\"number of participants with b-cell non-hodgkin's lymphoma who achieved disease response\"], 'safety and efficacy': ['safety and efficacy'], 'toxicities of pralatrexate': ['toxicities of pralatrexate'], 'plasma pk of [14c] tazemetostat, tazemetostat, and its metabolite epz-6930 after iv administration of approximately 12 µg of [14c] tazemetostat containing approximately 500 nci of radioactivity and oral bid administration of 800 mg tazemetostat': ['plasma pk of [14c] tazemetostat, tazemetostat, and its metabolite epz-6930 after iv administration of approximately 12 µg of [14c] tazemetostat containing approximately 500 nci of radioactivity and oral bid administration of 800 mg tazemetostat'], 'estimate tazemetostat absolute bioavailability  after repeated oral administration of 800 mg bid': ['estimate tazemetostat absolute bioavailability  after repeated oral administration of 800 mg bid'], 'compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14c] tazemetostat': ['compare the total radioactivity concentration-time profiles in blood and plasma after oral administration of [14c] tazemetostat'], 'plasma pk of tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 µci  of radioactivity': ['plasma pk of tazemetostat and epz6930 after administration of an oral 800 mg dose of [14c] tazemetostat containing approximately 400 µci  of radioactivity'], 'global response rate prior to asct': ['global response rate prior to asct'], 'toxicity according to the ctc criteria': ['toxicity according to the ctc criteria'], 'stem cell mobilization capacity': ['stem cell mobilization capacity'], 'time to hl progression': ['time to hl progression'], 'lymphoma-specific survival': ['lymphoma-specific survival'], 'time to next treatment': ['time to next treatment'], 'overall objective response rate': ['overall objective response rate'], 'fcγ-receptor polymorphism response to treatment': ['fcγ-receptor polymorphism response to treatment'], 'quantitative t-, b-, and nk-cell subsets using flow cytometry': ['quantitative t-, b-, and nk-cell subsets using flow cytometry'], 'access pharmacokinetics through auc0-∞': ['access pharmacokinetics through auc0-∞'], 'access pharmacokinetics through cmax': ['access pharmacokinetics through cmax'], 'establishment of maximum tolerable dose of valproate.': ['establishment of maximum tolerable dose of valproate.'], 'safety and tolerance of different dose levels': ['safety and tolerance of different dose levels'], 'lack of immunogenicity': ['lack of immunogenicity'], 'incidence of hematological toxicities > grade 2 by common terminology criteria v4.0': ['incidence of hematological toxicities > grade 2 by common terminology criteria v4.0'], 'evaluate imaging time window with ⁸⁹zr-df-iab22m2c': ['evaluate imaging time window with ⁸⁹zr-df-iab22m2c'], 'evaluate protein dose for imaging with ⁸⁹zr-df-iab22m2c': ['evaluate protein dose for imaging with ⁸⁹zr-df-iab22m2c'], 'evaluate the radioactive pharmacokinetics of ⁸⁹zr-df-iab22m2c by determining the time-activity curves for serum , auc, clearance, volume of distribution, tmax and cmax.': ['evaluate the radioactive pharmacokinetics of ⁸⁹zr-df-iab22m2c by determining the time-activity curves for serum , auc, clearance, volume of distribution, tmax and cmax.'], 'evaluate the dosimetry of a single dose of ⁸⁹zr-df-iab22m2c': ['evaluate the dosimetry of a single dose of ⁸⁹zr-df-iab22m2c'], 'establish recommended phase 2 dose, after completing dose escalation in part 1 and evaluating accumulated safety,pk,and pd data from the dose escalation phase': ['establish recommended phase 2 dose, after completing dose escalation in part 1 and evaluating accumulated safety,pk,and pd data from the dose escalation phase'], 'evaluate the pharmacokinetic parameters of avl-292': ['evaluate the pharmacokinetic parameters of avl-292'], 'evaluate the pharmacodynamics of avl-292 by measurement of free btk': ['evaluate the pharmacodynamics of avl-292 by measurement of free btk'], 'characterize preliminary anti-tumor efficacy of avl-292 in relapsed and/or refractory b-nhl, cll and wm': ['characterize preliminary anti-tumor efficacy of avl-292 in relapsed and/or refractory b-nhl, cll and wm'], 'to define the dose-limiting toxicity and maximum tolerable dose': ['to define the dose-limiting toxicity and maximum tolerable dose'], 'to evaluate the overall response rate': ['to evaluate the overall response rate'], 'to evaluate the safety and tolerability of the treatment combination': ['to evaluate the safety and tolerability of the treatment combination'], 'to estimate the time to progression and the duration of overall response': ['to estimate the time to progression and the duration of overall response'], 'phase i part: determination of the recommended dose of lenalidomide in combination with fixed doses of ga101': ['phase i part: determination of the recommended dose of lenalidomide in combination with fixed doses of ga101'], 'phase ii part: overall response rate  after 6 cycles': ['phase ii part: overall response rate  after 6 cycles'], 'response rate at the end of maintenance treatment': ['response rate at the end of maintenance treatment'], 'complete response rate after induction': ['complete response rate after induction'], 'complete response rate after 3 cycles': ['complete response rate after 3 cycles'], 'brentuximab vedotin concentration in blood': ['brentuximab vedotin concentration in blood'], 'antitherapeutic antibodies in blood': ['antitherapeutic antibodies in blood'], 'time to failure': ['time to failure'], 'number of participants with overall response rate': ['number of participants with overall response rate'], 'plasma blood concentrations of chemical markers': ['plasma blood concentrations of chemical markers'], 'measurement of pathway biomarkers in plasma': ['measurement of pathway biomarkers in plasma'], 'number of participants with dose-limiting toxicities as a measure of safety and tolerability': ['number of participants with dose-limiting toxicities as a measure of safety and tolerability'], 'determine the response rate to obatoclax in combination with bortezomib and characterize the safety profile': ['determine the response rate to obatoclax in combination with bortezomib and characterize the safety profile'], 'peripheral blood counts bone marrow aspirates and biopsies transfusion and growth factor requirements': ['peripheral blood counts bone marrow aspirates and biopsies transfusion and growth factor requirements'], 'overall response at the end of treatment': ['overall response at the end of treatment'], 'safety of association temsirolimus with the three chemotherapy regimens': ['safety of association temsirolimus with the three chemotherapy regimens'], 'body temperature': ['body temperature'], 'blood pressure- diastolic': ['blood pressure- diastolic'], 'blood pressure- systolic': ['blood pressure- systolic'], 'pulse rate': ['pulse rate'], 'respiratory rate': ['respiratory rate'], 'skin clinical response': ['skin clinical response'], 'relapse free and progression free survival': ['relapse free and progression free survival'], 'maximum tolerated dose of the combination of romidepsin and carfilzomib': ['maximum tolerated dose of the combination of romidepsin and carfilzomib'], 'best overall response rate  at the mtd': ['best overall response rate  at the mtd'], 'toxicity of the combination of romidepsin and carfilzomib': ['toxicity of the combination of romidepsin and carfilzomib'], 'best overall response at the mtd': ['best overall response at the mtd'], 'maximum percentage change in the radiological sum of the product of the diameters from baseline, assessed using the revised response criteria for malignant lymphoma': ['maximum percentage change in the radiological sum of the product of the diameters from baseline, assessed using the revised response criteria for malignant lymphoma'], 'duration of response from time of first documented response until relapse or progression': ['duration of response from time of first documented response until relapse or progression'], 'overall response rate for the combination of brentuximab vedotin and bendamustine': ['overall response rate for the combination of brentuximab vedotin and bendamustine'], 'response rate according to the harmonization project  or recist criteria.': ['response rate according to the harmonization project  or recist criteria.'], 'progression-free survival post-autologous stem cell transplant': ['progression-free survival post-autologous stem cell transplant'], 'to determine safety & tolerability by adverse event rates in order to determine recommended phase ii dose': ['to determine safety & tolerability by adverse event rates in order to determine recommended phase ii dose'], 'pharmacokinetics and pharmacodynamics': ['pharmacokinetics and pharmacodynamics'], 'phase i and phase ii: event free survival and overall survival': ['phase i and phase ii: event free survival and overall survival'], 'mtd defined as the dose level at which no more than one of 6 patients experiences a dlt summarized using the national cancer institute  ctcae version 4.0': ['mtd defined as the dose level at which no more than one of 6 patients experiences a dlt summarized using the national cancer institute  ctcae version 4.0'], 'change in correlative markers in blood, bone marrow and tumor tissue': ['change in correlative markers in blood, bone marrow and tumor tissue'], 'to characterize the safety profile of idec-114 and to define their duration and reversibility': ['to characterize the safety profile of idec-114 and to define their duration and reversibility'], 'to evaluate pk': ['to evaluate pk'], 'to monitor presence of human anti galiximab antibody': ['to monitor presence of human anti galiximab antibody'], 'to evaluate efficacy': ['to evaluate efficacy'], 'to identify nk functional assays that may predict galiximab efficacy': ['to identify nk functional assays that may predict galiximab efficacy'], 'progression-free survival according to the international workshop to standardize response criteria for nhl': ['progression-free survival according to the international workshop to standardize response criteria for nhl'], 'event-free survival according to the international workshop to standardize response criteria for nhl': ['event-free survival according to the international workshop to standardize response criteria for nhl'], 'area under the plasma concentration-time curve from time 0 to day 28  of ocrelizumab': ['area under the plasma concentration-time curve from time 0 to day 28  of ocrelizumab'], 'percentage of participants with overall response according to the international workshop to standardize response criteria for nhl': ['percentage of participants with overall response according to the international workshop to standardize response criteria for nhl'], 'number of participants with peripheral blood b-cell depletion': ['number of participants with peripheral blood b-cell depletion'], 'number of participants with peripheral blood b-cell recovery': ['number of participants with peripheral blood b-cell recovery'], 'frequency of dlt': ['frequency of dlt'], 'plasma concentration of s 55746': ['plasma concentration of s 55746'], 'the pk profile of s 55746: maximal concentration [cmax]': ['the pk profile of s 55746: maximal concentration [cmax]'], 'apoptotic activity from blood samples': ['apoptotic activity from blood samples'], 'phase 1 and 2: percentage of participants with serum chemistry toxicity grade shifts to grade 3 or higher resulting from increased parameter values': ['phase 1 and 2: percentage of participants with serum chemistry toxicity grade shifts to grade 3 or higher resulting from increased parameter values'], 'phase 1 and 2: percentage of participants with serum chemistry toxicity grade shifts to grade 3 or higher resulting from decreased parameter values': ['phase 1 and 2: percentage of participants with serum chemistry toxicity grade shifts to grade 3 or higher resulting from decreased parameter values'], 'phase 1 and 2: percentage of participants with hematology toxicity grade shifts to grade 3 or higher resulting from increased parameter values': ['phase 1 and 2: percentage of participants with hematology toxicity grade shifts to grade 3 or higher resulting from increased parameter values'], 'phase 1 and 2: percentage of participants with hematology toxicity grade shifts to grade 3 or higher resulting from decreased parameter values': ['phase 1 and 2: percentage of participants with hematology toxicity grade shifts to grade 3 or higher resulting from decreased parameter values'], 'phase 1 and 2: peak anti-cd19 car t-cell  level  in blood': ['phase 1 and 2: peak anti-cd19 car t-cell  level  in blood'], 'phase 1 and 2: percentage of participants with anti-kte-c19 antibodies': ['phase 1 and 2: percentage of participants with anti-kte-c19 antibodies'], 'phase 1 and 2: atezolizumab levels in blood': ['phase 1 and 2: atezolizumab levels in blood'], 'phase 1 and 2: percentage of participants with anti-atezolizumab antibodies': ['phase 1 and 2: percentage of participants with anti-atezolizumab antibodies'], 'phase 1 and 2: peak serum levels of c-reactive protein  in blood': ['phase 1 and 2: peak serum levels of c-reactive protein  in blood'], 'phase 1 and 2: peak serum levels of c-x-c motif chemokine 10 , interferon-gamma , interleukin-1 receptor antagonist , interleukin -2, il-6, il-8, il-15, and tumor necrosis factor-alpha  in blood': ['phase 1 and 2: peak serum levels of c-x-c motif chemokine 10 , interferon-gamma , interleukin-1 receptor antagonist , interleukin -2, il-6, il-8, il-15, and tumor necrosis factor-alpha  in blood'], 'phase 1 and 2: peak serum levels of ferritin in blood': ['phase 1 and 2: peak serum levels of ferritin in blood'], 'phase 1 and 2: peak serum levels of interleukin-2 receptor alpha  in blood': ['phase 1 and 2: peak serum levels of interleukin-2 receptor alpha  in blood'], 'phase i of the study: to evaluate the safety and the maximum-tolerated dose  of the combination r-eshap with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large b-cell lymphoma': ['phase i of the study: to evaluate the safety and the maximum-tolerated dose  of the combination r-eshap with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large b-cell lymphoma'], 'phase ii of the study: phase ii: to evaluate orr of lr-eshap in patients with relapsed or refractory dlbcl candidates to hdt and asct': ['phase ii of the study: phase ii: to evaluate orr of lr-eshap in patients with relapsed or refractory dlbcl candidates to hdt and asct'], 'phase i of the study: preliminarily analyze effectiveness (response rates , duration of response and survival': ['phase i of the study: preliminarily analyze effectiveness (response rates , duration of response and survival'], 'phase i of the study: evaluate haematopoietic progenitor cells mobilization after treatment with lr-eshap': ['phase i of the study: evaluate haematopoietic progenitor cells mobilization after treatment with lr-eshap'], 'phase i of the study: evaluate hematologic recovery after hsct': ['phase i of the study: evaluate hematologic recovery after hsct'], 'phase ii of the study: rate of transplanted patients': ['phase ii of the study: rate of transplanted patients'], 'phase ii of the study: evaluate mobilization after treatment with lr-eshap (number of stem cells (2 x 106/kg hematopoietic progenitor cell antigen + cells) collected after the salvage therapy.)': ['phase ii of the study: evaluate mobilization after treatment with lr-eshap (number of stem cells (2 x 106/kg hematopoietic progenitor cell antigen + cells) collected after the salvage therapy.)'], 'phase ii of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological  prognostic factors on response rates and survival.)': ['phase ii of the study: influence of clinical and biological prognostic factors on response rates and survival (influence of clinical and biological  prognostic factors on response rates and survival.)'], 'safety of association romidepsin-chop': ['safety of association romidepsin-chop'], 'auc0-t, at steady state  of romidepsin in phase 1 at cycle 1, day 15': ['auc0-t, at steady state  of romidepsin in phase 1 at cycle 1, day 15'], 'cmax, ss of romidepsin in phase 1 at cycle 1, day 15': ['cmax, ss of romidepsin in phase 1 at cycle 1, day 15'], 'tmax,ss of romidepsin in phase 1 at cycle 1, day 15': ['tmax,ss of romidepsin in phase 1 at cycle 1, day 15'], 'auc0-t, accumulation ratio of romidepsin in phase 1, cycle 1': ['auc0-t, accumulation ratio of romidepsin in phase 1, cycle 1'], 'cmax accumulation ratio of romidepsin in phase 1, cycle 1': ['cmax accumulation ratio of romidepsin in phase 1, cycle 1'], 'the percentage of participants with abnormal q-wave and t wave intervals': ['the percentage of participants with abnormal q-wave and t wave intervals'], 'percentage of ptcl participants with the best response in accordance with the modified 2007 international workshop response criteria as assessed by ier': ['percentage of ptcl participants with the best response in accordance with the modified 2007 international workshop response criteria as assessed by ier'], 'adverse event rate': ['adverse event rate'], 'tumor status  after chemotherapy': ['tumor status  after chemotherapy'], 'overall survival time': ['overall survival time'], \"to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma\": [\"to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma\"], \"12 patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma will receive a dosimetric dose of fission-derived iodine i 131 tositumomab\": [\"12 patients with previously untreated or relapsed follicular or transformed follicular non-hodgkin's lymphoma will receive a dosimetric dose of fission-derived iodine i 131 tositumomab\"], 'phase 1b: orr': ['phase 1b: orr'], 'phase 2: cr rate': ['phase 2: cr rate'], 'determine overall response rate - phase 2': ['determine overall response rate - phase 2'], 'determine pharmacokinetic parameters of alrn-6924 when administered to patients with advanced solid tumors or lymphomas': ['determine pharmacokinetic parameters of alrn-6924 when administered to patients with advanced solid tumors or lymphomas'], 'assess additional pharmacologic properties, including biomarkers and immunogenicity': ['assess additional pharmacologic properties, including biomarkers and immunogenicity'], 'number of participants with clinically significant change from baseline in clinical laboratory values': ['number of participants with clinically significant change from baseline in clinical laboratory values'], 'number of participants with clinically significant vital sign values': ['number of participants with clinically significant vital sign values'], 'number of participants with clinically significant electrocardiogram': ['number of participants with clinically significant electrocardiogram'], 't1/2: terminal half-life for eribulin mesylate': ['t1/2: terminal half-life for eribulin mesylate'], 'cmax: maximum observed plasma concentration for eribulin mesylate': ['cmax: maximum observed plasma concentration for eribulin mesylate'], 'cl: clearance for eribulin mesylate': ['cl: clearance for eribulin mesylate'], 'vd: volume of distribution for eribulin mesylate': ['vd: volume of distribution for eribulin mesylate'], 'proportion of responders': ['proportion of responders'], 'number of participants with dlts in non-dlbcl population': ['number of participants with dlts in non-dlbcl population'], 'number of participants with anti-polatuzumab vedotin antibodies': ['number of participants with anti-polatuzumab vedotin antibodies'], 'number of participants with anti-obinutuzumab antibodies': ['number of participants with anti-obinutuzumab antibodies'], 'plasma levels of cyclophosphamide': ['plasma levels of cyclophosphamide'], 'plasma levels of doxorubicin': ['plasma levels of doxorubicin'], 'peripheral neuropathy symptom interference: tinas numbness/tingling item score': ['peripheral neuropathy symptom interference: tinas numbness/tingling item score'], 'duration of response, as assessed by investigator using cheson criteria for dlbcl population': ['duration of response, as assessed by investigator using cheson criteria for dlbcl population'], 'duration of response, as assessed by investigator using cheson criteria for non-dlbcl population': ['duration of response, as assessed by investigator using cheson criteria for non-dlbcl population'], 'progression free survival, as assessed by investigator using cheson criteria for dlbcl population': ['progression free survival, as assessed by investigator using cheson criteria for dlbcl population'], 'progression free survival, as assessed by investigator using cheson criteria for non-dlbcl population': ['progression free survival, as assessed by investigator using cheson criteria for non-dlbcl population'], 'event free survival, as assessed by investigator using cheson criteria for dlbcl population': ['event free survival, as assessed by investigator using cheson criteria for dlbcl population'], 'event free survival, as assessed by investigator using cheson criteria for non-dlbcl population': ['event free survival, as assessed by investigator using cheson criteria for non-dlbcl population'], 'overall survival for dlbcl population': ['overall survival for dlbcl population'], 'overall survival for non-dlbcl population': ['overall survival for non-dlbcl population'], 'tumour response': ['tumour response'], 'pharmacokinetic analysis': ['pharmacokinetic analysis'], 'immunological monitoring': ['immunological monitoring'], 'percentage of participants with cr defined by pet/ct scan in previously untreated dlbcl co-expressing both bcl-2 and c-myc proteins  participants assessed by irc': ['percentage of participants with cr defined by pet/ct scan in previously untreated dlbcl co-expressing both bcl-2 and c-myc proteins  participants assessed by irc'], 'prednisone plasma pk: auc': ['prednisone plasma pk: auc'], 'prednisone plasma pk: tmax': ['prednisone plasma pk: tmax'], 'prednisone plasma pk: cmax': ['prednisone plasma pk: cmax'], 'rituximab pk: cmax': ['rituximab pk: cmax'], 'rituximab pk: cmin within the dosing interval': ['rituximab pk: cmin within the dosing interval'], 'obinutuzumab pk: cmax': ['obinutuzumab pk: cmax'], 'cyclophosphamide pk: cmax': ['cyclophosphamide pk: cmax'], 'doxorubicin pk: cmax': ['doxorubicin pk: cmax'], 'vincristine pk: cmax': ['vincristine pk: cmax'], 'percentage of participants with objective response defined as partial response  or complete response  defined by positron emission tomography-computed tomography  using the modified lugano classification assessed by irc': ['percentage of participants with objective response defined as partial response  or complete response  defined by positron emission tomography-computed tomography  using the modified lugano classification assessed by irc'], 'percentage of participants who are alive and without disease progression at month 12': ['percentage of participants who are alive and without disease progression at month 12'], 'safety: percentage of participants maintaining relative dose intensity of chop chemotherapy': ['safety: percentage of participants maintaining relative dose intensity of chop chemotherapy'], 'relative dose intensity of venetoclax': ['relative dose intensity of venetoclax'], 'determination of overall response rates': ['determination of overall response rates'], 'determination of duration of response.': ['determination of duration of response.'], 'evaluate the mean plasma concentrations of ff-10502-01': ['evaluate the mean plasma concentrations of ff-10502-01'], 'evaluate ff-10502-01 incorporation into whole blood cellular dna by lc-ms/ms as a pharmacodynamic marker': ['evaluate ff-10502-01 incorporation into whole blood cellular dna by lc-ms/ms as a pharmacodynamic marker'], 'to characterize the safety profile and to define the dose of galiximab to be used for the phase ii portion of the study': ['to characterize the safety profile and to define the dose of galiximab to be used for the phase ii portion of the study'], 'to monitor for the presence of human anti galiximab antibody and human antichimeric antibody formation': ['to monitor for the presence of human anti galiximab antibody and human antichimeric antibody formation'], 'determination of the recommended dose of r-cmc544': ['determination of the recommended dose of r-cmc544'], 'number of dose-limiting toxicities': ['number of dose-limiting toxicities'], 'treatment-related mortality': ['treatment-related mortality'], 'response rate measured by tumor imaging': ['response rate measured by tumor imaging'], 'the number of subjects experiencing a dose limiting toxicity at various dose levels when given multiple doses of cx-072 as a monotherapy or in combination with ipilimumab or vemurafenib': ['the number of subjects experiencing a dose limiting toxicity at various dose levels when given multiple doses of cx-072 as a monotherapy or in combination with ipilimumab or vemurafenib'], 'primary endpoints  - incidence rate of dlt and ae': ['primary endpoints  - incidence rate of dlt and ae'], 'primary endpoint  - response rate': ['primary endpoint  - response rate'], 'overall response rates': ['overall response rates'], 'the number of participants that tolerated the maximum drug dose': ['the number of participants that tolerated the maximum drug dose'], 'secondary end points: efficacy- cailds score': ['secondary end points: efficacy- cailds score'], 'secondary end points: efficacy- swat score': ['secondary end points: efficacy- swat score'], 'mtd': ['mtd'], 'safety of ha20 with this administration schedule and dosing': ['safety of ha20 with this administration schedule and dosing'], 'tolerance of ha20 with this administration schedule and dosing': ['tolerance of ha20 with this administration schedule and dosing'], 'immunogenicity of ha20 with this administration schedule and dosing': ['immunogenicity of ha20 with this administration schedule and dosing'], 'pharmacodynamics of ha20': ['pharmacodynamics of ha20'], 'pharmacokinetics ha20': ['pharmacokinetics ha20'], 'assess efficacy': ['assess efficacy'], 'serum concentration of total antibodies': ['serum concentration of total antibodies'], 'qtcf': ['qtcf'], 'tlast': ['tlast'], 'pr intervals': ['pr intervals'], 'qrs intervals': ['qrs intervals'], 'ecg waveform morphology': ['ecg waveform morphology'], 'qtcb': ['qtcb'], 'overall safety profile': ['overall safety profile'], 'plasma pharmacokinetics': ['plasma pharmacokinetics'], 'preliminary antitumor activity': ['preliminary antitumor activity'], 'abscopal response rate': ['abscopal response rate'], 'define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator nat2 genotype  patients with solid tumors and lymphomas.': ['define the maximum tolerated dose of batracylin administered daily x7 consecutive days, repeated every 28 days in slow acetylator nat2 genotype  patients with solid tumors and lymphomas.'], 'obtain preliminary evidence of anti-tumor activity of batracylin in patients with solid tumors or lymphoma.': ['obtain preliminary evidence of anti-tumor activity of batracylin in patients with solid tumors or lymphoma.'], 'maximally tolerated dose of bendamustine hydrochloride that can be combined with rituximab, carboplatin, and etoposide chemotherapy in patients with relapsed or refractory lymphoid malignancies': ['maximally tolerated dose of bendamustine hydrochloride that can be combined with rituximab, carboplatin, and etoposide chemotherapy in patients with relapsed or refractory lymphoid malignancies'], 'safety and toxicity of this regimen': ['safety and toxicity of this regimen'], 'preliminary assessment of the efficacy of this regimen': ['preliminary assessment of the efficacy of this regimen'], 'ability to proceed to peripheral blood stem cell  collection following treatment': ['ability to proceed to peripheral blood stem cell  collection following treatment'], 'number of participants with ada to polatuzumab vedotin': ['number of participants with ada to polatuzumab vedotin'], 'number of participants with ada to obinutuzumab': ['number of participants with ada to obinutuzumab'], 'aucinf of total antibody for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['aucinf of total antibody for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'cmax of total antibody for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['cmax of total antibody for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'cmax of acmmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['cmax of acmmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'cmax of unconjugated mmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['cmax of unconjugated mmae for pinatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'aucinf of total antibody for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['aucinf of total antibody for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'aucinf of acmmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['aucinf of acmmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'auclast of unconjugated mmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['auclast of unconjugated mmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'cmax of total antibody for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['cmax of total antibody for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'cmax of acmmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['cmax of acmmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'cmax of unconjugated mmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab': ['cmax of unconjugated mmae for polatuzumab vedotin at dose level 2.4 mg/kg given in combination with rituximab'], 'aucinf of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab': ['aucinf of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab'], 'aucinf of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab': ['aucinf of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab'], 'auclast of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab': ['auclast of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab'], 'cmax of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab': ['cmax of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab'], 'cmax of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab': ['cmax of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab'], 'cmax of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab': ['cmax of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with rituximab'], 'aucinf of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab': ['aucinf of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab'], 'aucinf of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab': ['aucinf of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab'], 'auclast of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab': ['auclast of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab'], 'cmax of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab': ['cmax of total antibody for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab'], 'cmax of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab': ['cmax of acmmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab'], 'cmax of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab': ['cmax of unconjugated mmae for polatuzumab vedotin at dose level 1.8 mg/kg given in combination with obinutuzumab'], 'dose-limiting toxicities and maximum tolerated dose': ['dose-limiting toxicities and maximum tolerated dose'], 'pharmacology and pharmacokinetics': ['pharmacology and pharmacokinetics'], 'acetylation of histones in peripheral blood': ['acetylation of histones in peripheral blood'], 'tumor response by ct scan every 12 weeks': ['tumor response by ct scan every 12 weeks'], 'complete response rate and overall response rate at the end of treatment': ['complete response rate and overall response rate at the end of treatment'], 'complete and overall response rates after induction': ['complete and overall response rates after induction'], 'progression-free survival and overall survival': ['progression-free survival and overall survival'], 'safety and tolerability of bexarotene in combination with ecp, assessed with nci toxicity assessment, at each treatment visit, every 3 weeks and at final one month foll': ['safety and tolerability of bexarotene in combination with ecp, assessed with nci toxicity assessment, at each treatment visit, every 3 weeks and at final one month foll'], \"time to response of bexarotene with ecp in patients with ctcl, at month 4  patient's response by organ system involvement, with an overall assessment: complete response, partial response, no change, or progressive disease, flare.\": [\"time to response of bexarotene with ecp in patients with ctcl, at month 4  patient's response by organ system involvement, with an overall assessment: complete response, partial response, no change, or progressive disease, flare.\"], \"another secondary outcome is whether combination of instruments provides relevant information on ctcl patients' health related quality of life during therapy\": [\"another secondary outcome is whether combination of instruments provides relevant information on ctcl patients' health related quality of life during therapy\"], 'toxicity data': ['toxicity data'], 'skin toxicity': ['skin toxicity'], 'hepatotoxicity': ['hepatotoxicity'], 'mucosal toxicity': ['mucosal toxicity'], 'hematologic toxicity': ['hematologic toxicity'], 'neurologic toxicity': ['neurologic toxicity'], 'treatment response': ['treatment response'], 'cd34+ cell count peak level': ['cd34+ cell count peak level'], 'time to cd34+ count peak level': ['time to cd34+ count peak level'], 'time to reach level >5 x 10^6.l': ['time to reach level >5 x 10^6.l'], 'area under curve for duration of time spent with cd34+ count >5 x 10^6/l': ['area under curve for duration of time spent with cd34+ count >5 x 10^6/l'], 'peripheral blood colony forming unit assays': ['peripheral blood colony forming unit assays'], 'peak cfu-gemm level': ['peak cfu-gemm level'], 'time to peak cfu-gemm level': ['time to peak cfu-gemm level'], 'percentage of participants with cr at eoi, as determined by the investigator using lugano 2014 criteria': ['percentage of participants with cr at eoi, as determined by the investigator using lugano 2014 criteria'], 'percentage of participants with cr at eoi, as determined by the irc using modified cheson 2007 criteria': ['percentage of participants with cr at eoi, as determined by the irc using modified cheson 2007 criteria'], 'percentage of participants with cr at eoi, as determined by the investigator using modified cheson 2007 criteria': ['percentage of participants with cr at eoi, as determined by the investigator using modified cheson 2007 criteria'], 'percentage of participants with best response of cr or pr during study, as determined by investigator using modified cheson 2007 criteria': ['percentage of participants with best response of cr or pr during study, as determined by investigator using modified cheson 2007 criteria'], 'observed serum atezolizumab concentration': ['observed serum atezolizumab concentration'], 'safety and tolerability of ct-322': ['safety and tolerability of ct-322'], 'to evaluate the pharmacokinetics of ct-322 in these patients': ['to evaluate the pharmacokinetics of ct-322 in these patients'], 'to assess whether antibodies to this drug develop in these patients and': ['to assess whether antibodies to this drug develop in these patients and'], 'to make a preliminary assessment of the biological activity of ct-322 to alter tumor growth.': ['to make a preliminary assessment of the biological activity of ct-322 to alter tumor growth.'], 'determine safety of carfilzomib by evaluating the toxicity profile.': ['determine safety of carfilzomib by evaluating the toxicity profile.'], 'to evaluate the efficacy of carfilzomib therapy in relapsed or refractory chromic lymphocytic leukemia /small lymphocytic leukemia /prolymphocytic leukemia': ['to evaluate the efficacy of carfilzomib therapy in relapsed or refractory chromic lymphocytic leukemia /small lymphocytic leukemia /prolymphocytic leukemia'], 'phase i-ii study of dose dense of peg-filgrastim and gm-csf combined with chop-r': ['phase i-ii study of dose dense of peg-filgrastim and gm-csf combined with chop-r'], 'number of phase i participants experiencing toxicity': ['number of phase i participants experiencing toxicity'], 'phase ii: overall survival rate at 2 years': ['phase ii: overall survival rate at 2 years'], 'phase ii: pre-irradiation chemotherapy tumor response rate': ['phase ii: pre-irradiation chemotherapy tumor response rate'], 'phase ii: progression-free survival': ['phase ii: progression-free survival'], \"complete response rate to rituximab and a combination of vorinostat with cyclophosphamide, etoposide, and prednisone in elderly pts with relapsed diffuse large b-cell lymphoma who aren't candidates for autologous stem cell transplantation.\": [\"complete response rate to rituximab and a combination of vorinostat with cyclophosphamide, etoposide, and prednisone in elderly pts with relapsed diffuse large b-cell lymphoma who aren't candidates for autologous stem cell transplantation.\"], 'clinical response following administration of rp6530': ['clinical response following administration of rp6530'], 'drug safety': ['drug safety'], 'rate of remission': ['rate of remission'], 'rate of mrd in bone marrow aspirate samples': ['rate of mrd in bone marrow aspirate samples'], 'pharmacokinetic measures of cmax and area under the curve by analysis of blood samples for the amount of each drug present at different timepoints.': ['pharmacokinetic measures of cmax and area under the curve by analysis of blood samples for the amount of each drug present at different timepoints.'], 'measure the extent of the disease by ct scan or flow cytometry analysis': ['measure the extent of the disease by ct scan or flow cytometry analysis'], 'recommended dose of adct-402 for part 2': ['recommended dose of adct-402 for part 2'], 'terminal half-life  of adct-402': ['terminal half-life  of adct-402'], 'number of subjects with dose-limiting toxicities': ['number of subjects with dose-limiting toxicities'], 'intensity of ae': ['intensity of ae'], 'recommended dose determined in the dose escalation/safety evaluation': ['recommended dose determined in the dose escalation/safety evaluation'], 'number and percentage of participants with adverse event, serious adverse event, clinically defined abnormal vital signs, laboratory values, ecg abnormalities': ['number and percentage of participants with adverse event, serious adverse event, clinically defined abnormal vital signs, laboratory values, ecg abnormalities'], 'plasma and urine concentrations of dzd8586': ['plasma and urine concentrations of dzd8586'], 'total number of subjects with a complete response  following myeloablative conditioning  and autologous stem cell transplantation': ['total number of subjects with a complete response  following myeloablative conditioning  and autologous stem cell transplantation'], 'total number of subjects with a disease relapse or progression following mac autosct': ['total number of subjects with a disease relapse or progression following mac autosct'], 'total number of subjects with partial response or stable disease following mac autosct': ['total number of subjects with partial response or stable disease following mac autosct'], \"toxicity of participants receiving bortezomib, rituximab, cyclophosphamide, and prednisone for treatment of non-hodgkin's lymphoma\": [\"toxicity of participants receiving bortezomib, rituximab, cyclophosphamide, and prednisone for treatment of non-hodgkin's lymphoma\"], 'safety of escalating doses on01910.na at day 28.': ['safety of escalating doses on01910.na at day 28.'], 'the reduction in lymph nodes, quantification of circulating lymphoma cells, assessment of extranodal disease sites, and/or measurement of the malignant monoclonal proteins in the serum or urine after 4 cycles of therapy .': ['the reduction in lymph nodes, quantification of circulating lymphoma cells, assessment of extranodal disease sites, and/or measurement of the malignant monoclonal proteins in the serum or urine after 4 cycles of therapy .'], 'tumor activity': ['tumor activity'], 'efficacy of treatment as measured by best overall response': ['efficacy of treatment as measured by best overall response'], 'effects of on htlv-1 dna after treatment as measured by proviral loads': ['effects of on htlv-1 dna after treatment as measured by proviral loads'], 'relation of nfκb gene expression profile on response': ['relation of nfκb gene expression profile on response'], 'effects of htlv-1 rna load after treatment as measured by hbz messenger rna': ['effects of htlv-1 rna load after treatment as measured by hbz messenger rna'], 'effects of htlv-1 integrase gene sequence after treatment as measured by nucleotide divergence': ['effects of htlv-1 integrase gene sequence after treatment as measured by nucleotide divergence'], 'effects of htlv-1 integration sites after treatment': ['effects of htlv-1 integration sites after treatment'], 'define the mtd': ['define the mtd'], 'translational biomarkers and pharmacokinetics': ['translational biomarkers and pharmacokinetics'], 'changes in vital signs, ecgs, and clinical laboratory results': ['changes in vital signs, ecgs, and clinical laboratory results'], 'pharmacokinetic parameters of gdc-0917': ['pharmacokinetic parameters of gdc-0917'], 'relief degree evaluated by the recist': ['relief degree evaluated by the recist'], 'number of participants who experienced dose limiting toxicities in phase i portion of study': ['number of participants who experienced dose limiting toxicities in phase i portion of study'], 'kinetics of stem cell mobilization using iv amd3100 as measured by median fold change in the number of cd34+ cells after amd3100 iv administration': ['kinetics of stem cell mobilization using iv amd3100 as measured by median fold change in the number of cd34+ cells after amd3100 iv administration'], 'pharmacodynamic response to a dose of sc amd3100 as measured by mean percentage of the circulating cd34+ count with the 34+ra-123+/- phenotype': ['pharmacodynamic response to a dose of sc amd3100 as measured by mean percentage of the circulating cd34+ count with the 34+ra-123+/- phenotype'], 'toxicity of the combination iv amd3100 and g-csf to mobilize ≥ 2 x 106 cd34+ cells/kg as measured by number of participants who experience grade 3 or higher adverse event broken down by adverse event': ['toxicity of the combination iv amd3100 and g-csf to mobilize ≥ 2 x 106 cd34+ cells/kg as measured by number of participants who experience grade 3 or higher adverse event broken down by adverse event'], 'maximum tolerated dose of di-leu16-il2': ['maximum tolerated dose of di-leu16-il2'], 'optimal biologic dose of di-leu16-il2': ['optimal biologic dose of di-leu16-il2'], 'toxicities associated with the di-leu16-il2 regimen': ['toxicities associated with the di-leu16-il2 regimen'], 'immunogenicity as a result of di-leu16-il2 administration': ['immunogenicity as a result of di-leu16-il2 administration'], 'pharmacokinetics of di-leu16-il2 administration': ['pharmacokinetics of di-leu16-il2 administration'], 'clinical responses and survival': ['clinical responses and survival'], 'maximum-tolerated dose and/or recommended phase ii dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma': ['maximum-tolerated dose and/or recommended phase ii dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma'], 'toxicities of imetelstat sodium': ['toxicities of imetelstat sodium'], 'overall response rate during the entire study': ['overall response rate during the entire study'], 'time to first response': ['time to first response'], 'kaplan-meier estimate of duration of response': ['kaplan-meier estimate of duration of response'], 'change from baseline in soluble programmed cell death ligand-1  concentration': ['change from baseline in soluble programmed cell death ligand-1  concentration'], 'to evaluate the pharmacokinetics and pharmacodynamics of npi-0052 and vorinostat': ['to evaluate the pharmacokinetics and pharmacodynamics of npi-0052 and vorinostat'], 'to evaluate the safety and toxicity profile of the combination of npi-0052 and vorinostat': ['to evaluate the safety and toxicity profile of the combination of npi-0052 and vorinostat'], 'to evaluate the anti-tumor activity of npi-0052 and vorinostat': ['to evaluate the anti-tumor activity of npi-0052 and vorinostat'], 'plasma concentration time profiles by treatment group in escalation phase': ['plasma concentration time profiles by treatment group in escalation phase'], 'plasma concentration time profiles by treatment group in expansion phase': ['plasma concentration time profiles by treatment group in expansion phase'], 'pk parameter: racc in dose escalation phase cycle 2 day 1': ['pk parameter: racc in dose escalation phase cycle 2 day 1'], 'overall response summary': ['overall response summary'], 'incidence of prolonged hematologic toxicity started in cycle 1': ['incidence of prolonged hematologic toxicity started in cycle 1'], 'sustained hematologic improvement in subjects with neutropenia, anemia, or thrombocytopenia at baseline': ['sustained hematologic improvement in subjects with neutropenia, anemia, or thrombocytopenia at baseline'], 'progression free survival rate at 12 months': ['progression free survival rate at 12 months'], 'to determine the feasibility and toxicity of the combination of etanercept and rituximab in patients with cll/sll.': ['to determine the feasibility and toxicity of the combination of etanercept and rituximab in patients with cll/sll.'], 'determine if etanercept increases the complete response rate while decreasing the frequency of infusion-related toxicity in patients with cll/sll receiving rituximab therapy.': ['determine if etanercept increases the complete response rate while decreasing the frequency of infusion-related toxicity in patients with cll/sll receiving rituximab therapy.'], 'the urine concentration of azd5153 and its co-former .': ['the urine concentration of azd5153 and its co-former .'], 'the effect of azd 5153 on qtc interval.': ['the effect of azd 5153 on qtc interval.'], 'number of participants with grade 4 cytokine release syndrome': ['number of participants with grade 4 cytokine release syndrome'], 'percentage of participants experiencing treatment-emergent laboratory abnormalities within 28 days of idelalisib exposure by worst grade at postbaseline': ['percentage of participants experiencing treatment-emergent laboratory abnormalities within 28 days of idelalisib exposure by worst grade at postbaseline'], 'percentage of participants who permanently discontinued idelalisib due to a teae within 28 days of idelalisib exposure': ['percentage of participants who permanently discontinued idelalisib due to a teae within 28 days of idelalisib exposure'], 'plasma concentration of idelalisib and its major metabolite gs-563117 on day 1': ['plasma concentration of idelalisib and its major metabolite gs-563117 on day 1'], 'plasma concentration of idelalisib and its major metabolite gs-563117 on day 8': ['plasma concentration of idelalisib and its major metabolite gs-563117 on day 8'], 'plasma concentration of idelalisib and its major metabolite gs-563117 on day 15': ['plasma concentration of idelalisib and its major metabolite gs-563117 on day 15'], 'plasma concentration of idelalisib and its major metabolite gs-563117 on day 22': ['plasma concentration of idelalisib and its major metabolite gs-563117 on day 22'], 'plasma concentration of idelalisib and its major metabolite gs-563117 on day 29': ['plasma concentration of idelalisib and its major metabolite gs-563117 on day 29'], 'percentage of participants experiencing treatment-emergent laboratory abnormalities beyond 28 days of idelalisib exposure by worst grade at postbaseline': ['percentage of participants experiencing treatment-emergent laboratory abnormalities beyond 28 days of idelalisib exposure by worst grade at postbaseline'], 'percentage of participants who permanently discontinued idelalisib due to a teae beyond 28 days of idelalisib exposure': ['percentage of participants who permanently discontinued idelalisib due to a teae beyond 28 days of idelalisib exposure'], 'number of participants who completed six cycles of study treatment': ['number of participants who completed six cycles of study treatment'], 'safety/tolerability of combination treatment for 4 weeks safety/tolerability of sb-485232 for additional 8 weeks': ['safety/tolerability of combination treatment for 4 weeks safety/tolerability of sb-485232 for additional 8 weeks'], 'assess blood values of combination treatment for 4 weeks assess blood values of sb-485232 for additional 8 weeks': ['assess blood values of combination treatment for 4 weeks assess blood values of sb-485232 for additional 8 weeks'], 'pharmacokinetic parameters for sb-485232 and rituxan: auctau, cmax, and cmin.': ['pharmacokinetic parameters for sb-485232 and rituxan: auctau, cmax, and cmin.'], 'pharmacodynamic biomarker responses:': ['pharmacodynamic biomarker responses:'], 'plasma ifn-γ, gmcsf, ip-10, mig, and mcp-1 changes': ['plasma ifn-γ, gmcsf, ip-10, mig, and mcp-1 changes'], 'plasma il-18bp change': ['plasma il-18bp change'], 'pbmc phenotype changes': ['pbmc phenotype changes'], 'activated nk cells': ['activated nk cells'], 'activated cytolytic t cells': ['activated cytolytic t cells'], 'activated b cells': ['activated b cells'], 'activated neutrophils/monocytes': ['activated neutrophils/monocytes'], 'regulatory t-cells': ['regulatory t-cells'], 'immunogenicity': ['immunogenicity'], 'anti-tumor activity': ['anti-tumor activity'], 'cd16  158v/f genotyping': ['cd16  158v/f genotyping'], 'complete response rates': ['complete response rates'], 'progressive-free survival': ['progressive-free survival'], 'volume of distribution': ['volume of distribution'], 'exploratory surrogate biomarker': ['exploratory surrogate biomarker'], 'preliminary tumor response': ['preliminary tumor response'], 'feasibility of adequate leucapheresis collection and generation of car19 t cells.': ['feasibility of adequate leucapheresis collection and generation of car19 t cells.'], 'toxicity evaluation following car19 t-cell administration.': ['toxicity evaluation following car19 t-cell administration.'], 'efficacy of car19 t-cells.': ['efficacy of car19 t-cells.'], 'car19 t-cell engraftment': ['car19 t-cell engraftment'], 'b cell compartment': ['b cell compartment'], 'cytokine profile': ['cytokine profile'], 'clinical complete response': ['clinical complete response'], 'eligibility to allogeneic transplantation': ['eligibility to allogeneic transplantation'], 'the proportion of patients who demonstrate each polymorphism': ['the proportion of patients who demonstrate each polymorphism'], 'proportion of confirmed tumor responses': ['proportion of confirmed tumor responses'], 'to determine the oral bioavailability of up to 6 different oral formulations in comparison to the subcutaneous formulation': ['to determine the oral bioavailability of up to 6 different oral formulations in comparison to the subcutaneous formulation'], 'to assess the safety and tolerability of subcutaneous and oral formulations of azacitidine': ['to assess the safety and tolerability of subcutaneous and oral formulations of azacitidine'], 'to assess response rates': ['to assess response rates'], 'to assess rbc transfusion independence': ['to assess rbc transfusion independence'], 'to investigate the pharmacokinetics of oral azacitidine': ['to investigate the pharmacokinetics of oral azacitidine'], 'to assess the pharmacodynamic effects of oral azacitidine': ['to assess the pharmacodynamic effects of oral azacitidine'], 'number of participants with a response assessed by the response criteria for malignant lymphoma': ['number of participants with a response assessed by the response criteria for malignant lymphoma'], 'the primary outcome for the study is the average deviation in set-up.': ['the primary outcome for the study is the average deviation in set-up.'], 'maximum tolerated dose graded according to nci ctcae version 5.0': ['maximum tolerated dose graded according to nci ctcae version 5.0'], 'pharmacokinetic assessment through analysis of blood and urine samples': ['pharmacokinetic assessment through analysis of blood and urine samples'], 'the number of patients who had disease response assessed by deauville scales among those in phase i with dose level 2.': ['the number of patients who had disease response assessed by deauville scales among those in phase i with dose level 2.'], 'the number of patients who had successful peripheral blood stem cell  collection': ['the number of patients who had successful peripheral blood stem cell  collection'], 'plasma level of thymus and activation-regulated chemokine': ['plasma level of thymus and activation-regulated chemokine'], 'correlation between micro ribonucleic acid  and disease response to protocol treatment': ['correlation between micro ribonucleic acid  and disease response to protocol treatment'], 'number of patients with fcyriiia-158 v/f  polymorphism': ['number of patients with fcyriiia-158 v/f  polymorphism'], 'treatment safety: monitored through recordings of ecg, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.': ['treatment safety: monitored through recordings of ecg, vital signs and safety laboratory measurements including haematology, clinical chemistry and urinalysis.'], 'main efficacy for ctcl': ['main efficacy for ctcl'], 'main efficacy for cgvhd': ['main efficacy for cgvhd'], 'dose defining': ['dose defining'], 'progression': ['progression'], 'symptomatic deterioration': ['symptomatic deterioration'], 'pk-cmax': ['pk-cmax'], 'pk-tmax': ['pk-tmax'], 'pk-λz': ['pk-λz'], 'pk-t1/2': ['pk-t1/2'], 'pk-auc0-∞': ['pk-auc0-∞'], 'presence of anti-drug antibodies against hlx01': ['presence of anti-drug antibodies against hlx01'], 'change from baseline of cd19+ b-cells': ['change from baseline of cd19+ b-cells'], 'mtd of photodynamic therapy': ['mtd of photodynamic therapy'], 'pharmacokinetic property of gdc-0425: determination of plasma drug concentration': ['pharmacokinetic property of gdc-0425: determination of plasma drug concentration'], 'pharmacokinetic property of gdc-0425: exposure': ['pharmacokinetic property of gdc-0425: exposure'], 'pharmacokinetic property of gdc-0425: half-life': ['pharmacokinetic property of gdc-0425: half-life'], 'antitumor activity of gdc-0425 in combination with gemcitabine: determination of tumor response using recist v1.1 for patients with measurable disease': ['antitumor activity of gdc-0425 in combination with gemcitabine: determination of tumor response using recist v1.1 for patients with measurable disease'], 'number of patients who achieved complete response': ['number of patients who achieved complete response'], 'determination of the maximum tolerable dose and evaluation of response rate': ['determination of the maximum tolerable dose and evaluation of response rate'], 'doe-limiting toxicity and pharmacogenomics': ['doe-limiting toxicity and pharmacogenomics'], 'overall safety of idelalisib': ['overall safety of idelalisib'], 'clinical response: overall response rate': ['clinical response: overall response rate'], 'flow cytometric measurement of constitutive or inducible phosphorylation of akt  and s6 within tumor b cells': ['flow cytometric measurement of constitutive or inducible phosphorylation of akt  and s6 within tumor b cells'], 'flow cytometric measurement of tumoral and peripheral blood t and nk cells': ['flow cytometric measurement of tumoral and peripheral blood t and nk cells'], 'changes in concentration of peripheral blood chemokines and cytokines': ['changes in concentration of peripheral blood chemokines and cytokines'], 'changes in liver imaging as assessed by magnetic resonance imaging  and gadoxetic acid  contrast': ['changes in liver imaging as assessed by magnetic resonance imaging  and gadoxetic acid  contrast'], 'percentage of participants experiencing dose-limiting toxicities': ['percentage of participants experiencing dose-limiting toxicities'], 'pk parameter: auctau of tirabrutinib': ['pk parameter: auctau of tirabrutinib'], 'the number of subjects with a successful product manufactured': ['the number of subjects with a successful product manufactured'], 'number of subjects with complete remission with incomplete blood count recovery .': ['number of subjects with complete remission with incomplete blood count recovery .'], 'maximum tolerated dose of lenalidomide when combined with ibrutinib': ['maximum tolerated dose of lenalidomide when combined with ibrutinib'], 'remission/response duration': ['remission/response duration'], 'phase i: incidence of any dlt attributed to dt2219 in the first cycle': ['phase i: incidence of any dlt attributed to dt2219 in the first cycle'], 'phase ll: overall disease response': ['phase ll: overall disease response'], 'phase ii : duration of response': ['phase ii : duration of response'], 'time to relapse/progression': ['time to relapse/progression'], \"response rate for participants with non-hodgkin's lymphoma\": [\"response rate for participants with non-hodgkin's lymphoma\"], 'participants evaluated for toxicity': ['participants evaluated for toxicity'], 'maximum tolerated dose of idarubicin': ['maximum tolerated dose of idarubicin'], 'remission rate after 4 cycles and 8 cycles': ['remission rate after 4 cycles and 8 cycles'], 'maximum tolerated dose and recommended phase ii dose of vorinostat and decitabine': ['maximum tolerated dose and recommended phase ii dose of vorinostat and decitabine'], 'minimal effective dose of vorinostat in combination with decitabine by bone marrow and/or peripheral blood': ['minimal effective dose of vorinostat in combination with decitabine by bone marrow and/or peripheral blood'], 'pharmacokinetics of vorinostat in conjunction with decitabine': ['pharmacokinetics of vorinostat in conjunction with decitabine'], 'antitumor activity': ['antitumor activity'], 'methylation status of gene promoter regions and gene expression': ['methylation status of gene promoter regions and gene expression'], 'altered response of leukemic cells to ppar and rar ligands': ['altered response of leukemic cells to ppar and rar ligands'], 'number of participants with positive anti-drug antibody': ['number of participants with positive anti-drug antibody'], 'number of participants with cd22 expression levels': ['number of participants with cd22 expression levels'], 'number of participants with clinically significant vital signs findings  [phase 1]': ['number of participants with clinically significant vital signs findings  [phase 1]'], 'number of participants with clinically significant changes in physical examination findings [phase 1]': ['number of participants with clinically significant changes in physical examination findings [phase 1]'], 'overall response rate [phase 2]': ['overall response rate [phase 2]'], 'overall response rate as assessed by the investigator [phase 1]': ['overall response rate as assessed by the investigator [phase 1]'], 'complete response rate [phase 2]': ['complete response rate [phase 2]'], 'number of participants with clinically significant vital signs findings [phase 2]': ['number of participants with clinically significant vital signs findings [phase 2]'], 'cmax: maximum plasma concentration for alisertib': ['cmax: maximum plasma concentration for alisertib'], 'tmax: time to first occurrence of cmax fo alisertib': ['tmax: time to first occurrence of cmax fo alisertib'], 'auct: area under the concentration time curve over the dosing interval from time 0 to time t for alisertib': ['auct: area under the concentration time curve over the dosing interval from time 0 to time t for alisertib'], 'cmax: maximum plasma concentration for vincristine': ['cmax: maximum plasma concentration for vincristine'], 'auct: area under the concentration-time time curve over the dosing interval from time 0 to time t for vincristine': ['auct: area under the concentration-time time curve over the dosing interval from time 0 to time t for vincristine'], 'auc∞: area under the concentration-time curve from time 0 to infinity for vincristine': ['auc∞: area under the concentration-time curve from time 0 to infinity for vincristine'], 't1/2: terminal disposition phase half-life for vincristine': ['t1/2: terminal disposition phase half-life for vincristine'], 'tolerance and safety as measured by any ≥ grade iv granulocyte toxicity or any grade iii toxicity thought to be drug related at 1 week after each course': ['tolerance and safety as measured by any ≥ grade iv granulocyte toxicity or any grade iii toxicity thought to be drug related at 1 week after each course'], 'phase i maximum tolerated dose': ['phase i maximum tolerated dose'], 'phase ii overall response': ['phase ii overall response'], 'maximum tolerated doses of carfilzomib and belinostat in combination': ['maximum tolerated doses of carfilzomib and belinostat in combination'], 'plasma concentration time profiles': ['plasma concentration time profiles'], 'anti-cancer activity of 4sc-205 after 6 weeks of treatment.': ['anti-cancer activity of 4sc-205 after 6 weeks of treatment.'], 'effects of eg5 inhibition on biomarker modulation.': ['effects of eg5 inhibition on biomarker modulation.'], 'to establish the maximum tolerated dose of sb1518 as a single agent when administered orally daily in subjects with advanced lymphoid malignancies.': ['to establish the maximum tolerated dose of sb1518 as a single agent when administered orally daily in subjects with advanced lymphoid malignancies.'], 'to assess the safety and tolerability of sb1518, administered orally once daily in subjects with advanced lymphoid malignancies.': ['to assess the safety and tolerability of sb1518, administered orally once daily in subjects with advanced lymphoid malignancies.'], 'to assess the pharmacokinetic and pharmacodynamic profile of sb1518.': ['to assess the pharmacokinetic and pharmacodynamic profile of sb1518.'], 'the greatest number of cycles received in each treatment group': ['the greatest number of cycles received in each treatment group'], 'the number of dose delays and reductions at the mtd': ['the number of dose delays and reductions at the mtd'], 'the prevalence of anti-tumor activity': ['the prevalence of anti-tumor activity'], 'pharmacodynamic markers of target effect in paired tissue biopsies': ['pharmacodynamic markers of target effect in paired tissue biopsies'], 'part 1 and 2: apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only': ['part 1 and 2: apparent total body clearance of drug from plasms after extravascular administration (acalabrutinib only'], 'part 1 and 2: metabolite to parent ratio based on aucinf and/or auclast': ['part 1 and 2: metabolite to parent ratio based on aucinf and/or auclast'], 'part 1 and 2: metabolite to parent ratio based on cmax': ['part 1 and 2: metabolite to parent ratio based on cmax'], 'to establish the mtd and dlt of pazopanib in groups of patients with varying degrees of hepatic dysfunction  to provide appropriate dosing recommendations for panzopanib in such patients.': ['to establish the mtd and dlt of pazopanib in groups of patients with varying degrees of hepatic dysfunction  to provide appropriate dosing recommendations for panzopanib in such patients.'], 'to characterize the pharmacokinetic  and pharmacodynamic  profiles of pazopanib and metabolites  in patients with varying degrees of hepatic dysfunction.': ['to characterize the pharmacokinetic  and pharmacodynamic  profiles of pazopanib and metabolites  in patients with varying degrees of hepatic dysfunction.'], 'effectiveness of rasburicase in treatment of patients with leukemia and/or lymphoma who are at high or potential risk for tls.': ['effectiveness of rasburicase in treatment of patients with leukemia and/or lymphoma who are at high or potential risk for tls.'], 'area under the serum concentration time curve from zero to day 7  of obinutuzumab on day 1, cycle 1': ['area under the serum concentration time curve from zero to day 7  of obinutuzumab on day 1, cycle 1'], 'cmax of obinutuzumab at cycle 8': ['cmax of obinutuzumab at cycle 8'], 'minimum observed serum concentration of obinutuzumab': ['minimum observed serum concentration of obinutuzumab'], 'percentage of participants with complete remission , cre with incomplete bm recovery  at end of treatment  in cll participants according to international workshop on chronic lymphocytic leukemia  2008 guidelines': ['percentage of participants with complete remission , cre with incomplete bm recovery  at end of treatment  in cll participants according to international workshop on chronic lymphocytic leukemia  2008 guidelines'], 'percentage of participants with pr, sd, and pd at end of treatment  in cll participants according to iwcll 2008 guidelines': ['percentage of participants with pr, sd, and pd at end of treatment  in cll participants according to iwcll 2008 guidelines'], 'percentage of participants with bor of cre, cri at anytime during the study in cll participants according to iwcll 2008 guidelines': ['percentage of participants with bor of cre, cri at anytime during the study in cll participants according to iwcll 2008 guidelines'], 'percentage of participants with bor of pr, sd, and pd at anytime during study in cll participants according to iwcll 2008 guidelines': ['percentage of participants with bor of pr, sd, and pd at anytime during study in cll participants according to iwcll 2008 guidelines'], 'number of participants with positive human anti-chimeric antibodies': ['number of participants with positive human anti-chimeric antibodies'], 'number of participants with b-cell depletion or recovery': ['number of participants with b-cell depletion or recovery'], 'duration of depletion of cd19+ b-cell': ['duration of depletion of cd19+ b-cell'], 'time to recovery of cd19+ b-cell': ['time to recovery of cd19+ b-cell'], 'feasibility of haploidentical hsct': ['feasibility of haploidentical hsct'], 'hematopoietic cell recovery and engraftment rates': ['hematopoietic cell recovery and engraftment rates'], 'infection rates and complications': ['infection rates and complications'], 'standardized measure of [18f]-fludarabine uptake in tumor tissue.': ['standardized measure of [18f]-fludarabine uptake in tumor tissue.'], 'calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body': ['calculation of the equivalent dose to all organs and evaluation of effective dose to the whole body'], 'biological effects': ['biological effects'], 'phase i': ['phase i'], 'phase ii': ['phase ii'], 'to assess the complete and partial response rate in patients with relapsed or refractory cll/sll when administered mgd once weekly at the mtd': ['to assess the complete and partial response rate in patients with relapsed or refractory cll/sll when administered mgd once weekly at the mtd'], 'to determine a safe dose recommended  for the routine application of oral vorinostat  in children and adolescents  with relapsed/refractory solid tumor, lymphoma or leukemia.': ['to determine a safe dose recommended  for the routine application of oral vorinostat  in children and adolescents  with relapsed/refractory solid tumor, lymphoma or leukemia.'], 'antitumor effectiveness': ['antitumor effectiveness'], 'association of the histone deacetylase -inhibiting activity with the dose administered, toxicity, and treatment response': ['association of the histone deacetylase -inhibiting activity with the dose administered, toxicity, and treatment response'], 'duration of response in responding patients': ['duration of response in responding patients'], 'immediate toxicity  as determined by the nci ctc': ['immediate toxicity  as determined by the nci ctc'], 'incidence and severity of renal dysfunction as determined by the nci ctc': ['incidence and severity of renal dysfunction as determined by the nci ctc'], 'incidence and severity of mucositis as determined by the nci ctc and who mucositis grading scale': ['incidence and severity of mucositis as determined by the nci ctc and who mucositis grading scale'], \"incidence and severity of cns toxicity and neurocognitive changes taken from patients' medical records and measured using the mini-mental state questionnaire and mri data\": [\"incidence and severity of cns toxicity and neurocognitive changes taken from patients' medical records and measured using the mini-mental state questionnaire and mri data\"], 'hematological toxicity': ['hematological toxicity'], 'incidence of infection': ['incidence of infection'], \"number of inpatient days taken from patients' medical records\": [\"number of inpatient days taken from patients' medical records\"], 'disease response and remission rates measured by serial mri scanning': ['disease response and remission rates measured by serial mri scanning'], 'relative dose intensity': ['relative dose intensity'], 'methotrexate levels post-glucarpidase': ['methotrexate levels post-glucarpidase'], 'incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy': ['incidence of antibodies to glucarpidase measured serologically at the start of each methotrexate course and at follow-up visits if present during therapy'], 'proportion of leukemia participants with positive minimal residual disease': ['proportion of leukemia participants with positive minimal residual disease'], 'number of participants with dose limiting toxicity events': ['number of participants with dose limiting toxicity events'], 'number of participants with progression free survival at 6 months': ['number of participants with progression free survival at 6 months'], 'maximum tolerated dose  of donor lymphocyte infusion': ['maximum tolerated dose  of donor lymphocyte infusion'], 'pb cd34+ kinetics using vtp195183 plus g-csf': ['pb cd34+ kinetics using vtp195183 plus g-csf'], 'the toxicity of vtp195183 pretreatment when used with g-csf': ['the toxicity of vtp195183 pretreatment when used with g-csf'], 'incidence of adverse event post transplant': ['incidence of adverse event post transplant'], 'success of hematopoietic stem cell engraftment': ['success of hematopoietic stem cell engraftment'], 'absence of tropism shift from r5 to dual/mixed or x4 at any point after day 0': ['absence of tropism shift from r5 to dual/mixed or x4 at any point after day 0'], 'quantify gene transfer efficiency and expression': ['quantify gene transfer efficiency and expression'], 'time to restart antiretroviral therapy': ['time to restart antiretroviral therapy'], 'secondary graft failure of t-cell infusions': ['secondary graft failure of t-cell infusions'], 'number of phase i participants with dose-limiting toxicity events': ['number of phase i participants with dose-limiting toxicity events'], 'proportion of complete response defined to be a cr or cri noted as the objective status': ['proportion of complete response defined to be a cr or cri noted as the objective status'], 'biomarker analysis': ['biomarker analysis'], 'fluorescent in situ hybridization  biomarker analysis': ['fluorescent in situ hybridization  biomarker analysis'], 'minimal-residual disease': ['minimal-residual disease'], 'treatment-free survival': ['treatment-free survival'], 'number of patients who received the highest dose level of nk cells  with sustained donor lymphoid engraftment': ['number of patients who received the highest dose level of nk cells  with sustained donor lymphoid engraftment'], 'overall survival since date of transplant': ['overall survival since date of transplant'], 'number of occurrences of viral infection and/or reactivation in allogeneic peripheral blood stem cell transplant  followed by natural killer-donor lymphocyte infusion': ['number of occurrences of viral infection and/or reactivation in allogeneic peripheral blood stem cell transplant  followed by natural killer-donor lymphocyte infusion'], 'number of participants with a decline in interleukin 7  and interleukin 15  cell numbers post-transplant': ['number of participants with a decline in interleukin 7  and interleukin 15  cell numbers post-transplant'], 'number of participants with presence of killer-cell immunoglobulin-like receptors  gene mismatch': ['number of participants with presence of killer-cell immunoglobulin-like receptors  gene mismatch'], 'to measure the amount of tumor motion in breathing synchronized ct scans and determine the fraction of patients whose radiation treatment planning margins would be modified based on this information.': ['to measure the amount of tumor motion in breathing synchronized ct scans and determine the fraction of patients whose radiation treatment planning margins would be modified based on this information.'], 'to measure changes in tumor definition with breathing synchronized pet compared to standard free breathing pet, and determine the fraction of patients whose radiation treatment plans would be modified based on this information.': ['to measure changes in tumor definition with breathing synchronized pet compared to standard free breathing pet, and determine the fraction of patients whose radiation treatment plans would be modified based on this information.'], 'changes in agt  activity': ['changes in agt  activity'], 'changes in the apoptosis': ['changes in the apoptosis'], 'changes in the cell cycle/proliferation': ['changes in the cell cycle/proliferation'], 'changes in dna damage- cytotoxicity': ['changes in dna damage- cytotoxicity'], 'changes in agt inactivation in non-responding patients': ['changes in agt inactivation in non-responding patients'], 'cmax: maximum observed plasma concentration for brigatinib at cycle 1 day 1': ['cmax: maximum observed plasma concentration for brigatinib at cycle 1 day 1'], 'cmax: maximum observed plasma concentration for brigatinib at cycle 2 day 1': ['cmax: maximum observed plasma concentration for brigatinib at cycle 2 day 1'], 't1/2: terminal phase elimination half-life for brigatinib at cycle 2 day 1': ['t1/2: terminal phase elimination half-life for brigatinib at cycle 2 day 1'], 'intracranial objective response rate': ['intracranial objective response rate'], 'duration of intracranial response': ['duration of intracranial response'], 'number of participants who died due to adverse event on the basis of relatedness to study drug': ['number of participants who died due to adverse event on the basis of relatedness to study drug'], 'area under the curve from time zero to end of the dosing interval [auc] on day 14/21 dose-corrected to 125 mg: multiple dose': ['area under the curve from time zero to end of the dosing interval [auc] on day 14/21 dose-corrected to 125 mg: multiple dose'], 'number of participants with best response': ['number of participants with best response'], 'inhibition of cyclin-dependent kinases 4 and 6  based on phosphorylated retinoblastoma  in tumor tissue': ['inhibition of cyclin-dependent kinases 4 and 6  based on phosphorylated retinoblastoma  in tumor tissue'], 'phase 1: recommended dose of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in a pediatric population': ['phase 1: recommended dose of brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine in a pediatric population'], 'phase 2: percentage of participants who were able to complete 6 cycles of protocol therapy at the recommended dose': ['phase 2: percentage of participants who were able to complete 6 cycles of protocol therapy at the recommended dose'], 'phase 1: percentage of participants who achieved a cr per irf assessment per iwg criteria at eot visit': ['phase 1: percentage of participants who achieved a cr per irf assessment per iwg criteria at eot visit'], 'phase 1: percentage of participants who achieved a pr per irf assessment per iwg criteria at eot visit': ['phase 1: percentage of participants who achieved a pr per irf assessment per iwg criteria at eot visit'], 'phase 1: percentage of participants who achieved an orr per irf assessment per iwg criteria at eot visit': ['phase 1: percentage of participants who achieved an orr per irf assessment per iwg criteria at eot visit'], 'phase 1: percentage of participants whose disease was pet negative after 2 cycles of protocol therapy per irf assessment': ['phase 1: percentage of participants whose disease was pet negative after 2 cycles of protocol therapy per irf assessment'], 'phase 1: percentage of participants whose disease was pet positive after 6 cycles of protocol therapy per irf assessment': ['phase 1: percentage of participants whose disease was pet positive after 6 cycles of protocol therapy per irf assessment'], 'phase 2: percentage of participants receiving irradiation for hl following study treatment': ['phase 2: percentage of participants receiving irradiation for hl following study treatment'], 'phase 2: percentage of participants who were ata positive, persistently positive, or transiently positive, and nata positive': ['phase 2: percentage of participants who were ata positive, persistently positive, or transiently positive, and nata positive'], 'phase 2: mean serum cmax of brentuximab vedotin and tab': ['phase 2: mean serum cmax of brentuximab vedotin and tab'], 'phase 2: mean plasma cmax of mmae': ['phase 2: mean plasma cmax of mmae'], 'phase 2: mean serum auc0-15d of brentuximab vedotin and tab': ['phase 2: mean serum auc0-15d of brentuximab vedotin and tab'], 'phase 2: mean plasma auc0-15 of mmae': ['phase 2: mean plasma auc0-15 of mmae'], 'phase 2: median tmax of brentuximab vedotin and tab in serum': ['phase 2: median tmax of brentuximab vedotin and tab in serum'], 'phase 2: median tmax of mmae in plasma': ['phase 2: median tmax of mmae in plasma'], 'phase 2: percentage of participants who experienced peripheral neuropathy, regardless of seriousness, from the first dose of protocol therapy': ['phase 2: percentage of participants who experienced peripheral neuropathy, regardless of seriousness, from the first dose of protocol therapy'], 'phase 2: time to onset and resolution for all peripheral neuropathy events': ['phase 2: time to onset and resolution for all peripheral neuropathy events'], 'phase 1: percentage of participants with low and high ata titer values': ['phase 1: percentage of participants with low and high ata titer values'], 'phase 2: percentage of participants with low and high ata titer values': ['phase 2: percentage of participants with low and high ata titer values'], 'phase 1: mean cmax of brentuximab vedotin in ata positive and ata negative participants': ['phase 1: mean cmax of brentuximab vedotin in ata positive and ata negative participants'], 'phase 1: mean auc 0-15d of brentuximab vedotin in ata positive and ata negative participants': ['phase 1: mean auc 0-15d of brentuximab vedotin in ata positive and ata negative participants'], 'phase 1: percentage of participants achieving cr per irf assessment per iwg criteria in ata positive and ata negative participants': ['phase 1: percentage of participants achieving cr per irf assessment per iwg criteria in ata positive and ata negative participants'], 'phase 2: mean cmax of brentuximab vedotin in ata positive and ata negative participants': ['phase 2: mean cmax of brentuximab vedotin in ata positive and ata negative participants'], 'phase 2: mean auc 0-15 of brentuximab vedotin in ata positive and ata negative participants': ['phase 2: mean auc 0-15 of brentuximab vedotin in ata positive and ata negative participants'], 'phase 2: percentage of participants achieving cr per irf assessment per iwg criteria in ata positive and ata negative participants': ['phase 2: percentage of participants achieving cr per irf assessment per iwg criteria in ata positive and ata negative participants'], 'phase 2: immune reconstitution-change from baseline in immunoglobulin a at eot': ['phase 2: immune reconstitution-change from baseline in immunoglobulin a at eot'], 'phase 2: immune reconstitution-change from baseline in tetanus at eot': ['phase 2: immune reconstitution-change from baseline in tetanus at eot'], 'phase 2: immune reconstitution-change from baseline in haemophilus influenzae b antibody, igg at eot': ['phase 2: immune reconstitution-change from baseline in haemophilus influenzae b antibody, igg at eot'], 'phase 2: immune reconstitution-change from baseline poliovirus antibodies ratio at eot': ['phase 2: immune reconstitution-change from baseline poliovirus antibodies ratio at eot'], 'phase 2: immune reconstitution-change from baseline total immunoglobulin at eot': ['phase 2: immune reconstitution-change from baseline total immunoglobulin at eot'], 'phase 2: immune reconstitution-change from baseline in peripheral blood cd34+a at eot': ['phase 2: immune reconstitution-change from baseline in peripheral blood cd34+a at eot'], 'phase 2: immune reconstitution-change from baseline in total lymphocyte count at eot': ['phase 2: immune reconstitution-change from baseline in total lymphocyte count at eot'], 'phase 2: immune reconstitution-change from baseline in the percentage of cd4+  subset of cells at eot': ['phase 2: immune reconstitution-change from baseline in the percentage of cd4+  subset of cells at eot'], 'phase 2: immune reconstitution-change from baseline in the percentage of cd8+  subset of cells at eot': ['phase 2: immune reconstitution-change from baseline in the percentage of cd8+  subset of cells at eot'], 'the effect of a high fat meal on the bioavailability of tazemetostat': ['the effect of a high fat meal on the bioavailability of tazemetostat'], 'the effect of tazemetostat on exposure of midazolam, a cyp3a4 substrate': ['the effect of tazemetostat on exposure of midazolam, a cyp3a4 substrate'], 'to assess the preliminary activity of tazemetostat': ['to assess the preliminary activity of tazemetostat'], 'the safety and tolerability of tazemetostat monotherapy and tazemetostat in combination with prenisolone': ['the safety and tolerability of tazemetostat monotherapy and tazemetostat in combination with prenisolone'], 'identify the maximum tolerated dose of lenalidomide when combined with bendamustine and rituximab in cll/sll': ['identify the maximum tolerated dose of lenalidomide when combined with bendamustine and rituximab in cll/sll'], 'define dose limiting toxicities of bendamustine, rituximab and lenalidomide in cll': ['define dose limiting toxicities of bendamustine, rituximab and lenalidomide in cll'], 'maximum tolerated dose of lenalidomide': ['maximum tolerated dose of lenalidomide'], 'change in platelet nadir': ['change in platelet nadir'], 'percentage of subjects experiencing grade 3 or 4 thrombocytopenia': ['percentage of subjects experiencing grade 3 or 4 thrombocytopenia'], 'duration of grade 3 or 4 thrombocytopenia': ['duration of grade 3 or 4 thrombocytopenia'], 'percentage of subjects that received platelet transfusions': ['percentage of subjects that received platelet transfusions'], 'safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation': ['safety will be evaluated from physical examinations, hematology and chemistry testing and toxicity evaluation'], 'evaluate the immunogenicity and safety of repeated infusions of 90y-hll2 in nhl patients.': ['evaluate the immunogenicity and safety of repeated infusions of 90y-hll2 in nhl patients.'], 'determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in nhl patients.': ['determine the therapeutic effects, in terms of objective response rate and duration, of the therapeutic agent in nhl patients.'], 'safety analysis - number of participant deaths': ['safety analysis - number of participant deaths'], 'safety analysis - number of participants with adverse advents': ['safety analysis - number of participants with adverse advents'], 'safety analysis - percentage of participants with thyroid test abnormalities': ['safety analysis - percentage of participants with thyroid test abnormalities'], 'safety analysis - percentage of participants with liver test abnormalities': ['safety analysis - percentage of participants with liver test abnormalities'], 'to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed hodgkin lymphoma after asct, as measured by dropout rate.': ['to evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed hodgkin lymphoma after asct, as measured by dropout rate.'], 'adverse event profile': ['adverse event profile'], 'conversion of partial response/stable disease post-asct to complete response.': ['conversion of partial response/stable disease post-asct to complete response.'], 'evaluate immune response': ['evaluate immune response'], 'mtd of azd3965': ['mtd of azd3965'], 'number of patients who experienced dlts': ['number of patients who experienced dlts'], 'auc from 0 to 12 hours post azd3965 dosing': ['auc from 0 to 12 hours post azd3965 dosing'], 'maximum observed plasma concentration of azd3965': ['maximum observed plasma concentration of azd3965'], 'time to maximum observed concentration of azd3965': ['time to maximum observed concentration of azd3965'], 'elimination half life for azd3965': ['elimination half life for azd3965'], 'plasma level of cell death marker m30': ['plasma level of cell death marker m30'], 'plasma level of cell death marker m65': ['plasma level of cell death marker m65'], 'plasma level of nucleosomal dna  as a measure of apoptosis': ['plasma level of nucleosomal dna  as a measure of apoptosis'], 'number of patients who experienced a complete response, partial response or stable disease according to recist 1.1 or a complete remission, partial remission or stable disease according to the iwg criteria for lymphoma': ['number of patients who experienced a complete response, partial response or stable disease according to recist 1.1 or a complete remission, partial remission or stable disease according to the iwg criteria for lymphoma'], 'determine rate of dose limiting toxicities': ['determine rate of dose limiting toxicities'], 'number of participants with dose limiting toxicities to determine maximum tolerated dose.': ['number of participants with dose limiting toxicities to determine maximum tolerated dose.'], 'pharmacokinetics: serum concentration of cpx-351 components  and metabolites.': ['pharmacokinetics: serum concentration of cpx-351 components  and metabolites.'], 'tumor measurement by bone marrow biopsy, blood counts, and/or pet/ct scan': ['tumor measurement by bone marrow biopsy, blood counts, and/or pet/ct scan'], 'serum levels of biomarkers  of cardiac injury.': ['serum levels of biomarkers  of cardiac injury.'], 'skin disease severity  - mf only': ['skin disease severity  - mf only'], 'overall response rate in the skin - mf': ['overall response rate in the skin - mf'], 'overall response rate - cll': ['overall response rate - cll'], 'overall response rate - dlbcl': ['overall response rate - dlbcl'], 'overall response rate - atll': ['overall response rate - atll'], 'incidence of dlts after course 1 assessed using nci ctcae version 4': ['incidence of dlts after course 1 assessed using nci ctcae version 4'], 'part a: number of participants with dose-limiting toxicities': ['part a: number of participants with dose-limiting toxicities'], 'part a: percent change from baseline in levels of phosphorylated ribosomal protein s6  in stimulated b cells': ['part a: percent change from baseline in levels of phosphorylated ribosomal protein s6  in stimulated b cells'], 'part a: percent change from baseline in levels of phosphorylated elongation i initiation binding protein  in stimulated t cells': ['part a: percent change from baseline in levels of phosphorylated elongation i initiation binding protein  in stimulated t cells'], 'part a: percent change from baseline in levels of phosphorylated protein kinase b  in stimulated monocytes': ['part a: percent change from baseline in levels of phosphorylated protein kinase b  in stimulated monocytes'], 'part b: percent change from baseline in p4e-bp1 in monocytes by tumor cohort': ['part b: percent change from baseline in p4e-bp1 in monocytes by tumor cohort'], 'part b: percent change from baseline in p4e-bp1 in monocytes in the hcc and net cohorts by dose': ['part b: percent change from baseline in p4e-bp1 in monocytes in the hcc and net cohorts by dose'], 'part b: percent change from baseline in levels of pakt in monocytes by tumor cohort': ['part b: percent change from baseline in levels of pakt in monocytes by tumor cohort'], 'part b: percent change from baseline in levels of pakt in monocytes in the hcc and net cohorts by dose': ['part b: percent change from baseline in levels of pakt in monocytes in the hcc and net cohorts by dose'], 'part b: percent change from baseline in ps6rp levels in tumor tissue by tumor type': ['part b: percent change from baseline in ps6rp levels in tumor tissue by tumor type'], 'part a: overall response rate': ['part a: overall response rate'], 'part b: overall response rate': ['part b: overall response rate'], 'obtaining a stable mean dna-tgn level > 500 fmol/microgram dna after addition of 6tg. dna-tgn calculated as a 4 weeks mean .': ['obtaining a stable mean dna-tgn level > 500 fmol/microgram dna after addition of 6tg. dna-tgn calculated as a 4 weeks mean .'], 'erythrocyte 6mp cytosol metabolite levels': ['erythrocyte 6mp cytosol metabolite levels'], 'myelotoxicity': ['myelotoxicity'], 'severe hepatotoxicity including sinusoidal obstruction syndrome': ['severe hepatotoxicity including sinusoidal obstruction syndrome'], 'eastern cooperative oncology group  performance status at each visit': ['eastern cooperative oncology group  performance status at each visit'], 'percentage of participants with solid tumors  who achieved an objective response': ['percentage of participants with solid tumors  who achieved an objective response'], 'percentage of participants with glioma who achieved an objective response': ['percentage of participants with glioma who achieved an objective response'], 'percentage of participants with aitl who achieved an objective response': ['percentage of participants with aitl who achieved an objective response'], 'all phase i-ii participants: safety': ['all phase i-ii participants: safety'], 'phase i participants: safety': ['phase i participants: safety'], 'pharmacokinetic profile': ['pharmacokinetic profile'], 'level of insulin-like growth factor receptor-1  on peripheral blood cells': ['level of insulin-like growth factor receptor-1  on peripheral blood cells'], 'tumor response measured by modified recist': ['tumor response measured by modified recist'], 'tumor glucose metabolism as measured by fludeoxyglucose f 18-pet/ct scan': ['tumor glucose metabolism as measured by fludeoxyglucose f 18-pet/ct scan'], 'anti-amg-479 antibody formation': ['anti-amg-479 antibody formation'], 'levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase  in blood': ['levels of cross-linked c-telopeptides of type 1 collagen and bone-specific alkaline phosphatase  in blood'], 'circulating levels of igf-1r and igf-bp3': ['circulating levels of igf-1r and igf-bp3'], 'qtc interval': ['qtc interval'], 'ecg parameters': ['ecg parameters'], 'blood mmae levels': ['blood mmae levels'], 'maximum-tolerated dose and recommended phase 2 dose of crizotinib': ['maximum-tolerated dose and recommended phase 2 dose of crizotinib'], 'number of participants with toxicities of crizotinib': ['number of participants with toxicities of crizotinib'], 'steady state c max of crizotinib': ['steady state c max of crizotinib'], 'steady state c average of crizotinib': ['steady state c average of crizotinib'], 'steady state auc of crizotinib': ['steady state auc of crizotinib'], 'steady state clearance of crizotinib': ['steady state clearance of crizotinib'], 'number of participants (relapsed or refractory solid tumors or anaplastic large cell lymphoma )with response to crizotinib': ['number of participants (relapsed or refractory solid tumors or anaplastic large cell lymphoma )with response to crizotinib'], 'number of participants (relapsed or refractory neuroblastoma or anaplastic large cell lymphoma ) with response to crizotinib': ['number of participants (relapsed or refractory neuroblastoma or anaplastic large cell lymphoma ) with response to crizotinib'], 'overall best response rate': ['overall best response rate'], 'number of participants with dlts in first 2 cycles of portion b': ['number of participants with dlts in first 2 cycles of portion b'], 'number of participants with hematology laboratory abnormalities by maximum nci ctcae grade in portion a': ['number of participants with hematology laboratory abnormalities by maximum nci ctcae grade in portion a'], 'number of participants with chemistries laboratory abnormalities by maximum nci ctcae grade in portion a': ['number of participants with chemistries laboratory abnormalities by maximum nci ctcae grade in portion a'], 'number of participants with clinically significant vital sign abnormalities in portion a': ['number of participants with clinically significant vital sign abnormalities in portion a'], 'number of participants with qtc interval meeting categorical summarization criteria in portion a': ['number of participants with qtc interval meeting categorical summarization criteria in portion a'], 'duration of response in portion a': ['duration of response in portion a'], 'time to response in portion a': ['time to response in portion a'], 'progression-free survival in portion a': ['progression-free survival in portion a'], 'overall survival in portion a': ['overall survival in portion a'], 'number of participants with hematology laboratory abnormalities by maximum nci ctcae grade in portion b': ['number of participants with hematology laboratory abnormalities by maximum nci ctcae grade in portion b'], 'number of participants with chemistries laboratory abnormalities by maximum nci ctcae grade in portion b': ['number of participants with chemistries laboratory abnormalities by maximum nci ctcae grade in portion b'], 'number of participants with clinically significant vital sign abnormalities in portion b': ['number of participants with clinically significant vital sign abnormalities in portion b'], 'pf-05082566 cmax in portion b': ['pf-05082566 cmax in portion b'], 'pf-05082566 ctrough in portion b': ['pf-05082566 ctrough in portion b'], 'pf-05082566 tmax in portion b': ['pf-05082566 tmax in portion b'], 'pf-05082566 auclast in portion b': ['pf-05082566 auclast in portion b'], 'pf-05082566 aucinf in portion b': ['pf-05082566 aucinf in portion b'], 'pf-05082566 auctau in portion b': ['pf-05082566 auctau in portion b'], 'pf-05082566 cl in portion b': ['pf-05082566 cl in portion b'], 'pf-05082566 vss in portion b': ['pf-05082566 vss in portion b'], 'rituximab cmax and ctrough in portion b': ['rituximab cmax and ctrough in portion b'], 'number of participants with positive ada for pf-05082566 and rituximab in portion b': ['number of participants with positive ada for pf-05082566 and rituximab in portion b'], 'number of participants with qtc interval meeting categorical summarization criteria in portion b': ['number of participants with qtc interval meeting categorical summarization criteria in portion b'], 'percentage of participants achieving objective response per cheson 2007 criteria in portion b': ['percentage of participants achieving objective response per cheson 2007 criteria in portion b'], 'duration of response in portion b': ['duration of response in portion b'], 'time to response in portion b': ['time to response in portion b'], 'progression-free survival in portion b': ['progression-free survival in portion b'], 'overall survival in portion b': ['overall survival in portion b'], 'maximum tolerated dose of cpg 7909 as determined using the number of participants with a dlt at each dose level': ['maximum tolerated dose of cpg 7909 as determined using the number of participants with a dlt at each dose level'], 'phase ii: time to progression': ['phase ii: time to progression'], 'phase ii: major response rate': ['phase ii: major response rate'], 'phase ii: minor response rate': ['phase ii: minor response rate'], 'phase ii: time to response': ['phase ii: time to response'], 'phase ii: duration of response': ['phase ii: duration of response'], 'phase ii: time to next therapy': ['phase ii: time to next therapy'], 'phase ii: overall survival': ['phase ii: overall survival'], 'recommended dose level of flavopiridol': ['recommended dose level of flavopiridol'], \"non-myeloablative maximum tolerated dose of i-131 tositumomab that can be given to patients with relapsed/refractory hodgkin's lymphoma.\": [\"non-myeloablative maximum tolerated dose of i-131 tositumomab that can be given to patients with relapsed/refractory hodgkin's lymphoma.\"], 'overall and complete response rates': ['overall and complete response rates'], 'median time to progression following i-131 tositumomab therapy.': ['median time to progression following i-131 tositumomab therapy.'], \"frequency of visualization of hodgkin's lymphoma with i-131 tositumomab imaging and tumor radiation absorbed dose\": [\"frequency of visualization of hodgkin's lymphoma with i-131 tositumomab imaging and tumor radiation absorbed dose\"], 'os rate at 12 months': ['os rate at 12 months'], 'os follow-up time': ['os follow-up time'], 'percentage of patients with progression-free survival at 2 years': ['percentage of patients with progression-free survival at 2 years'], 'maximum tolerated dose of veliparib when combined with bendamustine hydrochloride': ['maximum tolerated dose of veliparib when combined with bendamustine hydrochloride'], 'pharmacokinetic parameters of veliparib': ['pharmacokinetic parameters of veliparib'], 'progression-free survival using recist version 1.1': ['progression-free survival using recist version 1.1'], 'participants with dose limiting toxicities': ['participants with dose limiting toxicities'], 'maximum sar245408 plasma concentration': ['maximum sar245408 plasma concentration'], 'area under the sar245408 plasma concentration versus time curve': ['area under the sar245408 plasma concentration versus time curve'], 'efficacy - overall survival': ['efficacy - overall survival'], 'efficacy - progression free survival': ['efficacy - progression free survival'], 'efficacy - disease progression': ['efficacy - disease progression'], 'maximum sar245409 plasma concentration': ['maximum sar245409 plasma concentration'], 'area under the sar245409 plasma concentration versus time curve': ['area under the sar245409 plasma concentration versus time curve'], 'ratio of maximum sar245409 plasma concentration between fed and fasted dosing': ['ratio of maximum sar245409 plasma concentration between fed and fasted dosing'], 'ratio of area under the sar245409 plasma concentration versus time curve between fed and fasted dosing': ['ratio of area under the sar245409 plasma concentration versus time curve between fed and fasted dosing'], 'change in cd8 cell counts': ['change in cd8 cell counts'], 'changes in absolute cd4 cell counts': ['changes in absolute cd4 cell counts'], 'changes in epstein-barr virus  viral load': ['changes in epstein-barr virus  viral load'], 'changes in human herpes virus -8 viral load': ['changes in human herpes virus -8 viral load'], 'changes in human immunodeficiency virus  viral load': ['changes in human immunodeficiency virus  viral load'], 'change in plasma associated human immunodeficiency virus -1 ribonucleic acid': ['change in plasma associated human immunodeficiency virus -1 ribonucleic acid'], 'pharmacokinetic clearance': ['pharmacokinetic clearance'], 'evaluating the diagnostic quality of thoracic ct exams performed at 50% of standard dose parameters': ['evaluating the diagnostic quality of thoracic ct exams performed at 50% of standard dose parameters'], 'percentage of participants who have received some form of response': ['percentage of participants who have received some form of response'], 'pk profile': ['pk profile'], 'pharmacokinetics: auc': ['pharmacokinetics: auc'], 'pharmacokinetics: cmax': ['pharmacokinetics: cmax'], 'immunogenicity: percentage of ada positive patients': ['immunogenicity: percentage of ada positive patients'], 'objective response rate of complete response and partial response': ['objective response rate of complete response and partial response'], 'measurement of peripheral blood b-lymphocyte depletion during the bi-1206 treatment period using flow cytometry.': ['measurement of peripheral blood b-lymphocyte depletion during the bi-1206 treatment period using flow cytometry.'], 'assessment of best disease response according to criteria for malignant lymphoma  waldenström macroglobulinaemia assessment criteria  or nci chronic lymphocytic leukaemia  criteria .': ['assessment of best disease response according to criteria for malignant lymphoma  waldenström macroglobulinaemia assessment criteria  or nci chronic lymphocytic leukaemia  criteria .'], 'measure progression free survival at 1 year after the first bi-1206 administration on the study for all patients': ['measure progression free survival at 1 year after the first bi-1206 administration on the study for all patients'], 'measure overall survival at 1 year after the first bi-1206 administration on the study for all patients': ['measure overall survival at 1 year after the first bi-1206 administration on the study for all patients'], 'overall response rate based on blinded independent review committee  assessment': ['overall response rate based on blinded independent review committee  assessment'], 'progression-free survival based on investigator assessment': ['progression-free survival based on investigator assessment'], 'progression-free survival based on birc assessment': ['progression-free survival based on birc assessment'], 'maximum tolerated dose of sra737': ['maximum tolerated dose of sra737'], 'recommended phase 2 dose of sra737': ['recommended phase 2 dose of sra737'], '- to determine the maximum tolerated dose of gsk1120212': ['- to determine the maximum tolerated dose of gsk1120212'], '- to characterize the pk of gsk1120212 after single and repeat-dose administration': ['- to characterize the pk of gsk1120212 after single and repeat-dose administration'], '- to evaluate the pharmacodynamic response in tumors after treatment with gsk1120212': ['- to evaluate the pharmacodynamic response in tumors after treatment with gsk1120212'], '- to explore relationships between gsk1120212 pk, mapk signalling inhibition and clinical endpoints': ['- to explore relationships between gsk1120212 pk, mapk signalling inhibition and clinical endpoints'], '- to explore the clinical tumor response after treatment with gsk1120212': ['- to explore the clinical tumor response after treatment with gsk1120212'], '- to determine the association of clinical and pk endpoints with genetic and protein profiles from tumor tissue': ['- to determine the association of clinical and pk endpoints with genetic and protein profiles from tumor tissue'], 'generate autologous, ebv-specific, cytotoxic t cell lines  from individuals receiving or having received a solid organ transplant .': ['generate autologous, ebv-specific, cytotoxic t cell lines  from individuals receiving or having received a solid organ transplant .'], 'administer autologous, ebv-specific ctls to patients, to determine the safety of intravenous injections in these individuals': ['administer autologous, ebv-specific ctls to patients, to determine the safety of intravenous injections in these individuals'], 'evaluate the antiviral and immunological efficacy of the infused ctls': ['evaluate the antiviral and immunological efficacy of the infused ctls'], 'to determine the maximum tolerated dose of tpi 287 administered every 21 days': ['to determine the maximum tolerated dose of tpi 287 administered every 21 days'], 'to determine the safety of tpi 287': ['to determine the safety of tpi 287'], 'to determine the antitumor activity of tpi 287': ['to determine the antitumor activity of tpi 287'], 'to determine the pharmacokinetic profile of tpi 287': ['to determine the pharmacokinetic profile of tpi 287'], 'incidence of toxicities produced by alisertib in combination with vorinostat assessed by the nci ctcae version 4.0': ['incidence of toxicities produced by alisertib in combination with vorinostat assessed by the nci ctcae version 4.0'], 'clinical response rate': ['clinical response rate'], 'area under the plasma concentration time-curve from time 0 to 24-hour': ['area under the plasma concentration time-curve from time 0 to 24-hour'], 'engraftment of hla identical pbsc allografts': ['engraftment of hla identical pbsc allografts'], 'gene-re-expression of epigenetic modulation in peripheral blood mononuclear cells  as measured by change in epstein-barr virus  viral load  after treatment with azacitidine': ['gene-re-expression of epigenetic modulation in peripheral blood mononuclear cells  as measured by change in epstein-barr virus  viral load  after treatment with azacitidine'], 'change in tumor poly   levels from baseline to 3-6 hours after abt-888 administration': ['change in tumor poly   levels from baseline to 3-6 hours after abt-888 administration'], 'safety of administering 1 dose of abt-888': ['safety of administering 1 dose of abt-888'], 'changes in par levels in peripheral blood mononuclear cells from baseline to after abt-888 administration': ['changes in par levels in peripheral blood mononuclear cells from baseline to after abt-888 administration'], 'phase 2: percentage of participants with an overall response after 4 treatment cycles': ['phase 2: percentage of participants with an overall response after 4 treatment cycles'], 'percentage of participants with an overall response throughout the study': ['percentage of participants with an overall response throughout the study'], 'to recommend a dose for future trials with a new drug called di-b4 by finding the highest safe dose which can be given to patients': ['to recommend a dose for future trials with a new drug called di-b4 by finding the highest safe dose which can be given to patients'], 'measuring of pk parameter values for di-b4 including auc, cmax, tmax, and half life t1/2.': ['measuring of pk parameter values for di-b4 including auc, cmax, tmax, and half life t1/2.'], 'to evaluate the effect of di-b4 on the depletion of peripheral blood and bone marrow b-cells.': ['to evaluate the effect of di-b4 on the depletion of peripheral blood and bone marrow b-cells.'], 'to look for signs of anti-tumour activity of di-b4 in patients with relapsed or refractory indolent b-cell malignancies.': ['to look for signs of anti-tumour activity of di-b4 in patients with relapsed or refractory indolent b-cell malignancies.'], 'to assess immunogenicity of di-b4 in patients with relapsed or refractory indolent b-cell malignancies': ['to assess immunogenicity of di-b4 in patients with relapsed or refractory indolent b-cell malignancies'], 'to measure the time to disease progression and eighteen month survival': ['to measure the time to disease progression and eighteen month survival'], 'maximum tolerated dose and recommended phase ii dose of metformin hydrochloride when administered with temsirolimus': ['maximum tolerated dose and recommended phase ii dose of metformin hydrochloride when administered with temsirolimus'], 'toxicity and safety, with particular reference to glucose and lipid deregulation': ['toxicity and safety, with particular reference to glucose and lipid deregulation'], 'antitumor activity, including tumor response rate and time to progression': ['antitumor activity, including tumor response rate and time to progression'], 'incidence of toxicities, graded according to nci ctcae version 4.0': ['incidence of toxicities, graded according to nci ctcae version 4.0'], 'cc-122 plasma concentrations when administered alone or in combination with ibrutinib or obinutuzumab': ['cc-122 plasma concentrations when administered alone or in combination with ibrutinib or obinutuzumab'], 'ibrutinib plasma concentrations when administered in combination with cc-122': ['ibrutinib plasma concentrations when administered in combination with cc-122'], 'minimal residual disease response rate': ['minimal residual disease response rate'], 'cmax when administered alone or in combination with ibrutinib': ['cmax when administered alone or in combination with ibrutinib'], 'tmax of cc-122 when administered alone or in combination with ibrutinib': ['tmax of cc-122 when administered alone or in combination with ibrutinib'], 'auc of cc-122 when administered alone or in combination with ibrutinib': ['auc of cc-122 when administered alone or in combination with ibrutinib'], 'blood concentrations of sgn-cd70a and metabolites': ['blood concentrations of sgn-cd70a and metabolites'], 'phase ii: objective response rate': ['phase ii: objective response rate'], 'pk parameter for hmpl-523: auc0-t': ['pk parameter for hmpl-523: auc0-t'], 'pk parameter for hmpl-523: auc0-inf': ['pk parameter for hmpl-523: auc0-inf'], 'pk parameter for hmpl-523: cmax': ['pk parameter for hmpl-523: cmax'], 'auc0-t': ['auc0-t'], 'pk parameter for hmpl-523: tmax': ['pk parameter for hmpl-523: tmax'], 'assessment of safety procedures findings': ['assessment of safety procedures findings'], 'pk parameter for metabolite m1: auc0-t': ['pk parameter for metabolite m1: auc0-t'], 'pk parameter for metabolite m1: auc0-inf': ['pk parameter for metabolite m1: auc0-inf'], 'pk parameter for metabolite m1: cmax': ['pk parameter for metabolite m1: cmax'], 'safety and tolerability of sch 727965, including maximum administered dose and dose-limiting toxicity': ['safety and tolerability of sch 727965, including maximum administered dose and dose-limiting toxicity'], \"in part 1 and part 2, pharmacodynamic effects of sch 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.\": [\"in part 1 and part 2, pharmacodynamic effects of sch 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.\"], 'in part 3, area under the plasma concentration versus time curve and maximum concentration of sch 727965 administered as a 2 hour intravenous infusion with or without aprepitant in participants with advanced malignancies.': ['in part 3, area under the plasma concentration versus time curve and maximum concentration of sch 727965 administered as a 2 hour intravenous infusion with or without aprepitant in participants with advanced malignancies.'], 'maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity': ['maximum tolerated dose of dasatinib, defined as the highest dose level at which less than 33% of 6-9 evaluable patients experience dose-limiting toxicity'], 'pharmacokinetic parameters of dasatinib': ['pharmacokinetic parameters of dasatinib'], 'the primary out come is to assess the diagnostic quality of [18f]iso-1-pet/ct images at the proposed 8 mci dose.': ['the primary out come is to assess the diagnostic quality of [18f]iso-1-pet/ct images at the proposed 8 mci dose.'], 'secondary outcome is to quantitatively determine the relationship between tumor [18f]iso-1 uptake and ki-67, s-phase, mitotic index and sigma-2 receptors content of the tumor.': ['secondary outcome is to quantitatively determine the relationship between tumor [18f]iso-1 uptake and ki-67, s-phase, mitotic index and sigma-2 receptors content of the tumor.'], 'maximum plasma concentration of iacs-010759 [cmax]': ['maximum plasma concentration of iacs-010759 [cmax]'], 'objective response rate assessed according to response evaluation criteria in solid tumors version 1.1': ['objective response rate assessed according to response evaluation criteria in solid tumors version 1.1'], 'landmark survival rates': ['landmark survival rates'], 'duration of response for responding patients': ['duration of response for responding patients'], 'time to next therapy or death': ['time to next therapy or death'], 'freedom from new metastases': ['freedom from new metastases'], 'to determine the maximum tolerated dose of tpi 287': ['to determine the maximum tolerated dose of tpi 287'], 'to determine the pharmacodynamic profile of tpi 287': ['to determine the pharmacodynamic profile of tpi 287'], 'observed elimination rate constant associated with the terminal portion of the curve': ['observed elimination rate constant associated with the terminal portion of the curve'], 'last quantifiable drug concentration': ['last quantifiable drug concentration'], 'mean residence time': ['mean residence time'], 'changes in laboratory values': ['changes in laboratory values'], 'assessments of electrocardiograms': ['assessments of electrocardiograms'], 'assessments of dose interruptions, reductions, and dose intensity': ['assessments of dose interruptions, reductions, and dose intensity'], 'plasma pk parameter of ldk378 and auy922: tmax': ['plasma pk parameter of ldk378 and auy922: tmax'], 'plasma pk parameter of ldk378 and auy922: cmax': ['plasma pk parameter of ldk378 and auy922: cmax'], 'plasma pk parameter of ldk378 and auy922: auclast': ['plasma pk parameter of ldk378 and auy922: auclast'], 'plasma pk parameter of ldk378 and auy922: auctau': ['plasma pk parameter of ldk378 and auy922: auctau'], 'plasma pk parameter of ldk378 and auy922: cmin': ['plasma pk parameter of ldk378 and auy922: cmin'], 'plasma pk parameter of ldk378 and auy922: racc': ['plasma pk parameter of ldk378 and auy922: racc'], 'monitor for minimal residual disease': ['monitor for minimal residual disease'], 'parts a and b: safety and tolerability in terms of ae and sae , as recorded in safety measures.': ['parts a and b: safety and tolerability in terms of ae and sae , as recorded in safety measures.'], 'parts a&b: establish pharmacokinetics characteristics of azd6738 and its active metabolite from plasma analysis': ['parts a&b: establish pharmacokinetics characteristics of azd6738 and its active metabolite from plasma analysis'], 'part a and b: anti tumour activity by assessing tumour response via ct or mri scans': ['part a and b: anti tumour activity by assessing tumour response via ct or mri scans'], 'part a and b: measuring 4 beta-hydroxy cholesterol concentration for assessment of cyp3a4 induction potential': ['part a and b: measuring 4 beta-hydroxy cholesterol concentration for assessment of cyp3a4 induction potential'], 'part b: pharmacokinetic profile of azd6738 and its active metabolite from urinalysis': ['part b: pharmacokinetic profile of azd6738 and its active metabolite from urinalysis'], 'part b only: preliminary assessment of the effect of food on the pk parameters of azd6738 via urinalysis': ['part b only: preliminary assessment of the effect of food on the pk parameters of azd6738 via urinalysis'], 'part a: determine the extent of atr target inhibition using pharmacodynamic biomarkers': ['part a: determine the extent of atr target inhibition using pharmacodynamic biomarkers'], 'part a and b: biomarker analysis using lymph node biopsies': ['part a and b: biomarker analysis using lymph node biopsies'], 'part a and b: confirmation of tumour response assessment by analysing bone marrow / aspirate': ['part a and b: confirmation of tumour response assessment by analysing bone marrow / aspirate'], 'part a and b: bone marrow biopsy or aspirate will be analysed for biomarkers': ['part a and b: bone marrow biopsy or aspirate will be analysed for biomarkers'], \"part a and b: determination of 11q del status to investigate any potential changes in fish cytogenetic's post treatment\": [\"part a and b: determination of 11q del status to investigate any potential changes in fish cytogenetic's post treatment\"], 'parts a and b: identify patients with atm deficient status, determine atm mutation load and correlate this with clinical efficacy in order to better understand patient population which will most likely benefit from azd6738 treatment': ['parts a and b: identify patients with atm deficient status, determine atm mutation load and correlate this with clinical efficacy in order to better understand patient population which will most likely benefit from azd6738 treatment'], 'part b: the extent of atr target inhibition identified using pharmacodynamic biomarkers': ['part b: the extent of atr target inhibition identified using pharmacodynamic biomarkers'], 'objective response rate for phase ii': ['objective response rate for phase ii'], 'chronic gvhd response measured as change in physical exam and laboratory testing': ['chronic gvhd response measured as change in physical exam and laboratory testing'], 'chronic gvhd response measured as change in daily corticosteroid requirement': ['chronic gvhd response measured as change in daily corticosteroid requirement'], 'chronic gvhd response measured as frequency of treatment failure defined as discontinuation of study drug due to severe adverse effects or initiation of a new treatment for cgvhd': ['chronic gvhd response measured as frequency of treatment failure defined as discontinuation of study drug due to severe adverse effects or initiation of a new treatment for cgvhd'], 'chronic gvhd response measured as change in cgvhd symptom burden': ['chronic gvhd response measured as change in cgvhd symptom burden'], 'determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.': ['determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan.'], 'evaluate feasibility of repetitive cycles of this combination .': ['evaluate feasibility of repetitive cycles of this combination .'], 'estimate response rate in children and adolescents with recurrent solid tumors and lymphomas.': ['estimate response rate in children and adolescents with recurrent solid tumors and lymphomas.'], 'toxicity analysis': ['toxicity analysis'], 'efficacy analysis': ['efficacy analysis'], 'occurrence of any grade 4 or greater suspected adverse reaction': ['occurrence of any grade 4 or greater suspected adverse reaction'], 'occurrence of disease response': ['occurrence of disease response'], 'number of patients alive without progression': ['number of patients alive without progression'], 'to evaluate the safety of ublituximab in combination with ibrutinib in patients with select b-cell malignancies': ['to evaluate the safety of ublituximab in combination with ibrutinib in patients with select b-cell malignancies'], 'overall response rate   of the combination of pralatrexate and romidepsin in patients with relapsed/refractory t-cell lymphoma': ['overall response rate   of the combination of pralatrexate and romidepsin in patients with relapsed/refractory t-cell lymphoma'], 'maximum number of cycles received': ['maximum number of cycles received'], 'number of dose delays at the mtd': ['number of dose delays at the mtd'], 'number of dose reductions at the mtd': ['number of dose reductions at the mtd'], 'phase ii = fraction of responding patients according to lugano classification': ['phase ii = fraction of responding patients according to lugano classification'], 'phase ii = orr': ['phase ii = orr'], 'phase ii = number of patients with hematological recovery after each cycle': ['phase ii = number of patients with hematological recovery after each cycle'], 'phase ii = fraction of patients eligible for asct': ['phase ii = fraction of patients eligible for asct'], 'health-related quality of life': ['health-related quality of life'], 'quality of life c30 questionnaire': ['quality of life c30 questionnaire'], 'european quality of life-5 dimensions health state classifier to 5 levels': ['european quality of life-5 dimensions health state classifier to 5 levels'], 'severe infusional toxicity': ['severe infusional toxicity'], 'safety of administering fucosylated umbilical cord blood  regulatory t cells  in a cbt, mrd, or mud transplant': ['safety of administering fucosylated umbilical cord blood  regulatory t cells  in a cbt, mrd, or mud transplant'], 'local toxicity as measured by physical exam and punch biopsy': ['local toxicity as measured by physical exam and punch biopsy'], 'treatment efficacy as measured by physical exam and punch biopsy': ['treatment efficacy as measured by physical exam and punch biopsy'], 'number of participants with graft failure': ['number of participants with graft failure'], 'change in lymphocyte count': ['change in lymphocyte count'], 'change in quality of life': ['change in quality of life'], 'change in inflammation': ['change in inflammation'], 'change in metabolic profiles': ['change in metabolic profiles'], 'change in autophagy status': ['change in autophagy status'], 'immune cell gene expression profiles': ['immune cell gene expression profiles'], 'change in gut microbiome': ['change in gut microbiome'], 'recommended dose of ly3039478 in combination with dexamethasone': ['recommended dose of ly3039478 in combination with dexamethasone'], 'pharmacokinetics : area under the concentration-time curve  of ly3039478 in combination with dexamethasone in day 1': ['pharmacokinetics : area under the concentration-time curve  of ly3039478 in combination with dexamethasone in day 1'], 'pharmacokinetics : area under the concentration-time curve  of ly3039478 in combination with dexamethasone in day 8': ['pharmacokinetics : area under the concentration-time curve  of ly3039478 in combination with dexamethasone in day 8'], 'number of participants with cr or cri and notch-1 or fbxw7 mutations': ['number of participants with cr or cri and notch-1 or fbxw7 mutations'], 'phase 2: number of participants who achieve pr': ['phase 2: number of participants who achieve pr'], 'phase 2: change from baseline in the functional assessment of cancer therapy-leukemia-general  score': ['phase 2: change from baseline in the functional assessment of cancer therapy-leukemia-general  score'], 'estimate the maximum tolerated dose of dexamethasone given for 5 consecutive days when combined with fixed doses of irinotecan and vincristine in children with relapsed hematologic malignancies': ['estimate the maximum tolerated dose of dexamethasone given for 5 consecutive days when combined with fixed doses of irinotecan and vincristine in children with relapsed hematologic malignancies'], 'number of participants with overall best response': ['number of participants with overall best response'], 'incidence of dlt in patients treated with alvocidib and lenalidomide graded according to nci ctcae version 4.0': ['incidence of dlt in patients treated with alvocidib and lenalidomide graded according to nci ctcae version 4.0'], 'pharmacokinetic parameters of alvocidib and lenalidomide alone and in combination in plasma samples': ['pharmacokinetic parameters of alvocidib and lenalidomide alone and in combination in plasma samples'], 'plasma il-6 and selected cytokine levels': ['plasma il-6 and selected cytokine levels'], 'b-cell activation as assessed by surface antigen  expression': ['b-cell activation as assessed by surface antigen  expression'], 'intracellular pharmacodynamic targets including stat3, mcl-1, and nuclear factor kappa-light-chain-enhancer of activated b cells': ['intracellular pharmacodynamic targets including stat3, mcl-1, and nuclear factor kappa-light-chain-enhancer of activated b cells'], 'response assessed by national cancer institute-sponsored working group guidelines': ['response assessed by national cancer institute-sponsored working group guidelines'], 'toxicity graded according to nci ctcae version 4.0': ['toxicity graded according to nci ctcae version 4.0'], 'presence of minimal residual disease': ['presence of minimal residual disease'], 'auc0-tlast': ['auc0-tlast'], 'auc0-∞': ['auc0-∞'], 'tlag': ['tlag'], 'cl/f': ['cl/f'], 'vz/f': ['vz/f'], 'auc0-∞ plasma resminostat/total radioactivity ratio': ['auc0-∞ plasma resminostat/total radioactivity ratio'], 'auc0-∞ blood/plasma ratio': ['auc0-∞ blood/plasma ratio'], 'aeu': ['aeu'], 'cumulative aeu': ['cumulative aeu'], 'feu': ['feu'], 'cumulative feu': ['cumulative feu'], 'aef': ['aef'], 'cumulative aef': ['cumulative aef'], 'fef': ['fef'], 'cumulative fef.': ['cumulative fef.'], 'heart rhythm': ['heart rhythm'], 'ventricular rate': ['ventricular rate'], 'pr-interval': ['pr-interval'], 'qrs complex': ['qrs complex'], 'qt interval': ['qt interval'], 'qtcf interval': ['qtcf interval'], 'vital signs': ['vital signs'], 'physical examination': ['physical examination'], 'metabolic profiles of resminostat': ['metabolic profiles of resminostat'], 'identification and quantification of resminostat metabolites': ['identification and quantification of resminostat metabolites'], 'change in the absolute number of cmv-induced adaptive nk cells  between days 28 and 100 post-auto-hct in patients with lymphoid malignancies.': ['change in the absolute number of cmv-induced adaptive nk cells  between days 28 and 100 post-auto-hct in patients with lymphoid malignancies.'], 'change in absolute number of cmv-induced adaptive nk cells': ['change in absolute number of cmv-induced adaptive nk cells'], 'response to cmv-mva triplex vaccine in cmv seropositive vs. seronegative patients': ['response to cmv-mva triplex vaccine in cmv seropositive vs. seronegative patients'], 'response to cmv-mva triplex vaccine in lymphoma vs. myeloma patients': ['response to cmv-mva triplex vaccine in lymphoma vs. myeloma patients'], 'dose escalation: rp2d of tislelizumab': ['dose escalation: rp2d of tislelizumab'], 'maximum tolerated dose  or recommended phase 2 dose  of entinostat': ['maximum tolerated dose  or recommended phase 2 dose  of entinostat'], 'half-life of entinostat': ['half-life of entinostat'], 'peak plasma concentration of entinostat: c-max': ['peak plasma concentration of entinostat: c-max'], 'total area under the plasma concentration curve of entinostat: auc': ['total area under the plasma concentration curve of entinostat: auc'], 'time to reach maximum plasma concentration of entinostat: t-max': ['time to reach maximum plasma concentration of entinostat: t-max'], 'antitumor activity of entinostat': ['antitumor activity of entinostat'], 'change in histone h3 acetylation of entinostat': ['change in histone h3 acetylation of entinostat'], 'change in histone h4 acetylation of entinostat': ['change in histone h4 acetylation of entinostat'], 'inflammatory cytokines': ['inflammatory cytokines'], 'percentage of participants who experienced a dose-limiting toxicity in phase i of the study': ['percentage of participants who experienced a dose-limiting toxicity in phase i of the study'], 'percentage of participants with best overall response in phase ii of the study': ['percentage of participants with best overall response in phase ii of the study'], 'percentage of participants with complete response  in phase ii of the study': ['percentage of participants with complete response  in phase ii of the study'], 'duration of response by disease type in phase ii of the study': ['duration of response by disease type in phase ii of the study'], 'pharmacodynamics: participants with peripheral b-cell recovery after having had depletion at end of treatment during phase ii of the study': ['pharmacodynamics: participants with peripheral b-cell recovery after having had depletion at end of treatment during phase ii of the study'], 'percentage of retreated participants with response': ['percentage of retreated participants with response'], 'area under the concentration-time curve of obinutuzumab administered on day 1 of cycle 1 in phase i of the study': ['area under the concentration-time curve of obinutuzumab administered on day 1 of cycle 1 in phase i of the study'], 'incidence of grade 3 or higher treatment-related toxicity': ['incidence of grade 3 or higher treatment-related toxicity'], 'test the safety and tolerability of the combination of everolimus and alemtuzumab.': ['test the safety and tolerability of the combination of everolimus and alemtuzumab.'], 'time to subsequent therapy': ['time to subsequent therapy'], 'determine maximum tolerated dose of the drug': ['determine maximum tolerated dose of the drug'], 'pharmacokinetics, pharmacodynamics, efficacy': ['pharmacokinetics, pharmacodynamics, efficacy'], 'percentage of participants achieving response': ['percentage of participants achieving response'], 'midazolam blood concentrations +/- brentuximab vedotin': ['midazolam blood concentrations +/- brentuximab vedotin'], 'brentuximab vedotin blood concentrations +/- rifampin': ['brentuximab vedotin blood concentrations +/- rifampin'], 'brentuximab vedotin in urine, feces, and blood': ['brentuximab vedotin in urine, feces, and blood'], 'brentuximab vedotin blood concentrations in special populations': ['brentuximab vedotin blood concentrations in special populations'], 'brentuximab vedotin blood concentrations +/- ketoconazole': ['brentuximab vedotin blood concentrations +/- ketoconazole'], 'maximum-tolerated dose of dinaciclib when given in combination with ofatumumab, defined as a dose level where at most one of 6 evaluable patients has a dose limiting toxicity': ['maximum-tolerated dose of dinaciclib when given in combination with ofatumumab, defined as a dose level where at most one of 6 evaluable patients has a dose limiting toxicity'], 'number of patients with dose-limiting toxicity incidents graded according to the nci ctcae v4.0': ['number of patients with dose-limiting toxicity incidents graded according to the nci ctcae v4.0'], 'percentage of patients who achieve an overall response, defined as achieving a complete response, an unconfirmed complete response , or a partial response': ['percentage of patients who achieve an overall response, defined as achieving a complete response, an unconfirmed complete response , or a partial response'], 'number of patients with changes in laboratory parameters from baseline': ['number of patients with changes in laboratory parameters from baseline'], 'number of patients with changes in vital signs from baseline': ['number of patients with changes in vital signs from baseline'], 'percentage of patients with changes in laboratory parameters from baseline': ['percentage of patients with changes in laboratory parameters from baseline'], 'medi7247 maximum observed concentration for pk': ['medi7247 maximum observed concentration for pk'], 'medi7247 area under the concentration-time curve for pk': ['medi7247 area under the concentration-time curve for pk'], 'medi7247 clearance for pk': ['medi7247 clearance for pk'], 'medi7247 terminal half-life for pk': ['medi7247 terminal half-life for pk'], 'to determine the safety profile': ['to determine the safety profile'], 'effect on pharmacodynamic biomarkers': ['effect on pharmacodynamic biomarkers'], 'phase 1: number of participants achieving clinical benefit': ['phase 1: number of participants achieving clinical benefit'], 'phase 1: area under the plasma concentration-time curve from 0 to 12 hours  of cerdulatinib': ['phase 1: area under the plasma concentration-time curve from 0 to 12 hours  of cerdulatinib'], 'phase 2a: number of participants achieving clinical benefit': ['phase 2a: number of participants achieving clinical benefit'], 'phase 2a: number of participants achieving dominant mass response': ['phase 2a: number of participants achieving dominant mass response'], 'best response to dose level 0': ['best response to dose level 0'], 'overall survival for all eligible patients': ['overall survival for all eligible patients'], 'progression-free survival for all eligible patients': ['progression-free survival for all eligible patients'], 'duration of response for all eligible patients': ['duration of response for all eligible patients'], 'time to treatment failure for all eligible patients': ['time to treatment failure for all eligible patients'], 'number of dose-limiting toxicity  events of ipilimumab plus a fixed dose of sd-101': ['number of dose-limiting toxicity  events of ipilimumab plus a fixed dose of sd-101'], 'anti-tumor responses to tancart19/20 cell infusions': ['anti-tumor responses to tancart19/20 cell infusions'], 'to determine the safety of pnt2258 in patients with advanced solid tumors': ['to determine the safety of pnt2258 in patients with advanced solid tumors'], 'pharmacokinetic profile of pnt2258': ['pharmacokinetic profile of pnt2258'], 'rate of toxicity in study participants receiving protocol therapy': ['rate of toxicity in study participants receiving protocol therapy'], 'rate of clinical response in study participants receiving protocol therapy': ['rate of clinical response in study participants receiving protocol therapy'], 'pharmacodynamics : expression levels of endoplasmic reticulum  stress response and unfolded protein response  in primary all cells to pevonedistat therapy': ['pharmacodynamics : expression levels of endoplasmic reticulum  stress response and unfolded protein response  in primary all cells to pevonedistat therapy'], 'maximum dose tolerated of mln 9708': ['maximum dose tolerated of mln 9708'], 'percentage of participants with disease free survival': ['percentage of participants with disease free survival'], 'rate of toxicity': ['rate of toxicity'], 'tumor response to treatment': ['tumor response to treatment'], 'number of participants overall response': ['number of participants overall response'], 'safety of the anti-cd74 antibody will be evaluated based upon physical examinations, hematology and chemistry laboratory evaluations and toxicity events': ['safety of the anti-cd74 antibody will be evaluated based upon physical examinations, hematology and chemistry laboratory evaluations and toxicity events'], 'efficacy  in patients with nhl and cll': ['efficacy  in patients with nhl and cll'], \"pharmacodynamics '\": [\"pharmacodynamics '\"], 'optimal dose': ['optimal dose'], 'to determine the dose limiting toxicities': ['to determine the dose limiting toxicities'], 'area under the concentration time curve of mk-8628/otx015 from time 0 to infinity': ['area under the concentration time curve of mk-8628/otx015 from time 0 to infinity'], 'changes in cd8 t cell receptor vbeta repertoire': ['changes in cd8 t cell receptor vbeta repertoire'], 'toxicities': ['toxicities'], 'days to engraftment of neutrophils': ['days to engraftment of neutrophils'], 'days to engraftment of platelets': ['days to engraftment of platelets'], 'days to engraftment of lymphocytes': ['days to engraftment of lymphocytes'], 'early treatment related mortality': ['early treatment related mortality'], 'percentage of participants with late treatment related mortality': ['percentage of participants with late treatment related mortality'], 'decline in homeostatic cytokine interleukin 7  post-transplant': ['decline in homeostatic cytokine interleukin 7  post-transplant'], 'to assess the safety and tolerability of sns-032': ['to assess the safety and tolerability of sns-032'], 'to characterize the pharmacokinetic profile of sns-032': ['to characterize the pharmacokinetic profile of sns-032'], 'identify a recommended phase 2 dose and schedule of administration': ['identify a recommended phase 2 dose and schedule of administration'], 'to determine the effect of rifampin on the pharmacokinetics of navitoclax.': ['to determine the effect of rifampin on the pharmacokinetics of navitoclax.'], 'to determine the safety of navitoclax when administered alone and in combination with rifampin in these patients.': ['to determine the safety of navitoclax when administered alone and in combination with rifampin in these patients.'], 'pharmacodynamics: % inhibition of glutaminase in blood': ['pharmacodynamics: % inhibition of glutaminase in blood'], 'clinical activity: change in tumor size from baseline': ['clinical activity: change in tumor size from baseline'], 'safety/tolerability': ['safety/tolerability'], 'metabolic profile in plasma at the maximum tolerated dose': ['metabolic profile in plasma at the maximum tolerated dose'], 'number of patients without gvhd at 100 days': ['number of patients without gvhd at 100 days'], 'safety and tolerability of sch 727965, including maximum administered dose and dose-limiting toxicity.': ['safety and tolerability of sch 727965, including maximum administered dose and dose-limiting toxicity.'], \"in participants with advanced solid tumors, non hodgkin's lymphoma or multiple myeloma, pharmacodynamic effects of sch 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.\": [\"in participants with advanced solid tumors, non hodgkin's lymphoma or multiple myeloma, pharmacodynamic effects of sch 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.\"], 'maximum tolerated dose  of subcutaneous recombinant human il-15': ['maximum tolerated dose  of subcutaneous recombinant human il-15'], 'number of participants with a clinical response': ['number of participants with a clinical response'], 'percentages of circulating lymphocytes  and the t-cell subsets': ['percentages of circulating lymphocytes  and the t-cell subsets'], 'plasma levels of pro-inflammatory cytokines': ['plasma levels of pro-inflammatory cytokines'], 'assess preliminary efficacy of bmn 673 by evaluating per response publications': ['assess preliminary efficacy of bmn 673 by evaluating per response publications'], 'food effect cohort assessments': ['food effect cohort assessments'], 'progression free survival rate at 24 months': ['progression free survival rate at 24 months'], 'rifampin cohort: ctrough of crizotinib alone and when taken with rifampin': ['rifampin cohort: ctrough of crizotinib alone and when taken with rifampin'], 'probability of participant survival at month 6': ['probability of participant survival at month 6'], 'probability of participant survival at month 12': ['probability of participant survival at month 12'], 'maximum tolerated dose of bendamustine': ['maximum tolerated dose of bendamustine'], 'evaluate non-dose limiting toxicity': ['evaluate non-dose limiting toxicity'], 'pk': ['pk'], 'anti-tumor effects': ['anti-tumor effects'], 'time of peak plasma concentration': ['time of peak plasma concentration'], 'time for half of the drug to be absent in blood stream following dose': ['time for half of the drug to be absent in blood stream following dose'], 'observe patients for any evidence of anti-leukemic or anti-myelodysplastic activity of ft-1101': ['observe patients for any evidence of anti-leukemic or anti-myelodysplastic activity of ft-1101'], 'efficacy-antitumor activity of urelumab in combination with rituximab as measured by best overall response, progression-free survival, time to response, and duration of response': ['efficacy-antitumor activity of urelumab in combination with rituximab as measured by best overall response, progression-free survival, time to response, and duration of response'], 'area under the serum concentration-time curve from time zero to time of last quantifiable concentration (auc) of urelumab': ['area under the serum concentration-time curve from time zero to time of last quantifiable concentration (auc) of urelumab'], 'car t cell persistence': ['car t cell persistence'], 'tumor load': ['tumor load'], \"duration of donor nk cells in the recipient's blood\": [\"duration of donor nk cells in the recipient's blood\"], 'patient survival at 100 days and at one year post treatment': ['patient survival at 100 days and at one year post treatment'], 'occurrence of new cancer during the first year post infusion of allogeneic nk-cells': ['occurrence of new cancer during the first year post infusion of allogeneic nk-cells'], 'documented systemic infections during the first 30 days post infusion of allogeneic nk-cells.': ['documented systemic infections during the first 30 days post infusion of allogeneic nk-cells.'], 'occurrence of other possible nk-infusions related complications such as,fever, capillary leak syndrome and/or allergic reaction.': ['occurrence of other possible nk-infusions related complications such as,fever, capillary leak syndrome and/or allergic reaction.'], 'percentage of participants experiencing acute gvhd': ['percentage of participants experiencing acute gvhd'], 'percentage of participants experiencing chronic gvhd': ['percentage of participants experiencing chronic gvhd'], 'disease relapse': ['disease relapse'], 'use of immunosuppression': ['use of immunosuppression'], 'chimerism': ['chimerism'], 'number of participants with a tumor response': ['number of participants with a tumor response'], 'to assess safety of parathyroid hormone in combination with g-csf when used as a mobilization agent at four different dosing levels.': ['to assess safety of parathyroid hormone in combination with g-csf when used as a mobilization agent at four different dosing levels.'], 'to evaluate the peripheral blood cd34+ count after second mobilization.': ['to evaluate the peripheral blood cd34+ count after second mobilization.'], 'to evaluate cd34+ cells/kg from apheresis after second mobilization.': ['to evaluate cd34+ cells/kg from apheresis after second mobilization.'], 'to evaluate the percent of patients for whom adequate numbers of cd34+ cells are obtained.': ['to evaluate the percent of patients for whom adequate numbers of cd34+ cells are obtained.'], 'to evaluate transfusion support.': ['to evaluate transfusion support.'], 'to evaluate the days to neutrophil engraftment  post autologous transplant.': ['to evaluate the days to neutrophil engraftment  post autologous transplant.'], 'to evaluate the days to platelet engraftment .': ['to evaluate the days to platelet engraftment .'], 'evaluate plasma pharmacokinetics and estimate renal elimination of oral administration of xl184': ['evaluate plasma pharmacokinetics and estimate renal elimination of oral administration of xl184'], 'long-term safety/tolerability of xl184 after oral administration for up to 1 year': ['long-term safety/tolerability of xl184 after oral administration for up to 1 year'], 'evaluate preliminary tumor response after repeated xl184 administration': ['evaluate preliminary tumor response after repeated xl184 administration'], 'in mtd expanded cohort: progression-free survival and duration of response in subjects with advanced or recurrent medullary thyroid cancer': ['in mtd expanded cohort: progression-free survival and duration of response in subjects with advanced or recurrent medullary thyroid cancer'], 'number of participants with clinical responses': ['number of participants with clinical responses'], 'to determine the maximum tolerated dose of fenretinide': ['to determine the maximum tolerated dose of fenretinide'], 'to describe the toxicities of fenretinide': ['to describe the toxicities of fenretinide'], 'auc during a dosing interval for rituximab': ['auc during a dosing interval for rituximab'], 'pk and pd parameters': ['pk and pd parameters'], 'part b, c, d, e and f: number of participants with tumor response': ['part b, c, d, e and f: number of participants with tumor response'], 'part a: number of participants with tumor response': ['part a: number of participants with tumor response'], 'best clinical response to treatment': ['best clinical response to treatment'], 'to characterize the pk profile of 3 daily intravenous  doses of rhukgf before total body irradiation  / high-dose chemotherapy conditioning treatment and after pbpc transplantation': ['to characterize the pk profile of 3 daily intravenous  doses of rhukgf before total body irradiation  / high-dose chemotherapy conditioning treatment and after pbpc transplantation'], 'to assess the safety and tolerability of rhukgf in subjects with hematologic malignancies undergoing tbi and high-dose chemotherapy followed by pbpc transplantation.': ['to assess the safety and tolerability of rhukgf in subjects with hematologic malignancies undergoing tbi and high-dose chemotherapy followed by pbpc transplantation.'], 'to assess oral mucositis in subjects receiving rhukgf.': ['to assess oral mucositis in subjects receiving rhukgf.'], 'to determine safety, tolerability, and maximum tolerated dose of ap23573 when administered once daily for 5 days on a every 2 week schedule': ['to determine safety, tolerability, and maximum tolerated dose of ap23573 when administered once daily for 5 days on a every 2 week schedule'], 'area under the curve  of ridaforolimus': ['area under the curve  of ridaforolimus'], 'phosphorylated 4e binding protein 1  blood levels': ['phosphorylated 4e binding protein 1  blood levels'], 'to determine if there is significant toxicity associated with the administration of cd34-tk75 transduced donor lymphocytes after allogeneic bmt for relapsed hematologic malignancies': ['to determine if there is significant toxicity associated with the administration of cd34-tk75 transduced donor lymphocytes after allogeneic bmt for relapsed hematologic malignancies'], 'perform pet imaging to allow us to locate the donor t cells within the recipient as they exert anti-leukemic effects, and the t cells can then be eliminated in response to administration of ganciclovir, before morbidity and mortality from gvhd occurs': ['perform pet imaging to allow us to locate the donor t cells within the recipient as they exert anti-leukemic effects, and the t cells can then be eliminated in response to administration of ganciclovir, before morbidity and mortality from gvhd occurs'], 'to determine if the patient develops any evidence of anti-leukemic effect from the administration of cd34-tk75 transduced donor lymphocytes': ['to determine if the patient develops any evidence of anti-leukemic effect from the administration of cd34-tk75 transduced donor lymphocytes'], 'to determine if gcv administration to patients who develop gvhd results in clinical improvement after infusions of cd34-tk75 transduced lymphocytes.': ['to determine if gcv administration to patients who develop gvhd results in clinical improvement after infusions of cd34-tk75 transduced lymphocytes.'], 'safety and feasibility of donor cord blood transplant': ['safety and feasibility of donor cord blood transplant'], 'determine the safety and feasibility of performing donor umbilical cord blood transplantation  in patients with advanced hematologic malignancies': ['determine the safety and feasibility of performing donor umbilical cord blood transplantation  in patients with advanced hematologic malignancies'], 'determine if there are any dose limiting toxicities to this therapy, as well as the maximum tolerated dose.': ['determine if there are any dose limiting toxicities to this therapy, as well as the maximum tolerated dose.'], 'document any preliminary efficacy information from the nk-92 cell infusion.': ['document any preliminary efficacy information from the nk-92 cell infusion.'], 'assess any immune response directed against the infused nk-92 cells.': ['assess any immune response directed against the infused nk-92 cells.'], 'determine kinetics of infused nk92 cells.': ['determine kinetics of infused nk92 cells.'], 'number of participants with engraftment within 42 days': ['number of participants with engraftment within 42 days'], 'mean time to engraftment': ['mean time to engraftment'], 'occurrence of local skin reactions considered related to the vaccination': ['occurrence of local skin reactions considered related to the vaccination'], 'occurrence of drug-related systemic reactions': ['occurrence of drug-related systemic reactions'], 'demonstration by elispot assays of the frequency of t-lymphocytes recognizing major histocompatibility complex  class i and ii-restricted epitopes within ebna1 and lmp2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...': ['demonstration by elispot assays of the frequency of t-lymphocytes recognizing major histocompatibility complex  class i and ii-restricted epitopes within ebna1 and lmp2 in peripheral blood at sequential time-points before, during, and up to 9 mo ...'], 'measurement of ebv-genome levels in plasma': ['measurement of ebv-genome levels in plasma'], 'safety of ionis-stat3rx in patients with advanced cancers': ['safety of ionis-stat3rx in patients with advanced cancers'], 'clinical activity of ionis-stat3rx': ['clinical activity of ionis-stat3rx'], 'pharmacokinetics-cmax': ['pharmacokinetics-cmax'], 'stat3 and other biomarkers': ['stat3 and other biomarkers'], 'clinically significant or > or = to grade 3 ctcae changes in safety laboratory tests, physical exams, ecgs or vital signs': ['clinically significant or > or = to grade 3 ctcae changes in safety laboratory tests, physical exams, ecgs or vital signs'], 'pk parameters': ['pk parameters'], 'clinical/radiological response rate for cll subjects': ['clinical/radiological response rate for cll subjects'], 'phospho-akt level in circulating cll cells': ['phospho-akt level in circulating cll cells'], 'number of patients with clinical/radiological response': ['number of patients with clinical/radiological response'], 'levels of anti-cd27 antibodies in circulating blood.': ['levels of anti-cd27 antibodies in circulating blood.'], 'levels of cdx-1127 in circulating blood.': ['levels of cdx-1127 in circulating blood.'], 'activity evaluations': ['activity evaluations'], 'immune system effects': ['immune system effects'], 'to determine the recommended phase ii dose and schedule of gsk214179 using the following information: safety and tolerability, pharmacokinetic  and pharmacodynamic data': ['to determine the recommended phase ii dose and schedule of gsk214179 using the following information: safety and tolerability, pharmacokinetic  and pharmacodynamic data'], '• to explore the clinical efficacy of gsk2141795 in subjects with solid tumor malignancies or lymphomas': ['• to explore the clinical efficacy of gsk2141795 in subjects with solid tumor malignancies or lymphomas'], 'to characterize the metabolite profile of oral gsk2141795 after repeat dose administration in subjects with solid tumor malignancies or lymphoma': ['to characterize the metabolite profile of oral gsk2141795 after repeat dose administration in subjects with solid tumor malignancies or lymphoma'], 'blood serum levels of α-tea': ['blood serum levels of α-tea'], 'change from baseline local immune effects after repeated t-vec injections': ['change from baseline local immune effects after repeated t-vec injections'], 'detection of tumor regression using world health organization  response criteria': ['detection of tumor regression using world health organization  response criteria'], 'systemic immune response': ['systemic immune response'], 'to evaluate the safety of cal-101 and determine the dose limiting toxicity in patients with hematologic malignancies.': ['to evaluate the safety of cal-101 and determine the dose limiting toxicity in patients with hematologic malignancies.'], 'to evaluate the pharmacokinetic parameters, pharmacodynamic effects and clinical response rate following cal-101 treatment in patients with hematologic malignancies.': ['to evaluate the pharmacokinetic parameters, pharmacodynamic effects and clinical response rate following cal-101 treatment in patients with hematologic malignancies.'], \"best overall response rate based on investigator's assessment\": [\"best overall response rate based on investigator's assessment\"], 'number of participants with polymorphisms in gene encoding enzyme ugt1a1': ['number of participants with polymorphisms in gene encoding enzyme ugt1a1'], 'number of participants with polymorphisms in aurora a kinase': ['number of participants with polymorphisms in aurora a kinase'], 'area under the plasma concentration-time curve from time 0 to 8 hours post-dose': ['area under the plasma concentration-time curve from time 0 to 8 hours post-dose'], 'area under the plasma concentration-time curve from time zero to the last quantifiable time point': ['area under the plasma concentration-time curve from time zero to the last quantifiable time point'], 'area under the plasma concentration-time curve from time zero to infinity': ['area under the plasma concentration-time curve from time zero to infinity'], 'area under the plasma concentration-time curve from time 0 to 8 hours post-dose after single and multiple doses of azacitidine': ['area under the plasma concentration-time curve from time 0 to 8 hours post-dose after single and multiple doses of azacitidine'], 'area under the plasma concentration-time curve from time 0 to the last quantifiable time point after single and multiple doses of azacitidine': ['area under the plasma concentration-time curve from time 0 to the last quantifiable time point after single and multiple doses of azacitidine'], 'area under the plasma concentration-time curve from time 0 to infinity after single and multiple doses of azacitidine': ['area under the plasma concentration-time curve from time 0 to infinity after single and multiple doses of azacitidine'], 'dose limiting toxicity assessment at the end of the first 28 day cycle.': ['dose limiting toxicity assessment at the end of the first 28 day cycle.'], 'measure: adverse event assessed through 30 days after last dose of study drug measure: tumor response measure: pharmacokinetic/pharmacodynamic assessments': ['measure: adverse event assessed through 30 days after last dose of study drug measure: tumor response measure: pharmacokinetic/pharmacodynamic assessments'], 'patients with dose limiting toxicities after t-cell infusions': ['patients with dose limiting toxicities after t-cell infusions'], 'safety and response to a repeated dosage regimen': ['safety and response to a repeated dosage regimen'], 'analysis of immune function of ctls': ['analysis of immune function of ctls'], 'number of patients with an ebv and/or disease response to the ctls': ['number of patients with an ebv and/or disease response to the ctls'], 'dose-limiting toxicity and maximum tolerated dose': ['dose-limiting toxicity and maximum tolerated dose'], 'number of t-all/lbl participants with first-cycle dlt': ['number of t-all/lbl participants with first-cycle dlt'], 'number of participants with laboratory tests abnormalities meeting the criteria of potential clinical concern': ['number of participants with laboratory tests abnormalities meeting the criteria of potential clinical concern'], 'cmax after multiple dose on cycle 1 day 21': ['cmax after multiple dose on cycle 1 day 21'], 'auctau after multiple dose on cycle 1 day 21': ['auctau after multiple dose on cycle 1 day 21'], 'average serum concentration  at steady state on cycle 1 day 21': ['average serum concentration  at steady state on cycle 1 day 21'], 'auctau in the fasted state for solid tumor participants': ['auctau in the fasted state for solid tumor participants'], 'auctau in the fed state for solid tumor participants': ['auctau in the fed state for solid tumor participants'], 'cmax in the fasted state for solid tumor participants': ['cmax in the fasted state for solid tumor participants'], 'cmax in the fed state for solid tumor participants': ['cmax in the fed state for solid tumor participants'], 'auctau on cycle 2 day 1': ['auctau on cycle 2 day 1'], 'cmax on cycle 2 day 1': ['cmax on cycle 2 day 1'], 'tmax on cycle 2 day 1': ['tmax on cycle 2 day 1'], 'duration of response  for solid tumor participants': ['duration of response  for solid tumor participants'], 'percentage of t-all/lbl participants with or': ['percentage of t-all/lbl participants with or'], 'peripheral blast count reduction  for t-all/lbl participants': ['peripheral blast count reduction  for t-all/lbl participants'], 'changes in expression levels of notch 1 target genes in tumor biopsies for solid tumor participants: hairy and enhancer of split-4  gene expression levels on cycle 1 day 21 relative to that at baseline': ['changes in expression levels of notch 1 target genes in tumor biopsies for solid tumor participants: hairy and enhancer of split-4  gene expression levels on cycle 1 day 21 relative to that at baseline'], 'changes from baseline in expression levels of notch 1 target genes in peripheral blood for t-all/lbl participants: hes4 gene expression levels on cycle 1 day 8, cycle 1 day 15, cycle 1 day 21 relative to that at baseline': ['changes from baseline in expression levels of notch 1 target genes in peripheral blood for t-all/lbl participants: hes4 gene expression levels on cycle 1 day 8, cycle 1 day 15, cycle 1 day 21 relative to that at baseline'], 'changes in expression levels of notch 1 target genes in peripheral blood for solid tumor participants: hes4 gene expression level on cycle 1 day 8 and cycle 1 day 21 relative to that at baseline': ['changes in expression levels of notch 1 target genes in peripheral blood for solid tumor participants: hes4 gene expression level on cycle 1 day 8 and cycle 1 day 21 relative to that at baseline'], 'number of infusion reaction': ['number of infusion reaction'], 'number of graft failure': ['number of graft failure'], 'time to platelets engraftment': ['time to platelets engraftment'], 'number of disease free survivals': ['number of disease free survivals'], 'number of participants at risk of gvhd': ['number of participants at risk of gvhd'], 'number of infectious complications': ['number of infectious complications'], 'time to myeloid engraftment': ['time to myeloid engraftment'], 'time to lymphoid engraftment': ['time to lymphoid engraftment'], 'change in t cell count': ['change in t cell count'], 'pharmacokinetic profiles of parent drug and metabolite': ['pharmacokinetic profiles of parent drug and metabolite'], 'to determine the dose-limiting toxicity and maximum tolerated dose of plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure.': ['to determine the dose-limiting toxicity and maximum tolerated dose of plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure.'], 'receptor occupancy  of ak117 as monotherapy or in combination with ak104 to evaluate target engagement': ['receptor occupancy  of ak117 as monotherapy or in combination with ak104 to evaluate target engagement'], 'safety and tolerability of hsc835 for clinical use were measured by infusional toxicity  and absence of graft failure after 32 days in excess of that currently observed with ucbt.': ['safety and tolerability of hsc835 for clinical use were measured by infusional toxicity  and absence of graft failure after 32 days in excess of that currently observed with ucbt.'], 'incidence of neutrophil recovery within 42 days': ['incidence of neutrophil recovery within 42 days'], 'incidence of platelet recovery within six months': ['incidence of platelet recovery within six months'], 'frequency of expanded unit predominance at day 100': ['frequency of expanded unit predominance at day 100'], 'incidence of relapse within one year': ['incidence of relapse within one year'], 'number of participants dlt in arm 1 in dose escalation phase': ['number of participants dlt in arm 1 in dose escalation phase'], 'number of participants dlt in arm 2 in dose escalation phase': ['number of participants dlt in arm 2 in dose escalation phase'], \"response as per investigator assessment for patients with hodgkin's lymphoma\": [\"response as per investigator assessment for patients with hodgkin's lymphoma\"], 'maximum plasma concentration of panobinostat after the first dose in arms 1 and 2': ['maximum plasma concentration of panobinostat after the first dose in arms 1 and 2'], 'half life of panobinostat after the first dose in arms 1 and 2': ['half life of panobinostat after the first dose in arms 1 and 2'], 'maximum plasma concentration of panobinostat after multiple doses in arm 1 on day 15': ['maximum plasma concentration of panobinostat after multiple doses in arm 1 on day 15'], 'half life of panobinostat after multiple doses in arm 1 on day 15': ['half life of panobinostat after multiple doses in arm 1 on day 15'], 'geometric mean ratio  comparing treatment days in arm 1': ['geometric mean ratio  comparing treatment days in arm 1'], 'mtd of inotuzumab ozogamicin with cvp for patients with relapsed or refractory cd22+ acute leukemia': ['mtd of inotuzumab ozogamicin with cvp for patients with relapsed or refractory cd22+ acute leukemia'], 'response rate  among expansion cohort': ['response rate  among expansion cohort'], 'frequency and severity of toxicities': ['frequency and severity of toxicities'], 'maximal tolerated dose  of sar260301 in monotherapy': ['maximal tolerated dose  of sar260301 in monotherapy'], 'maximal tolerated dose  of sar260301 in combination with vemurafenib': ['maximal tolerated dose  of sar260301 in combination with vemurafenib'], 'number of patients with treatment emergent events': ['number of patients with treatment emergent events'], 'assessment of pk parameters for sar260301 and vemurafenib, including tmax, cmax, auc, rac , half-life, cl, ctrough': ['assessment of pk parameters for sar260301 and vemurafenib, including tmax, cmax, auc, rac , half-life, cl, ctrough'], 'assessment of pk parameters for sar260301 including tmax, cmax, auc fasting and fed': ['assessment of pk parameters for sar260301 including tmax, cmax, auc fasting and fed'], 'assessment of pk parameter rac  on auc and cmax': ['assessment of pk parameter rac  on auc and cmax'], 'assessment of pd parameter serine/threonine protein kinase akt  phosphorylation in blood platelets': ['assessment of pd parameter serine/threonine protein kinase akt  phosphorylation in blood platelets'], 'assessment of pd parameter akt phosphorylation in tumor': ['assessment of pd parameter akt phosphorylation in tumor'], 'assessment of preliminary antitumor activity as documented by tumor response (defined by recist1.1 criteria for solid tumors, international working group  and revised response for lymphomas, and tumor markers when relevant)': ['assessment of preliminary antitumor activity as documented by tumor response (defined by recist1.1 criteria for solid tumors, international working group  and revised response for lymphomas, and tumor markers when relevant)'], 'examination of potential food-effect on pharmacokinetics of ro5045337': ['examination of potential food-effect on pharmacokinetics of ro5045337'], 'evaluation of relative bioavailability of ro5045337': ['evaluation of relative bioavailability of ro5045337'], 'evaluation of safety and tolerability of ro5045337': ['evaluation of safety and tolerability of ro5045337'], 'evaluation of pharmacodynamics and biomarkers': ['evaluation of pharmacodynamics and biomarkers'], 'maximum tolerated dose/dose-limiting toxicities': ['maximum tolerated dose/dose-limiting toxicities'], 'pharmacokinetics: blood/urine concentrations': ['pharmacokinetics: blood/urine concentrations'], 'pharmacodynamics: blood leukemia cells/mic-1 protein level/cd33+cd34 markers': ['pharmacodynamics: blood leukemia cells/mic-1 protein level/cd33+cd34 markers'], 'clinical response: clinical/hematologic malignancy assessments': ['clinical response: clinical/hematologic malignancy assessments'], 'to determine the optimal regimen of post-graft immunosuppression with high-dose cy following fludarabine, busulfan, and transplantation of fully hla-matched bone marrow that leads to an acceptable incidence of grades iii/iv acute gvhd': ['to determine the optimal regimen of post-graft immunosuppression with high-dose cy following fludarabine, busulfan, and transplantation of fully hla-matched bone marrow that leads to an acceptable incidence of grades iii/iv acute gvhd'], 'cd34+ cells': ['cd34+ cells'], 'primary and secondary graft failure': ['primary and secondary graft failure'], 'acute and chronic gvhd': ['acute and chronic gvhd'], 'tcr alfa beta cells': ['tcr alfa beta cells'], 'safety and tolerability of cdx-1140 as assessed by ctcae v5.0': ['safety and tolerability of cdx-1140 as assessed by ctcae v5.0'], 'immunogenicity evaluation': ['immunogenicity evaluation'], 'pharmacokinetic evaluation': ['pharmacokinetic evaluation'], 'determination of toxicity related to allostim infusion in accordance with nci common toxicity criteria v.3': ['determination of toxicity related to allostim infusion in accordance with nci common toxicity criteria v.3'], 'evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated': ['evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated'], 'immunological response': ['immunological response'], 'number of patients with detectable treg cells': ['number of patients with detectable treg cells'], 'number of patients with sustained donor engraftment': ['number of patients with sustained donor engraftment'], 'number of patients with double chimerism': ['number of patients with double chimerism'], 'number of patients with disease-free survival': ['number of patients with disease-free survival'], 'number of patients with fungal and viral infections': ['number of patients with fungal and viral infections'], 'number of patients with disease relapse': ['number of patients with disease relapse'], 'percent of patients with immune cell recovery': ['percent of patients with immune cell recovery'], 'maximum tolerated dose, assessed according to nci ctcae v4.0': ['maximum tolerated dose, assessed according to nci ctcae v4.0'], 'phase 1 study: maximum tolerable dose of chidamide among participants': ['phase 1 study: maximum tolerable dose of chidamide among participants'], 'phase 2 safety management study': ['phase 2 safety management study'], 'efficacy of sintilimab plus chidamide in refractory and relapsed enktcl': ['efficacy of sintilimab plus chidamide in refractory and relapsed enktcl'], 'number of participants who experience dose limiting toxicity as defined in the protocol.': ['number of participants who experience dose limiting toxicity as defined in the protocol.'], 'incidence of primary graft failure': ['incidence of primary graft failure'], 'incidence of hyperacute gvhd': ['incidence of hyperacute gvhd'], 'incidence of grade d acute gvhd': ['incidence of grade d acute gvhd'], 'to describe the adverse event profile and tolerability of prt543': ['to describe the adverse event profile and tolerability of prt543'], 'neutrophil engraftment/chimerism': ['neutrophil engraftment/chimerism'], 'immune reconstitution': ['immune reconstitution'], 'donor search': ['donor search'], 'to determine the tolerance and toxicity profile': ['to determine the tolerance and toxicity profile'], 'evaluate immunomodulatory activity.': ['evaluate immunomodulatory activity.'], 'quantify antitumor effects': ['quantify antitumor effects'], 'neutrophil and platelet recovery': ['neutrophil and platelet recovery'], 'persistence of clt-008 derived cells': ['persistence of clt-008 derived cells'], 'infections': ['infections'], 'extent, degree, and duration of donor chimerism': ['extent, degree, and duration of donor chimerism'], 'confirmed complete or partial response': ['confirmed complete or partial response'], 'percentage of patients with 6-month progression-free survival': ['percentage of patients with 6-month progression-free survival'], 'regimen related toxicities': ['regimen related toxicities'], 'one-year overall survival rate for aml': ['one-year overall survival rate for aml'], 'two-year overall survival for all cases.': ['two-year overall survival for all cases.'], 'five year overall survival for all cases': ['five year overall survival for all cases'], 'maximum observed plasma concentration of azd4573': ['maximum observed plasma concentration of azd4573'], 'area under the concentration-time curve for plasma concentrations of azd4573': ['area under the concentration-time curve for plasma concentrations of azd4573'], 'percentage of participants with objective response according to recist v1.1 by investigator: phase i': ['percentage of participants with objective response according to recist v1.1 by investigator: phase i'], 'percentage of participants with objective response according to recist v1.1 by investigator: phase ii': ['percentage of participants with objective response according to recist v1.1 by investigator: phase ii'], 'percentage of participants with disease control according to recist v1.1 by investigator: phase ii': ['percentage of participants with disease control according to recist v1.1 by investigator: phase ii'], 'percentage of participants with disease progression according to recist v1.1 by irc or death : phase ii': ['percentage of participants with disease progression according to recist v1.1 by irc or death : phase ii'], 'percentage of participants with disease progression according to recist v1.1 by investigator or death : phase ii': ['percentage of participants with disease progression according to recist v1.1 by investigator or death : phase ii'], 'pfs according to recist v1.1 by investigator: phase ii': ['pfs according to recist v1.1 by investigator: phase ii'], 'percentage of participants who died due to any cause: phase ii': ['percentage of participants who died due to any cause: phase ii'], 'dor according to recist v1.1 by irc: phase ii': ['dor according to recist v1.1 by irc: phase ii'], 'dor according to recist v1.1 by investigator: phase ii': ['dor according to recist v1.1 by investigator: phase ii'], 'percentage of participants with central nervous system objective response  according to recist v1.1 by irc: phase ii': ['percentage of participants with central nervous system objective response  according to recist v1.1 by irc: phase ii'], 'cns duration of response  according to recist v1.1 by irc: phase ii': ['cns duration of response  according to recist v1.1 by irc: phase ii'], 'cdor according to rano criteria by irc: phase ii': ['cdor according to rano criteria by irc: phase ii'], 'percentage of participants with cns progression according to recist v1.1 by irc: phase ii': ['percentage of participants with cns progression according to recist v1.1 by irc: phase ii'], 'percentage of participants with cns progression according to rano criteria by irc: phase ii': ['percentage of participants with cns progression according to rano criteria by irc: phase ii'], 'cmax after multiple dose of alectinib: phase i': ['cmax after multiple dose of alectinib: phase i'], 'ctrough after multiple dose of alectinib: phase ii': ['ctrough after multiple dose of alectinib: phase ii'], 'change from baseline in european organization for research and treatment of cancer  quality of life questionnaire : phase ii': ['change from baseline in european organization for research and treatment of cancer  quality of life questionnaire : phase ii'], 'change from baseline in eortc quality of life questionnaire lung cancer 13 : phase ii': ['change from baseline in eortc quality of life questionnaire lung cancer 13 : phase ii'], 'percentage of participants achieving objective response  as assessed by independent radiological review committee  in response evaluable  population': ['percentage of participants achieving objective response  as assessed by independent radiological review committee  in response evaluable  population'], 'percentage of participants with pd as assessed by irc according to recist v1.1 or death from any cause in safety population': ['percentage of participants with pd as assessed by irc according to recist v1.1 or death from any cause in safety population'], 'percentage of participants who died of any cause': ['percentage of participants who died of any cause'], 'percentage of participants achieving central nervous system  objective response as assessed by irc according to recist v1.1': ['percentage of participants achieving central nervous system  objective response as assessed by irc according to recist v1.1'], 'cns duration of response  as assessed by irc according to recist v1.1': ['cns duration of response  as assessed by irc according to recist v1.1'], 'cdor as assessed by irc according to rano criteria': ['cdor as assessed by irc according to rano criteria'], 'percentage of participants with cns progression as assessed by irc according to recist v 1.1': ['percentage of participants with cns progression as assessed by irc according to recist v 1.1'], 'area under the plasma concentration-time curve from time 0 to 10 hours post-dose  of alectinib': ['area under the plasma concentration-time curve from time 0 to 10 hours post-dose  of alectinib'], 'area under the plasma concentration-time curve from time 0 to tlast  of alectinib': ['area under the plasma concentration-time curve from time 0 to tlast  of alectinib'], 'cmax of alectinib metabolite': ['cmax of alectinib metabolite'], 'tmax of alectinib metabolite': ['tmax of alectinib metabolite'], 'tlast of alectinib metabolite': ['tlast of alectinib metabolite'], 'ctrough of alectinib metabolite': ['ctrough of alectinib metabolite'], 'peak to trough ratio of alectinib': ['peak to trough ratio of alectinib'], 'accumulation ratio of alectinib': ['accumulation ratio of alectinib'], 'accumulation ratio of alectinib metabolite': ['accumulation ratio of alectinib metabolite'], 'bioequivalence': ['bioequivalence'], 'change in leukemia cell death': ['change in leukemia cell death'], 'percentage of recently born leukemia cells mobilized into the blood by pci-32765 treatment': ['percentage of recently born leukemia cells mobilized into the blood by pci-32765 treatment'], 'phase 2a: assessment of preliminary efficacy signals including biomarker assessment - continuous dosing.': ['phase 2a: assessment of preliminary efficacy signals including biomarker assessment - continuous dosing.'], 'extension study: continued assessment of the safety profile of abt-263': ['extension study: continued assessment of the safety profile of abt-263'], 'extension study: continued assessment of the preliminary efficacy signals of abt-263.': ['extension study: continued assessment of the preliminary efficacy signals of abt-263.'], 'phase 1a or phase 1b safety assessment': ['phase 1a or phase 1b safety assessment'], 'phase 1a, phase 1b, or phase 2a pharmacokinetic profile evaluation': ['phase 1a, phase 1b, or phase 2a pharmacokinetic profile evaluation'], 'phase 1a effect of food on bioavailability': ['phase 1a effect of food on bioavailability'], 'to evaluate the days to neutrophil engraftment .': ['to evaluate the days to neutrophil engraftment .'], 'to evaluate the days of platelet engraftment .': ['to evaluate the days of platelet engraftment .'], 'to evaluate the risk of acute and chronic graft versus host disease.': ['to evaluate the risk of acute and chronic graft versus host disease.'], 'to evaluate percent donor chimerism - contribution of each cord unit.': ['to evaluate percent donor chimerism - contribution of each cord unit.'], 'to evaluate relapse rate.': ['to evaluate relapse rate.'], 'to evaluate transfusion support needed to cord blood transplant recipients.': ['to evaluate transfusion support needed to cord blood transplant recipients.'], 'incidence of chronic gvhd': ['incidence of chronic gvhd'], 'mtd of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies': ['mtd of methoxyamine given in conjunction with fludarabine in subjects with relapsed or refractory hematologic malignancies'], 'pharmacokinetics of methoxyamine when given in combination with fludarabine as determined by methoxyamine levels at different time points.': ['pharmacokinetics of methoxyamine when given in combination with fludarabine as determined by methoxyamine levels at different time points.'], 'number of apurinic/pyrimidinic  sites.': ['number of apurinic/pyrimidinic  sites.'], 'change in mirna profiles in cll cells in a cohort of cll patients': ['change in mirna profiles in cll cells in a cohort of cll patients'], 'number of dna strand breaks determination by comet assay to monitor drug effects on dna damage in clinical studies.': ['number of dna strand breaks determination by comet assay to monitor drug effects on dna damage in clinical studies.'], 'measure of proteins': ['measure of proteins'], 'single-dose and steady-state cmax': ['single-dose and steady-state cmax'], 'single-dose and steady-state auc': ['single-dose and steady-state auc'], 'acute gvhd': ['acute gvhd'], 'chronic graft-versus-host disease': ['chronic graft-versus-host disease'], 'relapse of malignancy': ['relapse of malignancy'], 'neutrophil recovery': ['neutrophil recovery'], 'primary graft failure': ['primary graft failure'], 'secondary graft failure': ['secondary graft failure'], 'platelet recovery': ['platelet recovery'], 'donor cell engraftment': ['donor cell engraftment'], 'defervescence': ['defervescence'], 'clinical success or failure': ['clinical success or failure'], 'need for additional antimicrobials': ['need for additional antimicrobials'], 'mortality': ['mortality'], 'time to defervescence': ['time to defervescence'], 'hospital length of stay': ['hospital length of stay'], 'successful treatment of baseline infection': ['successful treatment of baseline infection'], 'occurrence  of dose-limiting toxicities': ['occurrence  of dose-limiting toxicities'], 'incidence of gvhd': ['incidence of gvhd'], 'disease response as assessed by complete remission, partial remission, stable disease, and progressive disease from radiographic and cellular or tissue samples': ['disease response as assessed by complete remission, partial remission, stable disease, and progressive disease from radiographic and cellular or tissue samples'], 'incidence of donor-specific chimerism assessed by str analysis': ['incidence of donor-specific chimerism assessed by str analysis'], 'to evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma.': ['to evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma.'], 'to evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.': ['to evaluate whether recombinant human thrombopoietin will reduce the time necessary for platelet counts to recover following chemotherapy.'], 'pharmacodynamic evaluations': ['pharmacodynamic evaluations'], 'mtd, defined as the highest dose level below the maximally administered dose at which no more than 1 out of 6 patients experience dlt graded according to nci ctcae version 4.0': ['mtd, defined as the highest dose level below the maximally administered dose at which no more than 1 out of 6 patients experience dlt graded according to nci ctcae version 4.0'], 'pharmacokinetics of at-101': ['pharmacokinetics of at-101'], 'pharmacokinetics of paclitaxel': ['pharmacokinetics of paclitaxel'], 'to determine the maximally tolerated dose  and/or optimal biological dose': ['to determine the maximally tolerated dose  and/or optimal biological dose'], 'to describe the adverse event profile and tolerability of prt1419': ['to describe the adverse event profile and tolerability of prt1419'], 'to describe the pharmacokinetic profile of prt1419': ['to describe the pharmacokinetic profile of prt1419'], 'to describe any anti-tumor activity of prt1419': ['to describe any anti-tumor activity of prt1419'], 'incidence of infectious episodes': ['incidence of infectious episodes'], 'safety and tolerability as monotherapy': ['safety and tolerability as monotherapy'], 'efficacy- including best overall response  derived from changes in tumor burden and metabolic response based on fdg-pet': ['efficacy- including best overall response  derived from changes in tumor burden and metabolic response based on fdg-pet'], 'exploratory biomarkers- are detection of apoptosis, cytokine analyses, cxcr4 expression, zap-70 and cd38 expression': ['exploratory biomarkers- are detection of apoptosis, cytokine analyses, cxcr4 expression, zap-70 and cd38 expression'], 'event-free survival by disease assessment': ['event-free survival by disease assessment'], 'number of participants with relapsed disease': ['number of participants with relapsed disease'], 'number of participants with grades iii-iv acute gvhd': ['number of participants with grades iii-iv acute gvhd'], 'number of non-relapse participant mortalities': ['number of non-relapse participant mortalities'], 'number of participants who experienced graft failure': ['number of participants who experienced graft failure'], 'number of subjects surviving post-transplant.': ['number of subjects surviving post-transplant.'], 'number of participants who experienced chronic extensive gvhd': ['number of participants who experienced chronic extensive gvhd'], 'cmax of incagn02385': ['cmax of incagn02385'], 'tmax of incagn02385': ['tmax of incagn02385'], 'cmin of incagn02385': ['cmin of incagn02385'], 'auc0-t of incagn02385': ['auc0-t of incagn02385'], 'dor in participants with dlbcl': ['dor in participants with dlbcl'], 'pfs in participants with dlbcl': ['pfs in participants with dlbcl'], 'disease free survival at 2 years': ['disease free survival at 2 years'], 'disease progression': ['disease progression'], 'incidence of acute gvhd': ['incidence of acute gvhd'], 'median time to anc>500/mm3': ['median time to anc>500/mm3'], 'median time to platelets>20k/mm3': ['median time to platelets>20k/mm3'], 'severity of acute gvhd': ['severity of acute gvhd'], 'severity of chronic gvhd': ['severity of chronic gvhd'], 'can il-2 be administered with gm-csf to efficiently mobilize autologous peripheral blood stem cells. this study will determine the maximum tolerated dose of il-2 and the optimal biological dose with gm-csf for stem cell mobilization.': ['can il-2 be administered with gm-csf to efficiently mobilize autologous peripheral blood stem cells. this study will determine the maximum tolerated dose of il-2 and the optimal biological dose with gm-csf for stem cell mobilization.'], 'will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and apbsct.': ['will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and apbsct.'], 'safety and toxicity assessment of study treatment': ['safety and toxicity assessment of study treatment'], 'feasibility assessment of study treatment': ['feasibility assessment of study treatment'], 'anti-tumor efficacy and duration of persistence, migration, and function of adoptively transferred bi-specific effector cells': ['anti-tumor efficacy and duration of persistence, migration, and function of adoptively transferred bi-specific effector cells'], 'to determine the maximum tolerated dose of expanded nk cells in research participants with relapsed or refractory hematologic malignancies and sarcomas.': ['to determine the maximum tolerated dose of expanded nk cells in research participants with relapsed or refractory hematologic malignancies and sarcomas.'], 'three-year relapse-free survival  rate at the maximum tolerated dose identified during phase i of the trial': ['three-year relapse-free survival  rate at the maximum tolerated dose identified during phase i of the trial'], 'capacity of test dosing of busulfan that would result in the desired area under the curve concentration exposure of patients receiving a full-dose busulfan regimen': ['capacity of test dosing of busulfan that would result in the desired area under the curve concentration exposure of patients receiving a full-dose busulfan regimen'], 'incidence of graft vs host disease in patients between one month and two years post transplant': ['incidence of graft vs host disease in patients between one month and two years post transplant'], 'incidence of dna chimerism in patients between one month post transplant': ['incidence of dna chimerism in patients between one month post transplant'], 'mtd of ex vivo expanded non-hla matched donor nk cells in combination with alt-803': ['mtd of ex vivo expanded non-hla matched donor nk cells in combination with alt-803'], 'number of patients with hematological response': ['number of patients with hematological response'], 'patients response for radiographically measurable lesions': ['patients response for radiographically measurable lesions'], 'patients with malignant lymphoma response': ['patients with malignant lymphoma response'], \"patients response for waldenstrom's macroglobulinemia\": [\"patients response for waldenstrom's macroglobulinemia\"], 'patients response for cutaneous lymphomas': ['patients response for cutaneous lymphomas'], 'patients response for multiple myeloma': ['patients response for multiple myeloma'], 'patients response for chronic myeloid leukemia': ['patients response for chronic myeloid leukemia'], 'patients response for metastatic colon/rectal carcinoma and soft tissue sarcomas': ['patients response for metastatic colon/rectal carcinoma and soft tissue sarcomas'], 'average duration of response': ['average duration of response'], 'average duration of overall survival': ['average duration of overall survival'], 'average duration of relapse free survival': ['average duration of relapse free survival'], 'maximum tolerated dose of targeted marrow irradiation defined as the dose level immediately below that in which greater than or equal to 2/6 subjects experience a dose limiting toxicity assessed using nci ctcae version 4.0': ['maximum tolerated dose of targeted marrow irradiation defined as the dose level immediately below that in which greater than or equal to 2/6 subjects experience a dose limiting toxicity assessed using nci ctcae version 4.0'], 'incidence of toxicities assessed using nci ctcae version 4.0': ['incidence of toxicities assessed using nci ctcae version 4.0'], 'patient mortality': ['patient mortality'], 'organ avoidance': ['organ avoidance'], 'target coverage': ['target coverage'], 'planning time': ['planning time'], 'treatment delivery time': ['treatment delivery time'], 'disease response status, assessed by standard criteria for the presence of relapse': ['disease response status, assessed by standard criteria for the presence of relapse'], 'rates of acute gvhd, graded and staged according to the blood and marrow transplant clinical trials network manual of operations': ['rates of acute gvhd, graded and staged according to the blood and marrow transplant clinical trials network manual of operations'], 'incidence of grade 3-5 infusional toxicity': ['incidence of grade 3-5 infusional toxicity'], 'relapse of disease': ['relapse of disease'], 'time to immune response': ['time to immune response'], \"wilm's tumor 1  enzyme-linked immunospot\": [\"wilm's tumor 1  enzyme-linked immunospot\"], 'maximum tolerated dose of genetically modified, cd19-specified t cells': ['maximum tolerated dose of genetically modified, cd19-specified t cells'], 'the proportion of patients for which a t cell product could not be prepared': ['the proportion of patients for which a t cell product could not be prepared'], 'proportion of patients experiencing response': ['proportion of patients experiencing response'], 'determine the safety/toxicity of jx-594 administered by it injection in this patient population': ['determine the safety/toxicity of jx-594 administered by it injection in this patient population'], 'determine the jx-594 pharmacokinetics and pharmacodynamics over time following it injection in this patient population': ['determine the jx-594 pharmacokinetics and pharmacodynamics over time following it injection in this patient population'], 'determine the immune response to jx-594 following it injection in this patient population': ['determine the immune response to jx-594 following it injection in this patient population'], 'uric acid levels': ['uric acid levels'], 'graft-versus-host and host-versus-graft immune responses': ['graft-versus-host and host-versus-graft immune responses'], 'to evaluate the safety and tolerability of escalating doses of twice weekly emd 121974 in patients with cancer.': ['to evaluate the safety and tolerability of escalating doses of twice weekly emd 121974 in patients with cancer.'], 'molecular pharmacodynamic effect of low dose daunorubicin on beta-catenin phosphorylation as assessed by quantitative immunohistochemistry assay performed on serial bone marrow samples of patients with relapsed leukemia.': ['molecular pharmacodynamic effect of low dose daunorubicin on beta-catenin phosphorylation as assessed by quantitative immunohistochemistry assay performed on serial bone marrow samples of patients with relapsed leukemia.'], 'maximum plasma concentration [cmax]': ['maximum plasma concentration [cmax]'], 'area under the curve [auc]': ['area under the curve [auc]'], 'acute toxicity associated with the infusion of nicord': ['acute toxicity associated with the infusion of nicord'], 'proportion of patients with neutrophil engraftment': ['proportion of patients with neutrophil engraftment'], 'proportion of patients who developed acute gvhd grade ii-iv and iii-iv': ['proportion of patients who developed acute gvhd grade ii-iv and iii-iv'], 'to assess the safety and tolerability of epz-5676 administered as a continuous intravenous  infusion': ['to assess the safety and tolerability of epz-5676 administered as a continuous intravenous  infusion'], 'evaluate early evidence of anti-tumor activity': ['evaluate early evidence of anti-tumor activity'], 'to assess the safety of chemotherapy and il-2 administration to facilitate transient nk-cell engraftment in research participants with chemotherapy refractory non-acute myelogenous leukemia  hematologic malignancies': ['to assess the safety of chemotherapy and il-2 administration to facilitate transient nk-cell engraftment in research participants with chemotherapy refractory non-acute myelogenous leukemia  hematologic malignancies'], 'to explore the efficacy of nk cell infusion in research participants with chemotherapy refractory hematologic malignancies': ['to explore the efficacy of nk cell infusion in research participants with chemotherapy refractory hematologic malignancies'], 'estimated dose to tumor sites based on the tumor to normal organ ratios derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of yttrium y 90 anti-cd45 monoclonal antibody bc8': ['estimated dose to tumor sites based on the tumor to normal organ ratios derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of yttrium y 90 anti-cd45 monoclonal antibody bc8'], 'the lowest antibody  dose  that is consistent with a favorable biodistribution rate >= 80% in lymphoma patients': ['the lowest antibody  dose  that is consistent with a favorable biodistribution rate >= 80% in lymphoma patients'], 'toxicities related to radiolabelled antibody.': ['toxicities related to radiolabelled antibody.'], 'dosimetry model': ['dosimetry model'], 'feasibility of nk-dli production': ['feasibility of nk-dli production'], 'safety of nk dli infusion': ['safety of nk dli infusion'], 'efficacy of nk dli infusions': ['efficacy of nk dli infusions'], 'pharmacokinetics: time of maximal concentration': ['pharmacokinetics: time of maximal concentration'], 'number of participants with tumor response': ['number of participants with tumor response'], 'potential of ly3023414 to inhibit cyp3a4-mediated metabolism': ['potential of ly3023414 to inhibit cyp3a4-mediated metabolism'], 'response rate of the combination of velcade and doxil in patients with metastatic breast cancer': ['response rate of the combination of velcade and doxil in patients with metastatic breast cancer'], 'duration of plasmatic asparagin depletion': ['duration of plasmatic asparagin depletion'], 'safety of dli following a non-myeloablative transplant, defined as incidence of grade iv acute gvhd': ['safety of dli following a non-myeloablative transplant, defined as incidence of grade iv acute gvhd'], 'incidence of graft rejection': ['incidence of graft rejection'], 'incidence of relapse/progression': ['incidence of relapse/progression'], 'incidence of grade ii-iv gvhd in patients undergoing dli following a non-myeloablative transplant': ['incidence of grade ii-iv gvhd in patients undergoing dli following a non-myeloablative transplant'], 'incidence of infections in patients undergoing dli following a non-myeloablative transplant': ['incidence of infections in patients undergoing dli following a non-myeloablative transplant'], 'risk of true graft rejection in patients with and without preceding chemotherapy': ['risk of true graft rejection in patients with and without preceding chemotherapy'], 'risk of grades ii-iv acute gvhd in those patients with sustained engraftment': ['risk of grades ii-iv acute gvhd in those patients with sustained engraftment'], 'incidence of reversing impending graft rejection': ['incidence of reversing impending graft rejection'], 'safety as assessed by a non-relapse mortality < 30% within day 100': ['safety as assessed by a non-relapse mortality < 30% within day 100'], 'hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion': ['hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion'], 'safety and feasibility': ['safety and feasibility'], '2. to determine the biologically active dose of chi lob 7/4, which is defined as the dose level at which peripheral blood b-cells are reduced by the end of therapy to 10% or less of the starting number.': ['2. to determine the biologically active dose of chi lob 7/4, which is defined as the dose level at which peripheral blood b-cells are reduced by the end of therapy to 10% or less of the starting number.'], '3. to determine the toxicity profile of chi lob 7/4  and to identify the dose limiting toxicity': ['3. to determine the toxicity profile of chi lob 7/4  and to identify the dose limiting toxicity'], '4. to propose a safe dose for phase ii evaluation': ['4. to propose a safe dose for phase ii evaluation'], '1. to examine the biological effects of chilob 7/4 treatment': ['1. to examine the biological effects of chilob 7/4 treatment'], '2. to examine the pharmacokinetics of chilob 7/4 treatment:': ['2. to examine the pharmacokinetics of chilob 7/4 treatment:'], '3. to examine the possible anti-tumour activity of chi lob 7/4': ['3. to examine the possible anti-tumour activity of chi lob 7/4'], 'pharmacodynamic biomarker p70s6k': ['pharmacodynamic biomarker p70s6k'], 'pharmacodynamic biomarkers p4ebp1 and pakt': ['pharmacodynamic biomarkers p4ebp1 and pakt'], 'tolerability - full physical exam': ['tolerability - full physical exam'], 'fasting serum glucose and triglycerides': ['fasting serum glucose and triglycerides'], 'metabolism': ['metabolism'], 'biodistribution': ['biodistribution'], 'radiation dosimetry': ['radiation dosimetry'], 'to evaluate pharmacokinetics, toxicity profile, biological activity, and anti-tumor activity of cpi-613 given twice weekly for three consecutive weeks in cancer patients': ['to evaluate pharmacokinetics, toxicity profile, biological activity, and anti-tumor activity of cpi-613 given twice weekly for three consecutive weeks in cancer patients'], 'safety measures: injection site and systemic reactions': ['safety measures: injection site and systemic reactions'], 'immunogencity measures: antigen-specific antibodies and cellular immune response': ['immunogencity measures: antigen-specific antibodies and cellular immune response'], 'quality of life during stem cell mobilization': ['quality of life during stem cell mobilization'], 'the primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality.': ['the primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality.'], 'the secondary objective will be to estimate the proportion of patients developing acute and chronic graft-versus-host disease, 100 day treatment-related mortality, and to measure disease-free survival.': ['the secondary objective will be to estimate the proportion of patients developing acute and chronic graft-versus-host disease, 100 day treatment-related mortality, and to measure disease-free survival.'], 'phase i study - safety and tolerability of pol6326 as a mobilization agent.': ['phase i study - safety and tolerability of pol6326 as a mobilization agent.'], 'phase ii study - determine the number of allogeneic donors who require a second leukapheresis': ['phase ii study - determine the number of allogeneic donors who require a second leukapheresis'], 'phase i study - define maximum tolerated dose of pol6326': ['phase i study - define maximum tolerated dose of pol6326'], 'phase ii study - the proportion of hla-identical sibling donors who experience grade 3-4 infusional toxicity and the proportion who are safely mobilized': ['phase ii study - the proportion of hla-identical sibling donors who experience grade 3-4 infusional toxicity and the proportion who are safely mobilized'], 'phase ii study - pharmacokinetics and pharmacodynamics of iv pol6326': ['phase ii study - pharmacokinetics and pharmacodynamics of iv pol6326'], 'phase ii study - rate of acute gvhd and chronic gvhd in patients who receive iv pol6326 mobilized peripheral blood stem cells.': ['phase ii study - rate of acute gvhd and chronic gvhd in patients who receive iv pol6326 mobilized peripheral blood stem cells.'], 'phase ii study - kinetics of neutrophil and platelet engraftment in recipients of pol6326 mobilized peripheral blood stem cells.': ['phase ii study - kinetics of neutrophil and platelet engraftment in recipients of pol6326 mobilized peripheral blood stem cells.'], 'cumulative incidence of grade 2-4 acute graft-versus-host disease': ['cumulative incidence of grade 2-4 acute graft-versus-host disease'], '1-year survival': ['1-year survival'], 'clinical efficacy of donor nk cell infusion, in terms of tumor response, response duration, and survival': ['clinical efficacy of donor nk cell infusion, in terms of tumor response, response duration, and survival'], 'regimen-related toxicities': ['regimen-related toxicities'], 'relapse mortality': ['relapse mortality'], 'define the toxicity spectrum of marqibo in children with cancer': ['define the toxicity spectrum of marqibo in children with cancer'], 'evaluate the plasma pharmacokinetics of marqibo in children with cancer.': ['evaluate the plasma pharmacokinetics of marqibo in children with cancer.'], 'overall response ,': ['overall response ,'], 'safety and tolerability as measured by ctcae v3.0': ['safety and tolerability as measured by ctcae v3.0'], 'correlate the expression of apoptosis specific genes': ['correlate the expression of apoptosis specific genes'], 'feasibility of expansion of frozen donor mononuclear cells into cik': ['feasibility of expansion of frozen donor mononuclear cells into cik'], 'toxicity including gvhd and marrow aplasia': ['toxicity including gvhd and marrow aplasia'], 'efficacy in terms of disease response as compared to previous treatment modality ie unmanipulated dli': ['efficacy in terms of disease response as compared to previous treatment modality ie unmanipulated dli'], 'safety of car nk-cd19 cell': ['safety of car nk-cd19 cell'], 'cell count of car nk-cd19': ['cell count of car nk-cd19'], 'cmax of car nk-cd19': ['cmax of car nk-cd19'], 'tmax of car nk-cd19': ['tmax of car nk-cd19'], 'auc of car nk-cd19': ['auc of car nk-cd19'], 'other pharmacokinetic of car nk-cd19 cell': ['other pharmacokinetic of car nk-cd19 cell'], 'the changes of cytokines': ['the changes of cytokines'], 'the recist criteria will be used for patients with all leukemias and myelodysplastic syndromes.': ['the recist criteria will be used for patients with all leukemias and myelodysplastic syndromes.'], \"patients with lymphoma or myeloma will be assessed by the international workshop to standardize response criteria for non-hodgkin's lymphomas.\": [\"patients with lymphoma or myeloma will be assessed by the international workshop to standardize response criteria for non-hodgkin's lymphomas.\"], 'ebmt, ibmtr and abmtr criteria for definition of response, relapse and progression in patients with multiple myeloma .': ['ebmt, ibmtr and abmtr criteria for definition of response, relapse and progression in patients with multiple myeloma .'], 'obtain the maximum tolerated dose of pcar-19b cells[safety and tolerability]': ['obtain the maximum tolerated dose of pcar-19b cells[safety and tolerability]'], 'objective response rate after pcar-19b infusion [effectiveness]': ['objective response rate after pcar-19b infusion [effectiveness]'], 'aucs of pcar-19b cells [cell dynamics]': ['aucs of pcar-19b cells [cell dynamics]'], 'cmax of pcar-19b cells [cell dynamics]': ['cmax of pcar-19b cells [cell dynamics]'], 'tmax of pcar-19b cells [cell dynamics]': ['tmax of pcar-19b cells [cell dynamics]'], 'pharmacodynamics of pcar-19b cells[cell dynamics]': ['pharmacodynamics of pcar-19b cells[cell dynamics]'], 'immunogenicity of pcar-19b cells': ['immunogenicity of pcar-19b cells'], 'number of participants with incidences of anti-blinatumomab antibodies': ['number of participants with incidences of anti-blinatumomab antibodies'], 'number of participants with incidences of anti-amg 404 antibodies': ['number of participants with incidences of anti-amg 404 antibodies'], 'clinically relevant responses to therapy determined by bone marrow biopsy': ['clinically relevant responses to therapy determined by bone marrow biopsy'], 'number of adverse event of cd19 car t cells treatment': ['number of adverse event of cd19 car t cells treatment'], 'grade of adverse event of cd19 car t cells treatment': ['grade of adverse event of cd19 car t cells treatment'], 'duration of in vivo survival of cd19 car t cells.': ['duration of in vivo survival of cd19 car t cells.'], 'molecular remission rate': ['molecular remission rate'], 'time to remission': ['time to remission'], 'to obtain high resolution spectra from tumors using surface coils to improve sensitivity.': ['to obtain high resolution spectra from tumors using surface coils to improve sensitivity.'], 'in some of these studies, to enhance our spectral resolution and obtain additional metabolic information, we propose to use decoupling, which will increase both signal quality  and spectral resolution.': ['in some of these studies, to enhance our spectral resolution and obtain additional metabolic information, we propose to use decoupling, which will increase both signal quality  and spectral resolution.'], 'clinical activity': ['clinical activity'], 'impact on biologic markers': ['impact on biologic markers'], 'determinants of response': ['determinants of response'], 'the number of participants with complete remission': ['the number of participants with complete remission'], 'the number of participants with biological response to treatment': ['the number of participants with biological response to treatment'], 'local reactions after each vaccination': ['local reactions after each vaccination'], 'systemic reaction': ['systemic reaction'], 'immunogenicity: number of participants with a post-titer greater than or equal to a fourfold titer rise': ['immunogenicity: number of participants with a post-titer greater than or equal to a fourfold titer rise'], 'immunogenicity:number of participants with a pre-titer ≥1:40': ['immunogenicity:number of participants with a pre-titer ≥1:40'], 'immunogenicity: number of participants with a post-titer ≥1:40': ['immunogenicity: number of participants with a post-titer ≥1:40'], 'immunogenicity: the geometric mean titers pre-vaccine in study participants': ['immunogenicity: the geometric mean titers pre-vaccine in study participants'], 'immunogenicity: geometric mean titers post-vaccine in study participants': ['immunogenicity: geometric mean titers post-vaccine in study participants'], 'to prospectively collect serum and bone marrow specimens to determine biomarkers of response and correlative ex vivo studies of the anti-leukemic activity of carfilzomib.': ['to prospectively collect serum and bone marrow specimens to determine biomarkers of response and correlative ex vivo studies of the anti-leukemic activity of carfilzomib.'], 'this study will determine the maximum tolerated dose of genetically modified nk cells in research participants with relapsed or refractory b-lineage all': ['this study will determine the maximum tolerated dose of genetically modified nk cells in research participants with relapsed or refractory b-lineage all'], 'this study will determine the persistence and phenotype of genetically modified nk cells in research participants with relapsed or refractory b-lineage all.': ['this study will determine the persistence and phenotype of genetically modified nk cells in research participants with relapsed or refractory b-lineage all.'], 'this study will explore the efficacy of genetically modified nk cells in research participants with relapsed or refractory b-lineage all.': ['this study will explore the efficacy of genetically modified nk cells in research participants with relapsed or refractory b-lineage all.'], 'the incidence of dlts  experienced with 1 cycle of this 5-drug regimen in this patient population': ['the incidence of dlts  experienced with 1 cycle of this 5-drug regimen in this patient population'], 'compare changes in gene expression signatures in steroid alone versus steroid plus rapamycin treated patients.': ['compare changes in gene expression signatures in steroid alone versus steroid plus rapamycin treated patients.'], 'compare biologic measures of \"pro-apoptotic state\" in steroid alone versus steroid plus rapamycin treated patients': ['compare biologic measures of \"pro-apoptotic state\" in steroid alone versus steroid plus rapamycin treated patients'], 'assess clinical response by percent reduction of peripheral leukemia blasts at day 2 of therapy and at completion of the 5-day investigational window': ['assess clinical response by percent reduction of peripheral leukemia blasts at day 2 of therapy and at completion of the 5-day investigational window'], 'aall08p1 safety outcome': ['aall08p1 safety outcome'], 'aall08p1 feasibility outcome': ['aall08p1 feasibility outcome'], 'clinical activity: % of tumor cells in bone marrow': ['clinical activity: % of tumor cells in bone marrow'], 'optimum dose of deglycosylated ricin a chain-conjugated anti-cd19 and anti-cd22 immunotoxins': ['optimum dose of deglycosylated ricin a chain-conjugated anti-cd19 and anti-cd22 immunotoxins'], 'efficacy of treatment': ['efficacy of treatment'], 'in this phase i study the endpoint is the determination of the maximum tolerable dose without toxicity.': ['in this phase i study the endpoint is the determination of the maximum tolerable dose without toxicity.'], 'a decrease in leukemic blasts. the study will be terminated if unacceptable dosesecondary endpoints are a decrease in leukemic blasts. the study will be terminated if unacceptable dose limiting toxicity is found. this is a phase i trial to study safety.': ['a decrease in leukemic blasts. the study will be terminated if unacceptable dosesecondary endpoints are a decrease in leukemic blasts. the study will be terminated if unacceptable dose limiting toxicity is found. this is a phase i trial to study safety.'], 'safety profile and tolerability': ['safety profile and tolerability'], 'number of participants experiencing potential efficacy of alt 803': ['number of participants experiencing potential efficacy of alt 803'], 'number of participants with excessive toxicity': ['number of participants with excessive toxicity'], 'number of participants with incidence of acute graft versus host disease': ['number of participants with incidence of acute graft versus host disease'], 'number of participants with incidence of chronic graft versus host disease': ['number of participants with incidence of chronic graft versus host disease'], 'to determine the clinical activity of this schedule of decitabine in this patient population.': ['to determine the clinical activity of this schedule of decitabine in this patient population.'], 'to determine the safety and tolerability of decitabine in combination with hypercvad based chemotherapy in patients with relapsed or refractory all.': ['to determine the safety and tolerability of decitabine in combination with hypercvad based chemotherapy in patients with relapsed or refractory all.'], 'to determine the clinical activity of this schedule of decitabine in combination with hypercvad in this patient population.': ['to determine the clinical activity of this schedule of decitabine in combination with hypercvad in this patient population.'], 'to determine the effects of decitabine administration on dna methylation and gene expression in this patient population.': ['to determine the effects of decitabine administration on dna methylation and gene expression in this patient population.'], 'the incidence of subjects with dose limiting toxicities within each dose level cohort.': ['the incidence of subjects with dose limiting toxicities within each dose level cohort.'], 'duration of ft500 persistence': ['duration of ft500 persistence'], 'to further assess the safety and tolerability of tak-901 at or below the mtd in an expanded cohort of subjects in order to select a dose for future studies.': ['to further assess the safety and tolerability of tak-901 at or below the mtd in an expanded cohort of subjects in order to select a dose for future studies.'], 'to make a preliminary assessment of the clinical activity of tak-901.': ['to make a preliminary assessment of the clinical activity of tak-901.'], 'to make a preliminary assessment of the effects of tak-901 on pharmacodynamic biomarkers.': ['to make a preliminary assessment of the effects of tak-901 on pharmacodynamic biomarkers.'], 'to make a preliminary assessment of the association between selected genetic markers and tak-901 response and/or pharmacokinetic parameters.': ['to make a preliminary assessment of the association between selected genetic markers and tak-901 response and/or pharmacokinetic parameters.'], 'anti tumour activity in injected tumour': ['anti tumour activity in injected tumour'], 'complete response  and partial response': ['complete response  and partial response'], 'rate of non-engraftment and secondary graft failure': ['rate of non-engraftment and secondary graft failure'], 'percentage of subjects who develop acute graft-versus-host disease.': ['percentage of subjects who develop acute graft-versus-host disease.'], 'percentage of subjects who develop chronic graft-versus-host disease.': ['percentage of subjects who develop chronic graft-versus-host disease.'], 'assess the maximum grade: limited versus extensive maximum severity: mild, moderate or severe) of chronic gvhd in patients who develop chronic graft-versus-': ['assess the maximum grade: limited versus extensive maximum severity: mild, moderate or severe) of chronic gvhd in patients who develop chronic graft-versus-'], 'time to relapsed disease': ['time to relapsed disease'], 'number of participants with grade change from baseline in vital signs-dbp & sbp-part 1': ['number of participants with grade change from baseline in vital signs-dbp & sbp-part 1'], 'number of participants with change from baseline in heart rate and temperature-part 1': ['number of participants with change from baseline in heart rate and temperature-part 1'], 'number of participants with grade change from baseline in clinical chemistry data-part 1': ['number of participants with grade change from baseline in clinical chemistry data-part 1'], 'number of participants with change from baseline in clinical chemistry data with respect to normal range-part 1': ['number of participants with change from baseline in clinical chemistry data with respect to normal range-part 1'], 'number of participants with grade change from baseline in hematology data-part 1': ['number of participants with grade change from baseline in hematology data-part 1'], 'number of participants with change from baseline in hematology data with respect to normal range-part 1': ['number of participants with change from baseline in hematology data with respect to normal range-part 1'], 'number of participants with worst-case urinalysis results post-baseline relative to baseline by dipstick method -part 1': ['number of participants with worst-case urinalysis results post-baseline relative to baseline by dipstick method -part 1'], 'area under the concentration-time curve from time zero extrapolated to infinite time  of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1': ['area under the concentration-time curve from time zero extrapolated to infinite time  of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1'], 'auc[0-infinity] of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg': ['auc[0-infinity] of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg'], 'area under the concentration-time curve over the dosing interval  of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1': ['area under the concentration-time curve over the dosing interval  of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1'], 'auc[0-tau] of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg': ['auc[0-tau] of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg'], 'area under the concentration-time curve from zero to time of last quantifiable concentration  of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1': ['area under the concentration-time curve from zero to time of last quantifiable concentration  of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1'], 'auc[0-tlast]) of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg': ['auc[0-tlast]) of gsk2857916 following iv dose in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg'], 'cl of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg': ['cl of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg'], 'cmax of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg': ['cmax of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg'], 'ctrough of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg': ['ctrough of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg'], 't1/2 of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg': ['t1/2 of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg'], 'vss of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg': ['vss of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg'], 'tmax of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg': ['tmax of gsk2857916 following iv dose in participants with relapsed/refractory mm - part 1: gsk2857916 2.50 mg/kg'], 'ctrough of gsk2857916 following iv dose in participants with relapsed/refractory mm-part 2': ['ctrough of gsk2857916 following iv dose in participants with relapsed/refractory mm-part 2'], 'ctrough of gsk2857916 following iv dose in participants with nhl-part 2': ['ctrough of gsk2857916 following iv dose in participants with nhl-part 2'], 'auc of cys monomethyl auristatin f  following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1': ['auc of cys monomethyl auristatin f  following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1'], 'cmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1': ['cmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1'], 'cmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg': ['cmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg'], 'ctrough of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1': ['ctrough of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1'], 'ctrough of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg': ['ctrough of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1: gsk2857916 2.50 mg/kg'], 'tmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1': ['tmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm- part 1'], 'tmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm-part 1: gsk2857916 2.50 mg/kg': ['tmax of cys-mcmmaf following iv dose of gsk2857916 in participants with relapsed/refractory mm-part 1: gsk2857916 2.50 mg/kg'], 'number of participants with at least one confirmed positive post-baseline anti-drug antibody result- part 1': ['number of participants with at least one confirmed positive post-baseline anti-drug antibody result- part 1'], 'number of participants with antibodies to gsk2857916 in serum over time- part 1': ['number of participants with antibodies to gsk2857916 in serum over time- part 1'], 'cbr- part 2': ['cbr- part 2'], \"feasibility of generating auto3: number of patients' cells successfully manufactured as a proportion of the number of patients undergoing leukapheresis\": [\"feasibility of generating auto3: number of patients' cells successfully manufactured as a proportion of the number of patients undergoing leukapheresis\"], 'number of patients with cd19- and/or cd22-negative relapse': ['number of patients with cd19- and/or cd22-negative relapse'], 'expansion of auto3 following adoptive transfer': ['expansion of auto3 following adoptive transfer'], 'persistence of auto3 following adoptive transfer': ['persistence of auto3 following adoptive transfer'], 'duration of b cell aplasia': ['duration of b cell aplasia'], 'cardiorespiratory exercise test': ['cardiorespiratory exercise test'], 'echocardiography': ['echocardiography'], 'functional mobility': ['functional mobility'], 'strength': ['strength'], 'flexibility': ['flexibility'], 'level of physical activity': ['level of physical activity'], 'phase 2: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment': ['phase 2: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment'], 'phase 1b adults: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment': ['phase 1b adults: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment'], 'phase 1b pediatric: percentage of participants with m1 remission within 2 cycles of treatment': ['phase 1b pediatric: percentage of participants with m1 remission within 2 cycles of treatment'], 'phase 1b and phase 2: duration of response': ['phase 1b and phase 2: duration of response'], 'phase 1b and phase 2: relapse-free survival': ['phase 1b and phase 2: relapse-free survival'], 'phase 1b and phase 2: overall survival': ['phase 1b and phase 2: overall survival'], 'phase 2: best overall response within 2 cycles of treatment': ['phase 2: best overall response within 2 cycles of treatment'], 'phase 2: percentage of participants who received an allogeneic hematopoietic stem cell transplant  during blinatumomab induced remission': ['phase 2: percentage of participants who received an allogeneic hematopoietic stem cell transplant  during blinatumomab induced remission'], 'phase 2: 100-day mortality after allogeneic hsct': ['phase 2: 100-day mortality after allogeneic hsct'], 'phase 1b and phase 2: serum blinatumomab concentration at steady state': ['phase 1b and phase 2: serum blinatumomab concentration at steady state'], 'phase 1b and phase 2: systemic clearance of blinatumomab': ['phase 1b and phase 2: systemic clearance of blinatumomab'], 'phase 1b and phase 2: terminal half-life of blinatumomab': ['phase 1b and phase 2: terminal half-life of blinatumomab'], 'phase 1b and phase 2: volume of distribution of blinatumomab': ['phase 1b and phase 2: volume of distribution of blinatumomab'], 'phase 1b and phase 2: number of participants who developed anti-blinatumomab antibodies': ['phase 1b and phase 2: number of participants who developed anti-blinatumomab antibodies'], 'phase 1b and phase 2: interleukin-2 concentration': ['phase 1b and phase 2: interleukin-2 concentration'], 'phase 1b and phase 2: interleukin-6 concentration': ['phase 1b and phase 2: interleukin-6 concentration'], 'phase 1b and phase 2: interleukin-10 concentration': ['phase 1b and phase 2: interleukin-10 concentration'], 'phase 1b and phase 2: tumor necrosis factor-alpha  concentration': ['phase 1b and phase 2: tumor necrosis factor-alpha  concentration'], 'phase 1b and phase 2: interferon gamma  concentration': ['phase 1b and phase 2: interferon gamma  concentration'], 'expansion cohort adult: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment': ['expansion cohort adult: percentage of participants with a best response of complete remission or complete remission with only partial hematological recovery within 2 cycles of treatment'], 'expansion cohort pediatric: percentage of participants with m1 remission within 2 cycles of treatment': ['expansion cohort pediatric: percentage of participants with m1 remission within 2 cycles of treatment'], 'percentage of participants with complete remission in the first two cycles': ['percentage of participants with complete remission in the first two cycles'], 'steady state concentration of blinatumomab': ['steady state concentration of blinatumomab'], 'time to hematological relapse': ['time to hematological relapse'], 'percentage of participants who received an allogeneic hematopoietic stem cell transplant during blinatumomab induced remission': ['percentage of participants who received an allogeneic hematopoietic stem cell transplant during blinatumomab induced remission'], 'number of participants who developed anti-blinatumomab antibodies': ['number of participants who developed anti-blinatumomab antibodies'], 'serum cytokine peak levels': ['serum cytokine peak levels'], 'occurrence of a dose-limiting toxicity': ['occurrence of a dose-limiting toxicity'], 'mtd of vsli': ['mtd of vsli'], 'remission re-induction  rate': ['remission re-induction  rate'], 'event-free survival rate': ['event-free survival rate'], 'participant responses by daily dose level assignment': ['participant responses by daily dose level assignment'], 'partial and complete remission, overall response rates': ['partial and complete remission, overall response rates'], 'valuation of tolerance, more particularly targeted at the immunodeficiency shortage, contagious complications and neurotoxicity assessed according to the nci  classification.': ['valuation of tolerance, more particularly targeted at the immunodeficiency shortage, contagious complications and neurotoxicity assessed according to the nci  classification.'], 'valuation of the response waiting time, from the first day of the induction treatment to the reevoluting.': ['valuation of the response waiting time, from the first day of the induction treatment to the reevoluting.'], 'biologic efects of drug combination': ['biologic efects of drug combination'], 'antiangiogenic properties of drug combination': ['antiangiogenic properties of drug combination'], 'days of persistence of adoptively-transferred haploidentical nk cells': ['days of persistence of adoptively-transferred haploidentical nk cells'], 'median time to leukocytes and platelets recovery': ['median time to leukocytes and platelets recovery'], 'number of t, b, nk, activated t and nk cells after immunotherapy': ['number of t, b, nk, activated t and nk cells after immunotherapy'], 'graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3': ['graft failure defined as survival to day 42 without absolute neutrophil count greater than or equal to 500/mm3'], 'cumulative incidence of sustained donor-derived neutrophil engraftment': ['cumulative incidence of sustained donor-derived neutrophil engraftment'], 'incidence of engraftment syndrome': ['incidence of engraftment syndrome'], 'cumulative incidence of graft failure': ['cumulative incidence of graft failure'], 'presence of post-transplant phenotype in hematopoietic cells of donor origin': ['presence of post-transplant phenotype in hematopoietic cells of donor origin'], 'cumulative incidence of chronic gvhd': ['cumulative incidence of chronic gvhd'], 'the frequency of grade 4 crs': ['the frequency of grade 4 crs'], 'mtd of brentuximab vedotin when administered with a gvhd prophylaxis regimen': ['mtd of brentuximab vedotin when administered with a gvhd prophylaxis regimen'], 'safety and tolerability of brentuximab vedotin when administered with a gvhd prophylaxis regimen': ['safety and tolerability of brentuximab vedotin when administered with a gvhd prophylaxis regimen'], 'rate of acute gvhd': ['rate of acute gvhd'], 'rate of chronic gvhd': ['rate of chronic gvhd'], 'overall survival.': ['overall survival.'], '1-year non-relapse mortality rate': ['1-year non-relapse mortality rate'], '2-year non-relapse mortality rate': ['2-year non-relapse mortality rate'], '1-year disease relapse rate': ['1-year disease relapse rate'], '2-year disease relapse rate': ['2-year disease relapse rate'], 'pharmacokinetic profile of epz-5676': ['pharmacokinetic profile of epz-5676'], 'anti-leukemic activity of epz-5676 in patients with acute leukemia harboring a mll-rearrangement': ['anti-leukemic activity of epz-5676 in patients with acute leukemia harboring a mll-rearrangement'], 'effects of epz-5676 on histone h3k79 methylation in peripheral blood mononuclear cells .': ['effects of epz-5676 on histone h3k79 methylation in peripheral blood mononuclear cells .'], 'effects of epz-5676 on histone h3k79 methylation in leukemia cells': ['effects of epz-5676 on histone h3k79 methylation in leukemia cells'], 'maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone': ['maximum tolerated dose of clofarabine in combination with etoposide, asparaginase, mitoxantrone and dexamethasone'], 'efficacy of clofarabine used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone': ['efficacy of clofarabine used in combination with etoposide, asparaginase, mitoxantrone and dexamethasone'], 'to determine the dose of dasatinib that can be safely administered with cytarabine, and high-dose mitoxantrone in patients with ph+ all / lymphoid blast crisis of known chronic myelogenous leukemia.': ['to determine the dose of dasatinib that can be safely administered with cytarabine, and high-dose mitoxantrone in patients with ph+ all / lymphoid blast crisis of known chronic myelogenous leukemia.'], 'to determine the toxicity of this combination in these patients.': ['to determine the toxicity of this combination in these patients.'], 'to determine abl-mutational status at baseline and at the time of disease progression as a possible mechanism of resistance.': ['to determine abl-mutational status at baseline and at the time of disease progression as a possible mechanism of resistance.'], 'maximum tolerable dose': ['maximum tolerable dose'], 'toxicities of lenalidomide': ['toxicities of lenalidomide'], 'preliminary clinical activity': ['preliminary clinical activity'], 'plasma and cellular pharmacokinetics': ['plasma and cellular pharmacokinetics'], 'to evaluate the toxicity and maximum tolerated dose of 9-ac administered as a 72 hour infusion in patients with relapsed/refractory leukemia.': ['to evaluate the toxicity and maximum tolerated dose of 9-ac administered as a 72 hour infusion in patients with relapsed/refractory leukemia.'], 'to analyze the pharmacokinetics in these patients.': ['to analyze the pharmacokinetics in these patients.'], 'engraftment one month after transplantation': ['engraftment one month after transplantation'], 'six months survival': ['six months survival'], 'to determine the maximum tolerated dose of cxd101 administered twice daily for 5 consecutive days every 21 days': ['to determine the maximum tolerated dose of cxd101 administered twice daily for 5 consecutive days every 21 days'], 'to enable a preliminary assessment of the anti-tumour activity of cxd101': ['to enable a preliminary assessment of the anti-tumour activity of cxd101'], 'to evaluate the tissue expression of the biomarker hr23b': ['to evaluate the tissue expression of the biomarker hr23b'], 'to assess the pharmacodynamic effect of cxd101': ['to assess the pharmacodynamic effect of cxd101'], 'anti-imc-3g3 antibody assessment': ['anti-imc-3g3 antibody assessment'], 'antitumor activity of imc-3g3 as monotherapy': ['antitumor activity of imc-3g3 as monotherapy'], 'maximum tolerated dose of abbv-075': ['maximum tolerated dose of abbv-075'], 'time to cmax  for abbv-075': ['time to cmax  for abbv-075'], 'mtd defined as the dose level at which fewer than 2 out of 6 patients experience dlt graded using ctcae-v3': ['mtd defined as the dose level at which fewer than 2 out of 6 patients experience dlt graded using ctcae-v3'], 'change in molecular inhibition of the egfr signaling pathway': ['change in molecular inhibition of the egfr signaling pathway'], 'obd defined as the dose at which either a >= 75% inhibition of phosphorylation of the egf receptor or of its downstream effectors p44/42 mapk or akt is observed, or ki67 is decreased by >= 25%': ['obd defined as the dose at which either a >= 75% inhibition of phosphorylation of the egf receptor or of its downstream effectors p44/42 mapk or akt is observed, or ki67 is decreased by >= 25%'], 'antitumor effect observed': ['antitumor effect observed'], 'efficacy of nonmyeloablative preparative regimen': ['efficacy of nonmyeloablative preparative regimen'], 'patient-reported chemotherapy-induced peripheral neuropathy': ['patient-reported chemotherapy-induced peripheral neuropathy'], 'duration of clinical benefit': ['duration of clinical benefit'], 'preliminary efficacy: control or regression of injected tumors by measurement of length, width and height  radio-graphically using computer tomography or magnetic resonance imaging to calculate tumor volumes  over time.': ['preliminary efficacy: control or regression of injected tumors by measurement of length, width and height  radio-graphically using computer tomography or magnetic resonance imaging to calculate tumor volumes  over time.'], 'determine pharmacokinetic parameter peak plasma  of each of the 3 main components of int230-6.': ['determine pharmacokinetic parameter peak plasma  of each of the 3 main components of int230-6.'], 'determine key pharmacokinetic parameter, area under the curve   of each of the 3 main components of int230-6.': ['determine key pharmacokinetic parameter, area under the curve   of each of the 3 main components of int230-6.'], 'phase 1, part 2: safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with dlts': ['phase 1, part 2: safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with dlts'], 'phase 1, part 1: orr per recist v1.1 and mrecist for subjects with solid tumors per cheson and mcheson criteria for subjects with b-cell nhl and per rano and mrano criteria for subjects with gbm': ['phase 1, part 1: orr per recist v1.1 and mrecist for subjects with solid tumors per cheson and mcheson criteria for subjects with b-cell nhl and per rano and mrano criteria for subjects with gbm'], 'phase 1, part 2: orr per recist v1.1 and modified recist for subjects with advanced or metastatic scchn and advanced or metastatic nsclc': ['phase 1, part 2: orr per recist v1.1 and modified recist for subjects with advanced or metastatic scchn and advanced or metastatic nsclc'], 'phase 1, part 2: pfs for subjects with advanced or metastatic scchn and advanced or metastatic nsclc': ['phase 1, part 2: pfs for subjects with advanced or metastatic scchn and advanced or metastatic nsclc'], 'participants with dose limiting toxicity in phase 1': ['participants with dose limiting toxicity in phase 1'], 'percentage of participants achieving a response over the first two treatment cycles in phase 2': ['percentage of participants achieving a response over the first two treatment cycles in phase 2'], 'percentage of participants achieving a response over the first two treatment cycles in phase 1': ['percentage of participants achieving a response over the first two treatment cycles in phase 1'], 'time to remission for participants who had a response in phase 1': ['time to remission for participants who had a response in phase 1'], 'number of participants with 4-month event free survival in phase 1': ['number of participants with 4-month event free survival in phase 1'], 'time to remission for participants who had a response in phase 2': ['time to remission for participants who had a response in phase 2'], 'number of participants with 4-month event free survival in phase 2': ['number of participants with 4-month event free survival in phase 2'], 'number of participants who proceed to course v within 2-6 weeks of the last dose of alemtuzumab': ['number of participants who proceed to course v within 2-6 weeks of the last dose of alemtuzumab'], 'disease-free survival, for only complete response patients': ['disease-free survival, for only complete response patients'], 'phase 2: duration of disease control': ['phase 2: duration of disease control'], 'phase 2: ordinal categorical response score': ['phase 2: ordinal categorical response score'], 'the identification of the maximum tolerated dose for twice or once weekly dosing, on three weeks out of four': ['the identification of the maximum tolerated dose for twice or once weekly dosing, on three weeks out of four'], 'pharmacokinetic profile, safety and tolerability of maximum tolerated dose, pharmacodynamic effect, identify dose limiting toxicities': ['pharmacokinetic profile, safety and tolerability of maximum tolerated dose, pharmacodynamic effect, identify dose limiting toxicities'], 'dose exposure relationship in patients with advanced malignancies treated with single and multipledoses of lipovnb': ['dose exposure relationship in patients with advanced malignancies treated with single and multipledoses of lipovnb'], 'lipovnb antitumor activity assessed by response rate': ['lipovnb antitumor activity assessed by response rate'], 'lipovnb antitumor activity assessed by duration of response': ['lipovnb antitumor activity assessed by duration of response'], 'tolerance of low transfusion threshold as assessed by the percentage of participants who crossed over from the low arm to the high arm.': ['tolerance of low transfusion threshold as assessed by the percentage of participants who crossed over from the low arm to the high arm.'], 'safety of low vs. high transfusion threshold as assessed by total difference in number of transfusions given per participant': ['safety of low vs. high transfusion threshold as assessed by total difference in number of transfusions given per participant'], 'safety of low vs. high transfusion threshold as assessed by number of participants experiencing neutropenic infections': ['safety of low vs. high transfusion threshold as assessed by number of participants experiencing neutropenic infections'], 'safety of low vs. high transfusion threshold as assessed by number of grade 3-4 bleeding events as defined by ctcae 4.0': ['safety of low vs. high transfusion threshold as assessed by number of grade 3-4 bleeding events as defined by ctcae 4.0'], 'safety of low vs. high transfusion threshold as assessed by number of deaths attributed to induction chemotherapy': ['safety of low vs. high transfusion threshold as assessed by number of deaths attributed to induction chemotherapy'], 'safety of low vs. high transfusion threshold as assessed by number of participants with at least one grade 3-5 non-hematological toxicity by ctcae 4.0.': ['safety of low vs. high transfusion threshold as assessed by number of participants with at least one grade 3-5 non-hematological toxicity by ctcae 4.0.'], 'feasibility as determined by percentage of participants consented': ['feasibility as determined by percentage of participants consented'], 'feasibility as determined by percentage of participants who tolerate 7g/dl transfusion': ['feasibility as determined by percentage of participants who tolerate 7g/dl transfusion'], 'feasibility as determined by percentage of participants who crossed over from the low arm to the high arm': ['feasibility as determined by percentage of participants who crossed over from the low arm to the high arm'], 'number of transfusions': ['number of transfusions'], 'neutropenic infections': ['neutropenic infections'], 'bleeding': ['bleeding'], 'length of stay': ['length of stay'], 'end organ dysfunction': ['end organ dysfunction'], 'performance status scores': ['performance status scores'], 'incidence of crossover': ['incidence of crossover'], 'cost savings': ['cost savings'], 'fatigue scores': ['fatigue scores'], 'disease response rate after treatment': ['disease response rate after treatment'], 'recommended phase 2 dose  of bez235 in acute lymphoblastic leukemia , acute myeloid leukemia  and chronic myeloid leukemia in blastic phase': ['recommended phase 2 dose  of bez235 in acute lymphoblastic leukemia , acute myeloid leukemia  and chronic myeloid leukemia in blastic phase'], 'remission duration': ['remission duration'], 'biomarker evaluation': ['biomarker evaluation'], 'bez235 and metabolite levels in plasma': ['bez235 and metabolite levels in plasma'], 'clinical laboratory tests as graded by nci ctcae v4.': ['clinical laboratory tests as graded by nci ctcae v4.'], 'pk parameter of the individual components of cpx-351, and their respective metabolites': ['pk parameter of the individual components of cpx-351, and their respective metabolites'], 'the dose of ac220 that is safe and biologically active when given in sequential combination with ara-c/etoposide': ['the dose of ac220 that is safe and biologically active when given in sequential combination with ara-c/etoposide'], 'count of participants according to inhibition of flt3 phosphorylation': ['count of participants according to inhibition of flt3 phosphorylation'], 'proportion of subjects who start a targeted drug': ['proportion of subjects who start a targeted drug'], 'proportion of patients who show sensitivity to each of the study kinase inhibitors': ['proportion of patients who show sensitivity to each of the study kinase inhibitors'], 'maximum tolerated dose as a measure of safety and tolerability': ['maximum tolerated dose as a measure of safety and tolerability'], 'adverse event profile after single cycle decitabine post transplant': ['adverse event profile after single cycle decitabine post transplant'], 'summary of nilotinib non-compartmental pk parameters: cmax': ['summary of nilotinib non-compartmental pk parameters: cmax'], 'summary of nilotinib non-compartmental pk parameters: tmax': ['summary of nilotinib non-compartmental pk parameters: tmax'], 'summary of nilotinib non-compartmental pk parameters: auclast': ['summary of nilotinib non-compartmental pk parameters: auclast'], 'summary of nilotinib non-compartmental pk parameters: auc0-12h': ['summary of nilotinib non-compartmental pk parameters: auc0-12h'], 'summary of nilotinib steady-state pk parameters: aucss': ['summary of nilotinib steady-state pk parameters: aucss'], 'summary of nilotinib steady-state pk parameters: clf (body surface area  adjusted)': ['summary of nilotinib steady-state pk parameters: clf (body surface area  adjusted)'], 'summary of nilotinib steady-state pk parameters: cmin': ['summary of nilotinib steady-state pk parameters: cmin'], 'number of ph+ cml participants with cytogenic response': ['number of ph+ cml participants with cytogenic response'], 'efficacy endpoints for ph+ all patients': ['efficacy endpoints for ph+ all patients'], 'maximum tolerated dose  of total marrow irradiation': ['maximum tolerated dose  of total marrow irradiation'], 'incidence of neutrophil engraftment': ['incidence of neutrophil engraftment'], 'incidence of platelet engraftment': ['incidence of platelet engraftment'], 'incidence of complete donor chimerism': ['incidence of complete donor chimerism'], 'incidence of transplantation-related mortality': ['incidence of transplantation-related mortality'], 'incidence of chronic gvhd after transplantation': ['incidence of chronic gvhd after transplantation'], 'incidence of relapse after transplantation': ['incidence of relapse after transplantation'], 'disease-free survival after transplantation': ['disease-free survival after transplantation'], 'durability of remission based on presence of rapid early response after transplantation': ['durability of remission based on presence of rapid early response after transplantation'], 'overall survival after transplantation': ['overall survival after transplantation'], 'to determine the safety profile  and tolerability of inno-406 in this patient population.': ['to determine the safety profile  and tolerability of inno-406 in this patient population.'], 'to assess bcr-abl transcript levels and to analyze bcr-abl mutations.': ['to assess bcr-abl transcript levels and to analyze bcr-abl mutations.'], 'to assess leukemia response rates in this patient population.': ['to assess leukemia response rates in this patient population.'], 'immune response': ['immune response'], 'asparaginase activity in serum': ['asparaginase activity in serum'], 'to establish the dlt and the mtd of ridaforolimus administered daily x 5 every 14 days in pediatric patients with recurrent/refractory solid tumors, including lymphoma and tumors of the central nervous system.': ['to establish the dlt and the mtd of ridaforolimus administered daily x 5 every 14 days in pediatric patients with recurrent/refractory solid tumors, including lymphoma and tumors of the central nervous system.'], 'to determine the pharmacokinetic and pharmacodynamic properties of ridaforolimus in pediatric patients with recurrent/refractory solid tumors, including tumors of the central nervous system. screening at day 1-18, cycle 2 day 1, cycle 2 day 15.': ['to determine the pharmacokinetic and pharmacodynamic properties of ridaforolimus in pediatric patients with recurrent/refractory solid tumors, including tumors of the central nervous system. screening at day 1-18, cycle 2 day 1, cycle 2 day 15.'], 'to evaluate the safety and efficacy data of ridaforolimus when administered at the mtd or recommended phase ii dose and schedule in an expanded cohort of patients when administered daily x 5 every 14 days': ['to evaluate the safety and efficacy data of ridaforolimus when administered at the mtd or recommended phase ii dose and schedule in an expanded cohort of patients when administered daily x 5 every 14 days'], 'to assess pharmacogenomic parameters from archival tumor specimens that may correlate with response to ridaforolimus.': ['to assess pharmacogenomic parameters from archival tumor specimens that may correlate with response to ridaforolimus.'], 'occurrence and severity of side effects of donor natural killer cell infusion': ['occurrence and severity of side effects of donor natural killer cell infusion'], 'anti-leukemia effect of donor natural killer cell infusion': ['anti-leukemia effect of donor natural killer cell infusion'], 'to define the toxicity and safety of the conditioning regimen of clofarabine, ara-c, tbi followed by allosct in children with all and anll.': ['to define the toxicity and safety of the conditioning regimen of clofarabine, ara-c, tbi followed by allosct in children with all and anll.'], 'to define the pharmacokinetics of clofarabine given in combination with ara-c and tbi followed by allosct in children with all and anll.': ['to define the pharmacokinetics of clofarabine given in combination with ara-c and tbi followed by allosct in children with all and anll.'], 'to estimate the time to hematopoietic reconstitution, stratified by cell source, following clofarabine, ara-c and tbi followed by allosct in children with all and aml.': ['to estimate the time to hematopoietic reconstitution, stratified by cell source, following clofarabine, ara-c and tbi followed by allosct in children with all and aml.'], 'to measure the changes in minimal residual disease with all and aml following clofarabine, ara-c and tbi followed by allosct': ['to measure the changes in minimal residual disease with all and aml following clofarabine, ara-c and tbi followed by allosct'], 'engraftment rate': ['engraftment rate'], 'relapse rate analysis': ['relapse rate analysis'], 'non-relapse mortality analysis': ['non-relapse mortality analysis'], 'incidence of acute gvhd, grades ii-iv': ['incidence of acute gvhd, grades ii-iv'], 'incidence of chronic gvhd, moderate and severe': ['incidence of chronic gvhd, moderate and severe'], 'overall survival analysis': ['overall survival analysis'], 'event-free survival analysis': ['event-free survival analysis'], 'infectious complications, including analysis of severe bacterial, fungal and viral infections incidence': ['infectious complications, including analysis of severe bacterial, fungal and viral infections incidence'], 'number of patients experiencing regimen-related toxicity events in study population': ['number of patients experiencing regimen-related toxicity events in study population'], 'number of patients experiencing graft failure': ['number of patients experiencing graft failure'], 'number of subjects who are without disease at one year as indicator of disease free survival.': ['number of subjects who are without disease at one year as indicator of disease free survival.'], 'hematologic response': ['hematologic response'], 'cytogenetic response': ['cytogenetic response'], 'bcr-abl transcript level': ['bcr-abl transcript level'], 'cmax of abl001 as measured in plasma': ['cmax of abl001 as measured in plasma'], 'cmin of abl001 as measured in plasma': ['cmin of abl001 as measured in plasma'], 'aucinf of abl001 as measured in plasma': ['aucinf of abl001 as measured in plasma'], 'auclast of abl001 as measured in plasma': ['auclast of abl001 as measured in plasma'], 'auctau of abl001 as measured in plasma': ['auctau of abl001 as measured in plasma'], 't1/2 of abl001 as measured in plasma': ['t1/2 of abl001 as measured in plasma'], 'establishment of mtd and recommended phase ii dose.': ['establishment of mtd and recommended phase ii dose.'], '1) hematologic response 2) cytogenetic response.': ['1) hematologic response 2) cytogenetic response.'], 'dose limiting toxicity of combination selinexor, fludarabine and cytarabine': ['dose limiting toxicity of combination selinexor, fludarabine and cytarabine'], 'to evaluate the pharmacokinetics activity of npi-0052': ['to evaluate the pharmacokinetics activity of npi-0052'], 'to evaluate the safety and tolerability of npi-0052': ['to evaluate the safety and tolerability of npi-0052'], 'to evaluate the pharmacodynamics of npi-0052': ['to evaluate the pharmacodynamics of npi-0052'], 'to estimate renal clearance of bpm31510': ['to estimate renal clearance of bpm31510'], 'safety of uld il-2 as gvhd proph': ['safety of uld il-2 as gvhd proph'], 'to determine the maximum tolerated dose of th-302': ['to determine the maximum tolerated dose of th-302'], 'to determine the dose-limiting toxicity of th-302': ['to determine the dose-limiting toxicity of th-302'], 'to determine the efficacy of th-302 via specific response criteria': ['to determine the efficacy of th-302 via specific response criteria'], 'study the pharmacokinetic interaction  of abt-348 as monotherapy and in combination': ['study the pharmacokinetic interaction  of abt-348 as monotherapy and in combination'], 'toxicity as assessed by nci ctcae v3.0': ['toxicity as assessed by nci ctcae v3.0'], 'area under the plasma concentration-time curve from time zero to 24 hours  of ibrutinib': ['area under the plasma concentration-time curve from time zero to 24 hours  of ibrutinib'], 'metabolite to parent  ratio of ibrutinib': ['metabolite to parent  ratio of ibrutinib'], 'partial area under the plasma concentration-time curve between 2 defined timepoints  of voriconazole': ['partial area under the plasma concentration-time curve between 2 defined timepoints  of voriconazole'], 'assess disease response': ['assess disease response'], 'heart corrected qt intervals': ['heart corrected qt intervals'], 'donor chimerism': ['donor chimerism'], 'relapse': ['relapse'], 'evaluate the safety and feasibility of administering prophylactic donor lymphocyte infusion  after non-myeloablative transplant .': ['evaluate the safety and feasibility of administering prophylactic donor lymphocyte infusion  after non-myeloablative transplant .'], 'recurrence-free survival': ['recurrence-free survival'], 'to assess efficacy in subjects with aml, all and blast-phase cml based on standard response criteria': ['to assess efficacy in subjects with aml, all and blast-phase cml based on standard response criteria'], 'to characterize the safety and tolerability of once-weekly sta-9090  in subjects with aml, all and blast-phase cml': ['to characterize the safety and tolerability of once-weekly sta-9090  in subjects with aml, all and blast-phase cml'], 'the mtd of radiation delivered via 90y-dota-bc8 when combined with flu and 2 gy tbi as a preparative regimen for patients aged ≥ 18 with advanced aml, all, and high-risk mds.': ['the mtd of radiation delivered via 90y-dota-bc8 when combined with flu and 2 gy tbi as a preparative regimen for patients aged ≥ 18 with advanced aml, all, and high-risk mds.'], 'achievement of remission': ['achievement of remission'], 'estimation of absorbed radiation doses to normal organs, marrow and tumor': ['estimation of absorbed radiation doses to normal organs, marrow and tumor'], 'rates of acute gvhd': ['rates of acute gvhd'], 'rates of donor chimerism': ['rates of donor chimerism'], 'rates of engraftment': ['rates of engraftment'], 'rates of non-relapse mortality': ['rates of non-relapse mortality'], 'define human intra-patient bioavailability of clofarabine compare the pharmacokinetics of intravenously-administered clofarabine when administered alone, with the pharmacokinetics of clofarabine when co-administered with cimetidine, an oct2 inhibitor.': ['define human intra-patient bioavailability of clofarabine compare the pharmacokinetics of intravenously-administered clofarabine when administered alone, with the pharmacokinetics of clofarabine when co-administered with cimetidine, an oct2 inhibitor.'], 'examine safety of orally-administered clofarabine examine the safety of a combined intravenous and oral clofarabine regimen': ['examine safety of orally-administered clofarabine examine the safety of a combined intravenous and oral clofarabine regimen'], 'examine efficacy of orally-administered clofarabine': ['examine efficacy of orally-administered clofarabine'], 'explore the influence of oct2-encoding single nucleotide polymorphisms on clofarabine pharmacokinetics and pharmacodynamics': ['explore the influence of oct2-encoding single nucleotide polymorphisms on clofarabine pharmacokinetics and pharmacodynamics'], 'safety of bp1001': ['safety of bp1001'], 'safety of bp1001 in combination with ldac': ['safety of bp1001 in combination with ldac'], 'optimal biologically active dose': ['optimal biologically active dose'], 'in vivo pharmacokinetics': ['in vivo pharmacokinetics'], 'correlate pk data with historical experience': ['correlate pk data with historical experience'], 'recommended phase ii doses for the combination of bortezomib and belinostat': ['recommended phase ii doses for the combination of bortezomib and belinostat'], 'pharmacodynamic response': ['pharmacodynamic response'], 'activity of belinostat and bortezomib': ['activity of belinostat and bortezomib'], 'dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib': ['dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib'], 'changes in apoptotic protein expression': ['changes in apoptotic protein expression'], 'farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells': ['farnesytransferase and proteasome inhibition in peripheral blood mononuclear cells'], 'overall safety': ['overall safety'], 'pharmacokinetic parameters of gs-9820 as measured by cmax, tmax, ctrough, and auc': ['pharmacokinetic parameters of gs-9820 as measured by cmax, tmax, ctrough, and auc'], 'pharmacodynamics to measure changes in the phosphatidylinositol 3-kinase  delta pathway activation and changes in plasma concentration of disease-associated chemokines and cytokines': ['pharmacodynamics to measure changes in the phosphatidylinositol 3-kinase  delta pathway activation and changes in plasma concentration of disease-associated chemokines and cytokines'], 'tumor control': ['tumor control'], 'patient well-being assessed using changes in baseline in hrql  domain and symptom scores based on the functional assessment of cancer therapy: lymphoma': ['patient well-being assessed using changes in baseline in hrql  domain and symptom scores based on the functional assessment of cancer therapy: lymphoma'], 'drug exposure': ['drug exposure'], 'to investigate the clinical pharmacology of on 01910.na including plasma pharmacokinetics, pharmacodynamics and biological effects on cell-cycle pathways.': ['to investigate the clinical pharmacology of on 01910.na including plasma pharmacokinetics, pharmacodynamics and biological effects on cell-cycle pathways.'], 'participants with chronic phase cml : percentage of participants with cytogenetic response': ['participants with chronic phase cml : percentage of participants with cytogenetic response'], 'participants with cml-accelerated or blast phase : percentage of participants with cytogenetic response': ['participants with cml-accelerated or blast phase : percentage of participants with cytogenetic response'], 'participants with ph+ acute lymphoblastic leukemia : percentage of participants with cytogenetic response': ['participants with ph+ acute lymphoblastic leukemia : percentage of participants with cytogenetic response'], 'participants with cml-ap/bp: percentage of participants with hematologic response': ['participants with cml-ap/bp: percentage of participants with hematologic response'], 'participants with ph+ all: percentage of participants with hematologic response': ['participants with ph+ all: percentage of participants with hematologic response'], 'participants with detectable mutations of rna  of bcr-abl at baseline and at best achievement': ['participants with detectable mutations of rna  of bcr-abl at baseline and at best achievement'], 'status of point mutations of bcr-abl at baseline  and end of study': ['status of point mutations of bcr-abl at baseline  and end of study'], 'collection of blood samples for pharmacokinetic analysis of dasatinib twice daily  that will contribute to population pharmacokinetic modeling': ['collection of blood samples for pharmacokinetic analysis of dasatinib twice daily  that will contribute to population pharmacokinetic modeling'], 'maximum tolerated dose of belinostat in combination with azacitidine': ['maximum tolerated dose of belinostat in combination with azacitidine'], 'changes in pharmacodynamic variables': ['changes in pharmacodynamic variables'], 'association of methylation status, categorized as positive or negative, with changes in target gene expression': ['association of methylation status, categorized as positive or negative, with changes in target gene expression'], 'cp-cml participants: percentage of participants with chr': ['cp-cml participants: percentage of participants with chr'], 'cp-cml, ap-cml, bp-cml, and ph+all participants: percentage of participants with confirmed mcyr': ['cp-cml, ap-cml, bp-cml, and ph+all participants: percentage of participants with confirmed mcyr'], 'cmax: maximum observed plasma concentration for ponatinib': ['cmax: maximum observed plasma concentration for ponatinib'], 'tmax: time to reach the cmax for ponatinib': ['tmax: time to reach the cmax for ponatinib'], 't1/2: terminal phase elimination half-life for ponatinib': ['t1/2: terminal phase elimination half-life for ponatinib'], 'duration of leukemia-free survival': ['duration of leukemia-free survival'], 'incidence of serious adverse reactions': ['incidence of serious adverse reactions'], 'duration of neutropenia': ['duration of neutropenia'], 'duration of thrombocytopenia': ['duration of thrombocytopenia'], 'duration of presence of clt-008 derived cells in blood': ['duration of presence of clt-008 derived cells in blood'], 'duration of presence of clt-008 derived cells in bone marrow': ['duration of presence of clt-008 derived cells in bone marrow'], 'incidence of mucositis': ['incidence of mucositis'], 'incidence of infections': ['incidence of infections'], 'duration of fever': ['duration of fever'], 'duration of antibiotic use': ['duration of antibiotic use'], 'incidence of hospitalization': ['incidence of hospitalization'], 'duration of hospitalization': ['duration of hospitalization'], 'presence of disease or antigen-specific lymphocytes': ['presence of disease or antigen-specific lymphocytes'], \"determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-hodgkin's lymphoma.\": [\"determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-hodgkin's lymphoma.\"], 'safety of escalating nk cell doses of adoptively infused ex vivo expanded autologous nk cells in subjects with treatment refractory metastatic tumors or hematological malignancies that are sensitized to nk cell toxicity with bortezomib.': ['safety of escalating nk cell doses of adoptively infused ex vivo expanded autologous nk cells in subjects with treatment refractory metastatic tumors or hematological malignancies that are sensitized to nk cell toxicity with bortezomib.'], 'effectiveness of donor nk cell infusion in preventing tumor relapse and graft failure after hla-haploidentical familial donor bone marrow transplantation': ['effectiveness of donor nk cell infusion in preventing tumor relapse and graft failure after hla-haploidentical familial donor bone marrow transplantation'], 'treatment failure': ['treatment failure'], 'time to development of cytomegalovirus  specific immune reconstitution': ['time to development of cytomegalovirus  specific immune reconstitution'], 'cmv dna levels': ['cmv dna levels'], 'time during post-infusion follow up at which the dominant cmv pp65 epitope for the donor is recognized by the cytotoxic t-cell lymphocyte recipient': ['time during post-infusion follow up at which the dominant cmv pp65 epitope for the donor is recognized by the cytotoxic t-cell lymphocyte recipient'], 'cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute gvhd': ['cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute gvhd'], 'average concentration from time 0 to 24 hours  of selinexor': ['average concentration from time 0 to 24 hours  of selinexor'], 'apparent total body clearance, uncorrected for fraction absorbed  of selinexor': ['apparent total body clearance, uncorrected for fraction absorbed  of selinexor'], 'number of participants with overall response of selinexor': ['number of participants with overall response of selinexor'], 'duration of at least stable disease': ['duration of at least stable disease'], 'maximum observed concentration in plasma of cc-115': ['maximum observed concentration in plasma of cc-115'], 'area under the concentration-time curve for cc-115': ['area under the concentration-time curve for cc-115'], 'time to maximum concentration of cc-115': ['time to maximum concentration of cc-115'], 'terminal half-life for cc-115': ['terminal half-life for cc-115'], 'apparent total body clearance of cc-115': ['apparent total body clearance of cc-115'], 'apparent volume of distribution of cc-115': ['apparent volume of distribution of cc-115'], 'accumulation index of cc-115': ['accumulation index of cc-115'], 'anti-tumor efficacy': ['anti-tumor efficacy'], 'maximum tolerated dose of romiplostim': ['maximum tolerated dose of romiplostim'], 'thrombocytopenia': ['thrombocytopenia'], 'bone marrow fibrosis': ['bone marrow fibrosis'], 'survival rates': ['survival rates'], 'qtcf change from baseline': ['qtcf change from baseline'], 'pharmacokinetic profile of bbi608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by maximum plasma concentration and area under the curve': ['pharmacokinetic profile of bbi608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by maximum plasma concentration and area under the curve'], 'pharmacodynamic activity of bbi608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by biomarker analysis': ['pharmacodynamic activity of bbi608 when administered in monotherapy and in combination with dexamethasone, bortezomib, imatinib or ibrutinib as assessed by biomarker analysis'], 'assessment of the preliminary anti-tumor activity by performing tumor assessments': ['assessment of the preliminary anti-tumor activity by performing tumor assessments'], 'number of participants who died': ['number of participants who died'], 'number of participants with on-treatment laboratory abnormalities in specific hepatics tests': ['number of participants with on-treatment laboratory abnormalities in specific hepatics tests'], 'bms-986016 concentration at the end of a dosing interval': ['bms-986016 concentration at the end of a dosing interval'], 'bms-986016 effective elimination half-life that explains the degree of auc accumulation observed': ['bms-986016 effective elimination half-life that explains the degree of auc accumulation observed'], 'bms-986016 total body clearance': ['bms-986016 total body clearance'], 'bms-986016 cmax accumulation index': ['bms-986016 cmax accumulation index'], 'bms-986016 accumulation index': ['bms-986016 accumulation index'], 'bms-986016 ctau accumulation index': ['bms-986016 ctau accumulation index'], 'bms-986016 average concentration over a dosing interval ([auc/tau]': ['bms-986016 average concentration over a dosing interval ([auc/tau]'], 'maximum tolerated dose of bosutinib defined as the highest dose level in which < 2 patients of 6 develop first course dose limiting toxicity': ['maximum tolerated dose of bosutinib defined as the highest dose level in which < 2 patients of 6 develop first course dose limiting toxicity'], 'complete response/complete response with incomplete bone marrow recovery for newly diagnosed philadelphia positive acute lymphoblastic leukemia or chronic myeloid leukemia or chronic myeloid leukemia- lymphoid blast phase with age >= 60': ['complete response/complete response with incomplete bone marrow recovery for newly diagnosed philadelphia positive acute lymphoblastic leukemia or chronic myeloid leukemia or chronic myeloid leukemia- lymphoid blast phase with age >= 60'], 'overall major hematologic response': ['overall major hematologic response'], 'number of patients with treatment-related dose limiting toxicity in cycle 1 by dose level': ['number of patients with treatment-related dose limiting toxicity in cycle 1 by dose level'], 'half-life of sorafenib': ['half-life of sorafenib'], 'number of patients with treatment-related dose limiting toxicities in later cycles by dose level': ['number of patients with treatment-related dose limiting toxicities in later cycles by dose level'], 'number of patients who respond using recist criteria': ['number of patients who respond using recist criteria'], 'mean concentration of vegf2': ['mean concentration of vegf2'], 'number of patients with demri': ['number of patients with demri'], 'leukemia mutations': ['leukemia mutations'], 'plasma inhibitory activity': ['plasma inhibitory activity'], 'number of participants with treatment safety failure': ['number of participants with treatment safety failure'], 'the proportion of patients at 1 year with treatment efficacy success': ['the proportion of patients at 1 year with treatment efficacy success'], 'patients alive with out relapse': ['patients alive with out relapse'], 'phase ii: major cytogenetic response': ['phase ii: major cytogenetic response'], 'phase i: complete hematologic response': ['phase i: complete hematologic response'], 'phase i: major cytogenetic response': ['phase i: major cytogenetic response'], 'phase i: safety and tolerability': ['phase i: safety and tolerability'], 'phase ii: complete hematologic response': ['phase ii: complete hematologic response'], 'the primary endpoint is all cause mortality at day 200, and the proportion of subjects who have survived at day 200 will be used to determine the sample size.': ['the primary endpoint is all cause mortality at day 200, and the proportion of subjects who have survived at day 200 will be used to determine the sample size.'], 'cumulative incidence of relapse': ['cumulative incidence of relapse'], 'secondary outcome measure: standard transplant outcome variables such as relapse, non-relapse mortality, neutrophil and platelet recovery kinetics, incidence and severity of acute gvhd and chronic gvhd. technical success rates and the use of dli...': ['secondary outcome measure: standard transplant outcome variables such as relapse, non-relapse mortality, neutrophil and platelet recovery kinetics, incidence and severity of acute gvhd and chronic gvhd. technical success rates and the use of dli...'], 'non relapse mortality': ['non relapse mortality'], 'days till anc greater than 500/ul': ['days till anc greater than 500/ul'], 'days till platelet greater than 20 k/ul': ['days till platelet greater than 20 k/ul'], 'number of participants confirmed overall hematological response': ['number of participants confirmed overall hematological response'], 'number of participants with overall major cytogenetic responses': ['number of participants with overall major cytogenetic responses'], 'number of participants with complete hematologic response': ['number of participants with complete hematologic response'], 'percentage of participants with cumulative incidence of grade ii to iv agvhd through day +100 based on investigator assessment': ['percentage of participants with cumulative incidence of grade ii to iv agvhd through day +100 based on investigator assessment'], '1-year gvhd-free, relapse-free survival': ['1-year gvhd-free, relapse-free survival'], 'percentage of subjects alive without relapse and without moderate or severe cgvhd at day +365 - mitt population': ['percentage of subjects alive without relapse and without moderate or severe cgvhd at day +365 - mitt population'], 'non-relapse mortality at 1 year': ['non-relapse mortality at 1 year'], 'incidence of acute and chronic graft-versus-host disease': ['incidence of acute and chronic graft-versus-host disease'], 'incidence of infectious complication': ['incidence of infectious complication'], 'immune reconstitution after transplantation': ['immune reconstitution after transplantation'], 'physical exam': ['physical exam'], 'clinical laboratory assessments': ['clinical laboratory assessments'], 'ecog peformance status': ['ecog peformance status'], 'pk - time to cmax [tmax]': ['pk - time to cmax [tmax]'], 'pk - apparent terminal phase elimination rate constant': ['pk - apparent terminal phase elimination rate constant'], 'metabolite profiling': ['metabolite profiling'], 'change in bone marrow blast cell and peripheral blood counts at 5, 13 and 25 weeks': ['change in bone marrow blast cell and peripheral blood counts at 5, 13 and 25 weeks'], 'concentration of on 01910.na in plasma': ['concentration of on 01910.na in plasma'], 'toxicity rate associated with infusing donor cd8+ ctl clones specific for wt1 in patients at high risk for post transplant relapse of cml, aml, or all': ['toxicity rate associated with infusing donor cd8+ ctl clones specific for wt1 in patients at high risk for post transplant relapse of cml, aml, or all'], 'part 1: number of participants with clinical laboratory abnormalities': ['part 1: number of participants with clinical laboratory abnormalities'], 'part 1: number of deaths': ['part 1: number of deaths'], 'part 1 and part 2: number of participants achieving a best response of partial response': ['part 1 and part 2: number of participants achieving a best response of partial response'], 'part 1 and part 2: number of participants achieving a best response of complete response': ['part 1 and part 2: number of participants achieving a best response of complete response'], 'part 1 and part 2: hematologic improvement in participants with cll': ['part 1 and part 2: hematologic improvement in participants with cll'], 'part 1 and part 2: steady state auclast of zanubrutinib': ['part 1 and part 2: steady state auclast of zanubrutinib'], 'part 1 and part 2: steady state cmax of zanubrutinib': ['part 1 and part 2: steady state cmax of zanubrutinib'], 'part 1 and part 2: steady state tmax of zanubrutinib': ['part 1 and part 2: steady state tmax of zanubrutinib'], 'part 2: number of participants with clinical laboratory abnormalities': ['part 2: number of participants with clinical laboratory abnormalities'], 'part 2: number of deaths': ['part 2: number of deaths'], 'to study the highest tolerable dose of vnp40101m that can be given to patients with a form of leukemia, mds, lymphoma, or myeloma in preparation for an autologous stem cell transplant.': ['to study the highest tolerable dose of vnp40101m that can be given to patients with a form of leukemia, mds, lymphoma, or myeloma in preparation for an autologous stem cell transplant.'], 'proportion of major adverse cardiac events': ['proportion of major adverse cardiac events'], 'proportion of other significant clinical events': ['proportion of other significant clinical events'], 'subjects with events precluding their receipt of product': ['subjects with events precluding their receipt of product'], 'subjects who receive less than 20 injections during spi': ['subjects who receive less than 20 injections during spi'], 'subjects who did not receive the study product': ['subjects who did not receive the study product'], 'subjects who have at least one cardiac mri endpoint measure that is uninterpretable': ['subjects who have at least one cardiac mri endpoint measure that is uninterpretable'], 'subjects who fail to complete follow-up': ['subjects who fail to complete follow-up'], 'change from baseline in left ventricular sphericity index': ['change from baseline in left ventricular sphericity index'], 'change from baseline in left ventricular sphericity index-trajectory': ['change from baseline in left ventricular sphericity index-trajectory'], 'change from baseline in area of injury': ['change from baseline in area of injury'], 'change from baseline in area of injury-trajectory': ['change from baseline in area of injury-trajectory'], 'change from baseline in minnesota living with heart failure questionnaire score': ['change from baseline in minnesota living with heart failure questionnaire score'], 'change from baseline in minnesota living with heart failure questionnaire score-trajectory': ['change from baseline in minnesota living with heart failure questionnaire score-trajectory'], 'cumulative days alive and out of hospital for heart failure': ['cumulative days alive and out of hospital for heart failure'], 'circulating cd3+ve t cell count at 4 months post-sct': ['circulating cd3+ve t cell count at 4 months post-sct'], 'incidence of grade ii-iv acute and chronic gvhd': ['incidence of grade ii-iv acute and chronic gvhd'], 'time to recovery of normal t-cell  and cd4  counts and normal tcr diversity as assessed by vb spectratyping': ['time to recovery of normal t-cell  and cd4  counts and normal tcr diversity as assessed by vb spectratyping'], 'in vitro anti-viral responses of circulating pbmc': ['in vitro anti-viral responses of circulating pbmc'], 'transplant related mortality at 1 year post-sct': ['transplant related mortality at 1 year post-sct'], 'disease-free survival at 1 year post-sct': ['disease-free survival at 1 year post-sct'], 'to determine the pharmacokinetic profile of arq 621.': ['to determine the pharmacokinetic profile of arq 621.'], 'to determine the pharmacodynamic profile  of arq 621.': ['to determine the pharmacodynamic profile  of arq 621.'], 'to assess the preliminary anti-tumor activity of arq 621.': ['to assess the preliminary anti-tumor activity of arq 621.'], 'the safety and toxicity of alt-801 in patients with progressive metastatic malignancies': ['the safety and toxicity of alt-801 in patients with progressive metastatic malignancies'], 'clinical antitumor response to alt-801': ['clinical antitumor response to alt-801'], 'alt-801 induced cell-mediated immune responses': ['alt-801 induced cell-mediated immune responses'], 'immunogenicity of alt-801': ['immunogenicity of alt-801'], 'pharmacokinetic interaction': ['pharmacokinetic interaction'], 'number of participants with a complete response or partial response': ['number of participants with a complete response or partial response'], 'brain tumor response': ['brain tumor response'], 'determination of dose limiting toxicities of 4sc-202': ['determination of dose limiting toxicities of 4sc-202'], 'determination of safety of 4sc-202': ['determination of safety of 4sc-202'], 'determination of pharmacokinetic profile of 4sc-202': ['determination of pharmacokinetic profile of 4sc-202'], 'determination of maximum tolerated dose of 4sc-202': ['determination of maximum tolerated dose of 4sc-202'], 'determination of tolerability of 4sc-202': ['determination of tolerability of 4sc-202'], 'assessment of potential anticancer activity of 4sc-202': ['assessment of potential anticancer activity of 4sc-202'], 'histone deacetylase  inhibition in peripheral mononuclear cells': ['histone deacetylase  inhibition in peripheral mononuclear cells'], 'histone acetylation in peripheral mononuclear cells': ['histone acetylation in peripheral mononuclear cells'], 'gene expression analysis in peripheral blood': ['gene expression analysis in peripheral blood'], 'cytokine and mirna levels in plasma': ['cytokine and mirna levels in plasma'], 'safety and tolerability of treatment with tkm-080301': ['safety and tolerability of treatment with tkm-080301'], 'determine dose-limiting toxicities and maximum tolerated dose of tkm-080301': ['determine dose-limiting toxicities and maximum tolerated dose of tkm-080301'], 'characterize the pharmacokinetics of tkm-080301': ['characterize the pharmacokinetics of tkm-080301'], 'assess preliminary evidence of anti-tumor activity': ['assess preliminary evidence of anti-tumor activity'], 'maximum tolerated dose of genotype-based dosing of folfiri with or without monoclonal antibody therapy': ['maximum tolerated dose of genotype-based dosing of folfiri with or without monoclonal antibody therapy'], 'response rate of genotype-based dosing in the subset of patients that has colorectal cancer': ['response rate of genotype-based dosing in the subset of patients that has colorectal cancer'], 'pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : concentration at the end of infusion': ['pharmacokinetic parameter for total antibody , antibody drug conjugate , and monomethyl auristatin e : concentration at the end of infusion'], 'incidence of anti-drug antibody  formation to the fully human monoclonal antibody  and antibody-drug conjugate': ['incidence of anti-drug antibody  formation to the fully human monoclonal antibody  and antibody-drug conjugate'], 'incidence of tumor response': ['incidence of tumor response'], 'safety of ebola and marburg vaccines assessed by clinical observation.': ['safety of ebola and marburg vaccines assessed by clinical observation.'], 'safety of ebola and marburg vaccines assessed by change from baseline in levels of creatinine.': ['safety of ebola and marburg vaccines assessed by change from baseline in levels of creatinine.'], 'safety of ebola and marburg vaccines assessed by change from baseline in levels of alanine transaminase .': ['safety of ebola and marburg vaccines assessed by change from baseline in levels of alanine transaminase .'], 'safety of ebola and marburg vaccines assessed by adverse experiences.': ['safety of ebola and marburg vaccines assessed by adverse experiences.'], 'safety of ebola and marburg vaccines assessed by serious adverse experiences.': ['safety of ebola and marburg vaccines assessed by serious adverse experiences.'], 'evaluation of antibody response to cad3-ebo-s and cad3 marburg vaccines': ['evaluation of antibody response to cad3-ebo-s and cad3 marburg vaccines'], 'collection of sufficient post-vaccination plasma to support further development of filovirus assays.': ['collection of sufficient post-vaccination plasma to support further development of filovirus assays.'], 'phase ii: kaplan-meier estimate of the percentage of patients who are alive and have not developed any \"event\"': ['phase ii: kaplan-meier estimate of the percentage of patients who are alive and have not developed any \"event\"'], 'phase ii: kaplan-meier estimate for progression/relapse-free survival time': ['phase ii: kaplan-meier estimate for progression/relapse-free survival time'], 'phase ii: kaplan-meier estimate for overall survival time': ['phase ii: kaplan-meier estimate for overall survival time'], 'number of regimen related toxicities': ['number of regimen related toxicities'], 'phase ii: cumulative incidence of acute gvhd': ['phase ii: cumulative incidence of acute gvhd'], 'phase ii: cumulative incidence of chronic gvhd': ['phase ii: cumulative incidence of chronic gvhd'], 'phase ii: cumulative incidence of non-relapse mortality': ['phase ii: cumulative incidence of non-relapse mortality'], 'assess safety and feasibility of monoclonal abs directed to cd45 and cd52 antigens, fludarabine and low dose tbi, as a non-myeloablative preparatory regimen for allo hsct. this will be determined by 100d non-relapse mortality and 100d graft rejection': ['assess safety and feasibility of monoclonal abs directed to cd45 and cd52 antigens, fludarabine and low dose tbi, as a non-myeloablative preparatory regimen for allo hsct. this will be determined by 100d non-relapse mortality and 100d graft rejection'], 'to obtain a preliminary estimate of the efficacy of this therapy as defined by: complete remission at day 100 and one-year disease free survival.': ['to obtain a preliminary estimate of the efficacy of this therapy as defined by: complete remission at day 100 and one-year disease free survival.'], 'phase ii: antitumour activity': ['phase ii: antitumour activity'], 'phase i: study of the variation of radioactivity of 131i or 124i in whole blood, at several time intervals': ['phase i: study of the variation of radioactivity of 131i or 124i in whole blood, at several time intervals'], 'phase ii: survival rate': ['phase ii: survival rate']}\n"
     ]
    }
   ],
   "source": [
    "with open(\"../data/synonymous_measure.json\") as f:\n",
    "    merged_measure_members = json.load(f)\n",
    "    parent = defaultdict(str)\n",
    "    for par, members in merged_measure_members.items():\n",
    "        for member in members:\n",
    "            if par not in merged_measure_count:\n",
    "                merged_measure_count[par] = measure_count[member]\n",
    "            else:\n",
    "                merged_measure_count[par] += measure_count[member]\n",
    "            parent[member] = par\n",
    "\n",
    "print(sorted(merged_measure_count.items(), key=lambda x: x[1], reverse=True)[:10])\n",
    "print(merged_measure_members)\n",
    "        \n",
    "# print(dsu.par['Duration of Hospital Stay Following Surgery.'.lower()])\n",
    "# merged_measure_count['safety']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "eb194d95",
   "metadata": {},
   "outputs": [],
   "source": [
    "top_10_measures = sorted(merged_measure_count.keys(), key=lambda x: merged_measure_count[x], reverse=True)[:10]\n",
    "for measure_name in top_10_measures:\n",
    "    df[f\"measure_{measure_name}\"] = df.outcome_measures.apply(lambda x: any(parent[m.lower()]==measure_name for m in processed_measure[x]))\n",
    "df[\"lead_outcome_measure\"] = df.outcome_measures.apply(lambda x: parent[processed_measure[x][0].lower()] if processed_measure[x] and parent[processed_measure[x][0].lower()] in top_10_measures else \"Others\")\n",
    "df[\"number_of_measures\"] = df.outcome_measures.apply(lambda x: len(x.split(\"|\")))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "e85d9431",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Immunologic response to vaccine\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>10</th>\n",
       "      <th>11</th>\n",
       "      <th>12</th>\n",
       "      <th>...</th>\n",
       "      <th>106</th>\n",
       "      <th>107</th>\n",
       "      <th>108</th>\n",
       "      <th>109</th>\n",
       "      <th>110</th>\n",
       "      <th>111</th>\n",
       "      <th>113</th>\n",
       "      <th>114</th>\n",
       "      <th>115</th>\n",
       "      <th>116</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>rank</th>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "      <td>6</td>\n",
       "      <td>7</td>\n",
       "      <td>11</td>\n",
       "      <td>12</td>\n",
       "      <td>13</td>\n",
       "      <td>...</td>\n",
       "      <td>107</td>\n",
       "      <td>108</td>\n",
       "      <td>109</td>\n",
       "      <td>110</td>\n",
       "      <td>111</td>\n",
       "      <td>112</td>\n",
       "      <td>114</td>\n",
       "      <td>115</td>\n",
       "      <td>116</td>\n",
       "      <td>117</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nct_number</th>\n",
       "      <td>NCT01829373</td>\n",
       "      <td>NCT00401778</td>\n",
       "      <td>NCT00132054</td>\n",
       "      <td>NCT02429843</td>\n",
       "      <td>NCT00084799</td>\n",
       "      <td>NCT01486602</td>\n",
       "      <td>NCT00005022</td>\n",
       "      <td>NCT00062322</td>\n",
       "      <td>NCT00059761</td>\n",
       "      <td>NCT00857025</td>\n",
       "      <td>...</td>\n",
       "      <td>NCT01121575</td>\n",
       "      <td>NCT01302808</td>\n",
       "      <td>NCT00569114</td>\n",
       "      <td>NCT00731952</td>\n",
       "      <td>NCT00633724</td>\n",
       "      <td>NCT01454102</td>\n",
       "      <td>NCT00874588</td>\n",
       "      <td>NCT00870532</td>\n",
       "      <td>NCT00654758</td>\n",
       "      <td>NCT00666692</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>title</th>\n",
       "      <td>Lung Cancer Vaccine Plus Oral Dietary Supplement</td>\n",
       "      <td>Trial of RAD001 in Patients With Operable Non-...</td>\n",
       "      <td>Amrubicin and Irinotecan in Treating Patients ...</td>\n",
       "      <td>A Study of TRC105 in Combination With Paclitax...</td>\n",
       "      <td>Monoclonal Antibody Therapy in Treating Patien...</td>\n",
       "      <td>Specialized Radiation Therapy and Chemotherapy...</td>\n",
       "      <td>Radiation Therapy Plus Combination Chemotherap...</td>\n",
       "      <td>Neoadjuvant Chemoradiotherapy Followed By Surg...</td>\n",
       "      <td>Chemotherapy Combined With Radiation Therapy i...</td>\n",
       "      <td>Beta-Glucan in Treating Patients With Locally ...</td>\n",
       "      <td>...</td>\n",
       "      <td>A Study Of Combined C- MET Inhibitor And PAN-H...</td>\n",
       "      <td>Romidepsin and Erlotinib Hydrochloride in Trea...</td>\n",
       "      <td>Phase 1 Study of TG01 and Erlotinib in Non-sma...</td>\n",
       "      <td>Phase I Study of Induction Therapy With VELCAD...</td>\n",
       "      <td>Multiple-Vaccine Therapy in Treating Patients ...</td>\n",
       "      <td>Study of Nivolumab (BMS-936558) in Combination...</td>\n",
       "      <td>Peptide Vaccine Targeting to Cancer Specific A...</td>\n",
       "      <td>Study of Combination of Metronomic Oral Vinore...</td>\n",
       "      <td>A Phase 1b Study With Volociximab in Combinati...</td>\n",
       "      <td>A Phase 1b Study With Volociximab in Combinati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>acronym</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>status</th>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_results</th>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>...</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>conditions</th>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>...</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Lung Cancer|Metastatic Cancer</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>interventions</th>\n",
       "      <td>Biological: vaccine 1650-G</td>\n",
       "      <td>Drug: RAD001</td>\n",
       "      <td>Drug: amrubicin hydrochloride|Drug: irinotecan...</td>\n",
       "      <td>Drug: TRC105</td>\n",
       "      <td>Biological: monoclonal antibody hu3S193</td>\n",
       "      <td>Drug: carboplatin|Drug: paclitaxel|Radiation: ...</td>\n",
       "      <td>Drug: cisplatin|Drug: etoposide|Radiation: rad...</td>\n",
       "      <td>Drug: cisplatin|Drug: irinotecan hydrochloride...</td>\n",
       "      <td>Drug: cisplatin|Drug: irinotecan hydrochloride...</td>\n",
       "      <td>Biological: beta-glucan MM-10-001|Other: flow ...</td>\n",
       "      <td>...</td>\n",
       "      <td>Drug: PF-02341066|Drug: PF-00299804</td>\n",
       "      <td>Combination Product: Erlotinib plus Romidepsin...</td>\n",
       "      <td>Drug: TG01</td>\n",
       "      <td>Drug: Velcade and Vorinostat</td>\n",
       "      <td>Biological: HLA-A*2402restricted URLC10, TTK, ...</td>\n",
       "      <td>Biological: Nivolumab|Drug: Gemcitabine|Drug: ...</td>\n",
       "      <td>Biological: HLA-A*2402restricted URLC10, CDCA1...</td>\n",
       "      <td>Drug: oral vinorelbine|Drug: sorafenib</td>\n",
       "      <td>Drug: M200 (Volociximab), Carboplatin, Paclitaxel</td>\n",
       "      <td>Drug: M200 (Volociximab), Carboplatin, Paclita...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>outcome_measures</th>\n",
       "      <td>Immunologic response to vaccine</td>\n",
       "      <td>Clinical Response as Assessed Metabolically by...</td>\n",
       "      <td></td>\n",
       "      <td>Number of patients with a change in medical ma...</td>\n",
       "      <td>Confirmation of Tumor Targeting as Measured by...</td>\n",
       "      <td>Maximum-tolerated RT dose fraction|Radiographi...</td>\n",
       "      <td>Frequency of patients developing unacceptable ...</td>\n",
       "      <td></td>\n",
       "      <td>Maximum tolerated dose of irinotecan in combin...</td>\n",
       "      <td>Safety|Maximum-tolerated dose|Toxicity as asse...</td>\n",
       "      <td>...</td>\n",
       "      <td>Overview of Treatment-emergent All Causalities...</td>\n",
       "      <td>Number of Participants With Dose Limiting Toxi...</td>\n",
       "      <td>Saftey, maximum tolerated dose, optimal biolog...</td>\n",
       "      <td>Adverse events|Tumor response</td>\n",
       "      <td>Adverse effects, dose limiting toxicity, and m...</td>\n",
       "      <td>Number of Participants Who Experienced Serious...</td>\n",
       "      <td>Adverse effects, dose limiting toxicity, and m...</td>\n",
       "      <td>to determine the optimal combination of metron...</td>\n",
       "      <td>To determine the maximum tolerated dose (MTD) ...</td>\n",
       "      <td>To determine the maximum tolerated dose (MTD) ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>sponsor/collaborators</th>\n",
       "      <td>Edward Hirschowitz|University of Louisville|Un...</td>\n",
       "      <td>Emory University</td>\n",
       "      <td>Japan Multinational Trial Organization|Nationa...</td>\n",
       "      <td>University of Alabama at Birmingham|Tracon Pha...</td>\n",
       "      <td>Ludwig Institute for Cancer Research|National ...</td>\n",
       "      <td>Alliance for Clinical Trials in Oncology|Natio...</td>\n",
       "      <td>Radiation Therapy Oncology Group|National Canc...</td>\n",
       "      <td>Fox Chase Cancer Center|National Cancer Instit...</td>\n",
       "      <td>Radiation Therapy Oncology Group|National Canc...</td>\n",
       "      <td>City of Hope Medical Center|National Cancer In...</td>\n",
       "      <td>...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>University of Texas Southwestern Medical Cente...</td>\n",
       "      <td>Tragara Pharmaceuticals, Inc.</td>\n",
       "      <td>University of Virginia</td>\n",
       "      <td>Fukushima Medical University|Human Genome Cent...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>Fukushima Medical University|Human Genome Cent...</td>\n",
       "      <td>National Cancer Centre, Singapore</td>\n",
       "      <td>AbbVie</td>\n",
       "      <td>Abbott</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gender</th>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>age</th>\n",
       "      <td>21 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>19 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years to 80 Years   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>...</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>21 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years to 99 Years   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>phases</th>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enrollment</th>\n",
       "      <td>5.0</td>\n",
       "      <td>33.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>36.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>...</td>\n",
       "      <td>70.0</td>\n",
       "      <td>17.0</td>\n",
       "      <td>45.0</td>\n",
       "      <td>21.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>472.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>33.0</td>\n",
       "      <td>7.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>funded_bys</th>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>...</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Industry</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_type</th>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_designs</th>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Primary Purpose: Treatment</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Primary Purpose: Treatment</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Par...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>other_ids</th>\n",
       "      <td>BG1006</td>\n",
       "      <td>IRB00024810</td>\n",
       "      <td>JMTO-LC03-03|CDR0000439464</td>\n",
       "      <td>F150128005 (UAB 1504)</td>\n",
       "      <td>LUD2002-015|MSKCC 04-012|CDR0000365621</td>\n",
       "      <td>CALGB 31102|CDR0000719011|NCI-2012-00087|U10CA...</td>\n",
       "      <td>RTOG-9712|CDR0000065797</td>\n",
       "      <td>CDR0000304720|P30CA006927|FCCC-02613</td>\n",
       "      <td>RTOG-0241|CDR0000269348</td>\n",
       "      <td>07243|P30CA033572|CHNMC-07243|CDR0000634737</td>\n",
       "      <td>...</td>\n",
       "      <td>A8081006</td>\n",
       "      <td>STU 012011-004|CDR0000653093|NCI-2011-01035</td>\n",
       "      <td>TP2001-101</td>\n",
       "      <td>12472</td>\n",
       "      <td>FVT-L0701</td>\n",
       "      <td>CA209-012</td>\n",
       "      <td>FVT-L0901</td>\n",
       "      <td>08-3-LUN</td>\n",
       "      <td>M200-1211|2007-003396-39</td>\n",
       "      <td>M200-1212</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>results_first_posted</th>\n",
       "      <td>NaN</td>\n",
       "      <td>July 14, 2015</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>February 8, 2022</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>March 30, 2015</td>\n",
       "      <td>January 20, 2021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>August 5, 2019</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>locations</th>\n",
       "      <td>University of Kentucky, Lexington, Kentucky, U...</td>\n",
       "      <td>Emory University Winship Cancer Institute, Atl...</td>\n",
       "      <td>Gunma Cancer Center, Gunma, Japan|National Hos...</td>\n",
       "      <td>UAB Comprehensive Cancer Center, Birmingham, A...</td>\n",
       "      <td>Memorial Sloan-Kettering Cancer Center, New Yo...</td>\n",
       "      <td>Mayo Clinic Hospital, Phoenix, Arizona, United...</td>\n",
       "      <td>University of Alabama at Birmingham Comprehens...</td>\n",
       "      <td>Fox Chase Cancer Center, Philadelphia, Pennsyl...</td>\n",
       "      <td>Comprehensive Cancer Center at University of A...</td>\n",
       "      <td>City of Hope Medical Center, Duarte, Californi...</td>\n",
       "      <td>...</td>\n",
       "      <td>Clinical Trials Office University of Colorado ...</td>\n",
       "      <td>Simmons Comprehensive Cancer Center at Univers...</td>\n",
       "      <td>Comprehensive Blood and Cancer Center, Bakersf...</td>\n",
       "      <td>University of Virginia, Charlottesville, Virgi...</td>\n",
       "      <td>Fukushima Medical University Hospital, Fukushi...</td>\n",
       "      <td>Ucla, Los Angeles, California, United States|Y...</td>\n",
       "      <td>Fukushima Medical University, Fukushima, Japan</td>\n",
       "      <td>National Cancer Centre, Singapore, Singapore, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Site Reference ID/Investigator# 70354, Bethesd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_documents</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>url</th>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01829373</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00401778</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00132054</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02429843</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00084799</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01486602</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00005022</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00062322</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00059761</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00857025</td>\n",
       "      <td>...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01121575</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01302808</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00569114</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00731952</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00633724</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01454102</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00874588</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00870532</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00654758</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00666692</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>duration</th>\n",
       "      <td>489.0</td>\n",
       "      <td>2587.0</td>\n",
       "      <td>1645.0</td>\n",
       "      <td>1490.0</td>\n",
       "      <td>877.0</td>\n",
       "      <td>2147.0</td>\n",
       "      <td>4503.0</td>\n",
       "      <td>2434.0</td>\n",
       "      <td>3898.0</td>\n",
       "      <td>4561.0</td>\n",
       "      <td>...</td>\n",
       "      <td>1280.0</td>\n",
       "      <td>1917.0</td>\n",
       "      <td>762.0</td>\n",
       "      <td>2830.0</td>\n",
       "      <td>1858.0</td>\n",
       "      <td>3507.0</td>\n",
       "      <td>1188.0</td>\n",
       "      <td>1918.0</td>\n",
       "      <td>882.0</td>\n",
       "      <td>183.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_PFS</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_OS</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_ORR</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_AEs</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_DOR</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_DLT</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_Cmax</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_</th>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_MTD</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_disease control rate</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lead_outcome_measure</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Others</td>\n",
       "      <td>...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>AEs</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>number_of_measures</th>\n",
       "      <td>1</td>\n",
       "      <td>5</td>\n",
       "      <td>1</td>\n",
       "      <td>8</td>\n",
       "      <td>7</td>\n",
       "      <td>6</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>7</td>\n",
       "      <td>...</td>\n",
       "      <td>42</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>4</td>\n",
       "      <td>6</td>\n",
       "      <td>4</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>35 rows × 106 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                            0    \\\n",
       "rank                                                                          1   \n",
       "nct_number                                                          NCT01829373   \n",
       "title                          Lung Cancer Vaccine Plus Oral Dietary Supplement   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                                        Biological: vaccine 1650-G   \n",
       "outcome_measures                                Immunologic response to vaccine   \n",
       "sponsor/collaborators         Edward Hirschowitz|University of Louisville|Un...   \n",
       "gender                                                                      All   \n",
       "age                                   21 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  5.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                                BG1006   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     University of Kentucky, Lexington, Kentucky, U...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01829373   \n",
       "duration                                                                  489.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "\n",
       "                                                                            1    \\\n",
       "rank                                                                          2   \n",
       "nct_number                                                          NCT00401778   \n",
       "title                         Trial of RAD001 in Patients With Operable Non-...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                                                      Drug: RAD001   \n",
       "outcome_measures              Clinical Response as Assessed Metabolically by...   \n",
       "sponsor/collaborators                                          Emory University   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 33.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                           IRB00024810   \n",
       "results_first_posted                                              July 14, 2015   \n",
       "locations                     Emory University Winship Cancer Institute, Atl...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00401778   \n",
       "duration                                                                 2587.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            5   \n",
       "\n",
       "                                                                            2    \\\n",
       "rank                                                                          3   \n",
       "nct_number                                                          NCT00132054   \n",
       "title                         Amrubicin and Irinotecan in Treating Patients ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: amrubicin hydrochloride|Drug: irinotecan...   \n",
       "outcome_measures                                                                  \n",
       "sponsor/collaborators         Japan Multinational Trial Organization|Nationa...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 30.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                                        Primary Purpose: Treatment   \n",
       "other_ids                                            JMTO-LC03-03|CDR0000439464   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Gunma Cancer Center, Gunma, Japan|National Hos...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00132054   \n",
       "duration                                                                 1645.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "\n",
       "                                                                            3    \\\n",
       "rank                                                                          4   \n",
       "nct_number                                                          NCT02429843   \n",
       "title                         A Study of TRC105 in Combination With Paclitax...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                                                      Drug: TRC105   \n",
       "outcome_measures              Number of patients with a change in medical ma...   \n",
       "sponsor/collaborators         University of Alabama at Birmingham|Tracon Pha...   \n",
       "gender                                                                      All   \n",
       "age                                   19 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 16.0   \n",
       "funded_bys                                                       Other|Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                 F150128005 (UAB 1504)   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     UAB Comprehensive Cancer Center, Birmingham, A...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT02429843   \n",
       "duration                                                                 1490.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                 True   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            8   \n",
       "\n",
       "                                                                            4    \\\n",
       "rank                                                                          5   \n",
       "nct_number                                                          NCT00084799   \n",
       "title                         Monoclonal Antibody Therapy in Treating Patien...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                           Biological: monoclonal antibody hu3S193   \n",
       "outcome_measures              Confirmation of Tumor Targeting as Measured by...   \n",
       "sponsor/collaborators         Ludwig Institute for Cancer Research|National ...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 10.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                LUD2002-015|MSKCC 04-012|CDR0000365621   \n",
       "results_first_posted                                           February 8, 2022   \n",
       "locations                     Memorial Sloan-Kettering Cancer Center, New Yo...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00084799   \n",
       "duration                                                                  877.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            7   \n",
       "\n",
       "                                                                            5    \\\n",
       "rank                                                                          6   \n",
       "nct_number                                                          NCT01486602   \n",
       "title                         Specialized Radiation Therapy and Chemotherapy...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: carboplatin|Drug: paclitaxel|Radiation: ...   \n",
       "outcome_measures              Maximum-tolerated RT dose fraction|Radiographi...   \n",
       "sponsor/collaborators         Alliance for Clinical Trials in Oncology|Natio...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 22.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                     CALGB 31102|CDR0000719011|NCI-2012-00087|U10CA...   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Mayo Clinic Hospital, Phoenix, Arizona, United...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01486602   \n",
       "duration                                                                 2147.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                 True   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            6   \n",
       "\n",
       "                                                                            6    \\\n",
       "rank                                                                          7   \n",
       "nct_number                                                          NCT00005022   \n",
       "title                         Radiation Therapy Plus Combination Chemotherap...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: cisplatin|Drug: etoposide|Radiation: rad...   \n",
       "outcome_measures              Frequency of patients developing unacceptable ...   \n",
       "sponsor/collaborators         Radiation Therapy Oncology Group|National Canc...   \n",
       "gender                                                                      All   \n",
       "age                                 18 Years to 80 Years   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 64.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                               RTOG-9712|CDR0000065797   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     University of Alabama at Birmingham Comprehens...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00005022   \n",
       "duration                                                                 4503.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "\n",
       "                                                                            10   \\\n",
       "rank                                                                         11   \n",
       "nct_number                                                          NCT00062322   \n",
       "title                         Neoadjuvant Chemoradiotherapy Followed By Surg...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: cisplatin|Drug: irinotecan hydrochloride...   \n",
       "outcome_measures                                                                  \n",
       "sponsor/collaborators         Fox Chase Cancer Center|National Cancer Instit...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  NaN   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                                        Primary Purpose: Treatment   \n",
       "other_ids                                  CDR0000304720|P30CA006927|FCCC-02613   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Fox Chase Cancer Center, Philadelphia, Pennsyl...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00062322   \n",
       "duration                                                                 2434.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "\n",
       "                                                                            11   \\\n",
       "rank                                                                         12   \n",
       "nct_number                                                          NCT00059761   \n",
       "title                         Chemotherapy Combined With Radiation Therapy i...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: cisplatin|Drug: irinotecan hydrochloride...   \n",
       "outcome_measures              Maximum tolerated dose of irinotecan in combin...   \n",
       "sponsor/collaborators         Radiation Therapy Oncology Group|National Canc...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 36.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                               RTOG-0241|CDR0000269348   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Comprehensive Cancer Center at University of A...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00059761   \n",
       "duration                                                                 3898.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "\n",
       "                                                                            12   \\\n",
       "rank                                                                         13   \n",
       "nct_number                                                          NCT00857025   \n",
       "title                         Beta-Glucan in Treating Patients With Locally ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Biological: beta-glucan MM-10-001|Other: flow ...   \n",
       "outcome_measures              Safety|Maximum-tolerated dose|Toxicity as asse...   \n",
       "sponsor/collaborators         City of Hope Medical Center|National Cancer In...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 20.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                           07243|P30CA033572|CHNMC-07243|CDR0000634737   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     City of Hope Medical Center, Duarte, Californi...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00857025   \n",
       "duration                                                                 4561.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                     Others   \n",
       "number_of_measures                                                            7   \n",
       "\n",
       "                              ...  \\\n",
       "rank                          ...   \n",
       "nct_number                    ...   \n",
       "title                         ...   \n",
       "acronym                       ...   \n",
       "status                        ...   \n",
       "study_results                 ...   \n",
       "conditions                    ...   \n",
       "interventions                 ...   \n",
       "outcome_measures              ...   \n",
       "sponsor/collaborators         ...   \n",
       "gender                        ...   \n",
       "age                           ...   \n",
       "phases                        ...   \n",
       "enrollment                    ...   \n",
       "funded_bys                    ...   \n",
       "study_type                    ...   \n",
       "study_designs                 ...   \n",
       "other_ids                     ...   \n",
       "results_first_posted          ...   \n",
       "locations                     ...   \n",
       "study_documents               ...   \n",
       "url                           ...   \n",
       "duration                      ...   \n",
       "measure_PFS                   ...   \n",
       "measure_OS                    ...   \n",
       "measure_ORR                   ...   \n",
       "measure_AEs                   ...   \n",
       "measure_DOR                   ...   \n",
       "measure_DLT                   ...   \n",
       "measure_Cmax                  ...   \n",
       "measure_                      ...   \n",
       "measure_MTD                   ...   \n",
       "measure_disease control rate  ...   \n",
       "lead_outcome_measure          ...   \n",
       "number_of_measures            ...   \n",
       "\n",
       "                                                                            106  \\\n",
       "rank                                                                        107   \n",
       "nct_number                                                          NCT01121575   \n",
       "title                         A Study Of Combined C- MET Inhibitor And PAN-H...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                               Drug: PF-02341066|Drug: PF-00299804   \n",
       "outcome_measures              Overview of Treatment-emergent All Causalities...   \n",
       "sponsor/collaborators                                                    Pfizer   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 70.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                              A8081006   \n",
       "results_first_posted                                             March 30, 2015   \n",
       "locations                     Clinical Trials Office University of Colorado ...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01121575   \n",
       "duration                                                                 1280.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                           42   \n",
       "\n",
       "                                                                            107  \\\n",
       "rank                                                                        108   \n",
       "nct_number                                                          NCT01302808   \n",
       "title                         Romidepsin and Erlotinib Hydrochloride in Trea...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                        Lung Cancer|Metastatic Cancer   \n",
       "interventions                 Combination Product: Erlotinib plus Romidepsin...   \n",
       "outcome_measures              Number of Participants With Dose Limiting Toxi...   \n",
       "sponsor/collaborators         University of Texas Southwestern Medical Cente...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 17.0   \n",
       "funded_bys                                                       Other|Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                           STU 012011-004|CDR0000653093|NCI-2011-01035   \n",
       "results_first_posted                                           January 20, 2021   \n",
       "locations                     Simmons Comprehensive Cancer Center at Univers...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01302808   \n",
       "duration                                                                 1917.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "\n",
       "                                                                            108  \\\n",
       "rank                                                                        109   \n",
       "nct_number                                                          NCT00569114   \n",
       "title                         Phase 1 Study of TG01 and Erlotinib in Non-sma...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non-small Cell Lung Cancer   \n",
       "interventions                                                        Drug: TG01   \n",
       "outcome_measures              Saftey, maximum tolerated dose, optimal biolog...   \n",
       "sponsor/collaborators                             Tragara Pharmaceuticals, Inc.   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 45.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                            TP2001-101   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Comprehensive Blood and Cancer Center, Bakersf...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00569114   \n",
       "duration                                                                  762.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "\n",
       "                                                                            109  \\\n",
       "rank                                                                        110   \n",
       "nct_number                                                          NCT00731952   \n",
       "title                         Phase I Study of Induction Therapy With VELCAD...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                                      Drug: Velcade and Vorinostat   \n",
       "outcome_measures                                  Adverse events|Tumor response   \n",
       "sponsor/collaborators                                    University of Virginia   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 21.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                                 12472   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     University of Virginia, Charlottesville, Virgi...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00731952   \n",
       "duration                                                                 2830.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                                True   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                  False   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                        AEs   \n",
       "number_of_measures                                                            2   \n",
       "\n",
       "                                                                            110  \\\n",
       "rank                                                                        111   \n",
       "nct_number                                                          NCT00633724   \n",
       "title                         Multiple-Vaccine Therapy in Treating Patients ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                 Biological: HLA-A*2402restricted URLC10, TTK, ...   \n",
       "outcome_measures              Adverse effects, dose limiting toxicity, and m...   \n",
       "sponsor/collaborators         Fukushima Medical University|Human Genome Cent...   \n",
       "gender                                                                      All   \n",
       "age                                   20 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  9.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                             FVT-L0701   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Fukushima Medical University Hospital, Fukushi...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00633724   \n",
       "duration                                                                 1858.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            4   \n",
       "\n",
       "                                                                            111  \\\n",
       "rank                                                                        112   \n",
       "nct_number                                                          NCT01454102   \n",
       "title                         Study of Nivolumab (BMS-936558) in Combination...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                           Non-small Cell Lung Cancer   \n",
       "interventions                 Biological: Nivolumab|Drug: Gemcitabine|Drug: ...   \n",
       "outcome_measures              Number of Participants Who Experienced Serious...   \n",
       "sponsor/collaborators                                      Bristol-Myers Squibb   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                472.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Randomized|Intervention Model: Par...   \n",
       "other_ids                                                             CA209-012   \n",
       "results_first_posted                                             August 5, 2019   \n",
       "locations                     Ucla, Los Angeles, California, United States|Y...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01454102   \n",
       "duration                                                                 3507.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                                True   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            6   \n",
       "\n",
       "                                                                            113  \\\n",
       "rank                                                                        114   \n",
       "nct_number                                                          NCT00874588   \n",
       "title                         Peptide Vaccine Targeting to Cancer Specific A...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                 Biological: HLA-A*2402restricted URLC10, CDCA1...   \n",
       "outcome_measures              Adverse effects, dose limiting toxicity, and m...   \n",
       "sponsor/collaborators         Fukushima Medical University|Human Genome Cent...   \n",
       "gender                                                                      All   \n",
       "age                                   20 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  6.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                             FVT-L0901   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                        Fukushima Medical University, Fukushima, Japan   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00874588   \n",
       "duration                                                                 1188.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            4   \n",
       "\n",
       "                                                                            114  \\\n",
       "rank                                                                        115   \n",
       "nct_number                                                          NCT00870532   \n",
       "title                         Study of Combination of Metronomic Oral Vinore...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non-Small Cell Lung Cancer   \n",
       "interventions                            Drug: oral vinorelbine|Drug: sorafenib   \n",
       "outcome_measures              to determine the optimal combination of metron...   \n",
       "sponsor/collaborators                         National Cancer Centre, Singapore   \n",
       "gender                                                                      All   \n",
       "age                                   21 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 52.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                              08-3-LUN   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     National Cancer Centre, Singapore, Singapore, ...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00870532   \n",
       "duration                                                                 1918.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "\n",
       "                                                                            115  \\\n",
       "rank                                                                        116   \n",
       "nct_number                                                          NCT00654758   \n",
       "title                         A Phase 1b Study With Volociximab in Combinati...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non-small Cell Lung Cancer   \n",
       "interventions                 Drug: M200 (Volociximab), Carboplatin, Paclitaxel   \n",
       "outcome_measures              To determine the maximum tolerated dose (MTD) ...   \n",
       "sponsor/collaborators                                                    AbbVie   \n",
       "gender                                                                      All   \n",
       "age                                 18 Years to 99 Years   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 33.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                              M200-1211|2007-003396-39   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                                                                   NaN   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00654758   \n",
       "duration                                                                  882.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            3   \n",
       "\n",
       "                                                                            116  \n",
       "rank                                                                        117  \n",
       "nct_number                                                          NCT00666692  \n",
       "title                         A Phase 1b Study With Volociximab in Combinati...  \n",
       "acronym                                                                     NaN  \n",
       "status                                                                Completed  \n",
       "study_results                                              No Results Available  \n",
       "conditions                                           Non-small Cell Lung Cancer  \n",
       "interventions                 Drug: M200 (Volociximab), Carboplatin, Paclita...  \n",
       "outcome_measures              To determine the maximum tolerated dose (MTD) ...  \n",
       "sponsor/collaborators                                                    Abbott  \n",
       "gender                                                                      All  \n",
       "age                                   18 Years and older   (Adult, Older Adult)  \n",
       "phases                                                                  Phase 1  \n",
       "enrollment                                                                  7.0  \n",
       "funded_bys                                                             Industry  \n",
       "study_type                                                       Interventional  \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...  \n",
       "other_ids                                                             M200-1212  \n",
       "results_first_posted                                                        NaN  \n",
       "locations                     Site Reference ID/Investigator# 70354, Bethesd...  \n",
       "study_documents                                                             NaN  \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00666692  \n",
       "duration                                                                  183.0  \n",
       "measure_PFS                                                               False  \n",
       "measure_OS                                                                False  \n",
       "measure_ORR                                                               False  \n",
       "measure_AEs                                                               False  \n",
       "measure_DOR                                                               False  \n",
       "measure_DLT                                                               False  \n",
       "measure_Cmax                                                              False  \n",
       "measure_                                                                   True  \n",
       "measure_MTD                                                               False  \n",
       "measure_disease control rate                                              False  \n",
       "lead_outcome_measure                                                             \n",
       "number_of_measures                                                            2  \n",
       "\n",
       "[35 rows x 106 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "print(df.outcome_measures[0])\n",
    "df.head(106).transpose()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "13951d66",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAkQAAAHFCAYAAAAT5Oa6AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAABBVUlEQVR4nO3df3xP9f//8ftrZhuy14y2WY1NvDG/EmKIsMyPVNIPWlrlzTtv8zPC542QGiqkRJQfvd+kelf6IashE5YfY36l5VdtNduw7NXINtvr+4evc+n1Rnnp9dprnNv1cnldLjvP5/Oc8zguvdp95zzPORa73W4XAACAiXl5ugAAAABPIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADT8/Z0AdeK0tJSZWVlqWrVqrJYLJ4uBwAAXAG73a5ff/1VoaGh8vK6/HkgAtEVysrKUlhYmKfLAAAAVyEzM1M333zzZfsJRFeoatWqks7/g/r7+3u4GgAAcCVsNpvCwsKM3+OXQyC6Qhcuk/n7+xOIAAC4xvzZdBcmVQMAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANMjEAEAANPzaCDauHGjevXqpdDQUFksFq1ateqiMQcOHNA999wjq9WqKlWqqFWrVsrIyDD6z549qyFDhqh69eq64YYb1KdPH+Xk5DhsIyMjQz179lTlypUVFBSkMWPG6Ny5c+4+PAAAcI3waCA6ffq0mjVrpnnz5l2y//Dhw2rfvr0aNGigDRs2aM+ePZo4caL8/PyMMSNHjtSnn36q999/X8nJycrKytL9999v9JeUlKhnz54qKirSli1btGzZMi1dulSTJk1y+/EBAIBrg8Vut9s9XYQkWSwWffTRR7rvvvuMtr59+6pixYr697//fcl18vPzdeONN2rFihV64IEHJEnfffedGjZsqJSUFLVp00Zr1qzR3XffraysLAUHB0uSFixYoLFjx+r48ePy8fG55LYLCwtVWFhoLNtsNoWFhSk/P1/+/v4uOmoA8Kzwcas9XQLK0A/Te3q6hDJns9lktVr/9Pd3uZ1DVFpaqtWrV+tvf/ubYmJiFBQUpNatWztcVktNTVVxcbGio6ONtgYNGqhWrVpKSUmRJKWkpKhJkyZGGJKkmJgY2Ww27d+//7L7T0hIkNVqNT5hYWGuP0gAAFAulNtAlJubq4KCAk2fPl3dunXTl19+qd69e+v+++9XcnKyJCk7O1s+Pj4KCAhwWDc4OFjZ2dnGmN+HoQv9F/ouZ/z48crPzzc+mZmZLjw6AABQnnh7uoDLKS0tlSTde++9GjlypCTp1ltv1ZYtW7RgwQJ17NjRrfv39fWVr6+vW/cBAADKh3J7hqhGjRry9vZWZGSkQ3vDhg2Nu8xCQkJUVFSkU6dOOYzJyclRSEiIMeZ/7zq7sHxhDAAAMLdyG4h8fHzUqlUrpaenO7R///33ql27tiSpRYsWqlixotatW2f0p6enKyMjQ1FRUZKkqKgo7d27V7m5ucaYpKQk+fv7XxS2AACAOXn0kllBQYEOHTpkLB89elRpaWkKDAxUrVq1NGbMGD388MPq0KGDOnXqpMTERH366afasGGDJMlqtWrAgAEaNWqUAgMD5e/vr6FDhyoqKkpt2rSRJHXt2lWRkZHq37+/Zs6cqezsbE2YMEFDhgzhkhgAAJDk4UC0Y8cOderUyVgeNWqUJCkuLk5Lly5V7969tWDBAiUkJGjYsGGqX7++PvjgA7Vv395YZ/bs2fLy8lKfPn1UWFiomJgYvf7660Z/hQoV9Nlnn2nw4MGKiopSlSpVFBcXp6lTp5bdgQIAgHKt3DyHqLy70ucYAMC1hOcQmQvPIboGn0MEAABQVghEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9AhEAADA9DwaiDZu3KhevXopNDRUFotFq1atuuzYp556ShaLRXPmzHFoz8vLU2xsrPz9/RUQEKABAwaooKDAYcyePXt0xx13yM/PT2FhYZo5c6YbjgYAAFyrPBqITp8+rWbNmmnevHl/OO6jjz7SN998o9DQ0Iv6YmNjtX//fiUlJemzzz7Txo0bNWjQIKPfZrOpa9euql27tlJTU/Xiiy9q8uTJWrhwocuPBwAAXJu8Pbnz7t27q3v37n845ueff9bQoUP1xRdfqGfPng59Bw4cUGJiorZv366WLVtKkl599VX16NFDL730kkJDQ7V8+XIVFRVp8eLF8vHxUaNGjZSWlqZZs2Y5BKf/VVhYqMLCQmPZZrP9hSMFAADlWbmeQ1RaWqr+/ftrzJgxatSo0UX9KSkpCggIMMKQJEVHR8vLy0tbt241xnTo0EE+Pj7GmJiYGKWnp+uXX3657L4TEhJktVqNT1hYmAuPDAAAlCflOhDNmDFD3t7eGjZs2CX7s7OzFRQU5NDm7e2twMBAZWdnG2OCg4MdxlxYvjDmUsaPH6/8/Hzjk5mZ+VcOBQAAlGMevWT2R1JTU/XKK69o586dslgsZb5/X19f+fr6lvl+AQBA2Su3Z4i+/vpr5ebmqlatWvL29pa3t7d+/PFHPf300woPD5ckhYSEKDc312G9c+fOKS8vTyEhIcaYnJwchzEXli+MAQAA5lZuA1H//v21Z88epaWlGZ/Q0FCNGTNGX3zxhSQpKipKp06dUmpqqrHe+vXrVVpaqtatWxtjNm7cqOLiYmNMUlKS6tevr2rVqpXtQQEAgHLJo5fMCgoKdOjQIWP56NGjSktLU2BgoGrVqqXq1as7jK9YsaJCQkJUv359SVLDhg3VrVs3DRw4UAsWLFBxcbHi4+PVt29f4xb9Rx55RFOmTNGAAQM0duxY7du3T6+88opmz55ddgcKAADKNY8Goh07dqhTp07G8qhRoyRJcXFxWrp06RVtY/ny5YqPj1eXLl3k5eWlPn36aO7cuUa/1WrVl19+qSFDhqhFixaqUaOGJk2a9Ie33AMAAHOx2O12u6eLuBbYbDZZrVbl5+fL39/f0+UAgEuEj1vt6RJQhn6Y3vPPB11nrvT3d7mdQwQAAFBWyu1t9yg/+AvSXMz4FyQAcIYIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYntOBKDMzUz/99JOxvG3bNo0YMUILFy50aWEAAABlxelA9Mgjj+irr76SJGVnZ+uuu+7Stm3b9K9//UtTp051eYEAAADu5nQg2rdvn26//XZJ0nvvvafGjRtry5YtWr58uZYuXerq+gAAANzO6UBUXFwsX19fSdLatWt1zz33SJIaNGigY8eOubY6AACAMuB0IGrUqJEWLFigr7/+WklJSerWrZskKSsrS9WrV3dqWxs3blSvXr0UGhoqi8WiVatWGX3FxcUaO3asmjRpoipVqig0NFSPPfaYsrKyHLaRl5en2NhY+fv7KyAgQAMGDFBBQYHDmD179uiOO+6Qn5+fwsLCNHPmTGcPGwAAXMecDkQzZszQG2+8oTvvvFP9+vVTs2bNJEmffPKJcSntSp0+fVrNmjXTvHnzLuo7c+aMdu7cqYkTJ2rnzp368MMPlZ6ebpyRuiA2Nlb79+9XUlKSPvvsM23cuFGDBg0y+m02m7p27aratWsrNTVVL774oiZPnswkcAAAYPB2doU777xTJ06ckM1mU7Vq1Yz2QYMGqXLlyk5tq3v37urevfsl+6xWq5KSkhzaXnvtNd1+++3KyMhQrVq1dODAASUmJmr79u1q2bKlJOnVV19Vjx499NJLLyk0NFTLly9XUVGRFi9eLB8fHzVq1EhpaWmaNWuWQ3ACAADm5fQZomeffVY//fSTQxiSpPDwcAUFBbmssEvJz8+XxWJRQECAJCklJUUBAQFGGJKk6OhoeXl5aevWrcaYDh06yMfHxxgTExOj9PR0/fLLL5fdV2FhoWw2m8MHAABcn5wORB9//LFuueUWdenSRStWrFBhYaE76rrI2bNnNXbsWPXr10/+/v6Szt/2/78hzNvbW4GBgcrOzjbGBAcHO4y5sHxhzKUkJCTIarUan7CwMFceDgAAKEecDkRpaWnavn27GjVqpOHDhyskJESDBw/W9u3b3VGfpPMTrB966CHZ7XbNnz/fbfv5vfHjxys/P9/4ZGZmlsl+AQBA2buqV3c0b95cc+fOVVZWlt566y399NNPateunZo2bapXXnlF+fn5LivwQhj68ccflZSUZJwdkqSQkBDl5uY6jD937pzy8vIUEhJijMnJyXEYc2H5wphL8fX1lb+/v8MHAABcn/7Su8zsdruKi4tVVFQku92uatWq6bXXXlNYWJjefffdv1zchTB08OBBrV279qLb+qOionTq1CmlpqYabevXr1dpaalat25tjNm4caOKi4uNMUlJSapfv/5F86AAAIA5XVUgSk1NVXx8vGrWrKmRI0eqefPmOnDggJKTk3Xw4EE9//zzGjZs2J9up6CgQGlpaUpLS5MkHT16VGlpacrIyFBxcbEeeOAB7dixQ8uXL1dJSYmys7OVnZ2toqIiSVLDhg3VrVs3DRw4UNu2bdPmzZsVHx+vvn37KjQ0VNL5V434+PhowIAB2r9/v95991298sorGjVq1NUcOgAAuA5Z7Ha73ZkVmjRpou+++05du3bVwIED1atXL1WoUMFhzIkTJxQUFKTS0tI/3NaGDRvUqVOni9rj4uI0efJkRUREXHK9r776Snfeeaek8w9mjI+P16effiovLy/16dNHc+fO1Q033GCM37Nnj4YMGaLt27erRo0aGjp0qMaOHevMYctms8lqtSo/P990l8/Cx632dAkoQz9M7+npElCG+H6bixm/31f6+9vp5xA99NBDevLJJ3XTTTdddkyNGjX+NAxJ559p9Ed57EqyWmBgoFasWPGHY5o2baqvv/76T7cFAADMyelANHHiRHfUAQAA4DFOByJJ+umnn/TJJ58oIyPDmM9zwaxZs1xSGAAAQFlxOhCtW7dO99xzj+rUqaPvvvtOjRs31g8//CC73a7bbrvNHTUCAAC4ldN3mY0fP16jR4/W3r175efnpw8++ECZmZnq2LGjHnzwQXfUCAAA4FZOB6IDBw7osccek3T+NRm//fabbrjhBk2dOlUzZsxweYEAAADu5nQgqlKlijFvqGbNmjp8+LDRd+LECddVBgAAUEacnkPUpk0bbdq0SQ0bNlSPHj309NNPa+/evfrwww/Vpk0bd9QIAADgVk4HolmzZqmgoECSNGXKFBUUFOjdd99VvXr1uMMMAABck5wORHXq1DF+rlKlihYsWODSggAAAMraX3q5KwAAwPXgis4QVatWTRaL5Yo2mJeX95cKAgAAKGtXFIjmzJlj/Hzy5ElNmzZNMTExioqKkiSlpKToiy++4LUeAADgmnRFgSguLs74uU+fPpo6dari4+ONtmHDhum1117T2rVrNXLkSNdXCQAA4EZOzyH64osv1K1bt4vau3XrprVr17qkKAAAgLLkdCCqXr26Pv7444vaP/74Y1WvXt0lRQEAAJQlp2+7nzJliv7+979rw4YNat26tSRp69atSkxM1KJFi1xeIAAAgLs5HYgef/xxNWzYUHPnztWHH34oSWrYsKE2bdpkBCQAAIBridOBSJJat26t5cuXu7oWAAAAj+DBjAAAwPQIRAAAwPQIRAAAwPQIRAAAwPQIRAAAwPScvsvs9OnTmj59utatW6fc3FyVlpY69B85csRlxQEAAJQFpwPR3//+dyUnJ6t///6qWbOmLBaLO+oCAAAoM04HojVr1mj16tVq166dO+oBAAAoc07PIapWrZoCAwPdUQsAAIBHOB2InnvuOU2aNElnzpxxRz0AAABlzulLZi+//LIOHz6s4OBghYeHq2LFig79O3fudFlxAAAAZcHpQHTfffe5oQwAAADPcToQPfvss+6oAwAAwGOu6m33kpSamqoDBw5Ikho1aqTmzZu7rCgAAICy5HQgys3NVd++fbVhwwYFBARIkk6dOqVOnTpp5cqVuvHGG11dIwAAgFs5fZfZ0KFD9euvv2r//v3Ky8tTXl6e9u3bJ5vNpmHDhjm1rY0bN6pXr14KDQ2VxWLRqlWrHPrtdrsmTZqkmjVrqlKlSoqOjtbBgwcdxuTl5Sk2Nlb+/v4KCAjQgAEDVFBQ4DBmz549uuOOO+Tn56ewsDDNnDnT2cMGAADXMacDUWJiol5//XU1bNjQaIuMjNS8efO0Zs0ap7Z1+vRpNWvWTPPmzbtk/8yZMzV37lwtWLBAW7duVZUqVRQTE6OzZ88aY2JjY7V//34lJSXps88+08aNGzVo0CCj32azqWvXrqpdu7ZSU1P14osvavLkyVq4cKGTRw4AAK5XTl8yKy0tvehWe0mqWLHiRe81+zPdu3dX9+7dL9lnt9s1Z84cTZgwQffee68k6e2331ZwcLBWrVqlvn376sCBA0pMTNT27dvVsmVLSdKrr76qHj166KWXXlJoaKiWL1+uoqIiLV68WD4+PmrUqJHS0tI0a9Ysh+AEAADMy+kzRJ07d9bw4cOVlZVltP38888aOXKkunTp4rLCjh49quzsbEVHRxttVqtVrVu3VkpKiiQpJSVFAQEBRhiSpOjoaHl5eWnr1q3GmA4dOsjHx8cYExMTo/T0dP3yyy+X3X9hYaFsNpvDBwAAXJ+cDkSvvfaabDabwsPDdcstt+iWW25RRESEbDabXn31VZcVlp2dLUkKDg52aA8ODjb6srOzFRQU5NDv7e2twMBAhzGX2sbv93EpCQkJslqtxicsLOyvHRAAACi3nL5kFhYWpp07d2rt2rX67rvvJEkNGzZ0OJNzPRg/frxGjRplLNtsNkIRAADXqat6DpHFYtFdd92lu+66y9X1GEJCQiRJOTk5qlmzptGek5OjW2+91RiTm5vrsN65c+eUl5dnrB8SEqKcnByHMReWL4y5FF9fX/n6+v7l4wAAAOXfFQWiuXPnatCgQfLz89PcuXP/cKyzt95fTkREhEJCQrRu3TojANlsNm3dulWDBw+WJEVFRenUqVNKTU1VixYtJEnr169XaWmpWrdubYz517/+peLiYmMyeFJSkurXr69q1aq5pFYAAHBtu6JANHv2bMXGxsrPz0+zZ8++7DiLxeJUICooKNChQ4eM5aNHjyotLU2BgYGqVauWRowYoWnTpqlevXqKiIjQxIkTFRoaarxPrWHDhurWrZsGDhyoBQsWqLi4WPHx8erbt69CQ0MlSY888oimTJmiAQMGaOzYsdq3b59eeeWVPzwOAABgLlcUiI4ePXrJn/+qHTt2qFOnTsbyhTk7cXFxWrp0qZ555hmdPn1agwYN0qlTp9S+fXslJibKz8/PWGf58uWKj49Xly5d5OXlpT59+jicxbJarfryyy81ZMgQtWjRQjVq1NCkSZO45R4AABgsdrvd7swKU6dO1ejRo1W5cmWH9t9++00vvviiJk2a5NICywubzSar1ar8/Hz5+/t7upwyFT5utadLQBn6YXpPT5eAMsT321zM+P2+0t/fTt92P2XKlItejSFJZ86c0ZQpU5zdHAAAgMc5HYjsdrssFstF7bt371ZgYKBLigIAAChLV3zbfbVq1WSxWGSxWPS3v/3NIRSVlJSooKBATz31lFuKBAAAcKcrDkRz5syR3W7Xk08+qSlTpshqtRp9Pj4+Cg8PV1RUlFuKBAAAcKcrDkRxcXGSzj8fqF27dvL2vqpnOgIAAJQ7Ts8h6tixo3788UdNmDBB/fr1M54UvWbNGu3fv9/lBQIAALib04EoOTlZTZo00datW/Xhhx8ad5zt3r1bzz77rMsLBAAAcDenA9G4ceM0bdo0JSUlycfHx2jv3LmzvvnmG5cWBwAAUBacDkR79+5V7969L2oPCgrSiRMnXFIUAABAWXI6EAUEBOjYsWMXte/atUs33XSTS4oCAAAoS04Hor59+2rs2LHKzs6WxWJRaWmpNm/erNGjR+uxxx5zR40AAABu5XQgeuGFF9SgQQOFhYWpoKBAkZGR6tChg9q2basJEya4o0YAAAC3cvphQj4+Plq0aJEmTpyoffv2qaCgQM2bN1e9evXcUR8AAIDbXfXTFWvVqqVatWq5shYAAACPuKJANGrUqCve4KxZs666GAAAAE+4okC0a9euK9rY71/4CgAAcK24okD01VdfubsOAAAAj3H6LrPfy8zMVGZmpqtqAQAA8AinA9G5c+c0ceJEWa1WhYeHKzw8XFarVRMmTFBxcbE7agQAAHArp+8yGzp0qD788EPNnDlTUVFRkqSUlBRNnjxZJ0+e1Pz5811eJAAAgDs5HYhWrFihlStXqnv37kZb06ZNFRYWpn79+hGIAADANcfpS2a+vr4KDw+/qD0iIkI+Pj6uqAkAAKBMOR2I4uPj9dxzz6mwsNBoKyws1PPPP6/4+HiXFgcAAFAWnL5ktmvXLq1bt04333yzmjVrJknavXu3ioqK1KVLF91///3G2A8//NB1lQIAALiJ04EoICBAffr0cWgLCwtzWUEAAABlzelAtGTJEnfUAQAA4DF/6cGMAAAA1wOnzxCdPHlSkyZN0ldffaXc3FyVlpY69Ofl5bmsOAAAgLLgdCDq37+/Dh06pAEDBig4OJgXugIAgGue04Ho66+/1qZNm4w7zAAAAK51Ts8hatCggX777Td31AIAAOARTgei119/Xf/617+UnJyskydPymazOXwAAACuNVf1HCKbzabOnTs7tNvtdlksFpWUlLisOAAAgLLg9Bmi2NhYVaxYUStWrNC6deu0fv16rV+/Xl999ZXWr1/v0uJKSko0ceJERUREqFKlSrrlllv03HPPyW63G2PsdrsmTZqkmjVrqlKlSoqOjtbBgwcdtpOXl6fY2Fj5+/srICBAAwYMUEFBgUtrBQAA1y6nzxDt27dPu3btUv369d1Rj4MZM2Zo/vz5WrZsmRo1aqQdO3boiSeekNVq1bBhwyRJM2fO1Ny5c7Vs2TJFRERo4sSJiomJ0bfffis/Pz9J50PcsWPHlJSUpOLiYj3xxBMaNGiQVqxY4fZjAAAA5Z/TZ4hatmypzMxMd9RykS1btujee+9Vz549FR4ergceeEBdu3bVtm3bJJ0/OzRnzhxNmDBB9957r5o2baq3335bWVlZWrVqlSTpwIEDSkxM1JtvvqnWrVurffv2evXVV7Vy5UplZWWVyXEAAIDyzelANHToUA0fPlxLly5Vamqq9uzZ4/BxpbZt22rdunX6/vvvJZ1/ieymTZvUvXt3SdLRo0eVnZ2t6OhoYx2r1arWrVsrJSVFkpSSkqKAgAC1bNnSGBMdHS0vLy9t3br1svsuLCxkwjgAACbh9CWzhx9+WJL05JNPGm0Wi8Utk6rHjRsnm82mBg0aqEKFCiopKdHzzz+v2NhYSVJ2drYkKTg42GG94OBgoy87O1tBQUEO/d7e3goMDDTGXEpCQoKmTJnismMBAADll9OB6OjRo+6o45Lee+89LV++XCtWrFCjRo2UlpamESNGKDQ0VHFxcW7d9/jx4zVq1Chj2WazKSwszK37BAAAnuF0IKpdu7Y76rikMWPGaNy4cerbt68kqUmTJvrxxx+VkJCguLg4hYSESJJycnJUs2ZNY72cnBzdeuutkqSQkBDl5uY6bPfcuXPKy8sz1r8UX19f+fr6uviIAABAeXRVb7s/fPiwhg4dqujoaEVHR2vYsGE6fPiwq2vTmTNn5OXlWGKFChWMF8pGREQoJCRE69atM/ptNpu2bt2qqKgoSVJUVJROnTql1NRUY8z69etVWlqq1q1bu7xmAABw7XE6EH3xxReKjIzUtm3b1LRpUzVt2lRbt25Vo0aNlJSU5NLievXqpeeff16rV6/WDz/8oI8++kizZs1S7969JZ2fuzRixAhNmzZNn3zyifbu3avHHntMoaGhuu+++yRJDRs2VLdu3TRw4EBt27ZNmzdvVnx8vPr27avQ0FCX1gsAAK5NTl8yGzdunEaOHKnp06df1D527FjdddddLivu1Vdf1cSJE/XPf/5Tubm5Cg0N1T/+8Q9NmjTJGPPMM8/o9OnTGjRokE6dOqX27dsrMTHReAaRJC1fvlzx8fHq0qWLvLy81KdPH82dO9dldQIAgGubxf77xz5fAT8/P+3du1f16tVzaP/+++/VtGlTnT171qUFlhc2m01Wq1X5+fny9/f3dDllKnzcak+XgDL0w/Seni4BZYjvt7mY8ft9pb+/nb5kduONNyotLe2i9rS0tItubwcAALgWOH3JbODAgRo0aJCOHDmitm3bSpI2b96sGTNmONymDgAAcK1wOhBNnDhRVatW1csvv6zx48dLkkJDQzV58mTj/WIAAADXEqcDkcVi0ciRIzVy5Ej9+uuvkqSqVau6vDAAAICyclVPqj537pzq1avnEIQOHjyoihUrKjw83JX1AQAAuJ3Tk6off/xxbdmy5aL2rVu36vHHH3dFTQAAAGXK6UC0a9cutWvX7qL2Nm3aXPLuMwAAgPLO6UBksViMuUO/l5+f79I33QMAAJQVpwNRhw4dlJCQ4BB+SkpKlJCQoPbt27u0OAAAgLLg9KTqGTNmqEOHDqpfv77uuOMOSdLXX38tm82m9evXu7xAAAAAd3P6DFFkZKT27Nmjhx56SLm5ufr111/12GOP6bvvvlPjxo3dUSMAAIBbOX2GSDr/IMYXXnjB1bUAAAB4hNNniAAAAK43BCIAAGB6BCIAAGB6BCIAAGB6VxWIzp07p7Vr1+qNN94wHtKYlZWlgoIClxYHAABQFpy+y+zHH39Ut27dlJGRocLCQt11112qWrWqZsyYocLCQi1YsMAddQIAALiN02eIhg8frpYtW+qXX35RpUqVjPbevXtr3bp1Li0OAACgLDh9hujrr7/Wli1b5OPj49AeHh6un3/+2WWFAQAAlBWnzxCVlpZe8iWuP/30k6pWreqSogAAAMqS04Goa9eumjNnjrFssVhUUFCgZ599Vj169HBlbQAAAGXC6UtmL7/8smJiYhQZGamzZ8/qkUce0cGDB1WjRg2988477qgRAADArZwORDfffLN2796tlStXas+ePSooKNCAAQMUGxvrMMkaAADgWnFVL3f19vbWo48+6upaAAAAPMLpQPTJJ59cst1iscjPz09169ZVRETEXy4MAACgrDgdiO677z5ZLBbZ7XaH9gttFotF7du316pVq1StWjWXFQoAAOAuTt9llpSUpFatWikpKUn5+fnKz89XUlKSWrdurc8++0wbN27UyZMnNXr0aHfUCwAA4HJOnyEaPny4Fi5cqLZt2xptXbp0kZ+fnwYNGqT9+/drzpw5evLJJ11aKAAAgLs4fYbo8OHD8vf3v6jd399fR44ckSTVq1dPJ06c+OvVAQAAlAGnA1GLFi00ZswYHT9+3Gg7fvy4nnnmGbVq1UqSdPDgQYWFhbmuSgAAADdy+pLZW2+9pXvvvVc333yzEXoyMzNVp04dffzxx5KkgoICTZgwwbWVAgAAuInTgah+/fr69ttv9eWXX+r777832u666y55eZ0/4XTfffe5tEgAAAB3cvqSmSR5eXmpW7duGjZsmIYNG6aYmBgjDLnazz//rEcffVTVq1dXpUqV1KRJE+3YscPot9vtmjRpkmrWrKlKlSopOjpaBw8edNhGXl6eYmNj5e/vr4CAAA0YMEAFBQVuqRcAAFx7rupJ1adPn1ZycrIyMjJUVFTk0Dds2DCXFCZJv/zyi9q1a6dOnTppzZo1uvHGG3Xw4EGH5xvNnDlTc+fO1bJlyxQREaGJEycqJiZG3377rfz8/CRJsbGxOnbsmJKSklRcXKwnnnhCgwYN0ooVK1xWKwAAuHY5HYh27dqlHj166MyZMzp9+rQCAwN14sQJVa5cWUFBQS4NRDNmzFBYWJiWLFlitP3+Kdh2u11z5szRhAkTdO+990qS3n77bQUHB2vVqlXq27evDhw4oMTERG3fvl0tW7aUJL366qvq0aOHXnrpJYWGhl5y34WFhSosLDSWbTaby44LAACUL05f5xo5cqR69eqlX375RZUqVdI333yjH3/8US1atNBLL73k0uI++eQTtWzZUg8++KCCgoLUvHlzLVq0yOg/evSosrOzFR0dbbRZrVa1bt1aKSkpkqSUlBQFBAQYYUiSoqOj5eXlpa1bt1523wkJCbJarcaHu+YAALh+OR2I0tLS9PTTT8vLy0sVKlRQYWGhwsLCNHPmTP3f//2fS4s7cuSI5s+fr3r16umLL77Q4MGDNWzYMC1btkySlJ2dLUkKDg52WC84ONjoy87OVlBQkEO/t7e3AgMDjTGXMn78eONJ3Pn5+crMzHTloQEAgHLE6UtmFStWNCZQBwUFKSMjQw0bNpTVanV5aCgtLVXLli31wgsvSJKaN2+uffv2acGCBYqLi3Ppvv6Xr6+vfH193boPAABQPjh9hqh58+bavn27JKljx46aNGmSli9frhEjRqhx48YuLa5mzZqKjIx0aGvYsKEyMjIkSSEhIZKknJwchzE5OTlGX0hIiHJzcx36z507p7y8PGMMAAAwN6cD0QsvvKCaNWtKkp5//nlVq1ZNgwcP1vHjx7Vw4UKXFteuXTulp6c7tH3//feqXbu2pPMTrENCQrRu3Tqj32azaevWrYqKipIkRUVF6dSpU0pNTTXGrF+/XqWlpWrdurVL6wUAANcmpy6Z2e12BQUFGWeCgoKClJiY6JbCpPMTuNu2basXXnhBDz30kLZt26aFCxcawctisWjEiBGaNm2a6tWrZ9x2HxoaajwcsmHDhurWrZsGDhyoBQsWqLi4WPHx8erbt+9l7zADAADm4tQZIrvdrrp165bZBONWrVrpo48+0jvvvKPGjRvrueee05w5cxQbG2uMeeaZZzR06FANGjRIrVq1UkFBgRITE41nEEnS8uXL1aBBA3Xp0kU9evRQ+/btXX42CwAAXLucOkPk5eWlevXq6eTJk6pXr567anJw99136+67775sv8Vi0dSpUzV16tTLjgkMDOQhjAAA4LKcnkM0ffp0jRkzRvv27XNHPQAAAGXO6dvuH3vsMZ05c0bNmjWTj4+PKlWq5NCfl5fnsuIAAADKgtOBaM6cOW4oAwAAwHOcDkTufiAiAABAWXN6DpEkHT58WBMmTFC/fv2Mhx6uWbNG+/fvd2lxAAAAZcHpQJScnKwmTZpo69at+vDDD1VQUCBJ2r17t5599lmXFwgAAOBuTgeicePGadq0aUpKSpKPj4/R3rlzZ33zzTcuLQ4AAKAsOB2I9u7dq969e1/UHhQUpBMnTrikKAAAgLLkdCAKCAjQsWPHLmrftWuXbrrpJpcUBQAAUJacDkR9+/bV2LFjlZ2dLYvFotLSUm3evFmjR4/WY4895o4aAQAA3Oqq3nbfoEEDhYWFqaCgQJGRkerQoYPatm2rCRMmuKNGAAAAt3L6OUQ+Pj5atGiRJk6cqH379qmgoEDNmzcvs3ebAQAAuJrTgWjTpk1q3769atWqpVq1armjJgAAgDLl9CWzzp07KyIiQv/3f/+nb7/91h01AQAAlCmnA1FWVpaefvppJScnq3Hjxrr11lv14osv6qeffnJHfQAAAG7ndCCqUaOG4uPjtXnzZh0+fFgPPvigli1bpvDwcHXu3NkdNQIAALjVVb3L7IKIiAiNGzdO06dPV5MmTZScnOyqugAAAMrMVQeizZs365///Kdq1qypRx55RI0bN9bq1atdWRsAAECZcPous/Hjx2vlypXKysrSXXfdpVdeeUX33nuvKleu7I76AAAA3M7pQLRx40aNGTNGDz30kGrUqOGOmgAAAMqU04Fo8+bN7qgDAADAY5wORBd8++23ysjIUFFRkUP7Pffc85eLAgAAKEtOB6IjR46od+/e2rt3rywWi+x2uyTJYrFIkkpKSlxbIQAAgJs5fZfZ8OHDFRERodzcXFWuXFn79+/Xxo0b1bJlS23YsMENJQIAALiX02eIUlJStH79etWoUUNeXl7y8vJS+/btlZCQoGHDhmnXrl3uqBMAAMBtnD5DVFJSoqpVq0o6/9TqrKwsSVLt2rWVnp7u2uoAAADKgNNniBo3bqzdu3crIiJCrVu31syZM+Xj46OFCxeqTp067qgRAADArZwORBMmTNDp06clSVOnTtXdd9+tO+64Q9WrV9e7777r8gIBAADczelAFBMTY/xct25dfffdd8rLy1O1atWMO80AAACuJVf9HKLfCwwMdMVmAAAAPOIvve0eAADgekAgAgAApkcgAgAApndNBaLp06fLYrFoxIgRRtvZs2c1ZMgQVa9eXTfccIP69OmjnJwch/UyMjLUs2dPVa5cWUFBQRozZozOnTtXxtUDAIDy6poJRNu3b9cbb7yhpk2bOrSPHDlSn376qd5//30lJycrKytL999/v9FfUlKinj17qqioSFu2bNGyZcu0dOlSTZo0qawPAQAAlFPXRCAqKChQbGysFi1apGrVqhnt+fn5euuttzRr1ix17txZLVq00JIlS7RlyxZ98803kqQvv/xS3377rf7zn//o1ltvVffu3fXcc89p3rx5Kioquuw+CwsLZbPZHD4AAOD6dE0EoiFDhqhnz56Kjo52aE9NTVVxcbFDe4MGDVSrVi2lpKRIOv/utSZNmig4ONgYExMTI5vNpv379192nwkJCbJarcYnLCzMxUcFAADKi3IfiFauXKmdO3cqISHhor7s7Gz5+PgoICDAoT04OFjZ2dnGmN+HoQv9F/ouZ/z48crPzzc+mZmZf/FIAABAeeWSBzO6S2ZmpoYPH66kpCT5+fmV6b59fX3l6+tbpvsEAACeUa7PEKWmpio3N1e33XabvL295e3treTkZM2dO1fe3t4KDg5WUVGRTp065bBeTk6OQkJCJEkhISEX3XV2YfnCGAAAYG7lOhB16dJFe/fuVVpamvFp2bKlYmNjjZ8rVqyodevWGeukp6crIyNDUVFRkqSoqCjt3btXubm5xpikpCT5+/srMjKyzI8JAACUP+X6klnVqlXVuHFjh7YqVaqoevXqRvuAAQM0atQoBQYGyt/fX0OHDlVUVJTatGkjSeratasiIyPVv39/zZw5U9nZ2ZowYYKGDBnCJTEAACCpnAeiKzF79mx5eXmpT58+KiwsVExMjF5//XWjv0KFCvrss880ePBgRUVFqUqVKoqLi9PUqVM9WDUAAChPrrlAtGHDBodlPz8/zZs3T/PmzbvsOrVr19bnn3/u5soAAMC1qlzPIQIAACgLBCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB65T4QJSQkqFWrVqpataqCgoJ03333KT093WHM2bNnNWTIEFWvXl033HCD+vTpo5ycHIcxGRkZ6tmzpypXrqygoCCNGTNG586dK8tDAQAA5VS5D0TJyckaMmSIvvnmGyUlJam4uFhdu3bV6dOnjTEjR47Up59+qvfff1/JycnKysrS/fffb/SXlJSoZ8+eKioq0pYtW7Rs2TItXbpUkyZN8sQhAQCAcsZit9vtni7CGcePH1dQUJCSk5PVoUMH5efn68Ybb9SKFSv0wAMPSJK+++47NWzYUCkpKWrTpo3WrFmju+++W1lZWQoODpYkLViwQGPHjtXx48fl4+Pzp/u12WyyWq3Kz8+Xv7+/W4+xvAkft9rTJaAM/TC9p6dLQBni+20uZvx+X+nv73J/huh/5efnS5ICAwMlSampqSouLlZ0dLQxpkGDBqpVq5ZSUlIkSSkpKWrSpIkRhiQpJiZGNptN+/fvv+R+CgsLZbPZHD4AAOD6dE0FotLSUo0YMULt2rVT48aNJUnZ2dny8fFRQECAw9jg4GBlZ2cbY34fhi70X+i7lISEBFmtVuMTFhbm4qMBAADlxTUViIYMGaJ9+/Zp5cqVbt/X+PHjlZ+fb3wyMzPdvk8AAOAZ3p4u4ErFx8frs88+08aNG3XzzTcb7SEhISoqKtKpU6cczhLl5OQoJCTEGLNt2zaH7V24C+3CmP/l6+srX19fFx8FAAAoj8r9GSK73a74+Hh99NFHWr9+vSIiIhz6W7RooYoVK2rdunVGW3p6ujIyMhQVFSVJioqK0t69e5Wbm2uMSUpKkr+/vyIjI8vmQAAAQLlV7s8QDRkyRCtWrNDHH3+sqlWrGnN+rFarKlWqJKvVqgEDBmjUqFEKDAyUv7+/hg4dqqioKLVp00aS1LVrV0VGRqp///6aOXOmsrOzNWHCBA0ZMoSzQAAAoPwHovnz50uS7rzzTof2JUuW6PHHH5ckzZ49W15eXurTp48KCwsVExOj119/3RhboUIFffbZZxo8eLCioqJUpUoVxcXFaerUqWV1GAAAoBwr94HoSh6T5Ofnp3nz5mnevHmXHVO7dm19/vnnriwNAABcJ8r9HCIAAAB3IxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTIxABAADTM1UgmjdvnsLDw+Xn56fWrVtr27Ztni4JAACUA6YJRO+++65GjRqlZ599Vjt37lSzZs0UExOj3NxcT5cGAAA8zDSBaNasWRo4cKCeeOIJRUZGasGCBapcubIWL17s6dIAAICHeXu6gLJQVFSk1NRUjR8/3mjz8vJSdHS0UlJSLrlOYWGhCgsLjeX8/HxJks1mc2+x5VBp4RlPl4AyZMb/xs2M77e5mPH7feGY7Xb7H44zRSA6ceKESkpKFBwc7NAeHBys77777pLrJCQkaMqUKRe1h4WFuaVGoLywzvF0BQDcxczf719//VVWq/Wy/aYIRFdj/PjxGjVqlLFcWlqqvLw8Va9eXRaLxYOVoSzYbDaFhYUpMzNT/v7+ni4HgAvx/TYXu92uX3/9VaGhoX84zhSBqEaNGqpQoYJycnIc2nNychQSEnLJdXx9feXr6+vQFhAQ4K4SUU75+/vzP0zgOsX32zz+6MzQBaaYVO3j46MWLVpo3bp1RltpaanWrVunqKgoD1YGAADKA1OcIZKkUaNGKS4uTi1bttTtt9+uOXPm6PTp03riiSc8XRoAAPAw0wSihx9+WMePH9ekSZOUnZ2tW2+9VYmJiRdNtAak85dMn3322YsumwK49vH9xqVY7H92HxoAAMB1zhRziAAAAP4IgQgAAJgegQgAAJgegQgAAJgegQgAAJgegQj4/77++ms9+uijioqK0s8//yxJ+ve//61NmzZ5uDIAgLsRiABJH3zwgWJiYlSpUiXt2rVLhYWFkqT8/Hy98MILHq4OgKsUFRUpPT1d586d83QpKGcIRICkadOmacGCBVq0aJEqVqxotLdr1047d+70YGUAXOHMmTMaMGCAKleurEaNGikjI0OSNHToUE2fPt3D1aE8IBABktLT09WhQ4eL2q1Wq06dOlX2BQFwqfHjx2v37t3asGGD/Pz8jPbo6Gi9++67HqwM5QWBCJAUEhKiQ4cOXdS+adMm1alTxwMVAXClVatW6bXXXlP79u1lsViM9kaNGunw4cMerAzlBYEIkDRw4EANHz5cW7dulcViUVZWlpYvX67Ro0dr8ODBni4PwF90/PhxBQUFXdR++vRph4AE8zLNy12BPzJu3DiVlpaqS5cuOnPmjDp06CBfX1+NHj1aQ4cO9XR5AP6ili1bavXq1cb3+UIIevPNNxUVFeXJ0lBO8HJX4HeKiop06NAhFRQUKDIyUjfccIOnSwLgAps2bVL37t316KOPaunSpfrHP/6hb7/9Vlu2bFFycrJatGjh6RLhYQQiAIApHD58WNOnT9fu3btVUFCg2267TWPHjlWTJk08XRrKAQIRIKlTp05/OI9g/fr1ZVgNAKCsMYcIkHTrrbc6LBcXFystLU379u1TXFycZ4oC4DI7d+5UxYoVjbNBH3/8sZYsWaLIyEhNnjxZPj4+Hq4QnsYZIuAPTJ48WQUFBXrppZc8XQqAv6BVq1YaN26c+vTpoyNHjigyMlL333+/tm/frp49e2rOnDmeLhEeRiAC/sChQ4d0++23Ky8vz9OlAPgLrFardu7cqVtuuUUzZszQ+vXr9cUXX2jz5s3q27evMjMzPV0iPIznEAF/ICUlxeGptgCuTXa7XaWlpZKktWvXqkePHpKksLAwnThxwpOloZxgDhEg6f7773dYttvtOnbsmHbs2KGJEyd6qCoArtKyZUtNmzZN0dHRSk5O1vz58yVJR48eVXBwsIerQ3lAIAJ0/nT673l5eal+/fqaOnWqunbt6qGqALjKnDlzFBsbq1WrVulf//qX6tatK0n673//q7Zt23q4OpQHzCGC6ZWUlGjz5s1q0qSJqlWr5ulyAJShs2fPqkKFCqpYsaKnS4GHEYgASX5+fjpw4IAiIiI8XQoAwAO4ZAZIaty4sY4cOUIgAq4j1apVu+IXt3InKQhEgKRp06Zp9OjReu6559SiRQtVqVLFod/f399DlQG4WjxbCM7gkhlMberUqXr66adVtWpVo+33f1Ha7XZZLBaVlJR4ojwAQBkhEMHUKlSooGPHjunAgQN/OK5jx45lVBEAdzt79qyKiooc2jgLDAIRTM3Ly0vZ2dkKCgrydCkA3Oj06dMaO3as3nvvPZ08efKifs4CgydVw/SudNIlgGvXM888o/Xr12v+/Pny9fXVm2++qSlTpig0NFRvv/22p8tDOcAZIpial5eXrFbrn4Yi7kABrm21atXS22+/rTvvvFP+/v7auXOn6tatq3//+99655139Pnnn3u6RHgYd5nB9KZMmXLRk6oBXF/y8vJUp04dSefnC134I6d9+/YaPHiwJ0tDOUEggun17duXOUTAda5OnTo6evSoatWqpQYNGui9997T7bffrk8//VQBAQGeLg/lAHOIYGrMHwKub0eOHFFpaameeOIJ7d69W5I0btw4zZs3T35+fho5cqTGjBnj4SpRHjCHCKbGXWbA9e3CozUufMcffvhhzZ07V2fPnlVqaqrq1q2rpk2berhKlAcEIgDAdet//+ipWrWqdu/ebcwnAi7gkhkAADA9AhEA4LplsVgumivI3EFcCneZAQCuW3a7XY8//rh8fX0lnX9tx1NPPXXRC5w//PBDT5SHcoRABAC4bsXFxTksP/roox6qBOUdk6oBAIDpMYcIAACYHoEIAACYHoEIAACYHoEIAACYHoEIAACYHoEIANwsJiZGFSpU0Pbt2y/qe/zxx42HB/7+061bNw9UCpgXzyECgP9ht9tVUlIib++//r/IjIwMbdmyRfHx8Vq8eLFatWp10Zhu3bppyZIlDm0XHiQIoGxwhgiAS915550aOnSoRowYoWrVqik4OFiLFi3S6dOn9cQTT6hq1aqqW7eu1qxZY6yzb98+de/eXTfccIOCg4PVv39/nThxwuhPTExU+/btFRAQoOrVq+vuu+/W4cOHjf6ioiLFx8erZs2a8vPzU+3atZWQkCBJ+uGHH2SxWJSWlmaMP3XqlCwWizZs2CBJ2rBhgywWi9asWaMWLVrI19dXmzZtUmlpqRISEhQREaFKlSqpWbNm+u9//+vUv8eSJUt09913a/DgwXrnnXf022+/XTTG19dXISEhDp9q1apJOh/OJk+erFq1asnX11ehoaEaNmyYUzUA+HMEIgAut2zZMtWoUUPbtm3T0KFDNXjwYD344INq27atdu7cqa5du6p///46c+aMTp06pc6dO6t58+basWOHEhMTlZOTo4ceesjY3unTpzVq1Cjt2LFD69atk5eXl3r37q3S0lJJ0ty5c/XJJ5/ovffeU3p6upYvX67w8HCn6x43bpymT5+uAwcOqGnTpkpISNDbb7+tBQsWaP/+/Ro5cqQeffRRJScnX9H27Ha7lixZokcffVQNGjRQ3bp1nQ5UH3zwgWbPnq033nhDBw8e1KpVq9SkSROnjw3An7ADgAt17NjR3r59e2P53Llz9ipVqtj79+9vtB07dswuyZ6SkmJ/7rnn7F27dnXYRmZmpl2SPT09/ZL7OH78uF2Sfe/evXa73W4fOnSovXPnzvbS0tKLxh49etQuyb5r1y6j7ZdffrFLsn/11Vd2u91u/+qrr+yS7KtWrTLGnD171l65cmX7li1bHLY3YMAAe79+/a7o3+LLL7+033jjjfbi4mK73W63z549296xY0eHMXFxcfYKFSrYq1Sp4vB5/vnn7Xa73f7yyy/b//a3v9mLioquaJ8Arg5niAC4XNOmTY2fK1SooOrVqzuc1QgODpYk5ebmavfu3frqq690ww03GJ8GDRpIknFZ7ODBg+rXr5/q1Kkjf39/4+xPRkaGpPMTk9PS0lS/fn0NGzZMX3755VXV3bJlS+PnQ4cO6cyZM7rrrrscanv77bcdLtf9kcWLF+vhhx825iL169dPmzdvvmj9Tp06KS0tzeHz1FNPSZIefPBB/fbbb6pTp44GDhyojz76SOfOnbuq4wNweUyqBuByFStWdFi2WCwObRaLRZJUWlqqgoIC9erVSzNmzLhoOzVr1pQk9erVS7Vr19aiRYsUGhqq0tJSNW7cWEVFRZKk2267TUePHtWaNWu0du1aPfTQQ4qOjtZ///tfeXmd/7vP/rvXNhYXF1+y7t+/Ab2goECStHr1at10000O465kwnNeXp4++ugjFRcXa/78+UZ7SUmJFi9erOeff95hv3Xr1r3kdsLCwpSenq61a9cqKSlJ//znP/Xiiy8qOTn5on9nAFePQATAo2677TZ98MEHCg8Pv+RdXSdPnlR6eroWLVqkO+64Q5K0adOmi8b5+/vr4Ycf1sMPP6wHHnhA3bp1U15enm688UZJ0rFjx9S8eXNJcphgfTmRkZHy9fVVRkaGOnbs6PRxLV++XDfffLNWrVrl0P7ll1/q5Zdf1tSpU1WhQoUr2lalSpXUq1cv9erVS0OGDFGDBg20d+9e3XbbbU7XBeDSCEQAPGrIkCFatGiR+vXrp2eeeUaBgYE6dOiQVq5cqTfffFPVqlVT9erVtXDhQtWsWVMZGRkaN26cwzZmzZqlmjVrqnnz5vLy8tL777+vkJAQBQQEyMvLS23atNH06dMVERGh3NxcTZgw4U/rqlq1qkaPHq2RI0eqtLRU7du3V35+vjZv3ix/f3/FxcX94fpvvfWWHnjgATVu3NihPSwsTOPHj1diYqJ69uwpSSosLFR2drbDOG9vb9WoUUNLly5VSUmJWrdurcqVK+s///mPKlWqpNq1a1/JPy+AK8QcIgAeFRoaqs2bN6ukpERdu3ZVkyZNNGLECCPMeHl5aeXKlUpNTVXjxo01cuRIvfjiiw7bqFq1qmbOnKmWLVuqVatW+uGHH/T5558bl8sWL16sc+fOqUWLFhoxYoSmTZt2RbU999xzmjhxohISEtSwYUN169ZNq1evVkRExB+ul5qaqt27d6tPnz4X9VmtVnXp0kVvvfWW0ZaYmKiaNWs6fNq3by9JCggI0KJFi9SuXTs1bdpUa9eu1aeffqrq1atf0TEAuDIW++8vrAMAAJgQZ4gAAIDpEYgA4Co89dRTDrfj//5z4ZZ5ANcOLpkBwFXIzc2VzWa7ZJ+/v7+CgoLKuCIAfwWBCAAAmB6XzAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOn9P4eZNoFRKq7OAAAAAElFTkSuQmCC",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "for col in df.columns:\n",
    "    if col.startswith(\"measure_\"):\n",
    "        df.groupby(col)['duration'].mean().sort_values().plot(kind = 'bar')\n",
    "        plt.ylabel('average completion days')\n",
    "        plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a88b4c17",
   "metadata": {},
   "source": [
    "## Analyze Interventions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "50b52474",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('Drug: Carboplatin', 44), ('Drug: Cisplatin', 33), ('Drug: Pemetrexed', 32), ('Drug: Paclitaxel', 29), ('Drug: cisplatin', 27), ('Drug: paclitaxel', 25), ('Drug: carboplatin', 23), ('Drug: Erlotinib', 23), ('Radiation: radiation therapy', 21), ('Other: laboratory biomarker analysis', 20)]\n",
      "[('drug', 1392), ('biological', 215), ('other', 99), ('radiation', 80), ('procedure', 72), ('device', 20), ('genetic', 12), ('combination product', 6), ('behavioral', 3), ('diagnostic test', 2)]\n"
     ]
    }
   ],
   "source": [
    "intervention_count = defaultdict(int)\n",
    "intervention_category_count = defaultdict(int)\n",
    "for interventions in df.interventions:\n",
    "    for intervention in interventions.split('|'):\n",
    "        intervention_count[intervention] += 1\n",
    "        intervention_category_count[intervention.split(':')[0].lower()] += 1\n",
    "print(sorted(intervention_count.items(), key=lambda x:x[1], reverse=True)[:10])\n",
    "print(sorted(intervention_category_count.items(), key=lambda x:x[1], reverse=True)[:10])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "728849b4",
   "metadata": {},
   "outputs": [],
   "source": [
    "top_5_intervention = sorted(intervention_category_count, key=lambda x: intervention_category_count[x], reverse=True)[:5]\n",
    "if 'radiation' not in top_5_intervention:\n",
    "    top_5_intervention.append('radiation')\n",
    "for category in top_5_intervention:\n",
    "    df[f\"{category}_included\"] = df.interventions.apply(lambda x: any(intervertion.split(':')[0].lower()==category for intervertion in x.split('|')))\n",
    "df['intervention_count'] = df.interventions.apply(lambda x: len(x.split(\"|\")))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "4aa08010",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Biological: vaccine 1650-G\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>10</th>\n",
       "      <th>11</th>\n",
       "      <th>12</th>\n",
       "      <th>...</th>\n",
       "      <th>104</th>\n",
       "      <th>105</th>\n",
       "      <th>106</th>\n",
       "      <th>107</th>\n",
       "      <th>108</th>\n",
       "      <th>109</th>\n",
       "      <th>110</th>\n",
       "      <th>111</th>\n",
       "      <th>113</th>\n",
       "      <th>114</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>rank</th>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "      <td>6</td>\n",
       "      <td>7</td>\n",
       "      <td>11</td>\n",
       "      <td>12</td>\n",
       "      <td>13</td>\n",
       "      <td>...</td>\n",
       "      <td>105</td>\n",
       "      <td>106</td>\n",
       "      <td>107</td>\n",
       "      <td>108</td>\n",
       "      <td>109</td>\n",
       "      <td>110</td>\n",
       "      <td>111</td>\n",
       "      <td>112</td>\n",
       "      <td>114</td>\n",
       "      <td>115</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nct_number</th>\n",
       "      <td>NCT01829373</td>\n",
       "      <td>NCT00401778</td>\n",
       "      <td>NCT00132054</td>\n",
       "      <td>NCT02429843</td>\n",
       "      <td>NCT00084799</td>\n",
       "      <td>NCT01486602</td>\n",
       "      <td>NCT00005022</td>\n",
       "      <td>NCT00062322</td>\n",
       "      <td>NCT00059761</td>\n",
       "      <td>NCT00857025</td>\n",
       "      <td>...</td>\n",
       "      <td>NCT01931787</td>\n",
       "      <td>NCT00555256</td>\n",
       "      <td>NCT01121575</td>\n",
       "      <td>NCT01302808</td>\n",
       "      <td>NCT00569114</td>\n",
       "      <td>NCT00731952</td>\n",
       "      <td>NCT00633724</td>\n",
       "      <td>NCT01454102</td>\n",
       "      <td>NCT00874588</td>\n",
       "      <td>NCT00870532</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>title</th>\n",
       "      <td>Lung Cancer Vaccine Plus Oral Dietary Supplement</td>\n",
       "      <td>Trial of RAD001 in Patients With Operable Non-...</td>\n",
       "      <td>Amrubicin and Irinotecan in Treating Patients ...</td>\n",
       "      <td>A Study of TRC105 in Combination With Paclitax...</td>\n",
       "      <td>Monoclonal Antibody Therapy in Treating Patien...</td>\n",
       "      <td>Specialized Radiation Therapy and Chemotherapy...</td>\n",
       "      <td>Radiation Therapy Plus Combination Chemotherap...</td>\n",
       "      <td>Neoadjuvant Chemoradiotherapy Followed By Surg...</td>\n",
       "      <td>Chemotherapy Combined With Radiation Therapy i...</td>\n",
       "      <td>Beta-Glucan in Treating Patients With Locally ...</td>\n",
       "      <td>...</td>\n",
       "      <td>CPI-613 in Treating Patients With Relapsed or ...</td>\n",
       "      <td>A Phase I Study of SUNITINIB and Rapamycin in ...</td>\n",
       "      <td>A Study Of Combined C- MET Inhibitor And PAN-H...</td>\n",
       "      <td>Romidepsin and Erlotinib Hydrochloride in Trea...</td>\n",
       "      <td>Phase 1 Study of TG01 and Erlotinib in Non-sma...</td>\n",
       "      <td>Phase I Study of Induction Therapy With VELCAD...</td>\n",
       "      <td>Multiple-Vaccine Therapy in Treating Patients ...</td>\n",
       "      <td>Study of Nivolumab (BMS-936558) in Combination...</td>\n",
       "      <td>Peptide Vaccine Targeting to Cancer Specific A...</td>\n",
       "      <td>Study of Combination of Metronomic Oral Vinore...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>acronym</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>SU/Rapamycin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>status</th>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_results</th>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>...</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Has Results</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>No Results Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>conditions</th>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>Lung Cancer</td>\n",
       "      <td>...</td>\n",
       "      <td>Recurrent Small Cell Lung Cancer</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Lung Cancer|Metastatic Cancer</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>Non Small Cell Lung Cancer</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>interventions</th>\n",
       "      <td>Biological: vaccine 1650-G</td>\n",
       "      <td>Drug: RAD001</td>\n",
       "      <td>Drug: amrubicin hydrochloride|Drug: irinotecan...</td>\n",
       "      <td>Drug: TRC105</td>\n",
       "      <td>Biological: monoclonal antibody hu3S193</td>\n",
       "      <td>Drug: carboplatin|Drug: paclitaxel|Radiation: ...</td>\n",
       "      <td>Drug: cisplatin|Drug: etoposide|Radiation: rad...</td>\n",
       "      <td>Drug: cisplatin|Drug: irinotecan hydrochloride...</td>\n",
       "      <td>Drug: cisplatin|Drug: irinotecan hydrochloride...</td>\n",
       "      <td>Biological: beta-glucan MM-10-001|Other: flow ...</td>\n",
       "      <td>...</td>\n",
       "      <td>Drug: 6,8-bis(benzylthio)octanoic acid</td>\n",
       "      <td>Drug: sunitinib and rapamycin (Drug will be held)</td>\n",
       "      <td>Drug: PF-02341066|Drug: PF-00299804</td>\n",
       "      <td>Combination Product: Erlotinib plus Romidepsin...</td>\n",
       "      <td>Drug: TG01</td>\n",
       "      <td>Drug: Velcade and Vorinostat</td>\n",
       "      <td>Biological: HLA-A*2402restricted URLC10, TTK, ...</td>\n",
       "      <td>Biological: Nivolumab|Drug: Gemcitabine|Drug: ...</td>\n",
       "      <td>Biological: HLA-A*2402restricted URLC10, CDCA1...</td>\n",
       "      <td>Drug: oral vinorelbine|Drug: sorafenib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>outcome_measures</th>\n",
       "      <td>Immunologic response to vaccine</td>\n",
       "      <td>Clinical Response as Assessed Metabolically by...</td>\n",
       "      <td></td>\n",
       "      <td>Number of patients with a change in medical ma...</td>\n",
       "      <td>Confirmation of Tumor Targeting as Measured by...</td>\n",
       "      <td>Maximum-tolerated RT dose fraction|Radiographi...</td>\n",
       "      <td>Frequency of patients developing unacceptable ...</td>\n",
       "      <td></td>\n",
       "      <td>Maximum tolerated dose of irinotecan in combin...</td>\n",
       "      <td>Safety|Maximum-tolerated dose|Toxicity as asse...</td>\n",
       "      <td>...</td>\n",
       "      <td>Tumor response rates, defined as the proportio...</td>\n",
       "      <td>To define the optimal dose of sunitinib when g...</td>\n",
       "      <td>Overview of Treatment-emergent All Causalities...</td>\n",
       "      <td>Number of Participants With Dose Limiting Toxi...</td>\n",
       "      <td>Saftey, maximum tolerated dose, optimal biolog...</td>\n",
       "      <td>Adverse events|Tumor response</td>\n",
       "      <td>Adverse effects, dose limiting toxicity, and m...</td>\n",
       "      <td>Number of Participants Who Experienced Serious...</td>\n",
       "      <td>Adverse effects, dose limiting toxicity, and m...</td>\n",
       "      <td>to determine the optimal combination of metron...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>sponsor/collaborators</th>\n",
       "      <td>Edward Hirschowitz|University of Louisville|Un...</td>\n",
       "      <td>Emory University</td>\n",
       "      <td>Japan Multinational Trial Organization|Nationa...</td>\n",
       "      <td>University of Alabama at Birmingham|Tracon Pha...</td>\n",
       "      <td>Ludwig Institute for Cancer Research|National ...</td>\n",
       "      <td>Alliance for Clinical Trials in Oncology|Natio...</td>\n",
       "      <td>Radiation Therapy Oncology Group|National Canc...</td>\n",
       "      <td>Fox Chase Cancer Center|National Cancer Instit...</td>\n",
       "      <td>Radiation Therapy Oncology Group|National Canc...</td>\n",
       "      <td>City of Hope Medical Center|National Cancer In...</td>\n",
       "      <td>...</td>\n",
       "      <td>Wake Forest University Health Sciences|Nationa...</td>\n",
       "      <td>Washington University School of Medicine|Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>University of Texas Southwestern Medical Cente...</td>\n",
       "      <td>Tragara Pharmaceuticals, Inc.</td>\n",
       "      <td>University of Virginia</td>\n",
       "      <td>Fukushima Medical University|Human Genome Cent...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>Fukushima Medical University|Human Genome Cent...</td>\n",
       "      <td>National Cancer Centre, Singapore</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gender</th>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "      <td>All</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>age</th>\n",
       "      <td>21 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>19 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years to 80 Years   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>...</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>18 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>20 Years and older   (Adult, Older Adult)</td>\n",
       "      <td>21 Years and older   (Adult, Older Adult)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>phases</th>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>...</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enrollment</th>\n",
       "      <td>5.0</td>\n",
       "      <td>33.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>36.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>...</td>\n",
       "      <td>15.0</td>\n",
       "      <td>19.0</td>\n",
       "      <td>70.0</td>\n",
       "      <td>17.0</td>\n",
       "      <td>45.0</td>\n",
       "      <td>21.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>472.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>52.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>funded_bys</th>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>...</td>\n",
       "      <td>Other|NIH</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Other|Industry</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "      <td>Industry</td>\n",
       "      <td>Other</td>\n",
       "      <td>Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_type</th>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Interventional</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_designs</th>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Primary Purpose: Treatment</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Primary Purpose: Treatment</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Randomized|Intervention Model: Par...</td>\n",
       "      <td>Allocation: N/A|Intervention Model: Single Gro...</td>\n",
       "      <td>Allocation: Non-Randomized|Intervention Model:...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>other_ids</th>\n",
       "      <td>BG1006</td>\n",
       "      <td>IRB00024810</td>\n",
       "      <td>JMTO-LC03-03|CDR0000439464</td>\n",
       "      <td>F150128005 (UAB 1504)</td>\n",
       "      <td>LUD2002-015|MSKCC 04-012|CDR0000365621</td>\n",
       "      <td>CALGB 31102|CDR0000719011|NCI-2012-00087|U10CA...</td>\n",
       "      <td>RTOG-9712|CDR0000065797</td>\n",
       "      <td>CDR0000304720|P30CA006927|FCCC-02613</td>\n",
       "      <td>RTOG-0241|CDR0000269348</td>\n",
       "      <td>07243|P30CA033572|CHNMC-07243|CDR0000634737</td>\n",
       "      <td>...</td>\n",
       "      <td>IRB00024405|NCI-2013-01653|CCCWFU 62113|P30CA0...</td>\n",
       "      <td>07-0562 / 201101709</td>\n",
       "      <td>A8081006</td>\n",
       "      <td>STU 012011-004|CDR0000653093|NCI-2011-01035</td>\n",
       "      <td>TP2001-101</td>\n",
       "      <td>12472</td>\n",
       "      <td>FVT-L0701</td>\n",
       "      <td>CA209-012</td>\n",
       "      <td>FVT-L0901</td>\n",
       "      <td>08-3-LUN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>results_first_posted</th>\n",
       "      <td>NaN</td>\n",
       "      <td>July 14, 2015</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>February 8, 2022</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>March 30, 2015</td>\n",
       "      <td>January 20, 2021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>August 5, 2019</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>locations</th>\n",
       "      <td>University of Kentucky, Lexington, Kentucky, U...</td>\n",
       "      <td>Emory University Winship Cancer Institute, Atl...</td>\n",
       "      <td>Gunma Cancer Center, Gunma, Japan|National Hos...</td>\n",
       "      <td>UAB Comprehensive Cancer Center, Birmingham, A...</td>\n",
       "      <td>Memorial Sloan-Kettering Cancer Center, New Yo...</td>\n",
       "      <td>Mayo Clinic Hospital, Phoenix, Arizona, United...</td>\n",
       "      <td>University of Alabama at Birmingham Comprehens...</td>\n",
       "      <td>Fox Chase Cancer Center, Philadelphia, Pennsyl...</td>\n",
       "      <td>Comprehensive Cancer Center at University of A...</td>\n",
       "      <td>City of Hope Medical Center, Duarte, Californi...</td>\n",
       "      <td>...</td>\n",
       "      <td>Comprehensive Cancer Center of Wake Forest Uni...</td>\n",
       "      <td>Washington University School of medicine, St. ...</td>\n",
       "      <td>Clinical Trials Office University of Colorado ...</td>\n",
       "      <td>Simmons Comprehensive Cancer Center at Univers...</td>\n",
       "      <td>Comprehensive Blood and Cancer Center, Bakersf...</td>\n",
       "      <td>University of Virginia, Charlottesville, Virgi...</td>\n",
       "      <td>Fukushima Medical University Hospital, Fukushi...</td>\n",
       "      <td>Ucla, Los Angeles, California, United States|Y...</td>\n",
       "      <td>Fukushima Medical University, Fukushima, Japan</td>\n",
       "      <td>National Cancer Centre, Singapore, Singapore, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>study_documents</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>url</th>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01829373</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00401778</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00132054</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT02429843</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00084799</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01486602</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00005022</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00062322</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00059761</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00857025</td>\n",
       "      <td>...</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01931787</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00555256</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01121575</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01302808</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00569114</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00731952</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00633724</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT01454102</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00874588</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT00870532</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>duration</th>\n",
       "      <td>489.0</td>\n",
       "      <td>2587.0</td>\n",
       "      <td>1645.0</td>\n",
       "      <td>1490.0</td>\n",
       "      <td>877.0</td>\n",
       "      <td>2147.0</td>\n",
       "      <td>4503.0</td>\n",
       "      <td>2434.0</td>\n",
       "      <td>3898.0</td>\n",
       "      <td>4561.0</td>\n",
       "      <td>...</td>\n",
       "      <td>791.0</td>\n",
       "      <td>1857.0</td>\n",
       "      <td>1280.0</td>\n",
       "      <td>1917.0</td>\n",
       "      <td>762.0</td>\n",
       "      <td>2830.0</td>\n",
       "      <td>1858.0</td>\n",
       "      <td>3507.0</td>\n",
       "      <td>1188.0</td>\n",
       "      <td>1918.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_PFS</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_OS</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_ORR</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_AEs</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_DOR</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_DLT</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_Cmax</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_</th>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_MTD</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>measure_disease control rate</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lead_outcome_measure</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Others</td>\n",
       "      <td>...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>AEs</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>number_of_measures</th>\n",
       "      <td>1</td>\n",
       "      <td>5</td>\n",
       "      <td>1</td>\n",
       "      <td>8</td>\n",
       "      <td>7</td>\n",
       "      <td>6</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>7</td>\n",
       "      <td>...</td>\n",
       "      <td>3</td>\n",
       "      <td>5</td>\n",
       "      <td>42</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>4</td>\n",
       "      <td>6</td>\n",
       "      <td>4</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>drug_included</th>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>biological_included</th>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>other_included</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>radiation_included</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>procedure_included</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>intervention_count</th>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "      <td>5</td>\n",
       "      <td>3</td>\n",
       "      <td>4</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>4</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>9</td>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>41 rows × 104 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                            0    \\\n",
       "rank                                                                          1   \n",
       "nct_number                                                          NCT01829373   \n",
       "title                          Lung Cancer Vaccine Plus Oral Dietary Supplement   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                                        Biological: vaccine 1650-G   \n",
       "outcome_measures                                Immunologic response to vaccine   \n",
       "sponsor/collaborators         Edward Hirschowitz|University of Louisville|Un...   \n",
       "gender                                                                      All   \n",
       "age                                   21 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  5.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                                BG1006   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     University of Kentucky, Lexington, Kentucky, U...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01829373   \n",
       "duration                                                                  489.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "drug_included                                                             False   \n",
       "biological_included                                                        True   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            1    \\\n",
       "rank                                                                          2   \n",
       "nct_number                                                          NCT00401778   \n",
       "title                         Trial of RAD001 in Patients With Operable Non-...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                                                      Drug: RAD001   \n",
       "outcome_measures              Clinical Response as Assessed Metabolically by...   \n",
       "sponsor/collaborators                                          Emory University   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 33.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                           IRB00024810   \n",
       "results_first_posted                                              July 14, 2015   \n",
       "locations                     Emory University Winship Cancer Institute, Atl...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00401778   \n",
       "duration                                                                 2587.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            5   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            2    \\\n",
       "rank                                                                          3   \n",
       "nct_number                                                          NCT00132054   \n",
       "title                         Amrubicin and Irinotecan in Treating Patients ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: amrubicin hydrochloride|Drug: irinotecan...   \n",
       "outcome_measures                                                                  \n",
       "sponsor/collaborators         Japan Multinational Trial Organization|Nationa...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 30.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                                        Primary Purpose: Treatment   \n",
       "other_ids                                            JMTO-LC03-03|CDR0000439464   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Gunma Cancer Center, Gunma, Japan|National Hos...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00132054   \n",
       "duration                                                                 1645.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            2   \n",
       "\n",
       "                                                                            3    \\\n",
       "rank                                                                          4   \n",
       "nct_number                                                          NCT02429843   \n",
       "title                         A Study of TRC105 in Combination With Paclitax...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                                                      Drug: TRC105   \n",
       "outcome_measures              Number of patients with a change in medical ma...   \n",
       "sponsor/collaborators         University of Alabama at Birmingham|Tracon Pha...   \n",
       "gender                                                                      All   \n",
       "age                                   19 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 16.0   \n",
       "funded_bys                                                       Other|Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                 F150128005 (UAB 1504)   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     UAB Comprehensive Cancer Center, Birmingham, A...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT02429843   \n",
       "duration                                                                 1490.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                 True   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            8   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            4    \\\n",
       "rank                                                                          5   \n",
       "nct_number                                                          NCT00084799   \n",
       "title                         Monoclonal Antibody Therapy in Treating Patien...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                           Biological: monoclonal antibody hu3S193   \n",
       "outcome_measures              Confirmation of Tumor Targeting as Measured by...   \n",
       "sponsor/collaborators         Ludwig Institute for Cancer Research|National ...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 10.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                LUD2002-015|MSKCC 04-012|CDR0000365621   \n",
       "results_first_posted                                           February 8, 2022   \n",
       "locations                     Memorial Sloan-Kettering Cancer Center, New Yo...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00084799   \n",
       "duration                                                                  877.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            7   \n",
       "drug_included                                                             False   \n",
       "biological_included                                                        True   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            5    \\\n",
       "rank                                                                          6   \n",
       "nct_number                                                          NCT01486602   \n",
       "title                         Specialized Radiation Therapy and Chemotherapy...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: carboplatin|Drug: paclitaxel|Radiation: ...   \n",
       "outcome_measures              Maximum-tolerated RT dose fraction|Radiographi...   \n",
       "sponsor/collaborators         Alliance for Clinical Trials in Oncology|Natio...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 22.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                     CALGB 31102|CDR0000719011|NCI-2012-00087|U10CA...   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Mayo Clinic Hospital, Phoenix, Arizona, United...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01486602   \n",
       "duration                                                                 2147.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                 True   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            6   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                         True   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            3   \n",
       "\n",
       "                                                                            6    \\\n",
       "rank                                                                          7   \n",
       "nct_number                                                          NCT00005022   \n",
       "title                         Radiation Therapy Plus Combination Chemotherap...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: cisplatin|Drug: etoposide|Radiation: rad...   \n",
       "outcome_measures              Frequency of patients developing unacceptable ...   \n",
       "sponsor/collaborators         Radiation Therapy Oncology Group|National Canc...   \n",
       "gender                                                                      All   \n",
       "age                                 18 Years to 80 Years   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 64.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                               RTOG-9712|CDR0000065797   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     University of Alabama at Birmingham Comprehens...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00005022   \n",
       "duration                                                                 4503.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                         True   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            3   \n",
       "\n",
       "                                                                            10   \\\n",
       "rank                                                                         11   \n",
       "nct_number                                                          NCT00062322   \n",
       "title                         Neoadjuvant Chemoradiotherapy Followed By Surg...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: cisplatin|Drug: irinotecan hydrochloride...   \n",
       "outcome_measures                                                                  \n",
       "sponsor/collaborators         Fox Chase Cancer Center|National Cancer Instit...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  NaN   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                                        Primary Purpose: Treatment   \n",
       "other_ids                                  CDR0000304720|P30CA006927|FCCC-02613   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Fox Chase Cancer Center, Philadelphia, Pennsyl...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00062322   \n",
       "duration                                                                 2434.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                         True   \n",
       "procedure_included                                                         True   \n",
       "intervention_count                                                            5   \n",
       "\n",
       "                                                                            11   \\\n",
       "rank                                                                         12   \n",
       "nct_number                                                          NCT00059761   \n",
       "title                         Chemotherapy Combined With Radiation Therapy i...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Drug: cisplatin|Drug: irinotecan hydrochloride...   \n",
       "outcome_measures              Maximum tolerated dose of irinotecan in combin...   \n",
       "sponsor/collaborators         Radiation Therapy Oncology Group|National Canc...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 36.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                               RTOG-0241|CDR0000269348   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Comprehensive Cancer Center at University of A...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00059761   \n",
       "duration                                                                 3898.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                         True   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            3   \n",
       "\n",
       "                                                                            12   \\\n",
       "rank                                                                         13   \n",
       "nct_number                                                          NCT00857025   \n",
       "title                         Beta-Glucan in Treating Patients With Locally ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                                          Lung Cancer   \n",
       "interventions                 Biological: beta-glucan MM-10-001|Other: flow ...   \n",
       "outcome_measures              Safety|Maximum-tolerated dose|Toxicity as asse...   \n",
       "sponsor/collaborators         City of Hope Medical Center|National Cancer In...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 20.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                           07243|P30CA033572|CHNMC-07243|CDR0000634737   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     City of Hope Medical Center, Duarte, Californi...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00857025   \n",
       "duration                                                                 4561.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                     Others   \n",
       "number_of_measures                                                            7   \n",
       "drug_included                                                             False   \n",
       "biological_included                                                        True   \n",
       "other_included                                                             True   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            4   \n",
       "\n",
       "                              ...  \\\n",
       "rank                          ...   \n",
       "nct_number                    ...   \n",
       "title                         ...   \n",
       "acronym                       ...   \n",
       "status                        ...   \n",
       "study_results                 ...   \n",
       "conditions                    ...   \n",
       "interventions                 ...   \n",
       "outcome_measures              ...   \n",
       "sponsor/collaborators         ...   \n",
       "gender                        ...   \n",
       "age                           ...   \n",
       "phases                        ...   \n",
       "enrollment                    ...   \n",
       "funded_bys                    ...   \n",
       "study_type                    ...   \n",
       "study_designs                 ...   \n",
       "other_ids                     ...   \n",
       "results_first_posted          ...   \n",
       "locations                     ...   \n",
       "study_documents               ...   \n",
       "url                           ...   \n",
       "duration                      ...   \n",
       "measure_PFS                   ...   \n",
       "measure_OS                    ...   \n",
       "measure_ORR                   ...   \n",
       "measure_AEs                   ...   \n",
       "measure_DOR                   ...   \n",
       "measure_DLT                   ...   \n",
       "measure_Cmax                  ...   \n",
       "measure_                      ...   \n",
       "measure_MTD                   ...   \n",
       "measure_disease control rate  ...   \n",
       "lead_outcome_measure          ...   \n",
       "number_of_measures            ...   \n",
       "drug_included                 ...   \n",
       "biological_included           ...   \n",
       "other_included                ...   \n",
       "radiation_included            ...   \n",
       "procedure_included            ...   \n",
       "intervention_count            ...   \n",
       "\n",
       "                                                                            104  \\\n",
       "rank                                                                        105   \n",
       "nct_number                                                          NCT01931787   \n",
       "title                         CPI-613 in Treating Patients With Relapsed or ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                     Recurrent Small Cell Lung Cancer   \n",
       "interventions                            Drug: 6,8-bis(benzylthio)octanoic acid   \n",
       "outcome_measures              Tumor response rates, defined as the proportio...   \n",
       "sponsor/collaborators         Wake Forest University Health Sciences|Nationa...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 15.0   \n",
       "funded_bys                                                            Other|NIH   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                     IRB00024405|NCI-2013-01653|CCCWFU 62113|P30CA0...   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Comprehensive Cancer Center of Wake Forest Uni...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01931787   \n",
       "duration                                                                  791.0   \n",
       "measure_PFS                                                                True   \n",
       "measure_OS                                                                 True   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            3   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            105  \\\n",
       "rank                                                                        106   \n",
       "nct_number                                                          NCT00555256   \n",
       "title                         A Phase I Study of SUNITINIB and Rapamycin in ...   \n",
       "acronym                                                            SU/Rapamycin   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non-Small Cell Lung Cancer   \n",
       "interventions                 Drug: sunitinib and rapamycin (Drug will be held)   \n",
       "outcome_measures              To define the optimal dose of sunitinib when g...   \n",
       "sponsor/collaborators           Washington University School of Medicine|Pfizer   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 19.0   \n",
       "funded_bys                                                       Other|Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                   07-0562 / 201101709   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Washington University School of medicine, St. ...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00555256   \n",
       "duration                                                                 1857.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                 True   \n",
       "measure_ORR                                                                True   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            5   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            106  \\\n",
       "rank                                                                        107   \n",
       "nct_number                                                          NCT01121575   \n",
       "title                         A Study Of Combined C- MET Inhibitor And PAN-H...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                               Drug: PF-02341066|Drug: PF-00299804   \n",
       "outcome_measures              Overview of Treatment-emergent All Causalities...   \n",
       "sponsor/collaborators                                                    Pfizer   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 70.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                              A8081006   \n",
       "results_first_posted                                             March 30, 2015   \n",
       "locations                     Clinical Trials Office University of Colorado ...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01121575   \n",
       "duration                                                                 1280.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                           42   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            2   \n",
       "\n",
       "                                                                            107  \\\n",
       "rank                                                                        108   \n",
       "nct_number                                                          NCT01302808   \n",
       "title                         Romidepsin and Erlotinib Hydrochloride in Trea...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                        Lung Cancer|Metastatic Cancer   \n",
       "interventions                 Combination Product: Erlotinib plus Romidepsin...   \n",
       "outcome_measures              Number of Participants With Dose Limiting Toxi...   \n",
       "sponsor/collaborators         University of Texas Southwestern Medical Cente...   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 17.0   \n",
       "funded_bys                                                       Other|Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                           STU 012011-004|CDR0000653093|NCI-2011-01035   \n",
       "results_first_posted                                           January 20, 2021   \n",
       "locations                     Simmons Comprehensive Cancer Center at Univers...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01302808   \n",
       "duration                                                                 1917.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            2   \n",
       "drug_included                                                             False   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            4   \n",
       "\n",
       "                                                                            108  \\\n",
       "rank                                                                        109   \n",
       "nct_number                                                          NCT00569114   \n",
       "title                         Phase 1 Study of TG01 and Erlotinib in Non-sma...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non-small Cell Lung Cancer   \n",
       "interventions                                                        Drug: TG01   \n",
       "outcome_measures              Saftey, maximum tolerated dose, optimal biolog...   \n",
       "sponsor/collaborators                             Tragara Pharmaceuticals, Inc.   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 45.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...   \n",
       "other_ids                                                            TP2001-101   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Comprehensive Blood and Cancer Center, Bakersf...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00569114   \n",
       "duration                                                                  762.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            1   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            109  \\\n",
       "rank                                                                        110   \n",
       "nct_number                                                          NCT00731952   \n",
       "title                         Phase I Study of Induction Therapy With VELCAD...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                                      Drug: Velcade and Vorinostat   \n",
       "outcome_measures                                  Adverse events|Tumor response   \n",
       "sponsor/collaborators                                    University of Virginia   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                 21.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                                 12472   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     University of Virginia, Charlottesville, Virgi...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00731952   \n",
       "duration                                                                 2830.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                                True   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                  False   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                        AEs   \n",
       "number_of_measures                                                            2   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                       False   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            110  \\\n",
       "rank                                                                        111   \n",
       "nct_number                                                          NCT00633724   \n",
       "title                         Multiple-Vaccine Therapy in Treating Patients ...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                 Biological: HLA-A*2402restricted URLC10, TTK, ...   \n",
       "outcome_measures              Adverse effects, dose limiting toxicity, and m...   \n",
       "sponsor/collaborators         Fukushima Medical University|Human Genome Cent...   \n",
       "gender                                                                      All   \n",
       "age                                   20 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  9.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                             FVT-L0701   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                     Fukushima Medical University Hospital, Fukushi...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00633724   \n",
       "duration                                                                 1858.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            4   \n",
       "drug_included                                                             False   \n",
       "biological_included                                                        True   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            111  \\\n",
       "rank                                                                        112   \n",
       "nct_number                                                          NCT01454102   \n",
       "title                         Study of Nivolumab (BMS-936558) in Combination...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                                       Has Results   \n",
       "conditions                                           Non-small Cell Lung Cancer   \n",
       "interventions                 Biological: Nivolumab|Drug: Gemcitabine|Drug: ...   \n",
       "outcome_measures              Number of Participants Who Experienced Serious...   \n",
       "sponsor/collaborators                                      Bristol-Myers Squibb   \n",
       "gender                                                                      All   \n",
       "age                                   18 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                472.0   \n",
       "funded_bys                                                             Industry   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: Randomized|Intervention Model: Par...   \n",
       "other_ids                                                             CA209-012   \n",
       "results_first_posted                                             August 5, 2019   \n",
       "locations                     Ucla, Los Angeles, California, United States|Y...   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT01454102   \n",
       "duration                                                                 3507.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                                True   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            6   \n",
       "drug_included                                                              True   \n",
       "biological_included                                                        True   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            9   \n",
       "\n",
       "                                                                            113  \\\n",
       "rank                                                                        114   \n",
       "nct_number                                                          NCT00874588   \n",
       "title                         Peptide Vaccine Targeting to Cancer Specific A...   \n",
       "acronym                                                                     NaN   \n",
       "status                                                                Completed   \n",
       "study_results                                              No Results Available   \n",
       "conditions                                           Non Small Cell Lung Cancer   \n",
       "interventions                 Biological: HLA-A*2402restricted URLC10, CDCA1...   \n",
       "outcome_measures              Adverse effects, dose limiting toxicity, and m...   \n",
       "sponsor/collaborators         Fukushima Medical University|Human Genome Cent...   \n",
       "gender                                                                      All   \n",
       "age                                   20 Years and older   (Adult, Older Adult)   \n",
       "phases                                                                  Phase 1   \n",
       "enrollment                                                                  6.0   \n",
       "funded_bys                                                                Other   \n",
       "study_type                                                       Interventional   \n",
       "study_designs                 Allocation: N/A|Intervention Model: Single Gro...   \n",
       "other_ids                                                             FVT-L0901   \n",
       "results_first_posted                                                        NaN   \n",
       "locations                        Fukushima Medical University, Fukushima, Japan   \n",
       "study_documents                                                             NaN   \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00874588   \n",
       "duration                                                                 1188.0   \n",
       "measure_PFS                                                               False   \n",
       "measure_OS                                                                False   \n",
       "measure_ORR                                                               False   \n",
       "measure_AEs                                                               False   \n",
       "measure_DOR                                                               False   \n",
       "measure_DLT                                                               False   \n",
       "measure_Cmax                                                              False   \n",
       "measure_                                                                   True   \n",
       "measure_MTD                                                               False   \n",
       "measure_disease control rate                                              False   \n",
       "lead_outcome_measure                                                              \n",
       "number_of_measures                                                            4   \n",
       "drug_included                                                             False   \n",
       "biological_included                                                        True   \n",
       "other_included                                                            False   \n",
       "radiation_included                                                        False   \n",
       "procedure_included                                                        False   \n",
       "intervention_count                                                            1   \n",
       "\n",
       "                                                                            114  \n",
       "rank                                                                        115  \n",
       "nct_number                                                          NCT00870532  \n",
       "title                         Study of Combination of Metronomic Oral Vinore...  \n",
       "acronym                                                                     NaN  \n",
       "status                                                                Completed  \n",
       "study_results                                              No Results Available  \n",
       "conditions                                           Non-Small Cell Lung Cancer  \n",
       "interventions                            Drug: oral vinorelbine|Drug: sorafenib  \n",
       "outcome_measures              to determine the optimal combination of metron...  \n",
       "sponsor/collaborators                         National Cancer Centre, Singapore  \n",
       "gender                                                                      All  \n",
       "age                                   21 Years and older   (Adult, Older Adult)  \n",
       "phases                                                                  Phase 1  \n",
       "enrollment                                                                 52.0  \n",
       "funded_bys                                                                Other  \n",
       "study_type                                                       Interventional  \n",
       "study_designs                 Allocation: Non-Randomized|Intervention Model:...  \n",
       "other_ids                                                              08-3-LUN  \n",
       "results_first_posted                                                        NaN  \n",
       "locations                     National Cancer Centre, Singapore, Singapore, ...  \n",
       "study_documents                                                             NaN  \n",
       "url                                 https://ClinicalTrials.gov/show/NCT00870532  \n",
       "duration                                                                 1918.0  \n",
       "measure_PFS                                                               False  \n",
       "measure_OS                                                                False  \n",
       "measure_ORR                                                               False  \n",
       "measure_AEs                                                               False  \n",
       "measure_DOR                                                               False  \n",
       "measure_DLT                                                               False  \n",
       "measure_Cmax                                                              False  \n",
       "measure_                                                                   True  \n",
       "measure_MTD                                                               False  \n",
       "measure_disease control rate                                              False  \n",
       "lead_outcome_measure                                                             \n",
       "number_of_measures                                                            2  \n",
       "drug_included                                                              True  \n",
       "biological_included                                                       False  \n",
       "other_included                                                            False  \n",
       "radiation_included                                                        False  \n",
       "procedure_included                                                        False  \n",
       "intervention_count                                                            2  \n",
       "\n",
       "[41 rows x 104 columns]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "print(df.interventions[0])\n",
    "df.head(104).transpose()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "b9bcbac8",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAkQAAAHFCAYAAAAT5Oa6AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAABCsElEQVR4nO3dfVwVdf7//+dBBNTkIBogBYLpKnhZWoqaWZKYrpW6lUVp5epm4mWauqmpWV6smVqurG2b1ke32u+WXW0YaeIV4SVeIutVQSGikpzQFVDm94c5v05oeewcDjqP++02t3Xe7/eZeQ3ukWcz75mxGYZhCAAAwMJ8vF0AAACAtxGIAACA5RGIAACA5RGIAACA5RGIAACA5RGIAACA5RGIAACA5fl6u4CrRXl5ufLy8lS7dm3ZbDZvlwMAAC6DYRj64YcfFB4eLh+fS58HIhBdpry8PEVERHi7DAAAcAVyc3N14403XrKfQHSZateuLen8DzQwMNDL1QAAgMvhcDgUERFh/h6/FALRZbpwmSwwMJBABADAVebXprswqRoAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFier7cLAAB4T9T4T71dAirR1zN7eruEKoszRAAAwPIIRAAAwPIIRAAAwPIIRAAAwPIIRAAAwPIIRAAAwPIIRAAAwPK8GojWrl2rXr16KTw8XDabTStWrKgwJisrS/fee6/sdrtq1aqlW2+9VTk5OWb/mTNnNHToUNWtW1fXXXed+vbtq6NHjzptIycnRz179lTNmjUVEhKisWPH6uzZs54+PAAAcJXwaiA6deqUWrVqpYULF160/+DBg+rUqZOaNm2qNWvWaOfOnZo0aZICAgLMMaNGjdLHH3+sf/3rX0pLS1NeXp769Olj9p87d049e/ZUaWmpNm7cqKVLl2rJkiWaPHmyx48PAABcHWyGYRjeLkKSbDabPvjgA91///1mW79+/VS9enW9/fbbF/1MUVGRrr/+ei1fvlx/+MMfJEn79u1TTEyM0tPT1b59e3322Wf6/e9/r7y8PIWGhkqSkpOTNW7cOB07dkx+fn4X3XZJSYlKSkrMdYfDoYiICBUVFSkwMNBNRw0A3sWTqq3Fik+qdjgcstvtv/r7u8rOISovL9enn36q3/3ud0pISFBISIjatWvndFlt69atKisrU3x8vNnWtGlTRUZGKj09XZKUnp6uFi1amGFIkhISEuRwOLRnz55L7n/GjBmy2+3mEhER4f6DBAAAVUKVDUQFBQUqLi7WzJkz1b17d33++efq3bu3+vTpo7S0NElSfn6+/Pz8FBQU5PTZ0NBQ5efnm2N+GoYu9F/ou5QJEyaoqKjIXHJzc914dAAAoCqpsi93LS8vlyTdd999GjVqlCSpdevW2rhxo5KTk3XHHXd4dP/+/v7y9/f36D4AAEDVUGXPENWrV0++vr6KjY11ao+JiTHvMgsLC1NpaalOnjzpNObo0aMKCwszx/z8rrML6xfGAAAAa6uygcjPz0+33nqrsrOzndr/+9//qkGDBpKkNm3aqHr16lq1apXZn52drZycHMXFxUmS4uLitGvXLhUUFJhjUlNTFRgYWCFsAQAAa/LqJbPi4mIdOHDAXD98+LAyMzMVHBysyMhIjR07Vg899JA6d+6sO++8UykpKfr444+1Zs0aSZLdbtfAgQM1evRoBQcHKzAwUMOGDVNcXJzat28vSerWrZtiY2P12GOPafbs2crPz9fEiRM1dOhQLokBAABJXg5EW7Zs0Z133mmujx49WpI0YMAALVmyRL1791ZycrJmzJih4cOHq0mTJvr3v/+tTp06mZ955ZVX5OPjo759+6qkpEQJCQn661//avZXq1ZNn3zyiYYMGaK4uDjVqlVLAwYM0LRp0yrvQAEAQJVWZZ5DVNVd7nMMrkU8p8RarPicEivj+20tVvx+X/XPIQIAAKgsBCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5BCIAAGB5Xg1Ea9euVa9evRQeHi6bzaYVK1ZccuxTTz0lm82mefPmObUXFhYqMTFRgYGBCgoK0sCBA1VcXOw0ZufOnbr99tsVEBCgiIgIzZ492wNHAwAArlZeDUSnTp1Sq1attHDhwl8c98EHH+irr75SeHh4hb7ExETt2bNHqamp+uSTT7R27VoNHjzY7Hc4HOrWrZsaNGigrVu36i9/+YumTJmixYsXu/14AADA1cnXmzu/5557dM899/zimO+++07Dhg3TypUr1bNnT6e+rKwspaSkaPPmzWrbtq0k6dVXX1WPHj00Z84chYeHa9myZSotLdU//vEP+fn5qVmzZsrMzNTcuXOdghMAALCuKj2HqLy8XI899pjGjh2rZs2aVehPT09XUFCQGYYkKT4+Xj4+PsrIyDDHdO7cWX5+fuaYhIQEZWdn6/vvv7/kvktKSuRwOJwWAABwbarSgWjWrFny9fXV8OHDL9qfn5+vkJAQpzZfX18FBwcrPz/fHBMaGuo05sL6hTEXM2PGDNntdnOJiIj4LYcCAACqsCobiLZu3ar58+dryZIlstlslb7/CRMmqKioyFxyc3MrvQYAAFA5qmwgWrdunQoKChQZGSlfX1/5+vrqm2++0TPPPKOoqChJUlhYmAoKCpw+d/bsWRUWFiosLMwcc/ToUacxF9YvjLkYf39/BQYGOi0AAODaVGUD0WOPPaadO3cqMzPTXMLDwzV27FitXLlSkhQXF6eTJ09q69at5udWr16t8vJytWvXzhyzdu1alZWVmWNSU1PVpEkT1alTp3IPCgAAVElevcusuLhYBw4cMNcPHz6szMxMBQcHKzIyUnXr1nUaX716dYWFhalJkyaSpJiYGHXv3l2DBg1ScnKyysrKlJSUpH79+pm36D/yyCOaOnWqBg4cqHHjxmn37t2aP3++Xnnllco7UAAAUKV5NRBt2bJFd955p7k+evRoSdKAAQO0ZMmSy9rGsmXLlJSUpK5du8rHx0d9+/bVggULzH673a7PP/9cQ4cOVZs2bVSvXj1NnjyZW+4BAIDJq4GoS5cuMgzjssd//fXXFdqCg4O1fPnyX/xcy5YttW7dOlfLAwAAFlFl5xABAABUFgIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPAIRAACwPJcDUW5urr799ltzfdOmTRo5cqQWL17s1sIAAAAqi8uB6JFHHtGXX34pScrPz9fdd9+tTZs26bnnntO0adPcXiAAAICnuRyIdu/erdtuu02S9N5776l58+bauHGjli1bpiVLlri7PgAAAI9zORCVlZXJ399fkvTFF1/o3nvvlSQ1bdpUR44ccW91AAAAlcDlQNSsWTMlJydr3bp1Sk1NVffu3SVJeXl5qlu3rtsLBAAA8DSXA9GsWbP0t7/9TV26dNHDDz+sVq1aSZI++ugj81IaAADA1cTX1Q906dJFx48fl8PhUJ06dcz2wYMHq2bNmm4tDgAAoDK4fIbo+eef17fffusUhiQpKipKISEhbisMAACgsrgciD788EPddNNN6tq1q5YvX66SkhJP1AUAAFBpXA5EmZmZ2rx5s5o1a6YRI0YoLCxMQ4YM0ebNmz1RHwAAgMdd0as7br75Zi1YsEB5eXl644039O2336pjx45q2bKl5s+fr6KiInfXCQAA4DG/6V1mhmGorKxMpaWlMgxDderU0WuvvaaIiAi9++677qoRAADAo64oEG3dulVJSUmqX7++Ro0apZtvvllZWVlKS0vT/v379eKLL2r48OG/up21a9eqV69eCg8Pl81m04oVK8y+srIyjRs3Ti1atFCtWrUUHh6u/v37Ky8vz2kbhYWFSkxMVGBgoIKCgjRw4EAVFxc7jdm5c6duv/12BQQEKCIiQrNnz76SwwYAANcolwNRixYt1L59ex0+fFhvvPGGcnNzNXPmTDVq1Mgc8/DDD+vYsWO/uq1Tp06pVatWWrhwYYW+06dPa9u2bZo0aZK2bdum999/X9nZ2eaTsS9ITEzUnj17lJqaqk8++URr167V4MGDzX6Hw6Fu3bqpQYMG2rp1q/7yl79oypQpvIwWAACYXH4O0YMPPqgnn3xSN9xwwyXH1KtXT+Xl5b+6rXvuuUf33HPPRfvsdrtSU1Od2l577TXddtttysnJUWRkpLKyspSSkqLNmzerbdu2kqRXX31VPXr00Jw5cxQeHq5ly5aptLRU//jHP+Tn56dmzZopMzNTc+fOdQpOP1dSUuJ0B53D4fjV4wEAAFcnl88QTZo06RfDkCcVFRXJZrMpKChIkpSenq6goCAzDElSfHy8fHx8lJGRYY7p3Lmz/Pz8zDEJCQnKzs7W999/f8l9zZgxQ3a73VwiIiI8c1AAAMDrXD5DJEnffvutPvroI+Xk5Ki0tNSpb+7cuW4p7OfOnDmjcePG6eGHH1ZgYKAkKT8/v8LDIH19fRUcHKz8/HxzTHR0tNOY0NBQs+/nD5i8YMKECRo9erS57nA4CEUAAFyjXA5Eq1at0r333quGDRtq3759at68ub7++msZhqFbbrnFEzWqrKxMDz74oAzD0KJFizyyj5/z9/eXv79/pewLAAB4l8uXzCZMmKAxY8Zo165dCggI0L///W/l5ubqjjvu0AMPPOD2Ai+EoW+++Uapqanm2SFJCgsLU0FBgdP4s2fPqrCwUGFhYeaYo0ePOo25sH5hDAAAsDaXA1FWVpb69+8v6fzlqf/973+67rrrNG3aNM2aNcutxV0IQ/v379cXX3yhunXrOvXHxcXp5MmT2rp1q9m2evVqlZeXq127duaYtWvXqqyszByTmpqqJk2aXPJyGQAAsBaXA1GtWrXMeUP169fXwYMHzb7jx4+7tK3i4mJlZmYqMzNTknT48GFlZmYqJydHZWVl+sMf/qAtW7Zo2bJlOnfunPLz85Wfn2/uPyYmRt27d9egQYO0adMmbdiwQUlJSerXr5/Cw8MlSY888oj8/Pw0cOBA7dmzR++++67mz5/vND8IAABYm8tziNq3b6/169crJiZGPXr00DPPPKNdu3bp/fffV/v27V3a1pYtW3TnnXea6xdCyoABAzRlyhR99NFHkqTWrVs7fe7LL79Uly5dJEnLli1TUlKSunbtKh8fH/Xt21cLFiwwx9rtdn3++ecaOnSo2rRpo3r16mny5Mm/eMs9AACwFpcD0dy5c80nQU+dOlXFxcV699131bhxY5fvMOvSpYsMw7hk/y/1XRAcHKzly5f/4piWLVtq3bp1LtUGAACsw+VA1LBhQ/PPtWrVUnJyslsLAgAAqGy/6eWuAAAA14LLOkNUp04d2Wy2y9pgYWHhbyoIAACgsl1WIJo3b5755xMnTmj69OlKSEhQXFycpPOvx1i5cqUmTZrkkSIBAAA86bIC0YABA8w/9+3bV9OmTVNSUpLZNnz4cL322mv64osvNGrUKPdXCQAA4EEuzyFauXKlunfvXqG9e/fu+uKLL9xSFAAAQGVyORDVrVtXH374YYX2Dz/8sMKTpAEAAK4GLt92P3XqVP3xj3/UmjVrzNdjZGRkKCUlRa+//rrbCwQAAPA0lwPR448/rpiYGC1YsEDvv/++pPOv0Fi/fr0ZkAAAAK4mLgciSWrXrp2WLVvm7loAAAC8ggczAgAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAy3P5LrNTp05p5syZWrVqlQoKClReXu7Uf+jQIbcVBwAAUBlcDkR//OMflZaWpscee0z169eXzWbzRF0AAACVxuVA9Nlnn+nTTz9Vx44dPVEPAABApXN5DlGdOnUUHBzsiVoAAAC8wuVA9MILL2jy5Mk6ffq0J+oBAACodC5fMnv55Zd18OBBhYaGKioqStWrV3fq37Ztm9uKAwAAqAwuB6L777/fA2UAAAB4j8uB6Pnnn/dEHQAAAF5zRW+7l6StW7cqKytLktSsWTPdfPPNbisKAACgMrkciAoKCtSvXz+tWbNGQUFBkqSTJ0/qzjvv1DvvvKPrr7/e3TUCAAB4lMt3mQ0bNkw//PCD9uzZo8LCQhUWFmr37t1yOBwaPny4J2oEAADwKJfPEKWkpOiLL75QTEyM2RYbG6uFCxeqW7dubi0OAACgMrh8hqi8vLzCrfaSVL169QrvNQMAALgauByI7rrrLo0YMUJ5eXlm23fffadRo0apa9eubi0OAACgMrgciF577TU5HA5FRUXppptu0k033aTo6Gg5HA69+uqrnqgRAADAo1yeQxQREaFt27bpiy++0L59+yRJMTExio+Pd3txAAAAlcHlM0SSZLPZdPfdd2vYsGEaNmzYFYehtWvXqlevXgoPD5fNZtOKFSuc+g3D0OTJk1W/fn3VqFFD8fHx2r9/v9OYwsJCJSYmKjAwUEFBQRo4cKCKi4udxuzcuVO33367AgICFBERodmzZ19RvQAA4Np0WWeIFixYoMGDBysgIEALFiz4xbGu3Hp/6tQptWrVSk8++aT69OlToX/27NlasGCBli5dqujoaE2aNEkJCQnau3evAgICJEmJiYk6cuSIUlNTVVZWpieeeEKDBw/W8uXLJUkOh0PdunVTfHy8kpOTtWvXLj355JMKCgrS4MGDL7tWAABw7bIZhmH82qDo6Ght2bJFdevWVXR09KU3ZrPp0KFDV1aIzaYPPvjAfFeaYRgKDw/XM888ozFjxkiSioqKFBoaqiVLlqhfv37KyspSbGysNm/erLZt20o6/1iAHj166Ntvv1V4eLgWLVqk5557Tvn5+fLz85MkjR8/XitWrDAv+V0Oh8Mhu92uoqIiBQYGXtExXq2ixn/q7RJQib6e2dPbJaAS8f22Fit+vy/39/dlnSE6fPjwRf/sSYcPH1Z+fr7T5Ti73a527dopPT1d/fr1U3p6uoKCgswwJEnx8fHy8fFRRkaGevfurfT0dHXu3NkMQ5KUkJCgWbNm6fvvv1edOnUuuv+SkhKVlJSY6w6HwwNHCQAAqgKX5xBNmzZNp0+frtD+v//9T9OmTXNLUZKUn58vSQoNDXVqDw0NNfvy8/MVEhLi1O/r66vg4GCnMRfbxk/3cTEzZsyQ3W43l4iIiN92QAAAoMpyORBNnTq1wqRlSTp9+rSmTp3qlqKqggkTJqioqMhccnNzvV0SAADwEJcDkWEYstlsFdp37Nih4OBgtxQlSWFhYZKko0ePOrUfPXrU7AsLC1NBQYFT/9mzZ1VYWOg05mLb+Ok+Lsbf31+BgYFOCwAAuDZddiCqU6eOgoODZbPZ9Lvf/U7BwcHmYrfbdffdd+vBBx90W2HR0dEKCwvTqlWrzDaHw6GMjAzFxcVJkuLi4nTy5Elt3brVHLN69WqVl5erXbt25pi1a9eqrKzMHJOamqomTZpccv4QAACwlst+MOO8efNkGIaefPJJTZ06VXa73ezz8/NTVFSUGVQuV3FxsQ4cOGCuHz58WJmZmQoODlZkZKRGjhyp6dOnq3HjxuZt9+Hh4eadaDExMerevbsGDRqk5ORklZWVKSkpSf369VN4eLgk6ZFHHtHUqVM1cOBAjRs3Trt379b8+fP1yiuvuFQrAAC4dl12IBowYICk82duOnbsKF9flx9yXcGWLVt05513muujR48297VkyRI9++yzOnXqlAYPHqyTJ0+qU6dOSklJMZ9BJEnLli1TUlKSunbtKh8fH/Xt29fpWUl2u12ff/65hg4dqjZt2qhevXqaPHkyzyACAACmy3oO0c8dPHhQb775pg4ePKj58+crJCREn332mSIjI9WsWTNP1Ol1PIcIVmHF55RYGd9va7Hi9/tyf3+7PKk6LS1NLVq0UEZGht5//33zjrMdO3bo+eefv/KKAQAAvMTlQDR+/HhNnz5dqampTg87vOuuu/TVV1+5tTgAAIDK4HIg2rVrl3r37l2hPSQkRMePH3dLUQAAAJXJ5UAUFBSkI0eOVGjfvn27brjhBrcUBQAAUJlcDkT9+vXTuHHjlJ+fL5vNpvLycm3YsEFjxoxR//79PVEjAACAR7kciF566SU1bdpUERERKi4uVmxsrDp37qwOHTpo4sSJnqgRAADAo1x+mJCfn59ef/11TZo0Sbt371ZxcbFuvvlmNW7c2BP1AQAAeNwVP10xMjJSkZGR7qwFAADAKy4rEF14gvTlmDt37hUXAwAA4A2XFYi2b99+WRuz2Wy/qRgAAABvuKxA9OWXX3q6DgAAAK9x+S6zn8rNzVVubq67agEAAPAKlwPR2bNnNWnSJNntdkVFRSkqKkp2u10TJ05UWVmZJ2oEAADwKJfvMhs2bJjef/99zZ49W3FxcZKk9PR0TZkyRSdOnNCiRYvcXiQAAIAnuRyIli9frnfeeUf33HOP2dayZUtFRETo4YcfJhABAICrjsuXzPz9/RUVFVWhPTo6Wn5+fu6oCQAAoFK5HIiSkpL0wgsvqKSkxGwrKSnRiy++qKSkJLcWBwAAUBlcvmS2fft2rVq1SjfeeKNatWolSdqxY4dKS0vVtWtX9enTxxz7/vvvu69SAAAAD3E5EAUFBalv375ObREREW4rCAAAoLK5HIjefPNNT9QBAADgNb/pwYwAAADXApfPEJ04cUKTJ0/Wl19+qYKCApWXlzv1FxYWuq04AACAyuByIHrsscd04MABDRw4UKGhobzQFQAAXPVcDkTr1q3T+vXrzTvMAAAArnYuzyFq2rSp/ve//3miFgAAAK9wORD99a9/1XPPPae0tDSdOHFCDofDaQEAALjaXNFziBwOh+666y6ndsMwZLPZdO7cObcVBwAAUBlcDkSJiYmqXr26li9fzqRqAABwTXA5EO3evVvbt29XkyZNPFEPAABApXN5DlHbtm2Vm5vriVoAAAC8wuUzRMOGDdOIESM0duxYtWjRQtWrV3fqb9mypduKAwAAqAwuB6KHHnpIkvTkk0+abTabjUnVAADgquXyJbPDhw9XWA4dOmT+rzudO3dOkyZNUnR0tGrUqKGbbrpJL7zwggzDMMcYhqHJkyerfv36qlGjhuLj47V//36n7RQWFioxMVGBgYEKCgrSwIEDVVxc7NZaAQDA1cvlM0QNGjTwRB0XNWvWLC1atEhLly5Vs2bNtGXLFj3xxBOy2+0aPny4JGn27NlasGCBli5dqujoaE2aNEkJCQnau3evAgICJJ2/M+7IkSNKTU1VWVmZnnjiCQ0ePFjLly+vtGMBAABVl8uBSJIOHjyoefPmKSsrS5IUGxurESNG6KabbnJrcRs3btR9992nnj17SpKioqL0z3/+U5s2bZJ0/uzQvHnzNHHiRN13332SpLfeekuhoaFasWKF+vXrp6ysLKWkpGjz5s1q27atJOnVV19Vjx49NGfOHIWHh1903yUlJSopKTHXeegkAADXLpcvma1cuVKxsbHatGmTWrZsqZYtWyojI0PNmjVTamqqW4vr0KGDVq1apf/+97+SpB07dmj9+vW65557JJ2/fJefn6/4+HjzM3a7Xe3atVN6erokKT09XUFBQWYYkqT4+Hj5+PgoIyPjkvueMWOG7Ha7uURERLj12AAAQNXh8hmi8ePHa9SoUZo5c2aF9nHjxunuu+92W3Hjx4+Xw+FQ06ZNVa1aNZ07d04vvviiEhMTJUn5+fmSpNDQUKfPhYaGmn35+fkKCQlx6vf19VVwcLA55mImTJig0aNHm+sOh4NQBADANcrlQJSVlaX33nuvQvuTTz6pefPmuaMm03vvvadly5Zp+fLlatasmTIzMzVy5EiFh4drwIABbt3Xz/n7+8vf39+j+wAAAFWDy5fMrr/+emVmZlZoz8zMrHAm5rcaO3asxo8fr379+qlFixZ67LHHNGrUKM2YMUOSFBYWJkk6evSo0+eOHj1q9oWFhamgoMCp/+zZsyosLDTHAAAAa3P5DNGgQYM0ePBgHTp0SB06dJAkbdiwQbNmzXK6xOQOp0+flo+Pc2arVq2aysvLJUnR0dEKCwvTqlWr1Lp1a0nnL21lZGRoyJAhkqS4uDidPHlSW7duVZs2bSRJq1evVnl5udq1a+fWegEAwNXJ5UA0adIk1a5dWy+//LImTJggSQoPD9eUKVPMW+HdpVevXnrxxRcVGRmpZs2aafv27Zo7d675UEibzaaRI0dq+vTpaty4sXnbfXh4uO6//35JUkxMjLp3765BgwYpOTlZZWVlSkpKUr9+/S55hxkAALAWlwORzWbTqFGjNGrUKP3www+SpNq1a7u9MOn87fGTJk3S008/rYKCAoWHh+tPf/qTJk+ebI559tlnderUKQ0ePFgnT55Up06dlJKSYj6DSJKWLVumpKQkde3aVT4+Purbt68WLFjgkZoBAMDVx2b89LHPl+Hw4cM6e/asGjdu7NS+f/9+Va9eXVFRUe6sr8pwOByy2+0qKipSYGCgt8upVFHjP/V2CahEX8/s6e0SUIn4fluLFb/fl/v72+VJ1Y8//rg2btxYoT0jI0OPP/64q5sDAADwOpcD0fbt29WxY8cK7e3bt7/o3WcAAABVncuByGazmXOHfqqoqIg33QMAgKuSy4Goc+fOmjFjhlP4OXfunGbMmKFOnTq5tTgAAIDK4PJdZrNmzVLnzp3VpEkT3X777ZKkdevWyeFwaPXq1W4vEAAAwNNcPkMUGxurnTt36sEHH1RBQYF++OEH9e/fX/v27VPz5s09USMAAIBHuXyGSDr/IMaXXnrJ3bUAAAB4hctniAAAAK41BCIAAGB5BCIAAGB5BCIAAGB5VxSIzp49qy+++EJ/+9vfzIc05uXlqbi42K3FAQAAVAaX7zL75ptv1L17d+Xk5KikpER33323ateurVmzZqmkpETJycmeqBMAAMBjXD5DNGLECLVt21bff/+9atSoYbb37t1bq1atcmtxAAAAlcHlM0Tr1q3Txo0b5efn59QeFRWl7777zm2FAQAAVBaXzxCVl5df9CWu3377rWrXru2WogAAACqTy4GoW7dumjdvnrlus9lUXFys559/Xj169HBnbQAAAJXC5UtmL7/8shISEhQbG6szZ87okUce0f79+1WvXj3985//9ESNAAAAHuVyILrxxhu1Y8cOvfPOO9q5c6eKi4s1cOBAJSYmOk2yBgAAuFpc0ctdfX199eijj7q7FgAAAK9wORB99NFHF2232WwKCAhQo0aNFB0d/ZsLAwAAqCwuB6L7779fNptNhmE4tV9os9ls6tSpk1asWKE6deq4rVAAAABPcfkus9TUVN16661KTU1VUVGRioqKlJqaqnbt2umTTz7R2rVrdeLECY0ZM8YT9QIAALidy2eIRowYocWLF6tDhw5mW9euXRUQEKDBgwdrz549mjdvnp588km3FgoAAOApLp8hOnjwoAIDAyu0BwYG6tChQ5Kkxo0b6/jx47+9OgAAgErgciBq06aNxo4dq2PHjpltx44d07PPPqtbb71VkrR//35FRES4r0oAAAAPcvmS2RtvvKH77rtPN954oxl6cnNz1bBhQ3344YeSpOLiYk2cONG9lQIAAHiIy4GoSZMm2rt3rz7//HP997//Ndvuvvtu+ficP+F0//33u7VIAAAAT7qiBzP6+Pioe/fu6t69u7vrAQAAqHRXFIhOnTqltLQ05eTkqLS01Klv+PDhbikMAACgsrgciLZv364ePXro9OnTOnXqlIKDg3X8+HHVrFlTISEhBCIAAHDVcfkus1GjRqlXr176/vvvVaNGDX311Vf65ptv1KZNG82ZM8ftBX733Xd69NFHVbduXdWoUUMtWrTQli1bzH7DMDR58mTVr19fNWrUUHx8vPbv3++0jcLCQiUmJiowMFBBQUEaOHCgiouL3V4rAAC4OrkciDIzM/XMM8/Ix8dH1apVU0lJiSIiIjR79mz9+c9/dmtx33//vTp27Kjq1avrs88+0969e/Xyyy87vRJk9uzZWrBggZKTk5WRkaFatWopISFBZ86cMcckJiZqz549Sk1NNZ+mPXjwYLfWCgAArl4uXzKrXr26eTdZSEiIcnJyFBMTI7vdrtzcXLcWN2vWLEVEROjNN98023764ljDMDRv3jxNnDhR9913nyTprbfeUmhoqFasWKF+/fopKytLKSkp2rx5s9q2bStJevXVV9WjRw/NmTNH4eHhbq0ZAABcfVw+Q3TzzTdr8+bNkqQ77rhDkydP1rJlyzRy5Eg1b97crcV99NFHatu2rR544AGFhITo5ptv1uuvv272Hz58WPn5+YqPjzfb7Ha72rVrp/T0dElSenq6goKCzDAkSfHx8fLx8VFGRsYl911SUiKHw+G0AACAa5PLgeill15S/fr1JUkvvvii6tSpoyFDhujYsWNavHixW4s7dOiQFi1apMaNG2vlypUaMmSIhg8frqVLl0qS8vPzJUmhoaFOnwsNDTX78vPzFRIS4tTv6+ur4OBgc8zFzJgxQ3a73Vx48jYAANculy6ZGYahkJAQ80xQSEiIUlJSPFKYJJWXl6tt27Z66aWXJJ0/O7V7924lJydrwIABHtuvJE2YMEGjR4821x0OB6EIAIBrlEtniAzDUKNGjdw+V+hS6tevr9jYWKe2mJgY5eTkSJLCwsIkSUePHnUac/ToUbMvLCxMBQUFTv1nz55VYWGhOeZi/P39FRgY6LQAAIBrk0uByMfHR40bN9aJEyc8VY+Tjh07Kjs726ntv//9rxo0aCDp/ATrsLAwrVq1yux3OBzKyMhQXFycJCkuLk4nT57U1q1bzTGrV69WeXm52rVrVwlHAQAAqjqX5xDNnDlTY8eO1e7duz1Rj5NRo0bpq6++0ksvvaQDBw5o+fLlWrx4sYYOHSpJstlsGjlypKZPn66PPvpIu3btUv/+/RUeHm6+Ty0mJkbdu3fXoEGDtGnTJm3YsEFJSUnq168fd5gBAABJV3Dbff/+/XX69Gm1atVKfn5+qlGjhlN/YWGh24q79dZb9cEHH2jChAmaNm2aoqOjNW/ePCUmJppjnn32WZ06dUqDBw/WyZMn1alTJ6WkpCggIMAcs2zZMiUlJalr167y8fFR3759tWDBArfVCQAArm42wzAMVz5w4Q6vS/H0ZGdvcTgcstvtKioqstx8oqjxn3q7BFSir2f29HYJqER8v63Fit/vy/397fIZoms18AAAAOtyeQ6RJB08eFATJ07Uww8/bN7B9dlnn2nPnj1uLQ4AAKAyuByI0tLS1KJFC2VkZOj99983X5K6Y8cOPf/8824vEAAAwNNcDkTjx4/X9OnTlZqaKj8/P7P9rrvu0ldffeXW4gAAACqDy4Fo165d6t27d4X2kJAQHT9+3C1FAQAAVCaXA1FQUJCOHDlSoX379u264YYb3FIUAABAZXI5EPXr10/jxo1Tfn6+bDabysvLtWHDBo0ZM0b9+/f3RI0AAAAedUVvu2/atKkiIiJUXFys2NhYde7cWR06dNDEiRM9USMAAIBHufwcIj8/P73++uuaNGmSdu/ereLiYt18881q3LixJ+oDAADwOJcD0fr169WpUydFRkYqMjLSEzUBAABUKpcvmd11112Kjo7Wn//8Z+3du9cTNQEAAFQqlwNRXl6ennnmGaWlpal58+Zq3bq1/vKXv+jbb7/1RH0AAAAe53IgqlevnpKSkrRhwwYdPHhQDzzwgJYuXaqoqCjdddddnqgRAADAo67oXWYXREdHa/z48Zo5c6ZatGihtLQ0d9UFAABQaa44EG3YsEFPP/206tevr0ceeUTNmzfXp59+6s7aAAAAKoXLd5lNmDBB77zzjvLy8nT33Xdr/vz5uu+++1SzZk1P1AcAAOBxLgeitWvXauzYsXrwwQdVr149T9QEAABQqVwORBs2bPBEHQAAAF7jciC6YO/evcrJyVFpaalT+7333vubiwIAAKhMLgeiQ4cOqXfv3tq1a5dsNpsMw5Ak2Ww2SdK5c+fcWyEAAICHuXyX2YgRIxQdHa2CggLVrFlTe/bs0dq1a9W2bVutWbPGAyUCAAB4lstniNLT07V69WrVq1dPPj4+8vHxUadOnTRjxgwNHz5c27dv90SdAAAAHuPyGaJz586pdu3aks4/tTovL0+S1KBBA2VnZ7u3OgAAgErg8hmi5s2ba8eOHYqOjla7du00e/Zs+fn5afHixWrYsKEnagQAAPAolwPRxIkTderUKUnStGnT9Pvf/16333676tatq3fffdftBQIAAHiay4EoISHB/HOjRo20b98+FRYWqk6dOuadZgAAAFeTK34O0U8FBwe7YzMAAABe8Zvedg8AAHAtIBABAADLIxABAADLIxABAADLIxABAADLu6oC0cyZM2Wz2TRy5Eiz7cyZMxo6dKjq1q2r6667Tn379tXRo0edPpeTk6OePXuqZs2aCgkJ0dixY3X27NlKrh4AAFRVV00g2rx5s/72t7+pZcuWTu2jRo3Sxx9/rH/9619KS0tTXl6e+vTpY/afO3dOPXv2VGlpqTZu3KilS5dqyZIlmjx5cmUfAgAAqKKuikBUXFysxMREvf7666pTp47ZXlRUpDfeeENz587VXXfdpTZt2ujNN9/Uxo0b9dVXX0mSPv/8c+3du1f/93//p9atW+uee+7RCy+8oIULF6q0tNRbhwQAAKqQqyIQDR06VD179lR8fLxT+9atW1VWVubU3rRpU0VGRio9PV2SlJ6erhYtWig0NNQck5CQIIfDoT179lxynyUlJXI4HE4LAAC4NrnlSdWe9M4772jbtm3avHlzhb78/Hz5+fkpKCjIqT00NFT5+fnmmJ+GoQv9F/ouZcaMGZo6depvrB4AAFwNqvQZotzcXI0YMULLli1TQEBApe57woQJKioqMpfc3NxK3T8AAKg8VToQbd26VQUFBbrlllvk6+srX19fpaWlacGCBfL19VVoaKhKS0t18uRJp88dPXpUYWFhkqSwsLAKd51dWL8w5mL8/f0VGBjotAAAgGtTlQ5EXbt21a5du5SZmWkubdu2VWJiovnn6tWra9WqVeZnsrOzlZOTo7i4OElSXFycdu3apYKCAnNMamqqAgMDFRsbW+nHBAAAqp4qPYeodu3aat68uVNbrVq1VLduXbN94MCBGj16tIKDgxUYGKhhw4YpLi5O7du3lyR169ZNsbGxeuyxxzR79mzl5+dr4sSJGjp0qPz9/Sv9mAAAQNVTpQPR5XjllVfk4+Ojvn37qqSkRAkJCfrrX/9q9lerVk2ffPKJhgwZori4ONWqVUsDBgzQtGnTvFg1AACoSq66QLRmzRqn9YCAAC1cuFALFy685GcaNGig//znPx6uDAAAXK2q9BwiAACAykAgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAlkcgAgAAllflA9GMGTN06623qnbt2goJCdH999+v7OxspzFnzpzR0KFDVbduXV133XXq27evjh496jQmJydHPXv2VM2aNRUSEqKxY8fq7NmzlXkoAACgiqrygSgtLU1Dhw7VV199pdTUVJWVlalbt246deqUOWbUqFH6+OOP9a9//UtpaWnKy8tTnz59zP5z586pZ8+eKi0t1caNG7V06VItWbJEkydP9sYhAQCAKsZmGIbh7SJccezYMYWEhCgtLU2dO3dWUVGRrr/+ei1fvlx/+MMfJEn79u1TTEyM0tPT1b59e3322Wf6/e9/r7y8PIWGhkqSkpOTNW7cOB07dkx+fn4V9lNSUqKSkhJz3eFwKCIiQkVFRQoMDKycg60iosZ/6u0SUIm+ntnT2yWgEvH9thYrfr8dDofsdvuv/v6u8meIfq6oqEiSFBwcLEnaunWrysrKFB8fb45p2rSpIiMjlZ6eLklKT09XixYtzDAkSQkJCXI4HNqzZ89F9zNjxgzZ7XZziYiI8NQhAQAAL7uqAlF5eblGjhypjh07qnnz5pKk/Px8+fn5KSgoyGlsaGio8vPzzTE/DUMX+i/0XcyECRNUVFRkLrm5uW4+GgAAUFX4ersAVwwdOlS7d+/W+vXrPb4vf39/+fv7e3w/AADA+66aM0RJSUn65JNP9OWXX+rGG28028PCwlRaWqqTJ086jT969KjCwsLMMT+/6+zC+oUxAADAuqp8IDIMQ0lJSfrggw+0evVqRUdHO/W3adNG1atX16pVq8y27Oxs5eTkKC4uTpIUFxenXbt2qaCgwByTmpqqwMBAxcbGVs6BAACAKqvKXzIbOnSoli9frg8//FC1a9c25/zY7XbVqFFDdrtdAwcO1OjRoxUcHKzAwEANGzZMcXFxat++vSSpW7duio2N1WOPPabZs2crPz9fEydO1NChQ7ksBgAAqn4gWrRokSSpS5cuTu1vvvmmHn/8cUnSK6+8Ih8fH/Xt21clJSVKSEjQX//6V3NstWrV9Mknn2jIkCGKi4tTrVq1NGDAAE2bNq2yDgMAAFRhVT4QXc5jkgICArRw4UItXLjwkmMaNGig//znP+4sDQAAXCOq/BwiAAAATyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAyyMQAQAAy7NUIFq4cKGioqIUEBCgdu3aadOmTd4uCQAAVAGWCUTvvvuuRo8ereeff17btm1Tq1atlJCQoIKCAm+XBgAAvMwygWju3LkaNGiQnnjiCcXGxio5OVk1a9bUP/7xD2+XBgAAvMzX2wVUhtLSUm3dulUTJkww23x8fBQfH6/09PSLfqakpEQlJSXmelFRkSTJ4XB4ttgqqLzktLdLQCWy4v/HrYzvt7VY8ft94ZgNw/jFcZYIRMePH9e5c+cUGhrq1B4aGqp9+/Zd9DMzZszQ1KlTK7RHRER4pEagqrDP83YFADzFyt/vH374QXa7/ZL9lghEV2LChAkaPXq0uV5eXq7CwkLVrVtXNpvNi5WhMjgcDkVERCg3N1eBgYHeLgeAG/H9thbDMPTDDz8oPDz8F8dZIhDVq1dP1apV09GjR53ajx49qrCwsIt+xt/fX/7+/k5tQUFBnioRVVRgYCD/YALXKL7f1vFLZ4YusMSkaj8/P7Vp00arVq0y28rLy7Vq1SrFxcV5sTIAAFAVWOIMkSSNHj1aAwYMUNu2bXXbbbdp3rx5OnXqlJ544glvlwYAALzMMoHooYce0rFjxzR58mTl5+erdevWSklJqTDRGpDOXzJ9/vnnK1w2BXD14/uNi7EZv3YfGgAAwDXOEnOIAAAAfgmBCAAAWB6BCAAAWB6BCAAAWB6BCAAAWB6BCABwzVu3bp0effRRxcXF6bvvvpMkvf3221q/fr2XK0NVQSACfqa0tFTZ2dk6e/ast0sB4Ab//ve/lZCQoBo1amj79u0qKSmRJBUVFemll17ycnWoKghEwI9Onz6tgQMHqmbNmmrWrJlycnIkScOGDdPMmTO9XB2AKzV9+nQlJyfr9ddfV/Xq1c32jh07atu2bV6sDFUJgQj40YQJE7Rjxw6tWbNGAQEBZnt8fLzeffddL1YG4LfIzs5W586dK7Tb7XadPHmy8gtClUQgAn60YsUKvfbaa+rUqZNsNpvZ3qxZMx08eNCLlQH4LcLCwnTgwIEK7evXr1fDhg29UBGqIgIR8KNjx44pJCSkQvupU6ecAhKAq8ugQYM0YsQIZWRkyGazKS8vT8uWLdOYMWM0ZMgQb5eHKsIyL3cFfk3btm316aefatiwYZJkhqC///3viouL82ZpAH6D8ePHq7y8XF27dtXp06fVuXNn+fv7a8yYMeb3HeDlrsCP1q9fr3vuuUePPvqolixZoj/96U/au3evNm7cqLS0NLVp08bbJQL4DUpLS3XgwAEVFxcrNjZW1113nbdLQhVCIAJ+4uDBg5o5c6Z27Nih4uJi3XLLLRo3bpxatGjh7dIAAB5EIAIAXNPuvPPOX5wHuHr16kqsBlUVc4iAH23btk3Vq1c3zwZ9+OGHevPNNxUbG6spU6bIz8/PyxUCuBKtW7d2Wi8rK1NmZqZ2796tAQMGeKcoVDmcIQJ+dOutt2r8+PHq27evDh06pNjYWPXp00ebN29Wz549NW/ePG+XCMCNpkyZouLiYs2ZM8fbpaAKIBABP7Lb7dq2bZtuuukmzZo1S6tXr9bKlSu1YcMG9evXT7m5ud4uEYAbHThwQLfddpsKCwu9XQqqAJ5DBPzIMAyVl5dLkr744gv16NFDkhQREaHjx497szQAHpCenu70VHpYG3OIgB+1bdtW06dPV3x8vNLS0rRo0SJJ0uHDhxUaGurl6gBcqT59+jitG4ahI0eOaMuWLZo0aZKXqkJVQyACfjRv3jwlJiZqxYoVeu6559SoUSNJ0v/7f/9PHTp08HJ1AK6U3W53Wvfx8VGTJk00bdo0devWzUtVoaphDhHwK86cOaNq1ao5vSUbwNXh3Llz2rBhg1q0aKE6dep4uxxUYQQiAMA1LSAgQFlZWYqOjvZ2KajCuGQGS6tTp85lv7iVO1GAq1Pz5s116NAhAhF+EYEIlsazhYBr3/Tp0zVmzBi98MILatOmjWrVquXUHxgY6KXKUJVwyQwAcE2aNm2annnmGdWuXdts++kZYcMwZLPZdO7cOW+UhyqGQARcxJkzZ1RaWurUxn9FAleXatWq6ciRI8rKyvrFcXfccUclVYSqjEAE/OjUqVMaN26c3nvvPZ04caJCP/8VCVxdfHx8lJ+fr5CQEG+XgqsAT6oGfvTss89q9erVWrRokfz9/fX3v/9dU6dOVXh4uN566y1vlwfgClzuTRMAZ4iAH0VGRuqtt95Sly5dFBgYqG3btqlRo0Z6++239c9//lP/+c9/vF0iABf4+PjIbrf/aijiDlJI3GUGmAoLC9WwYUNJ5+cLXfhHslOnThoyZIg3SwNwhaZOnVrhSdXAxRCIgB81bNhQhw8fVmRkpJo2bar33ntPt912mz7++GMFBQV5uzwAV6Bfv37MIcJlYQ4RLO/QoUMqLy/XE088oR07dkiSxo8fr4ULFyogIECjRo3S2LFjvVwlAFcxfwiuYA4RLO/CrbkX/ivyoYce0oIFC3TmzBlt3bpVjRo1UsuWLb1cJQBXcZcZXEEgguX9/B/N2rVra8eOHeZ8IgDAtY9LZgAAwPIIRLA8m81WYa4Bcw8AwFq4ywyWZxiGHn/8cfn7+0s6/9qOp556qsILIN9//31vlAcAqAQEIljegAEDnNYfffRRL1UCAPAWJlUDAADLYw4RAACwPAIRAACwPAIRAACwPAIRAACwPAIRYHFdunTRyJEjL9kfFRWlefPmXfb2pkyZotatW//mun5qzZo1stlsOnnypFu29/XXX8tmsykzM7PS9y2df87VihUrftM2lixZ4paXDrujFuBawG33AH7R5s2bKzyTqbJ16NBBR44ckd1ut9S+AVQeAhGAX3T99dd7uwT5+fkpLCzMcvsGUHm4ZAZAZ8+eVVJSkux2u+rVq6dJkybpwiPKfn7JLCcnR/fdd5+uu+46BQYG6sEHH9TRo0cvue3y8nJNmzZNN954o/z9/dW6dWulpKQ4jdm4caNat26tgIAAtW3bVitWrHC6pHWxy1YbNmxQly5dVLNmTdWpU0cJCQn6/vvvJUkpKSnq1KmTgoKCVLduXf3+97/XwYMHr+hn8/N9X7hUtXLlSsXExOi6665T9+7ddeTIEafP/eMf/1CzZs3k7++v+vXrKykp6bK2L0mZmZmy2Wz6+uuvzbYlS5YoMjJSNWvWVO/evXXixIkK2/rwww91yy23KCAgQA0bNtTUqVN19uxZs3///v3q3LmzAgICFBsbq9TU1Cv6mQDXIgIRAC1dulS+vr7atGmT5s+fr7lz5+rvf/97hXHl5eW67777VFhYqLS0NKWmpurQoUN66KGHLrnt+fPn6+WXX9acOXO0c+dOJSQk6N5779X+/fslSQ6HQ7169VKLFi20bds2vfDCCxo3btwv1puZmamuXbsqNjZW6enpWr9+vXr16qVz585Jkk6dOqXRo0dry5YtWrVqlXx8fNS7d2+Vl5f/hp/S/+/06dOaM2eO3n77ba1du1Y5OTkaM2aM2b9o0SINHTpUgwcP1q5du/TRRx+pUaNGV7y/jIwMDRw4UElJScrMzNSdd96p6dOnO41Zt26d+vfvrxEjRmjv3r3629/+piVLlujFF1+UdP7vrk+fPvLz81NGRoaSk5N/9ecMWIoBwNLuuOMOIyYmxigvLzfbxo0bZ8TExBiGYRgNGjQwXnnlFcMwDOPzzz83qlWrZuTk5Jhj9+zZY0gyNm3aZBiGYTz//PNGq1atzP7w8HDjxRdfdNrnrbfeajz99NOGYRjGokWLjLp16xr/+9//zP7XX3/dkGRs377dMAzD+PLLLw1Jxvfff28YhmE8/PDDRseOHS/7GI8dO2ZIMnbt2mUYhmEcPnzYafu/5Of7fvPNNw1JxoEDB8wxCxcuNEJDQ52O+bnnnrvkNiUZH3zwwUW3bxiGsX37dkOScfjwYcMwzh9vjx49nLbx0EMPGXa73Vzv2rWr8dJLLzmNefvtt4369esbhmEYK1euNHx9fY3vvvvO7P/ss8+cagGsjDNEANS+fXvZbDZzPS4uTvv37zfPuFyQlZWliIgIRUREmG2xsbEKCgpSVlZWhe06HA7l5eWpY8eOTu0dO3Y0x2dnZ6tly5YKCAgw+2+77bZfrPfCGaJL2b9/vx5++GE1bNhQgYGBioqKknT+cp871KxZUzfddJO5Xr9+fRUUFEiSCgoKlJeX94v1uSorK0vt2rVzaouLi3Na37Fjh6ZNm6brrrvOXAYNGqQjR47o9OnT5t9deHj4JbcBWBmTqgFcdWrUqPGL/b169VKDBg30+uuvKzw8XOXl5WrevLlKS0vdsv/q1as7rdtsNnPO1a/V9nM+Puf/u9T4yWsly8rKXK6puLhYU6dOVZ8+fSr0/TRsArg4zhABUEZGhtP6V199pcaNG6tatWpO7TExMcrNzVVubq7ZtnfvXp08eVKxsbEVthsYGKjw8HBt2LDBqX3Dhg3m+CZNmmjXrl0qKSkx+zdv3vyL9bZs2VKrVq26aN+JEyeUnZ2tiRMnqmvXroqJiTEnW1eG2rVrKyoq6pL1/dyFu/h+Oin7589HiomJuejf0U/dcsstys7OVqNGjSosPj4+5t/dT/fz820AVkYgAqCcnByNHj1a2dnZ+uc//6lXX31VI0aMqDAuPj5eLVq0UGJiorZt26ZNmzapf//+uuOOO9S2bduLbnvs2LGaNWuW3n33XWVnZ2v8+PHKzMw0t//II4+ovLxcgwcPVlZWllauXKk5c+ZIktNlvJ+aMGGCNm/erKefflo7d+7Uvn37tGjRIh0/flx16tRR3bp1tXjxYh04cECrV6/W6NGj3fSTujxTpkzRyy+/rAULFmj//v3atm2bXn311YuObdSokSIiIjRlyhTt379fn376qV5++WWnMcOHD1dKSormzJmj/fv367XXXqtwp97kyZP11ltvaerUqdqzZ4+ysrL0zjvvaOLEiZLO/9397ne/04ABA7Rjxw6tW7dOzz33nGd+AMDVyNuTmAB41x133GE8/fTTxlNPPWUEBgYaderUMf785z+bk6x/OqnaMAzjm2++Me69916jVq1aRu3atY0HHnjAyM/PN/t/Pqn63LlzxpQpU4wbbrjBqF69utGqVSvjs88+c6phw4YNRsuWLQ0/Pz+jTZs2xvLlyw1Jxr59+wzDuPjE4zVr1hgdOnQw/P39jaCgICMhIcHsT01NNWJiYgx/f3+jZcuWxpo1a5wmD//WSdU/ncxsGIbxwQcfGD//5zQ5Odlo0qSJUb16daN+/frGsGHDzD79bCLz+vXrjRYtWhgBAQHG7bffbvzrX/9ymlRtGIbxxhtvGDfeeKNRo0YNo1evXsacOXMq1JGSkmJ06NDBqFGjhhEYGGjcdtttxuLFi83+7Oxso1OnToafn5/xu9/9zkhJSWFSNfAjm2H85MI1AFQBy5Yt0xNPPKGioiKX5+QAwJVgUjUAr3vrrbfUsGFD3XDDDdqxY4fGjRunBx98kDAEoNIwhwiA1+Xn5+vRRx9VTEyMRo0apQceeECLFy+ulH0/9dRTTreq/3R56qmnKqUGAN7HJTMAllZQUCCHw3HRvsDAQIWEhFRyRQC8gUAEAAAsj0tmAADA8ghEAADA8ghEAADA8ghEAADA8ghEAADA8ghEAADA8ghEAADA8v4/XWik/FHp6BkAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAkQAAAHFCAYAAAAT5Oa6AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAAA77UlEQVR4nO3dd3RUdeL+8WcCKYCpQJoGEopAIKFqjCIdQvmqKF+VJiARlAVBEISslBALMSqiKxZcwbJhwV35oYuKJJTQQidB6kIAA0IIfQwsKWR+fyjzdTaoTJzJJNz365w5Z+7nfubOc/ds9PG2MVksFosAAAAMzM3VAQAAAFyNQgQAAAyPQgQAAAyPQgQAAAyPQgQAAAyPQgQAAAyPQgQAAAyvuqsDVAWlpaU6ceKEvL29ZTKZXB0HAADcAIvFoh9//FGhoaFyc/vtY0AUohtw4sQJhYWFuToGAAAoh2PHjum22277zTkUohvg7e0t6af/QX18fFycBgAA3Aiz2aywsDDrv8d/C4XoBlw7Tebj40MhAgCgirmRy124qBoAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABgehQgAABhedVcHAAC4RviUr1wdARXoaHIfV0eo1DhCBAAADI9CBAAADI9CBAAADM+lhWjt2rW67777FBoaKpPJpKVLl9qsN5lM1329+uqr1jnh4eFl1icnJ9tsZ9euXbr33nvl5eWlsLAwpaSkVMTuAQCAKsKlhejSpUtq2bKl5s6de931J0+etHnNnz9fJpNJ/fr1s5mXlJRkM+/pp5+2rjObzerRo4fq16+v7du369VXX1ViYqLmzZvn1H0DAABVh0vvMuvVq5d69er1q+uDg4Ntlr/44gt17txZDRo0sBn39vYuM/ea1NRUFRUVaf78+fLw8FDz5s2VlZWl2bNna+TIkX98JwAAQJVXZa4hOnXqlL766ivFx8eXWZecnKzatWurdevWevXVV1VSUmJdl5mZqQ4dOsjDw8M6FhcXpwMHDuj8+fPX/a7CwkKZzWabFwAAuHlVmecQffzxx/L29tZDDz1kMz527Fi1adNGAQEB2rhxoxISEnTy5EnNnj1bkpSXl6eIiAibzwQFBVnX+fv7l/muWbNmaebMmU7aEwAAUNlUmUI0f/58DRo0SF5eXjbjEyZMsL6Pjo6Wh4eHnnzySc2aNUuenp7l+q6EhASb7ZrNZoWFhZUvOAAAqPSqRCFat26dDhw4oMWLF//u3JiYGJWUlOjo0aNq0qSJgoODderUKZs515Z/7bojT0/PcpcpAABQ9VSJa4g+/PBDtW3bVi1btvzduVlZWXJzc1NgYKAkKTY2VmvXrlVxcbF1Tlpampo0aXLd02UAAMB4XFqICgoKlJWVpaysLEnSkSNHlJWVpdzcXOscs9msf/zjH3riiSfKfD4zM1Nz5sxRdna2Dh8+rNTUVI0fP16DBw+2lp2BAwfKw8ND8fHx2rNnjxYvXqw333zT5pQYAAAwNpeeMtu2bZs6d+5sXb5WUoYOHaqPPvpIkrRo0SJZLBYNGDCgzOc9PT21aNEiJSYmqrCwUBERERo/frxN2fH19dWKFSs0evRotW3bVnXq1NH06dO55R4AAFiZLBaLxdUhKjuz2SxfX19dvHhRPj4+ro4DAA7Br90bixF/7d6ef39XiWuIAAAAnIlCBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADK+6qwOgcguf8pWrI6ACHU3u4+oIAOASHCECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACG59JCtHbtWt13330KDQ2VyWTS0qVLbdYPGzZMJpPJ5tWzZ0+bOefOndOgQYPk4+MjPz8/xcfHq6CgwGbOrl27dO+998rLy0thYWFKSUlx9q4BAIAqxKWF6NKlS2rZsqXmzp37q3N69uypkydPWl9///vfbdYPGjRIe/bsUVpampYtW6a1a9dq5MiR1vVms1k9evRQ/fr1tX37dr366qtKTEzUvHnznLZfAACganHpb5n16tVLvXr1+s05np6eCg4Ovu66ffv2afny5dq6davatWsnSfrLX/6i3r1767XXXlNoaKhSU1NVVFSk+fPny8PDQ82bN1dWVpZmz55tU5wAAIBxVfpriNasWaPAwEA1adJEo0aN0tmzZ63rMjMz5efnZy1DktStWze5ublp8+bN1jkdOnSQh4eHdU5cXJwOHDig8+fPX/c7CwsLZTabbV4AAODmVakLUc+ePfXJJ59o5cqVeuWVV5SRkaFevXrp6tWrkqS8vDwFBgbafKZ69eoKCAhQXl6edU5QUJDNnGvL1+b8t1mzZsnX19f6CgsLc/SuAQCASsSlp8x+T//+/a3vo6KiFB0drYYNG2rNmjXq2rWr0743ISFBEyZMsC6bzWZKEQAAN7FKfYTovzVo0EB16tTRoUOHJEnBwcHKz8+3mVNSUqJz585ZrzsKDg7WqVOnbOZcW/61a5M8PT3l4+Nj8wIAADevKlWIjh8/rrNnzyokJESSFBsbqwsXLmj79u3WOatWrVJpaaliYmKsc9auXavi4mLrnLS0NDVp0kT+/v4VuwMAAKBScmkhKigoUFZWlrKysiRJR44cUVZWlnJzc1VQUKBJkyZp06ZNOnr0qFauXKkHHnhAjRo1UlxcnCSpWbNm6tmzp0aMGKEtW7Zow4YNGjNmjPr376/Q0FBJ0sCBA+Xh4aH4+Hjt2bNHixcv1ptvvmlzSgwAABibSwvRtm3b1Lp1a7Vu3VqSNGHCBLVu3VrTp09XtWrVtGvXLt1///26/fbbFR8fr7Zt22rdunXy9PS0biM1NVVNmzZV165d1bt3b7Vv397mGUO+vr5asWKFjhw5orZt2+rZZ5/V9OnTueUeAABYufSi6k6dOslisfzq+m+//fZ3txEQEKCFCxf+5pzo6GitW7fO7nwAAMAYqtQ1RAAAAM5AIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZHIQIAAIZndyE6duyYjh8/bl3esmWLnnnmGc2bN8+hwQAAACqK3YVo4MCBWr16tSQpLy9P3bt315YtW/T8888rKSnJ4QEBAACcze5CtHv3bt15552SpM8++0wtWrTQxo0blZqaqo8++sjR+QAAAJzO7kJUXFwsT09PSVJ6erruv/9+SVLTpk118uRJx6YDAACoAHYXoubNm+u9997TunXrlJaWpp49e0qSTpw4odq1azs8IAAAgLPZXYheeeUVvf/+++rUqZMGDBigli1bSpK+/PJL66k0AACAqqS6vR/o1KmTzpw5I7PZLH9/f+v4yJEjVbNmTYeGAwAAqAh2HyGaMWOGjh8/blOGJCk8PFyBgYEOCwYAAFBR7C5EX3zxhRo2bKiuXbtq4cKFKiwsdEYuAACACmN3IcrKytLWrVvVvHlzjRs3TsHBwRo1apS2bt3qjHwAAABOV66f7mjdurXeeustnThxQh9++KGOHz+ue+65R9HR0XrzzTd18eJFR+cEAABwmj/0W2YWi0XFxcUqKiqSxWKRv7+/3n77bYWFhWnx4sWOyggAAOBU5SpE27dv15gxYxQSEqLx48erdevW2rdvnzIyMnTw4EG99NJLGjt2rKOzAgAAOIXdhSgqKkp33XWXjhw5og8//FDHjh1TcnKyGjVqZJ0zYMAAnT592qFBAQAAnMXu5xA98sgjGj58uG699dZfnVOnTh2Vlpb+oWAAAAAVxe5CNG3aNGfkAAAAcBm7C5EkHT9+XF9++aVyc3NVVFRks2727NkOCQYAAFBR7C5EK1eu1P33368GDRpo//79atGihY4ePSqLxaI2bdo4IyMAAIBT2X1RdUJCgiZOnKjvvvtOXl5e+vzzz3Xs2DF17NhRDz/8sDMyAgAAOJXdhWjfvn0aMmSIJKl69er6z3/+o1tuuUVJSUl65ZVXHB4QAADA2ewuRLVq1bJeNxQSEqKcnBzrujNnzjguGQAAQAWxuxDdddddWr9+vSSpd+/eevbZZ/XSSy9p+PDhuuuuu+za1tq1a3XfffcpNDRUJpNJS5cuta4rLi7W5MmTFRUVpVq1aik0NFRDhgzRiRMnbLYRHh4uk8lk80pOTraZs2vXLt17773y8vJSWFiYUlJS7N1tAABwE7P7ourZs2eroKBAkjRz5kwVFBRo8eLFaty4sd13mF26dEktW7bU8OHD9dBDD9msu3z5snbs2KFp06apZcuWOn/+vMaNG6f7779f27Zts5mblJSkESNGWJe9vb2t781ms3r06KFu3brpvffe03fffafhw4fLz89PI0eOtHf3AQDATcjuQtSgQQPr+1q1aum9994r95f36tVLvXr1uu46X19fpaWl2Yy9/fbbuvPOO5Wbm6t69epZx729vRUcHHzd7aSmpqqoqEjz58+Xh4eHmjdvrqysLM2ePZtCBAAAJP3BH3etaBcvXpTJZJKfn5/NeHJysmrXrq3WrVvr1VdfVUlJiXVdZmamOnToIA8PD+tYXFycDhw4oPPnz1/3ewoLC2U2m21eAADg5nVDR4j8/f1lMpluaIPnzp37Q4F+zZUrVzR58mQNGDBAPj4+1vGxY8eqTZs2CggI0MaNG5WQkKCTJ09aT9/l5eUpIiLCZltBQUHWdf7+/mW+a9asWZo5c6ZT9gMAAFQ+N1SI5syZY31/9uxZvfjii4qLi1NsbKykn47CfPvtt077WY/i4mI98sgjslgsevfdd23WTZgwwfo+OjpaHh4eevLJJzVr1ix5enqW6/sSEhJstms2mxUWFla+8AAAoNK7oUI0dOhQ6/t+/fopKSlJY8aMsY6NHTtWb7/9ttLT0zV+/HiHBrxWhr7//nutWrXK5ujQ9cTExKikpERHjx5VkyZNFBwcrFOnTtnMubb8a9cdeXp6lrtMAQCAqsfua4i+/fZb9ezZs8x4z549lZ6e7pBQ11wrQwcPHlR6erpq1679u5/JysqSm5ubAgMDJUmxsbFau3atiouLrXPS0tLUpEmT654uAwAAxmN3Iapdu7a++OKLMuNffPHFDRWWXyooKFBWVpaysrIkSUeOHFFWVpZyc3NVXFys//3f/9W2bduUmpqqq1evKi8vT3l5edYHQ2ZmZmrOnDnKzs7W4cOHlZqaqvHjx2vw4MHWsjNw4EB5eHgoPj5ee/bs0eLFi/Xmm2/anBIDAADGZvdt9zNnztQTTzyhNWvWKCYmRpK0efNmLV++XB988IFd29q2bZs6d+5sXb5WUoYOHarExER9+eWXkqRWrVrZfG716tXq1KmTPD09tWjRIiUmJqqwsFAREREaP368Tdnx9fXVihUrNHr0aLVt21Z16tTR9OnTueUeAABY2V2Ihg0bpmbNmumtt97SkiVLJEnNmjXT+vXrrQXpRnXq1EkWi+VX1//WOklq06aNNm3a9LvfEx0drXXr1tmVDQAAGIfdhUj66cLl1NRUR2cBAABwiSr1YEYAAABnoBABAADDoxABAADDoxABAADDoxABAADDs/sus0uXLik5OVkrV65Ufn6+SktLbdYfPnzYYeEAAAAqgt2F6IknnlBGRoYee+wxhYSEyGQyOSMXAABAhbG7EH3zzTf66quvdM899zgjDwAAQIWz+xoif39/BQQEOCMLAACAS9hdiF544QVNnz5dly9fdkYeAACACmf3KbPXX39dOTk5CgoKUnh4uNzd3W3W79ixw2HhAAAAKoLdhahv375OiAEAAOA6dheiGTNmOCMHAACAy5Tr1+4lafv27dq3b58kqXnz5mrdurXDQgEAAFQkuwtRfn6++vfvrzVr1sjPz0+SdOHCBXXu3FmLFi1S3bp1HZ0RAADAqey+y+zpp5/Wjz/+qD179ujcuXM6d+6cdu/eLbPZrLFjxzojIwAAgFPZfYRo+fLlSk9PV7NmzaxjkZGRmjt3rnr06OHQcAAAABXB7iNEpaWlZW61lyR3d/cyv2sGAABQFdhdiLp06aJx48bpxIkT1rEffvhB48ePV9euXR0aDgAAoCLYXYjefvttmc1mhYeHq2HDhmrYsKEiIiJkNpv1l7/8xRkZAQAAnMrua4jCwsK0Y8cOpaena//+/ZKkZs2aqVu3bg4PBwAAUBHK9Rwik8mk7t27q3v37o7OAwAAUOFuqBC99dZbGjlypLy8vPTWW2/95lxuvQcAAFXNDRWiN954Q4MGDZKXl5feeOONX51nMpkoRAAAoMq5oUJ05MiR674HAAC4Gdh9l1lSUpIuX75cZvw///mPkpKSHBIKAACgItldiGbOnKmCgoIy45cvX9bMmTMdEgoAAKAi2V2ILBaLTCZTmfHs7GwFBAQ4JBQAAEBFuuHb7v39/WUymWQymXT77bfblKKrV6+qoKBATz31lFNCAgAAONMNF6I5c+bIYrFo+PDhmjlzpnx9fa3rPDw8FB4ertjYWKeEBAAAcKYbLkRDhw6VJEVEROiee+5R9erleqYjAABApWP3NUQdO3bU999/r6lTp2rAgAHKz8+XJH3zzTfas2ePwwMCAAA4m92FKCMjQ1FRUdq8ebOWLFliveMsOztbM2bMcHhAAAAAZ7O7EE2ZMkUvvvii0tLS5OHhYR3v0qWLNm3a5NBwAAAAFcHuQvTdd9/pwQcfLDMeGBioM2fOOCQUAABARbK7EPn5+enkyZNlxnfu3Klbb73VIaEAAAAqkt2FqH///po8ebLy8vJkMplUWlqqDRs2aOLEiRoyZIgzMgIAADiV3YXo5ZdfVtOmTRUWFqaCggJFRkaqQ4cOuvvuuzV16lRnZAQAAHAquwuRh4eHPvjgA+Xk5GjZsmX629/+pv379+vTTz9VtWrV7NrW2rVrdd999yk0NFQmk0lLly61WW+xWDR9+nSFhISoRo0a6tatmw4ePGgz59y5cxo0aJB8fHzk5+en+Pj4Mr+1tmvXLt17773y8vJSWFiYUlJS7N1tAABwE7O7EF1Tr1499e7dW4888ogaN25crm1cunRJLVu21Ny5c6+7PiUlRW+99Zbee+89bd68WbVq1VJcXJyuXLlinTNo0CDt2bNHaWlpWrZsmdauXauRI0da15vNZvXo0UP169fX9u3b9eqrryoxMVHz5s0rV2YAAHDzuaHHTU+YMOGGNzh79uwbnturVy/16tXruussFovmzJmjqVOn6oEHHpAkffLJJwoKCtLSpUvVv39/7du3T8uXL9fWrVvVrl07SdJf/vIX9e7dW6+99ppCQ0OVmpqqoqIizZ8/Xx4eHmrevLmysrI0e/Zsm+L0S4WFhSosLLQum83mG94nAABQ9dxQIdq5c+cNbeyXP/j6Rx05ckR5eXnq1q2bdczX11cxMTHKzMxU//79lZmZKT8/P2sZkqRu3brJzc1Nmzdv1oMPPqjMzEx16NDB5plJcXFxeuWVV3T+/Hn5+/uX+e5Zs2Zp5syZDtsXAABQud1QIVq9erWzc5SRl5cnSQoKCrIZDwoKsq7Ly8tTYGCgzfrq1asrICDAZk5ERESZbVxbd71ClJCQYHNUzGw2Kyws7A/uEQAAqKz+0C+0Hjt2TJJuurLg6ekpT09PV8cAAAAVxO6LqktKSjRt2jT5+voqPDxc4eHh8vX11dSpU1VcXOywYMHBwZKkU6dO2YyfOnXKui44ONj647K/zHfu3DmbOdfbxi+/AwAAGJvdhejpp5/WvHnzlJKSop07d2rnzp1KSUnRhx9+qLFjxzosWEREhIKDg7Vy5UrrmNls1ubNmxUbGytJio2N1YULF7R9+3brnFWrVqm0tFQxMTHWOWvXrrUpa2lpaWrSpMl1T5cBAADjsfuU2cKFC7Vo0SKbu8Oio6MVFhamAQMG6N13373hbRUUFOjQoUPW5SNHjigrK0sBAQGqV6+ennnmGb344otq3LixIiIiNG3aNIWGhqpv376SpGbNmqlnz54aMWKE3nvvPRUXF2vMmDHq37+/QkNDJUkDBw7UzJkzFR8fr8mTJ2v37t1688039cYbb9i76wAA4CZldyHy9PRUeHh4mfGIiAibO7luxLZt29S5c2fr8rULmYcOHaqPPvpIzz33nC5duqSRI0fqwoULat++vZYvXy4vLy/rZ1JTUzVmzBh17dpVbm5u6tevn9566y3rel9fX61YsUKjR49W27ZtVadOHU2fPv1Xb7kHAADGY7JYLBZ7PpCUlKT9+/drwYIF1guPCwsLFR8fr8aNG2vGjBlOCepKZrNZvr6+unjxonx8fFwdp0KFT/nK1RFQgY4m93F1BFQg/r6NxYh/3/b8+9vuI0Q7d+7UypUrddttt6lly5aSpOzsbBUVFalr16566KGHrHOXLFli7+YBAAAqnN2FyM/PT/369bMZu9luuwcAAMZidyFasGCBM3IAAAC4TLl/3BUAAOBmYfcRorNnz2r69OlavXq18vPzVVpaarP+3LlzDgsHAABQEewuRI899pgOHTqk+Ph4BQUFOfQHXQEAAFzB7kK0bt06rV+/3nqHGQAAQFVn9zVETZs21X/+8x9nZAEAAHAJuwvRO++8o+eff14ZGRk6e/aszGazzQsAAKCqKddziMxms7p06WIzbrFYZDKZdPXqVYeFAwAAqAh2F6JBgwbJ3d1dCxcu5KJqAABwU7C7EO3evVs7d+5UkyZNnJEHAACgwtl9DVG7du107NgxZ2QBAABwCbuPED399NMaN26cJk2apKioKLm7u9usj46Odlg4AACAimB3IXr00UclScOHD7eOmUwmLqoGAABVlt2F6MiRI87IAQAA4DJ2F6L69es7IwcAAIDL2F2IJCknJ0dz5szRvn37JEmRkZEaN26cGjZs6NBwAAAAFcHuu8y+/fZbRUZGasuWLYqOjlZ0dLQ2b96s5s2bKy0tzRkZAQAAnMruI0RTpkzR+PHjlZycXGZ88uTJ6t69u8PCAQAAVAS7jxDt27dP8fHxZcaHDx+uvXv3OiQUAABARbK7ENWtW1dZWVllxrOyshQYGOiITAAAABXK7lNmI0aM0MiRI3X48GHdfffdkqQNGzbolVde0YQJExweEAAAwNnsLkTTpk2Tt7e3Xn/9dSUkJEiSQkNDlZiYqLFjxzo8IAAAgLPZXYhMJpPGjx+v8ePH68cff5QkeXt7OzwYAABARSnXk6pLSkrUuHFjmyJ08OBBubu7Kzw83JH5AAAAnM7ui6qHDRumjRs3lhnfvHmzhg0b5ohMAAAAFcruQrRz507dc889Zcbvuuuu6959BgAAUNnZXYhMJpP12qFfunjxIr90DwAAqiS7C1GHDh00a9Ysm/Jz9epVzZo1S+3bt3doOAAAgIpg90XVr7zyijp06KAmTZro3nvvlSStW7dOZrNZq1atcnhAAAAAZ7P7CFFkZKR27dqlRx55RPn5+frxxx81ZMgQ7d+/Xy1atHBGRgAAAKey+wiR9NODGF9++WVHZwEAAHAJu48QAQAA3GwoRAAAwPAoRAAAwPAoRAAAwPDKVYhKSkqUnp6u999/3/qQxhMnTqigoMCh4QAAACqC3YXo+++/V1RUlB544AGNHj1ap0+flvTT84kmTpzo8IDh4eEymUxlXqNHj5YkderUqcy6p556ymYbubm56tOnj2rWrKnAwEBNmjRJJSUlDs8KAACqJrtvux83bpzatWun7Oxs1a5d2zr+4IMPasSIEQ4NJ0lbt261eSr27t271b17dz388MPWsREjRigpKcm6XLNmTev7q1evqk+fPgoODtbGjRt18uRJDRkyRO7u7jw6AAAASCpHIVq3bp02btwoDw8Pm/Hw8HD98MMPDgt2Td26dW2Wk5OT1bBhQ3Xs2NE6VrNmTQUHB1/38ytWrNDevXuVnp6uoKAgtWrVSi+88IImT56sxMTEMvshSYWFhSosLLQum81mB+0NAACojOw+ZVZaWnrdH3E9fvy4vL29HRLq1xQVFelvf/ubhg8fLpPJZB1PTU1VnTp11KJFCyUkJOjy5cvWdZmZmYqKilJQUJB1LC4uTmazWXv27Lnu98yaNUu+vr7WV1hYmPN2CgAAuJzdhahHjx6aM2eOddlkMqmgoEAzZsxQ7969HZmtjKVLl+rChQsaNmyYdWzgwIH629/+ptWrVyshIUGffvqpBg8ebF2fl5dnU4YkWZfz8vKu+z0JCQm6ePGi9XXs2DHH7wwAAKg07D5l9vrrrysuLk6RkZG6cuWKBg4cqIMHD6pOnTr6+9//7oyMVh9++KF69eql0NBQ69jIkSOt76OiohQSEqKuXbsqJydHDRs2LNf3eHp6ytPT8w/nBQAAVYPdhei2225Tdna2Fi1apF27dqmgoEDx8fEaNGiQatSo4YyMkn66uy09PV1Lliz5zXkxMTGSpEOHDqlhw4YKDg7Wli1bbOacOnVKkn71uiMAAGAs5fpx1+rVq9uclqoICxYsUGBgoPr06fOb87KysiRJISEhkqTY2Fi99NJLys/PV2BgoCQpLS1NPj4+ioyMdGpmAABQNdhdiL788svrjptMJnl5ealRo0aKiIj4w8F+qbS0VAsWLNDQoUNVvfr/Rc7JydHChQvVu3dv1a5dW7t27dL48ePVoUMHRUdHS/rpmqfIyEg99thjSklJUV5enqZOnarRo0dzWgwAAEgqRyHq27evTCaTLBaLzfi1MZPJpPbt22vp0qXy9/d3SMj09HTl5uZq+PDhNuMeHh5KT0/XnDlzdOnSJYWFhalfv36aOnWqdU61atW0bNkyjRo1SrGxsapVq5aGDh1q89wiAABgbHbfZZaWlqY77rhDaWlp1ruw0tLSFBMTo2XLlmnt2rU6e/asQ59a3aNHD1ksFt1+++0242FhYcrIyNDZs2d15coVHTx4UCkpKfLx8bGZV79+fX399de6fPmyTp8+rddee83mSBMAADC2cj2pet68ebr77rutY127dpWXl5dGjhypPXv2aM6cOWWO5gAAAFRWdh8hysnJKXMERpJ8fHx0+PBhSVLjxo115syZP54OAACgAthdiNq2batJkyZZf9RVkk6fPq3nnntOd9xxhyTp4MGDPN0ZAABUGXafMvvwww/1wAMP6LbbbrOWnmPHjqlBgwb64osvJEkFBQU2FzYDAABUZnYXoiZNmmjv3r1asWKF/v3vf1vHunfvLje3nw449e3b16EhAQAAnKlct1q5ubmpZ8+e6tmzp6PzAAAAVLhyFaJLly4pIyNDubm5Kioqslk3duxYhwQDAACoKHYXop07d6p37966fPmyLl26pICAAJ05c0Y1a9ZUYGAghQgAAFQ5dt9lNn78eN133306f/68atSooU2bNun7779X27Zt9dprrzkjIwAAgFPZXYiysrL07LPPys3NTdWqVVNhYaHCwsKUkpKiP//5z87ICAAA4FR2FyJ3d3fr3WSBgYHKzc2VJPn6+urYsWOOTQcAAFAB7L6GqHXr1tq6dasaN26sjh07avr06Tpz5ow+/fRTtWjRwhkZAQAAnMruI0Qvv/yyQkJCJEkvvfSS/P39NWrUKJ0+fVrz5s1zeEAAAABns+sIkcViUWBgoPVIUGBgoJYvX+6UYAAAABXFriNEFotFjRo14lohAABwU7GrELm5ualx48Y6e/ass/IAAABUOLuvIUpOTtakSZO0e/duZ+QBAACocHbfZTZkyBBdvnxZLVu2lIeHh2rUqGGz/ty5cw4LBwAAUBHsLkRz5sxxQgwAAADXsbsQDR061Bk5AAAAXMbua4gkKScnR1OnTtWAAQOUn58vSfrmm2+0Z88eh4YDAACoCHYXooyMDEVFRWnz5s1asmSJCgoKJEnZ2dmaMWOGwwMCAAA4m92FaMqUKXrxxReVlpYmDw8P63iXLl20adMmh4YDAACoCHYXou+++04PPvhgmfHAwECdOXPGIaEAAAAqkt2FyM/PTydPniwzvnPnTt16660OCQUAAFCR7C5E/fv31+TJk5WXlyeTyaTS0lJt2LBBEydO1JAhQ5yREQAAwKnK9Wv3TZs2VVhYmAoKChQZGakOHTro7rvv1tSpU52REQAAwKnsfg6Rh4eHPvjgA02bNk27d+9WQUGBWrdurcaNGzsjHwAAgNPZXYjWr1+v9u3bq169eqpXr54zMgEAAFQou0+ZdenSRREREfrzn/+svXv3OiMTAABAhbK7EJ04cULPPvusMjIy1KJFC7Vq1Uqvvvqqjh8/7ox8AAAATmd3IapTp47GjBmjDRs2KCcnRw8//LA+/vhjhYeHq0uXLs7ICAAA4FTl+i2zayIiIjRlyhQlJycrKipKGRkZjsoFAABQYcpdiDZs2KA//elPCgkJ0cCBA9WiRQt99dVXjswGAABQIey+yywhIUGLFi3SiRMn1L17d7355pt64IEHVLNmTWfkAwAAcDq7C9HatWs1adIkPfLII6pTp44zMgEAAFQouwvRhg0bnJEDAADAZewuRNfs3btXubm5Kioqshm///77/3AoAACAimT3RdWHDx9Wy5Yt1aJFC/Xp00d9+/ZV37599eCDD+rBBx90aLjExESZTCabV9OmTa3rr1y5otGjR6t27dq65ZZb1K9fP506dcpmG7m5uerTp49q1qypwMBATZo0SSUlJQ7NCQAAqja7C9G4ceMUERGh/Px81axZU3v27NHatWvVrl07rVmzxuEBmzdvrpMnT1pf69evt64bP368/vWvf+kf//iHMjIydOLECT300EPW9VevXlWfPn1UVFSkjRs36uOPP9ZHH32k6dOnOzwnAACouuw+ZZaZmalVq1apTp06cnNzk5ubm9q3b69Zs2Zp7Nix2rlzp2MDVq+u4ODgMuMXL17Uhx9+qIULF1ofCLlgwQI1a9ZMmzZt0l133aUVK1Zo7969Sk9PV1BQkFq1aqUXXnhBkydPVmJiojw8PK77nYWFhSosLLQum81mh+4TAACoXOw+QnT16lV5e3tL+ump1SdOnJAk1a9fXwcOHHBsOkkHDx5UaGioGjRooEGDBik3N1eStH37dhUXF6tbt27WuU2bNlW9evWUmZkp6afyFhUVpaCgIOucuLg4mc1m7dmz51e/c9asWfL19bW+wsLCHL5fAACg8rC7ELVo0ULZ2dmSpJiYGKWkpGjDhg1KSkpSgwYNHBouJiZGH330kZYvX653331XR44c0b333qsff/xReXl58vDwkJ+fn81ngoKClJeXJ0nKy8uzKUPX1l9b92sSEhJ08eJF6+vYsWMO3S8AAFC52H3KbOrUqbp06ZIkKSkpSf/zP/+je++9V7Vr19bixYsdGq5Xr17W99HR0YqJiVH9+vX12WefqUaNGg79rl/y9PSUp6en07YPAAAqF7sLUVxcnPV9o0aNtH//fp07d07+/v4ymUwODfff/Pz8dPvtt+vQoUPq3r27ioqKdOHCBZujRKdOnbJecxQcHKwtW7bYbOPaXWjXuy4JAAAY0x/6cddrAgICnF6GJKmgoEA5OTkKCQlR27Zt5e7urpUrV1rXHzhwQLm5uYqNjZUkxcbG6rvvvlN+fr51Tlpamnx8fBQZGen0vAAAoGoo94MZK8LEiRN13333qX79+jpx4oRmzJihatWqacCAAfL19VV8fLwmTJiggIAA+fj46Omnn1ZsbKzuuusuSVKPHj0UGRmpxx57TCkpKcrLy9PUqVM1evRoTokBAACrSl2Ijh8/rgEDBujs2bOqW7eu2rdvr02bNqlu3bqSpDfeeENubm7q16+fCgsLFRcXp3feecf6+WrVqmnZsmUaNWqUYmNjVatWLQ0dOlRJSUmu2iUAAFAJVepCtGjRot9c7+Xlpblz52ru3Lm/Oqd+/fr6+uuvHR0NAADcRBxyDREAAEBVRiECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGRyECAACGV6kL0axZs3THHXfI29tbgYGB6tu3rw4cOGAzp1OnTjKZTDavp556ymZObm6u+vTpo5o1ayowMFCTJk1SSUlJRe4KAACoxKq7OsBvycjI0OjRo3XHHXeopKREf/7zn9WjRw/t3btXtWrVss4bMWKEkpKSrMs1a9a0vr969ar69Omj4OBgbdy4USdPntSQIUPk7u6ul19+uUL3BwAAVE6VuhAtX77cZvmjjz5SYGCgtm/frg4dOljHa9asqeDg4OtuY8WKFdq7d6/S09MVFBSkVq1a6YUXXtDkyZOVmJgoDw8Pp+4DAACo/Cr1KbP/dvHiRUlSQECAzXhqaqrq1KmjFi1aKCEhQZcvX7auy8zMVFRUlIKCgqxjcXFxMpvN2rNnz3W/p7CwUGaz2eYFAABuXpX6CNEvlZaW6plnntE999yjFi1aWMcHDhyo+vXrKzQ0VLt27dLkyZN14MABLVmyRJKUl5dnU4YkWZfz8vKu+12zZs3SzJkznbQnAACgsqkyhWj06NHavXu31q9fbzM+cuRI6/uoqCiFhISoa9euysnJUcOGDcv1XQkJCZowYYJ12Ww2KywsrHzBAQBApVclTpmNGTNGy5Yt0+rVq3Xbbbf95tyYmBhJ0qFDhyRJwcHBOnXqlM2ca8u/dt2Rp6enfHx8bF4AAODmVakLkcVi0ZgxY/T//t//06pVqxQREfG7n8nKypIkhYSESJJiY2P13XffKT8/3zonLS1NPj4+ioyMdEpuAABQtVTqU2ajR4/WwoUL9cUXX8jb29t6zY+vr69q1KihnJwcLVy4UL1791bt2rW1a9cujR8/Xh06dFB0dLQkqUePHoqMjNRjjz2mlJQU5eXlaerUqRo9erQ8PT1duXsAAKCSqNRHiN59911dvHhRnTp1UkhIiPW1ePFiSZKHh4fS09PVo0cPNW3aVM8++6z69eunf/3rX9ZtVKtWTcuWLVO1atUUGxurwYMHa8iQITbPLQIAAMZWqY8QWSyW31wfFhamjIyM391O/fr19fXXXzsqFgAAuMlU6iNEAAAAFYFCBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADI9CBAAADM9QhWju3LkKDw+Xl5eXYmJitGXLFldHAgAAlYBhCtHixYs1YcIEzZgxQzt27FDLli0VFxen/Px8V0cDAAAuZphCNHv2bI0YMUKPP/64IiMj9d5776lmzZqaP3++q6MBAAAXq+7qABWhqKhI27dvV0JCgnXMzc1N3bp1U2ZmZpn5hYWFKiwstC5fvHhRkmQ2m50ftpIpLbzs6gioQEb8/7iR8fdtLEb8+762zxaL5XfnGqIQnTlzRlevXlVQUJDNeFBQkPbv319m/qxZszRz5swy42FhYU7LCFQGvnNcnQCAsxj57/vHH3+Ur6/vb84xRCGyV0JCgiZMmGBdLi0t1blz51S7dm2ZTCYXJkNFMJvNCgsL07Fjx+Tj4+PqOAAciL9vY7FYLPrxxx8VGhr6u3MNUYjq1KmjatWq6dSpUzbjp06dUnBwcJn5np6e8vT0tBnz8/NzZkRUQj4+PvwDE7hJ8fdtHL93ZOgaQ1xU7eHhobZt22rlypXWsdLSUq1cuVKxsbEuTAYAACoDQxwhkqQJEyZo6NChateune68807NmTNHly5d0uOPP+7qaAAAwMUMU4geffRRnT59WtOnT1deXp5atWql5cuXl7nQGvD09NSMGTPKnDYFUPXx941fY7LcyL1oAAAANzFDXEMEAADwWyhEAADA8ChEAADA8ChEAADA8ChEAADA8ChEAICb2rp16zR48GDFxsbqhx9+kCR9+umnWr9+vYuToTKhEAH/paioSAcOHFBJSYmrowD4gz7//HPFxcWpRo0a2rlzpwoLCyVJFy9e1Msvv+zidKhMKETAzy5fvqz4+HjVrFlTzZs3V25uriTp6aefVnJysovTASiPF198Ue+9954++OADubu7W8fvuece7dixw4XJUNlQiICfJSQkKDs7W2vWrJGXl5d1vFu3blq8eLELkwEorwMHDqhDhw5lxn19fXXhwoWKD4RKi0IE/Gzp0qV6++231b59e5lMJut48+bNlZOT48JkAMorODhYhw4dKjO+fv16NWjQwAWJUFlRiICfnT59WoGBgWXGL126ZFOQAFQdI0aM0Lhx47R582aZTCadOHFCqampmjhxokaNGuXqeKhEDPPjrsDvadeunb766is9/fTTkmQtQX/9618VGxvrymgAymnKlCkqLS1V165ddfnyZXXo0EGenp6aOHGi9W8dkPhxV8Bq/fr16tWrlwYPHqyPPvpITz75pPbu3auNGzcqIyNDbdu2dXVEAOVUVFSkQ4cOqaCgQJGRkbrllltcHQmVDIUI+IWcnBwlJycrOztbBQUFatOmjSZPnqyoqChXRwMAOBGFCABw0+rcufNvXgO4atWqCkyDyoxriICf7dixQ+7u7tajQV988YUWLFigyMhIJSYmysPDw8UJAdirVatWNsvFxcXKysrS7t27NXToUNeEQqXEESLgZ3fccYemTJmifv366fDhw4qMjNRDDz2krVu3qk+fPpozZ46rIwJwkMTERBUUFOi1115zdRRUEhQi4Ge+vr7asWOHGjZsqFdeeUWrVq3St99+qw0bNqh///46duyYqyMCcJBDhw7pzjvv1Llz51wdBZUEzyECfmaxWFRaWipJSk9PV+/evSVJYWFhOnPmjCujAXCwzMxMmyfSA1xDBPysXbt2evHFF9WtWzdlZGTo3XfflSQdOXJEQUFBLk4HoDweeughm2WLxaKTJ09q27ZtmjZtmotSoTKiEAE/mzNnjgYNGqSlS5fq+eefV6NGjSRJ//znP3X33Xe7OB2A8vD19bVZdnNzU5MmTZSUlKQePXq4KBUqI64hAn7HlStXVK1aNZtfygZQ+V29elUbNmxQVFSU/P39XR0HlRyFCABw0/Ly8tK+ffsUERHh6iio5DhlBkPz9/e/4R9u5W4UoOpp0aKFDh8+TCHC76IQwdB4thBwc3vxxRc1ceJEvfDCC2rbtq1q1apls97Hx8dFyVDZcMoMAHDTSUpK0rPPPitvb2/r2C+PBlssFplMJl29etUV8VAJUYiA67hy5YqKiopsxvgvSaDqqFatmk6ePKl9+/b95ryOHTtWUCJUdhQi4GeXLl3S5MmT9dlnn+ns2bNl1vNfkkDV4ebmpry8PAUGBro6CqoInlQN/Oy5557TqlWr9O6778rT01N//etfNXPmTIWGhuqTTz5xdTwAdrrRGyYAiSNEgFW9evX0ySefqFOnTvLx8dGOHTvUqFEjffrpp/r73/+ur7/+2tURAdwgNzc3+fr6/m4p4u5RXMNdZsDPzp07pwYNGkj66Xqha/+gbN++vUaNGuXKaADKYebMmWWeVA38GgoR8LMGDRroyJEjqlevnpo2barPPvtMd955p/71r3/Jz8/P1fEA2Kl///5cQ4QbxjVEMLzDhw+rtLRUjz/+uLKzsyVJU6ZM0dy5c+Xl5aXx48dr0qRJLk4JwB5cPwR7cQ0RDO/a7bnX/kvy0Ucf1VtvvaUrV65o+/btatSokaKjo12cEoA9uMsM9qIQwfD++x+c3t7eys7Otl5PBAC4+XHKDAAAGB6FCIZnMpnKXG/A9QcAYCzcZQbDs1gsGjZsmDw9PSX99LMdTz31VJkfgVyyZIkr4gEAKgCFCIY3dOhQm+XBgwe7KAkAwFW4qBoAABge1xABAADDoxABAADDoxABAADDoxABAADDoxABqHCdOnXSM888U+W/NzExUa1atfrD2wkPD9ecOXMqRRbAqLjtHoDTrFmzRp07d9b58+fl5+fn6jhasmSJ3N3dXR0DQCVEIQJwUygqKpKHh8dvzgkICKigNACqGk6ZAfhDCgsLNXbsWAUGBsrLy0vt27fX1q1bdfToUXXu3FmS5O/vL5PJpGHDhlk/V1paqueee04BAQEKDg5WYmKizXYvXLigJ554QnXr1pWPj4+6dOmi7Oxs6/prp4j++te/KiIiQl5eXr+b9b9PmYWHh+vll1/W8OHD5e3trXr16mnevHk2nzl+/LgGDBiggIAA1apVS+3atdPmzZtvaPuS1LdvX5v9zs/P13333acaNWooIiJCqampZbbze/suScnJyQoKCpK3t7fi4+N15cqV391/AL+OQgTgD3nuuef0+eef6+OPP9aOHTvUqFEjxcXFydvbW59//rkk6cCBAzp58qTefPNN6+c+/vhj1apVS5s3b1ZKSoqSkpKUlpZmXf/www8rPz9f33zzjbZv3642bdqoa9euOnfunHXOoUOH9Pnnn2vJkiXKysoqV/7XX39d7dq1086dO/WnP/1Jo0aN0oEDByRJBQUF6tixo3744Qd9+eWXys7O1nPPPafS0tJyfZckDRs2TMeOHdPq1av1z3/+U++8847y8/Nt5vzevn/22WdKTEzUyy+/rG3btikkJETvvPNOuTMBkGQBgHIqKCiwuLu7W1JTU61jRUVFltDQUEtKSopl9erVFkmW8+fP23yuY8eOlvbt29uM3XHHHZbJkydbLBaLZd26dRYfHx/LlStXbOY0bNjQ8v7771ssFotlxowZFnd3d0t+fv4N5+3YsaNl3Lhx1uX69etbBg8ebF0uLS21BAYGWt59912LxWKxvP/++xZvb2/L2bNnr7u9GTNmWFq2bPmr27dYLJYHHnjAMnToUIvFYrEcOHDAIsmyZcsW6/p9+/ZZJFneeOONG9732NhYy5/+9Ceb9TExMTZZANiHI0QAyi0nJ0fFxcW65557rGPu7u668847tW/fvt/8bHR0tM1ySEiI9UhJdna2CgoKVLt2bd1yyy3W15EjR5STk2P9TP369VW3bt0/tA+/zGEymRQcHGzNkZWVpdatWzvs2qN9+/apevXqatu2rXWsadOmNhec38i+79u3TzExMTbbjo2NdUhGwKi4qBqAS/z33V4mk8l6KqqgoEAhISFas2ZNmc/9sjzUqlXLqTlq1Khh17bc3Nxk+a+fhywuLrZrGze67wAciyNEAMqtYcOG8vDw0IYNG6xjxcXF2rp1qyIjI613fV29etWu7bZp00Z5eXmqXr26GjVqZPOqU6eOQ/fht0RHRysrK8vmuqXfUrduXZ08edK6fPXqVe3evdu63LRpU5WUlGj79u3WsQMHDujChQvW5RvZ92bNmpW5sHvTpk3l2UUAP6MQASi3WrVqadSoUZo0aZKWL1+uvXv3asSIEbp8+bLi4+NVv359mUwmLVu2TKdPn1ZBQcENbbdbt26KjY1V3759tWLFCh09elQbN27U888/r23btjl5r/7PgAEDFBwcrL59+2rDhg06fPiwPv/8c2VmZl53fpcuXfTVV1/pq6++0v79+zVq1CibstOkSRP17NlTTz75pDZv3qzt27friSeesDkSdSP7Pm7cOM2fP18LFizQv//9b82YMUN79uxx6v8WwM2OQgTgD0lOTla/fv302GOPqU2bNjp06JC+/fZb+fv769Zbb9XMmTM1ZcoUBQUFacyYMTe0TZPJpK+//lodOnTQ448/rttvv139+/fX999/r6CgICfv0f/x8PDQihUrFBgYqN69eysqKkrJycmqVq3adecPHz5cQ4cO1ZAhQ9SxY0c1aNDA+uiBaxYsWKDQ0FB17NhRDz30kEaOHKnAwEDr+hvZ90cffVTTpk3Tc889p7Zt2+r777/XqFGjnPc/BGAAJst/n/AGAAAwGI4QAQAAw6MQAbgp5Obm2tym/t+v3NxcV0cEUIlxygzATaGkpERHjx791fXh4eGqXp0njQC4PgoRAAAwPE6ZAQAAw6MQAQAAw6MQAQAAw6MQAQAAw6MQAQAAw6MQAQAAw6MQAQAAw/v/FSH4P/fXumEAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "for col in df.columns:\n",
    "    if col.endswith(\"_included\"):\n",
    "        df.groupby(col)['duration'].mean().sort_index().plot(kind = 'bar')\n",
    "        plt.ylabel('average completion days')\n",
    "        plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "f49b58ce",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'average completion days')"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df.groupby('intervention_count')['duration'].mean().plot(kind = 'bar')\n",
    "plt.ylabel('average completion days')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "825be404",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1     346\n",
      "2     238\n",
      "3     125\n",
      "4      60\n",
      "5      27\n",
      "6      18\n",
      "7      10\n",
      "8       6\n",
      "9       5\n",
      "12      2\n",
      "11      2\n",
      "13      1\n",
      "Name: intervention_count, dtype: int64\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "print(df.intervention_count.value_counts())\n",
    "df['multiple_interverions'] = df.intervention_count>1\n",
    "df['multiple_interverions'].value_counts().sort_index().plot(kind = 'bar')\n",
    "plt.ylabel('counts')\n",
    "plt.show()\n",
    "\n",
    "df.groupby('multiple_interverions')['duration'].mean().sort_index().plot(kind = 'bar')\n",
    "plt.ylabel('average completion days')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e1ddb94d",
   "metadata": {},
   "source": [
    "## Analyze Locations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "4d2b3056",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('Memorial Sloan Kettering Cancer Center, New York, New York, United States', 38), ('Massachusetts General Hospital, Boston, Massachusetts, United States', 29), ('University of Texas MD Anderson Cancer Center, Houston, Texas, United States', 29), ('', 28), ('Roswell Park Cancer Institute, Buffalo, New York, United States', 23), ('Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States', 23), ('Sarah Cannon Research Institute, Nashville, Tennessee, United States', 23), ('MD Anderson Cancer Center, Houston, Texas, United States', 22), ('Research Site, Seoul, Korea, Republic of', 21), ('Memorial Sloan-Kettering Cancer Center, New York, New York, United States', 20)]\n",
      "[('United States', 4703), ('Spain', 347), ('France', 211), ('Canada', 205), ('United Kingdom', 184), ('Republic of', 160), ('Italy', 145), ('Germany', 137), ('Japan', 136), ('Australia', 118)]\n"
     ]
    }
   ],
   "source": [
    "location_count = defaultdict(int)\n",
    "country_count = defaultdict(int)\n",
    "df.locations = df.locations.fillna('')\n",
    "for locations in df.locations:\n",
    "    try:\n",
    "        for location in locations.split('|'):\n",
    "            location_count[location] += 1\n",
    "            country_count[location.split(',')[-1].strip()] += 1\n",
    "    except:\n",
    "        print(locations)\n",
    "print(sorted(location_count.items(), key=lambda x:x[1], reverse=True)[:10])\n",
    "print(sorted(country_count.items(), key=lambda x:x[1], reverse=True)[:10])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "f19991bc",
   "metadata": {},
   "outputs": [],
   "source": [
    "for country in sorted(country_count, key=lambda x: country_count[x], reverse=True)[:10]:\n",
    "    df[f\"include_country_{country}\"] = df.locations.apply(lambda x: any(location.split(',')[-1].strip()==country for location in x.split('|')))\n",
    "\n",
    "def get_lead_country(locations):\n",
    "    if not locations:\n",
    "        return 'Others'\n",
    "    location_list = locations.split('|')\n",
    "    lead_country = location_list[0].split(',')[-1].strip()\n",
    "    if lead_country in sorted(country_count, key=lambda x: country_count[x], reverse=True)[:4]:\n",
    "        return lead_country\n",
    "    return 'Others'\n",
    "df[f\"lead_country\"] = df.locations.apply(get_lead_country)\n",
    "df['location_count'] = df.locations.apply(lambda x: len(x.split(\"|\")))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "136d0cf5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "for col in df.columns:\n",
    "    if col.startswith(\"include_country_\"):\n",
    "        df.groupby(col)['duration'].mean().sort_index().plot(kind = 'bar')\n",
    "        plt.ylabel('average completion days')\n",
    "        plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "1014625d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "United States    595\n",
      "Others           199\n",
      "Canada            29\n",
      "France            10\n",
      "Spain              7\n",
      "Name: lead_country, dtype: int64\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "print(df.lead_country.value_counts())\n",
    "df.groupby('lead_country')['duration'].mean().sort_values().plot(kind = 'bar')\n",
    "plt.ylabel('average completion days')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "d16d77a3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1     351\n",
      "2      73\n",
      "4      60\n",
      "3      51\n",
      "5      42\n",
      "     ... \n",
      "49      1\n",
      "87      1\n",
      "69      1\n",
      "51      1\n",
      "74      1\n",
      "Name: location_count, Length: 65, dtype: int64\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "print(df.location_count.value_counts())\n",
    "df['multiple_locations'] = df.location_count>1\n",
    "df['multiple_locations'].value_counts().sort_index().plot(kind = 'bar')\n",
    "plt.ylabel('counts')\n",
    "plt.show()\n",
    "\n",
    "df.groupby('multiple_locations')['duration'].mean().sort_index().plot(kind = 'bar')\n",
    "plt.ylabel('average completion days')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bd0f8c17",
   "metadata": {},
   "source": [
    "## Analyze Sponsor/Collaborators"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "3b9acc85",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('National Cancer Institute (NCI)', 128), ('AstraZeneca', 40), ('Merck Sharp & Dohme LLC', 33), ('Eli Lilly and Company', 32), ('Bristol-Myers Squibb', 30)]\n"
     ]
    }
   ],
   "source": [
    "sponsor_count = defaultdict(int)\n",
    "for sonpsors in df['sponsor/collaborators']:\n",
    "    for sponsor in sonpsors.split('|'):\n",
    "        sponsor_count[sponsor] += 1\n",
    "print(sorted(sponsor_count.items(), key=lambda x:x[1], reverse=True)[:5])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "c94fd3d9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False    712\n",
      "True     128\n",
      "Name: national_cancer_institute_(nci)_as_sponsor, dtype: int64\n",
      "national_cancer_institute_(nci)_as_sponsor\n",
      "False    1475.830056\n",
      "True     2186.789062\n",
      "Name: duration, dtype: float64\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False    800\n",
      "True      40\n",
      "Name: astrazeneca_as_sponsor, dtype: int64\n",
      "astrazeneca_as_sponsor\n",
      "False    1581.85375\n",
      "True     1630.42500\n",
      "Name: duration, dtype: float64\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False    807\n",
      "True      33\n",
      "Name: merck_sharp_&_dohme_llc_as_sponsor, dtype: int64\n",
      "merck_sharp_&_dohme_llc_as_sponsor\n",
      "False    1584.254027\n",
      "True     1582.030303\n",
      "Name: duration, dtype: float64\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAkQAAAHFCAYAAAAT5Oa6AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAABJ00lEQVR4nO3deVhV5f7+8XujAg6MKiCFYo7gWFpKmmaiODTbKYpMy/Rk4pypJ2fNqTKzTNNKq6Nl55sNWqmoiaZIiOKAOGZCKZKSEJqAsH5/lOvXziG2bQZd79d17etiPc+z1vqszd5yu0abYRiGAAAALMyltAsAAAAobQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeeVLu4BrRWFhoY4dOyYPDw/ZbLbSLgcAABSBYRj69ddfFRgYKBeXy+8HIhAV0bFjxxQUFFTaZQAAgKuQlpamG2+88bL9BKIi8vDwkPT7G+rp6VnK1QAAgKLIzs5WUFCQ+Xf8cghERXThMJmnpyeBCACAa8zfne7CSdUAAMDyCEQAAMDyCEQAAMDyCEQAAMDyCEQAAMDyCEQAAMDyCEQAAMDyCEQAAMDySjUQbdy4Uffcc48CAwNls9n02WefXTQmJSVF9957r7y8vFS5cmXdeuutSk1NNfvPnTunAQMGqGrVqqpSpYp69OihEydO2C0jNTVV3bt3V6VKleTn56cRI0bo/Pnzxb15AADgGlGqgejMmTNq1qyZ5s6de8n+w4cPq23btmrYsKE2bNigXbt2aezYsXJ3dzfHDB06VCtWrND//vc/xcbG6tixY3rwwQfN/oKCAnXv3l15eXnasmWL3nvvPS1evFjjxo0r9u0DAADXBpthGEZpFyH9fkvtTz/9VPfff7/ZFhkZqQoVKuiDDz645DxZWVmqXr26li5dqoceekiStG/fPoWEhCguLk6tW7fW119/rbvvvlvHjh2Tv7+/JGn+/PkaOXKkfv75Z7m6ul5y2bm5ucrNzTWnLzwLJSsri0d3AABwjcjOzpaXl9ff/v0us+cQFRYW6ssvv1T9+vUVEREhPz8/tWrVyu6wWmJiovLz8xUeHm62NWzYUDVr1lRcXJwkKS4uTk2aNDHDkCRFREQoOztbycnJl13/tGnT5OXlZb540j0AANevMhuIMjIylJOTo+nTp6tLly5as2aNHnjgAT344IOKjY2VJKWnp8vV1VXe3t528/r7+ys9Pd0c8+cwdKH/Qt/ljB49WllZWeYrLS3NiVsHAADKkjL7tPvCwkJJ0n333aehQ4dKkpo3b64tW7Zo/vz5at++fbGu383NTW5ubsW6DgAAUDaU2T1E1apVU/ny5RUaGmrXHhISYl5lFhAQoLy8PJ0+fdpuzIkTJxQQEGCO+etVZxemL4wBAADWVmb3ELm6uurWW2/V/v377doPHDigWrVqSZJatGihChUqaN26derRo4ckaf/+/UpNTVVYWJgkKSwsTC+++KIyMjLk5+cnSYqJiZGnp+dFYQuXFjzqy9IuASXoh+ndS7sElCC+39bC9/vySjUQ5eTk6NChQ+b0kSNHlJSUJF9fX9WsWVMjRozQI488onbt2qlDhw5atWqVVqxYoQ0bNkiSvLy81KdPHw0bNky+vr7y9PTUwIEDFRYWptatW0uSOnfurNDQUPXs2VMzZ85Uenq6xowZowEDBnBIDAAASCrlQLRt2zZ16NDBnB42bJgkqVevXlq8eLEeeOABzZ8/X9OmTdOgQYPUoEEDffLJJ2rbtq05z6uvvioXFxf16NFDubm5ioiI0Jtvvmn2lytXTitXrlT//v0VFhamypUrq1evXpo0aVLJbSgAACjTysx9iMq6ot7H4HrELnVrYZe6tfD9thYrfr+v+fsQAQAAlBQCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEQAAsLxSDUQbN27UPffco8DAQNlsNn322WeXHfvMM8/IZrNp9uzZdu2ZmZmKioqSp6envL291adPH+Xk5NiN2bVrl+644w65u7srKChIM2fOLIatAQAA16pSDURnzpxRs2bNNHfu3CuO+/TTT7V161YFBgZe1BcVFaXk5GTFxMRo5cqV2rhxo/r162f2Z2dnq3PnzqpVq5YSExP10ksvacKECVqwYIHTtwcAAFybypfmyrt27aquXbteccxPP/2kgQMHavXq1erevbtdX0pKilatWqWEhAS1bNlSkvT666+rW7duevnllxUYGKglS5YoLy9P7777rlxdXdWoUSMlJSVp1qxZdsEJAABYV5k+h6iwsFA9e/bUiBEj1KhRo4v64+Li5O3tbYYhSQoPD5eLi4vi4+PNMe3atZOrq6s5JiIiQvv379cvv/xy2XXn5uYqOzvb7gUAAK5PZToQzZgxQ+XLl9egQYMu2Z+eni4/Pz+7tvLly8vX11fp6enmGH9/f7sxF6YvjLmUadOmycvLy3wFBQX9k00BAABlWJkNRImJiXrttde0ePFi2Wy2El//6NGjlZWVZb7S0tJKvAYAAFAyymwg2rRpkzIyMlSzZk2VL19e5cuX19GjRzV8+HAFBwdLkgICApSRkWE33/nz55WZmamAgABzzIkTJ+zGXJi+MOZS3Nzc5OnpafcCAADXpzIbiHr27Kldu3YpKSnJfAUGBmrEiBFavXq1JCksLEynT59WYmKiOd/69etVWFioVq1amWM2btyo/Px8c0xMTIwaNGggHx+fkt0oAABQJpXqVWY5OTk6dOiQOX3kyBElJSXJ19dXNWvWVNWqVe3GV6hQQQEBAWrQoIEkKSQkRF26dFHfvn01f/585efnKzo6WpGRkeYl+o899pgmTpyoPn36aOTIkdqzZ49ee+01vfrqqyW3oQAAoEwr1UC0bds2dejQwZweNmyYJKlXr15avHhxkZaxZMkSRUdHq2PHjnJxcVGPHj00Z84cs9/Ly0tr1qzRgAED1KJFC1WrVk3jxo3jknsAAGAq1UB05513yjCMIo//4YcfLmrz9fXV0qVLrzhf06ZNtWnTJkfLAwAAFlFmzyECAAAoKQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQ4HorS0NP3444/m9HfffachQ4ZowYIFDq9848aNuueeexQYGCibzabPPvvM7MvPz9fIkSPVpEkTVa5cWYGBgXriiSd07Ngxu2VkZmYqKipKnp6e8vb2Vp8+fZSTk2M3ZteuXbrjjjvk7u6uoKAgzZw50+FaAQDA9cvhQPTYY4/pm2++kSSlp6erU6dO+u677/TCCy9o0qRJDi3rzJkzatasmebOnXtR39mzZ7V9+3aNHTtW27dv1/Lly7V//37de++9duOioqKUnJysmJgYrVy5Uhs3blS/fv3M/uzsbHXu3Fm1atVSYmKiXnrpJU2YMOGqAhwAALg+lXd0hj179ui2226TJH388cdq3LixNm/erDVr1uiZZ57RuHHjirysrl27qmvXrpfs8/LyUkxMjF3bG2+8odtuu02pqamqWbOmUlJStGrVKiUkJKhly5aSpNdff13dunXTyy+/rMDAQC1ZskR5eXl699135erqqkaNGikpKUmzZs2yC04AAMC6HN5DlJ+fLzc3N0nS2rVrzT02DRs21PHjx51b3V9kZWXJZrPJ29tbkhQXFydvb28zDElSeHi4XFxcFB8fb45p166dXF1dzTERERHav3+/fvnll8uuKzc3V9nZ2XYvAABwfXI4EDVq1Ejz58/Xpk2bFBMToy5dukiSjh07pqpVqzq9wAvOnTunkSNH6tFHH5Wnp6ek3w/Z+fn52Y0rX768fH19lZ6ebo7x9/e3G3Nh+sKYS5k2bZq8vLzMV1BQkDM3BwAAlCEOB6IZM2borbfe0p133qlHH31UzZo1kyR98cUX5qE0Z8vPz9fDDz8swzA0b968YlnHX40ePVpZWVnmKy0trUTWCwAASp7D5xDdeeedOnnypLKzs+Xj42O29+vXT5UqVXJqcdL/D0NHjx7V+vXrzb1DkhQQEKCMjAy78efPn1dmZqYCAgLMMSdOnLAbc2H6wphLcXNzMw8NAgCA65vDe4jGjx+vH3/80S4MSVJwcPBFh6/+qQth6ODBg1q7du1Fh+TCwsJ0+vRpJSYmmm3r169XYWGhWrVqZY7ZuHGj8vPzzTExMTFq0KDBRdsAAACsyeFA9Pnnn6tOnTrq2LGjli5dqtzc3KteeU5OjpKSkpSUlCRJOnLkiJKSkpSamqr8/Hw99NBD2rZtm5YsWaKCggKlp6crPT1deXl5kqSQkBB16dJFffv21XfffafNmzcrOjpakZGRCgwMlPT7bQJcXV3Vp08fJScna9myZXrttdc0bNiwq64bAABcXxwORElJSUpISFCjRo00ePBgBQQEqH///kpISHB45du2bdPNN9+sm2++WZI0bNgw3XzzzRo3bpx++uknffHFF/rxxx/VvHlz1ahRw3xt2bLFXMaSJUvUsGFDdezYUd26dVPbtm3t7jHk5eWlNWvW6MiRI2rRooWGDx+ucePGcck9AAAw2QzDMK525vz8fK1YsUKLFi3S6tWr1bBhQ/Xp00e9e/eWl5eXM+ssddnZ2fLy8lJWVpbdeUxWEDzqy9IuASXoh+ndS7sElCC+39Zixe93Uf9+/6NnmRmGofz8fOXl5ckwDPn4+OiNN95QUFCQli1b9k8WDQAAUGKuKhAlJiYqOjpaNWrU0NChQ3XzzTcrJSVFsbGxOnjwoF588UUNGjTI2bUCAAAUC4cDUZMmTdS6dWsdOXJE77zzjtLS0jR9+nTVrVvXHPPoo4/q559/dmqhAAAAxcXh+xA9/PDDeuqpp3TDDTdcdky1atVUWFj4jwoDAAAoKQ4HorFjxxZHHQAAAKXG4UAkST/++KO++OILpaammvcEumDWrFlOKQwAAKCkOByI1q1bp3vvvVc33XST9u3bp8aNG+uHH36QYRi65ZZbiqNGAACAYuXwSdWjR4/Wc889p927d8vd3V2ffPKJ0tLS1L59e/3rX/8qjhoBAACKlcOBKCUlRU888YQkqXz58vrtt99UpUoVTZo0STNmzHB6gQAAAMXN4UBUuXJl87yhGjVq6PDhw2bfyZMnnVcZAABACXH4HKLWrVvr22+/VUhIiLp166bhw4dr9+7dWr58uVq3bl0cNQIAABQrhwPRrFmzlJOTI0maOHGicnJytGzZMtWrV48rzAAAwDXJ4UB00003mT9XrlxZ8+fPd2pBAAAAJe0fPdwVAADgelCkPUQ+Pj6y2WxFWmBmZuY/KggAAKCkFSkQzZ492/z51KlTmjJliiIiIhQWFiZJiouL0+rVq3msBwAAuCYVKRD16tXL/LlHjx6aNGmSoqOjzbZBgwbpjTfe0Nq1azV06FDnVwkAAFCMHD6HaPXq1erSpctF7V26dNHatWudUhQAAEBJcjgQVa1aVZ9//vlF7Z9//rmqVq3qlKIAAABKksOX3U+cOFFPP/20NmzYoFatWkmS4uPjtWrVKi1cuNDpBQIAABQ3hwNR7969FRISojlz5mj58uWSpJCQEH377bdmQAIAALiWOByIJKlVq1ZasmSJs2sBAAAoFdyYEQAAWB6BCAAAWB6BCAAAWB6BCAAAWB6BCAAAWJ7DV5mdOXNG06dP17p165SRkaHCwkK7/u+//95pxQEAAJQEhwPR008/rdjYWPXs2VM1atSQzWYrjroAAABKjMOB6Ouvv9aXX36pNm3aFEc9AAAAJc7hc4h8fHzk6+tbHLUAAACUCocD0eTJkzVu3DidPXu2OOoBAAAocQ4fMnvllVd0+PBh+fv7Kzg4WBUqVLDr3759u9OKAwAAKAkOB6L777+/GMoAAAAoPQ4HovHjxztt5Rs3btRLL72kxMREHT9+XJ9++qld4DIMQ+PHj9fChQt1+vRptWnTRvPmzVO9evXMMZmZmRo4cKBWrFghFxcX9ejRQ6+99pqqVKlijtm1a5cGDBighIQEVa9eXQMHDtTzzz/vtO0AAADXtqu+MWNiYqL++9//6r///a927NhxVcs4c+aMmjVrprlz516yf+bMmZozZ47mz5+v+Ph4Va5cWRERETp37pw5JioqSsnJyYqJidHKlSu1ceNG9evXz+zPzs5W586dVatWLSUmJuqll17ShAkTtGDBgquqGQAAXH8c3kOUkZGhyMhIbdiwQd7e3pKk06dPq0OHDvroo49UvXr1Ii+ra9eu6tq16yX7DMPQ7NmzNWbMGN13332SpPfff1/+/v767LPPFBkZqZSUFK1atUoJCQlq2bKlJOn1119Xt27d9PLLLyswMFBLlixRXl6e3n33Xbm6uqpRo0ZKSkrSrFmz7IITAACwLof3EA0cOFC//vqrkpOTlZmZqczMTO3Zs0fZ2dkaNGiQ0wo7cuSI0tPTFR4ebrZ5eXmpVatWiouLkyTFxcXJ29vbDEOSFB4eLhcXF8XHx5tj2rVrJ1dXV3NMRESE9u/fr19++eWy68/NzVV2drbdCwAAXJ8cDkSrVq3Sm2++qZCQELMtNDRUc+fO1ddff+20wtLT0yVJ/v7+du3+/v5mX3p6uvz8/Oz6y5cvL19fX7sxl1rGn9dxKdOmTZOXl5f5CgoK+mcbBAAAyiyHA1FhYeFFl9pLUoUKFS56rtm1bPTo0crKyjJfaWlppV0SAAAoJg4HorvuukuDBw/WsWPHzLaffvpJQ4cOVceOHZ1WWEBAgCTpxIkTdu0nTpww+wICApSRkWHXf/78eWVmZtqNudQy/ryOS3Fzc5Onp6fdCwAAXJ8cDkRvvPGGsrOzFRwcrDp16qhOnTqqXbu2srOz9frrrzutsNq1aysgIEDr1q0z27KzsxUfH6+wsDBJUlhYmE6fPq3ExERzzPr161VYWKhWrVqZYzZu3Kj8/HxzTExMjBo0aCAfHx+n1QsAAK5dDl9lFhQUpO3bt2vt2rXat2+fJCkkJMTu5OeiysnJ0aFDh8zpI0eOKCkpSb6+vqpZs6aGDBmiKVOmqF69eqpdu7bGjh2rwMBA815FISEh6tKli/r27av58+crPz9f0dHRioyMVGBgoCTpscce08SJE9WnTx+NHDlSe/bs0WuvvaZXX33V4XoBAMD1yeFAJEk2m02dOnVSp06d/tHKt23bpg4dOpjTw4YNkyT16tVLixcv1vPPP68zZ86oX79+On36tNq2batVq1bJ3d3dnGfJkiWKjo5Wx44dzRszzpkzx+z38vLSmjVrNGDAALVo0ULVqlXTuHHjuOQeAACYbIZhGH83aM6cOerXr5/c3d3twsalOPPS+7IkOztbXl5eysrKstz5RMGjviztElCCfpjevbRLQAni+20tVvx+F/Xvd5H2EL366quKioqSu7v7FQ812Wy26zYQAQCA61eRAtGRI0cu+TMAAMD1wOGrzCZNmqSzZ89e1P7bb79p0qRJTikKAACgJDkciCZOnKicnJyL2s+ePauJEyc6pSgAAICS5HAgMgxDNpvtovadO3fK19fXKUUBAACUpCJfdu/j4yObzSabzab69evbhaKCggLl5OTomWeeKZYiAQAAilORA9Hs2bNlGIaeeuopTZw4UV5eXmafq6urgoODzTtIAwAAXEuKHIh69eol6fdHarRp00bly1/VPR0BAADKHIfPIWrfvr2OHj2qMWPG6NFHHzUfrvr1118rOTnZ6QUCAAAUN4cDUWxsrJo0aaL4+HgtX77cvOJs586dGj9+vNMLBAAAKG4OB6JRo0ZpypQpiomJkaurq9l+1113aevWrU4tDgAAoCQ4HIh2796tBx544KJ2Pz8/nTx50ilFAQAAlCSHA5G3t7eOHz9+UfuOHTt0ww03OKUoAACAkuRwIIqMjNTIkSOVnp4um82mwsJCbd68Wc8995yeeOKJ4qgRAACgWDkciKZOnaqGDRsqKChIOTk5Cg0NVbt27XT77bdrzJgxxVEjAABAsXL4ZkKurq5auHChxo4dqz179ignJ0c333yz6tWrVxz1AQAAFLurvrtizZo1VbNmTWfWAgAAUCqKFIiGDRtW5AXOmjXrqosBAAAoDUUKRDt27CjSwv78wFcAAIBrRZEC0TfffFPcdQAAAJQah68y+7O0tDSlpaU5qxYAAIBS4XAgOn/+vMaOHSsvLy8FBwcrODhYXl5eGjNmjPLz84ujRgAAgGLl8FVmAwcO1PLlyzVz5kyFhYVJkuLi4jRhwgSdOnVK8+bNc3qRAAAAxcnhQLR06VJ99NFH6tq1q9nWtGlTBQUF6dFHHyUQAQCAa47Dh8zc3NwUHBx8UXvt2rXl6urqjJoAAABKlMOBKDo6WpMnT1Zubq7ZlpubqxdffFHR0dFOLQ4AAKAkOHzIbMeOHVq3bp1uvPFGNWvWTJK0c+dO5eXlqWPHjnrwwQfNscuXL3depQAAAMXE4UDk7e2tHj162LUFBQU5rSAAAICS5nAgWrRoUXHUAQAAUGr+0Y0ZAQAArgcO7yE6deqUxo0bp2+++UYZGRkqLCy068/MzHRacQAAACXB4UDUs2dPHTp0SH369JG/vz8PdAUAANc8hwPRpk2b9O2335pXmAEAAFzrHD6HqGHDhvrtt9+Ko5aLFBQUaOzYsapdu7YqVqyoOnXqaPLkyTIMwxxjGIbGjRunGjVqqGLFigoPD9fBgwftlpOZmamoqCh5enrK29tbffr0UU5OTolsAwAAKPscDkRvvvmmXnjhBcXGxurUqVPKzs62eznTjBkzNG/ePL3xxhtKSUnRjBkzNHPmTL3++uvmmJkzZ2rOnDmaP3++4uPjVblyZUVEROjcuXPmmKioKCUnJysmJkYrV67Uxo0b1a9fP6fWCgAArl1XdR+i7Oxs3XXXXXbthmHIZrOpoKDAacVt2bJF9913n7p37y5JCg4O1ocffqjvvvvOXOfs2bM1ZswY3XfffZKk999/X/7+/vrss88UGRmplJQUrVq1SgkJCWrZsqUk6fXXX1e3bt308ssvKzAw0Gn1AgCAa5PDgSgqKkoVKlTQ0qVLi/2k6ttvv10LFizQgQMHVL9+fe3cuVPffvutZs2aJUk6cuSI0tPTFR4ebs7j5eWlVq1aKS4uTpGRkYqLi5O3t7cZhiQpPDxcLi4uio+P1wMPPHDJdefm5to9nsTZe78AAEDZ4XAg2rNnj3bs2KEGDRoURz12Ro0apezsbDVs2FDlypVTQUGBXnzxRUVFRUmS0tPTJUn+/v528/n7+5t96enp8vPzs+svX768fH19zTGXMm3aNE2cONGZmwMAAMooh88hatmypdLS0oqjlot8/PHHWrJkiZYuXart27frvffe08svv6z33nuv2Nc9evRoZWVlma+S2mYAAFDyHN5DNHDgQA0ePFgjRoxQkyZNVKFCBbv+pk2bOq24ESNGaNSoUYqMjJQkNWnSREePHtW0adPUq1cvBQQESJJOnDihGjVqmPOdOHFCzZs3lyQFBAQoIyPDbrnnz59XZmamOf+luLm5yc3NzWnbAgAAyi6HA9EjjzwiSXrqqafMNpvNViwnVZ89e1YuLvY7scqVK2feHbt27doKCAjQunXrzACUnZ2t+Ph49e/fX5IUFham06dPKzExUS1atJAkrV+/XoWFhWrVqpXTagUAANcuhwPRkSNHiqOOS7rnnnv04osvqmbNmmrUqJF27NihWbNmmWHMZrNpyJAhmjJliurVq6fatWtr7NixCgwM1P333y9JCgkJUZcuXdS3b1/Nnz9f+fn5io6OVmRkJFeYAQAASVcRiGrVqlUcdVzS66+/rrFjx+rZZ59VRkaGAgMD9e9//1vjxo0zxzz//PM6c+aM+vXrp9OnT6tt27ZatWqV3N3dzTFLlixRdHS0OnbsKBcXF/Xo0UNz5swpse0AAABlm834822fi+jw4cOaPXu2UlJSJEmhoaEaPHiw6tSp4/QCy4rs7Gx5eXkpKytLnp6epV1OiQoe9WVpl4AS9MP07qVdAkoQ329rseL3u6h/vx2+ymz16tUKDQ3Vd999p6ZNm6pp06aKj49Xo0aNFBMT84+KBgAAKA0OHzIbNWqUhg4dqunTp1/UPnLkSHXq1MlpxQEAAJQEh/cQpaSkqE+fPhe1P/XUU9q7d69TigIAAChJDgei6tWrKykp6aL2pKSki+4IDQAAcC1w+JBZ37591a9fP33//fe6/fbbJUmbN2/WjBkzNGzYMKcXCAAAUNwcDkRjx46Vh4eHXnnlFY0ePVqSFBgYqAkTJmjQoEFOLxAAAKC4ORyIbDabhg4dqqFDh+rXX3+VJHl4eDi9MAAAgJJyVXeqPn/+vOrVq2cXhA4ePKgKFSooODjYmfUBAAAUO4dPqu7du7e2bNlyUXt8fLx69+7tjJoAAABKlMOBaMeOHWrTps1F7a1bt77k1WcAAABlncOByGazmecO/VlWVpZTn3QPAABQUhwORO3atdO0adPswk9BQYGmTZumtm3bOrU4AACAkuDwSdUzZsxQu3bt1KBBA91xxx2SpE2bNik7O1vr1693eoEAAADFzeE9RKGhodq1a5cefvhhZWRk6Ndff9UTTzyhffv2qXHjxsVRIwAAQLFyeA+R9PuNGKdOnersWgAAAEqFw3uIAAAArjcEIgAAYHkEIgAAYHkEIgAAYHlXFYjOnz+vtWvX6q233jJv0njs2DHl5OQ4tTgAAICS4PBVZkePHlWXLl2Umpqq3NxcderUSR4eHpoxY4Zyc3M1f/784qgTAACg2Di8h2jw4MFq2bKlfvnlF1WsWNFsf+CBB7Ru3TqnFgcAAFASHN5DtGnTJm3ZskWurq527cHBwfrpp5+cVhgAAEBJcXgPUWFh4SUf4vrjjz/Kw8PDKUUBAACUJIcDUefOnTV79mxz2mazKScnR+PHj1e3bt2cWRsAAECJcPiQ2SuvvKKIiAiFhobq3Llzeuyxx3Tw4EFVq1ZNH374YXHUCAAAUKwcDkQ33nijdu7cqY8++ki7du1STk6O+vTpo6ioKLuTrAEAAK4VV/Vw1/Lly+vxxx93di0AAAClwuFA9MUXX1yy3Wazyd3dXXXr1lXt2rX/cWEAAAAlxeFAdP/998tms8kwDLv2C202m01t27bVZ599Jh8fH6cVCgAAUFwcvsosJiZGt956q2JiYpSVlaWsrCzFxMSoVatWWrlypTZu3KhTp07pueeeK456AQAAnM7hPUSDBw/WggULdPvtt5ttHTt2lLu7u/r166fk5GTNnj1bTz31lFMLBQAAKC4O7yE6fPiwPD09L2r39PTU999/L0mqV6+eTp48+c+rAwAAKAEOB6IWLVpoxIgR+vnnn822n3/+Wc8//7xuvfVWSdLBgwcVFBTkvCoBAACKkcOB6J133tGRI0d04403qm7duqpbt65uvPFG/fDDD3r77bclSTk5ORozZoxTCvzpp5/0+OOPq2rVqqpYsaKaNGmibdu2mf2GYWjcuHGqUaOGKlasqPDwcB08eNBuGZmZmYqKipKnp6e8vb3Vp08f5eTkOKU+AABw7XP4HKIGDRpo7969WrNmjQ4cOGC2derUSS4uv+er+++/3ynF/fLLL2rTpo06dOigr7/+WtWrV9fBgwftrl6bOXOm5syZo/fee0+1a9fW2LFjFRERob1798rd3V2SFBUVpePHjysmJkb5+fl68skn1a9fPy1dutQpdQIAgGubzfjr9fNlyKhRo7R582Zt2rTpkv2GYSgwMFDDhw83r2rLysqSv7+/Fi9erMjISKWkpCg0NFQJCQlq2bKlJGnVqlXq1q2bfvzxRwUGBl5y2bm5ucrNzTWns7OzFRQUpKysrEueQ3U9Cx71ZWmXgBL0w/TupV0CShDfb2ux4vc7OztbXl5ef/v3+6ruVH3mzBnFxsYqNTVVeXl5dn2DBg26mkVe0hdffKGIiAj961//UmxsrG644QY9++yz6tu3ryTpyJEjSk9PV3h4uDmPl5eXWrVqpbi4OEVGRiouLk7e3t5mGJKk8PBwubi4KD4+Xg888MAl1z1t2jRNnDjRadsCAADKLocD0Y4dO9StWzedPXtWZ86cka+vr06ePKlKlSrJz8/PqYHo+++/17x58zRs2DD95z//UUJCggYNGiRXV1f16tVL6enpkiR/f3+7+fz9/c2+9PR0+fn52fWXL19evr6+5phLGT16tIYNG2ZOX9hDBAAArj8OB6KhQ4fqnnvu0fz58+Xl5aWtW7eqQoUKevzxxzV48GCnFldYWKiWLVtq6tSpkqSbb75Ze/bs0fz589WrVy+nruuv3Nzc5ObmVqzrAAAAZYPDV5klJSVp+PDhcnFxUbly5ZSbm6ugoCDNnDlT//nPf5xaXI0aNRQaGmrXFhISotTUVElSQECAJOnEiRN2Y06cOGH2BQQEKCMjw67//PnzyszMNMcAAABrczgQVahQwbyazM/PzwwnXl5eSktLc2pxbdq00f79++3aDhw4oFq1akmSateurYCAAK1bt87sz87OVnx8vMLCwiRJYWFhOn36tBITE80x69evV2FhoVq1auXUegEAwLXJ4UNmN998sxISElSvXj21b99e48aN08mTJ/XBBx+ocePGTi1u6NChuv322zV16lQ9/PDD+u6777RgwQItWLBA0u8PlB0yZIimTJmievXqmZfdBwYGmpf+h4SEqEuXLurbt6/mz5+v/Px8RUdHKzIy8rJXmAEAAGtxeA/R1KlTVaNGDUnSiy++KB8fH/Xv318///yzGVSc5dZbb9Wnn36qDz/8UI0bN9bkyZM1e/ZsRUVFmWOef/55DRw4UP369dOtt96qnJwcrVq1yrwHkSQtWbJEDRs2VMeOHdWtWze1bdvW6bUCAIBrl0P3ITIMQ2lpafLz87MLHFZQ1PsYXI+4T4m1WPE+JVbG99tarPj9Lurfb4f2EBmGobp16zr9XCEAAIDS5FAgcnFxUb169XTq1KniqgcAAKDEOXwO0fTp0zVixAjt2bOnOOoBAAAocQ5fZfbEE0/o7NmzatasmVxdXVWxYkW7/szMTKcVBwAAUBIcDkSzZ88uhjIAAABKj8OBqLgfmQEAAFDSHD6HSJIOHz6sMWPG6NFHHzUfi/H1118rOTnZqcUBAACUBIcDUWxsrJo0aaL4+HgtX75cOTk5kqSdO3dq/PjxTi8QAACguDkciEaNGqUpU6YoJiZGrq6uZvtdd92lrVu3OrU4AACAkuBwINq9e7ceeOCBi9r9/Px08uRJpxQFAABQkhwORN7e3jp+/PhF7Tt27NANN9zglKIAAABKksOBKDIyUiNHjlR6erpsNpsKCwu1efNmPffcc3riiSeKo0YAAIBidVVPu2/YsKGCgoKUk5Oj0NBQtWvXTrfffrvGjBlTHDUCAAAUK4fvQ+Tq6qqFCxdq7Nix2rNnj3JycnTzzTerXr16xVEfAABAsXM4EH377bdq27atatasqZo1axZHTQAAACXK4UNmd911l2rXrq3//Oc/2rt3b3HUBAAAUKIcDkTHjh3T8OHDFRsbq8aNG6t58+Z66aWX9OOPPxZHfQAAAMXO4UBUrVo1RUdHa/PmzTp8+LD+9a9/6b333lNwcLDuuuuu4qgRAACgWF3Vs8wuqF27tkaNGqXp06erSZMmio2NdVZdAAAAJeaqA9HmzZv17LPPqkaNGnrsscfUuHFjffnll86sDQAAoEQ4fJXZ6NGj9dFHH+nYsWPq1KmTXnvtNd13332qVKlScdQHAABQ7BwORBs3btSIESP08MMPq1q1asVREwAAQIlyOBBt3ry5OOoAAAAoNQ4Hogv27t2r1NRU5eXl2bXfe++9/7goAACAkuRwIPr+++/1wAMPaPfu3bLZbDIMQ5Jks9kkSQUFBc6tEAAAoJg5fJXZ4MGDVbt2bWVkZKhSpUpKTk7Wxo0b1bJlS23YsKEYSgQAACheDu8hiouL0/r161WtWjW5uLjIxcVFbdu21bRp0zRo0CDt2LGjOOoEAAAoNg7vISooKJCHh4ek3+9afezYMUlSrVq1tH//fudWBwAAUAIc3kPUuHFj7dy5U7Vr11arVq00c+ZMubq6asGCBbrpppuKo0YAAIBi5XAgGjNmjM6cOSNJmjRpku6++27dcccdqlq1qpYtW+b0AgEAAIqbw4EoIiLC/Llu3brat2+fMjMz5ePjY15pBgAAcC256vsQ/Zmvr68zFgMAAFAq/tHT7gEAAK4H11Qgmj59umw2m4YMGWK2nTt3TgMGDFDVqlVVpUoV9ejRQydOnLCbLzU1Vd27d1elSpXk5+enESNG6Pz58yVcPQAAKKuumUCUkJCgt956S02bNrVrHzp0qFasWKH//e9/io2N1bFjx/Tggw+a/QUFBerevbvy8vK0ZcsWvffee1q8eLHGjRtX0psAAADKqGsiEOXk5CgqKkoLFy6Uj4+P2Z6VlaV33nlHs2bN0l133aUWLVpo0aJF2rJli7Zu3SpJWrNmjfbu3av//ve/at68ubp27arJkydr7ty5Fz2HDQAAWNM1EYgGDBig7t27Kzw83K49MTFR+fn5du0NGzZUzZo1FRcXJ+n3O2s3adJE/v7+5piIiAhlZ2crOTn5suvMzc1Vdna23QsAAFyfnHKVWXH66KOPtH37diUkJFzUl56eLldXV3l7e9u1+/v7Kz093Rzz5zB0of9C3+VMmzZNEydO/IfVAwCAa0GZ3kOUlpamwYMHa8mSJXJ3dy/RdY8ePVpZWVnmKy0trUTXDwAASk6ZDkSJiYnKyMjQLbfcovLly6t8+fKKjY3VnDlzVL58efn7+ysvL0+nT5+2m+/EiRMKCAiQJAUEBFx01dmF6QtjLsXNzU2enp52LwAAcH0q04GoY8eO2r17t5KSksxXy5YtFRUVZf5coUIFrVu3zpxn//79Sk1NVVhYmCQpLCxMu3fvVkZGhjkmJiZGnp6eCg0NLfFtAgAAZU+ZPofIw8NDjRs3tmurXLmyqlatarb36dNHw4YNk6+vrzw9PTVw4ECFhYWpdevWkqTOnTsrNDRUPXv21MyZM5Wenq4xY8ZowIABcnNzK/FtAgAAZU+ZDkRF8eqrr8rFxUU9evRQbm6uIiIi9Oabb5r95cqV08qVK9W/f3+FhYWpcuXK6tWrlyZNmlSKVQMAgLLkmgtEGzZssJt2d3fX3LlzNXfu3MvOU6tWLX311VfFXBkAALhWlelziAAAAEoCgQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFgegQgAAFhemQ9E06ZN06233ioPDw/5+fnp/vvv1/79++3GnDt3TgMGDFDVqlVVpUoV9ejRQydOnLAbk5qaqu7du6tSpUry8/PTiBEjdP78+ZLcFAAAUEaV+UAUGxurAQMGaOvWrYqJiVF+fr46d+6sM2fOmGOGDh2qFStW6H//+59iY2N17NgxPfjgg2Z/QUGBunfvrry8PG3ZskXvvfeeFi9erHHjxpXGJgEAgDLGZhiGUdpFOOLnn3+Wn5+fYmNj1a5dO2VlZal69epaunSpHnroIUnSvn37FBISori4OLVu3Vpff/217r77bh07dkz+/v6SpPnz52vkyJH6+eef5erqetF6cnNzlZuba05nZ2crKChIWVlZ8vT0LJmNLSOCR31Z2iWgBP0wvXtpl4ASxPfbWqz4/c7OzpaXl9ff/v0u83uI/iorK0uS5OvrK0lKTExUfn6+wsPDzTENGzZUzZo1FRcXJ0mKi4tTkyZNzDAkSREREcrOzlZycvIl1zNt2jR5eXmZr6CgoOLaJAAAUMquqUBUWFioIUOGqE2bNmrcuLEkKT09Xa6urvL29rYb6+/vr/T0dHPMn8PQhf4LfZcyevRoZWVlma+0tDQnbw0AACgrypd2AY4YMGCA9uzZo2+//bbY1+Xm5iY3N7diXw8AACh918weoujoaK1cuVLffPONbrzxRrM9ICBAeXl5On36tN34EydOKCAgwBzz16vOLkxfGAMAAKyrzAciwzAUHR2tTz/9VOvXr1ft2rXt+lu0aKEKFSpo3bp1Ztv+/fuVmpqqsLAwSVJYWJh2796tjIwMc0xMTIw8PT0VGhpaMhsCAADKrDJ/yGzAgAFaunSpPv/8c3l4eJjn/Hh5ealixYry8vJSnz59NGzYMPn6+srT01MDBw5UWFiYWrduLUnq3LmzQkND1bNnT82cOVPp6ekaM2aMBgwYwGExAABQ9gPRvHnzJEl33nmnXfuiRYvUu3dvSdKrr74qFxcX9ejRQ7m5uYqIiNCbb75pji1XrpxWrlyp/v37KywsTJUrV1avXr00adKkktoMAABQhpX5QFSU2yS5u7tr7ty5mjt37mXH1KpVS1999ZUzSwMAANeJMn8OEQAAQHEjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMsjEAEAAMuzVCCaO3eugoOD5e7urlatWum7774r7ZIAAEAZYJlAtGzZMg0bNkzjx4/X9u3b1axZM0VERCgjI6O0SwMAAKXMMoFo1qxZ6tu3r5588kmFhoZq/vz5qlSpkt59993SLg0AAJSy8qVdQEnIy8tTYmKiRo8ebba5uLgoPDxccXFxl5wnNzdXubm55nRWVpYkKTs7u3iLLYMKc8+WdgkoQVb8jFsZ329rseL3+8I2G4ZxxXGWCEQnT55UQUGB/P397dr9/f21b9++S84zbdo0TZw48aL2oKCgYqkRKCu8Zpd2BQCKi5W/37/++qu8vLwu22+JQHQ1Ro8erWHDhpnThYWFyszMVNWqVWWz2UqxMpSE7OxsBQUFKS0tTZ6enqVdDgAn4vttLYZh6Ndff1VgYOAVx1kiEFWrVk3lypXTiRMn7NpPnDihgICAS87j5uYmNzc3uzZvb+/iKhFllKenJ/9gAtcpvt/WcaU9QxdY4qRqV1dXtWjRQuvWrTPbCgsLtW7dOoWFhZViZQAAoCywxB4iSRo2bJh69eqlli1b6rbbbtPs2bN15swZPfnkk6VdGgAAKGWWCUSPPPKIfv75Z40bN07p6elq3ry5Vq1addGJ1oD0+yHT8ePHX3TYFMC1j+83LsVm/N11aAAAANc5S5xDBAAAcCUEIgAAYHkEIgAAYHkEIgAAYHkEIgAAYHkEIgDAdW/Tpk16/PHHFRYWpp9++kmS9MEHH+jbb78t5cpQVhCIgL/Iy8vT/v37df78+dIuBYATfPLJJ4qIiFDFihW1Y8cO5ebmSpKysrI0derUUq4OZQWBCPjD2bNn1adPH1WqVEmNGjVSamqqJGngwIGaPn16KVcH4GpNmTJF8+fP18KFC1WhQgWzvU2bNtq+fXspVoayhEAE/GH06NHauXOnNmzYIHd3d7M9PDxcy5YtK8XKAPwT+/fvV7t27S5q9/Ly0unTp0u+IJRJBCLgD5999pneeOMNtW3bVjabzWxv1KiRDh8+XIqVAfgnAgICdOjQoYvav/32W910002lUBHKIgIR8Ieff/5Zfn5+F7WfOXPGLiABuLb07dtXgwcPVnx8vGw2m44dO6YlS5boueeeU//+/Uu7PJQRlnm4K/B3WrZsqS+//FIDBw6UJDMEvf322woLCyvN0gD8A6NGjVJhYaE6duyos2fPql27dnJzc9Nzzz1nft8BHu4K/OHbb79V165d9fjjj2vx4sX697//rb1792rLli2KjY1VixYtSrtEAP9AXl6eDh06pJycHIWGhqpKlSqlXRLKEAIR8CeHDx/W9OnTtXPnTuXk5OiWW27RyJEj1aRJk9IuDQBQjAhEAIDrWocOHa54HuD69etLsBqUVZxDBPxh+/btqlChgrk36PPPP9eiRYsUGhqqCRMmyNXVtZQrBHA1mjdvbjedn5+vpKQk7dmzR7169SqdolDmsIcI+MOtt96qUaNGqUePHvr+++8VGhqqBx98UAkJCerevbtmz55d2iUCcKIJEyYoJydHL7/8cmmXgjKAQAT8wcvLS9u3b1edOnU0Y8YMrV+/XqtXr9bmzZsVGRmptLS00i4RgBMdOnRIt912mzIzM0u7FJQB3IcI+INhGCosLJQkrV27Vt26dZMkBQUF6eTJk6VZGoBiEBcXZ3dXelgb5xABf2jZsqWmTJmi8PBwxcbGat68eZKkI0eOyN/fv5SrA3C1HnzwQbtpwzB0/Phxbdu2TWPHji2lqlDWEIiAP8yePVtRUVH67LPP9MILL6hu3bqSpP/7v//T7bffXsrVAbhaXl5edtMuLi5q0KCBJk2apM6dO5dSVShrOIcI+Bvnzp1TuXLl7J6SDeDaUFBQoM2bN6tJkyby8fEp7XJQhhGIAADXNXd3d6WkpKh27dqlXQrKMA6ZwdJ8fHyK/OBWrkQBrk2NGzfW999/TyDCFRGIYGncWwi4/k2ZMkXPPfecJk+erBYtWqhy5cp2/Z6enqVUGcoSDpkBAK5LkyZN0vDhw+Xh4WG2/XmPsGEYstlsKigoKI3yUMYQiIBLOHfunPLy8uza+F8kcG0pV66cjh8/rpSUlCuOa9++fQlVhLKMQAT84cyZMxo5cqQ+/vhjnTp16qJ+/hcJXFtcXFyUnp4uPz+/0i4F1wDuVA384fnnn9f69es1b948ubm56e2339bEiRMVGBio999/v7TLA3AVinrRBMAeIuAPNWvW1Pvvv68777xTnp6e2r59u+rWrasPPvhAH374ob766qvSLhGAA1xcXOTl5fW3oYgrSCFxlRlgyszM1E033STp9/OFLvwj2bZtW/Xv3780SwNwlSZOnHjRnaqBSyEQAX+46aabdOTIEdWsWVMNGzbUxx9/rNtuu00rVqyQt7d3aZcH4CpERkZyDhGKhHOIYHnff/+9CgsL9eSTT2rnzp2SpFGjRmnu3Llyd3fX0KFDNWLEiFKuEoCjOH8IjuAcIljehUtzL/wv8pFHHtGcOXN07tw5JSYmqm7dumratGkpVwnAUVxlBkcQiGB5f/1H08PDQzt37jTPJwIAXP84ZAYAACyPQATLs9lsF51rwLkHAGAtXGUGyzMMQ71795abm5uk3x/b8cwzz1z0AMjly5eXRnkAgBJAIILl9erVy2768ccfL6VKAAClhZOqAQCA5XEOEQAAsDwCEQAAsDwCEQAAsDwCEQAAsDwCEVBKevfurfvvv9/py128eLElH0br6Pu5YcMG2Ww2nT59uthquhoTJkxQ8+bNzeni+pwAsEcgAlCifvvtNz399NOqXr26qlSpottuu01btmwp7bIAWBz3IQKKQV5enlxdXUu7DKfKz89XhQoV/vFyXnrpJf3f//2fli1bpvr162vPnj0qX55/ilC2XI/fYVwZe4hgOXfeeacGDhyoIUOGyMfHR/7+/lq4cKHOnDmjJ598Uh4eHqpbt66+/vprc549e/aoa9euqlKlivz9/dWzZ0+dPHnSbpnR0dEaMmSIqlWrpoiICElScnKy7r77bnl6esrDw0N33HGHDh8+fMm6EhISVL16dc2YMeNvt2Hnzp3q0KGDPDw85OnpqRYtWmjbtm12Y1avXq2QkBBVqVJFXbp00fHjx+3W1alTJ1WrVk1eXl5q3769tm/fbje/zWbTvHnzdO+996py5cp68cUXzcNMX375pZo2bSp3d3e1bt1ae/bs+fs3/g8uLi4KDQ1VRESEateurXvuuUe33XZbkeeXpIKCAg0bNkze3t6qWrWqnn/+ef31lmq5ubkaNGiQ/Pz85O7urrZt2yohIeGiZSUmJqply5aqVKmSbr/9du3fv9/su3D46t1331XNmjVVpUoVPfvssyooKNDMmTMVEBAgPz8/vfjii3bLPH36tLkXzNPTU3fddZd27tzp0DZeTmFhoWbOnKm6devKzc1NNWvWvGj9lzNy5EjVr19flSpV0k033aSxY8cqPz/f7C/K5+pSjh49qnvuuUc+Pj6qXLmyGjVqpK+++kqSivyZ+eSTT9SoUSO5ubkpODhYr7zyil1/cHCwpk6dqqeeekoeHh6qWbOmFixYYPbn5eUpOjpaNWrUkLu7u2rVqqVp06aZ/ampqbrvvvtUpUoVeXp66uGHH9aJEyfM/gu/67ffflu1a9eWu7t7kd5TXEcMwGLat29veHh4GJMnTzYOHDhgTJ482ShXrpzRtWtXY8GCBcaBAweM/v37G1WrVjXOnDlj/PLLL0b16tWN0aNHGykpKcb27duNTp06GR06dLBbZpUqVYwRI0YY+/btM/bt22f8+OOPhq+vr/Hggw8aCQkJxv79+413333X2Ldvn2EYhtGrVy/jvvvuMwzDMNatW2d4eXkZb731VpG2oVGjRsbjjz9upKSkGAcOHDA+/vhjIykpyTAMw1i0aJFRoUIFIzw83EhISDASExONkJAQ47HHHjPnX7dunfHBBx8YKSkpxt69e40+ffoY/v7+RnZ2tjlGkuHn52e8++67xuHDh42jR48a33zzjSHJCAkJMdasWWPs2rXLuPvuu43g4GAjLy+vSLUnJSUZLi4uxttvv12k8ZcyY8YMw8fHx/jkk0/M+j08PMz30zAMY9CgQUZgYKDx1VdfGcnJyUavXr0MHx8f49SpU4ZhGOa2tGrVytiwYYORnJxs3HHHHcbtt99uLmP8+PFGlSpVjIceeshITk42vvjiC8PV1dWIiIgwBg4caOzbt8949913DUnG1q1bzfnCw8ONe+65x0hISDAOHDhgDB8+3Khataq57isZP3680axZM3P6z58TwzCM559/3vDx8TEWL15sHDp0yNi0aZOxcOHCIr1vkydPNjZv3mwcOXLE+OKLLwx/f39jxowZZv+VPldX0r17d6NTp07Grl27jMOHDxsrVqwwYmNjDcMwivSZ2bZtm+Hi4mJMmjTJ2L9/v7Fo0SKjYsWKxqJFi8x11KpVy/D19TXmzp1rHDx40Jg2bZrh4uJifp9eeuklIygoyNi4caPxww8/GJs2bTKWLl1qGIZhFBQUGM2bNzfatm1rbNu2zdi6davRokULo3379nbve+XKlY0uXboY27dvN3bu3Fmk9xTXDwIRLKd9+/ZG27Ztzenz588blStXNnr27Gm2HT9+3JBkxMXFGZMnTzY6d+5st4y0tDRDkrF//35zmTfffLPdmNGjRxu1a9e+bFC48Idu+fLlRpUqVYyPPvqoyNvg4eFhLF68+JJ9ixYtMiQZhw4dMtvmzp1r+Pv7X3Z5BQUFhoeHh7FixQqzTZIxZMgQu3EX/rj9udZTp04ZFStWNJYtW/a3daenpxsBAQHG6NGjjXr16hmzZ882+06ePGlIMhISEv52OTVq1DBmzpxpTufn5xs33nijGRxycnKMChUqGEuWLDHH5OXlGYGBgeZ8F7Zl7dq15pgvv/zSkGT89ttvhmH8/keyUqVKdkExIiLCCA4ONgoKCsy2Bg0aGNOmTTMMwzA2bdpkeHp6GufOnbOruU6dOkUKvFcKRNnZ2Yabm1uRA9Dfeemll4wWLVqY01f6XF1JkyZNjAkTJlyyryifmccee8zo1KmT3XwjRowwQkNDzelatWoZjz/+uDldWFho+Pn5GfPmzTMMwzAGDhxo3HXXXUZhYeFFNaxZs8YoV66ckZqaarYlJycbkozvvvvOMIzf3/cKFSoYGRkZjm4+rhMcMoMlNW3a1Py5XLlyqlq1qpo0aWK2+fv7S5IyMjK0c+dOffPNN6pSpYr5atiwoSTZHf5q0aKF3TqSkpJ0xx13XPG8m/j4eP3rX//SBx98oEceeaTI9Q8bNkxPP/20wsPDNX369IsOw1WqVEl16tQxp2vUqKGMjAxz+sSJE+rbt6/q1asnLy8veXp6KicnR6mpqXbLadmy5SXXHxYWZv7s6+urBg0aKCUl5W/rfuWVV1SzZk1NnTpVMTExeuWVVzRmzBhJ0u7du+Xh4aFmzZpdcRlZWVk6fvy4WrVqZbaVL1/ertbDhw8rPz9fbdq0MdsqVKig22677aI6//xZqFGjhiTZvVfBwcHy8PAwp/39/RUaGioXFxe7tgvz7Ny5Uzk5OapatardZ+bIkSOXPVxaVCkpKcrNzVXHjh2vav5ly5apTZs2CggIUJUqVTRmzBi73/nffa4uZ9CgQZoyZYratGmj8ePHa9euXReNudJnJiUlxe53JUlt2rTRwYMHVVBQYLb9+Xdls9kUEBBgvu+9e/dWUlKSGjRooEGDBmnNmjXm2JSUFAUFBSkoKMhsCw0Nlbe3t93noVatWqpevXqRthnXHwIRLOmvIcVms9m12Ww2Sb+fr5GTk6N77rlHSUlJdq+DBw+qXbt25jyVK1e2W2bFihX/to46deqoYcOGevfdd+3O5fg7EyZMUHJysrp3767169crNDRUn3766RW3z/jTOTa9evVSUlKSXnvtNW3ZskVJSUmqWrWq8vLy7Ob76zb9U7t27TIvKa9Vq5bWrl2rhQsX6t///rfeeustPf744045cdsRl/u9X6r/wphLtV2YJycnRzVq1Ljo87J//36NGDHiH9ValM/U5cTFxSkqKkrdunXTypUrtWPHDr3wwgt2v/O/+1xdztNPP63vv/9ePXv21O7du9WyZUu9/vrrV13r5Vzpfb/lllt05MgRTZ48Wb/99psefvhhPfTQQw4t39mfd1xbCETA37jllluUnJys4OBg1a1b1+51pX9AmzZtqk2bNl0x6FSrVk3r16/XoUOH9PDDDzsUiurXr6+hQ4dqzZo1evDBB7Vo0aIiz7t582YNGjRI3bp1M09k/fNJ4n9n69at5s+//PKLDhw4oJCQkL+d74YbbtCWLVvM//XXr19fa9as0ccff6xPP/1UY8eO/dtleHl5qUaNGoqPjzfbzp8/r8TERHO6Tp06cnV11ebNm822/Px8JSQkKDQ0tEjbeLVuueUWpaenq3z58hd9XqpVq/aPll2vXj1VrFhR69atc3jeLVu2qFatWnrhhRfUsmVL1atXT0ePHr1o3NV+roKCgvTMM89o+fLlGj58uBYuXGjXf6XPTEhIiN3vSvr9M1q/fn2VK1euyNvo6empRx55RAsXLtSyZcv0ySefKDMzUyEhIUpLS1NaWpo5du/evTp9+nSxfx5w7SAQAX9jwIAByszM1KOPPqqEhAQdPnxYq1ev1pNPPmm3O/+voqOjlZ2drcjISG3btk0HDx7UBx98YHcVkyT5+flp/fr12rdvnx599FGdP3/+ivX89ttvio6O1oYNG3T06FFt3rxZCQkJRQokF9SrV08ffPCBUlJSFB8fr6ioKIf2PkyaNEnr1q3Tnj171Lt3b1WrVq1INw8cNGiQDh06pMjISG3fvl3Jyclau3atuc0ffPBBkdY/ePBgTZ8+XZ999pn27dunZ5991u4Gi5UrV1b//v01YsQIrVq1Snv37lXfvn119uxZ9enTp8jbeTXCw8MVFham+++/X2vWrNEPP/ygLVu26IUXXijSFVtX4u7urpEjR+r555/X+++/r8OHD2vr1q165513/nbeevXqKTU1VR999JEOHz6sOXPm2O39+SefqyFDhmj16tU6cuSItm/frm+++eai+a70mRk+fLjWrVunyZMn68CBA3rvvff0xhtv6LnnnivyezNr1ix9+OGH2rdvnw4cOKD//e9/CggIkLe3t8LDw9WkSRNFRUVp+/bt+u677/TEE0+offv2lz0sDOshEAF/IzAwUJs3b1ZBQYE6d+6sJk2aaMiQIfL29rY7j+SvqlatqvXr1ysnJ0ft27dXixYttHDhwkseEgoICND69eu1e/duRUVFXTFolStXTqdOndITTzyh+vXr6+GHH1bXrl01ceLEIm/TO++8o19++UW33HKLevbsaV6eXlTTp0/X4MGD1aJFC6Wnp2vFihVFumdLs2bNFBcXp5ycHHXq1EmtW7fW2rVrFRMTo7ffflujR4/WJ5988rfLGT58uHr27KlevXopLCxMHh4eeuCBBy6qsUePHurZs6duueUWHTp0SKtXr5aPj0+Rt/Nq2Gw2ffXVV2rXrp2efPJJ1a9fX5GRkTp69Kh5bto/MXbsWA0fPlzjxo1TSEiIHnnkEbtzni7n3nvv1dChQxUdHa3mzZtry5Ytdnvk/snnqqCgQAMGDFBISIi6dOmi+vXr680337Qbc6XPzC233KKPP/5YH330kRo3bqxx48Zp0qRJ6t27d5HfFw8PD82cOVMtW7bUrbfeqh9++EFfffWVXFxcZLPZ9Pnnn8vHx0ft2rVTeHi4brrpJi1btqzIy8f1z2YYf7l5BwBcxoYNG9ShQwf98ssvlnw8CBzHZwbXCvYQAQAAyyMQAWVQo0aN7C7Z/vNryZIlpV3eZV24m/elXlOnTi3yci63jCpVqmjTpk3FuAXFr7h+t1OnTr3scrt27fqPanbW7xUoyzhkBpRBR48evewVZ/7+/nb3xSlLfvrpJ/3222+X7PP19ZWvr2+RlnPo0KHL9t1www3/6PLz0lZcv9vMzExlZmZesq9ixYq64YYbrmq5kvN+r0BZRiACAACWxyEzAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgeQQiAABgef8PFwYHAGmzsgEAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False    808\n",
      "True      32\n",
      "Name: eli_lilly_and_company_as_sponsor, dtype: int64\n",
      "eli_lilly_and_company_as_sponsor\n",
      "False    1588.457921\n",
      "True     1475.812500\n",
      "Name: duration, dtype: float64\n"
     ]
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAkQAAAHFCAYAAAAT5Oa6AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjcuMSwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/bCgiHAAAACXBIWXMAAA9hAAAPYQGoP6dpAABIWElEQVR4nO3deVwV9f7H8fdBBUQFRC8ghkKuoLikpqSZJYlL5nZvaWZYpC3uW+rNPQs1M5cs00qtq203M3ONNHEjUhT3zK3QFHGF0CsgnN8f5fw6qcWxczjovJ6Px3k8nO/3OzOfIU+8nfnOjMVqtVoFAABgYm6uLgAAAMDVCEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0iru6gFtFfn6+Tpw4oTJlyshisbi6HAAAUABWq1W//PKLgoKC5OZ24/NABKICOnHihIKDg11dBgAAuAnHjh3THXfcccN+AlEBlSlTRtKvP1Bvb28XVwMAAAoiMzNTwcHBxu/xGyEQFdDVy2Te3t4EIgAAbjF/Nd2FSdUAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0CEQAAMD0XBqINmzYoPbt2ysoKEgWi0VLly69Zsz+/fv18MMPy8fHR6VKlVKjRo2Umppq9F++fFl9+vRRuXLlVLp0aXXp0kWnTp2y2UZqaqratWsnLy8v+fv7a9iwYbpy5YqzDw8AANwiXBqILl68qLp162r27NnX7T98+LCaNWummjVrav369dq1a5dGjx4tT09PY8ygQYP05Zdf6tNPP1VCQoJOnDihzp07G/15eXlq166dcnJytGXLFi1cuFALFizQmDFjnH58AADg1mCxWq1WVxch/fqOkc8//1wdO3Y02rp27aoSJUrogw8+uO46GRkZ+sc//qHFixfrn//8pyTp+++/V1hYmBITE9WkSROtWrVKDz30kE6cOKGAgABJ0pw5czR8+HCdPn1a7u7u1912dna2srOzjeWrL4fLyMjgXWYAANwiMjMz5ePj85e/v4vsHKL8/HytWLFC1atXV3R0tPz9/dW4cWOby2rJycnKzc1VVFSU0VazZk1VqlRJiYmJkqTExERFREQYYUiSoqOjlZmZqb17995w/3FxcfLx8TE+wcHBjj9IAABQJBTZQJSenq6srCxNmjRJrVu31ldffaVOnTqpc+fOSkhIkCSlpaXJ3d1dvr6+NusGBAQoLS3NGPP7MHS1/2rfjYwcOVIZGRnG59ixYw48OgAAUJQUd3UBN5Kfny9J6tChgwYNGiRJqlevnrZs2aI5c+bovvvuc+r+PTw85OHh4dR9AACAoqHIBqLy5curePHiCg8Pt2kPCwvTpk2bJEmBgYHKycnRhQsXbM4SnTp1SoGBgcaY7777zmYbV+9CuzoGfy5kxApXl4BC9OOkdq4uAQAKXZG9ZObu7q5GjRrpwIEDNu0//PCDKleuLElq0KCBSpQoobVr1xr9Bw4cUGpqqiIjIyVJkZGR2r17t9LT040x8fHx8vb2viZsAQAAc3LpGaKsrCwdOnTIWD569KhSUlLk5+enSpUqadiwYXr00UfVvHlz3X///Vq9erW+/PJLrV+/XpLk4+Oj2NhYDR48WH5+fvL29la/fv0UGRmpJk2aSJJatWql8PBw9ejRQ1OmTFFaWppGjRqlPn36cEkMAABIcnEg2rZtm+6//35jefDgwZKkmJgYLViwQJ06ddKcOXMUFxen/v37q0aNGvrss8/UrFkzY53XX39dbm5u6tKli7KzsxUdHa0333zT6C9WrJiWL1+u5557TpGRkSpVqpRiYmI0YcKEwjtQAABQpBWZ5xAVdQV9jsHtiDlE5sIcIgC3k1v+OUQAAACFhUAEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMj0AEAABMr7irCwAAuE7IiBWuLgGF6MdJ7VxdQpHFGSIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6BCIAAGB6Lg1EGzZsUPv27RUUFCSLxaKlS5fecOyzzz4ri8Wi6dOn27SfO3dO3bt3l7e3t3x9fRUbG6usrCybMbt27dK9994rT09PBQcHa8qUKU44GgAAcKtyaSC6ePGi6tatq9mzZ//puM8//1zffvutgoKCrunr3r279u7dq/j4eC1fvlwbNmxQ7969jf7MzEy1atVKlStXVnJysl599VWNGzdOc+fOdfjxAACAW1NxV+68TZs2atOmzZ+O+fnnn9WvXz+tWbNG7dq1s+nbv3+/Vq9era1bt6phw4aSpFmzZqlt27aaOnWqgoKCtGjRIuXk5Oi9996Tu7u7atWqpZSUFE2bNs0mOP1Rdna2srOzjeXMzMy/caQAAKAoK9JziPLz89WjRw8NGzZMtWrVuqY/MTFRvr6+RhiSpKioKLm5uSkpKckY07x5c7m7uxtjoqOjdeDAAZ0/f/6G+46Li5OPj4/xCQ4OduCRAQCAoqRIB6LJkyerePHi6t+//3X709LS5O/vb9NWvHhx+fn5KS0tzRgTEBBgM+bq8tUx1zNy5EhlZGQYn2PHjv2dQwEAAEWYSy+Z/Znk5GTNmDFD27dvl8ViKfT9e3h4yMPDo9D3CwAACl+RPUO0ceNGpaenq1KlSipevLiKFy+un376SUOGDFFISIgkKTAwUOnp6TbrXblyRefOnVNgYKAx5tSpUzZjri5fHQMAAMytyAaiHj16aNeuXUpJSTE+QUFBGjZsmNasWSNJioyM1IULF5ScnGyst27dOuXn56tx48bGmA0bNig3N9cYEx8frxo1aqhs2bKFe1AAAKBIcukls6ysLB06dMhYPnr0qFJSUuTn56dKlSqpXLlyNuNLlCihwMBA1ahRQ5IUFham1q1bq1evXpozZ45yc3PVt29fde3a1bhF/7HHHtP48eMVGxur4cOHa8+ePZoxY4Zef/31wjtQAABQpLk0EG3btk3333+/sTx48GBJUkxMjBYsWFCgbSxatEh9+/ZVy5Yt5ebmpi5dumjmzJlGv4+Pj7766iv16dNHDRo0UPny5TVmzJg/veUeAACYi0sDUYsWLWS1Wgs8/scff7ymzc/PT4sXL/7T9erUqaONGzfaWx4AADCJIjuHCAAAoLAQiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOnZHYiOHTum48ePG8vfffedBg4cqLlz5zq0MAAAgMJidyB67LHH9M0330iS0tLS9OCDD+q7777Tiy++qAkTJti1rQ0bNqh9+/YKCgqSxWLR0qVLjb7c3FwNHz5cERERKlWqlIKCgvTEE0/oxIkTNts4d+6cunfvLm9vb/n6+io2NlZZWVk2Y3bt2qV7771Xnp6eCg4O1pQpU+w9bAAAcBuzOxDt2bNHd999tyTpk08+Ue3atbVlyxYtWrRICxYssGtbFy9eVN26dTV79uxr+i5duqTt27dr9OjR2r59u5YsWaIDBw7o4YcfthnXvXt37d27V/Hx8Vq+fLk2bNig3r17G/2ZmZlq1aqVKleurOTkZL366qsaN24cZ7QAAIChuL0r5ObmysPDQ5L09ddfGwGlZs2aOnnypF3batOmjdq0aXPdPh8fH8XHx9u0vfHGG7r77ruVmpqqSpUqaf/+/Vq9erW2bt2qhg0bSpJmzZqltm3baurUqQoKCtKiRYuUk5Oj9957T+7u7qpVq5ZSUlI0bdo0m+AEAADMy+4zRLVq1dKcOXO0ceNGxcfHq3Xr1pKkEydOqFy5cg4v8PcyMjJksVjk6+srSUpMTJSvr68RhiQpKipKbm5uSkpKMsY0b95c7u7uxpjo6GgdOHBA58+fv+G+srOzlZmZafMBAAC3J7sD0eTJk/X222+rRYsW6tatm+rWrStJWrZsmXEpzRkuX76s4cOHq1u3bvL29pb06xwmf39/m3HFixeXn5+f0tLSjDEBAQE2Y64uXx1zPXFxcfLx8TE+wcHBjjwcAABQhNh9yaxFixY6c+aMMjMzVbZsWaO9d+/e8vLycmhxV+Xm5uqRRx6R1WrVW2+95ZR9/NHIkSM1ePBgYzkzM5NQBADAbcruM0Rjx47V8ePHbcKQJIWEhFxztsYRroahn376SfHx8cbZIUkKDAxUenq6zfgrV67o3LlzCgwMNMacOnXKZszV5atjrsfDw0Pe3t42HwAAcHuyOxB98cUXqlKlilq2bKnFixcrOzvbGXVJ+v8wdPDgQX399dfXzFGKjIzUhQsXlJycbLStW7dO+fn5aty4sTFmw4YNys3NNcbEx8erRo0a14Q6AABgTnYHopSUFG3dulW1atXSgAEDFBgYqOeee05bt261e+dZWVlKSUlRSkqKJOno0aNKSUlRamqqcnNz9c9//lPbtm3TokWLlJeXp7S0NKWlpSknJ0eSFBYWptatW6tXr1767rvvtHnzZvXt21ddu3ZVUFCQpF+fm+Tu7q7Y2Fjt3btXH3/8sWbMmGFzOQwAAJjbTb26o379+po5c6ZOnDihd999V8ePH1fTpk1Vp04dzZgxQxkZGQXazrZt21S/fn3Vr19fkjR48GDVr19fY8aM0c8//6xly5bp+PHjqlevnipUqGB8tmzZYmxj0aJFqlmzplq2bKm2bduqWbNmNs8Y8vHx0VdffaWjR4+qQYMGGjJkiMaMGcMt9wAAwGD3pOrfs1qtys3NVU5OjqxWq8qWLas33nhDo0eP1rx58/Too4/+6fotWrSQ1Wr90+3/FT8/Py1evPhPx9SpU0cbN278y20BAABzuqkzRMnJyerbt68qVKigQYMGqX79+tq/f78SEhJ08OBBvfzyy+rfv7+jawUAAHAKuwNRRESEmjRpoqNHj+rdd9/VsWPHNGnSJFWtWtUY061bN50+fdqhhQIAADiL3ZfMHnnkET311FOqWLHiDceUL19e+fn5f6swAACAwmJ3IBo9erQz6gAAAHCZm5pUffz4cS1btkypqanGLfBXTZs2zSGFAQAAFBa7A9HatWv18MMP684779T333+v2rVr68cff5TVatVdd93ljBoBAACcyu5J1SNHjtTQoUO1e/dueXp66rPPPtOxY8d033336V//+pczagQAAHAquwPR/v379cQTT0j69c3y//vf/1S6dGlNmDBBkydPdniBAAAAzmZ3ICpVqpQxb6hChQo6fPiw0XfmzBnHVQYAAFBI7J5D1KRJE23atElhYWFq27athgwZot27d2vJkiVq0qSJM2oEAABwKrsD0bRp05SVlSVJGj9+vLKysvTxxx+rWrVq3GEGAABuSXYHojvvvNP4c6lSpTRnzhyHFgQAAFDYbupdZgAAALeTAp0hKlu2rCwWS4E2eO7cub9VEAAAQGErUCCaPn268eezZ89q4sSJio6OVmRkpCQpMTFRa9as4bUeAADgllSgQBQTE2P8uUuXLpowYYL69u1rtPXv319vvPGGvv76aw0aNMjxVQIAADiR3XOI1qxZo9atW1/T3rp1a3399dcOKQoAAKAw2R2IypUrpy+++OKa9i+++ELlypVzSFEAAACFye7b7sePH6+nn35a69evV+PGjSVJSUlJWr16tebNm+fwAgEAAJzN7kDUs2dPhYWFaebMmVqyZIkkKSwsTJs2bTICEgAAwK3E7kAkSY0bN9aiRYscXQsAAIBL8GBGAABgegQiAABgegQiAABgegQiAABgegQiAABgenbfZXbx4kVNmjRJa9euVXp6uvLz8236jxw54rDiAAAACoPdgejpp59WQkKCevTooQoVKshisTijLgAAgEJjdyBatWqVVqxYoaZNmzqjHgAAgEJn9xyismXLys/Pzxm1AAAAuITdgeill17SmDFjdOnSJWfUAwAAUOjsvmT22muv6fDhwwoICFBISIhKlChh0799+3aHFQcAAFAY7A5EHTt2dEIZAAAArmN3IBo7dqwz6gAAAHCZm34wY3Jysv7zn//oP//5j3bs2HFT29iwYYPat2+voKAgWSwWLV261KbfarVqzJgxqlChgkqWLKmoqCgdPHjQZsy5c+fUvXt3eXt7y9fXV7GxscrKyrIZs2vXLt17773y9PRUcHCwpkyZclP1AgCA25PdgSg9PV0PPPCAGjVqpP79+6t///5q0KCBWrZsqdOnT9u1rYsXL6pu3bqaPXv2dfunTJmimTNnas6cOUpKSlKpUqUUHR2ty5cvG2O6d++uvXv3Kj4+XsuXL9eGDRvUu3dvoz8zM1OtWrVS5cqVlZycrFdffVXjxo3T3Llz7T10AABwm7L7klm/fv30yy+/aO/evQoLC5Mk7du3TzExMerfv78+/PDDAm+rTZs2atOmzXX7rFarpk+frlGjRqlDhw6SpPfff18BAQFaunSpunbtqv3792v16tXaunWrGjZsKEmaNWuW2rZtq6lTpyooKEiLFi1STk6O3nvvPbm7u6tWrVpKSUnRtGnTbILTH2VnZys7O9tYzszMLPBxAQCAW4vdZ4hWr16tN9980whDkhQeHq7Zs2dr1apVDivs6NGjSktLU1RUlNHm4+Ojxo0bKzExUZKUmJgoX19fIwxJUlRUlNzc3JSUlGSMad68udzd3Y0x0dHROnDggM6fP3/D/cfFxcnHx8f4BAcHO+zYAABA0WJ3IMrPz7/mVntJKlGixDXvNfs70tLSJEkBAQE27QEBAUZfWlqa/P39bfqLFy8uPz8/mzHX28bv93E9I0eOVEZGhvE5duzY3zsgAABQZNkdiB544AENGDBAJ06cMNp+/vlnDRo0SC1btnRoca7k4eEhb29vmw8AALg92R2I3njjDWVmZiokJERVqlRRlSpVFBoaqszMTM2aNcthhQUGBkqSTp06ZdN+6tQpoy8wMFDp6ek2/VeuXNG5c+dsxlxvG7/fBwAAMDe7J1UHBwdr+/bt+vrrr/X9999LksLCwmzm+jhCaGioAgMDtXbtWtWrV0/SrxObk5KS9Nxzz0mSIiMjdeHCBSUnJ6tBgwaSpHXr1ik/P1+NGzc2xrz44ovKzc01LvXFx8erRo0aKlu2rENrBgAAtya7A5EkWSwWPfjgg3rwwQf/1s6zsrJ06NAhY/no0aNKSUmRn5+fKlWqpIEDB2rixImqVq2aQkNDNXr0aAUFBRlPyw4LC1Pr1q3Vq1cvzZkzR7m5uerbt6+6du2qoKAgSdJjjz2m8ePHKzY2VsOHD9eePXs0Y8YMvf7663+rdgAAcPsoUCCaOXOmevfuLU9PT82cOfNPx/bv37/AO9+2bZvuv/9+Y3nw4MGSpJiYGC1YsEAvvPCCLl68qN69e+vChQtq1qyZVq9eLU9PT2OdRYsWqW/fvmrZsqXc3NzUpUsXmxp9fHz01VdfqU+fPmrQoIHKly+vMWPG/Okt9wAAwFwsVqvV+leDQkNDtW3bNpUrV06hoaE33pjFoiNHjji0wKIiMzNTPj4+ysjIMN0E65ARK1xdAgrRj5PauboEFCK+3+Zixu93QX9/F+gM0dGjR6/7ZwAAgNuB3XeZTZgwQZcuXbqm/X//+58mTJjgkKIAAAAKk92BaPz48de8PFWSLl26pPHjxzukKAAAgMJkdyCyWq2yWCzXtO/cuVN+fn4OKQoAAKAwFfi2+7Jly8pischisah69eo2oSgvL09ZWVl69tlnnVIkAACAMxU4EE2fPl1Wq1VPPfWUxo8fLx8fH6PP3d1dISEhioyMdEqRAAAAzlTgQBQTEyPp11vwmzZtquLFb+qZjgAAAEWO3XOI7rvvPv30008aNWqUunXrZrxLbNWqVdq7d6/DCwQAAHA2uwNRQkKCIiIilJSUpCVLlhh3nO3cuVNjx451eIEAAADOZncgGjFihCZOnKj4+Hi5u7sb7Q888IC+/fZbhxYHAABQGOwORLt371anTp2uaff399eZM2ccUhQAAEBhsjsQ+fr66uTJk9e079ixQxUrVnRIUQAAAIXJ7kDUtWtXDR8+XGlpabJYLMrPz9fmzZs1dOhQPfHEE86oEQAAwKnsDkSvvPKKatasqeDgYGVlZSk8PFzNmzfXPffco1GjRjmjRgAAAKey+2FC7u7umjdvnkaPHq09e/YoKytL9evXV7Vq1ZxRHwAAgNPd9NMVK1WqpEqVKjmyFgAAAJcoUCAaPHhwgTc4bdq0my4GAADAFQoUiHbs2FGgjf3+ha8AAAC3igIFom+++cbZdQAAALiM3XeZ/d6xY8d07NgxR9UCAADgEnYHoitXrmj06NHy8fFRSEiIQkJC5OPjo1GjRik3N9cZNQIAADiV3XeZ9evXT0uWLNGUKVMUGRkpSUpMTNS4ceN09uxZvfXWWw4vEgAAwJnsDkSLFy/WRx99pDZt2hhtderUUXBwsLp160YgAgAAtxy7L5l5eHgoJCTkmvbQ0FC5u7s7oiYAAIBCZXcg6tu3r1566SVlZ2cbbdnZ2Xr55ZfVt29fhxYHAABQGOy+ZLZjxw6tXbtWd9xxh+rWrStJ2rlzp3JyctSyZUt17tzZGLtkyRLHVQoAAOAkdgciX19fdenSxaYtODjYYQUBAAAUNrsD0fz5851RBwAAgMv8rQczAgAA3A7sPkN09uxZjRkzRt98843S09OVn59v03/u3DmHFQcAAFAY7A5EPXr00KFDhxQbG6uAgABe6AoAAG55dgeijRs3atOmTcYdZgAAALc6u+cQ1axZU//73/+cUQsAAIBL2B2I3nzzTb344otKSEjQ2bNnlZmZafNxpLy8PI0ePVqhoaEqWbKkqlSpopdeeklWq9UYY7VaNWbMGFWoUEElS5ZUVFSUDh48aLOdc+fOqXv37vL29pavr69iY2OVlZXl0FoBAMCt66aeQ5SZmakHHnjApt1qtcpisSgvL89hxU2ePFlvvfWWFi5cqFq1amnbtm168skn5ePjo/79+0uSpkyZopkzZ2rhwoUKDQ3V6NGjFR0drX379snT01OS1L17d508eVLx8fHKzc3Vk08+qd69e2vx4sUOqxUAANy67A5E3bt3V4kSJbR48WKnT6resmWLOnTooHbt2kmSQkJC9OGHH+q7776T9GsImz59ukaNGqUOHTpIkt5//30FBARo6dKl6tq1q/bv36/Vq1dr69atatiwoSRp1qxZatu2raZOnaqgoKDr7js7O9vm9SSOPvsFAACKDrsD0Z49e7Rjxw7VqFHDGfXYuOeeezR37lz98MMPql69unbu3KlNmzZp2rRpkqSjR48qLS1NUVFRxjo+Pj5q3LixEhMT1bVrVyUmJsrX19cIQ5IUFRUlNzc3JSUlqVOnTtfdd1xcnMaPH+/cAwQAAEWC3XOIGjZsqGPHjjmjlmuMGDFCXbt2Vc2aNVWiRAnVr19fAwcOVPfu3SVJaWlpkqSAgACb9QICAoy+tLQ0+fv72/QXL15cfn5+xpjrGTlypDIyMoxPYR0zAAAofHafIerXr58GDBigYcOGKSIiQiVKlLDpr1OnjsOK++STT7Ro0SItXrxYtWrVUkpKigYOHKigoCDFxMQ4bD/X4+HhIQ8PD6fuAwAAFA12B6JHH31UkvTUU08ZbRaLxSmTqocNG2acJZKkiIgI/fTTT4qLi1NMTIwCAwMlSadOnVKFChWM9U6dOqV69epJkgIDA5Wenm6z3StXrujcuXPG+gAAwNzsDkRHjx51Rh3XdenSJbm52V7VK1asmPG6kNDQUAUGBmrt2rVGAMrMzFRSUpKee+45SVJkZKQuXLig5ORkNWjQQJK0bt065efnq3HjxoV2LAAAoOiyOxBVrlzZGXVcV/v27fXyyy+rUqVKqlWrlnbs2KFp06YZZ6csFosGDhyoiRMnqlq1asZt90FBQerYsaMkKSwsTK1bt1avXr00Z84c5ebmqm/fvuratesN7zADAADmYncgkqTDhw9r+vTp2r9/vyQpPDxcAwYMUJUqVRxa3KxZszR69Gg9//zzSk9PV1BQkJ555hmNGTPGGPPCCy/o4sWL6t27ty5cuKBmzZpp9erVxjOIJGnRokXq27evWrZsKTc3N3Xp0kUzZ850aK0AAODWZbH+/rHPBbBmzRo9/PDDqlevnpo2bSpJ2rx5s3bu3Kkvv/xSDz74oFMKdbXMzEz5+PgoIyND3t7eri6nUIWMWOHqElCIfpzUztUloBDx/TYXM36/C/r72+4zRCNGjNCgQYM0adKka9qHDx9+2wYiAABw+7L7OUT79+9XbGzsNe1PPfWU9u3b55CiAAAACpPdgegf//iHUlJSrmlPSUm55gGIAAAAtwK7L5n16tVLvXv31pEjR3TPPfdI+nUO0eTJkzV48GCHFwgAAOBsdgei0aNHq0yZMnrttdc0cuRISVJQUJDGjRtnvIEeAADgVmJ3ILJYLBo0aJAGDRqkX375RZJUpkwZhxcGAABQWG7qSdVXrlxRtWrVbILQwYMHVaJECYWEhDiyPgAAAKeze1J1z549tWXLlmvak5KS1LNnT0fUBAAAUKjsDkQ7duwwHsj4e02aNLnu3WcAAABFnd2ByGKxGHOHfi8jI8Ohb7oHAAAoLHYHoubNmysuLs4m/OTl5SkuLk7NmjVzaHEAAACFwe5J1ZMnT1bz5s1Vo0YN3XvvvZKkjRs3KjMzU+vWrXN4gQAAAM5m9xmi8PBw7dq1S4888ojS09P1yy+/6IknntD333+v2rVrO6NGAAAAp7L7DJH064MYX3nlFUfXAgAA4BJ2nyECAAC43RCIAACA6RGIAACA6RGIAACA6d1UILpy5Yq+/vprvf3228ZDGk+cOKGsrCyHFgcAAFAY7L7L7KefflLr1q2Vmpqq7OxsPfjggypTpowmT56s7OxszZkzxxl1AgAAOI3dZ4gGDBighg0b6vz58ypZsqTR3qlTJ61du9ahxQEAABQGu88Qbdy4UVu2bJG7u7tNe0hIiH7++WeHFQYAAFBY7D5DlJ+ff92XuB4/flxlypRxSFEAAACFye5A1KpVK02fPt1YtlgsysrK0tixY9W2bVtH1gYAAFAo7L5k9tprryk6Olrh4eG6fPmyHnvsMR08eFDly5fXhx9+6IwaAQAAnMruQHTHHXdo586d+uijj7Rr1y5lZWUpNjZW3bt3t5lkDQAAcKu4qZe7Fi9eXI8//rijawEAAHAJuwPRsmXLrttusVjk6empqlWrKjQ09G8XBgAAUFjsDkQdO3aUxWKR1Wq1ab/aZrFY1KxZMy1dulRly5Z1WKEAAADOYvddZvHx8WrUqJHi4+OVkZGhjIwMxcfHq3Hjxlq+fLk2bNigs2fPaujQoc6oFwAAwOHsPkM0YMAAzZ07V/fcc4/R1rJlS3l6eqp3797au3evpk+frqeeesqhhQIAADiL3WeIDh8+LG9v72vavb29deTIEUlStWrVdObMmb9fHQAAQCGwOxA1aNBAw4YN0+nTp42206dP64UXXlCjRo0kSQcPHlRwcLDjqgQAAHAiuwPRu+++q6NHj+qOO+5Q1apVVbVqVd1xxx368ccf9c4770iSsrKyNGrUKIcU+PPPP+vxxx9XuXLlVLJkSUVERGjbtm1Gv9Vq1ZgxY1ShQgWVLFlSUVFROnjwoM02zp07p+7du8vb21u+vr6KjY1VVlaWQ+oDAAC3PrvnENWoUUP79u3TV199pR9++MFoe/DBB+Xm9mu+6tixo0OKO3/+vJo2bar7779fq1at0j/+8Q8dPHjQ5u61KVOmaObMmVq4cKFCQ0M1evRoRUdHa9++ffL09JQkde/eXSdPnlR8fLxyc3P15JNPqnfv3lq8eLFD6gQAALc2i/WP988XISNGjNDmzZu1cePG6/ZbrVYFBQVpyJAhxl1tGRkZCggI0IIFC9S1a1ft379f4eHh2rp1qxo2bChJWr16tdq2bavjx48rKCioQLVkZmbKx8dHGRkZ151DdTsLGbHC1SWgEP04qZ2rS0Ah4vttLmb8fhf09/dNPan64sWLSkhIUGpqqnJycmz6+vfvfzObvK5ly5YpOjpa//rXv5SQkKCKFSvq+eefV69evSRJR48eVVpamqKioox1fHx81LhxYyUmJqpr165KTEyUr6+vEYYkKSoqSm5ubkpKSlKnTp2uu+/s7GxlZ2cby5mZmQ47LgAAULTYHYh27Nihtm3b6tKlS7p48aL8/Px05swZeXl5yd/f36GB6MiRI3rrrbc0ePBg/fvf/9bWrVvVv39/ubu7KyYmRmlpaZKkgIAAm/UCAgKMvrS0NPn7+9v0Fy9eXH5+fsaY64mLi9P48eMddiwAAKDosntS9aBBg9S+fXudP39eJUuW1LfffquffvpJDRo00NSpUx1aXH5+vu666y698sorql+/vnr37q1evXppzpw5Dt3P9YwcOdJ48GRGRoaOHTvm9H0CAADXsDsQpaSkaMiQIXJzc1OxYsWUnZ2t4OBgTZkyRf/+978dWlyFChUUHh5u0xYWFqbU1FRJUmBgoCTp1KlTNmNOnTpl9AUGBio9Pd2m/8qVKzp37pwx5no8PDzk7e1t8wEAALcnuwNRiRIljLvJ/P39jXDi4+Pj8LMoTZs21YEDB2zafvjhB1WuXFmSFBoaqsDAQK1du9boz8zMVFJSkiIjIyVJkZGRunDhgpKTk40x69atU35+vho3buzQegEAwK3J7jlE9evX19atW1WtWjXdd999GjNmjM6cOaMPPvhAtWvXdmhxgwYN0j333KNXXnlFjzzyiL777jvNnTtXc+fOlfTrC2UHDhyoiRMnqlq1asZt90FBQcat/2FhYWrdurVxqS03N1d9+/ZV165dC3yHGQAAuL3ZfYbolVdeUYUKFSRJL7/8ssqWLavnnntOp0+fNoKKozRq1Eiff/65PvzwQ9WuXVsvvfSSpk+fru7duxtjXnjhBfXr10+9e/dWo0aNlJWVpdWrVxvPIJKkRYsWqWbNmmrZsqXatm2rZs2aObxWAABw67LrOURWq1XHjh2Tv7+/TeAwA55DBLMw43NKzIzvt7mY8ftd0N/fdp0hslqtqlq1KndcAQCA24pdgcjNzU3VqlXT2bNnnVUPAABAobN7DtGkSZM0bNgw7dmzxxn1AAAAFDq77zJ74okndOnSJdWtW1fu7u4qWbKkTf+5c+ccVhwAAEBhsDsQTZ8+3QllAAAAuI7dgSgmJsYZdQAAALiM3XOIJOnw4cMaNWqUunXrZrwWY9WqVdq7d69DiwMAACgMdgeihIQERUREKCkpSUuWLFFWVpYkaefOnRo7dqzDCwQAAHA2uwPRiBEjNHHiRMXHx8vd3d1of+CBB/Ttt986tDgAAIDCYHcg2r17tzp16nRNu7+/v86cOeOQogAAAAqT3YHI19dXJ0+evKZ9x44dqlixokOKAgAAKEx2B6KuXbtq+PDhSktLk8ViUX5+vjZv3qyhQ4fqiSeecEaNAAAATnVTb7uvWbOmgoODlZWVpfDwcDVv3lz33HOPRo0a5YwaAQAAnMru5xC5u7tr3rx5Gj16tPbs2aOsrCzVr19f1apVc0Z9AAAATmd3INq0aZOaNWumSpUqqVKlSs6oCQAAoFDZfcnsgQceUGhoqP79739r3759zqgJAACgUNkdiE6cOKEhQ4YoISFBtWvXVr169fTqq6/q+PHjzqgPAADA6ewOROXLl1ffvn21efNmHT58WP/617+0cOFChYSE6IEHHnBGjQAAAE51U+8yuyo0NFQjRozQpEmTFBERoYSEBEfVBQAAUGhuOhBt3rxZzz//vCpUqKDHHntMtWvX1ooVKxxZGwAAQKGw+y6zkSNH6qOPPtKJEyf04IMPasaMGerQoYO8vLycUR8AAIDT2R2INmzYoGHDhumRRx5R+fLlnVETAABAobI7EG3evNkZdQAAALiM3YHoqn379ik1NVU5OTk27Q8//PDfLgoAAKAw2R2Ijhw5ok6dOmn37t2yWCyyWq2SJIvFIknKy8tzbIUAAABOZvddZgMGDFBoaKjS09Pl5eWlvXv3asOGDWrYsKHWr1/vhBIBAACcy+4zRImJiVq3bp3Kly8vNzc3ubm5qVmzZoqLi1P//v21Y8cOZ9QJAADgNHafIcrLy1OZMmUk/frU6hMnTkiSKleurAMHDji2OgAAgEJg9xmi2rVra+fOnQoNDVXjxo01ZcoUubu7a+7cubrzzjudUSMAAIBT2R2IRo0apYsXL0qSJkyYoIceekj33nuvypUrp48//tjhBQIAADib3YEoOjra+HPVqlX1/fff69y5cypbtqxxpxkAAMCt5KafQ/R7fn5+jtgMAACAS/ytt90DAADcDm6pQDRp0iRZLBYNHDjQaLt8+bL69OmjcuXKqXTp0urSpYtOnTpls15qaqratWsnLy8v+fv7a9iwYbpy5UohVw8AAIqqWyYQbd26VW+//bbq1Klj0z5o0CB9+eWX+vTTT5WQkKATJ06oc+fORn9eXp7atWunnJwcbdmyRQsXLtSCBQs0ZsyYwj4EAABQRN0SgSgrK0vdu3fXvHnzVLZsWaM9IyND7777rqZNm6YHHnhADRo00Pz587VlyxZ9++23kqSvvvpK+/bt03/+8x/Vq1dPbdq00UsvvaTZs2df8x42AABgTrdEIOrTp4/atWunqKgom/bk5GTl5ubatNesWVOVKlVSYmKipF+frB0REaGAgABjTHR0tDIzM7V3794b7jM7O1uZmZk2HwAAcHtyyF1mzvTRRx9p+/bt2rp16zV9aWlpcnd3l6+vr017QECA0tLSjDG/D0NX+6/23UhcXJzGjx//N6sHAAC3giJ9hujYsWMaMGCAFi1aJE9Pz0Ld98iRI5WRkWF8jh07Vqj7BwAAhadIB6Lk5GSlp6frrrvuUvHixVW8eHElJCRo5syZKl68uAICApSTk6MLFy7YrHfq1CkFBgZKkgIDA6+56+zq8tUx1+Ph4SFvb2+bDwAAuD0V6UDUsmVL7d69WykpKcanYcOG6t69u/HnEiVKaO3atcY6Bw4cUGpqqiIjIyVJkZGR2r17t9LT040x8fHx8vb2Vnh4eKEfEwAAKHqK9ByiMmXKqHbt2jZtpUqVUrly5Yz22NhYDR48WH5+fvL29la/fv0UGRmpJk2aSJJatWql8PBw9ejRQ1OmTFFaWppGjRqlPn36yMPDo9CPCQAAFD1FOhAVxOuvvy43Nzd16dJF2dnZio6O1ptvvmn0FytWTMuXL9dzzz2nyMhIlSpVSjExMZowYYILqwYAAEXJLReI1q9fb7Ps6emp2bNna/bs2Tdcp3Llylq5cqWTKwMAALeqIj2HCAAAoDAQiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkRiAAAgOkV+UAUFxenRo0aqUyZMvL391fHjh114MABmzGXL19Wnz59VK5cOZUuXVpdunTRqVOnbMakpqaqXbt28vLykr+/v4YNG6YrV64U5qEAAIAiqsgHooSEBPXp00fffvut4uPjlZubq1atWunixYvGmEGDBunLL7/Up59+qoSEBJ04cUKdO3c2+vPy8tSuXTvl5ORoy5YtWrhwoRYsWKAxY8a44pAAAEARY7FarVZXF2GP06dPy9/fXwkJCWrevLkyMjL0j3/8Q4sXL9Y///lPSdL333+vsLAwJSYmqkmTJlq1apUeeughnThxQgEBAZKkOXPmaPjw4Tp9+rTc3d2v2U92drays7ON5czMTAUHBysjI0Pe3t6Fc7BFRMiIFa4uAYXox0ntXF0CChHfb3Mx4/c7MzNTPj4+f/n7u8ifIfqjjIwMSZKfn58kKTk5Wbm5uYqKijLG1KxZU5UqVVJiYqIkKTExUREREUYYkqTo6GhlZmZq7969191PXFycfHx8jE9wcLCzDgkAALjYLRWI8vPzNXDgQDVt2lS1a9eWJKWlpcnd3V2+vr42YwMCApSWlmaM+X0Yutp/te96Ro4cqYyMDONz7NgxBx8NAAAoKoq7ugB79OnTR3v27NGmTZucvi8PDw95eHg4fT8AAMD1bpkzRH379tXy5cv1zTff6I477jDaAwMDlZOTowsXLtiMP3XqlAIDA40xf7zr7Ory1TEAAMC8inwgslqt6tu3rz7//HOtW7dOoaGhNv0NGjRQiRIltHbtWqPtwIEDSk1NVWRkpCQpMjJSu3fvVnp6ujEmPj5e3t7eCg8PL5wDAQAARVaRv2TWp08fLV68WF988YXKlCljzPnx8fFRyZIl5ePjo9jYWA0ePFh+fn7y9vZWv379FBkZqSZNmkiSWrVqpfDwcPXo0UNTpkxRWlqaRo0apT59+nBZDAAAFP1A9NZbb0mSWrRoYdM+f/589ezZU5L0+uuvy83NTV26dFF2draio6P15ptvGmOLFSum5cuX67nnnlNkZKRKlSqlmJgYTZgwobAOAwAAFGFFPhAV5DFJnp6emj17tmbPnn3DMZUrV9bKlSsdWRoAALhNFPk5RAAAAM5GIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZHIAIAAKZnqkA0e/ZshYSEyNPTU40bN9Z3333n6pIAAEARYJpA9PHHH2vw4MEaO3astm/frrp16yo6Olrp6emuLg0AALiYaQLRtGnT1KtXLz355JMKDw/XnDlz5OXlpffee8/VpQEAABcr7uoCCkNOTo6Sk5M1cuRIo83NzU1RUVFKTEy87jrZ2dnKzs42ljMyMiRJmZmZzi22CMrPvuTqElCIzPh33Mz4fpuLGb/fV4/ZarX+6ThTBKIzZ84oLy9PAQEBNu0BAQH6/vvvr7tOXFycxo8ff017cHCwU2oEigqf6a6uAICzmPn7/csvv8jHx+eG/aYIRDdj5MiRGjx4sLGcn5+vc+fOqVy5crJYLC6sDIUhMzNTwcHBOnbsmLy9vV1dDgAH4vttLlarVb/88ouCgoL+dJwpAlH58uVVrFgxnTp1yqb91KlTCgwMvO46Hh4e8vDwsGnz9fV1Vokoory9vfkfJnCb4vttHn92ZugqU0yqdnd3V4MGDbR27VqjLT8/X2vXrlVkZKQLKwMAAEWBKc4QSdLgwYMVExOjhg0b6u6779b06dN18eJFPfnkk64uDQAAuJhpAtGjjz6q06dPa8yYMUpLS1O9evW0evXqayZaA9Kvl0zHjh17zWVTALc+vt+4Hov1r+5DAwAAuM2ZYg4RAADAnyEQAQAA0yMQAQAA0yMQAQAA0yMQAQAA0yMQAQBuexs3btTjjz+uyMhI/fzzz5KkDz74QJs2bXJxZSgqCETAH+Tk5OjAgQO6cuWKq0sB4ACfffaZoqOjVbJkSe3YsUPZ2dmSpIyMDL3yyisurg5FBYEI+M2lS5cUGxsrLy8v1apVS6mpqZKkfv36adKkSS6uDsDNmjhxoubMmaN58+apRIkSRnvTpk21fft2F1aGooRABPxm5MiR2rlzp9avXy9PT0+jPSoqSh9//LELKwPwdxw4cEDNmze/pt3Hx0cXLlwo/IJQJBGIgN8sXbpUb7zxhpo1ayaLxWK016pVS4cPH3ZhZQD+jsDAQB06dOia9k2bNunOO+90QUUoighEwG9Onz4tf3//a9ovXrxoE5AA3Fp69eqlAQMGKCkpSRaLRSdOnNCiRYs0dOhQPffcc64uD0WEaV7uCvyVhg0basWKFerXr58kGSHonXfeUWRkpCtLA/A3jBgxQvn5+WrZsqUuXbqk5s2by8PDQ0OHDjW+7wAvdwV+s2nTJrVp00aPP/64FixYoGeeeUb79u3Tli1blJCQoAYNGri6RAB/Q05Ojg4dOqSsrCyFh4erdOnSri4JRQiBCPidw4cPa9KkSdq5c6eysrJ01113afjw4YqIiHB1aQAAJyIQAQBua/fff/+fzgNct25dIVaDooo5RMBvtm/frhIlShhng7744gvNnz9f4eHhGjdunNzd3V1cIYCbUa9ePZvl3NxcpaSkaM+ePYqJiXFNUShyOEME/KZRo0YaMWKEunTpoiNHjig8PFydO3fW1q1b1a5dO02fPt3VJQJwoHHjxikrK0tTp051dSkoAghEwG98fHy0fft2ValSRZMnT9a6deu0Zs0abd68WV27dtWxY8dcXSIABzp06JDuvvtunTt3ztWloAjgOUTAb6xWq/Lz8yVJX3/9tdq2bStJCg4O1pkzZ1xZGgAnSExMtHkqPcyNOUTAbxo2bKiJEycqKipKCQkJeuuttyRJR48eVUBAgIurA3CzOnfubLNstVp18uRJbdu2TaNHj3ZRVShqCETAb6ZPn67u3btr6dKlevHFF1W1alVJ0n//+1/dc889Lq4OwM3y8fGxWXZzc1ONGjU0YcIEtWrVykVVoahhDhHwFy5fvqxixYrZvCUbwK0hLy9PmzdvVkREhMqWLevqclCEEYgAALc1T09P7d+/X6Ghoa4uBUUYl8xgamXLli3wi1u5EwW4NdWuXVtHjhwhEOFPEYhgajxbCLj9TZw4UUOHDtVLL72kBg0aqFSpUjb93t7eLqoMRQmXzAAAt6UJEyZoyJAhKlOmjNH2+zPCVqtVFotFeXl5rigPRQyBCLiOy5cvKycnx6aNf0UCt5ZixYrp5MmT2r9//5+Ou++++wqpIhRlBCLgNxcvXtTw4cP1ySef6OzZs9f0869I4Nbi5uamtLQ0+fv7u7oU3AJ4UjXwmxdeeEHr1q3TW2+9JQ8PD73zzjsaP368goKC9P7777u6PAA3oaA3TQCcIQJ+U6lSJb3//vtq0aKFvL29tX37dlWtWlUffPCBPvzwQ61cudLVJQKwg5ubm3x8fP4yFHEHKSTuMgMM586d05133inp1/lCV/8n2axZMz333HOuLA3ATRo/fvw1T6oGrodABPzmzjvv1NGjR1WpUiXVrFlTn3zyie6++259+eWX8vX1dXV5AG5C165dmUOEAmEOEUzvyJEjys/P15NPPqmdO3dKkkaMGKHZs2fL09NTgwYN0rBhw1xcJQB7MX8I9mAOEUzv6q25V/8V+eijj2rmzJm6fPmykpOTVbVqVdWpU8fFVQKwF3eZwR4EIpjeH/+nWaZMGe3cudOYTwQAuP1xyQwAAJgegQimZ7FYrplrwNwDADAX7jKD6VmtVvXs2VMeHh6Sfn1tx7PPPnvNCyCXLFniivIAAIWAQATTi4mJsVl+/PHHXVQJAMBVmFQNAABMjzlEAADA9AhEAADA9AhEAADA9AhEAADA9AhEgIOtX79eFotFFy5ckCQtWLCgwC+HHTdunOrVq2cs9+zZUx07djSWW7RooYEDBxrLISEhmj59+t+u2ZnsOX4AcBVuuwec7NFHH1Xbtm1vat0ZM2aIG0EBwPkIRICTlSxZUiVLlrypdX18fBxcDWAOOTk5cnd3d3UZuIVwyQy4Cfn5+YqLi1NoaKhKliypunXr6r///e91x/6dS0Z/vGT2Z5566ik99NBDNm25ubny9/fXu++++5frr169Ws2aNZOvr6/KlSunhx56SIcPHzb6f/zxR1ksFi1ZskT333+/vLy8VLduXSUmJtpsZ8GCBapUqZK8vLzUqVMnnT17tkD1X/Xll1+qUaNG8vT0VPny5dWpUyej7/z583riiSdUtmxZeXl5qU2bNjp48KDNvn19fbV8+XLVqFFDXl5e+uc//6lLly5p4cKFCgkJUdmyZdW/f3/l5eUZ64WEhOill15St27dVKpUKVWsWFGzZ8+2qWvatGmKiIhQqVKlFBwcrOeff15ZWVnX7HvNmjUKCwtT6dKl1bp1a508eVKStGHDBpUoUUJpaWk22x04cKDuvffev/y5nD17Vt26dVPFihXl5eWliIgIffjhhzZj/vvf/yoiIkIlS5ZUuXLlFBUVpYsXL/7lttevX6+7775bpUqVkq+vr5o2baqffvpJ0v9fxn377bcVHBwsLy8vPfLII8rIyDDWz8/P14QJE3THHXfIw8ND9erV0+rVq43+gvzd+emnn9S+fXuVLVtWpUqVUq1atbRy5UqjPyEhQXfffbc8PDxUoUIFjRgxQleuXDH6W7Roob59+2rgwIEqX768oqOj//K4gd8jEAE3IS4uTu+//77mzJmjvXv3atCgQXr88ceVkJDgspqefvpprV692vgFLEnLly/XpUuX9Oijj/7l+hcvXtTgwYO1bds2rV27Vm5uburUqZPy8/Ntxr344osaOnSoUlJSVL16dXXr1s34xZSUlKTY2Fj17dtXKSkpuv/++zVx4sQCH8OKFSvUqVMntW3bVjt27NDatWt19913G/09e/bUtm3btGzZMiUmJspqtapt27bKzc01xly6dEkzZ87URx99pNWrV2v9+vXq1KmTVq5cqZUrV+qDDz7Q22+/fU2AffXVV1W3bl3t2LFDI0aM0IABAxQfH2/0u7m5aebMmdq7d68WLlyodevW6YUXXrDZxqVLlzR16lR98MEH2rBhg1JTUzV06FBJUvPmzXXnnXfqgw8+MMbn5uZq0aJFeuqpp/7yZ3P58mU1aNBAK1as0J49e9S7d2/16NFD3333nSTp5MmT6tatm5566int379f69evV+fOnf/ykuuVK1fUsWNH3Xfffdq1a5cSExPVu3dvm/f5HTp0SJ988om+/PJLrV69Wjt27NDzzz9v9M+YMUOvvfaapk6dql27dik6OloPP/ywTViV/vzvTp8+fZSdna0NGzZo9+7dmjx5skqXLi1J+vnnn9W2bVs1atRIO3fu1FtvvaV33333mr9bCxculLu7uzZv3qw5c+b85c8UsGEFYJfLly9bvby8rFu2bLFpj42NtXbr1s36zTffWCVZz58/b7Vardb58+dbfXx8CrTtsWPHWuvWrWssx8TEWDt06GAs33fffdYBAwYYy5UrV7a+/vrrxnJ4eLh18uTJxnL79u2tPXv2LOih2Th9+rRVknX37t1Wq9VqPXr0qFWS9Z133jHG7N271yrJun//fqvVarV269bN2rZtW5vtPProowU+/sjISGv37t2v2/fDDz9YJVk3b95stJ05c8ZasmRJ6yeffGK1Wn/9WUuyHjp0yBjzzDPPWL28vKy//PKL0RYdHW195plnjOXKlStbW7dufU3dbdq0uWGtn376qbVcuXLG8vX2PXv2bGtAQICxPHnyZGtYWJix/Nlnn1lLly5tzcrKuuF+/ky7du2sQ4YMsVqtVmtycrJVkvXHH3+0axtnz561SrKuX7/+uv1jx461FitWzHr8+HGjbdWqVVY3NzfryZMnrVar1RoUFGR9+eWXbdZr1KiR9fnnn7darQX7uxMREWEdN27cdWv497//ba1Ro4Y1Pz/faJs9e7a1dOnS1ry8PKvV+ut3o379+nYdO/B7nCEC7HTo0CFdunRJDz74oEqXLm183n//fZtLTK7w9NNPa/78+ZKkU6dOadWqVQU6+yBJBw8eVLdu3XTnnXfK29tbISEhkqTU1FSbcXXq1DH+XKFCBUlSenq6JGn//v1q3LixzfjIyMgC15+SkqKWLVtet2///v0qXry4zfbLlSunGjVqaP/+/Uabl5eXqlSpYiwHBAQoJCTEONtwte1qzTeqMzIy0ma7X3/9tVq2bKmKFSuqTJky6tGjh86ePatLly7dcN8VKlSw2U/Pnj116NAhffvtt5J+vcz2yCOPXPMi4evJy8vTSy+9pIiICPn5+al06dJas2aN8d+nbt26atmypSIiIvSvf/1L8+bN0/nz5/9yu35+furZs6eio6PVvn17zZgxw+YsoyRVqlRJFStWtPnZ5Ofn68CBA8rMzNSJEyfUtGlTm3WaNm1q8/OT/vzvTv/+/TVx4kQ1bdpUY8eO1a5du4yx+/fvV2RkpM1Zq6ZNmyorK0vHjx832ho0aPCXxwvcCIEIsNPVeSMrVqxQSkqK8dm3b98N5xEVlieeeEJHjhxRYmKi/vOf/yg0NLRA81MkqX379jp37pzmzZunpKQkJSUlSfp1curvlShRwvjz1V9Qf7ysdrNudvL57/2+PunXGq/XZk/NP/74ox566CHVqVNHn332mZKTk405Rr//+VxvP9bfXbLy9/dX+/btNX/+fLsD66uvvqoZM2Zo+PDh+uabb5SSkqLo6Ghj/8WKFVN8fLxWrVql8PBwzZo1SzVq1NDRo0f/ctvz589XYmKi7rnnHn388ceqXr26Edoc6c/+7jz99NM6cuSIevTood27d6thw4aaNWuWXdsvSLAEboRABNgpPDxcHh4eSk1NVdWqVW0+wcHBLq2tXLly6tixo+bPn68FCxboySefLNB6Z8+e1YEDBzRq1Ci1bNlSYWFhBTq78EdhYWFGkLrKnl+sderU0dq1a2+47StXrths/2rd4eHhdtf6R3+s89tvv1VYWJgkKTk5Wfn5+XrttdfUpEkTVa9eXSdOnLip/Tz99NP6+OOPNXfuXFWpUuWaMys3snnzZnXo0EGPP/646tatqzvvvFM//PCDzRiLxaKmTZtq/Pjx2rFjh9zd3fX5558XaPv169fXyJEjtWXLFtWuXVuLFy82+lJTU22O99tvv5Wbm5tq1Kghb29vBQUFafPmzdfUa+9/l+DgYD377LNasmSJhgwZonnz5kn69b/91Tljv99+mTJldMcdd9i1D+BGuO0esFOZMmU0dOhQDRo0SPn5+WrWrJkyMjK0efNmeXt7q3Llyi6t7+mnn9ZDDz2kvLw8xcTEFGidsmXLqly5cpo7d64qVKig1NRUjRgxwu599+/fX02bNtXUqVPVoUMHrVmzxuZuo78yduxYtWzZUlWqVFHXrl115coVrVy5UsOHD1e1atXUoUMH9erVS2+//bbKlCmjESNGqGLFiurQoYPdtf7R5s2bNWXKFHXs2FHx8fH69NNPtWLFCklS1apVlZubq1mzZql9+/Z/a9JudHS0vL29NXHiRE2YMKHA61WrVk3//e9/tWXLFpUtW1bTpk3TqVOnjNCRlJSktWvXqlWrVvL391dSUpJOnz5thLobOXr0qObOnauHH35YQUFBOnDggA4ePKgnnnjCGOPp6amYmBhNnTpVmZmZ6t+/vx555BEFBgZKkoYNG6axY8eqSpUqqlevnubPn6+UlBQtWrSowMc3cOBAtWnTRtWrV9f58+f1zTffGLU///zzmj59uvr166e+ffvqwIEDGjt2rAYPHiw3N/5dD8fgbxJwE1566SWNHj1acXFxCgsLU+vWrbVixQqFhoa6ujRFRUWpQoUKio6OVlBQUIHWcXNz00cffaTk5GTVrl1bgwYN0quvvmr3vps0aaJ58+ZpxowZqlu3rr766iuNGjWqwOu3aNFCn376qZYtW6Z69erpgQceMO6ikn69tNOgQQM99NBDioyMlNVq1cqVK6+5VHUzhgwZom3btql+/fqaOHGipk2bZty6XbduXU2bNk2TJ09W7dq1tWjRIsXFxd3Uftzc3NSzZ0/l5eXZhI6/MmrUKN11112Kjo5WixYtFBgYaPNIBm9vb23YsEFt27ZV9erVNWrUKL322mtq06bNn27Xy8tL33//vbp06aLq1aurd+/e6tOnj5555hljTNWqVdW5c2e1bdtWrVq1Up06dfTmm28a/f3799fgwYM1ZMgQRUREaPXq1Vq2bJmqVatW4OPLy8tTnz59jO9T9erVjX1UrFhRK1eu1Hfffae6devq2WefVWxsrF1/t4C/YrFaeQwucDvJyspSxYoVNX/+fHXu3NnV5dwSQkJCNHDgQJvXojhTbGysTp8+rWXLlhXK/v6OcePGaenSpUpJSXF1KYBTcckMuE3k5+frzJkzeu211+Tr66uHH37Y1SXhDzIyMrR7924tXrz4lghDgJlwyQwoRLVq1bK5Vf/3H3vmW1xPamqqAgICtHjxYr333nsqXry4Td+N9lu6dOlrbq13Fmce/62gQ4cOatWqlZ599lk9+OCDNn1t2rS54c/mlVde+Vv7/bP/9hs3bvxb2wZuF1wyAwrRTz/9ZPNU5d8LCAhQmTJlnLLfK1eu6Mcff7xhf0hIiE2AchZXHf+t4Oeff9b//ve/6/b5+fnJz8/vprd96NChG/ZVrFjRIY87AG51BCIAAGB6XDIDAACmRyACAACmRyACAACmRyACAACmRyACAACmRyACAACmRyACAACm939/g0cu72DrgwAAAABJRU5ErkJggg==",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "False    810\n",
      "True      30\n",
      "Name: bristol-myers_squibb_as_sponsor, dtype: int64\n",
      "bristol-myers_squibb_as_sponsor\n",
      "False    1577.81358\n",
      "True     1755.70000\n",
      "Name: duration, dtype: float64\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "top_5_sponsor = sorted(sponsor_count.keys(), key=lambda x:sponsor_count[x], reverse=True)[:5]\n",
    "for sponsor in top_5_sponsor:\n",
    "    col_name = f'{sponsor}_as_sponsor'\n",
    "    col_name = col_name.lower().replace(\" \", \"_\").replace(\",\", \"\")\n",
    "    df[col_name] = df['sponsor/collaborators'].apply(lambda x: sponsor in x.split(\"|\"))\n",
    "    print(df[col_name].value_counts())\n",
    "    print(df.groupby(col_name)['duration'].mean())\n",
    "    df.groupby(col_name)['duration'].mean().sort_index().plot(kind = 'bar')\n",
    "    plt.ylabel('average completion days')\n",
    "    plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "be240dfc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>10</th>\n",
       "      <th>11</th>\n",
       "      <th>12</th>\n",
       "      <th>...</th>\n",
       "      <th>100</th>\n",
       "      <th>101</th>\n",
       "      <th>102</th>\n",
       "      <th>103</th>\n",
       "      <th>104</th>\n",
       "      <th>105</th>\n",
       "      <th>106</th>\n",
       "      <th>107</th>\n",
       "      <th>108</th>\n",
       "      <th>109</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>rank</th>\n",
       "      <td>1</td>\n",
       "      <td>2</td>\n",
       "      <td>3</td>\n",
       "      <td>4</td>\n",
       "      <td>5</td>\n",
       "      <td>6</td>\n",
       "      <td>7</td>\n",
       "      <td>11</td>\n",
       "      <td>12</td>\n",
       "      <td>13</td>\n",
       "      <td>...</td>\n",
       "      <td>101</td>\n",
       "      <td>102</td>\n",
       "      <td>103</td>\n",
       "      <td>104</td>\n",
       "      <td>105</td>\n",
       "      <td>106</td>\n",
       "      <td>107</td>\n",
       "      <td>108</td>\n",
       "      <td>109</td>\n",
       "      <td>110</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>nct_number</th>\n",
       "      <td>NCT01829373</td>\n",
       "      <td>NCT00401778</td>\n",
       "      <td>NCT00132054</td>\n",
       "      <td>NCT02429843</td>\n",
       "      <td>NCT00084799</td>\n",
       "      <td>NCT01486602</td>\n",
       "      <td>NCT00005022</td>\n",
       "      <td>NCT00062322</td>\n",
       "      <td>NCT00059761</td>\n",
       "      <td>NCT00857025</td>\n",
       "      <td>...</td>\n",
       "      <td>NCT02503358</td>\n",
       "      <td>NCT01189968</td>\n",
       "      <td>NCT01165216</td>\n",
       "      <td>NCT01225302</td>\n",
       "      <td>NCT01931787</td>\n",
       "      <td>NCT00555256</td>\n",
       "      <td>NCT01121575</td>\n",
       "      <td>NCT01302808</td>\n",
       "      <td>NCT00569114</td>\n",
       "      <td>NCT00731952</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>title</th>\n",
       "      <td>Lung Cancer Vaccine Plus Oral Dietary Supplement</td>\n",
       "      <td>Trial of RAD001 in Patients With Operable Non-...</td>\n",
       "      <td>Amrubicin and Irinotecan in Treating Patients ...</td>\n",
       "      <td>A Study of TRC105 in Combination With Paclitax...</td>\n",
       "      <td>Monoclonal Antibody Therapy in Treating Patien...</td>\n",
       "      <td>Specialized Radiation Therapy and Chemotherapy...</td>\n",
       "      <td>Radiation Therapy Plus Combination Chemotherap...</td>\n",
       "      <td>Neoadjuvant Chemoradiotherapy Followed By Surg...</td>\n",
       "      <td>Chemotherapy Combined With Radiation Therapy i...</td>\n",
       "      <td>Beta-Glucan in Treating Patients With Locally ...</td>\n",
       "      <td>...</td>\n",
       "      <td>Selumetinib and Paclitaxel as Second-Line Trea...</td>\n",
       "      <td>A Study of Carboplatin and Pemetrexed Plus Dem...</td>\n",
       "      <td>Japanese Study of Ipilimumab Administered in C...</td>\n",
       "      <td>A Study of Linifanib (ABT-869) in Combination ...</td>\n",
       "      <td>CPI-613 in Treating Patients With Relapsed or ...</td>\n",
       "      <td>A Phase I Study of SUNITINIB and Rapamycin in ...</td>\n",
       "      <td>A Study Of Combined C- MET Inhibitor And PAN-H...</td>\n",
       "      <td>Romidepsin and Erlotinib Hydrochloride in Trea...</td>\n",
       "      <td>Phase 1 Study of TG01 and Erlotinib in Non-sma...</td>\n",
       "      <td>Phase I Study of Induction Therapy With VELCAD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>acronym</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>SU/Rapamycin</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>status</th>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Completed</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>eli_lilly_and_company_as_sponsor</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>bristol-myers_squibb_as_sponsor</th>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>...</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lead_aes</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lead_mtd</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lead_dlt</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>63 rows × 100 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                               0    \\\n",
       "rank                                                                             1   \n",
       "nct_number                                                             NCT01829373   \n",
       "title                             Lung Cancer Vaccine Plus Oral Dietary Supplement   \n",
       "acronym                                                                        NaN   \n",
       "status                                                                   Completed   \n",
       "...                                                                            ...   \n",
       "eli_lilly_and_company_as_sponsor                                             False   \n",
       "bristol-myers_squibb_as_sponsor                                              False   \n",
       "lead_aes                                                                         0   \n",
       "lead_mtd                                                                         0   \n",
       "lead_dlt                                                                         0   \n",
       "\n",
       "                                                                                1    \\\n",
       "rank                                                                              2   \n",
       "nct_number                                                              NCT00401778   \n",
       "title                             Trial of RAD001 in Patients With Operable Non-...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                2    \\\n",
       "rank                                                                              3   \n",
       "nct_number                                                              NCT00132054   \n",
       "title                             Amrubicin and Irinotecan in Treating Patients ...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                3    \\\n",
       "rank                                                                              4   \n",
       "nct_number                                                              NCT02429843   \n",
       "title                             A Study of TRC105 in Combination With Paclitax...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                4    \\\n",
       "rank                                                                              5   \n",
       "nct_number                                                              NCT00084799   \n",
       "title                             Monoclonal Antibody Therapy in Treating Patien...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                5    \\\n",
       "rank                                                                              6   \n",
       "nct_number                                                              NCT01486602   \n",
       "title                             Specialized Radiation Therapy and Chemotherapy...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                6    \\\n",
       "rank                                                                              7   \n",
       "nct_number                                                              NCT00005022   \n",
       "title                             Radiation Therapy Plus Combination Chemotherap...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                10   \\\n",
       "rank                                                                             11   \n",
       "nct_number                                                              NCT00062322   \n",
       "title                             Neoadjuvant Chemoradiotherapy Followed By Surg...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                11   \\\n",
       "rank                                                                             12   \n",
       "nct_number                                                              NCT00059761   \n",
       "title                             Chemotherapy Combined With Radiation Therapy i...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                12   \\\n",
       "rank                                                                             13   \n",
       "nct_number                                                              NCT00857025   \n",
       "title                             Beta-Glucan in Treating Patients With Locally ...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                  ...  \\\n",
       "rank                              ...   \n",
       "nct_number                        ...   \n",
       "title                             ...   \n",
       "acronym                           ...   \n",
       "status                            ...   \n",
       "...                               ...   \n",
       "eli_lilly_and_company_as_sponsor  ...   \n",
       "bristol-myers_squibb_as_sponsor   ...   \n",
       "lead_aes                          ...   \n",
       "lead_mtd                          ...   \n",
       "lead_dlt                          ...   \n",
       "\n",
       "                                                                                100  \\\n",
       "rank                                                                            101   \n",
       "nct_number                                                              NCT02503358   \n",
       "title                             Selumetinib and Paclitaxel as Second-Line Trea...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                101  \\\n",
       "rank                                                                            102   \n",
       "nct_number                                                              NCT01189968   \n",
       "title                             A Study of Carboplatin and Pemetrexed Plus Dem...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                102  \\\n",
       "rank                                                                            103   \n",
       "nct_number                                                              NCT01165216   \n",
       "title                             Japanese Study of Ipilimumab Administered in C...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                                True   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                103  \\\n",
       "rank                                                                            104   \n",
       "nct_number                                                              NCT01225302   \n",
       "title                             A Study of Linifanib (ABT-869) in Combination ...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                104  \\\n",
       "rank                                                                            105   \n",
       "nct_number                                                              NCT01931787   \n",
       "title                             CPI-613 in Treating Patients With Relapsed or ...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                105  \\\n",
       "rank                                                                            106   \n",
       "nct_number                                                              NCT00555256   \n",
       "title                             A Phase I Study of SUNITINIB and Rapamycin in ...   \n",
       "acronym                                                                SU/Rapamycin   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                106  \\\n",
       "rank                                                                            107   \n",
       "nct_number                                                              NCT01121575   \n",
       "title                             A Study Of Combined C- MET Inhibitor And PAN-H...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                107  \\\n",
       "rank                                                                            108   \n",
       "nct_number                                                              NCT01302808   \n",
       "title                             Romidepsin and Erlotinib Hydrochloride in Trea...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                108  \\\n",
       "rank                                                                            109   \n",
       "nct_number                                                              NCT00569114   \n",
       "title                             Phase 1 Study of TG01 and Erlotinib in Non-sma...   \n",
       "acronym                                                                         NaN   \n",
       "status                                                                    Completed   \n",
       "...                                                                             ...   \n",
       "eli_lilly_and_company_as_sponsor                                              False   \n",
       "bristol-myers_squibb_as_sponsor                                               False   \n",
       "lead_aes                                                                          0   \n",
       "lead_mtd                                                                          0   \n",
       "lead_dlt                                                                          0   \n",
       "\n",
       "                                                                                109  \n",
       "rank                                                                            110  \n",
       "nct_number                                                              NCT00731952  \n",
       "title                             Phase I Study of Induction Therapy With VELCAD...  \n",
       "acronym                                                                         NaN  \n",
       "status                                                                    Completed  \n",
       "...                                                                             ...  \n",
       "eli_lilly_and_company_as_sponsor                                              False  \n",
       "bristol-myers_squibb_as_sponsor                                               False  \n",
       "lead_aes                                                                          1  \n",
       "lead_mtd                                                                          0  \n",
       "lead_dlt                                                                          0  \n",
       "\n",
       "[63 rows x 100 columns]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "for col in df.columns:\n",
    "    df[col] = df[col].apply(lambda x: x.replace(\";\", \"\") if type(x)==str else x)\n",
    "df['lead_aes'] = df['lead_outcome_measure'].apply(lambda x: 1 if x=='AEs' else 0)\n",
    "df['lead_mtd'] = df['lead_outcome_measure'].apply(lambda x: 1 if x=='MTD' else 0)\n",
    "df['lead_dlt'] = df['lead_outcome_measure'].apply(lambda x: 1 if x=='DLT' else 0)\n",
    "df.to_csv(f\"../data/updated_{filename}.csv\", index=False)\n",
    "df.head(100).transpose()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6be90f9f",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.0"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
